https://aibio.space/Biotech Investor Relations NewsenSat, 31 Oct 2026 12:00:00 GMT https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/Fri, 30 Oct 2026 12:00:00 GMTDebt FinancingHorizon Technology Finance is collateral agent and a lender on the amended loan. The new Loan I and Loan J commitments run to December 31, 2027.SEC filing (Exhibit 10.6) https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/Fri, 30 Oct 2026 12:00:00 GMTDebt FinancingThe 0.25% notes due 2031 will be issued partly in exchange for 2028 notes and partly for cash, with a conversion price of approximately $226.37.Repligen Corporation (2026-10-30) https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/Thu, 29 Oct 2026 12:00:00 GMTCompany UpdatesSephience revenue reached $182 million in the quarter, the company acquired ST-920 for $111.0 million upfront, and it now expects total revenue of $1.29 to $1.32 billion for 2026.PTC Therapeutics, Inc. Exhibit 99.1 (2026-10-29) https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/Thu, 29 Oct 2026 12:00:00 GMTCompany UpdatesProcessa said the FDA cleared an IND for a study of VT-7208 in chronic spontaneous urticaria, expected to enroll approximately 120 adults, and that its cash should fund operations into the second half of 2029.Processa Pharmaceuticals, Inc. 8-K (2026-10-29) https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/Thu, 29 Oct 2026 12:00:00 GMTCompany UpdatesKiora will pay $3.5 million upfront for exclusive rights outside Asia to KIO-401 from Senju Pharmaceutical. The company plans a multinational Phase 3 trial in CRAO, targeted to start in 2027.Kiora Pharmaceuticals, Inc. 8-K (2026-10-29) https://aibio.space/news/azitra-expands-atr-04-trial-rash-kras-mek-inhibitors/https://aibio.space/news/azitra-expands-atr-04-trial-rash-kras-mek-inhibitors/Thu, 29 Oct 2026 12:00:00 GMTCompany UpdatesProtocol amendments add patients with rash from KRAS and MEK inhibitors, including people with neurofibromatosis type 1, and shorten some washout periods.Azitra Inc 8-K (2026-10-29) https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/Thu, 29 Oct 2026 12:00:00 GMTDebt FinancingFOXO Technologies signed agreements to acquire preferred stock carrying majority voting power in Ludwig Enterprises, Inc. and to buy certain Ludwig notes. The transactions have not closed.FOXO TECHNOLOGIES INC. 8-K (2026-10-29) https://aibio.space/news/dermata-enrolls-first-participant-tome-clearing-treatment-trial/https://aibio.space/news/dermata-enrolls-first-participant-tome-clearing-treatment-trial/Thu, 29 Oct 2026 12:00:00 GMTCompany UpdatesDermata Therapeutics enrolled the first participant in a clinical trial of Tome Clearing Treatment, its once-weekly acne treatment. The company expects to launch its second commercial product in the first half of 2027.Dermata Therapeutics, Inc. 8-K (2026-10-29) https://aibio.space/news/alnylam-details-texas-patent-suit-two-cipla-patent-cases-u-s-attorney/https://aibio.space/news/alnylam-details-texas-patent-suit-two-cipla-patent-cases-u-s-attorney/Thu, 29 Oct 2026 12:00:00 GMTLegalAlnylam's 10-Q for the quarter ended September 30, 2026 says the University of Texas System's patent suit over Onpattro now sits in Massachusetts, with trial set for August 2027. Alnylam is the plaintiff in two patent suits against Cipla, and a U.S. Attorney's Office subpoena on pricing records is open.Alnylam 10-Q for the quarter ended September 30, 2026 (SEC EDGAR) https://aibio.space/news/viking-ligand-dispute-vk2809-license-termination-san-diego-court/https://aibio.space/news/viking-ligand-dispute-vk2809-license-termination-san-diego-court/Thu, 29 Oct 2026 12:00:00 GMTLegalLigand sued Viking on May 19, 2026 after purporting to end the TR-Beta license. Viking cross-sued Ligand and Metabasis. A hearing on Ligand's demurrer is set for February 26, 2027.Viking Therapeutics 10-Q for the quarter ended September 30, 2026 (SEC EDGAR) https://aibio.space/news/vikings-itc-trade-secret-ruling-against-ascletis-appeal-federal/https://aibio.space/news/vikings-itc-trade-secret-ruling-against-ascletis-appeal-federal/Thu, 29 Oct 2026 12:00:00 GMTLegalThe ITC affirmed sanctions against Ascletis Bioscience, Gannex, Ascletis Pharmaceuticals, Ascletis Pharma and Jinzi Jason Wu in May 2025. Both sides appealed, and argument is expected in Q4 2027.Viking Therapeutics 10-Q for the quarter ended September 30, 2026 (SEC EDGAR) https://aibio.space/news/court-rules-teva-apotex-vandas-hetlioz-patent-suits/https://aibio.space/news/court-rules-teva-apotex-vandas-hetlioz-patent-suits/Thu, 29 Oct 2026 12:00:00 GMTLegalA Delaware federal court granted summary judgment of non-infringement for Teva and Apotex in September 2026. Vanda is weighing its options, and its 10-Q also reports a DOJ notice and new generic-drug suits.Vanda Pharmaceuticals 10-Q for the quarter ended September 30, 2026 (SEC EDGAR) https://aibio.space/news/indivior-discloses-suboxone-dental-injury-mdl-about-22-098-plaintiffs/https://aibio.space/news/indivior-discloses-suboxone-dental-injury-mdl-about-22-098-plaintiffs/Thu, 29 Oct 2026 12:00:00 GMTLegalIndivior Pharmaceuticals, Inc. is the named defendant in the Northern District of Ohio MDL. Canadian class actions name subsidiaries, and a qui tam case names Indivior Inc.Indivior Pharmaceuticals 10-Q for the quarter ended September 30, 2026 (SEC EDGAR) https://aibio.space/news/altimmune-draws-10-0-million-third-tranche-hercules-loan-facility/https://aibio.space/news/altimmune-draws-10-0-million-third-tranche-hercules-loan-facility/Thu, 29 Oct 2026 12:00:00 GMTDebt FinancingAltimmune drew $10.0 million on October 27, 2026, and the draw extended the interest-only period to June 1, 2028 while adding a minimum cash covenant tied to the loan balance.Altimmune, Inc. 8-K (2026-10-29) https://aibio.space/news/european-patent-court-rules-enanta-patent-invalid-paxlovid-suit/https://aibio.space/news/european-patent-court-rules-enanta-patent-invalid-paxlovid-suit/Thu, 29 Oct 2026 12:00:00 GMTLegalThe Unified Patent Court found the '265 Patent invalid on Pfizer's counterclaim and called Enanta's infringement action unfounded.Enanta Pharmaceuticals, Inc. 8-K (2026-10-29) https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/Thu, 29 Oct 2026 12:00:00 GMTFinancingsThe offering priced at $1.50 a share, and the warrants carry a $1.65 exercise price. The auditor's report on the 2025 accounts includes a going-concern paragraph, and cash was $18.4 million at June 30, 2026.INmune Bio Inc. 424B5 (2026-10-29) https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/Thu, 29 Oct 2026 12:00:00 GMTFinancingsLexeo's new Form S-3 would let it sell up to $300,000,000 of securities and rolls over $135,387,220.20 of unsold securities from a December 2024 shelf. No offering has been priced.Lexeo Therapeutics, Inc. S-3 (2026-10-29) https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/Thu, 29 Oct 2026 12:00:00 GMTDistressA termination agreement ends the license and assigns the patents and know-how to Mineralys. Up to $255.0 million in commercial milestones still applies.Mineralys Therapeutics, Inc. 8-K (2026-10-29) https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/Thu, 29 Oct 2026 12:00:00 GMTListingsNasdaq gave Propanc no 180-day compliance period because it reverse split within the past year. The company says it will appeal by October 30, 2026. Its fiscal 2026 net loss was $18.9 million.Propanc Biopharma, Inc. 8-K (2026-10-29) https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/Thu, 29 Oct 2026 12:00:00 GMTFinancingsProKidney can sell up to $200,000,000 of Class A stock through Jefferies LLC at a commission of up to 3.0%, under a $650,000,000 shelf that the filings say must take effect before any sale. The stock last sold at $1.52 on October 28, 2026.ProKidney Corp. S-3 (2026-10-29) https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/Thu, 29 Oct 2026 12:00:00 GMTDistressBristol Myers Squibb will end its PRX019 license on January 28, 2027, dropping up to $617.5 million in milestones it could have owed. The 8-K cites an internal strategic review and gives no further reason.Prothena Corporation plc 8-K (2026-10-29) https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/Thu, 29 Oct 2026 12:00:00 GMTListingsThe proposal goes to a virtual annual meeting on December 18, 2026. The board would pick the ratio and could decide not to split at all.Reviva Pharmaceuticals Holdings, Inc. PRE 14A (2026-10-29) https://aibio.space/news/metavia-present-phase-1-da-1726-data-precision-liver-symposium/https://aibio.space/news/metavia-present-phase-1-da-1726-data-precision-liver-symposium/Wed, 28 Oct 2026 12:00:00 GMTCompany UpdatesAn abstract on the Phase 1 trial of DA-1726 was accepted for an oral presentation at the Precision Liver Symposium 2026 in Denver on November 4, 2026.MetaVia Inc. 8-K (2026-10-28) https://aibio.space/news/jaguar-health-adds-six-fold-stock-plan-increase-ahead-november-vote/https://aibio.space/news/jaguar-health-adds-six-fold-stock-plan-increase-ahead-november-vote/Wed, 28 Oct 2026 12:00:00 GMTCompany UpdatesA proxy supplement filed after a stock dividend explains a six-fold increase in shares available under the 2014 Stock Incentive Plan, which stockholders vote on November 6, 2026.Jaguar Health, Inc. 8-K (2026-10-28) https://aibio.space/news/genprex-present-tusc2-aging-research-gsa-2026-meeting/https://aibio.space/news/genprex-present-tusc2-aging-research-gsa-2026-meeting/Wed, 28 Oct 2026 12:00:00 GMTCompany UpdatesA poster from the company's Meharry Medical College collaboration is scheduled for the Gerontological Society of America meeting in National Harbor, Maryland, in November 2026.Genprex, Inc. 8-K (2026-10-28) https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/Wed, 28 Oct 2026 12:00:00 GMTListingsNasdaq's Hearings Panel determined to delist Glucotrack common stock after its closing bid price was $0.87 on October 14, 2026, and trading is suspended at the open on October 30, 2026.Glucotrack, Inc. 8-K (2026-10-29) https://aibio.space/news/sanuwave-gets-jpmorgan-waiver-fixed-charge-ratio-tightens-limits/https://aibio.space/news/sanuwave-gets-jpmorgan-waiver-fixed-charge-ratio-tightens-limits/Wed, 28 Oct 2026 12:00:00 GMTDebt FinancingThe amendment lowers a prepayment figure and three investment baskets from $500,000 to $250,000 and requires Required Lenders consent for certain acquisitions and equity redemptions. JPMorgan Chase Bank, N.A. is administrative agent.SEC Form 8-K exhibit https://aibio.space/news/skye-bioscience-faces-nimacimab-securities-class-action-two-derivative/https://aibio.space/news/skye-bioscience-faces-nimacimab-securities-class-action-two-derivative/Wed, 28 Oct 2026 12:00:00 GMTLegalStout v. Skye Bioscience alleges misleading statements about nimacimab from November 4, 2024 to October 3, 2025. Two derivative suits captioned against Dhillon are stayed, and consolidation was sought on August 11.Skye Bioscience 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/skye-bioscience-faces-october-2026-retrial-cunning-whistleblower-suit/https://aibio.space/news/skye-bioscience-faces-october-2026-retrial-cunning-whistleblower-suit/Wed, 28 Oct 2026 12:00:00 GMTLegalA jury found for former employee Wendy Cunning in 2023. The Ninth Circuit vacated the judgment in 2024. Skye now estimates the legal contingency at $5,417,250 and cites settlement talks.Skye Bioscience 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/amarin-settles-hikma-patent-antitrust-cases-generic-vascepa/https://aibio.space/news/amarin-settles-hikma-patent-antitrust-cases-generic-vascepa/Wed, 28 Oct 2026 12:00:00 GMTLegalThe 10-Q says the patent claims and Hikma's antitrust claims are to be dismissed with prejudice under settlements agreed on Oct 13. It also lists antitrust complaints from Dr. Reddy's, Teva and Apotex in New Jersey.Amarin 10-Q for the quarter ended Sept 30, 2026 (SEC EDGAR) https://aibio.space/news/replimune-10-q-lists-two-massachusetts-securities-class-actions/https://aibio.space/news/replimune-10-q-lists-two-massachusetts-securities-class-actions/Wed, 28 Oct 2026 12:00:00 GMTLegalThe first class action was filed shortly after the FDA's first RP1 complete response letter. A motion to dismiss it is due to be fully briefed in December; the SEC closed its probe in June without recommending action.Replimune Group 10-Q for the quarter ended September 30, 2026 (SEC EDGAR) https://aibio.space/news/actuate-therapeutics-prices-11-0-million-offering-shares-warrants/https://aibio.space/news/actuate-therapeutics-prices-11-0-million-offering-shares-warrants/Wed, 28 Oct 2026 12:00:00 GMTFinancingsActuate Therapeutics priced 30,985,900 shares and warrants for 15,492,950 more shares at $0.71 per set, for about $11.0 million before costs. The stock last sold at $0.40, and the company reported $4.4 million of cash at June 30, 2026.Actuate Therapeutics, Inc. 424B5 (2026-10-28) https://aibio.space/news/adial-pharmaceuticals-renames-itself-azora-therapeutics-after/https://aibio.space/news/adial-pharmaceuticals-renames-itself-azora-therapeutics-after/Wed, 28 Oct 2026 12:00:00 GMTFinancingsAdial Pharmaceuticals becomes Azora Therapeutics and is expected to trade as AZR from October 29, 2026, after stockholders approved converting the preferred stock issued in its June 2026 acquisition of Azora. The October release does not mention AD04, the drug the company's March 2026 annual report called its lead asset.Adial Pharmaceuticals, Inc 8-K, Exhibit 99.1 (2026-10-28) https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/Wed, 28 Oct 2026 12:00:00 GMTDistressThe VIZZ maker targets approximately $70 million to $75 million in 2027 operating expenses, and CEO Eef Schimmelpennink will step down December 1, 2026.LENZ Therapeutics, Inc. 8-K, Exhibit 99.1 (2026-10-28) https://aibio.space/news/milestone-pharmaceuticals-falls-below-nasdaqs-1-00-minimum-bid-rule/https://aibio.space/news/milestone-pharmaceuticals-falls-below-nasdaqs-1-00-minimum-bid-rule/Wed, 28 Oct 2026 12:00:00 GMTListingsMilestone has until April 21, 2027 to close at $1.00 or more for 10 consecutive business days, after 30 consecutive business days below that level.Milestone Pharmaceuticals Inc. 8-K (2026-10-28) https://aibio.space/news/nasdaq-panel-delists-osr-health-1-00-bid-price-rule/https://aibio.space/news/nasdaq-panel-delists-osr-health-1-00-bid-price-rule/Wed, 28 Oct 2026 12:00:00 GMTListingsOSR Health, whose shares have traded over the counter since Nasdaq suspended them on August 26, 2026, says it will update shareholders by November 6, 2026 on how it plans to regain a listing.OSR Health, Inc. 8-K (2026-10-28) https://aibio.space/news/silexion-files-register-resale-up-8-813-531-shares/https://aibio.space/news/silexion-files-register-resale-up-8-813-531-shares/Wed, 28 Oct 2026 12:00:00 GMTFinancingsSilexion's S-3 registers resale of up to 8,813,531 ordinary shares by selling shareholders from an August warrant inducement, a converted sponsor note and stock paid to LifeSci Advisors. The filing also discloses a June 2026 complaint from the sponsor, which seeks repayment of $3.433 million.Silexion Therapeutics Corp S-3 (2026-10-28) https://aibio.space/news/lifeward-names-ronen-tsimerman-chief-financial-officer/https://aibio.space/news/lifeward-names-ronen-tsimerman-chief-financial-officer/Tue, 27 Oct 2026 12:00:00 GMTCompany UpdatesThe board appointed Ronen Tsimerman as chief financial officer, effective November 1, 2026. His employment agreement is subject to shareholder approval of a renewed compensation policy.Lifeward Ltd. 8-K (2026-10-27) https://aibio.space/news/60-degrees-reports-pcr-negative-results-five-babesiosis-patients/https://aibio.space/news/60-degrees-reports-pcr-negative-results-five-babesiosis-patients/Tue, 27 Oct 2026 12:00:00 GMTCompany UpdatesAll five patients who finished the expanded access study reported improved outcomes and negative conventional PCR tests, and four of five were also negative on a highly sensitive test.60 Degrees Pharmaceuticals, Inc. 8-K (2026-10-27) https://aibio.space/news/volitionrx-prepays-500-000-lind-note-defers-two-monthly-payments/https://aibio.space/news/volitionrx-prepays-500-000-lind-note-defers-two-monthly-payments/Tue, 27 Oct 2026 12:00:00 GMTDebt FinancingThe remaining balance is $706,667 after the payment. Lind agreed not to convert before January 1, 2027 unless the stock closes at $0.275 or more.VolitionRx press release (SEC Form 8-K) https://aibio.space/news/beta-bionics-discloses-securities-class-action-ilet-statements/https://aibio.space/news/beta-bionics-discloses-securities-class-action-ilet-statements/Tue, 27 Oct 2026 12:00:00 GMTLegalA purported stockholder sued Beta Bionics and certain executive officers in a California federal court in September. The company says a loss is not currently probable nor estimable.Beta Bionics 10-Q for the quarter ended Sept 30, 2026 (SEC EDGAR) https://aibio.space/news/aclaris-therapeutics-prices-49-999-934-stock-pre-funded-warrant/https://aibio.space/news/aclaris-therapeutics-prices-49-999-934-stock-pre-funded-warrant/Tue, 27 Oct 2026 12:00:00 GMTFinancingsAclaris priced 7,785,714 shares at $3.50 and pre-funded warrants for 6,500,000 more shares, $49,999,934 before costs, on the day it announced small Phase 1b results for its antibody ATI-052. The prospectus puts cash at approximately $204.6 million on September 30, 2026.Aclaris Therapeutics (SEC Form 424B5) https://aibio.space/news/artiva-drops-allonk-cuts-about-94-percent-staff-weighs-strategic/https://aibio.space/news/artiva-drops-allonk-cuts-about-94-percent-staff-weighs-strategic/Tue, 27 Oct 2026 12:00:00 GMTDistressThe company ended AlloNK development after two patient deaths and durability data that did not meet its threshold. It reported about $319.1 million in cash, cash equivalents and investments at September 30, 2026, a preliminary figure.Artiva Biotherapeutics (SEC Form 8-K, Exhibit 99.1) https://aibio.space/news/atyr-pharma-sets-1-40-reverse-split-shares-trade-adjusted-october-29/https://aibio.space/news/atyr-pharma-sets-1-40-reverse-split-shares-trade-adjusted-october-29/Tue, 27 Oct 2026 12:00:00 GMTListingsThe split cuts aTyr's outstanding common stock from approximately 100.5 million shares to approximately 2.5 million. The 8-K does not give a reason for the ratio.aTyr Pharma (SEC Form 8-K) https://aibio.space/news/cdt-equity-seeks-votes-reverse-splits-up-1-1-000-astor-note-shares/https://aibio.space/news/cdt-equity-seeks-votes-reverse-splits-up-1-1-000-astor-note-shares/Tue, 27 Oct 2026 12:00:00 GMTListingsThe November 12, 2026 meeting will vote on issuing stock under the Astor notes and warrants, and on reverse splits of up to 1-for-1,000. There were 9,322,805 shares outstanding on the October 23, 2026 record date.CDT Equity (SEC Schedule 14A, definitive proxy) https://aibio.space/news/endovia-health-sciences-raises-equity-line-ceiling-135-million/https://aibio.space/news/endovia-health-sciences-raises-equity-line-ceiling-135-million/Tue, 27 Oct 2026 12:00:00 GMTFinancingsAn addendum with C/M Capital Master Fund lifts the facility's maximum commitment from $35 million to $135 million. The filing does not say how much stock has been sold under it.Endovia Health Sciences (SEC Form 8-K) https://aibio.space/news/enlivex-gets-nasdaq-delisting-notice-plans-appeal-1-16-reverse-split/https://aibio.space/news/enlivex-gets-nasdaq-delisting-notice-plans-appeal-1-16-reverse-split/Tue, 27 Oct 2026 12:00:00 GMTListingsBecause Enlivex already did a reverse split within the past 12 months, it is not entitled to a 180-day period to regain compliance.Enlivex (SEC Form 6-K, Exhibit 99.1) https://aibio.space/news/geovax-signs-1-000-000-credit-line-five-directors-make-way-lender/https://aibio.space/news/geovax-signs-1-000-000-credit-line-five-directors-make-way-lender/Tue, 27 Oct 2026 12:00:00 GMTListingsGeoVax can borrow up to $1,000,000 at 12% interest from Bowery Consulting Group, and it agreed to pursue a public offering of at least $5,000,000. The lender designated the new directors.GeoVax Labs (SEC Form 8-K) https://aibio.space/news/geovax-stockholders-approve-reverse-split-up-1-25-warrant-share/https://aibio.space/news/geovax-stockholders-approve-reverse-split-up-1-25-warrant-share/Tue, 27 Oct 2026 12:00:00 GMTListingsThe board will pick a reverse split ratio between 1-for-10 and 1-for-25. Holders also approved up to 11,395,256 shares for warrants issued in August 2026, against 9,093,871 shares outstanding at the record date.GeoVax Labs (SEC Form 8-K) https://aibio.space/news/imunon-files-share-offering-350-percent-warrant-coverage-four-tranches/https://aibio.space/news/imunon-files-share-offering-350-percent-warrant-coverage-four-tranches/Tue, 27 Oct 2026 12:00:00 GMTFinancingsImunon's preliminary prospectus covers up to 20,000,000 shares, sold with warrants that could cover up to 70,000,000 more. The auditor's opinion on 2025 results includes substantial doubt about the company's ability to continue as a going concern.Imunon (SEC Form S-1) https://aibio.space/news/inmed-sets-november-5-record-date-cvrs-tied-mentari-merger/https://aibio.space/news/inmed-sets-november-5-record-date-cvrs-tied-mentari-merger/Tue, 27 Oct 2026 12:00:00 GMTMergersHolders of record on November 5, 2026 would get one CVR per share, but only if shareholders approve a return of capital proposal on November 4. The company had $2.2 million in cash at June 30, 2026.InMed Pharmaceuticals (SEC Form 425) https://aibio.space/news/pulmatrix-stockholders-approve-eos-senolytix-merger-reverse-split/https://aibio.space/news/pulmatrix-stockholders-approve-eos-senolytix-merger-reverse-split/Tue, 27 Oct 2026 12:00:00 GMTListingsPulmatrix stockholders approved all nine proposals on October 26, 2026, including a share issue above 20% to Eos holders, certain noteholders and adviser Palladium, and a reverse split of one new share for every 2 to 10. The 8-K says Eos and Pulmatrix holders could end up owning more or less of the combined company if the exchange ratio is adjusted.Pulmatrix (SEC Form 8-K) https://aibio.space/news/rapport-therapeutics-launches-stock-offering-convertible-notes-due/https://aibio.space/news/rapport-therapeutics-launches-stock-offering-convertible-notes-due/Tue, 27 Oct 2026 12:00:00 GMTFinancingsRapport Therapeutics filed preliminary terms on October 27, 2026 for a stock offering and convertible notes due 2032. Both deal sizes are blank in the filings, and the company's cash was about $395.0 million at September 30, a figure it calls preliminary.Rapport Therapeutics (SEC Form 424B5, common stock) https://aibio.space/news/sangamo-ends-july-chapter-11-16-906-955-cash/https://aibio.space/news/sangamo-ends-july-chapter-11-16-906-955-cash/Tue, 27 Oct 2026 12:00:00 GMTDistressAn amended monthly operating report for the period ended July 31, 2026 shows $16,906,955 in cash and a July loss of $11,165,298. It also lists an $18 million replacement debtor-in-possession loan.Sangamo Therapeutics (SEC Form 8-K, Exhibit 99.1) https://aibio.space/news/valion-bio-sells-preferred-stock-mostly-settle-overdue-series/https://aibio.space/news/valion-bio-sells-preferred-stock-mostly-settle-overdue-series/Tue, 27 Oct 2026 12:00:00 GMTFinancingsValion Bio sold 4,717.73 Series C preferred shares for $4,717,717.61, but $3,217,717.61 of that stays with the buyers to cover overdue cash true-up payments. The company receives $1,500,000 in cash.Valion Bio (SEC Form 8-K) https://aibio.space/news/aptevo-says-ten-frontline-aml-patients-mipletamig-reached-stem-cell/https://aibio.space/news/aptevo-says-ten-frontline-aml-patients-mipletamig-reached-stem-cell/Mon, 26 Oct 2026 12:00:00 GMTCompany UpdatesTen patients with newly diagnosed AML advanced to transplant after treatment with mipletamig, venetoclax and azacitidine, according to Aptevo's October 26, 2026 release.Aptevo Therapeutics Inc. 8-K (2026-10-26) https://aibio.space/news/rallybio-declares-estimated-82-7-million-cash-distribution-tied-avenzo/https://aibio.space/news/rallybio-declares-estimated-82-7-million-cash-distribution-tied-avenzo/Mon, 26 Oct 2026 12:00:00 GMTMergersRallybio's board declared an estimated $13.56 per share special cash distribution on October 25, 2026. Payment is conditioned on stockholder approval at a November 4, 2026 meeting, with closing expected November 6, 2026.Rallybio Corporation 8-K (2026-10-26) https://aibio.space/news/west-pharmaceutical-enters-750-million-revolver-200-million-term-loan/https://aibio.space/news/west-pharmaceutical-enters-750-million-revolver-200-million-term-loan/Mon, 26 Oct 2026 12:00:00 GMTDebt FinancingBank of America, N.A. is administrative agent under the new unsecured credit agreement. The company repaid $130.0 million under its 2019 credit agreement.SEC Form 8-K https://aibio.space/news/acumen-pharmaceuticals-files-500-000-000-shelf-registration/https://aibio.space/news/acumen-pharmaceuticals-files-500-000-000-shelf-registration/Mon, 26 Oct 2026 12:00:00 GMTFinancingsThe S-3 covers common stock, preferred stock, debt securities and warrants, with pricing and terms to come in later prospectus supplements. Acumen's auditor included a going concern paragraph in its report on the 2025 financial statements.Acumen Pharmaceuticals, Inc. S-3 (2026-10-26) https://aibio.space/news/aeon-biopharma-seeks-approval-reverse-split-up-1-100/https://aibio.space/news/aeon-biopharma-seeks-approval-reverse-split-up-1-100/Mon, 26 Oct 2026 12:00:00 GMTListingsAEON Biopharma asked stockholders to approve a reverse stock split of between 1-for-2 and 1-for-100, to be voted on December 15, 2026. The stock last sold at $0.24 on October 23, and NYSE American's cumulative ratio limit counts the company's 1-for-72 split of February 2025.AEON Biopharma, Inc. DEF 14A (2026-10-26) https://aibio.space/news/first-eq504-dosing-unlocks-20-million-private-placement-tranche/https://aibio.space/news/first-eq504-dosing-unlocks-20-million-private-placement-tranche/Mon, 26 Oct 2026 12:00:00 GMTFinancingsEquillium says the first subject has been dosed in a Phase 1 trial of EQ504, which releases a $20 million tranche of its 2025 private placement. The company says that with this closing its cash should fund planned operations into 2029.Equillium, Inc. 8-K (2026-10-26) https://aibio.space/news/onconetix-sets-1-10-reverse-stock-split-november-6/https://aibio.space/news/onconetix-sets-1-10-reverse-stock-split-november-6/Mon, 26 Oct 2026 12:00:00 GMTListingsThe split cuts the share count to about 588,677 from roughly 5,886,774. The stock keeps trading on Nasdaq as ONCO under a new CUSIP.Onconetix, Inc. 8-K (2026-10-26) https://aibio.space/news/skye-bioscience-files-preliminary-proxy-redx-pharma-acquisition/https://aibio.space/news/skye-bioscience-files-preliminary-proxy-redx-pharma-acquisition/Mon, 26 Oct 2026 12:00:00 GMTMergersRedx holders would own about 59.74% of the combined company and Skye holders about 5.38%, at an assumed exchange ratio of 0.0892. Skye also plans a reverse stock split, and its proxy warns that stockholders will vote without certainty about the combined company's Nasdaq listing.Skye Bioscience, Inc. PREM14A (2026-10-26) https://aibio.space/news/silexion-shareholders-back-1-24-reverse-split-more-authorized-shares/https://aibio.space/news/silexion-shareholders-back-1-24-reverse-split-more-authorized-shares/Mon, 26 Oct 2026 12:00:00 GMTListingsSilexion shareholders approved a 500,000,000-share increase in authorized capital and a reverse split. The board chose 1-for-24 from a range of 1-for-15 to 1-for-25. Holders of about 18.6% of shares attended the reconvened meeting, which the articles treat as a quorum.Silexion Therapeutics Corp 8-K (2026-10-26) https://aibio.space/news/supernus-ends-ubs-credit-line-ahead-indivior-merger/https://aibio.space/news/supernus-ends-ubs-credit-line-ahead-indivior-merger/Mon, 26 Oct 2026 12:00:00 GMTDistressSupernus ended its UBS credit line on October 20, 2026, with nothing drawn and no penalty. The filing says the combined company is to enter a new senior secured facility at closing, but it gives no closing date and no terms.Supernus Pharmaceuticals, Inc. 8-K (2026-10-26) https://aibio.space/news/tscan-therapeutics-asks-stockholders-approve-reverse-split-up-one/https://aibio.space/news/tscan-therapeutics-asks-stockholders-approve-reverse-split-up-one/Mon, 26 Oct 2026 12:00:00 GMTListingsTScan's board will set the reverse split ratio between one-for-two and one-for-fifty, and stockholders vote on November 20, 2026. Nasdaq's bid price deadline is February 23, 2027, and the stock closed at $0.2379 on October 12, 2026.TScan Therapeutics, Inc. DEF 14A (2026-10-26) https://aibio.space/news/neuphoria-extends-rights-agreement-october-27-2027/https://aibio.space/news/neuphoria-extends-rights-agreement-october-27-2027/Fri, 23 Oct 2026 12:00:00 GMTCompany UpdatesThe board approved Amendment No. 1 to the rights agreement with Computershare, moving the final expiration date to the close of business on October 27, 2027.Neuphoria Therapeutics Inc. 8-K (2026-10-23) https://aibio.space/news/aquabountys-preferred-stock-converts-8-077-043-common-shares/https://aibio.space/news/aquabountys-preferred-stock-converts-8-077-043-common-shares/Fri, 23 Oct 2026 12:00:00 GMTCompany UpdatesOn October 23, 2026, after its resale registration became effective, all Series A and Series B preferred shares converted into common stock, leaving 13,291,953 common shares outstanding.AquaBounty Technologies, Inc. 8-K (2026-10-23) https://aibio.space/news/china-resources-pharmaceutical-issues-rmb800-million-third-tranche/https://aibio.space/news/china-resources-pharmaceutical-issues-rmb800-million-third-tranche/Fri, 23 Oct 2026 12:00:00 GMTDebt FinancingA wholly owned subsidiary completed the third 2026 tranche of medium term notes, RMB800 million at 1.45% per annum over three years.China Resources Pharmaceutical Group Limited announcement (2026-10-23) https://aibio.space/news/integra-lifesciences-details-new-jersey-class-action-two-derivative/https://aibio.space/news/integra-lifesciences-details-new-jersey-class-action-two-derivative/Fri, 23 Oct 2026 12:00:00 GMTLegalThe 2023 Pembroke Pines suit over FDA findings at the Boston plant is still being contested after a supplemental amended complaint. Two derivative suits are stayed behind it.Integra LifeSciences 10-Q for the quarter ended September 30, 2026 (SEC EDGAR) https://aibio.space/news/akebia-therapeutics-gets-nasdaq-bid-price-notice-has-until-april-19/https://aibio.space/news/akebia-therapeutics-gets-nasdaq-bid-price-notice-has-until-april-19/Fri, 23 Oct 2026 12:00:00 GMTListingsNasdaq says the stock closed below $1.00 for 30 consecutive business days. Cash fell from $184.8 million at year-end 2025 to $155.5 million at June 30, 2026, and the company says it could seek a reverse stock split.Akebia Therapeutics, Inc. 8-K (2026-10-23) https://aibio.space/news/bolt-biotherapeutics-buys-prana-therapies-raises-120-million/https://aibio.space/news/bolt-biotherapeutics-buys-prana-therapies-raises-120-million/Fri, 23 Oct 2026 12:00:00 GMTMergersBolt Biotherapeutics has agreed to acquire Prana Therapies in a stock-for-stock reverse merger and raise $120 million in a concurrent private placement. After the deal, Bolt's own holders are expected to own about 6.9% of the common stock, and the company says the cash lasts into 2028.Bolt Biotherapeutics (SEC Form 8-K, Exhibit 99.1) https://aibio.space/news/citius-oncology-gets-nasdaq-extension-april-19-2027-bid-price/https://aibio.space/news/citius-oncology-gets-nasdaq-extension-april-19-2027-bid-price/Fri, 23 Oct 2026 12:00:00 GMTListingsCitius Oncology has until April 19, 2027 to show a closing bid of $1.00 or more for ten consecutive business days. Its parent owned about 77.9% of the company in December 2025, and fiscal 2025 cash used in operations was $5.5 million against a net loss of $24.8 million.Citius Oncology, Inc. 8-K (2026-10-23) https://aibio.space/news/lunai-bioworks-gets-nasdaq-delisting-notice-plans-leave-exchange/https://aibio.space/news/lunai-bioworks-gets-nasdaq-delisting-notice-plans-leave-exchange/Fri, 23 Oct 2026 12:00:00 GMTListingsLunai Bioworks will not appeal a Nasdaq staff decision to delist its stock and plans to deregister with the SEC. Trading on Nasdaq is expected to be suspended on October 30, 2026.Lunai Bioworks Inc. 8-K (2026-10-23) https://aibio.space/news/medicus-pharma-regains-nasdaq-1-00-bid-price-compliance-days-after/https://aibio.space/news/medicus-pharma-regains-nasdaq-1-00-bid-price-compliance-days-after/Fri, 23 Oct 2026 12:00:00 GMTListingsNasdaq closed Medicus Pharma's bid price case on October 23, 2026, three days after a delisting letter. The 8-K does not say whether the company now meets the $5 million stockholders' equity standard Nasdaq cited.Medicus Pharma Ltd. 8-K (2026-10-23) https://aibio.space/news/traws-pharma-signs-50-000-000-stock-purchase-agreement-roth-principal/https://aibio.space/news/traws-pharma-signs-50-000-000-stock-purchase-agreement-roth-principal/Fri, 23 Oct 2026 12:00:00 GMTFinancingsTraws can sell up to $50,000,000 of new stock to Roth over 36 months, but no shares can be sold until the SEC declares a resale registration effective. Cash was $5.0 million on June 30, 2026, and cash used in operations was $18.2 million in 2025.Traws Pharma, Inc. 8-K (2026-10-23) https://aibio.space/news/fractyl-cuts-about-45-percent-staff-drops-rejuva-gene-therapy-fund/https://aibio.space/news/fractyl-cuts-about-45-percent-staff-drops-rejuva-gene-therapy-fund/Thu, 22 Oct 2026 12:00:00 GMTDistressThe company expects quarterly cash burn to fall by about half, to roughly $8 million, and says its cash lasts into the second quarter of 2027.Fractyl Health (press release via BiopharmaWatch) https://aibio.space/news/united-therapeutics-authorizes-another-2-billion-share-repurchase/https://aibio.space/news/united-therapeutics-authorizes-another-2-billion-share-repurchase/Thu, 22 Oct 2026 12:00:00 GMTFinancingsThe new program runs through Oct. 21, 2027, on top of a September accelerated repurchase that is still open. The company's cash was $3.80 billion at June 30.United Therapeutics press release (SEC exhibit) https://aibio.space/news/csl-faces-shareholder-class-action-fy26-guidance-disclosure/https://aibio.space/news/csl-faces-shareholder-class-action-fy26-guidance-disclosure/Thu, 22 Oct 2026 12:00:00 GMTLegalThe suit, filed in the Supreme Court of Victoria, covers investors who bought CSL securities between February 2025 and May 2026. CSL denies liability and says it will defend the case.CSL Limited (ASX announcement) https://aibio.space/news/nuwellis-sets-one-nine-reverse-stock-split-effective-october-26/https://aibio.space/news/nuwellis-sets-one-nine-reverse-stock-split-effective-october-26/Thu, 22 Oct 2026 12:00:00 GMTListingsThe split takes effect at 5:00 p.m. Eastern Time on October 26, 2026, and NUWE shares trade split-adjusted from October 27.Nuwellis, Inc. 8-K (2026-10-23) https://aibio.space/news/azitra-carry-out-1-10-reverse-stock-split-october-26/https://aibio.space/news/azitra-carry-out-1-10-reverse-stock-split-october-26/Thu, 22 Oct 2026 12:00:00 GMTListingsEvery 10 shares of common stock will combine into one share on NYSE American, with the stock trading on a split-adjusted basis from market open on October 26, 2026.Azitra Inc 8-K (2026-10-22) https://aibio.space/news/glucotrack-sells-secured-convertible-notes-warrants-dawson-james/https://aibio.space/news/glucotrack-sells-secured-convertible-notes-warrants-dawson-james/Thu, 22 Oct 2026 12:00:00 GMTDebt FinancingThe senior secured convertible notes carry a 22% original issue discount, 8% interest and a 9-month term. Dawson James Securities, Inc. is named as placement agent.SEC filing (Exhibit 10.1) https://aibio.space/news/medpace-discloses-plaintiff-dropped-ohio-securities-class-action-book/https://aibio.space/news/medpace-discloses-plaintiff-dropped-ohio-securities-class-action-book/Thu, 22 Oct 2026 12:00:00 GMTLegalDefendants: Medpace Holdings, August J. Troendle, Jesse J. Geiger and Kevin M. Brady. Plaintiff filed a voluntary dismissal without prejudice on October 12, and a derivative suit was also dropped.Medpace Holdings 10-Q for the quarter ended Sept 30, 2026 (SEC EDGAR) https://aibio.space/news/enlivex-announces-1-16-reverse-share-split-effective-october-27-2026/https://aibio.space/news/enlivex-announces-1-16-reverse-share-split-effective-october-27-2026/Thu, 22 Oct 2026 12:00:00 GMTListingsIssued shares will fall from 24,511,905 to about 1,531,995. The stock stays on the Nasdaq Capital Market under ENLV.Enlivex Ltd. 6-K (2026-10-22) https://aibio.space/news/sagimet-expects-cash-115-million-offering-fund-operations-mid-2029/https://aibio.space/news/sagimet-expects-cash-115-million-offering-fund-operations-mid-2029/Thu, 22 Oct 2026 12:00:00 GMTFinancingsSagimet's investor presentation says $257.6 million in cash, cash equivalents and marketable securities at June 30, 2026, plus a $115 million underwritten offering completed in September, should fund operations to mid-2029. The presentation does not name the underwriters.Sagimet Biosciences Inc. 8-K (2026-10-22) https://aibio.space/news/biotech-reverse-mergers-reach-highest-count-since-2021-pipes-return/https://aibio.space/news/biotech-reverse-mergers-reach-highest-count-since-2021-pipes-return/Wed, 21 Oct 2026 12:00:00 GMTMergersJ.P. Morgan counted 27 reverse mergers worth $7.5 billion in the first nine months of 2026. Nineteen came with private placements, against three of 12 in 2025.Fierce Biotech https://aibio.space/news/arcus-raises-250-million-17-50-share-day-after-kidney-cancer-data/https://aibio.space/news/arcus-raises-250-million-17-50-share-day-after-kidney-cancer-data/Wed, 21 Oct 2026 12:00:00 GMTFinancingsThe offering priced below the $19.10 last reported sale price. Arcus says the money goes mainly to casdatifan, its HIF-2 alpha inhibitor now in two phase 3 programs.Arcus Biosciences https://aibio.space/news/genprex-reports-mouse-research-linking-tusc2-healthy-brain-aging/https://aibio.space/news/genprex-reports-mouse-research-linking-tusc2-healthy-brain-aging/Wed, 21 Oct 2026 12:00:00 GMTCompany UpdatesA peer-reviewed mouse study tied the TUSC2 gene, used in Genprex's REQORSA program, to protein balance and synaptic function in the hippocampus.Genprex, Inc. 8-K (2026-10-21) https://aibio.space/news/somalogic-stockholder-suit-heads-2027-trial-without-standard-biotools/https://aibio.space/news/somalogic-stockholder-suit-heads-2027-trial-without-standard-biotools/Wed, 21 Oct 2026 12:00:00 GMTLegalA Delaware suit naming Casdin Capital and SomaLogic directors is set for a March 2027 bench trial. SRS had claimed up to $17.5 million in Palamedrix milestones; that matter is resolved and the company paid Illumina $7.5 million on its indemnity.Standard BioTools 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/china-sxt-ends-purchasers-right-buy-up-12-million-more-shares/https://aibio.space/news/china-sxt-ends-purchasers-right-buy-up-12-million-more-shares/Wed, 21 Oct 2026 12:00:00 GMTFinancingsChina SXT and the purchasers in its October 8, 2026 registered direct offering agreed to cancel, in full, a right to buy up to $12 million more shares. The company says the offering's securities already issued are not affected.China SXT Pharmaceuticals, Inc. 6-K (2026-10-21) https://aibio.space/news/alaunos-therapeutics-says-350-0-million-financing-restores-nasdaq/https://aibio.space/news/alaunos-therapeutics-says-350-0-million-financing-restores-nasdaq/Wed, 21 Oct 2026 12:00:00 GMTListingsAlaunos told the SEC on October 21, 2026 that it believes its $350.0 million financing restored compliance with Nasdaq's $2,500,000 equity rule. The same filing says Nasdaq may not agree, and a November 10 hearing was still set.Alaunos Therapeutics, Inc. 8-K (2026-10-21) https://aibio.space/news/disc-medicine-raises-450-million-75-share-after-phase-3-win/https://aibio.space/news/disc-medicine-raises-450-million-75-share-after-phase-3-win/Tue, 20 Oct 2026 12:00:00 GMTFinancingsThe upsized offering funds a planned bitopertin launch. Disc says cash plus proceeds lasts into 2030 and had an estimated $682.8 million before the deal.Disc Medicine (SEC Form 8-K exhibit) https://aibio.space/news/quoin-publishes-peer-reviewed-paper-qrx003-netherton-syndrome/https://aibio.space/news/quoin-publishes-peer-reviewed-paper-qrx003-netherton-syndrome/Tue, 20 Oct 2026 12:00:00 GMTCompany UpdatesThe paper, published online on October 13, 2026, includes a pediatric compassionate-use case report. Quoin also described interim results from its Phase 2/3 study.Quoin Pharmaceuticals, Ltd. 8-K (2026-10-20) https://aibio.space/news/premier-air-charters-chief-financial-officer-resigns-ceo-named-interim/https://aibio.space/news/premier-air-charters-chief-financial-officer-resigns-ceo-named-interim/Tue, 20 Oct 2026 12:00:00 GMTCompany UpdatesMatt Aune resigned as chief financial officer on October 19, 2026, and the board named Sandra J. Bonar interim principal financial officer effective October 20, 2026.Premier Air Charter Holdings Inc. 8-K (2026-10-23) https://aibio.space/news/surrozen-closes-second-tranche-march-2025-private-placement-about-95-1/https://aibio.space/news/surrozen-closes-second-tranche-march-2025-private-placement-about-95-1/Tue, 20 Oct 2026 12:00:00 GMTFinancingsSurrozen sold 5,741,605 shares, pre-funded warrants and Series E warrants after FDA cleared its SZN-8141 IND application. It expects its cash, cash equivalents and marketable securities to last into 2029.Surrozen, Inc./DE Form 8-K filed October 20, 2026 (SEC EDGAR) https://aibio.space/news/lifecore-reports-july-hearing-securities-class-action-settlement/https://aibio.space/news/lifecore-reports-july-hearing-securities-class-action-settlement/Tue, 20 Oct 2026 12:00:00 GMTLegalCarew v. Lifecore Biomedical names the company and unnamed executive officers. The final approval hearing was held on July 28, 2026. A separate New York suit by 22NW Fund continues against the company.Lifecore Biomedical 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/fifth-circuit-vacates-class-certification-filana-securities-class/https://aibio.space/news/fifth-circuit-vacates-class-certification-filana-securities-class/Tue, 20 Oct 2026 12:00:00 GMTLegalThe appeals court sent the Texas case back for new class certification proceedings. A $31.25 million settlement was filed in June, and Remi Barbier and Lindsay Burns, named in the 10-Q, are not parties to it.Filana Therapeutics 8-K, Oct 20, 2026 (SEC EDGAR) https://aibio.space/news/bioatla-signs-40-0-million-standby-equity-deal-yorkville/https://aibio.space/news/bioatla-signs-40-0-million-standby-equity-deal-yorkville/Tue, 20 Oct 2026 12:00:00 GMTFinancingsBioAtla can sell up to $40.0 million of stock to Yorkville over 36 months, but its cash was $1.5 million at June 30, 2026, and its prior $15.0 million line raised about $0.4 million.BioAtla, Inc. 8-K (2026-10-20) https://aibio.space/news/indaptus-therapeutics-closes-24-0-million-private-placement-20-338-974/https://aibio.space/news/indaptus-therapeutics-closes-24-0-million-private-placement-20-338-974/Tue, 20 Oct 2026 12:00:00 GMTFinancingsIndaptus sold 20,338,974 shares for approximately $24.0 million after the closing date was pushed back. Its cash was $7.6 million at June 30, 2026, and its 2025 net loss was $20.8 million.Indaptus Therapeutics, Inc. 8-K (2026-10-20) https://aibio.space/news/surrozen-closes-95-1-million-second-tranche-march-2025-private/https://aibio.space/news/surrozen-closes-95-1-million-second-tranche-march-2025-private/Tue, 20 Oct 2026 12:00:00 GMTFinancingsThe second tranche brought in about $95.1 million gross, before placement agent fees, and the company expects cash to last into 2029. The first patient in its SZN-8141 trial is not expected to be dosed until the fourth quarter of 2026, after a rival Wnt drug met its primary endpoint in a Phase 2b/3 trial in the same eye disease.Surrozen, Inc. 8-K (2026-10-20) https://aibio.space/news/alpha-teknova-launches-stock-offering-then-prices-8-000-000-shares-5/https://aibio.space/news/alpha-teknova-launches-stock-offering-then-prices-8-000-000-shares-5/Tue, 20 Oct 2026 12:00:00 GMTFinancingsThe offering totals $40,000,000 at the public offering price, with $37,600,000 to Teknova before expenses. Underwriters have a 30-day option to buy up to 1,200,000 more shares.Alpha Teknova, Inc. 424B5 (2026-10-21) https://aibio.space/news/merck-kgaa-agrees-buy-silence-therapeutics-20-ads-get-pv-drug/https://aibio.space/news/merck-kgaa-agrees-buy-silence-therapeutics-20-ads-get-pv-drug/Mon, 19 Oct 2026 12:00:00 GMTMergersThe all-cash deal values Silence at about $1.1 billion in enterprise value, an 82% premium to its 30-day average price. Closing is expected in the first quarter of 2027.BioSpace https://aibio.space/news/eyepoint-cuts-about-half-staff-after-second-duravyu-wet-amd-phase-3/https://aibio.space/news/eyepoint-cuts-about-half-staff-after-second-duravyu-wet-amd-phase-3/Mon, 19 Oct 2026 12:00:00 GMTDistressLucia missed its non-inferiority goal against Eylea. EyePoint will end both wet AMD trials early and put its cash behind two diabetic macular edema studies due in late 2027.BioSpace https://aibio.space/news/cosmos-health-expects-fourth-quarter-u-s-revenue-about-15-million/https://aibio.space/news/cosmos-health-expects-fourth-quarter-u-s-revenue-about-15-million/Mon, 19 Oct 2026 12:00:00 GMTCompany UpdatesCosmos Health said active U.S. subscriptions reached 8,940 as of October 19, 2026. It expects fourth-quarter U.S. revenue of approximately $15 million and gross profit of approximately $10.5 million. The figures are preliminary and unaudited.Cosmos Health press release (Form 8-K, Exhibit 99.1) https://aibio.space/news/two-polomar-health-directors-resign-leaving-three-board/https://aibio.space/news/two-polomar-health-directors-resign-leaving-three-board/Mon, 19 Oct 2026 12:00:00 GMTCompany UpdatesAlexandra Peterson and Gabrielle Toledano resigned effective October 14, 2026, and the board reduced its size from five to three. The board has not decided whether to fill the vacancies.Polomar Health Services, Inc. 8-K (2026-10-19) https://aibio.space/news/silexion-adjourns-vote-500-million-new-shares-reverse-split-october-26/https://aibio.space/news/silexion-adjourns-vote-500-million-new-shares-reverse-split-october-26/Mon, 19 Oct 2026 12:00:00 GMTListingsThe company says it needs both measures to protect its Nasdaq listing, with 14,473,292 shares already outstanding against 15,900,000 authorized. Shareholders rejected smaller versions in September.SEC EDGAR: Silexion DEFA14A https://aibio.space/news/integra-lifesciences-sells-450-million-9-500-percent-senior-secured/https://aibio.space/news/integra-lifesciences-sells-450-million-9-500-percent-senior-secured/Mon, 19 Oct 2026 12:00:00 GMTDebt FinancingIntegra refinanced a $1.3 billion revolver and a $775 million term loan with $450 million of 9.500% notes due 2033 and a $1.65 billion credit agreement, after reporting a 2025 net loss of $516.5 million.INTEGRA LIFESCIENCES HOLDINGS CORP Form 8-K filed October 19, 2026 (SEC EDGAR) https://aibio.space/news/curanex-discloses-two-new-york-class-actions-tied-august-2025-ipo/https://aibio.space/news/curanex-discloses-two-new-york-class-actions-tied-august-2025-ipo/Mon, 19 Oct 2026 12:00:00 GMTLegalCuranex Pharmaceuticals is a defendant, with underwriters Dominari Securities LLC, Pacific Century Securities, LLC and Revere Securities LLC, in two New York class actions over its August 2025 IPO. Both suits allege Securities Act violations in the offering documents.Curanex Pharmaceuticals 8-K (SEC EDGAR) https://aibio.space/news/collegium-settles-grunenthal-patent-suit-nucynta-er-generic-17-000-000/https://aibio.space/news/collegium-settles-grunenthal-patent-suit-nucynta-er-generic-17-000-000/Mon, 19 Oct 2026 12:00:00 GMTLegalThe drugmaker ends its Nucynta license and royalties with Grünenthal and gets certain patents assigned to it. Grünenthal has filed a motion to dismiss the New Jersey case.Collegium Pharmaceutical 8-K, Oct 19, 2026 (SEC EDGAR) https://aibio.space/news/ultragenyx-baylor-settle-dojolvi-patent-litigation-navinta-generic/https://aibio.space/news/ultragenyx-baylor-settle-dojolvi-patent-litigation-navinta-generic/Mon, 19 Oct 2026 12:00:00 GMTLegalThe 8-K says the New Jersey case followed Navinta's generic application. Navinta gets a royalty-free license from January 1, 2033; suits against other filers continue.Ultragenyx Pharmaceutical 8-K (SEC EDGAR) https://aibio.space/news/collegium-pays-grunenthal-17-000-000-settle-nucynta-suit-end-license/https://aibio.space/news/collegium-pays-grunenthal-17-000-000-settle-nucynta-suit-end-license/Mon, 19 Oct 2026 12:00:00 GMTDistressCollegium will pay Grünenthal $17,000,000 to end a February 2026 patent suit and a Nucynta license that carried royalties. The 8-K does not say what those royalties cost the company.Collegium Pharmaceutical, Inc. 8-K (2026-10-19) https://aibio.space/news/curis-agrees-sell-stock-warrants-about-8-5-million-gross-proceeds/https://aibio.space/news/curis-agrees-sell-stock-warrants-about-8-5-million-gross-proceeds/Mon, 19 Oct 2026 12:00:00 GMTFinancingsCuris sold shares and pre-funded warrants at an effective $0.51 a share, with common warrants at $0.60. A.G.P./Alliance Global Partners, the lead placement agent, earns a 6.5% cash fee on the gross proceeds.Curis, Inc. 8-K (2026-10-19) https://aibio.space/news/dogwood-therapeutics-agrees-sell-5-million-stock-top-holder-ck-life/https://aibio.space/news/dogwood-therapeutics-agrees-sell-5-million-stock-top-holder-ck-life/Mon, 19 Oct 2026 12:00:00 GMTFinancingsDogwood will issue 4,098,360 shares at $1.22 each, with no warrants, in a deal expected to close by October 29, 2026. The company says the proceeds extend its runway through March 2027, after cash of $9.6 million at June 30, 2026.Dogwood Therapeutics, Inc. 8-K (2026-10-19) https://aibio.space/news/os-therapies-gets-7-2-million-gross-initial-warrant-inducement-closing/https://aibio.space/news/os-therapies-gets-7-2-million-gross-initial-warrant-inducement-closing/Mon, 19 Oct 2026 12:00:00 GMTFinancingsOS Therapies raised $7.2 million gross in the first closing of a warrant inducement, but the holders who exercised received new warrants for the same number of shares at $1.40, and the company reported only $205,035 in cash at June 30, 2026.OS Therapies Incorporated 8-K (2026-10-19) https://aibio.space/news/city-therapeutics-raises-200-million-upsized-ipo-priced-18/https://aibio.space/news/city-therapeutics-raises-200-million-upsized-ipo-priced-18/Fri, 16 Oct 2026 12:00:00 GMTFinancingsThe Cambridge RNAi developer sold 11.1 million shares at the midpoint of its range. Its lead drug, a Factor XI siRNA for blood clots, has more phase 1 data due in late 2026.Renaissance Capital https://aibio.space/news/fractyl-shares-fall-48-percent-even-revita-meets-six-month-remain-1/https://aibio.space/news/fractyl-shares-fall-48-percent-even-revita-meets-six-month-remain-1/Fri, 16 Oct 2026 12:00:00 GMTDistressPatients kept about 80% of their tirzepatide weight loss after one Revita procedure versus 67% after sham. Fractyl plans a De Novo filing in late fourth quarter 2026.RTTNews https://aibio.space/news/vivosim-amends-organovo-lease-giving-up-part-san-diego-office/https://aibio.space/news/vivosim-amends-organovo-lease-giving-up-part-san-diego-office/Fri, 16 Oct 2026 12:00:00 GMTCompany UpdatesOrganovo, a VivoSim subsidiary, agreed on October 13, 2026 to vacate Suite 202 by February 28, 2027, extend Suite 100 through April 30, 2028 and receive a partial rent abatement.VivoSim Labs, INC. 8-K (2026-10-16) https://aibio.space/news/tenon-medical-obtains-investor-waiver-increase-market-sales/https://aibio.space/news/tenon-medical-obtains-investor-waiver-increase-market-sales/Fri, 16 Oct 2026 12:00:00 GMTFinancingsThe investor waived limits that would have blocked a larger at-the-market offering, in exchange for a new warrant at $5.02 per share. WallachBeth Capital LLC also waived its rights under the sales agreement.Tenon Medical, Inc. 8-K (2026-10-22) https://aibio.space/news/china-resources-pharmaceutical-unit-issues-rmb900-million-corporate/https://aibio.space/news/china-resources-pharmaceutical-unit-issues-rmb900-million-corporate/Fri, 16 Oct 2026 12:00:00 GMTDebt FinancingA wholly owned subsidiary completed the second tranche of its 2026 corporate bonds in the PRC, RMB900 million at 1.48% per annum over three years.China Resources Pharmaceutical Group Limited announcement (2026-10-16) https://aibio.space/news/mimedx-sanara-medtech-receive-ftc-second-request-merger/https://aibio.space/news/mimedx-sanara-medtech-receive-ftc-second-request-merger/Fri, 16 Oct 2026 12:00:00 GMTMergersThe request extends the antitrust waiting period until 30 days after the companies substantially comply. MiMedx says it is working constructively with the FTC.MIMEDX GROUP, INC. Form 8-K filed October 16, 2026 (SEC EDGAR) https://aibio.space/news/alector-prices-75-030-000-stock-offering-2-05-above-prior-close/https://aibio.space/news/alector-prices-75-030-000-stock-offering-2-05-above-prior-close/Fri, 16 Oct 2026 12:00:00 GMTFinancingsAlector priced 36,600,000 shares at $2.05 for $75,030,000 gross. Its 2025 revenue fell to $21.0 million and cash used in operations was $184.0 million, against $59.9 million of cash on June 30, 2026.Alector, Inc. 8-K (2026-10-16) https://aibio.space/news/clearmind-medicine-sell-2-000-000-convertible-notes-1-800-000-cash/https://aibio.space/news/clearmind-medicine-sell-2-000-000-convertible-notes-1-800-000-cash/Fri, 16 Oct 2026 12:00:00 GMTDebt FinancingThe sale draws on an agreement allowing up to $10,000,000 of convertible promissory notes. The company expects it to close on or before October 19, 2026.Clearmind Medicine Inc. 6-K (2026-10-16) https://aibio.space/news/maze-therapeutics-swaps-2-776-007-frazier-held-shares-pre-funded/https://aibio.space/news/maze-therapeutics-swaps-2-776-007-frazier-held-shares-pre-funded/Fri, 16 Oct 2026 12:00:00 GMTFinancingsThe exchange leaves Maze with 53,931,889 shares of common stock outstanding as of October 16, 2026.Maze Therapeutics, Inc. 8-K (2026-10-16) https://aibio.space/news/mimedx-sanara-receive-ftc-second-request-proposed-merger/https://aibio.space/news/mimedx-sanara-receive-ftc-second-request-proposed-merger/Fri, 16 Oct 2026 12:00:00 GMTMergersThe request extends the antitrust waiting period until 30 days after the companies substantially comply. MiMedx says it is working constructively with the FTC.MiMedx Group, Inc. 8-K (2026-10-16) https://aibio.space/news/recursion-raises-200-million-3-25-share-sanofi-options-first-candidate/https://aibio.space/news/recursion-raises-200-million-3-25-share-sanofi-options-first-candidate/Thu, 15 Oct 2026 12:00:00 GMTFinancingsThe company says cash now lasts into 2029. Sanofi's option on an inflammatory disease molecule triggered a $10 million milestone.Recursion Pharmaceuticals (SEC 8-K) https://aibio.space/news/adial-adjourns-annual-meeting-again-nasdaq-approval-pending/https://aibio.space/news/adial-adjourns-annual-meeting-again-nasdaq-approval-pending/Thu, 15 Oct 2026 12:00:00 GMTCompany UpdatesAdial reconvened its 2026 Annual Meeting on October 15, 2026 for four proposals and adjourned it a second time to October 26, 2026, while its Nasdaq listing application remains without approval.Adial Pharmaceuticals, Inc 8-K (2026-10-16) https://aibio.space/news/velocity-bioworks-completes-nmr-feasibility-test-larmorbio/https://aibio.space/news/velocity-bioworks-completes-nmr-feasibility-test-larmorbio/Thu, 15 Oct 2026 12:00:00 GMTCompany UpdatesValion's CDMO unit finished an initial evaluation of LarmorBio's BioScan-NMR platform for continuous bioprocess monitoring.Valion Bio, Inc. 8-K (2026-10-15) https://aibio.space/news/profusa-issues-769-230-77-secured-convertible-note-ascent-partners/https://aibio.space/news/profusa-issues-769-230-77-secured-convertible-note-ascent-partners/Thu, 15 Oct 2026 12:00:00 GMTDebt FinancingThe note carries 7% interest, converts at $4.28 a share and matures in October 2027.SEC EDGAR Form 8-K https://aibio.space/news/osr-health-amends-vxm01-license-allow-up-15-000-000-convertible-notes/https://aibio.space/news/osr-health-amends-vxm01-license-allow-up-15-000-000-convertible-notes/Thu, 15 Oct 2026 12:00:00 GMTDebt FinancingUnder an amended license with BCM Europe AG, OSR Health can elect to take up to $15,000,000 of convertible notes in place of an equity purchase option.OSR Health, Inc. 8-K (2026-10-16) https://aibio.space/news/rallybio-holders-own-2-8-percent-combined-company-avenzo-reverse/https://aibio.space/news/rallybio-holders-own-2-8-percent-combined-company-avenzo-reverse/Thu, 15 Oct 2026 12:00:00 GMTMergersRallybio's holders would keep 2.8% of the merged company, while Avenzo's holders would own 56.6% and investors in a $215.0 million financing 40.6%. Rallybio stockholders vote on the deal on November 4.Rallybio Form 424B3 proxy statement/prospectus (SEC) https://aibio.space/news/supernus-inherits-sage-securities-class-action-derivative-suits-sec/https://aibio.space/news/supernus-inherits-sage-securities-class-action-derivative-suits-sec/Thu, 15 Oct 2026 12:00:00 GMTLegalSupernus (Nasdaq: SUPN) took on Sage's New York class action naming Barry Greene and Kimi Iguchi, three derivative suits against sixteen unnamed insiders, and an SEC subpoena. Supernus faces two merger suits of its own.Supernus Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/actinium-securities-class-action-dismissed-prejudice-plaintiffs-file/https://aibio.space/news/actinium-securities-class-action-dismissed-prejudice-plaintiffs-file/Thu, 15 Oct 2026 12:00:00 GMTLegalThe case names Actinium and executives Sandesh Seth, Avinash Desai, Madhuri Vusirikala and Sergio Giralt. Four derivative suits against directors and officers follow the same allegations.Actinium Pharmaceuticals definitive proxy statement filed October 15, 2026 (SEC EDGAR) https://aibio.space/news/jasper-therapeutics-faced-oct-15-hearing-motion-dismiss-briquilimab/https://aibio.space/news/jasper-therapeutics-faced-oct-15-hearing-motion-dismiss-briquilimab/Thu, 15 Oct 2026 12:00:00 GMTLegalDefendants: Jasper and unnamed current and former officers; derivative suits are captioned against Martell and others. A motion to dismiss was set for hearing October 15, and no ruling is reported.Jasper Therapeutics 10-Q (SEC EDGAR) https://aibio.space/news/sangamos-nasdaq-delisting-becomes-final-chapter-11-case-continues/https://aibio.space/news/sangamos-nasdaq-delisting-becomes-final-chapter-11-case-continues/Thu, 15 Oct 2026 12:00:00 GMTListingsNasdaq filed Form 25 on Oct. 7, ending a listing that began unravelling over the minimum bid price. The stock trades OTC as SGMOQ after Sangamo agreed to sell its Fabry program to PTC for $111 million in cash.SEC EDGAR, Sangamo Therapeutics Form 8-K https://aibio.space/news/aditxt-unit-ignite-proteomics-copley-acquisition-corp-end-spac-merger/https://aibio.space/news/aditxt-unit-ignite-proteomics-copley-acquisition-corp-end-spac-merger/Thu, 15 Oct 2026 12:00:00 GMTMergersAditxt's subsidiary Ignite Proteomics and the blank-check company Copley Acquisition Corp ended their June 2026 business combination agreement on October 9, 2026. Each side bears its own expenses, and the 8-K gives no reason for the termination.Aditxt, Inc. 8-K (2026-10-15) https://aibio.space/news/alx-oncology-swaps-13-353-384-shares-pre-funded-warrants-investors/https://aibio.space/news/alx-oncology-swaps-13-353-384-shares-pre-funded-warrants-investors/Thu, 15 Oct 2026 12:00:00 GMTFinancingsALX Oncology's exchange trades 13,353,384 common shares for pre-funded warrants with a $0.001 exercise price, and the 8-K describes no cash payment to the company.ALX Oncology Holdings Inc. 8-K (2026-10-15) https://aibio.space/news/evofem-biosciences-pushes-adjuvant-note-maturity-december-1-2026/https://aibio.space/news/evofem-biosciences-pushes-adjuvant-note-maturity-december-1-2026/Thu, 15 Oct 2026 12:00:00 GMTFinancingsEvofem moved the maturity of convertible notes held by Adjuvant to December 1, 2026, and removed some affirmative covenants. The 8-K gives no repayment plan, and the company's year-end cash was $578,000.Evofem Biosciences, Inc. 8-K (2026-10-15) https://aibio.space/news/iambic-therapeutics-prices-ipo-9-375-000-shares-16-00/https://aibio.space/news/iambic-therapeutics-prices-ipo-9-375-000-shares-16-00/Thu, 15 Oct 2026 12:00:00 GMTFinancingsThe offering totals $150,000,000 before fees. The stock has been approved for listing on the Nasdaq Global Select Market under the symbol IAM.Iambic Therapeutics, Inc. 424B4 (2026-10-15) https://aibio.space/news/mustang-bio-gets-second-180-day-nasdaq-grace-period-fix-bid-price/https://aibio.space/news/mustang-bio-gets-second-180-day-nasdaq-grace-period-fix-bid-price/Thu, 15 Oct 2026 12:00:00 GMTListingsNasdaq gave Mustang Bio until April 12, 2027 to lift its bid price to $1.00. The company has said it intends to do a reverse stock split if necessary.Mustang Bio, Inc. 8-K (2026-10-15) https://aibio.space/news/first-tracks-biotherapeutics-agrees-sell-6-106-870-shares-32-75-about/https://aibio.space/news/first-tracks-biotherapeutics-agrees-sell-6-106-870-shares-32-75-about/Thu, 15 Oct 2026 12:00:00 GMTFinancingsThe company expects approximately $200 million in gross proceeds before fees and expenses. In a later filing it said the placement closed on October 19, 2026.First Tracks Biotherapeutics, Inc. 8-K (2026-10-15) https://aibio.space/news/ultragenyx-agrees-transfer-two-priority-review-vouchers-413-million/https://aibio.space/news/ultragenyx-agrees-transfer-two-priority-review-vouchers-413-million/Wed, 14 Oct 2026 12:00:00 GMTFinancingsThe company will receive $210 million and $203 million in cash, subject to antitrust clearance. The NIH is owed 20% of the first sale.SEC Form 8-K, Ultragenyx https://aibio.space/news/aibotics-completes-purchase-playjamaica-robotics-drone-assets/https://aibio.space/news/aibotics-completes-purchase-playjamaica-robotics-drone-assets/Wed, 14 Oct 2026 12:00:00 GMTMergersAibotics signed an asset purchase agreement with PlayJamaica Limited on October 12, 2026, and completed the acquisition on October 14, issuing 22,500 shares of Series B Preferred Stock.AIBOTICS, INC. 8-K (2026-10-16) https://aibio.space/news/ema-grants-orphan-drug-designation-qrx003-peeling-skin-syndrome/https://aibio.space/news/ema-grants-orphan-drug-designation-qrx003-peeling-skin-syndrome/Wed, 14 Oct 2026 12:00:00 GMTCompany UpdatesThe designation is the eighth regulatory milestone for QRX003, according to the company. If QRX003 is approved in the EU, it would receive 10 years of market exclusivity.Quoin Pharmaceuticals, Ltd. 8-K (2026-10-14) https://aibio.space/news/aptevo-present-cd40-multispecific-platform-data-sitc-2026/https://aibio.space/news/aptevo-present-cd40-multispecific-platform-data-sitc-2026/Wed, 14 Oct 2026 12:00:00 GMTCompany UpdatesAptevo will present its CD40-directed multispecific portfolio at the Society for Immunotherapy of Cancer annual meeting in Phoenix, November 4 to 8, 2026.Aptevo Therapeutics Inc. 8-K (2026-10-14) https://aibio.space/news/mannatech-says-regained-nasdaq-stockholders-equity-compliance/https://aibio.space/news/mannatech-says-regained-nasdaq-stockholders-equity-compliance/Wed, 14 Oct 2026 12:00:00 GMTListingsMannatech said a Swiss holding company transaction and a pro forma tax adjustment put it back above Nasdaq's stockholders' equity minimum, subject to review and to Nasdaq's view.MANNATECH INC 8-K (2026-10-14) https://aibio.space/news/interpace-biosciences-expects-third-quarter-revenue-10-1-million-10-4/https://aibio.space/news/interpace-biosciences-expects-third-quarter-revenue-10-1-million-10-4/Wed, 14 Oct 2026 12:00:00 GMTCompany UpdatesThe preliminary, unaudited range is approximately 11% to 14% above the second quarter of 2026 and approximately 15% to 18% above the third quarter of 2025.Form 8-K, Exhibit 99.1 (SEC EDGAR) https://aibio.space/news/liquidia-settles-all-patent-trade-secret-litigation-united/https://aibio.space/news/liquidia-settles-all-patent-trade-secret-litigation-united/Wed, 14 Oct 2026 12:00:00 GMTLegalThe 8-K lists a net $175.0 million payment to UTC, a further $145.4 million in installments, and a YUTREPIA label change removing PH-ILD. Three parties are also paid to end the RareGen case, and one of them is a related party.Liquidia Corporation 8-K filed October 14, 2026 (SEC EDGAR) https://aibio.space/news/xeris-sues-torrent-rising-others-new-jersey-generic-keveyis-patent/https://aibio.space/news/xeris-sues-torrent-rising-others-new-jersey-generic-keveyis-patent/Wed, 14 Oct 2026 12:00:00 GMTLegalXeris Biopharma's subsidiary filed two patent infringement suits on October 13 after a new Keveyis patent was granted. The 8-K names seven defendants.Xeris Biopharma Holdings 8-K (SEC EDGAR) https://aibio.space/news/eton-pharmaceuticals-pays-10-0-million-upfront-us-rights-aquestives/https://aibio.space/news/eton-pharmaceuticals-pays-10-0-million-upfront-us-rights-aquestives/Wed, 14 Oct 2026 12:00:00 GMTMergersMilestones could add up to $47.5 million, plus royalties at a mid-teens percentage of net sales. The product has tentative FDA approval only, and Aquestive will be its exclusive manufacturer under a 20-year supply agreement.Eton Pharmaceuticals, Inc. 8-K (2026-10-14) https://aibio.space/news/immutep-ltd-regains-nasdaq-bid-price-compliance-after-ads-ratio-change/https://aibio.space/news/immutep-ltd-regains-nasdaq-bid-price-compliance-after-ads-ratio-change/Wed, 14 Oct 2026 12:00:00 GMTListingsNasdaq confirmed on October 12, 2026 that the matter is closed. The company changed its ADS ratio from 10 to 200 ordinary shares effective September 28, 2026.Immutep Ltd 6-K (2026-10-14) https://aibio.space/news/liquidia-pay-net-175-million-global-settlement-united-therapeutics/https://aibio.space/news/liquidia-pay-net-175-million-global-settlement-united-therapeutics/Wed, 14 Oct 2026 12:00:00 GMTDistressThe deal ends six lawsuits. Liquidia also owes $145.4 million in two installments due in 2027 and $60.3 million to other parties this month.Liquidia Corporation 8-K (2026-10-14) https://aibio.space/news/silo-pharma-issues-150-000-shares-buy-software-intellectual-property/https://aibio.space/news/silo-pharma-issues-150-000-shares-buy-software-intellectual-property/Wed, 14 Oct 2026 12:00:00 GMTFinancingsSilo Pharma agreed on October 13, 2026 to buy certain software and related intellectual property from Larry King in exchange for 150,000 shares of common stock. The shares are locked up for up to twelve months, and the 8-K names no underwriter or placement agent.Silo Pharma, Inc. 8-K (2026-10-14) https://aibio.space/news/vir-biotechnology-agrees-sell-gilead-1-765-486-shares-about-25-million/https://aibio.space/news/vir-biotechnology-agrees-sell-gilead-1-765-486-shares-about-25-million/Wed, 14 Oct 2026 12:00:00 GMTFinancingsThe stock purchase comes with a collaboration to engineer three T-cell engager candidates for solid tumors. Closing is subject to customary conditions.Vir Biotechnology, Inc. 8-K (2026-10-14) https://aibio.space/news/metavia-appoints-sarah-browne-chief-medical-officer/https://aibio.space/news/metavia-appoints-sarah-browne-chief-medical-officer/Tue, 13 Oct 2026 12:00:00 GMTCompany UpdatesSarah Browne, M.D., joins MetaVia as Chief Medical Officer effective October 12, 2026, ahead of the fourth quarter 2026 topline readout from Part 3 of the DA-1726 Phase 1 trial.MetaVia Inc. 8-K (2026-10-13) https://aibio.space/news/bluejay-completes-toray-manufacturing-site-ahead-deadline/https://aibio.space/news/bluejay-completes-toray-manufacturing-site-ahead-deadline/Tue, 13 Oct 2026 12:00:00 GMTCompany UpdatesBluejay Diagnostics said it finished establishing a Symphony cartridge manufacturing site under its amended Toray license, ahead of an October 23, 2026 deadline.Bluejay Diagnostics, Inc. 8-K (2026-10-13) https://aibio.space/news/logicmark-completes-merger-holders-receive-1-31-share-cash/https://aibio.space/news/logicmark-completes-merger-holders-receive-1-31-share-cash/Tue, 13 Oct 2026 12:00:00 GMTMergersThe merger with Langham Merger Sub took effect on October 13, 2026, and LogicMark is now a wholly owned subsidiary of Langham Project LLC.LogicMark, Inc. 8-K (2026-10-13) https://aibio.space/news/phio-completes-first-commercial-scale-cgmp-batch-ph-762-drug-substance/https://aibio.space/news/phio-completes-first-commercial-scale-cgmp-batch-ph-762-drug-substance/Tue, 13 Oct 2026 12:00:00 GMTCompany UpdatesThe batch is a manufacturing milestone that supports the planned start of a Phase 2b trial in the first quarter of 2027. The company issued a press release announcing it on October 13, 2026.Phio Pharmaceuticals Corp. 8-K (2026-10-13) https://aibio.space/news/scienture-expects-preliminary-third-quarter-revenue-about-1-22-million/https://aibio.space/news/scienture-expects-preliminary-third-quarter-revenue-about-1-22-million/Tue, 13 Oct 2026 12:00:00 GMTCompany UpdatesPreliminary revenue rose 256% from the second quarter after the REZENOPY launch and higher Arbli wholesale unit sales. The figures are unaudited.Scienture Holdings, Inc. 8-K (2026-10-19) https://aibio.space/news/weird-science-demands-10-million-end-delaware-chancery-suit-other/https://aibio.space/news/weird-science-demands-10-million-end-delaware-chancery-suit-other/Tue, 13 Oct 2026 12:00:00 GMTLegalLunai's 10-K says the Oct 7 demand covers all pending litigation. The Chancery case alleges breach of a 2018 investor rights agreement, and mediation has not been scheduled.Lunai Bioworks 10-K for the fiscal year ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/adc-therapeutics-agrees-86-6-million-pipe-plans-loan-cut-50-0-million/https://aibio.space/news/adc-therapeutics-agrees-86-6-million-pipe-plans-loan-cut-50-0-million/Tue, 13 Oct 2026 12:00:00 GMTDebt FinancingADC Therapeutics agreed to an $86.6 million private placement and to cut its senior loan to $50.0 million, and its royalty holder gave up a $150 million change-of-control payment. The changes depend on the placement closing, and expected cash at September 30, 2026 was $189.2 million, against $219.1 million at June 30.ADC Therapeutics SA 8-K (2026-10-13) https://aibio.space/news/cdt-equity-gets-3-000-000-first-tranche-6-750-000-convertible-note/https://aibio.space/news/cdt-equity-gets-3-000-000-first-tranche-6-750-000-convertible-note/Tue, 13 Oct 2026 12:00:00 GMTDebt FinancingThe first tranche brought in $3,000,000, with net proceeds of $2,869,850 after closing fees. The lender can convert at 70% of the lowest recent close, with a floor of $0.18354, and the company reported $747,000 of cash at June 30, 2026.CDT Equity Inc. 8-K (2026-10-13) https://aibio.space/news/cytomed-therapeutics-gets-nasdaq-bid-price-notice-has-until-april-5/https://aibio.space/news/cytomed-therapeutics-gets-nasdaq-bid-price-notice-has-until-april-5/Tue, 13 Oct 2026 12:00:00 GMTListingsNasdaq said the ordinary shares closed below US$1.00 for 30 consecutive business days. The letter has no current effect on the listing or trading.CytoMed Therapeutics Limited 6-K (2026-10-13) https://aibio.space/news/pulmatrix-stockholders-vote-october-26-2026-eos-senolytix-merger/https://aibio.space/news/pulmatrix-stockholders-vote-october-26-2026-eos-senolytix-merger/Tue, 13 Oct 2026 12:00:00 GMTMergersPulmatrix stockholders are due to vote October 26, 2026 on a merger with Eos SENOLYTIX, Inc., whose lead data so far are mouse studies. The filing gives no amount for the merger-associated financings it expects, and the company's cash was $2.2 million at June 30, 2026.Pulmatrix, Inc. 425 (2026-10-13) https://aibio.space/news/senti-biosciences-adjourns-annual-meeting-seek-more-votes-merger/https://aibio.space/news/senti-biosciences-adjourns-annual-meeting-seek-more-votes-merger/Tue, 13 Oct 2026 12:00:00 GMTMergersSenti adjourned its October 8, 2026 annual meeting without conducting any business to seek more votes for a merger proposal. The company reported $6.5 million of cash and cash equivalents at June 30, 2026, after using $43.4 million in operations in 2025.Senti Biosciences Holdings, Inc. 8-K (2026-10-13) https://aibio.space/news/alaunos-therapeutics-acquires-velaris-closes-350-million-private/https://aibio.space/news/alaunos-therapeutics-acquires-velaris-closes-350-million-private/Tue, 13 Oct 2026 12:00:00 GMTMergersAlaunos bought Velaris in a stock deal and closed a $350 million private placement led by Fairmount. Velaris has no product candidate tested in humans, and Alaunos had $124,000 in cash at June 30, 2026, according to its quarterly report.Alaunos Therapeutics, Inc. 8-K (2026-10-13) https://aibio.space/news/vaxcyte-raises-about-1-1-billion-stock-convertible-notes-after-phase-3/https://aibio.space/news/vaxcyte-raises-about-1-1-billion-stock-convertible-notes-after-phase-3/Fri, 09 Oct 2026 12:00:00 GMTFinancingsThe company sold shares at $64 and $575 million of 1.50% notes due 2032, adding to $2.5 billion it held at the end of June.Vaxcyte (SEC 8-K) https://aibio.space/news/integra-lifesciences-prices-450-000-000-senior-secured-notes/https://aibio.space/news/integra-lifesciences-prices-450-000-000-senior-secured-notes/Fri, 09 Oct 2026 12:00:00 GMTDebt FinancingThe 9.500% notes are due 2033 and will help refinance the company's existing credit facilities.SEC EDGAR filing https://aibio.space/news/tuhura-biosciences-draws-650-000-more-parkview-credit-line-2/https://aibio.space/news/tuhura-biosciences-draws-650-000-more-parkview-credit-line-2/Fri, 09 Oct 2026 12:00:00 GMTDebt FinancingTuHURA Biosciences borrowed an additional $650,000 under a revolving credit facility with Parkview Holdings One LLC on October 9, 2026. The facility has a maximum loan availability of $50 million.TuHURA Biosciences, Inc. 8-K (2026-10-16) https://aibio.space/news/ss-innovations-issues-21-025-000-00-secured-convertible-note/https://aibio.space/news/ss-innovations-issues-21-025-000-00-secured-convertible-note/Fri, 09 Oct 2026 12:00:00 GMTDebt FinancingGrowth Capital Partners, LLC is the lender. The note carries 8.75% interest, matures 36 months after the purchase price date and converts at 95% of a market price.SEC EDGAR filing https://aibio.space/news/co-diagnostics-issues-senior-secured-convertible-note-j-j-astor/https://aibio.space/news/co-diagnostics-issues-senior-secured-convertible-note-j-j-astor/Fri, 09 Oct 2026 12:00:00 GMTDebt FinancingThe note has an original principal amount of $2,835,000, repaid in weekly installments of $94,500. The final maturity date is May 7, 2027.Co-Diagnostics, Inc. 8-K (2026-10-13) https://aibio.space/news/co-diagnostics-takes-up-3-1-million-secured-convertible-loans/https://aibio.space/news/co-diagnostics-takes-up-3-1-million-secured-convertible-loans/Fri, 09 Oct 2026 12:00:00 GMTDebt FinancingJ.J. Astor & Co. is the lender. The initial note carries a $2.835 million principal amount, and the company says the proceeds will fund working capital.SEC filing (Form 8-K/A) https://aibio.space/news/passage-bio-holders-would-keep-about-6-percent-remix-reverse-merger/https://aibio.space/news/passage-bio-holders-would-keep-about-6-percent-remix-reverse-merger/Fri, 09 Oct 2026 12:00:00 GMTMergersThe amended deal, signed September 2, values Remix at $226.0 million against about $20.0 million for Passage Bio, with $100.0 million of concurrent financing. The final proxy was filed October 9.Passage Bio Form 424B3 proxy statement/prospectus (SEC) https://aibio.space/news/alaunos-therapeutics-gets-nasdaq-delisting-notice-under-2-500-000/https://aibio.space/news/alaunos-therapeutics-gets-nasdaq-delisting-notice-under-2-500-000/Fri, 09 Oct 2026 12:00:00 GMTListingsNasdaq staff told Alaunos on October 5, 2026 that its securities are subject to delisting under Listing Rule 5550(b)(1). The company plans to request a hearing and says it is working with a financial advisor on potential transactions.Alaunos Therapeutics, Inc. Form 8-K filed October 9, 2026 (SEC EDGAR) https://aibio.space/news/lunai-bioworks-cites-delaware-suit-against-seven-points-capital-nasdaq/https://aibio.space/news/lunai-bioworks-cites-delaware-suit-against-seven-points-capital-nasdaq/Fri, 09 Oct 2026 12:00:00 GMTLegalLunai's 8-K asks Nasdaq to suspend trading, citing records from its Delaware suit. A later 8-K says trading will be suspended on October 30 unless the company asks for a hearing, and it does not plan to ask.Lunai Bioworks 8-K filed October 9, 2026 (SEC EDGAR) https://aibio.space/news/artelo-biosciences-flags-exposure-nasdaqs-new-5-000-000-market-value/https://aibio.space/news/artelo-biosciences-flags-exposure-nasdaqs-new-5-000-000-market-value/Fri, 09 Oct 2026 12:00:00 GMTListingsArtelo was among about 180 Nasdaq companies first identified as below the new threshold. The company gives no market value figure, and the rule is on a temporary stay.Artelo Biosciences, Inc. 8-K (2026-10-09) https://aibio.space/news/retension-pharmaceuticals-prices-ipo-3-750-000-shares-12-00/https://aibio.space/news/retension-pharmaceuticals-prices-ipo-3-750-000-shares-12-00/Fri, 09 Oct 2026 12:00:00 GMTFinancingsThe offering totals $45,000,000 before fees. The prospectus discloses a restatement of 2025 financial statements, a material weakness in internal control and going concern doubt.Retension Pharmaceuticals, Inc. 424B4 (2026-10-09) https://aibio.space/news/trex-bio-prices-ipo-8-333-334-shares-14-00-each/https://aibio.space/news/trex-bio-prices-ipo-8-333-334-shares-14-00-each/Fri, 09 Oct 2026 12:00:00 GMTFinancingsTRex Bio priced 8,333,334 shares at $14.00 each, for $116,666,676 before underwriting fees. Eli Lilly, which paid the company a $55.0 million upfront in 2023, has indicated interest in buying shares, but the indication is not binding.TRex Bio, Inc. 424B4 (2026-10-09) https://aibio.space/news/revolution-medicines-borrows-250-0-million-under-royalty-pharma-loan/https://aibio.space/news/revolution-medicines-borrows-250-0-million-under-royalty-pharma-loan/Thu, 08 Oct 2026 12:00:00 GMTDebt FinancingRevolution Medicines borrowed $250.0 million on October 8, 2026, under a senior secured term loan with Royalty Pharma Development Funding, LLC. The loan carries a floating rate of three-month Term SOFR plus 5.75%.Revolution Medicines, Inc. 8-K (2026-10-13) https://aibio.space/news/x4-pharmaceuticals-replaces-loan-up-150-million-k2-facility/https://aibio.space/news/x4-pharmaceuticals-replaces-loan-up-150-million-k2-facility/Thu, 08 Oct 2026 12:00:00 GMTDebt FinancingThe first $80 million tranche repaid the prior loan in full, including $75 million of principal.X4 Pharmaceuticals, Inc. (2026-10-08) https://aibio.space/news/aquabounty-convert-all-preferred-stock-8-077-043-common-shares/https://aibio.space/news/aquabounty-convert-all-preferred-stock-8-077-043-common-shares/Thu, 08 Oct 2026 12:00:00 GMTFinancingsAquaBounty agreed on October 7, 2026 that all Series A and Series B preferred stock will convert into 8,077,043 common shares by October 30, 2026 at the latest, with the resale shares to be registered.AquaBounty Technologies, Inc. 8-K (2026-10-08) https://aibio.space/news/biodexa-changes-ads-ratio-400-ordinary-shares-one-eight-reverse-ads/https://aibio.space/news/biodexa-changes-ads-ratio-400-ordinary-shares-one-eight-reverse-ads/Thu, 08 Oct 2026 12:00:00 GMTListingsThe exchange is expected on or about October 26, 2026. Holders must surrender eight old ADSs for one new one, and the release gives no reason for the change.Biodexa Pharmaceuticals plc 6-K (2026-10-08) https://aibio.space/news/boundless-bio-files-s-4-serapha-merger-partner-later-reports-early/https://aibio.space/news/boundless-bio-files-s-4-serapha-merger-partner-later-reports-early/Thu, 08 Oct 2026 12:00:00 GMTMergersBoundless Bio filed a Form S-4 on October 8, 2026 for its merger with private Serapha Bio. The filing estimates about 8.6737 Boundless shares for each Serapha share before a planned reverse split, and expects existing Boundless holders to own about 3.8% of the combined company.Boundless Bio, Inc. S-4 (2026-10-08) https://aibio.space/news/viatris-agrees-acquire-pacira-biosciences-36-50-share-cash/https://aibio.space/news/viatris-agrees-acquire-pacira-biosciences-36-50-share-cash/Thu, 08 Oct 2026 12:00:00 GMTMergersViatris agreed to buy Pacira for $36.50 a share in cash, an equity value of $1.65 billion, through a tender offer and a second-step merger. The release states no premium to the recent share price.Pacira BioSciences, Inc. 8-K (2026-10-08) https://aibio.space/news/atrium-therapeutics-agrees-private-placement-about-50-million-7-93/https://aibio.space/news/atrium-therapeutics-agrees-private-placement-about-50-million-7-93/Thu, 08 Oct 2026 12:00:00 GMTFinancingsThe deal includes 5,170,384 shares and pre-funded warrants for up to 1,134,930 shares, with gross proceeds of approximately $50 million before placement agent fees. The company estimates the money and existing cash will fund operations through 2028, but the release gives no cash balance to test that estimate.Atrium Therapeutics, Inc. 8-K (2026-10-08) https://aibio.space/news/valion-bio-files-100-000-000-shelf-5-000-000-market-program/https://aibio.space/news/valion-bio-files-100-000-000-shelf-5-000-000-market-program/Thu, 08 Oct 2026 12:00:00 GMTFinancingsValion Bio filed a $100,000,000 shelf registration on October 7, 2026, and the same day agreed to sell 3i $50,000 of Series B preferred and warrants. The public float used for the shelf was based on a $7.75 price, while the last reported sale on October 5 was $2.48.Valion Bio, Inc. S-3 (2026-10-08) https://aibio.space/news/x4-pharmaceuticals-signs-up-150-million-senior-loan-k2-healthventures/https://aibio.space/news/x4-pharmaceuticals-signs-up-150-million-senior-loan-k2-healthventures/Thu, 08 Oct 2026 12:00:00 GMTDebt FinancingThe first $80 million tranche repaid $75 million of principal and fees owed under the prior loan. Another $70 million may be available at X4's request, subject to K2HV approval.X4 Pharmaceuticals, Inc. 8-K (2026-10-08) https://aibio.space/news/cero-agrees-sell-operating-unit-srx-global/https://aibio.space/news/cero-agrees-sell-operating-unit-srx-global/Wed, 07 Oct 2026 12:00:00 GMTDebt FinancingCERo Therapeutics Holdings agreed on October 6, 2026 to sell its operating subsidiary to SRX Global Inc. The buyer would discharge the Consolidated Note, which had an outstanding principal balance of $8,249,643.77.CERo Therapeutics Holdings, Inc. 8-K (2026-10-07) https://aibio.space/news/biorestorative-appoints-donald-j-currie-board/https://aibio.space/news/biorestorative-appoints-donald-j-currie-board/Wed, 07 Oct 2026 12:00:00 GMTCompany UpdatesThe board appointed Donald J. Currie as a Class I director on October 7, 2026 to fill the seat left by Katharyn Field, and named him to two committees.BioRestorative Therapies, Inc. 8-K (2026-10-09) https://aibio.space/news/bionexus-signs-exclusive-malaysian-healthcare-licence-cogniai/https://aibio.space/news/bionexus-signs-exclusive-malaysian-healthcare-licence-cogniai/Wed, 07 Oct 2026 12:00:00 GMTCompany UpdatesThe licence is payable in BioNexus shares, and closing remains subject to technology delivery and approvals.BioNexus Gene Lab Corp 8-K (2026-10-07) https://aibio.space/news/cosmos-health-reports-preliminary-nine-month-revenue-54-3-million/https://aibio.space/news/cosmos-health-reports-preliminary-nine-month-revenue-54-3-million/Wed, 07 Oct 2026 12:00:00 GMTCompany UpdatesCosmos Health said preliminary revenue for the nine months ended September 30, 2026 was approximately $54.3 million, up 19%. The company reaffirmed its outlook for full-year 2026 revenue of more than $90 million.Cosmos Health press release (Form 8-K, Exhibit 99.1) https://aibio.space/news/nexgel-sets-1-20-reverse-stock-split-effective-october-12-2026/https://aibio.space/news/nexgel-sets-1-20-reverse-stock-split-effective-october-12-2026/Wed, 07 Oct 2026 12:00:00 GMTListingsEvery 20 shares of common stock will combine into one share at 12:01 a.m. Eastern Time on October 12, 2026. The common stock will keep its Nasdaq Capital Market listing under NXGL with a new CUSIP.NEXGEL, INC. 8-K (2026-10-07) https://aibio.space/news/fibrobiologics-sells-1-200-000-convertible-debenture-peak-one/https://aibio.space/news/fibrobiologics-sells-1-200-000-convertible-debenture-peak-one/Wed, 07 Oct 2026 12:00:00 GMTDebt FinancingFibroBiologics sold a $1,200,000 convertible debenture to Peak One Opportunity Fund, L.P. for $1,020,000, an original issue discount of 15%. The debenture matures October 8, 2027 and converts only after a default, at $0.78 per share.FibroBiologics, Inc. 8-K (2026-10-08) https://aibio.space/news/envoy-medical-ends-atlas-spac-redemption-suit-delaware-no-payment/https://aibio.space/news/envoy-medical-ends-atlas-spac-redemption-suit-delaware-no-payment/Wed, 07 Oct 2026 12:00:00 GMTLegalAtlas Merchant Capital agreed to dismiss its Chancery Court claims with prejudice, the hearing health company says. Two former executives were also named as defendants.Envoy Medical 8-K, Oct 7, 2026 (SEC EDGAR) https://aibio.space/news/neogen-discloses-appeal-dismissed-michigan-securities-suit-two-related/https://aibio.space/news/neogen-discloses-appeal-dismissed-michigan-securities-suit-two-related/Wed, 07 Oct 2026 12:00:00 GMTLegalA federal court dismissed the Michigan class action with prejudice on August 10, 2026 and plaintiffs have appealed. A Minnesota Securities Act class action and a Michigan derivative suit remain pending.Neogen 10-Q for the quarter ended August 31, 2026 (SEC EDGAR) https://aibio.space/news/nasdaq-files-remove-aditxt-common-stock-listing/https://aibio.space/news/nasdaq-files-remove-aditxt-common-stock-listing/Wed, 07 Oct 2026 12:00:00 GMTListingsThe Nasdaq Stock Market has filed a Form 25 to remove Aditxt's common stock from listing, dated October 7, 2026. The form does not say why Nasdaq acted, and the company reported $268,852 of cash at March 31, 2026.Aditxt, Inc. 25-NSE (2026-10-07) https://aibio.space/news/jasper-therapeutics-offers-0-324-warrant-buy-back-up-12-345-707/https://aibio.space/news/jasper-therapeutics-offers-0-324-warrant-buy-back-up-12-345-707/Wed, 07 Oct 2026 12:00:00 GMTMergersJasper Therapeutics will pay $0.324 in cash per warrant for up to 12,345,707 warrants, about $4.0 million if all are tendered, and the offer runs until November 6, 2026.Jasper Therapeutics, Inc. 8-K (2026-10-07) https://aibio.space/news/redhill-biopharma-gets-180-more-days-nasdaq-bid-price-april-5-2027/https://aibio.space/news/redhill-biopharma-gets-180-more-days-nasdaq-bid-price-april-5-2027/Wed, 07 Oct 2026 12:00:00 GMTListingsNasdaq gave Redhill Biopharma until April 5, 2027 to regain the $1.00 minimum bid price, in a letter dated October 6, 2026. The American Depositary Shares keep trading on The Nasdaq Capital Market as RDHL, but the company's cash was last reported at $2.9 million in mid-2025.Redhill Biopharma Ltd. 6-K (2026-10-07) https://aibio.space/news/nasdaq-files-sec-notice-remove-sangamo-therapeutics-stock-listing/https://aibio.space/news/nasdaq-files-sec-notice-remove-sangamo-therapeutics-stock-listing/Wed, 07 Oct 2026 12:00:00 GMTListingsNasdaq signed the Form 25 itself on October 6, 2026, and the form gives no reason. Sangamo's latest annual report warned it might cease operations, liquidate or seek bankruptcy protection.Sangamo Therapeutics, Inc. 25-NSE (2026-10-07) https://aibio.space/news/vivosim-labs-stockholders-elect-two-directors-approve-split-range/https://aibio.space/news/vivosim-labs-stockholders-elect-two-directors-approve-split-range/Tue, 06 Oct 2026 12:00:00 GMTCompany UpdatesAt its September 30, 2026 annual meeting, VivoSim Labs stockholders elected Keith Murphy and Adam Stern and approved a reverse stock split range of 1-to-5 to 1-to-20.VivoSim Labs, INC. 8-K (2026-10-06) https://aibio.space/news/60-degrees-outlines-next-steps-after-babesiosis-hospital-study-interim/https://aibio.space/news/60-degrees-outlines-next-steps-after-babesiosis-hospital-study-interim/Tue, 06 Oct 2026 12:00:00 GMTCompany UpdatesAt an October 6, 2026 webinar, the company said 30 patients were enrolled in its hospital study and that it plans to complete the current dataset and move to unblinding.60 Degrees Pharmaceuticals, Inc. 8-K (2026-10-06) https://aibio.space/news/bluejay-reports-symon-ii-baseline-patient-characteristics/https://aibio.space/news/bluejay-reports-symon-ii-baseline-patient-characteristics/Tue, 06 Oct 2026 12:00:00 GMTCompany UpdatesThe preliminary analysis covers 777 evaluable patients with an overall 28-day mortality rate of approximately 18%. The company says the baseline data do not yet establish the test's performance.Bluejay Diagnostics, Inc. 8-K (2026-10-06) https://aibio.space/news/global-innovative-platforms-appoints-david-r-wells-fractional-chief/https://aibio.space/news/global-innovative-platforms-appoints-david-r-wells-fractional-chief/Tue, 06 Oct 2026 12:00:00 GMTCompany UpdatesWells takes the role effective October 1, 2026 under a services agreement with Atlas Bookkeeping, LLC, and becomes the company's principal financial and accounting officer.Form 8-K, Exhibit 99.1 (SEC EDGAR) https://aibio.space/news/kairos-pharma-reports-positive-interim-phase-2-data-env-105-prostate/https://aibio.space/news/kairos-pharma-reports-positive-interim-phase-2-data-env-105-prostate/Tue, 06 Oct 2026 12:00:00 GMTCompany UpdatesKairos Pharma says median progression-free survival was 17.7 months with ENV-105 plus apalutamide, compared with 2 months on apalutamide alone, and has changed the trial to enroll patients earlier.Kairos Pharma, Ltd. 8-K (2026-10-06) https://aibio.space/news/nomad-launches-26-stop-mobile-power-demonstration-tour/https://aibio.space/news/nomad-launches-26-stop-mobile-power-demonstration-tour/Tue, 06 Oct 2026 12:00:00 GMTCompany UpdatesNOMAD Power Solutions began a tour of its Voyager battery systems on October 6, 2026. Three regional roadshows run through November 16, with stops in the Mountain West, Northeast and Southwest.NOMAD POWER SOLUTIONS, INC. 8-K (2026-10-06) https://aibio.space/news/hepion-acquires-gravitas-life-sciences-related-party-deal/https://aibio.space/news/hepion-acquires-gravitas-life-sciences-related-party-deal/Tue, 06 Oct 2026 12:00:00 GMTMergersThe purchase closed October 6, 2026 for $2,000,000 in cash and 25,000,000 shares, and four directors have ties to the seller's group.Hepion Pharmaceuticals, Inc. 8-K (2026-10-09) https://aibio.space/news/adia-med-agrees-sell-30-percent-adia-labs-qcm-biologics-1-500-000/https://aibio.space/news/adia-med-agrees-sell-30-percent-adia-labs-qcm-biologics-1-500-000/Tue, 06 Oct 2026 12:00:00 GMTMergersThe buyer, run by David Konn, pays $1,000,000 in cash and signs a $500,000 note at 7% interest, secured by a pledge of the units.Adia Med, Inc. 8-K (2026-10-06) https://aibio.space/news/sonoma-pharmaceuticals-adopts-new-section-382-rights-agreement/https://aibio.space/news/sonoma-pharmaceuticals-adopts-new-section-382-rights-agreement/Tue, 06 Oct 2026 12:00:00 GMTCompany UpdatesThe board replaced an expiring rights agreement with one meant to protect net operating loss carryforwards, with rights tied to holders of record on October 13, 2026.Sonoma Pharmaceuticals, Inc. 8-K (2026-10-06) https://aibio.space/news/premier-air-charter-says-lessors-terminated-cj3-aircraft-leases/https://aibio.space/news/premier-air-charter-says-lessors-terminated-cj3-aircraft-leases/Tue, 06 Oct 2026 12:00:00 GMTDistressThe company did not cure asserted defaults, returned two Citation CJ3 aircraft on October 1, 2026, and lessors claim approximately $514,557 under the leases.Premier Air Charter Holdings Inc. 8-K (2026-10-13) https://aibio.space/news/vaxcyte-offers-500-000-000-1-50-percent-convertible-notes-due-2032/https://aibio.space/news/vaxcyte-offers-500-000-000-1-50-percent-convertible-notes-due-2032/Tue, 06 Oct 2026 12:00:00 GMTDebt FinancingVaxcyte is selling common stock and pre-funded warrants alongside $500,000,000 of convertible senior notes due 2032, a day after reporting Phase 3 data for VAX-31.Vaxcyte, Inc. 424B5 (2026-10-08) https://aibio.space/news/nuo-therapeutics-receives-325-000-second-funding-under-loan/https://aibio.space/news/nuo-therapeutics-receives-325-000-second-funding-under-loan/Tue, 06 Oct 2026 12:00:00 GMTDebt FinancingDirector Scott M. Pittman is among the lenders. The second notes carry 12% interest and mature December 31, 2028.SEC EDGAR Form 8-K https://aibio.space/news/rocket-pharmaceuticals-secures-credit-facility-up-150-million-hercules/https://aibio.space/news/rocket-pharmaceuticals-secures-credit-facility-up-150-million-hercules/Tue, 06 Oct 2026 12:00:00 GMTDebt FinancingHercules Capital is the lender. Rocket received $35 million at closing, reported no revenue in 2025 or 2024, and held $283.7 million in cash and investments at June 30, 2026.Rocket Pharmaceuticals, Inc. release (2026-10-06) https://aibio.space/news/caribou-explores-strategic-alternatives-ends-allogeneic-car-t-programs/https://aibio.space/news/caribou-explores-strategic-alternatives-ends-allogeneic-car-t-programs/Tue, 06 Oct 2026 12:00:00 GMTDistressThe Berkeley CRISPR company will discontinue vispa-cel and CB-011, cut staff and hire Wedbush. It had $113.8 million in cash on June 30 and expects $15 million to $19 million in restructuring costs.Caribou Biosciences (press release and SEC Form 8-K) https://aibio.space/news/beyondspring-completes-sale-subsidiary-holding-china-unit-bulin-non/https://aibio.space/news/beyondspring-completes-sale-subsidiary-holding-china-unit-bulin-non/Tue, 06 Oct 2026 12:00:00 GMTMergersBeyondSpring closed the sale of the holding company for its China unit, Bulin, on September 30, 2026. The buyer paid no cash at closing. It took on the China portion of the DUBLIN-4 Phase 3 trial in exchange, and BeyondSpring will receive the clinical data from that work.BeyondSpring Inc. Form 8-K filed October 6, 2026 (SEC EDGAR) https://aibio.space/news/inovio-faces-securities-class-action-five-derivative-suits-ino-3107/https://aibio.space/news/inovio-faces-securities-class-action-five-derivative-suits-ino-3107/Tue, 06 Oct 2026 12:00:00 GMTLegalInovio, CEO Jacqueline Shea and CFO Peter Kies are defendants in a Pennsylvania class action. Shea, Kies and seven directors are named in derivative suits. A lead plaintiff was appointed July 27, 2026.Inovio Pharmaceuticals, Inc. 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/beyondspring-sells-beyondspring-ltd-trial-data-rights-instead-cash/https://aibio.space/news/beyondspring-sells-beyondspring-ltd-trial-data-rights-instead-cash/Tue, 06 Oct 2026 12:00:00 GMTMergersBeyondSpring Inc. completed the sale of BeyondSpring Ltd. to Biolin Investment Limited on September 30, 2026. No cash changed hands. The company received a license to China trial data, a funding commitment from the buyer, and a clawback, and it gave up control of SEED Therapeutics.BeyondSpring, Inc. 8-K (2026-10-06) https://aibio.space/news/kyntra-bio-gets-nasdaq-delisting-determination-requests-hearing/https://aibio.space/news/kyntra-bio-gets-nasdaq-delisting-determination-requests-hearing/Tue, 06 Oct 2026 12:00:00 GMTListingsNasdaq staff said Kyntra Bio had not shown compliance with Listing Rule 5450(b) by the September 29, 2026 deadline. A hearing request keeps the stock trading for now.Kyntra Bio, Inc. 8-K (2026-10-06) https://aibio.space/news/rocket-pharmaceuticals-secures-credit-facility-up-150-million-hercules/https://aibio.space/news/rocket-pharmaceuticals-secures-credit-facility-up-150-million-hercules/Tue, 06 Oct 2026 12:00:00 GMTDebt FinancingRocket Pharmaceuticals received $35 million at closing under a credit facility of up to $150 million with Hercules Capital. The company expects its cash, with that first draw, to fund operations into the third quarter of 2028, and it says more borrowing could extend that into 2029.Rocket Pharmaceuticals, Inc. 8-K (2026-10-06) https://aibio.space/news/range-impact-issues-654-434-shares-each-mrr-wicks-end-option-deals/https://aibio.space/news/range-impact-issues-654-434-shares-each-mrr-wicks-end-option-deals/Tue, 06 Oct 2026 12:00:00 GMTFinancingsRange Impact issued 654,434 shares each to MRR CNG and Wicks Building, priced at $0.764, to end two land option deals. Both buyers' $500,000 option fees were counted as the share price, and the 8-K names no adviser or placement agent for the issuances.Range Impact Inc. 8-K (2026-10-06) https://aibio.space/news/telomir-pharmaceuticals-sells-about-5-6-million-common-stock-pipe/https://aibio.space/news/telomir-pharmaceuticals-sells-about-5-6-million-common-stock-pipe/Tue, 06 Oct 2026 12:00:00 GMTFinancingsTelomir sold 4,843,300 shares at $1.16 each, a 5% discount to its 10-day VWAP, in a PIPE with no warrants. Alexander Capital, L.P. was placement agent, and John Paul DeJoria put in an additional $1.0 million.Telomir Pharmaceuticals, Inc. 8-K (2026-10-06) https://aibio.space/news/universe-pharmaceuticals-holders-approve-conditional-10-1-share/https://aibio.space/news/universe-pharmaceuticals-holders-approve-conditional-10-1-share/Tue, 06 Oct 2026 12:00:00 GMTListingsA 10-into-1 share consolidation takes effect only if the Class A bid price is below $1.00 for three consecutive trading days within 12 months. The 6-K gives no current share price and does not say whether Nasdaq has sent a notice.Universe Pharmaceuticals Inc 6-K (2026-10-06) https://aibio.space/news/seastar-medical-collects-about-3-3-million-warrant-exercises/https://aibio.space/news/seastar-medical-collects-about-3-3-million-warrant-exercises/Mon, 05 Oct 2026 12:00:00 GMTFinancingsHolders exercised older warrants at a reduced $3.866 per share and received new warrants. H.C. Wainwright & Co., LLC acted as exclusive placement agent, and the offering closed on October 5, 2026.SeaStar Medical Holding Corp 8-K (2026-10-05) https://aibio.space/news/immunome-pays-bristol-myers-squibb-20-0-million-4-425-487-shares-end/https://aibio.space/news/immunome-pays-bristol-myers-squibb-20-0-million-4-425-487-shares-end/Mon, 05 Oct 2026 12:00:00 GMTFinancingsImmunome paid Bristol-Myers Squibb $20.0 million and 4,425,487 shares under Amendment No. 4, which ends its milestone and royalty obligations. The 8-K names no underwriter or placement agent; at June 30, 2026 the company held $217.7 million in cash and equivalents plus $302.3 million in short-term investments.Immunome, Inc. 8-K (2026-10-05) https://aibio.space/news/apimeds-unit-mindwave-signs-assurechain-deal-blockassure/https://aibio.space/news/apimeds-unit-mindwave-signs-assurechain-deal-blockassure/Sun, 04 Oct 2026 12:00:00 GMTCompany UpdatesMindWave will build, run and host an insurance network for BlockAssure and receive development fees plus 20% of the AssureCoin supply.Apimeds Pharmaceuticals US, Inc. 8-K (2026-10-13) https://aibio.space/news/profusa-amends-ascent-partners-convertible-note-terms/https://aibio.space/news/profusa-amends-ascent-partners-convertible-note-terms/Sun, 04 Oct 2026 12:00:00 GMTDebt FinancingAscent Partners Fund LLC is the holder and collateral agent. The exhibit sets a $0.338 floor, a 150% share reserve and waivers on three later notes, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026.Profusa, Inc. 8-K (2026-10-05) https://aibio.space/news/aibotics-agrees-acquire-empulser-series-c-preferred-stock/https://aibio.space/news/aibotics-agrees-acquire-empulser-series-c-preferred-stock/Fri, 02 Oct 2026 12:00:00 GMTCompany UpdatesThe October 2, 2026 exchange agreement would give Aibotics all membership interests in Empulser Enterprises LLC in return for Series C Preferred Stock with a stated value of up to $22,000,000.AIBOTICS, INC. 8-K (2026-10-05) https://aibio.space/news/silo-pharma-buys-norsight-software-assets-warrant/https://aibio.space/news/silo-pharma-buys-norsight-software-assets-warrant/Fri, 02 Oct 2026 12:00:00 GMTCompany UpdatesSilo Pharma agreed on October 1, 2026, to acquire software, technology and intellectual property from Norsight Consulting in exchange for a warrant to buy 300,000 shares.Silo Pharma, Inc. 8-K (2026-10-02) https://aibio.space/news/tonix-gets-paragraph-iv-patent-notice-dr-reddys-generic-tonmya/https://aibio.space/news/tonix-gets-paragraph-iv-patent-notice-dr-reddys-generic-tonmya/Fri, 02 Oct 2026 12:00:00 GMTLegalDr. Reddy's told Tonix on October 1, 2026 that it filed an ANDA for a generic version of TONMYA 2.8 mg sublingual tablets and certified that four Orange Book patents are invalid, unenforceable or not infringed. No lawsuit has been filed, and Tonix says it intends to enforce its rights.Tonix Pharmaceuticals Holding Corp. Form 8-K filed October 2, 2026 (SEC EDGAR) https://aibio.space/news/lantheus-discloses-three-stockholder-suits-curium-merger-16-demand/https://aibio.space/news/lantheus-discloses-three-stockholder-suits-curium-merger-16-demand/Fri, 02 Oct 2026 12:00:00 GMTLegalDefendants: Lantheus Holdings and unnamed Board members, per the 8-K. Two New York and one Massachusetts complaint allege proxy omissions; the company says they lack merit.Lantheus Holdings 8-K, Oct 2, 2026 (SEC EDGAR) https://aibio.space/news/beyondspring-gets-nasdaq-notice-after-market-value-falls-below-35/https://aibio.space/news/beyondspring-gets-nasdaq-notice-after-market-value-falls-below-35/Fri, 02 Oct 2026 12:00:00 GMTListingsBeyondSpring Inc. received a Nasdaq letter on September 29, 2026 saying its market value of listed securities has been below $35 million for 30 consecutive business days. It has until March 29, 2027 to regain compliance, and its shares keep trading in the meantime.BeyondSpring, Inc. 8-K (2026-10-02) https://aibio.space/news/dare-bioscience-gets-nasdaq-notice-stock-below-1-00/https://aibio.space/news/dare-bioscience-gets-nasdaq-notice-stock-below-1-00/Fri, 02 Oct 2026 12:00:00 GMTListingsDaré Bioscience has until March 29, 2027 to show a $1.00 closing bid price for 10 consecutive business days. A second 180-day period is possible only if it meets the other listing standards and says it will cure the shortfall, by a reverse split if needed. Its cash fell to $12.6 million by June 30, 2026.Dare Bioscience, Inc. 8-K (2026-10-02) https://aibio.space/news/sunshine-biopharma-files-7-000-000-unit-offering-later-priced-0-55/https://aibio.space/news/sunshine-biopharma-files-7-000-000-unit-offering-later-priced-0-55/Fri, 02 Oct 2026 12:00:00 GMTFinancingsA preliminary prospectus dated October 2, 2026 set out a best efforts offering of units with Series D warrants. The deal was later priced to raise about $6.0 million before fees.Sunshine Biopharma Inc. S-1 (2026-10-02) https://aibio.space/news/surrozen-ind-clearance-sets-up-expected-95-1-million-second-private/https://aibio.space/news/surrozen-ind-clearance-sets-up-expected-95-1-million-second-private/Fri, 02 Oct 2026 12:00:00 GMTFinancingsFDA clearance of the SZN-8141 IND satisfies the second closing milestone in Surrozen's March 2025 private placement, which is expected to bring about $95.1 million gross on or about October 20, 2026. First patient dosing is not expected until the fourth quarter of 2026, with initial data in the second half of 2027.Surrozen, Inc. 8-K (2026-10-02) https://aibio.space/news/adagio-medical-converts-776-111-notes-4-978-869-shares/https://aibio.space/news/adagio-medical-converts-776-111-notes-4-978-869-shares/Thu, 01 Oct 2026 12:00:00 GMTFinancingsA holder converted senior secured convertible notes at alternate prices set during the company's strategic review, according to an October 1 filing.Adagio Medical Holdings, Inc. 8-K (2026-10-01) https://aibio.space/news/endra-amends-merger-agreement-asp-isotopes-renergen/https://aibio.space/news/endra-amends-merger-agreement-asp-isotopes-renergen/Thu, 01 Oct 2026 12:00:00 GMTMergersThe October 1, 2026 amendment sets a $3,800,002.59 minimum cash condition, drops the classified board requirement, and lets Renergen borrow up to $120 million from ASP Isotopes.ENDRA Life Sciences Inc. 8-K (2026-10-01) https://aibio.space/news/azitra-advances-atr-04-trial-cohort-2-after-safety-review/https://aibio.space/news/azitra-advances-atr-04-trial-cohort-2-after-safety-review/Thu, 01 Oct 2026 12:00:00 GMTCompany UpdatesThe safety review committee recommended moving to Cohort 2 after reviewing safety data from Cohort 1. About 24 patients are expected to enroll in the second cohort.Azitra Inc 8-K (2026-10-01) https://aibio.space/news/scientific-industries-signs-cfo-agreement-extends-two-others/https://aibio.space/news/scientific-industries-signs-cfo-agreement-extends-two-others/Thu, 01 Oct 2026 12:00:00 GMTCompany UpdatesZachary Rovinsky signed an employment agreement as chief financial officer, and the agreements of Helena Santos and John A. Moore were extended through September 30, 2027.SCIENTIFIC INDUSTRIES INC 8-K (2026-10-02) https://aibio.space/news/aethlon-stockholders-approve-200-000-000-authorized-common-shares/https://aibio.space/news/aethlon-stockholders-approve-200-000-000-authorized-common-shares/Thu, 01 Oct 2026 12:00:00 GMTCompany UpdatesAt an October 1, 2026 virtual annual meeting, stockholders also approved 100,000 more shares for the equity plan and 20,000,000 authorized preferred shares.AETHLON MEDICAL INC 8-K (2026-10-01) https://aibio.space/news/spyglass-buys-lens-maker-advanced-vision-science-santen-about-13/https://aibio.space/news/spyglass-buys-lens-maker-advanced-vision-science-santen-about-13/Thu, 01 Oct 2026 12:00:00 GMTMergersThe cash deal brings in house the company that makes the intraocular lens used in both of SpyGlass's Phase 3 glaucoma trials. The seller, Santen, gets an exclusive right to sell AVS's Eternity lenses in Japan.SEC EDGAR: SpyGlass Pharma 8-K https://aibio.space/news/lantern-pharma-gets-nasdaq-notice-35-000-000-market-value-rule/https://aibio.space/news/lantern-pharma-gets-nasdaq-notice-35-000-000-market-value-rule/Thu, 01 Oct 2026 12:00:00 GMTListingsLantern has until March 24, 2027 to restore the $35,000,000 market value minimum after a Nasdaq notice dated September 25, 2026. Its 2025 net loss was $17.1 million.Lantern Pharma Inc. 8-K (2026-10-01) https://aibio.space/news/mangoceuticals-unit-mangorx-ip-gets-2-5-million-commitment-receives-1/https://aibio.space/news/mangoceuticals-unit-mangorx-ip-gets-2-5-million-commitment-receives-1/Thu, 01 Oct 2026 12:00:00 GMTMergersTwo strategic investors paid the first $1.75 million tranche for a 17.5% interest in MangoRx IP, a former subsidiary of Mangoceuticals. The other $750,000, for 7.5%, is due by November 28, 2026, and the company's cash had fallen to $228,688 by June 30.Mangoceuticals, Inc. 8-K (2026-10-01) https://aibio.space/news/q32-bio-reports-week-36-signal-aa-part-b-results-bempikibart/https://aibio.space/news/q32-bio-reports-week-36-signal-aa-part-b-results-bempikibart/Wed, 30 Sep 2026 12:00:00 GMTCompany UpdatesBempikibart showed a 35.3% mean reduction in SALT score at Week 36 in alopecia areata. The company intends to start a registration-directed program in the first half of 2027.Q32 Bio Inc. 8-K (2026-09-30) https://aibio.space/news/apimeds-names-eric-sherb-chief-financial-officer/https://aibio.space/news/apimeds-names-eric-sherb-chief-financial-officer/Wed, 30 Sep 2026 12:00:00 GMTCompany UpdatesErick Frim resigned as interim chief financial officer on September 29, 2026, and the board appointed Eric Sherb effective October 1, 2026, at a base salary of $60,000 a year.Apimeds Pharmaceuticals US, Inc. 8-K (2026-10-01) https://aibio.space/news/osr-health-chief-scientific-officer-resigns-effective-immediately/https://aibio.space/news/osr-health-chief-scientific-officer-resigns-effective-immediately/Wed, 30 Sep 2026 12:00:00 GMTCompany UpdatesDr. Constance Hoefer gave notice on September 30, 2026, and her resignation took effect at once, the company reported in an 8-K filed October 2.OSR Health, Inc. 8-K (2026-10-02) https://aibio.space/news/nomad-issues-6-57-million-secured-note-9-percent-rate/https://aibio.space/news/nomad-issues-6-57-million-secured-note-9-percent-rate/Wed, 30 Sep 2026 12:00:00 GMTFinancingsNOMAD Power Solutions agreed to a secured note with a $6.57 million principal amount, for $6.0 million in gross proceeds. The note matures 12 months after its purchase price date and carries a 9% interest rate.NOMAD POWER SOLUTIONS, INC. 8-K (2026-09-30) https://aibio.space/news/valion-skl-complete-oral-mucosal-entolimod-formulation/https://aibio.space/news/valion-skl-complete-oral-mucosal-entolimod-formulation/Wed, 30 Sep 2026 12:00:00 GMTCompany UpdatesValion and Shear Kershman Laboratories finished formulation work on a needle-free Entolimod, with systemic exposure testing next.Valion Bio, Inc. 8-K (2026-10-01) https://aibio.space/news/aeon-says-fda-feedback-may-support-streamlined-abp-450-development/https://aibio.space/news/aeon-says-fda-feedback-may-support-streamlined-abp-450-development/Wed, 30 Sep 2026 12:00:00 GMTCompany UpdatesAEON Biopharma received official minutes from a Type 2b meeting with the FDA on its BOTOX biosimilar. It plans to file an IND for a comparative pharmacodynamic study in the fourth quarter of 2026.AEON Biopharma, Inc. 8-K (2026-09-30) https://aibio.space/news/itonic-holdings-extends-maturity-bank-loan-march-2027/https://aibio.space/news/itonic-holdings-extends-maturity-bank-loan-march-2027/Wed, 30 Sep 2026 12:00:00 GMTDebt FinancingBeijing Rural Commercial Bank is the lender. A director gave an unsecured personal guarantee for the loan without consideration, and the company held $779,367 in cash and cash equivalents at June 30, 2026.iTonic Holdings Ltd 8-K (2026-09-30) https://aibio.space/news/positron-issues-three-promissory-notes-20-percent-interest-warrants/https://aibio.space/news/positron-issues-three-promissory-notes-20-percent-interest-warrants/Wed, 30 Sep 2026 12:00:00 GMTDebt FinancingThe notes carry 20% interest and a September 30, 2027 maturity. Each lender also gets a warrant at an exercise price of $2.00 per share.SEC filing (Form 8-K) https://aibio.space/news/nasdaq-files-removal-notice-nutriband-public-warrants-expire/https://aibio.space/news/nasdaq-files-removal-notice-nutriband-public-warrants-expire/Wed, 30 Sep 2026 12:00:00 GMTListingsNutriband's public warrants expired on September 30 without extension or repricing. Nasdaq filed a Form 25 to remove them. The company said its common stock is not affected.Nasdaq 25-NSE https://aibio.space/news/lantern-pharma-closes-registered-direct-offering-about-4-0-million/https://aibio.space/news/lantern-pharma-closes-registered-direct-offering-about-4-0-million/Wed, 30 Sep 2026 12:00:00 GMTFinancingsLantern sold 1,469,725 shares at $1.09 each plus pre-funded warrants for up to 2,200,000 shares. A concurrent private placement of warrants for up to 3,669,725 shares needs stockholder approval before exercise.Lantern Pharma Inc. Form 8-K filed September 30, 2026 (SEC EDGAR) https://aibio.space/news/nasdaq-files-remove-abpro-holdings-stock-warrants-listing/https://aibio.space/news/nasdaq-files-remove-abpro-holdings-stock-warrants-listing/Wed, 30 Sep 2026 12:00:00 GMTListingsNasdaq filed a Form 25 notice dated 2026-09-30 to strike Abpro Holdings' Class A Common Stock and warrants from listing. The company had already received a delisting notice effective February 23, 2026, and its shares trade on the OTC Pink Limited Market.Abpro Holdings Inc. 25-NSE (2026-09-30) https://aibio.space/news/biostem-technologies-prices-3-million-private-placement-4-08-share/https://aibio.space/news/biostem-technologies-prices-3-million-private-placement-4-08-share/Wed, 30 Sep 2026 12:00:00 GMTFinancingsBioStem Technologies has agreed to issue 735,296 shares at $4.08 each in a private placement, with Series A and Series B warrants for the same number of shares at $3.83. The company expects gross proceeds of about $3 million, and about $5.6 million more if all the warrants are exercised for cash.BioStem Technologies, Inc. 8-K (2026-09-30) https://aibio.space/news/calcimedica-files-sell-up-25-000-000-stock-through-market-program/https://aibio.space/news/calcimedica-files-sell-up-25-000-000-stock-through-market-program/Wed, 30 Sep 2026 12:00:00 GMTFinancingsCalciMedica filed a prospectus supplement on September 30, 2026 for up to $25,000,000 of stock, sold through H.C. Wainwright & Co., LLC as sales agent for a 3.0% commission. The company has stopped one Phase 2 trial of its lead drug and now plans a Phase 2b step first.CalciMedica, Inc. 424B5 (2026-09-30) https://aibio.space/news/chemomab-amends-domestication-merger-terms-ahead-scipher-medicine-deal/https://aibio.space/news/chemomab-amends-domestication-merger-terms-ahead-scipher-medicine-deal/Wed, 30 Sep 2026 12:00:00 GMTMergersA technical amendment sets a formula-based exchange ratio for a combined company of 10,000,000 shares. A later amendment cut that number to 5,000,000.Chemomab Therapeutics Ltd. 6-K (2026-09-30) https://aibio.space/news/clearmind-medicine-effect-1-8-reverse-share-split-trading-october-5/https://aibio.space/news/clearmind-medicine-effect-1-8-reverse-share-split-trading-october-5/Wed, 30 Sep 2026 12:00:00 GMTListingsIssued common shares will fall from 4,059,227 to 507,404, subject to fractional-share adjustments.Clearmind Medicine Inc. 6-K (2026-09-30) https://aibio.space/news/evogene-gets-extra-180-days-nasdaq-fix-bid-price-march-29-2027/https://aibio.space/news/evogene-gets-extra-180-days-nasdaq-fix-bid-price-march-29-2027/Wed, 30 Sep 2026 12:00:00 GMTListingsNasdaq has given Evogene until March 29, 2027 to lift its ordinary shares back above $1.00. The company says it may consider a reverse split. In 2025 it used $13.5 million in operations, and year-end cash was $13.0 million.Evogene Ltd. 6-K (2026-09-30) https://aibio.space/news/petros-pharmaceuticals-assigns-all-assets-creditors-halts-operations/https://aibio.space/news/petros-pharmaceuticals-assigns-all-assets-creditors-halts-operations/Wed, 30 Sep 2026 12:00:00 GMTDistressPetros Pharmaceuticals assigned all of its assets to PT Liquidation, LLC for the benefit of creditors on September 30, 2026, and says it has ceased substantially all operations. The executive chairman and two directors resigned the same day, and the Series A preferred stock must be redeemed immediately.Petros Pharmaceuticals, Inc. 8-K (2026-09-30) https://aibio.space/news/scisparc-reports-4-436-thousand-cash-6-051-thousand-loss-first-half/https://aibio.space/news/scisparc-reports-4-436-thousand-cash-6-051-thousand-loss-first-half/Wed, 30 Sep 2026 12:00:00 GMTListingsSciSparc reported $4,436 thousand of cash and a $6,051 thousand net loss for the six months to June 30, 2026. Its own going concern note says these factors raise substantial doubt about its ability to continue as a going concern.SciSparc Ltd. 6-K (2026-09-30) https://aibio.space/news/tevogen-regains-compliance-nasdaq-global-market-listing-rules/https://aibio.space/news/tevogen-regains-compliance-nasdaq-global-market-listing-rules/Wed, 30 Sep 2026 12:00:00 GMTListingsNasdaq confirmed on September 29, 2026 that Tevogen meets the $50 million minimum market value of listed securities rule. The company had $1.1 million of cash at June 30, 2026, after cash used in operations of $12.3 million in 2025.Tevogen Inc. 8-K (2026-09-30) https://aibio.space/news/alzamend-neuro-presents-lithium-brain-imaging-results-phase-1-2a-trial/https://aibio.space/news/alzamend-neuro-presents-lithium-brain-imaging-results-phase-1-2a-trial/Tue, 29 Sep 2026 12:00:00 GMTCompany UpdatesSlides filed with the SEC say the differences between AL001 and lithium carbonate were not statistically significant in the healthy cohort.Alzamend Neuro, Inc. 8-K (2026-09-29) https://aibio.space/news/moleculin-completes-enrollment-part-miracle-trial/https://aibio.space/news/moleculin-completes-enrollment-part-miracle-trial/Tue, 29 Sep 2026 12:00:00 GMTCompany UpdatesThe company reports 89 subjects enrolled, with two more in screening, and says it remains on track for a Part A readout in the first quarter of 2027.Moleculin Biotech, Inc. 8-K (2026-09-29) https://aibio.space/news/pelthos-stockholders-approve-2026-equity-plan-elect-eight-directors/https://aibio.space/news/pelthos-stockholders-approve-2026-equity-plan-elect-eight-directors/Tue, 29 Sep 2026 12:00:00 GMTCompany UpdatesThe plan replaces the 2023 Equity Incentive Plan, as amended and restated, and took effect on approval at the September 29, 2026 annual meeting. Grant Thornton LLP was ratified as auditor for 2026.Pelthos Therapeutics Form 8-K https://aibio.space/news/odyssey-health-extends-two-note-maturities-january-2027/https://aibio.space/news/odyssey-health-extends-two-note-maturities-january-2027/Tue, 29 Sep 2026 12:00:00 GMTDebt FinancingTwo notes held by LGH Investments, LLC and Peter J. D'Arruda now mature on January 31, 2027. All other terms stay the same, the filing says.Odyssey Health, Inc. 8-K (2026-10-05) https://aibio.space/news/beyondspring-sets-up-market-program-up-11-942-800-shares/https://aibio.space/news/beyondspring-sets-up-market-program-up-11-942-800-shares/Tue, 29 Sep 2026 12:00:00 GMTFinancingsBeyondSpring has set up an at-the-market program through Citizens for up to 9,200,000 ordinary shares, capped at $11,942,800 by its public float limit. The prospectus supplement is dated September 29, 2026, and the same day the company agreed to sell its Chinese subsidiary to Biolin Investment Limited.BeyondSpring, Inc. 424B5 (2026-09-29) https://aibio.space/news/cuprina-closes-allotment-648-373-shares-1-15-raising-offering-about-5/https://aibio.space/news/cuprina-closes-allotment-648-373-shares-1-15-raising-offering-about-5/Tue, 29 Sep 2026 12:00:00 GMTFinancingsCuprina closed the sale of 648,373 more Class A shares at $1.15 after the underwriter exercised its over-allotment option in full. Total gross proceeds reached about $5,716,491, and R. F. Lafferty & Co., Inc. was the sole book-running manager.Cuprina Holdings (Cayman) Limited 6-K (2026-09-29) https://aibio.space/news/immix-biopharma-prices-125-million-stock-offering-11-00-share/https://aibio.space/news/immix-biopharma-prices-125-million-stock-offering-11-00-share/Tue, 29 Sep 2026 12:00:00 GMTFinancingsThe company is selling 11,363,637 shares through J.P. Morgan. Proceeds will fund development of its CAR-T candidate NXC-201.Immix Biopharma, Inc. 424B5 (2026-09-29) https://aibio.space/news/imunon-agrees-swap-1-200-000-streeterville-note-series-b-preferred/https://aibio.space/news/imunon-agrees-swap-1-200-000-streeterville-note-series-b-preferred/Tue, 29 Sep 2026 12:00:00 GMTFinancingsImunon will exchange $1,200,000 of a Streeterville note for 120 Series B preferred shares that cannot convert into common stock but carry an 8% return. Cash and cash equivalents were $6.9 million at June 30, 2026.Imunon, Inc. 8-K (2026-09-29) https://aibio.space/news/lakewood-amedex-holders-approve-share-increase-reverse-split-authority/https://aibio.space/news/lakewood-amedex-holders-approve-share-increase-reverse-split-authority/Tue, 29 Sep 2026 12:00:00 GMTListingsStockholders voted on September 22, 2026 to raise authorized common shares from 12,500,000 to 100,000,000. The board may now carry out reverse splits at a cumulative ratio up to one-for-twenty.Lakewood-Amedex Biotherapeutics Inc. 8-K (2026-09-29) https://aibio.space/news/liminatus-pharma-regains-nasdaq-compliance-after-1-50-reverse-split/https://aibio.space/news/liminatus-pharma-regains-nasdaq-compliance-after-1-50-reverse-split/Tue, 29 Sep 2026 12:00:00 GMTListingsNasdaq told the company on September 24, 2026 that its shares had closed above $1.00 for 13 straight trading days, closing the matter.Liminatus Pharma, Inc. 8-K (2026-09-29) https://aibio.space/news/lunai-bioworks-delays-annual-report-expects-net-loss-about-3-2-million/https://aibio.space/news/lunai-bioworks-delays-annual-report-expects-net-loss-about-3-2-million/Tue, 29 Sep 2026 12:00:00 GMTDistressThe company, formerly Renovaro Inc., expects to file its Form 10-K for the year ended June 30, 2026 within the 15-day grace period. Its net loss for the prior year was about $178.0 million.Lunai Bioworks Inc. NT 10-K (2026-09-29) https://aibio.space/news/lexeo-completes-mantle-therapeutics-deal-5-300-000-cash-plus-3-000-000/https://aibio.space/news/lexeo-completes-mantle-therapeutics-deal-5-300-000-cash-plus-3-000-000/Tue, 29 Sep 2026 12:00:00 GMTMergersLexeo paid $5,300,000 in cash and $3,000,000 in common stock upfront. Up to $12,000,000 in milestones and a $1,000,000 cash payment are not guaranteed.Lexeo Therapeutics, Inc. 8-K (2026-09-29) https://aibio.space/news/pyxis-oncology-prices-109-998-133-stock-warrant-offering-2-90/https://aibio.space/news/pyxis-oncology-prices-109-998-133-stock-warrant-offering-2-90/Tue, 29 Sep 2026 12:00:00 GMTFinancingsPyxis Oncology is selling 36,047,919 shares at $2.900 and pre-funded warrants, with common warrants at $3.50 that cannot be exercised until stockholders approve more authorized shares. Its auditor's report on the 2025 financial statements carries a going-concern warning.Pyxis Oncology, Inc. 424B5 (2026-09-29) https://aibio.space/news/tela-bio-gets-lender-consent-pause-revenue-covenant-test/https://aibio.space/news/tela-bio-gets-lender-consent-pause-revenue-covenant-test/Mon, 28 Sep 2026 12:00:00 GMTDebt FinancingThe consent sets aside the minimum Revenue covenant for two quarters, through December 31, 2026. Perceptive Credit Holdings V, LP is administrative agent.SEC Form 8-K https://aibio.space/news/glucotrack-amends-terms-senior-secured-convertible-note/https://aibio.space/news/glucotrack-amends-terms-senior-secured-convertible-note/Mon, 28 Sep 2026 12:00:00 GMTDebt FinancingThe amendment makes the floor price a hard limit and requires any make-whole payment to be made in cash. Glucotrack had $1.1 million in cash and cash equivalents at June 30, 2026.Glucotrack, Inc. 8-K (2026-09-28) https://aibio.space/news/silexion-cuts-warrant-price-0-2603-raise-about-0-84-million/https://aibio.space/news/silexion-cuts-warrant-price-0-2603-raise-about-0-84-million/Mon, 28 Sep 2026 12:00:00 GMTFinancingsHolders exercising 3,216,928 existing warrants receive 6,433,856 new warrants that cannot be used until shareholders approve more authorized shares.SEC EDGAR: Silexion 8-K https://aibio.space/news/unicycive-discloses-another-securities-class-action-olc-application/https://aibio.space/news/unicycive-discloses-another-securities-class-action-olc-application/Mon, 28 Sep 2026 12:00:00 GMTLegalUnicycive disclosed in an 8-K dated September 28, 2026 that a second securities class action was filed on September 3, 2026 against the company and certain of its officers over its oxylanthanum carbonate application. An earlier class action and two derivative suits are pending in the same federal court.Unicycive Therapeutics Form 8-K dated September 28, 2026 (SEC EDGAR) https://aibio.space/news/adarx-pharmaceuticals-closes-ipo-26-250-000-shares-17-00-each/https://aibio.space/news/adarx-pharmaceuticals-closes-ipo-26-250-000-shares-17-00-each/Mon, 28 Sep 2026 12:00:00 GMTFinancingsADARx Pharmaceuticals sold 26,250,000 shares at $17.00 in its IPO for about $446.3 million gross, and AbbVie bought 5,255,542 shares in a concurrent private placement worth about $89.3 million. The company had net losses of $46.4 million in 2024 and $73.1 million in 2025.ADARx Pharmaceuticals, Inc. 424B4 (2026-09-28) https://aibio.space/news/advanced-biomed-files-late-notice-annual-report-audit-not-complete/https://aibio.space/news/advanced-biomed-files-late-notice-annual-report-audit-not-complete/Mon, 28 Sep 2026 12:00:00 GMTDistressAdvanced Biomed told the SEC it could not file its annual report for the year ended June 30, 2026 on time because the audit was not finished. The notice does not name the auditor or explain the delay beyond that.Advanced Biomed Inc. NT 10-K (2026-09-28) https://aibio.space/news/celularity-sells-11-01-million-secured-convertible-notes-deal-up-25-0/https://aibio.space/news/celularity-sells-11-01-million-secured-convertible-notes-deal-up-25-0/Mon, 28 Sep 2026 12:00:00 GMTDebt FinancingCelularity sold about $11.01 million of notes that convert at $1.50 a share, with warrants for about 4,037,000 shares. A second tranche of up to $10.0 million is available at the buyers' election through September 30, 2027.Celularity Inc. 8-K (2026-09-28) https://aibio.space/news/gossamer-bio-regains-nasdaq-minimum-bid-price-compliance/https://aibio.space/news/gossamer-bio-regains-nasdaq-minimum-bid-price-compliance/Mon, 28 Sep 2026 12:00:00 GMTListingsNasdaq closed the bid price matter on September 25, 2026, after an April notice. The 1-for-80 reverse split took effect on September 10, 2026, and the 2025 net loss was $170.4 million.Gossamer Bio, Inc. 8-K (2026-09-28) https://aibio.space/news/jaguar-health-issues-481-584-shares-cut-streeterville-note-3-400-000/https://aibio.space/news/jaguar-health-issues-481-584-shares-cut-streeterville-note-3-400-000/Mon, 28 Sep 2026 12:00:00 GMTFinancingsJaguar issued 481,584 shares to Streeterville Capital in exchange for a $3,400,000 cut to a note first sold in 2021. The company reported about 1,945,542 shares outstanding as of September 25, 2026.Jaguar Health, Inc. 8-K (2026-09-28) https://aibio.space/news/lifecore-biomedical-agrees-6-28-share-cash-sale-webster-equity/https://aibio.space/news/lifecore-biomedical-agrees-6-28-share-cash-sale-webster-equity/Mon, 28 Sep 2026 12:00:00 GMTMergersThe deal is valued at up to $663.7 million if performance milestones are met. Contingent value rights could lift total payout to $9.67 per share.Lifecore Biomedical, Inc. 8-K (2026-09-28) https://aibio.space/news/polyrizon-reports-8-410-thousand-cash-june-30-2026/https://aibio.space/news/polyrizon-reports-8-410-thousand-cash-june-30-2026/Mon, 28 Sep 2026 12:00:00 GMTListingsPolyrizon furnished unaudited financial statements for the six months to June 30, 2026, showing $8,410 thousand of cash against a net loss of $1,424 thousand. The loss was narrowed by $2,900 thousand of financial income, and management says existing resources cover planned operations for at least 12 months.Polyrizon Ltd. 6-K (2026-09-28) https://aibio.space/news/zeo-scientifix-says-cannot-file-eight-month-transition-report-time/https://aibio.space/news/zeo-scientifix-says-cannot-file-eight-month-transition-report-time/Mon, 28 Sep 2026 12:00:00 GMTDistressThe Form 10-KT covers the eight months ended June 30, 2026. The company expects to file within the 15-day grace period.Zeo ScientifiX Inc. NT 10-K (2026-09-28) https://aibio.space/news/cdt-equity-do-1-25-reverse-stock-split-nasdaq/https://aibio.space/news/cdt-equity-do-1-25-reverse-stock-split-nasdaq/Fri, 25 Sep 2026 12:00:00 GMTListingsThe split takes effect September 28, 2026, to keep the company in compliance with the Nasdaq bid-price rule, and trading on the split-adjusted basis starts September 29.CDT Equity Inc. 8-K (2026-09-25) https://aibio.space/news/calidi-biotherapeutics-receives-nyse-american-equity-deficiency-notice/https://aibio.space/news/calidi-biotherapeutics-receives-nyse-american-equity-deficiency-notice/Fri, 25 Sep 2026 12:00:00 GMTListingsThe notice, received September 21, 2026, says Calidi does not meet the exchange's stockholders' equity standard. The company must submit a compliance plan by October 21, 2026.Calidi Biotherapeutics, Inc. 8-K (2026-09-25) https://aibio.space/news/matinas-biopharma-effects-one-fifteen-reverse-stock-split/https://aibio.space/news/matinas-biopharma-effects-one-fifteen-reverse-stock-split/Fri, 25 Sep 2026 12:00:00 GMTListingsThe reverse split of Matinas BioPharma Holdings took effect at 12:01 a.m. Eastern Time on September 28, 2026. Every 15 shares of common stock became one share.Form 8-K, SEC EDGAR https://aibio.space/news/silexion-adds-bid-price-deficiency-pending-nasdaq-panel-review/https://aibio.space/news/silexion-adds-bid-price-deficiency-pending-nasdaq-panel-review/Fri, 25 Sep 2026 12:00:00 GMTListingsA Nasdaq hearings panel is already weighing a delisting over low shareholders' equity. The closing bid price has been below $1.00 for 30 consecutive business days.SEC EDGAR: Silexion 8-K https://aibio.space/news/jury-awards-nektar-90-million-lilly-contract-case-securities-class/https://aibio.space/news/jury-awards-nektar-90-million-lilly-contract-case-securities-class/Fri, 25 Sep 2026 12:00:00 GMTLegalA federal jury found that Eli Lilly breached the implied covenant of good faith in a rezpegaldesleukin license with Nektar and awarded $90 million, according to an 8-K filed September 25, 2026. Nektar is also a defendant in a securities class action, Schramke v. Nektar Therapeutics, filed in March 2026.Nektar Therapeutics 8-K filed September 25, 2026 (SEC EDGAR) https://aibio.space/news/outlook-therapeutics-gets-nasdaq-bid-price-notice-weeks-after-drugs/https://aibio.space/news/outlook-therapeutics-gets-nasdaq-bid-price-notice-weeks-after-drugs/Fri, 25 Sep 2026 12:00:00 GMTListingsNasdaq says OTLK closed under $1.00 for 30 straight business days. The company has until March 24, 2027 to cure, and its latest 10-Q carried a going-concern warning.SEC EDGAR, Outlook Therapeutics Form 8-K https://aibio.space/news/america-great-health-says-cannot-file-annual-report-september-30-2026/https://aibio.space/news/america-great-health-says-cannot-file-annual-report-september-30-2026/Fri, 25 Sep 2026 12:00:00 GMTDistressThe company filed a late-filing notice for the year ended June 30, 2026. It says it has not been able to compile the financial data for its Form 10-K.America Great Health NT 10-K (2026-09-25) https://aibio.space/news/viking-raises-575-million-stock-convertible-notes-after-maintenance/https://aibio.space/news/viking-raises-575-million-stock-convertible-notes-after-maintenance/Thu, 24 Sep 2026 12:00:00 GMTFinancingsViking sold shares at $35 and 2% notes due 2032 that convert at about $50.75. Both deals were upsized from $200 million each, and full exercise of the underwriters' options lifted gross proceeds to $575 million.Viking Therapeutics https://aibio.space/news/aptevo-advances-trispecific-candidates-toward-scalable-manufacturing/https://aibio.space/news/aptevo-advances-trispecific-candidates-toward-scalable-manufacturing/Thu, 24 Sep 2026 12:00:00 GMTCompany UpdatesAptevo is optimizing several trispecific candidates for scalable manufacturing and expects IND-enabling studies for its lead candidate, APVO451, in the first half of 2027.Aptevo Therapeutics Inc. 8-K (2026-09-24) https://aibio.space/news/bgm-group-announces-30-1-share-consolidation-trading-october-1-2026/https://aibio.space/news/bgm-group-announces-30-1-share-consolidation-trading-october-1-2026/Thu, 24 Sep 2026 12:00:00 GMTListingsClass A shares outstanding will fall from 380,623,358 to 12,687,445 when the 30-for-1 consolidation takes effect on October 1, 2026. Shareholders approved it on September 5, 2026, and authorised share capital rises to US$15,090,000.BGM Group Ltd. 6-K (2026-09-24) https://aibio.space/news/nanobiotix-reports-110-9-million-cash-after-86-million-follow-runway/https://aibio.space/news/nanobiotix-reports-110-9-million-cash-after-86-million-follow-runway/Thu, 24 Sep 2026 12:00:00 GMTFinancingsThe company says cash of €110.9 million funds operations into 2029. Its first half net loss was €34.3 million, and revenue fell to €5.6 million from a year earlier that included a one-off €21.2 million gain.Nanobiotix SA 6-K (2026-09-24) https://aibio.space/news/adagio-medical-starts-strategic-review-cuts-workforce/https://aibio.space/news/adagio-medical-starts-strategic-review-cuts-workforce/Wed, 23 Sep 2026 12:00:00 GMTDistressThe board opened a formal process to explore alternatives that may include an acquisition, merger or other transaction, and the company has set no timetable.Adagio Medical Holdings, Inc. 8-K (2026-09-23) https://aibio.space/news/moleculin-sells-888-400-shares-through-market-program-september/https://aibio.space/news/moleculin-sells-888-400-shares-through-market-program-september/Wed, 23 Sep 2026 12:00:00 GMTFinancingsThe sales raised $0.48 million, and anti-dilution terms cut the exercise price of the August 2026 Series I Warrants to $0.51.Moleculin Biotech, Inc. 8-K (2026-09-23) https://aibio.space/news/glucotrack-ceo-outlines-lokahi-priorities-lt-100-ai2-platform/https://aibio.space/news/glucotrack-ceo-outlines-lokahi-priorities-lt-100-ai2-platform/Wed, 23 Sep 2026 12:00:00 GMTMergersIn a strategic update dated September 23, 2026, Glucotrack and Lokahi Therapeutics said LT-100 is the immediate priority, with a clinical protocol submitted for regulatory review.Glucotrack, Inc. 8-K (2026-09-23) https://aibio.space/news/evofem-adds-second-manufacturer-phexx/https://aibio.space/news/evofem-adds-second-manufacturer-phexx/Wed, 23 Sep 2026 12:00:00 GMTCompany UpdatesSubject to regulatory approval, the new source is expected to reduce unit costs by 40% or more. Evofem expects to submit a supplemental NDA in mid-2027.Evofem Biosciences, Inc. 8-K (2026-09-23) https://aibio.space/news/valion-names-dean-zikria-interim-ceo-changes-board-chair/https://aibio.space/news/valion-names-dean-zikria-interim-ceo-changes-board-chair/Wed, 23 Sep 2026 12:00:00 GMTCompany UpdatesBoard member Dean Zikria becomes interim chief executive officer, Thomas Jensen takes the board chair, and Lisa Wolf keeps her roles.Valion Bio, Inc. 8-K (2026-09-23) https://aibio.space/news/jazz-pharmaceuticals-extends-term-loan-2033-adds-273-310-355-18/https://aibio.space/news/jazz-pharmaceuticals-extends-term-loan-2033-adds-273-310-355-18/Wed, 23 Sep 2026 12:00:00 GMTDebt FinancingBank of America, N.A. is administrative agent. The maturity of the dollar term loans moves from May 5, 2028 to May 5, 2033, and year-end 2025 cash fell to $1.39 billion from $2.41 billion a year earlier.Jazz Pharmaceuticals plc 8-K (2026-09-23) https://aibio.space/news/iqvia-issues-2-000-000-000-6-375-percent-senior-notes-due-2034/https://aibio.space/news/iqvia-issues-2-000-000-000-6-375-percent-senior-notes-due-2034/Wed, 23 Sep 2026 12:00:00 GMTDebt FinancingThe notes are governed by an indenture dated September 23, 2026, with U.S. Bank Trust Company, National Association, as trustee.SEC filing (Form 8-K) https://aibio.space/news/viking-therapeutics-sells-225-000-000-2-00-percent-convertible-notes/https://aibio.space/news/viking-therapeutics-sells-225-000-000-2-00-percent-convertible-notes/Wed, 23 Sep 2026 12:00:00 GMTDebt FinancingMorgan Stanley & Co. LLC and J.P. Morgan Securities LLC are the underwriters' representatives. The initial conversion price is about $50.75 a share, and the company sold 7,857,143 common shares at $35.00 in a separate offering the same day.Viking Therapeutics, Inc. 8-K (2026-09-28) https://aibio.space/news/procept-biorobotics-amends-canadian-imperial-bank-term-loan-maturity/https://aibio.space/news/procept-biorobotics-amends-canadian-imperial-bank-term-loan-maturity/Wed, 23 Sep 2026 12:00:00 GMTDebt FinancingThe amendment extends the term loan maturity by one year, to the 72nd payment date after closing. PROCEPT BioRobotics paid a $26,000.00 extension fee.SEC Form 8-K https://aibio.space/news/quidelortho-amends-credit-agreement-resets-covenant-levels-2029/https://aibio.space/news/quidelortho-amends-credit-agreement-resets-covenant-levels-2029/Wed, 23 Sep 2026 12:00:00 GMTDebt FinancingBank of America, N.A. is administrative agent. The leverage and interest coverage tests now reset through the quarter ending September 30, 2029, and QuidelOrtho's cash and cash equivalents were $123.4 million at June 28, 2026.SEC Form 8-K https://aibio.space/news/bayer-places-2-billion-euros-hybrid-bonds/https://aibio.space/news/bayer-places-2-billion-euros-hybrid-bonds/Wed, 23 Sep 2026 12:00:00 GMTDebt FinancingTwo tranches, with non-call periods of six and nine years, raise 2 billion euros for general corporate purposes.Bayer AG release (2026-09-23) https://aibio.space/news/maplight-resale-registration-13-2-million-private-placement-shares/https://aibio.space/news/maplight-resale-registration-13-2-million-private-placement-shares/Wed, 23 Sep 2026 12:00:00 GMTFinancingsMapLight's resale prospectus lets the investors in its $150.0 million August placement sell up to 13,181,055 shares. The company receives no proceeds from those sales.MPLT 424B3 https://aibio.space/news/zymeworks-completes-theravance-biopharma-acquisition-350-million/https://aibio.space/news/zymeworks-completes-theravance-biopharma-acquisition-350-million/Wed, 23 Sep 2026 12:00:00 GMTMergersZymeworks subsidiaries sold $350,000,000 of 8.25% senior secured notes due December 31, 2036 to an OMERS Private Capital affiliate, and former Theravance holders received contingent value rights that the filing calls highly speculative.Zymeworks Inc. Form 8-K filed September 23, 2026 (SEC EDGAR) https://aibio.space/news/sarepta-faces-securities-class-action-five-derivative-suits-elevidys/https://aibio.space/news/sarepta-faces-securities-class-action-five-derivative-suits-elevidys/Wed, 23 Sep 2026 12:00:00 GMTLegalThe class action names Sarepta, Douglas Ingram, Louise Rodino-Klapac and Ian Estepan. Derivative suits name eight directors. A $39.0 million patent settlement with REGENXBIO followed on September 23, 2026.Sarepta Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/xenetic-files-investor-presentation-proposed-transaction-santersus/https://aibio.space/news/xenetic-files-investor-presentation-proposed-transaction-santersus/Wed, 23 Sep 2026 12:00:00 GMTListingsThe September 2026 deck's risk list includes a possible reverse stock split to meet Nasdaq listing requirements.Xenetic Biosciences, Inc. 8-K (2026-09-23) https://aibio.space/news/fda-grants-fast-track-designation-qrx003-peeling-skin-syndrome/https://aibio.space/news/fda-grants-fast-track-designation-qrx003-peeling-skin-syndrome/Tue, 22 Sep 2026 12:00:00 GMTCompany UpdatesThe designation is the second Fast Track for QRX003, after Netherton Syndrome in March 2026. It follows an IND that the FDA cleared in July 2026.Quoin Pharmaceuticals, Ltd. 8-K (2026-09-22) https://aibio.space/news/leonabio-series-warrants-become-exercisable-6-35-share/https://aibio.space/news/leonabio-series-warrants-become-exercisable-6-35-share/Tue, 22 Sep 2026 12:00:00 GMTFinancingsLeonaBio said its Series A common warrants became exercisable on September 18, 2026 and remain exercisable until October 19, 2026, with about $146.2 million of cash if fully exercised.LeonaBio, Inc. 8-K (2026-09-22) https://aibio.space/news/halozyme-therapeutics-sells-1-500-0-million-1-50-percent-convertible/https://aibio.space/news/halozyme-therapeutics-sells-1-500-0-million-1-50-percent-convertible/Tue, 22 Sep 2026 12:00:00 GMTDebt FinancingThe Bank of New York Mellon Trust Company, N.A. is trustee. The company used $187.5 million of the net proceeds on capped calls and expects to buy back older convertible notes, and its cash and cash equivalents were $163.1 million at June 30, 2026.Halozyme Therapeutics, Inc. 8-K (2026-09-22) https://aibio.space/news/aytu-biopharmas-adzenys-patent-suit-against-granules-heads-january/https://aibio.space/news/aytu-biopharmas-adzenys-patent-suit-against-granules-heads-january/Tue, 22 Sep 2026 12:00:00 GMTLegalAytu (Nasdaq: AYTU) is the plaintiff against Granules Pharmaceuticals in Delaware, with trial moved to January 12, 2027. It is also a nominal plaintiff in a Section 16(b) suit against Armistice, now on appeal.Aytu BioPharma 10-K for the year ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/enlivex-terminates-private-placement-66-666-667-shares-payable-rain/https://aibio.space/news/enlivex-terminates-private-placement-66-666-667-shares-payable-rain/Tue, 22 Sep 2026 12:00:00 GMTFinancingsThe agreement with the Rain Foundation was subject to shareholder approval. The company says it will not complete the placement or seek that approval.Enlivex Ltd. 6-K (2026-09-22) https://aibio.space/news/ptc-completes-acquisition-st-920-fabry-gene-therapy-sangamo/https://aibio.space/news/ptc-completes-acquisition-st-920-fabry-gene-therapy-sangamo/Mon, 21 Sep 2026 12:00:00 GMTCompany UpdatesPTC says the rolling BLA for ST-920 is expected to be completed in the fourth quarter of 2026, with the goal of accelerated approval.PTC Therapeutics, Inc. Exhibit 99.1 (2026-09-21) https://aibio.space/news/jaguar-health-completes-1-15-reverse-split-removes-old-preferred/https://aibio.space/news/jaguar-health-completes-1-15-reverse-split-removes-old-preferred/Mon, 21 Sep 2026 12:00:00 GMTListingsThe company effected the reverse split on September 17, 2026, and filed a certificate removing the terms of fourteen older preferred stock series from its charter, leaving about 520,088 common shares outstanding.Jaguar Health, Inc. 8-K (2026-09-21) https://aibio.space/news/insulet-amends-credit-agreement-refinancing-475-million-term-loans/https://aibio.space/news/insulet-amends-credit-agreement-refinancing-475-million-term-loans/Mon, 21 Sep 2026 12:00:00 GMTDebt FinancingMorgan Stanley Senior Funding, Inc. is administrative agent. The margin on the refinanced term loans falls 0.25%, and cash and cash equivalents were $534.9 million at June 30, 2026, down from $716.1 million at the end of 2025.INSULET CORP 8-K (2026-09-21) https://aibio.space/news/tuhura-biosciences-draws-another-650-000-parkview-credit-line/https://aibio.space/news/tuhura-biosciences-draws-another-650-000-parkview-credit-line/Mon, 21 Sep 2026 12:00:00 GMTDebt FinancingParkview Holdings One LLC is the lender. The $650,000 draw is small against $27.6 million of cash used in operations in 2025, and TuHURA reported $995,977 in cash and cash equivalents at June 30, 2026.TuHURA Biosciences, Inc. 8-K (2026-09-24) https://aibio.space/news/anaptysbio-awaits-post-trial-argument-delaware-suit-against-gsk-tesaro/https://aibio.space/news/anaptysbio-awaits-post-trial-argument-delaware-suit-against-gsk-tesaro/Mon, 21 Sep 2026 12:00:00 GMTLegalAnaptysBio sued TESARO, Inc. and GSK on Nov. 20, 2025 over the dostarlimab collaboration. Trial ended July 17, 2026, and post-trial argument is set for Oct. 20. Tesaro's claim that AnaptysBio breached its duties was dismissed April 24.AnaptysBio 10-KT for the transition period ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/iambic-therapeutics-files-ipo-plans-nasdaq-listing-iam/https://aibio.space/news/iambic-therapeutics-files-ipo-plans-nasdaq-listing-iam/Mon, 21 Sep 2026 12:00:00 GMTFinancingsIambic Therapeutics, Inc. filed a Form S-1 on September 21, 2026. The cover leaves the share count and price range blank.Iambic Therapeutics, Inc. S-1 (2026-09-21) https://aibio.space/news/scinai-immunotherapeutics-regains-nasdaq-bid-price-compliance/https://aibio.space/news/scinai-immunotherapeutics-regains-nasdaq-bid-price-compliance/Mon, 21 Sep 2026 12:00:00 GMTListingsNasdaq's September 18, 2026 letter says the ADSs closed at $1.00 or more for 19 consecutive business days. The matter is closed.Scinai Immunotherapeutics Ltd. 6-K (2026-09-21) https://aibio.space/news/xenon-pauses-depression-trial-enrollment-after-psychosis-reports/https://aibio.space/news/xenon-pauses-depression-trial-enrollment-after-psychosis-reports/Fri, 18 Sep 2026 12:00:00 GMTDistressThe company stopped enrolling in its phase 3 MDD and bipolar studies of azetukalner. Fierce Biotech reported the shares fell 26% pre-market the next day.Fierce Biotech https://aibio.space/news/alaunos-sells-1-120-000-stock-warrants-registered-direct-offering/https://aibio.space/news/alaunos-sells-1-120-000-stock-warrants-registered-direct-offering/Fri, 18 Sep 2026 12:00:00 GMTFinancingsDawson James Securities is sole placement agent for the offering, priced at $1.46 per share under Nasdaq at-the-market rules.Alaunos Therapeutics, Inc. 8-K (2026-09-22) https://aibio.space/news/inmed-receives-nasdaq-notice-minimum-shareholders-equity/https://aibio.space/news/inmed-receives-nasdaq-notice-minimum-shareholders-equity/Fri, 18 Sep 2026 12:00:00 GMTListingsShareholders' equity of $1,075,007 in the 10-K for the year ended June 30, 2026 fell below the $2,500,000 Nasdaq minimum. The company has 45 calendar days to submit a plan.InMed Pharmaceuticals Inc. 8-K (2026-09-18) https://aibio.space/news/trafalgar-international-names-carlos-septien-chief-executive-officer/https://aibio.space/news/trafalgar-international-names-carlos-septien-chief-executive-officer/Fri, 18 Sep 2026 12:00:00 GMTCompany UpdatesPorfirio Sanchez Talavera resigned as chief executive officer on September 18, 2026, and Carlos Septién, previously chief operating officer, took the post.TRAFALGAR INTERNATIONAL, INC. 8-K (2026-09-21) https://aibio.space/news/endovia-closes-510-000-secured-convertible-note-c-m-capital/https://aibio.space/news/endovia-closes-510-000-secured-convertible-note-c-m-capital/Fri, 18 Sep 2026 12:00:00 GMTDebt FinancingC/M Capital Master Fund, LP is the investor. The $510,000 note converts at the lower of $1.75 and $0.01 above the closing price, and the company had $242,702 in cash and cash equivalents at June 30, 2026.Endovia Health Sciences, Inc. Form 8-K (2026-09-24) https://aibio.space/news/moleculin-biotech-gets-nasdaq-staff-determination-bid-price-plans/https://aibio.space/news/moleculin-biotech-gets-nasdaq-staff-determination-bid-price-plans/Fri, 18 Sep 2026 12:00:00 GMTListingsNasdaq staff says Moleculin is not eligible for a compliance period because it effected a 1-for-25 reverse stock split on December 1, 2025. The company plans to request a hearing, which stays any delisting action while it is pending.Moleculin Biotech, Inc. Form 8-K filed September 18, 2026 (SEC EDGAR) https://aibio.space/news/beyondspring-gets-nasdaq-minimum-bid-price-notice-has-until-march-16/https://aibio.space/news/beyondspring-gets-nasdaq-minimum-bid-price-notice-has-until-march-16/Fri, 18 Sep 2026 12:00:00 GMTListingsNasdaq told BeyondSpring on September 17, 2026 that its ordinary shares closed below $1.00 for 30 consecutive business days. Trading continues during a 180 calendar day compliance period that ends March 16, 2027.BeyondSpring Inc. Form 8-K filed September 18, 2026 (SEC EDGAR) https://aibio.space/news/biostem-technologies-signs-committed-equity-facility-sell-up-40-000/https://aibio.space/news/biostem-technologies-signs-committed-equity-facility-sell-up-40-000/Fri, 18 Sep 2026 12:00:00 GMTFinancingsBioStem (Nasdaq: BSEM) may sell shares to Roth Principal Investments over up to 36 months at a 3.0% or 5.0% discount to average price. The company pays a $400,000 cash commitment fee.BioStem Technologies, Inc. Form 8-K filed September 18, 2026 (SEC EDGAR) https://aibio.space/news/electra-therapeutics-prices-ipo-23-333-334-shares-15-00-about-350/https://aibio.space/news/electra-therapeutics-prices-ipo-23-333-334-shares-15-00-about-350/Fri, 18 Sep 2026 12:00:00 GMTFinancingsElectra Therapeutics sold 23,333,334 shares at $15.00 in its initial public offering. The final prospectus repeats the auditor's going concern paragraph from the registration statement.Electra Therapeutics, Inc. 424B4 (2026-09-18) https://aibio.space/news/filana-therapeutics-gets-nasdaq-bid-price-notice-has-until-march-16/https://aibio.space/news/filana-therapeutics-gets-nasdaq-bid-price-notice-has-until-march-16/Fri, 18 Sep 2026 12:00:00 GMTListingsNasdaq gives Filana until March 16, 2027 to regain compliance. Cash and equivalents fell to $86.6 million at March 31, 2026, from $128.6 million at the end of 2024.Filana Therapeutics, Inc. 8-K (2026-09-18) https://aibio.space/news/nasus-pharma-sets-up-market-program-btig-up-8-500-000-shares/https://aibio.space/news/nasus-pharma-sets-up-market-program-btig-up-8-500-000-shares/Fri, 18 Sep 2026 12:00:00 GMTFinancingsNasus Pharma can sell up to $8,500,000 of shares through BTIG but is not obliged to. Its June 30, 2026 balance sheet held $11,904 thousand in cash, restricted cash and short-term deposits, and its prospectus supplement lists substantial doubt about going concern among its risks.Nasus Pharma Ltd. 6-K (2026-09-18) https://aibio.space/news/retension-pharmaceuticals-files-ipo-seeks-nasdaq-listing-rtsn/https://aibio.space/news/retension-pharmaceuticals-files-ipo-seeks-nasdaq-listing-rtsn/Fri, 18 Sep 2026 12:00:00 GMTFinancingsRetension Pharmaceuticals, a Falls Church, Virginia developer of a hypertension drug, filed a Form S-1 on September 18, 2026. The preliminary prospectus leaves the share count and price blank, and its 2025 financial statements have been restated.Retension Pharmaceuticals, Inc. S-1 (2026-09-18) https://aibio.space/news/trex-bio-files-ipo-eli-lilly-signals-interest-buying-shares/https://aibio.space/news/trex-bio-files-ipo-eli-lilly-signals-interest-buying-shares/Fri, 18 Sep 2026 12:00:00 GMTFinancingsTRex Bio filed for a Nasdaq IPO on September 18, 2026. Eli Lilly, which signed a research collaboration with the company in 2023, has indicated interest in buying shares, but the indication is not binding and the price range and share count are still blank.TRex Bio, Inc. S-1 (2026-09-18) https://aibio.space/news/halozyme-prices-upsized-1-3-billion-convertible-offering-retires-older/https://aibio.space/news/halozyme-prices-upsized-1-3-billion-convertible-offering-retires-older/Thu, 17 Sep 2026 12:00:00 GMTFinancingsThe 1.50% notes due 2033 convert at about $139.84 a share, a 27.5% premium to the Sept. 17 close. Part of the proceeds repurchases 2027 and 2028 notes and pays for capped calls.Halozyme Therapeutics (SEC Form 8-K, Exhibit 99.1) https://aibio.space/news/soligenix-stockholders-approve-reverse-split-authority-share-increase/https://aibio.space/news/soligenix-stockholders-approve-reverse-split-authority-share-increase/Thu, 17 Sep 2026 12:00:00 GMTListingsAt its September 17, 2026 annual meeting, stockholders approved a reverse split at a ratio of 1-for-2 to 1-for-20 and raised authorized common shares from 75,000,000 to 125,000,000.Soligenix, Inc. 8-K (2026-09-21) https://aibio.space/news/adial-stockholders-approve-equity-plans-larger-share-authorization/https://aibio.space/news/adial-stockholders-approve-equity-plans-larger-share-authorization/Thu, 17 Sep 2026 12:00:00 GMTCompany UpdatesStockholders approved a 2017 plan amendment, a 2026 equity plan, a 2026 employee stock purchase plan and an increase in authorized shares to 500,000,000 at the September 17, 2026 meeting.Adial Pharmaceuticals, Inc 8-K (2026-09-18) https://aibio.space/news/nasdaq-delist-aditxt-common-stock-after-june-suspension/https://aibio.space/news/nasdaq-delist-aditxt-common-stock-after-june-suspension/Thu, 17 Sep 2026 12:00:00 GMTListingsThe Nasdaq Stock Market said on September 17, 2026 that it will delist the common stock of Aditxt, Inc. The stock was suspended on June 25, 2026 and has not traded on Nasdaq since then.Aditxt, Inc. 8-K (2026-09-23) https://aibio.space/news/impact-biomedical-reports-zoar-f-4-filing-business-combination/https://aibio.space/news/impact-biomedical-reports-zoar-f-4-filing-business-combination/Thu, 17 Sep 2026 12:00:00 GMTMergersZoar Limited filed a Form F-4 on September 10, 2026 that includes Impact BioMedical's preliminary proxy statement for the proposed business combination with Zoar Labs Limited.Impact BioMedical Inc. 8-K (2026-09-17) https://aibio.space/news/aethlon-merge-north-immunology-all-stock-deal/https://aibio.space/news/aethlon-merge-north-immunology-all-stock-deal/Thu, 17 Sep 2026 12:00:00 GMTMergersThe deal comes with an oversubscribed $180 million private placement. Aethlon holders are expected to own about 4.75% of the combined company at closing, expected in the first quarter of 2027.AETHLON MEDICAL INC 8-K (2026-09-17) https://aibio.space/news/aquestive-faces-securities-class-action-derivative-suit-anaphylm-nda/https://aibio.space/news/aquestive-faces-securities-class-action-derivative-suit-anaphylm-nda/Thu, 17 Sep 2026 12:00:00 GMTLegalModica v. Aquestive names the company and chief executive Daniel Barber in New Jersey federal court. A derivative suit, Wilson v. Brown, is stayed behind it.Aquestive Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/quantum-biopharma-closes-fourth-debenture-tranche-100-000-cancels/https://aibio.space/news/quantum-biopharma-closes-fourth-debenture-tranche-100-000-cancels/Thu, 17 Sep 2026 12:00:00 GMTDebt FinancingA news release dated March 7, 2025, filed with the SEC in a 6-K in September 2026, reports a $100,000 debenture tranche and the swap of a director's warrants for options. It names no placement agent for the debentures.Quantum Biopharma Ltd. 6-K (2026-09-17) https://aibio.space/news/alaunos-lowers-stockholder-meeting-quorum-one-third-voting-power/https://aibio.space/news/alaunos-lowers-stockholder-meeting-quorum-one-third-voting-power/Wed, 16 Sep 2026 12:00:00 GMTCompany UpdatesThe board adopted Second Amended and Restated By-Laws on September 16, 2026, effective immediately.Alaunos Therapeutics, Inc. 8-K (2026-09-17) https://aibio.space/news/pasithea-warrants-expire-september-17-2026/https://aibio.space/news/pasithea-warrants-expire-september-17-2026/Wed, 16 Sep 2026 12:00:00 GMTListingsPasithea Therapeutics said its KTTAW warrants will expire on September 17, 2026 and stop trading on Nasdaq, while its common stock keeps trading as KTTA.Pasithea Therapeutics Corp. 8-K (2026-09-16) https://aibio.space/news/co-diagnostics-readygo-evaluate-blood-testing-ebola/https://aibio.space/news/co-diagnostics-readygo-evaluate-blood-testing-ebola/Wed, 16 Sep 2026 12:00:00 GMTCompany UpdatesThe companies will test whether ReadyGo's sample-preparation technology can work with the Co-Dx PCR platform on blood samples. Compatibility has not yet been established.Co-Diagnostics, Inc. 8-K (2026-09-16) https://aibio.space/news/matinas-biopharma-sets-one-fifteen-reverse-stock-split/https://aibio.space/news/matinas-biopharma-sets-one-fifteen-reverse-stock-split/Wed, 16 Sep 2026 12:00:00 GMTListingsThe board approved a one-for-fifteen reverse split of the common stock, effective 12:01 a.m. Eastern Time on September 28, 2026, under the existing MTNB symbol.Matinas Biopharma Holdings, Inc. 8-K (2026-09-16) https://aibio.space/news/halozyme-plans-1-05-billion-convertible-notes-offering/https://aibio.space/news/halozyme-plans-1-05-billion-convertible-notes-offering/Wed, 16 Sep 2026 12:00:00 GMTDebt FinancingHalozyme intends to offer $1.05 billion of convertible senior notes due 2033, with a 13-day option for up to $150 million more. Rate and conversion terms will be set at pricing, and the release names no bank.Halozyme Therapeutics, Inc. press release (Exhibit 99.1) https://aibio.space/news/profusa-sells-senior-secured-convertible-note-ascent-partners-fund/https://aibio.space/news/profusa-sells-senior-secured-convertible-note-ascent-partners-fund/Wed, 16 Sep 2026 12:00:00 GMTDebt FinancingAscent Partners Fund LLC bought the note as initial purchaser and also acts as collateral agent. The $384,615.38 note was sold for $350,000, and Profusa had $719,000 in cash and cash equivalents at June 30, 2026.Profusa, Inc. 8-K (2026-09-16) https://aibio.space/news/bone-biologics-gets-nasdaq-minimum-bid-price-notice-has-until-march-9/https://aibio.space/news/bone-biologics-gets-nasdaq-minimum-bid-price-notice-has-until-march-9/Wed, 16 Sep 2026 12:00:00 GMTListingsNasdaq says the closing bid has been below $1 for 30 consecutive business days. The company completed a 1-for-6 reverse split in June 2025 and plans to seek approval for another at its next annual meeting.Bone Biologics Corp Form 8-K filed September 16, 2026 (SEC EDGAR) https://aibio.space/news/xenetic-biosciences-agrees-acquire-santersus-ag-all-stock-share/https://aibio.space/news/xenetic-biosciences-agrees-acquire-santersus-ag-all-stock-share/Wed, 16 Sep 2026 12:00:00 GMTFinancingsThe deal needs Xenetic stockholder approval. Pro forma, current Xenetic holders would own approximately 15.0% and Santersus holders approximately 85.0%.Xenetic Biosciences, Inc. 8-K (2026-09-16) https://aibio.space/news/jaguar-health-swaps-note-preferred-shares-common-stock/https://aibio.space/news/jaguar-health-swaps-note-preferred-shares-common-stock/Tue, 15 Sep 2026 12:00:00 GMTFinancingsJaguar Health exchanged a convertible note and Series Q preferred shares for common stock in September 2026, and issued 535,000 common shares plus a pre-funded warrant to acquire the Napo Therapeutics shares of a minority holder.Jaguar Health, Inc. 8-K (2026-09-15) https://aibio.space/news/beta-bionics-discloses-securities-class-action-filed-september-4-2026/https://aibio.space/news/beta-bionics-discloses-securities-class-action-filed-september-4-2026/Tue, 15 Sep 2026 12:00:00 GMTLegalA purported stockholder sued Beta Bionics and certain executive officers in federal court in California, alleging misstatements about iLet. The company says it intends to defend and that any loss is not currently probable or estimable.Beta Bionics, Inc. Form 8-K filed September 15, 2026 (SEC EDGAR) https://aibio.space/news/tyra-biosciences-prices-400-million-offering-shares-pre-funded/https://aibio.space/news/tyra-biosciences-prices-400-million-offering-shares-pre-funded/Tue, 15 Sep 2026 12:00:00 GMTFinancingsTyra Biosciences priced 9,079,000 common shares and pre-funded warrants for 9,078,529 more, expecting about $400.0 million gross at $22.03 a share. The company had $73.8 million of cash at June 30, 2026, and a 2025 net loss of $119.9 million.Tyra Biosciences, Inc. 424B5 (2026-09-15) https://aibio.space/news/ascendis-takes-back-obesity-rights-novo-nordisk-authorizes-400-million/https://aibio.space/news/ascendis-takes-back-obesity-rights-novo-nordisk-authorizes-400-million/Mon, 14 Sep 2026 12:00:00 GMTFinancingsAll TransCon licenses in metabolic and cardiovascular disease, including once-monthly semaglutide, revert to Ascendis with no continuing financial obligations.Ascendis Pharma (SEC Form 6-K) https://aibio.space/news/q32-bio-appoints-jose-trevejo-chief-medical-officer-ellie-hershberger/https://aibio.space/news/q32-bio-appoints-jose-trevejo-chief-medical-officer-ellie-hershberger/Mon, 14 Sep 2026 12:00:00 GMTCompany UpdatesBoth hires come as Q32 Bio prepares a registration-directed program for bempikibart in alopecia areata. The company plans to start it in the first half of 2027.Q32 Bio Inc. 8-K (2026-09-14) https://aibio.space/news/onconetix-provides-2-5-million-bridge-advance-realbotix-before/https://aibio.space/news/onconetix-provides-2-5-million-bridge-advance-realbotix-before/Mon, 14 Sep 2026 12:00:00 GMTCompany UpdatesThe bridge facility provides up to $5,000,000 to Realbotix LLC, the target of a pending all-stock share exchange, with an initial advance of $2,500,000.Onconetix press release https://aibio.space/news/phio-reports-ph-762-fda-submission-planned-phase-2b-study/https://aibio.space/news/phio-reports-ph-762-fda-submission-planned-phase-2b-study/Mon, 14 Sep 2026 12:00:00 GMTCompany UpdatesPhio Pharmaceuticals said on September 14, 2026 that it reached a development milestone for PH-762, including the submission of materials to the FDA and a planned Phase 2b neoadjuvant study.Phio Pharmaceuticals Corp. 8-K (2026-09-14) https://aibio.space/news/biofrontera-gets-fda-approval-ameluz-superficial-basal-cell-carcinoma/https://aibio.space/news/biofrontera-gets-fda-approval-ameluz-superficial-basal-cell-carcinoma/Mon, 14 Sep 2026 12:00:00 GMTCompany UpdatesThe company says Ameluz with the RhodoLED lamp is the first and only photodynamic therapy approved in the United States to treat a skin cancer. It plans a launch from late fourth quarter 2026 through first quarter 2027.Biofrontera Inc. Form 8-K https://aibio.space/news/glucotrack-director-resigns-citing-possible-conflict-merger-terms/https://aibio.space/news/glucotrack-director-resigns-citing-possible-conflict-merger-terms/Mon, 14 Sep 2026 12:00:00 GMTCompany UpdatesDirector Paul V. Goode resigned effective immediately after notifying the board on September 14, 2026, saying the merger agreement with Lokahi Therapeutics, Inc. could create a conflict of interest between the company and its subsidiary.Glucotrack, Inc. 8-K (2026-09-18) https://aibio.space/news/mindwalk-signs-binding-30-million-credit-facility-term-sheet/https://aibio.space/news/mindwalk-signs-binding-30-million-credit-facility-term-sheet/Mon, 14 Sep 2026 12:00:00 GMTDebt FinancingMindWalk Holdings signed a binding term sheet with Sanabil (Cayman) for a revolving credit facility of up to $30 million at a fixed 7.00% annual rate. The definitive agreement is not yet signed.MindWalk Holdings Corp. press release (Exhibit 99.1) https://aibio.space/news/tuhura-biosciences-makes-650-000-draw-parkview-credit-line/https://aibio.space/news/tuhura-biosciences-makes-650-000-draw-parkview-credit-line/Mon, 14 Sep 2026 12:00:00 GMTDebt FinancingTuHURA reported the draw in an 8-K dated September 17, 2026. Parkview Holdings One LLC is the lender, and cash and cash equivalents were $995,977 at June 30, 2026.TuHURA Biosciences, Inc. 8-K (2026-09-17) https://aibio.space/news/cdt-equity-issues-2-126-250-secured-convertible-note-j-j-astor-co/https://aibio.space/news/cdt-equity-issues-2-126-250-secured-convertible-note-j-j-astor-co/Mon, 14 Sep 2026 12:00:00 GMTDebt FinancingThe note matures March 1, 2027 and is payable in 24 weekly installments of $88,593.75. The lender can convert at the greater of 70% of the lowest volume-weighted average price or a $0.05 floor.CDT Equity Inc. 8-K (2026-09-18) https://aibio.space/news/cardiff-oncology-settles-onvansertib-license-lawsuit-nerviano-medical/https://aibio.space/news/cardiff-oncology-settles-onvansertib-license-lawsuit-nerviano-medical/Mon, 14 Sep 2026 12:00:00 GMTLegalCardiff Oncology settled its lawsuit against Nerviano Medical Sciences, the licensor of its lead drug onvansertib, on September 14, 2026. The case is dismissed with prejudice and the license is amended. Nerviano was the only defendant in the suit.Cardiff Oncology Form 8-K dated September 14, 2026 (SEC EDGAR) https://aibio.space/news/sionna-therapeutics-cuts-about-46-percent-workforce-sees-cash-second/https://aibio.space/news/sionna-therapeutics-cuts-about-46-percent-workforce-sees-cash-second/Mon, 14 Sep 2026 12:00:00 GMTDistressSionna Therapeutics said it will cut about 46% of its workforce, expects about $6.4 million in restructuring charges, and expects its cash to last into the second half of 2029. The cuts follow a missed key endpoint for SION-719 in a Phase 2a trial.Sionna Therapeutics, Inc. 8-K (2026-09-14) https://aibio.space/news/60-degrees-seeks-fda-priority-voucher-tafenoquine-babesiosis/https://aibio.space/news/60-degrees-seeks-fda-priority-voucher-tafenoquine-babesiosis/Sat, 12 Sep 2026 12:00:00 GMTCompany UpdatesA September 12, 2026 submission asks FDA for a Commissioner's National Priority Voucher for an efficacy supplement to ARAKODA in babesiosis.60 Degrees Pharmaceuticals, Inc. 8-K (2026-09-14) https://aibio.space/news/tenon-medical-announces-warrant-inducement-2-872-338-58-gross/https://aibio.space/news/tenon-medical-announces-warrant-inducement-2-872-338-58-gross/Fri, 11 Sep 2026 12:00:00 GMTFinancingsHolders exercised 572,179 existing warrants for cash and received new warrants for 858,269 shares at $5.02 per share. WallachBeth Capital acted as financial advisor, and the closing was expected on or about September 14, 2026.Tenon Medical, Inc. 8-K (2026-09-16) https://aibio.space/news/biovie-enters-sales-agreement-up-6-464-341-common-stock/https://aibio.space/news/biovie-enters-sales-agreement-up-6-464-341-common-stock/Fri, 11 Sep 2026 12:00:00 GMTFinancingsBioVie agreed with A.G.P./Alliance Global Partners to sell up to $6,464,341 of Class A common stock through an at-the-market program, with a 3.0% commission on gross proceeds.BioVie Inc. 8-K (2026-09-14) https://aibio.space/news/glucotrack-issues-secured-convertible-notes-warrants-private-placement/https://aibio.space/news/glucotrack-issues-secured-convertible-notes-warrants-private-placement/Fri, 11 Sep 2026 12:00:00 GMTDebt FinancingThe nine-month notes carry 8% interest and a 22% original issue discount, with Dawson James Securities, Inc. as placement agent and an exchange cap of 19.99%.Glucotrack, Inc. 8-K (2026-09-11) https://aibio.space/news/acadia-derivative-settlement-gets-preliminary-approval-securities/https://aibio.space/news/acadia-derivative-settlement-gets-preliminary-approval-securities/Fri, 11 Sep 2026 12:00:00 GMTLegalNine individuals are named in the derivative suit: Baker, Biggar, Soland, Brege, Davis, Garofalo, Daly, Harrigan and Srdjan (Serge) Stankovic. The class action names Acadia and unnamed officers.Acadia Pharmaceuticals Form 8-K filed September 11, 2026 (SEC EDGAR) https://aibio.space/news/regentis-reports-9-0-million-cash-after-6-5-million-june-private/https://aibio.space/news/regentis-reports-9-0-million-cash-after-6-5-million-june-private/Fri, 11 Sep 2026 12:00:00 GMTFinancingsRegentis Biomaterials reported on September 11, 2026 that it had about $9.0 million in cash at June 30, 2026, after a $6.5 million private placement in June. It says it has repaid its debt entirely, and it now expects the U.S. pivotal trial of GelrinC to finish enrolling at about year end 2026.Regentis Biomaterials Ltd. 6-K (2026-09-11) https://aibio.space/news/apimeds-pharmaceuticals-adds-sungjoon-chae-board/https://aibio.space/news/apimeds-pharmaceuticals-adds-sungjoon-chae-board/Thu, 10 Sep 2026 12:00:00 GMTCompany UpdatesThe appointment on September 10, 2026 followed a First Amendment to a settlement agreement that sets the board's interim makeup. Chae has been Co-Chief Executive Officer since May 4, 2026.Apimeds Pharmaceuticals US, Inc. 8-K (2026-09-11) https://aibio.space/news/cerenome-gets-up-20-million-royalty-based-facility-3i-lp/https://aibio.space/news/cerenome-gets-up-20-million-royalty-based-facility-3i-lp/Thu, 10 Sep 2026 12:00:00 GMTDebt FinancingCerenome, Inc. received initial funding under a senior secured facility of up to $20 million from 3i, LP, with royalty-based repayments. The company says its cash runway now reaches well into 2028.Cerenome, Inc. 8-K (2026-09-10) https://aibio.space/news/karyopharm-gets-forbearance-after-missed-loan-note-payments/https://aibio.space/news/karyopharm-gets-forbearance-after-missed-loan-note-payments/Thu, 10 Sep 2026 12:00:00 GMTDebt FinancingLenders and noteholders agreed to forbear from enforcing remedies for a limited period. The forbearance period is set to end October 15, 2026 unless extended, and can end sooner on several triggers.SEC Form 8-K https://aibio.space/news/tarsus-pharmaceuticals-completes-alkeus-acquisition-270-000-000-cash/https://aibio.space/news/tarsus-pharmaceuticals-completes-alkeus-acquisition-270-000-000-cash/Thu, 10 Sep 2026 12:00:00 GMTMergersTarsus paid $270,000,000 in cash and issued 2,908,692 shares at closing. Up to $350,000,000 in milestones and tiered revenue sharing on gildeuretinol sales remain to be paid.Tarsus Pharmaceuticals, Inc. Form 8-K filed September 10, 2026 (SEC EDGAR) https://aibio.space/news/metavia-reports-da-1726-tissue-distribution-data-preclinical-study/https://aibio.space/news/metavia-reports-da-1726-tissue-distribution-data-preclinical-study/Wed, 09 Sep 2026 12:00:00 GMTCompany UpdatesA preclinical study found DA-1726-derived radioactivity concentrated in adipose tissue and retained over time, which MetaVia says supports the waist circumference reduction seen in clinical studies.MetaVia Inc. 8-K (2026-09-09) https://aibio.space/news/rallybio-cfo-jonathan-lieber-moves-part-time-employment/https://aibio.space/news/rallybio-cfo-jonathan-lieber-moves-part-time-employment/Wed, 09 Sep 2026 12:00:00 GMTCompany UpdatesRallybio said Jonathan Lieber will move to part-time employment on September 15, 2026 and remain Chief Financial Officer. His employment ends at the closing of the pending Avenzo Therapeutics merger.Rallybio Corporation 8-K (2026-09-09) https://aibio.space/news/tenon-medical-repays-convertible-notes-ahead-september-11-maturity/https://aibio.space/news/tenon-medical-repays-convertible-notes-ahead-september-11-maturity/Wed, 09 Sep 2026 12:00:00 GMTDebt FinancingTenon repaid in full original issue discount senior convertible promissory notes with an aggregate principal balance of approximately $5.16 million, issued March 11, 2026. The release names no noteholder or agent.Tenon Medical, Inc. 8-K (2026-09-09) https://aibio.space/news/cocrystal-doses-last-subject-cdi-988-norovirus-challenge-study/https://aibio.space/news/cocrystal-doses-last-subject-cdi-988-norovirus-challenge-study/Wed, 09 Sep 2026 12:00:00 GMTCompany UpdatesCocrystal Pharma said on September 9, 2026 that it dosed the last subject in its Phase 1b norovirus challenge study of CDI-988, with preliminary efficacy results expected in late 2026 or early 2027.Cocrystal Pharma, Inc. 8-K (2026-09-09) https://aibio.space/news/lexaria-agrees-warrant-inducement-approximately-5-9-million-gross/https://aibio.space/news/lexaria-agrees-warrant-inducement-approximately-5-9-million-gross/Wed, 09 Sep 2026 12:00:00 GMTFinancingsLexaria Bioscience cut the exercise price on 453,969 existing warrants to $12.92 a share, for about $5.9 million in gross proceeds. In return it issued two new warrant series, each for the same number of shares, at $12.67.Lexaria Bioscience Corp. Form 8-K filed September 9, 2026 (SEC EDGAR) https://aibio.space/news/lexaria-agrees-warrant-exercise-reduced-12-92-price-about-5-9-million/https://aibio.space/news/lexaria-agrees-warrant-exercise-reduced-12-92-price-about-5-9-million/Wed, 09 Sep 2026 12:00:00 GMTFinancingsThe warrants will be exercised at $12.92 per share for gross proceeds of about $5.9 million, with H.C. Wainwright & Co. as exclusive placement agent. Holders receive new Series A and Series B warrants at $12.67.Lexaria Bioscience Corp. 8-K (2026-09-09) https://aibio.space/news/protagonist-authorizes-300-million-share-buyback-after-two-drug/https://aibio.space/news/protagonist-authorizes-300-million-share-buyback-after-two-drug/Tue, 08 Sep 2026 12:00:00 GMTFinancingsThe peptide drug developer will fund repurchases from cash and royalty income. It held $849.5 million at June 30, before $275 million in Takeda payments due in the fourth quarter.Protagonist Therapeutics via Newswire https://aibio.space/news/fda-grants-rare-pediatric-disease-designation-qrx003-peeling-skin/https://aibio.space/news/fda-grants-rare-pediatric-disease-designation-qrx003-peeling-skin/Tue, 08 Sep 2026 12:00:00 GMTCompany UpdatesThe designation is the second Rare Pediatric Disease Designation for QRX003. Quoin said an approved application could qualify it for a priority review voucher.Quoin Pharmaceuticals, Ltd. 8-K (2026-09-10) https://aibio.space/news/lifeward-investor-deck-lays-out-pipeline-reimbursement-oramed-platform/https://aibio.space/news/lifeward-investor-deck-lays-out-pipeline-reimbursement-oramed-platform/Tue, 08 Sep 2026 12:00:00 GMTCompany UpdatesA September 2026 investor presentation filed as Exhibit 99.1 sets out the company's product timeline, its Oramed-linked oral delivery program and its reported cash and revenue.Lifeward Ltd. 8-K (2026-09-08) https://aibio.space/news/60-degrees-presents-july-financing-cash-runway-investors/https://aibio.space/news/60-degrees-presents-july-financing-cash-runway-investors/Tue, 08 Sep 2026 12:00:00 GMTFinancingsA September 2026 investor presentation lists a $1.0M July 31 private placement, about $1.0M of cash at June 30, 2026, and a runway the slide dates to early October 2026.60 Degrees Pharmaceuticals, Inc. 8-K (2026-09-08) https://aibio.space/news/bluejay-signs-federal-distribution-partnership-lovell-government/https://aibio.space/news/bluejay-signs-federal-distribution-partnership-lovell-government/Tue, 08 Sep 2026 12:00:00 GMTCompany UpdatesLovell will be Bluejay's exclusive distributor for federal procurement opportunities that favor veteran-owned small businesses, once its products receive FDA clearance or other required authorization.Bluejay Diagnostics, Inc. 8-K (2026-09-08) https://aibio.space/news/ispecimen-gets-until-november-25-2026-meet-nasdaq-equity-rule/https://aibio.space/news/ispecimen-gets-until-november-25-2026-meet-nasdaq-equity-rule/Tue, 08 Sep 2026 12:00:00 GMTListingsThe company plans a public offering of approximately $5 million, and its projections show stockholders' equity of approximately $5.1 million through June 30, 2027.Form 8-K https://aibio.space/news/kiora-appoints-keith-lane-executive-vice-president-clinical/https://aibio.space/news/kiora-appoints-keith-lane-executive-vice-president-clinical/Tue, 08 Sep 2026 12:00:00 GMTCompany UpdatesKiora named Keith J. Lane, previously Chief Scientific Officer at Ora, Inc., to lead clinical development and regulatory affairs. The appointment supports the KIO-301 retinitis pigmentosa program.Kiora Pharmaceuticals, Inc. 8-K (2026-09-08) https://aibio.space/news/stimcell-hires-stonegate-capital-markets-non-exclusive-advisor/https://aibio.space/news/stimcell-hires-stonegate-capital-markets-non-exclusive-advisor/Tue, 08 Sep 2026 12:00:00 GMTCompany UpdatesThe advisor will introduce investors and strategic partners for transactions the company approves, under an agreement effective August 24, 2026.Press release (SEC Exhibit 99.1) https://aibio.space/news/gri-bio-presents-new-phase-2a-data-gri-0621-ipf/https://aibio.space/news/gri-bio-presents-new-phase-2a-data-gri-0621-ipf/Tue, 08 Sep 2026 12:00:00 GMTCompany UpdatesGRI Bio said new whole-blood, serum and flow cytometry data from its 35-patient Phase 2a study support nine mechanistic pillars for GRI-0621 in idiopathic pulmonary fibrosis.GRI Bio, Inc. 8-K (2026-09-08) https://aibio.space/news/evommune-drops-evo756-atopic-dermatitis-after-phase-2b-misses-all/https://aibio.space/news/evommune-drops-evo756-atopic-dermatitis-after-phase-2b-misses-all/Tue, 08 Sep 2026 12:00:00 GMTDistressThe 121-patient trial failed at every dose. Evommune will keep testing EVO756 in migraine, move EVO301 forward and says cash lasts into 2029, a forecast that rests on revised plans.EVMN 8-K https://aibio.space/news/can-fite-details-1-3-000-reverse-split-ads-ratio-change-6/https://aibio.space/news/can-fite-details-1-3-000-reverse-split-ads-ratio-change-6/Tue, 08 Sep 2026 12:00:00 GMTListingsA September 2026 report sets out a 1-for-3,000 reverse split of Can-Fite's ordinary shares in January 2026, and a change that cut each ADS from 300 ordinary shares to two. The company also lists the risk of failing NYSE American continued listing standards.Can-Fite BioPharma Ltd. 6-K (2026-09-08) https://aibio.space/news/keros-therapeutics-authorizes-5-million-share-buyback-after-20-million/https://aibio.space/news/keros-therapeutics-authorizes-5-million-share-buyback-after-20-million/Tue, 08 Sep 2026 12:00:00 GMTFinancingsThe board approved the program after Keros received a development milestone payment under its elritercept license with Takeda. The program does not oblige Keros to buy any shares.Keros Therapeutics, Inc. 8-K (2026-09-08) https://aibio.space/news/ispecimen-agrees-buy-foldlab-ai-software-assets-4-500-000/https://aibio.space/news/ispecimen-agrees-buy-foldlab-ai-software-assets-4-500-000/Fri, 04 Sep 2026 12:00:00 GMTListingsThe deal pays $2,000,000 in cash, including milestone payments, and $2,500,000 in stock held in a five-year escrow.Form 8-K https://aibio.space/news/biorestoratives-r-d-vice-president-resigns-claims-severance/https://aibio.space/news/biorestoratives-r-d-vice-president-resigns-claims-severance/Fri, 04 Sep 2026 12:00:00 GMTCompany UpdatesThe company's board does not accept that the resignation was for good reason. The notice seeks about $1.29 million in cash severance under a disputed agreement.BioRestorative Therapies, Inc. 8-K (2026-09-11) https://aibio.space/news/matinas-biopharma-receives-nyse-american-stockholders-equity-notice/https://aibio.space/news/matinas-biopharma-receives-nyse-american-stockholders-equity-notice/Fri, 04 Sep 2026 12:00:00 GMTListingsThe exchange says stockholders' equity was $1.8 million at June 30, 2026, below the $2.0 million standard, and the listing continues under an accepted plan through October 2, 2027.Matinas Biopharma Holdings, Inc. 8-K (2026-09-04) https://aibio.space/news/intellia-therapeutics-gets-up-400-million-term-loan-orbimed/https://aibio.space/news/intellia-therapeutics-gets-up-400-million-term-loan-orbimed/Fri, 04 Sep 2026 12:00:00 GMTDebt FinancingIntellia Therapeutics will receive $75 million at closing under the facility. Up to $225 million more depends mainly on milestones for lonvo-z.Intellia Therapeutics, Inc. 8-K (2026-09-04) https://aibio.space/news/nutriband-reports-3-42-million-cash-says-operations-will-fund-next/https://aibio.space/news/nutriband-reports-3-42-million-cash-says-operations-will-fund-next/Fri, 04 Sep 2026 12:00:00 GMTFinancingsNutriband says its operations will fund the next year and that going-concern doubt is gone, but revenue and spending both fell in the quarter and the company still burned cash.NTRB 10-Q https://aibio.space/news/nutriband-says-lawsuit-ended-offering-engagement-remains-discovery/https://aibio.space/news/nutriband-says-lawsuit-ended-offering-engagement-remains-discovery/Fri, 04 Sep 2026 12:00:00 GMTLegalJoseph Gunnar and Lucosky Brookman sued Nutriband, CEO Gareth Sheridan, President Serguei Melnik, Vitalie Botgros, TII Jet Services and Wolf Blitz in 2023 over a terminated offering engagement. Nutriband denies the claims and has counterclaimed.NTRB 10-Q https://aibio.space/news/quince-therapeutics-now-irulya-therapeutics-gets-nasdaq-stockholders/https://aibio.space/news/quince-therapeutics-now-irulya-therapeutics-gets-nasdaq-stockholders/Fri, 04 Sep 2026 12:00:00 GMTListingsNasdaq told Quince Therapeutics its stockholders' equity was ($35,324,000), below the $10,000,000 minimum. The company has until October 15, 2026 to submit a compliance plan and has filed an initial listing application that would come with a name change.IRulya Therapeutics Inc. Form 8-K filed September 4, 2026 (SEC EDGAR) https://aibio.space/news/adarx-pharmaceuticals-files-ipo-plans-nasdaq-listing-adrx/https://aibio.space/news/adarx-pharmaceuticals-files-ipo-plans-nasdaq-listing-adrx/Fri, 04 Sep 2026 12:00:00 GMTFinancingsADARx Pharmaceuticals filed an S-1 for a Nasdaq IPO under ADRX, with five banks on the cover and the share count and price range left blank. Its net loss was $73,088 thousand in 2025, and it holds a $335.0 million upfront payment from AbbVie.ADARx Pharmaceuticals, Inc. S-1 (2026-09-04) https://aibio.space/news/clearmind-medicine-agrees-buy-51-percent-charging-robotics-2-5-million/https://aibio.space/news/clearmind-medicine-agrees-buy-51-percent-charging-robotics-2-5-million/Fri, 04 Sep 2026 12:00:00 GMTMergersClearmind will also lend Charging Robotics $1.5 million at 4% as a condition of closing, which is expected the week of September 7, 2026.Clearmind Medicine Inc. 6-K (2026-09-04) https://aibio.space/news/polyrizon-closes-4-0-million-registered-direct-offering-private/https://aibio.space/news/polyrizon-closes-4-0-million-registered-direct-offering-private/Fri, 04 Sep 2026 12:00:00 GMTFinancingsPolyrizon closed about $4.0 million from a registered direct offering and a concurrent private placement sold to one institutional investor, at $12.00 per unit. Aegis Capital Corp. acted as placement agent, and its fee took 8% of the registered portion.Polyrizon Ltd. 424B5 (2026-09-04) https://aibio.space/news/xortx-therapeutics-files-2-500-000-paid-promotion-agreement-ir-agency/https://aibio.space/news/xortx-therapeutics-files-2-500-000-paid-promotion-agreement-ir-agency/Fri, 04 Sep 2026 12:00:00 GMTListingsThe consulting agreement covers up to 10 news releases over 3 months starting 9/3/2026. The fee is non-refundable, and the agreement says the services are promotional.XORTX Therapeutics Inc. 6-K (2026-09-04) https://aibio.space/news/aptevo-reports-93-percent-clinical-benefit-rate-mipletamig-tp53/https://aibio.space/news/aptevo-reports-93-percent-clinical-benefit-rate-mipletamig-tp53/Thu, 03 Sep 2026 12:00:00 GMTCompany UpdatesThirteen of 14 evaluable TP53-mutated frontline AML patients treated with mipletamig, venetoclax and azacitidine had clinical benefit, according to Aptevo's September 3, 2026 release.Aptevo Therapeutics Inc. 8-K (2026-09-03) https://aibio.space/news/hepion-pharmaceuticals-issues-500-000-secured-convertible-note/https://aibio.space/news/hepion-pharmaceuticals-issues-500-000-secured-convertible-note/Thu, 03 Sep 2026 12:00:00 GMTDebt FinancingThe note bears 8% interest payable in kind and matures September 3, 2027. It converts at $0.04 per share after stockholders approve more authorized shares.Hepion Pharmaceuticals, Inc. 8-K (2026-09-08) https://aibio.space/news/senti-biosciences-unit-sells-2-0-million-convertible-notes-nsg/https://aibio.space/news/senti-biosciences-unit-sells-2-0-million-convertible-notes-nsg/Thu, 03 Sep 2026 12:00:00 GMTDebt FinancingThe notes were issued under an April 27, 2026 purchase agreement, as amended on September 1, 2026. A separate $2.5 million equity commitment was signed the same day.Senti Biosciences Holdings, Inc. 8-K (2026-09-04) https://aibio.space/news/prf-technologies-reports-8-526-thousand-cash-june-30-2026/https://aibio.space/news/prf-technologies-reports-8-526-thousand-cash-june-30-2026/Thu, 03 Sep 2026 12:00:00 GMTListingsCash rose to $8,526 thousand at June 30, 2026, from $3,125 thousand at year end, while the six-month loss was $2,942 thousand. Most of the cash came from a $10.0 million equity line that has since ended.PRF Technologies Ltd. 6-K (2026-09-03) https://aibio.space/news/tuhura-biosciences-borrows-1-500-000-under-parkview-revolving-facility/https://aibio.space/news/tuhura-biosciences-borrows-1-500-000-under-parkview-revolving-facility/Wed, 02 Sep 2026 12:00:00 GMTDebt FinancingThe company borrowed $1,500,000 on September 2, 2026 under a loan agreement with Parkview Holdings One LLC. The facility allows up to $50 million and matures on April 21, 2031.TuHURA Biosciences, Inc. 8-K (2026-09-04) https://aibio.space/news/volitionrx-gets-lind-waiver-atm-sales-above-10-million/https://aibio.space/news/volitionrx-gets-lind-waiver-atm-sales-above-10-million/Wed, 02 Sep 2026 12:00:00 GMTDebt FinancingLind Global Asset Management XII waived defaults tied to at-the-market sales above the $10 million annual cap on notes issued in 2025 and 2026.VOLITIONRX LTD 8-K (2026-09-02) https://aibio.space/news/tscan-cuts-75-percent-staff-pauses-phase-3-trial-lack-capital/https://aibio.space/news/tscan-cuts-75-percent-staff-pauses-phase-3-trial-lack-capital/Wed, 02 Sep 2026 12:00:00 GMTDistressTScan will cut about 75% of its workforce, stop enrolling its phase 3 ALLOHA-2 trial for lack of capital and focus on solid tumors. Amgen is also ending a Crohn's disease collaboration, and Nasdaq has warned that the stock failed the $1.00 minimum bid for 30 straight trading days.TScan Therapeutics (press release and SEC Form 8-K) https://aibio.space/news/biorestorative-gets-nasdaq-late-filing-notice-then-does-1-20-reverse/https://aibio.space/news/biorestorative-gets-nasdaq-late-filing-notice-then-does-1-20-reverse/Wed, 02 Sep 2026 12:00:00 GMTListingsNasdaq flagged a missing June-quarter 10-Q on Aug. 21. Days later the company announced a reverse split that cut its shares outstanding to about 1.38 million to fix a separate bid-price shortfall.SEC EDGAR, BioRestorative Therapies Form 8-K (press release) https://aibio.space/news/anavex-regains-nasdaq-compliance-after-filing-overdue-10-qs-august-28/https://aibio.space/news/anavex-regains-nasdaq-compliance-after-filing-overdue-10-qs-august-28/Wed, 02 Sep 2026 12:00:00 GMTListingsNasdaq says Anavex has regained compliance after filing overdue quarterly reports, but the release does not say why they were late.Anavex Life Sciences Corp. 8-K (2026-09-02) https://aibio.space/news/immuteps-fy2026-loss-widens-29-1-percent-after-tacti-004-lung-cancer/https://aibio.space/news/immuteps-fy2026-loss-widens-29-1-percent-after-tacti-004-lung-cancer/Wed, 02 Sep 2026 12:00:00 GMTFinancingsLoss after tax attributable to owners was 79,304,563 for the year ended 30 June 2026, up from 61,434,165. Revenue included $14.6 million from licensing partner Dr Reddy's.Immutep Ltd 6-K (2026-09-02) https://aibio.space/news/quantum-biopharma-applies-delist-class-b-shares-cse/https://aibio.space/news/quantum-biopharma-applies-delist-class-b-shares-cse/Wed, 02 Sep 2026 12:00:00 GMTListingsQuantum BioPharma has applied to delist its Class B shares from the Canadian Securities Exchange, with September 4, 2026 expected as the last trading day, subject to approval. The company's own release does not give the trading volumes behind the decision.Quantum Biopharma Ltd. 6-K (2026-09-02) https://aibio.space/news/intelligent-bio-solutions-places-up-15-million-one-investor/https://aibio.space/news/intelligent-bio-solutions-places-up-15-million-one-investor/Tue, 01 Sep 2026 12:00:00 GMTFinancingsThe private placement brings about $5.0 million at closing, with a further $5 million tranche of warrants, and Ladenburg Thalmann & Co. Inc. acts as placement agent.INTELLIGENT BIO SOLUTIONS INC. 8-K (2026-09-02) https://aibio.space/news/international-stem-cell-completes-sale-lifeline-cell-technology-atcc/https://aibio.space/news/international-stem-cell-completes-sale-lifeline-cell-technology-atcc/Tue, 01 Sep 2026 12:00:00 GMTMergersThe sale closed September 1, 2026 at an adjusted price of $25,250,000, and the company filed unaudited pro forma statements showing its effect.International Stem Cell CORP 8-K (2026-09-08) https://aibio.space/news/profusa-sells-another-senior-secured-convertible-note-ascent/https://aibio.space/news/profusa-sells-another-senior-secured-convertible-note-ascent/Tue, 01 Sep 2026 12:00:00 GMTDebt FinancingThe note has a principal amount of $329,670.33 and was sold for $300,000.00, reflecting original issue discount. Ascent Partners Fund LLC is the initial purchaser.Profusa, Inc. 8-K (2026-09-01) https://aibio.space/news/kpc-gets-registration-rmb1-billion-medium-term-notes/https://aibio.space/news/kpc-gets-registration-rmb1-billion-medium-term-notes/Tue, 01 Sep 2026 12:00:00 GMTDebt FinancingA non-wholly owned subsidiary of China Resources Pharmaceutical received a two-year registration for up to RMB1 billion of medium term notes.China Resources Pharmaceutical Group Limited announcement (2026-09-01) https://aibio.space/news/earth-science-tech-holders-approve-reverse-split-authority-uplisting/https://aibio.space/news/earth-science-tech-holders-approve-reverse-split-authority-uplisting/Tue, 01 Sep 2026 12:00:00 GMTListingsShareholders approved authority for a reverse split tied to an uplisting, and a special committee to negotiate retiring the Series B preferred stock. The company's release reports no vote counts.Earth Science Tech, Inc. 8-K (2026-09-01) https://aibio.space/news/lifeward-chief-executive-mark-grant-departs-josh-hexter-named-interim/https://aibio.space/news/lifeward-chief-executive-mark-grant-departs-josh-hexter-named-interim/Mon, 31 Aug 2026 12:00:00 GMTCompany UpdatesMark Grant leaves as president, chief executive and director effective August 31, 2026, and Josh Hexter becomes interim chief executive on September 1. Rami Aviram is named chief financial officer effective November 1, 2026.Lifeward Ltd. 8-K (2026-08-31) https://aibio.space/news/aim-immunotech-satisfies-streeterville-note-full-through-share/https://aibio.space/news/aim-immunotech-satisfies-streeterville-note-full-through-share/Mon, 31 Aug 2026 12:00:00 GMTDebt FinancingAIM ImmunoTech converted approximately $1,224,341 of a February 16, 2024 promissory note held by Streeterville Capital, LLC into 5,065,840 shares, and the note was satisfied in full as of September 3, 2026.AIM ImmunoTech Inc. 8-K (2026-09-04) https://aibio.space/news/pds-biotechnology-amends-6-000-000-promissory-note/https://aibio.space/news/pds-biotechnology-amends-6-000-000-promissory-note/Mon, 31 Aug 2026 12:00:00 GMTDebt FinancingPDS Biotechnology amended a $6,000,000 note with YA II PN, Ltd. to require weekly remittances from at-the-market sales and to apply other equity proceeds to a mandatory redemption payment.PDS Biotechnology Corporation 8-K (2026-09-04) https://aibio.space/news/kyntra-bio-cuts-royalty-financing-cap-65-million/https://aibio.space/news/kyntra-bio-cuts-royalty-financing-cap-65-million/Mon, 31 Aug 2026 12:00:00 GMTDebt FinancingKyntra Bio amended its royalty financing agreement with NQ Project Phoebus, L.P., lowering the maximum payments and making a $42.6 million upfront payment.Kyntra Bio, Inc. 8-K (2026-08-31) https://aibio.space/news/cdt-equity-issues-541-620-senior-secured-convertible-note-j-j-astor/https://aibio.space/news/cdt-equity-issues-541-620-senior-secured-convertible-note-j-j-astor/Mon, 31 Aug 2026 12:00:00 GMTDebt FinancingThe note was issued on August 31, 2026 and repaid in full on September 4, 2026. It came with warrants for 237,000 shares.CDT Equity Inc. 8-K (2026-09-04) https://aibio.space/news/moderna-sells-3-0-billion-zero-coupon-convertible-notes-after-upsized/https://aibio.space/news/moderna-sells-3-0-billion-zero-coupon-convertible-notes-after-upsized/Fri, 28 Aug 2026 12:00:00 GMTDebt FinancingThe notes convert at about $210.58 a share, 47.5% above the August 27 close, and proceeds may fund the oncology business.Moderna (SEC Form 8-K) https://aibio.space/news/teva-bids-57-5-million-upfront-bioxcels-agitation-drug-bankruptcy-sale/https://aibio.space/news/teva-bids-57-5-million-upfront-bioxcels-agitation-drug-bankruptcy-sale/Fri, 28 Aug 2026 12:00:00 GMTDistressTeva is the stalking horse bidder for BioXcel's dexmedetomidine film, which faces an FDA decision on at-home use by Nov. 14. Other bidders can still top the offer.Teva Pharmaceutical Industries https://aibio.space/news/aprea-therapeutics-reports-expanded-patent-portfolio-wee1-atr-programs/https://aibio.space/news/aprea-therapeutics-reports-expanded-patent-portfolio-wee1-atr-programs/Fri, 28 Aug 2026 12:00:00 GMTCompany UpdatesAprea said it holds 28 issued and 30 pending patents for its precision oncology programs, with the WEE1 family of applications expiring in 2047 if granted.Aprea Therapeutics, Inc. 8-K (2026-08-28) https://aibio.space/news/vyome-names-jerry-leonard-chief-financial-officer/https://aibio.space/news/vyome-names-jerry-leonard-chief-financial-officer/Fri, 28 Aug 2026 12:00:00 GMTCompany UpdatesThe board appointed Jerry Leonard as chief financial officer on August 27, 2026, effective September 1, 2026, under a consulting agreement with ClearbridgeCFO, LLC, after interim CFO Robert Dickey gave notice of his resignation.Vyome Holdings, Inc. 8-K (2026-08-28) https://aibio.space/news/tenon-medical-prices-3-0-million-private-placement-warrants/https://aibio.space/news/tenon-medical-prices-3-0-million-private-placement-warrants/Fri, 28 Aug 2026 12:00:00 GMTFinancingsTenon Medical agreed to sell 597,610 shares, or pre-funded warrants, to an institutional investor, with warrants for up to 1,058,517 more shares. WallachBeth Capital LLC is the exclusive placement agent.Tenon Medical, Inc. 8-K (2026-08-31) https://aibio.space/news/oragenics-receives-nyse-american-deficiency-letter-equity/https://aibio.space/news/oragenics-receives-nyse-american-deficiency-letter-equity/Fri, 28 Aug 2026 12:00:00 GMTListingsNYSE American notified Oragenics on August 26, 2026 that it is not in compliance with two continued listing standards on stockholders' equity. The company has 45 days to submit a compliance plan and says it intends to do so.Oragenics Inc. 8-K (2026-08-28) https://aibio.space/news/glucotrack-effects-1-15-reverse-stock-split/https://aibio.space/news/glucotrack-effects-1-15-reverse-stock-split/Fri, 28 Aug 2026 12:00:00 GMTListingsThe reverse split took effect August 28, 2026, with trading on a split-adjusted basis from August 31, 2026, and shares outstanding were reduced from 11,972,157 to approximately 798,144.Glucotrack, Inc. 8-K (2026-08-28) https://aibio.space/news/envue-medical-announces-1-12-reverse-stock-split-effective-september-1/https://aibio.space/news/envue-medical-announces-1-12-reverse-stock-split-effective-september-1/Fri, 28 Aug 2026 12:00:00 GMTListingsEach 12 shares will combine into one, which would reduce the 11,084,616 common shares outstanding to about 923,718. The release says trading begins on the Nasdaq Capital Market on September 1, 2026, under the FEED symbol.ENvue Medical press release (Form 8-K, Exhibit 99.1) https://aibio.space/news/insilico-medicine-plans-us-305-million-convertible-bond-sale/https://aibio.space/news/insilico-medicine-plans-us-305-million-convertible-bond-sale/Fri, 28 Aug 2026 12:00:00 GMTDebt FinancingThe company agreed on August 27, 2026 to issue convertible bonds with an initial conversion price of HK$58.07 per share.InSilico Medicine Cayman TopCo announcement (2026-08-28) https://aibio.space/news/biolinerx-raises-3-75m-2-78-ads-1-5x-warrant-coverage/https://aibio.space/news/biolinerx-raises-3-75m-2-78-ads-1-5x-warrant-coverage/Fri, 28 Aug 2026 12:00:00 GMTFinancingsBioLineRx sold 1,348,921 ADSs at $2.78 each and issued warrants on 2,023,382 more ADSs. It also amended older warrants on 277,273 ADSs and cut its at-the-market facility to zero.BioLineRx press release (SEC Form 6-K, Exhibit 1) https://aibio.space/news/quoin-pharmaceuticals-agrees-private-placement-about-30-8-million/https://aibio.space/news/quoin-pharmaceuticals-agrees-private-placement-about-30-8-million/Fri, 28 Aug 2026 12:00:00 GMTFinancingsQuoin agreed to sell 6,305,300 ADSs or pre-funded warrants at $4.88 and warrants for up to 3,152,650 ADSs, for about $30.8 million at closing. The same day it reported interim results from six patients, and its 10-K carries a going-concern warning.Quoin Pharmaceuticals Ltd. Form 8-K filed August 28, 2026 (SEC EDGAR) https://aibio.space/news/shuttle-pharmaceuticals-gets-nasdaq-deficiency-notice-late-form-10/https://aibio.space/news/shuttle-pharmaceuticals-gets-nasdaq-deficiency-notice-late-form-10/Fri, 28 Aug 2026 12:00:00 GMTListingsNasdaq says Shuttle no longer meets Listing Rule 5250(c)(1) because its quarterly report for the period ended June 30, 2026 is late. A plan to regain compliance is due October 27, 2026.Shuttle Pharmaceuticals Holdings, Inc. Form 8-K filed August 28, 2026 (SEC EDGAR) https://aibio.space/news/can-fite-files-100-000-000-shelf-market-program-up-1-065-000/https://aibio.space/news/can-fite-files-100-000-000-shelf-market-program-up-1-065-000/Fri, 28 Aug 2026 12:00:00 GMTFinancingsCan-Fite BioPharma's shelf sets a ceiling of $100,000,000, but the at-the-market sales agreement with H.C. Wainwright & Co., LLC covers only $1,065,000, a limit set by its public float.Can-Fite BioPharma Ltd. F-3 (2026-08-28) https://aibio.space/news/electra-therapeutics-files-ipo-plans-nasdaq-listing-etra/https://aibio.space/news/electra-therapeutics-files-ipo-plans-nasdaq-listing-etra/Fri, 28 Aug 2026 12:00:00 GMTFinancingsElectra Therapeutics filed a Form S-1 on August 28, 2026, and the cover leaves the share count and price range blank. Its auditor's report includes a going concern paragraph, and the company says its cash may not cover the next 12 months.Electra Therapeutics, Inc. S-1 (2026-08-28) https://aibio.space/news/china-sxt-cuts-pre-paid-share-purchase-floor-price-back-0-20-16-00/https://aibio.space/news/china-sxt-cuts-pre-paid-share-purchase-floor-price-back-0-20-16-00/Fri, 28 Aug 2026 12:00:00 GMTListingsThe July 3, 2026 agreement allows pre-paid purchases of up to $31,500,000 before an original issue discount. The August 27 amendment restores the $0.20 floor after a 1-for-80 share consolidation had raised it to $16.00.China SXT Pharmaceuticals, Inc. 6-K (2026-08-28) https://aibio.space/news/jazz-prices-1-1-billion-exchangeable-notes-repurchases-225-million/https://aibio.space/news/jazz-prices-1-1-billion-exchangeable-notes-repurchases-225-million/Thu, 27 Aug 2026 12:00:00 GMTFinancingsThe 1.875% notes due 2032 carry an exchange price of about $355.24, a 42.5% premium to the Aug. 26 close. The offering was upsized from $1.0 billion.Jazz Pharmaceuticals (SEC Form 8-K, Exhibit 99.2) https://aibio.space/news/osr-health-hearing-before-nasdaq-panel-set-september-29/https://aibio.space/news/osr-health-hearing-before-nasdaq-panel-set-september-29/Thu, 27 Aug 2026 12:00:00 GMTListingsThe Nasdaq Hearings Panel scheduled OSR Health's hearing for September 29, 2026, while trading in its securities remains suspended under the company's own filing.OSR Health, Inc. 8-K (2026-08-28) https://aibio.space/news/artelo-biosciences-sets-1-9-reverse-split-trading-august-31-2026/https://aibio.space/news/artelo-biosciences-sets-1-9-reverse-split-trading-august-31-2026/Thu, 27 Aug 2026 12:00:00 GMTListingsArtelo will combine every nine shares of common stock into one, with split-adjusted trading beginning August 31, 2026, and about 547,774 shares outstanding afterward.Artelo Biosciences, Inc. 8-K (2026-08-27) https://aibio.space/news/valion-sets-1-25-reverse-stock-split-regain-nasdaq-compliance/https://aibio.space/news/valion-sets-1-25-reverse-stock-split-regain-nasdaq-compliance/Thu, 27 Aug 2026 12:00:00 GMTListingsThe split takes effect August 31, 2026 under the same VBIO symbol, and the company says it aims to meet the Nasdaq minimum bid price rule.Valion Bio, Inc. 8-K (2026-08-27) https://aibio.space/news/moderna-plans-2-0-billion-convertible-notes-private-placement/https://aibio.space/news/moderna-plans-2-0-billion-convertible-notes-private-placement/Thu, 27 Aug 2026 12:00:00 GMTDebt FinancingModerna said it intends to sell $2.0 billion of notes due 2032, with an option for up to $300.0 million more. It would also enter capped call transactions to reduce potential dilution.Moderna, Inc. 8-K (2026-09-01) https://aibio.space/news/cero-therapeutics-consolidates-older-notes-secured-srx-global-loan/https://aibio.space/news/cero-therapeutics-consolidates-older-notes-secured-srx-global-loan/Thu, 27 Aug 2026 12:00:00 GMTDebt FinancingThe note combines earlier notes and lets SRX advance up to $6,000,000 in total at 10% interest. Principal and interest are due October 15, 2026.CERo Therapeutics Holdings, Inc. 8-K (2026-08-31) https://aibio.space/news/pharmaron-agrees-issue-rmb2-180-million-convertible-bonds/https://aibio.space/news/pharmaron-agrees-issue-rmb2-180-million-convertible-bonds/Thu, 27 Aug 2026 12:00:00 GMTDebt FinancingPharmaron Beijing signed an agreement on August 26, 2026 for convertible bonds with an initial conversion price of HK$36.08 per H share.Pharmaron Beijing Co., Ltd. announcement (2026-08-27) https://aibio.space/news/bioxcel-files-chapter-11-teva-57-5-million-stalking-horse-bidder/https://aibio.space/news/bioxcel-files-chapter-11-teva-57-5-million-stalking-horse-bidder/Thu, 27 Aug 2026 12:00:00 GMTDistressBioXcel filed Chapter 11 on Aug 27 with Teva's $57.5 million upfront bid as the floor for a court auction. That upfront sum is below the company's $107,152 thousand of total debt at June 30.BioXcel Therapeutics (SEC Form 8-K) https://aibio.space/news/cyclerion-now-korsana-biosciences-shareholders-approve-merger-issuance/https://aibio.space/news/cyclerion-now-korsana-biosciences-shareholders-approve-merger-issuance/Thu, 27 Aug 2026 12:00:00 GMTMergersShareholders backed the Korsana merger share issuance and change of control on August 26, 2026. The combined company expects to trade on Nasdaq as KRSA from September 9, 2026; a Cayman redomestication failed.Korsana Biosciences, Inc. Form 8-K filed August 27, 2026 (SEC EDGAR) https://aibio.space/news/senti-biosciences-gets-two-nasdaq-notices-bid-price-3-4m-equity/https://aibio.space/news/senti-biosciences-gets-two-nasdaq-notices-bid-price-3-4m-equity/Thu, 27 Aug 2026 12:00:00 GMTListingsNasdaq flagged Senti's sub-$1 share price and a stockholders' deficit below the $2.5 million minimum. The bid-price clock runs to Feb. 23, 2027; the equity plan is due Oct. 11.SEC EDGAR, Senti Biosciences Form 8-K https://aibio.space/news/optimi-health-sets-up-equity-line-sell-up-us-100-million-shares-seven/https://aibio.space/news/optimi-health-sets-up-equity-line-sell-up-us-100-million-shares-seven/Thu, 27 Aug 2026 12:00:00 GMTFinancingsOptimi can sell shares to Seven Knots, LLC at its discretion, up to US$2 million per draw. It issued a US$1.5 million convertible note as a commitment fee.Optimi Health Corp. 6-K (2026-08-27) https://aibio.space/news/nuwellis-investor-presentation-cites-20-percent-first-half-revenue/https://aibio.space/news/nuwellis-investor-presentation-cites-20-percent-first-half-revenue/Wed, 26 Aug 2026 12:00:00 GMTCompany UpdatesThe August 2026 deck says first-half revenue rose 20% and that cash runway extends through 2Q27.Nuwellis, Inc. 8-K (2026-08-26) https://aibio.space/news/leonabio-enrolls-500th-subject-phase-3-elaine-3-trial/https://aibio.space/news/leonabio-enrolls-500th-subject-phase-3-elaine-3-trial/Wed, 26 Aug 2026 12:00:00 GMTFinancingsLeonaBio said it enrolled the 500th subject in its ELAINE-3 trial of lasofoxifene, an announcement that also sets a date used in the exercise terms of its Series A warrants.LeonaBio, Inc. 8-K (2026-08-26) https://aibio.space/news/interpace-biosciences-sets-1-5-reverse-stock-split-support-nasdaq-bid/https://aibio.space/news/interpace-biosciences-sets-1-5-reverse-stock-split-support-nasdaq-bid/Wed, 26 Aug 2026 12:00:00 GMTListingsThe split takes effect August 27, 2026 and reduces outstanding shares from approximately 27.7 million to approximately 5.5 million, aimed at Nasdaq's minimum bid price requirement.Form 8-K, Exhibit 99.1 (SEC EDGAR) https://aibio.space/news/jazz-plans-1-0-billion-exchangeable-notes-offering-share-buyback/https://aibio.space/news/jazz-plans-1-0-billion-exchangeable-notes-offering-share-buyback/Wed, 26 Aug 2026 12:00:00 GMTDebt FinancingJazz Investments I Limited plans to sell $1.0 billion of exchangeable notes due 2032. Jazz also expects to buy back up to $225.0 million of its ordinary shares from note purchasers.Jazz Pharmaceuticals plc 8-K (2026-08-31) https://aibio.space/news/turn-sells-1-35-million-stock-existing-investors-10-00-share/https://aibio.space/news/turn-sells-1-35-million-stock-existing-investors-10-00-share/Wed, 26 Aug 2026 12:00:00 GMTFinancingsA Form D filed August 26, 2026 reports $1,650,000 sold to eight investors, while the August 14 agreements covered $1.35 million. The shares carry registration rights.SEC EDGAR: Turn Therapeutics D https://aibio.space/news/immatics-agrees-sell-shares-warrants-8-69-150-million-offering/https://aibio.space/news/immatics-agrees-sell-shares-warrants-8-69-150-million-offering/Wed, 26 Aug 2026 12:00:00 GMTFinancingsImmatics agreed to sell 12,945,916 ordinary shares at $8.69, plus pre-funded warrants for 4,315,304 shares, for expected gross proceeds of $150 million. Its 2025 net loss was €196.4 million, after net income of €15.2 million in 2024.Immatics N.V. 6-K (2026-08-26) https://aibio.space/news/ptc-agrees-buy-sangamos-fabry-gene-therapy-st-920-bankruptcy/https://aibio.space/news/ptc-agrees-buy-sangamos-fabry-gene-therapy-st-920-bankruptcy/Tue, 25 Aug 2026 12:00:00 GMTDistressPTC Therapeutics will pay $111 million upfront and up to $100 million more in milestones for ST-920, subject to approval by the bankruptcy court.PTC Therapeutics, Inc. 8-K (2026-08-28) https://aibio.space/news/miles-suk-steps-down-abpro-holdings-chairman-but-stays-board/https://aibio.space/news/miles-suk-steps-down-abpro-holdings-chairman-but-stays-board/Tue, 25 Aug 2026 12:00:00 GMTCompany UpdatesAbpro Holdings said Miles Suk resigned as chairman of its board effective August 25, 2026. The board will appoint a successor chair at its next regularly scheduled meeting.Abpro Holdings Form 8-K (Item 5.02) https://aibio.space/news/ensysce-gets-nasdaq-bid-price-extension-february-2027/https://aibio.space/news/ensysce-gets-nasdaq-bid-price-extension-february-2027/Tue, 25 Aug 2026 12:00:00 GMTListingsNasdaq extended the Ensysce Biosciences bid price deadline to February 22, 2027, and said the company must meet initial listing criteria after its Cy Biopharma acquisition.Ensysce Biosciences, Inc. 8-K (2026-08-25) https://aibio.space/news/hepion-sells-8-000-000-shares-warrants-400-000-private-placement/https://aibio.space/news/hepion-sells-8-000-000-shares-warrants-400-000-private-placement/Tue, 25 Aug 2026 12:00:00 GMTFinancingsThe agreements are dated August 25, 2026, and priced at $0.05 per share. The filing names no underwriter or placement agent.Hepion Pharmaceuticals, Inc. 8-K (2026-08-27) https://aibio.space/news/pds-biotechnology-cut-about-36-percent-workforce-removes-chief/https://aibio.space/news/pds-biotechnology-cut-about-36-percent-workforce-removes-chief/Tue, 25 Aug 2026 12:00:00 GMTDistressPDS Biotechnology approved a reduction in force on August 6, 2026 and estimates a one-time charge of approximately $842,000. It also ended Stephan Toutain's role as Chief Operating Officer.PDS Biotechnology Corp Form 8-K filed August 25, 2026 (SEC EDGAR) https://aibio.space/news/bioxcel-takes-1-250-000-additional-term-loans-lenders/https://aibio.space/news/bioxcel-takes-1-250-000-additional-term-loans-lenders/Mon, 24 Aug 2026 12:00:00 GMTDebt FinancingThe amendment also lowers the minimum cash liquidity covenant to $250,000 and sets an August 31, 2026 deadline for a transaction acceptable to the lenders.BioXcel Therapeutics, Inc. 8-K (2026-08-25) https://aibio.space/news/longeveron-does-1-10-reverse-split-meet-nasdaqs-1-bid-minimum/https://aibio.space/news/longeveron-does-1-10-reverse-split-meet-nasdaqs-1-bid-minimum/Mon, 24 Aug 2026 12:00:00 GMTListingsThe split took effect Aug. 26 and cut Class A shares to about 3.04 million. Three weeks later the company reported that its HLHS trial missed its primary endpoint.SEC EDGAR, Longeveron press release (Form 8-K Ex. 99.1) https://aibio.space/news/arbutus-biopharma-starts-tender-offer-up-us-230-million-shares/https://aibio.space/news/arbutus-biopharma-starts-tender-offer-up-us-230-million-shares/Mon, 24 Aug 2026 12:00:00 GMTFinancingsArbutus filed a Schedule TO on August 24, 2026 to start an issuer tender offer for up to US$230 million of its common shares, paid in cash. The filing points to an Offer to Purchase dated the same day, and it does not state the start or expiry dates in its own text.Arbutus Biopharma Corporation SC TO-I (2026-08-24) https://aibio.space/news/skye-bioscience-signs-equity-line-redmile-affiliate-up-22-000-000/https://aibio.space/news/skye-bioscience-signs-equity-line-redmile-affiliate-up-22-000-000/Mon, 24 Aug 2026 12:00:00 GMTFinancingsSkye Bioscience's equity line with a Redmile affiliate covers up to $22,000,000 and requires purchases of up to $2,000,000 a month once it starts. The line is reduced if the PIPE exceeds $103,000,000 and falls away at $125,000,000.Skye Bioscience, Inc. 8-K (2026-08-24) https://aibio.space/news/vivosim-labs-receives-nasdaq-bid-price-notice-february-2027-deadline/https://aibio.space/news/vivosim-labs-receives-nasdaq-bid-price-notice-february-2027-deadline/Fri, 21 Aug 2026 12:00:00 GMTListingsNasdaq staff said VivoSim Labs has until February 16, 2027 to show a closing bid price of at least $1 for ten consecutive business days, and the company is weighing a reverse split.VivoSim Labs, INC. 8-K (2026-08-21) https://aibio.space/news/pasithea-receives-nasdaq-extension-regain-bid-price-compliance/https://aibio.space/news/pasithea-receives-nasdaq-extension-regain-bid-price-compliance/Fri, 21 Aug 2026 12:00:00 GMTListingsNasdaq granted Pasithea Therapeutics 180 more days, to February 16, 2027, to regain the $1.00 minimum closing bid price required for continued listing.Pasithea Therapeutics Corp. 8-K (2026-08-21) https://aibio.space/news/azitra-regains-nyse-american-continued-listing-compliance/https://aibio.space/news/azitra-regains-nyse-american-continued-listing-compliance/Fri, 21 Aug 2026 12:00:00 GMTListingsNYSE Regulation's August 19, 2026 letter says the company resolved deficiencies under two continued listing standards. A new lapse within 12 months could bring faster action.Azitra Inc 8-K (2026-08-21) https://aibio.space/news/kairos-pharma-sets-1-7-reverse-stock-split-effective-september-1-2026/https://aibio.space/news/kairos-pharma-sets-1-7-reverse-stock-split-effective-september-1-2026/Fri, 21 Aug 2026 12:00:00 GMTListingsSplit-adjusted shares will trade under the existing KAPA symbol at market open on September 1, 2026, and the company says the split is meant to help it keep its NYSE American listing.Kairos Pharma, Ltd. 8-K (2026-08-21) https://aibio.space/news/nexgel-names-brian-kieser-interim-ceo-forms-strategic-review-committee/https://aibio.space/news/nexgel-names-brian-kieser-interim-ceo-forms-strategic-review-committee/Fri, 21 Aug 2026 12:00:00 GMTCompany UpdatesBrian Kieser became interim chief executive on August 21, 2026, as Adam Levy left the role. A special committee will review non-core assets, liquidity and the company's long-term strategic direction.NEXGEL, INC. 8-K (2026-08-21) https://aibio.space/news/nexalin-issues-1-170-000-00-promissory-note-streeterville-capital/https://aibio.space/news/nexalin-issues-1-170-000-00-promissory-note-streeterville-capital/Fri, 21 Aug 2026 12:00:00 GMTDebt FinancingThe unsecured note carries a $150,000.00 original issue discount and a $20,000.00 transaction expense amount. The purchase price is $1,000,000.00, and the lender is Streeterville Capital, LLC.Nexalin Technology, Inc. 8-K (2026-08-21) https://aibio.space/news/bcal-diagnostics-details-convertible-note-draws-under-10-million/https://aibio.space/news/bcal-diagnostics-details-convertible-note-draws-under-10-million/Fri, 21 Aug 2026 12:00:00 GMTDebt FinancingAfter raising $3.1 million by February, BCAL drew further notes and plans more, which use up its Listing Rule 7.1 capacity.BCAL Diagnostics Limited release (2026-08-21) https://aibio.space/news/imugene-amends-cvi-convertible-notes-issues-new-warrants/https://aibio.space/news/imugene-amends-cvi-convertible-notes-issues-new-warrants/Fri, 21 Aug 2026 12:00:00 GMTDebt FinancingA$2.1 million of existing notes is redeemed and replaced by new zero-coupon notes, and the remaining notes amortise in five instalments.Imugene Limited release (2026-08-21) https://aibio.space/news/moleculin-lifts-atm-19-7m-weeks-after-9-3m-deal-3x-warrants/https://aibio.space/news/moleculin-lifts-atm-19-7m-weeks-after-9-3m-deal-3x-warrants/Fri, 21 Aug 2026 12:00:00 GMTFinancingsMoleculin can now sell up to $19,700,000 under its at-the-market program, weeks after a July deal with warrants on 37,130,001 shares. The trial figures it cited are blinded and preliminary, drawn from 62 patients.Moleculin Form 424B5 prospectus supplement No. 2 (SEC) https://aibio.space/news/veradermics-ceo-technical-chief-two-large-holders-sell-shares-august/https://aibio.space/news/veradermics-ceo-technical-chief-two-large-holders-sell-shares-august/Fri, 21 Aug 2026 12:00:00 GMTFinancingsInsiders and large holders sold Veradermics stock in August, with a resale prospectus dated August 14 covering selling stockholders. The company receives none of the proceeds from those sales.SEC EDGAR: Veradermics SCHEDULE 13D/A https://aibio.space/news/estrella-immunopharma-gets-nasdaq-minimum-bid-price-notice-has-until/https://aibio.space/news/estrella-immunopharma-gets-nasdaq-minimum-bid-price-notice-has-until/Fri, 21 Aug 2026 12:00:00 GMTListingsNasdaq notified Estrella on August 17, 2026 that its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days, until February 16, 2027, to regain compliance. Its year-end 2025 cash was $1.4 million.Estrella Immunopharma, Inc. Form 8-K filed August 21, 2026 (SEC EDGAR) https://aibio.space/news/elutia-completes-simpliderm-business-sale-cellution-biologics-receives/https://aibio.space/news/elutia-completes-simpliderm-business-sale-cellution-biologics-receives/Fri, 21 Aug 2026 12:00:00 GMTMergersThe August 17, 2026 closing leaves the price open to an inventory adjustment and up to $3 million in contingent payments. Elutia says it will focus on NXT-41x and believes it has funding through the first full year of its commercial launch in 2028.ELUTIA INC. Form 8-K filed August 21, 2026 (SEC EDGAR) https://aibio.space/news/adial-pharmaceuticals-gets-nasdaq-stockholders-equity-notice-plan-due/https://aibio.space/news/adial-pharmaceuticals-gets-nasdaq-stockholders-equity-notice-plan-due/Fri, 21 Aug 2026 12:00:00 GMTListingsNasdaq told Adial on August 18, 2026 that it no longer meets the $2,500,000 stockholders' equity requirement. The company says it anticipates regaining compliance once holders approve conversion of its Series A Non-Voting Convertible Preferred Stock.ADIAL PHARMACEUTICALS, INC. Form 8-K filed August 21, 2026 (SEC EDGAR) https://aibio.space/news/gossamer-bio-private-placement-has-150-million-committed-25-0-million/https://aibio.space/news/gossamer-bio-private-placement-has-150-million-committed-25-0-million/Fri, 21 Aug 2026 12:00:00 GMTFinancingsGossamer Bio's private placement of up to $250 million opens with $25.0 million at a first closing. A $125.0 million second closing depends on FDA acceptance of its seralutinib filing, and warrants that could add about $100.0 million depend on FDA approval.Gossamer Bio, Inc. Form 8-K filed August 21, 2026 (SEC EDGAR) https://aibio.space/news/arbutus-plans-us-230-million-dutch-auction-tender-offer-shares/https://aibio.space/news/arbutus-plans-us-230-million-dutch-auction-tender-offer-shares/Fri, 21 Aug 2026 12:00:00 GMTMergersArbutus said on August 21, 2026 that it plans a modified Dutch auction tender offer for up to US$230 million of its common shares at US$5.00 to US$5.75 each, funded from cash on hand. The offer has not started, and the company says it needs exemptive relief in Canada and the United States first.Arbutus Biopharma Corporation 8-K (2026-08-21) https://aibio.space/news/citius-pharmaceuticals-gets-nasdaq-extension-february-8-2027-bid-price/https://aibio.space/news/citius-pharmaceuticals-gets-nasdaq-extension-february-8-2027-bid-price/Fri, 21 Aug 2026 12:00:00 GMTListingsNasdaq gave Citius Pharmaceuticals until February 8, 2027 to show compliance with its $1.00 minimum bid price. The 8-K gives no closing price and no plan, and the company says it cannot assure it will regain compliance.Citius Pharmaceuticals, Inc. 8-K (2026-08-21) https://aibio.space/news/oruka-therapeutics-files-1-000-000-000-shelf-500-000-000-sales-program/https://aibio.space/news/oruka-therapeutics-files-1-000-000-000-shelf-500-000-000-sales-program/Fri, 21 Aug 2026 12:00:00 GMTFinancingsTD Cowen is the sales agent for up to $500,000,000 of common stock under a sales agreement that sits inside a $1,000,000,000 shelf. The filing puts the outstanding count at 61,069,887 shares on June 30, 2026.Oruka Therapeutics, Inc. S-3 (2026-08-21) https://aibio.space/news/profusa-reports-q2-2026-results-progress-g3-option/https://aibio.space/news/profusa-reports-q2-2026-results-progress-g3-option/Thu, 20 Aug 2026 12:00:00 GMTListingsProfusa reported cash of $719,000 at June 30, 2026, and said it expects stockholders' equity of $28.4 million as of July 31, 2026.Profusa, Inc. 8-K (2026-08-20) https://aibio.space/news/adaptin-bio-opens-enrollment-phase-1-trial-aptn-101-glioblastoma/https://aibio.space/news/adaptin-bio-opens-enrollment-phase-1-trial-aptn-101-glioblastoma/Thu, 20 Aug 2026 12:00:00 GMTCompany UpdatesAdaptin Bio said on August 20, 2026 that enrollment has opened for a Phase 1 study of APTN-101 in patients with glioblastoma. The study is being conducted with Duke University and expects to enroll up to 15 adults.Adaptin Bio press release (Form 8-K, Exhibit 99.1) https://aibio.space/news/protagenic-reports-fda-pre-ind-feedback-pt00114-generalized-anxiety/https://aibio.space/news/protagenic-reports-fda-pre-ind-feedback-pt00114-generalized-anxiety/Thu, 20 Aug 2026 12:00:00 GMTCompany UpdatesThe FDA raised no objection to the planned Phase 1 design and identified no clinical hold issues. Protagenic plans to submit the IND before the end of 2026.Protagenic Therapeutics Form 8-K https://aibio.space/news/curanex-regains-nasdaq-bid-price-compliance-after-1-20-reverse-split/https://aibio.space/news/curanex-regains-nasdaq-bid-price-compliance-after-1-20-reverse-split/Thu, 20 Aug 2026 12:00:00 GMTListingsCuranex's 1-for-20 reverse split took effect on August 20, 2026. Nasdaq closed its bid-price matter on September 3, after the stock traded at or above $1.00 for ten consecutive business days.Curanex 8-K https://aibio.space/news/abbott-agrees-settle-gill-case-preterm-formula-nec-claims/https://aibio.space/news/abbott-agrees-settle-gill-case-preterm-formula-nec-claims/Thu, 20 Aug 2026 12:00:00 GMTLegalAbbott Laboratories, a defendant in numerous NEC lawsuits, agreed to resolve the Gill case, where a jury awarded $495 million, and claims for about 2,000 other infants. About 1,700 lawsuits remain pending.ABBOTT LABORATORIES Form 8-K filed August 20, 2026 (SEC EDGAR) https://aibio.space/news/urogen-signs-option-deal-intragel-agrees-invest-up-7-000-000/https://aibio.space/news/urogen-signs-option-deal-intragel-agrees-invest-up-7-000-000/Thu, 20 Aug 2026 12:00:00 GMTFinancingsUroGen gets an option on IntraGel's TumoCure for advanced head and neck cancer and agrees to invest up to $7,000,000 in IntraGel's equity. The 8-K gives no clinical data, no option fee and no exercise deadline.UroGen Pharma Ltd. 8-K (2026-08-20) https://aibio.space/news/jaguar-health-reports-second-quarter-2026-net-loss-12-7-million/https://aibio.space/news/jaguar-health-reports-second-quarter-2026-net-loss-12-7-million/Wed, 19 Aug 2026 12:00:00 GMTCompany UpdatesNet loss attributable to common stockholders was $12.7 million for the quarter ended June 30, 2026, as U.S. revenue from its two main prescription products now flows to licensee Future Pak under a January 2026 agreement.Jaguar Health, Inc. 8-K (2026-08-19) https://aibio.space/news/osr-health-receives-nasdaq-delisting-determination-will-request/https://aibio.space/news/osr-health-receives-nasdaq-delisting-determination-will-request/Wed, 19 Aug 2026 12:00:00 GMTListingsNasdaq staff said OSR Health did not regain compliance with the $1.00 minimum bid price, and trading in its common stock and warrants will be suspended on August 26, 2026.OSR Health, Inc. 8-K (2026-08-19) https://aibio.space/news/apimeds-pharmaceuticals-takes-assignment-apitox-rights/https://aibio.space/news/apimeds-pharmaceuticals-takes-assignment-apitox-rights/Wed, 19 Aug 2026 12:00:00 GMTCompany UpdatesUnder an agreement dated August 19, 2026, FreeT Inc. assigned to Apimeds Pharmaceuticals a set of Apitox rights, including 100% of the Korean medicine clinic market and a 25% royalty entitlement on U.S. proceeds.Apimeds Pharmaceuticals US, Inc. 8-K (2026-08-21) https://aibio.space/news/kiora-licenses-kio-301-rights-south-korea-chong-kun-dang/https://aibio.space/news/kiora-licenses-kio-301-rights-south-korea-chong-kun-dang/Wed, 19 Aug 2026 12:00:00 GMTCompany UpdatesKiora will receive a $1 million upfront payment from Chong Kun Dang for KIO-301 rights in South Korea. Kiora says its partners will coordinate a single global Phase 3 trial in retinitis pigmentosa.Kiora Pharmaceuticals, Inc. 8-K (2026-08-19) https://aibio.space/news/cosmos-health-reports-second-quarter-2026-revenue-18-99-million/https://aibio.space/news/cosmos-health-reports-second-quarter-2026-revenue-18-99-million/Wed, 19 Aug 2026 12:00:00 GMTCompany UpdatesRevenue rose 28.8% and total liabilities fell 13.3% from year-end 2025, the company said.Cosmos Health Inc. 8-K (2026-08-20) https://aibio.space/news/intelligent-bio-solutions-reports-fiscal-2026-revenue-4-215-175/https://aibio.space/news/intelligent-bio-solutions-reports-fiscal-2026-revenue-4-215-175/Wed, 19 Aug 2026 12:00:00 GMTCompany UpdatesRevenue rose 38% and gross margin reached 48.63%, and the company says its FDA 510(k) submission remains on track for the second half of calendar 2026.INTELLIGENT BIO SOLUTIONS INC. 8-K (2026-08-19) https://aibio.space/news/hepion-appoints-james-liddy-director/https://aibio.space/news/hepion-appoints-james-liddy-director/Wed, 19 Aug 2026 12:00:00 GMTCompany UpdatesThe board approved the appointment on August 19, 2026, effective immediately. The filing says no arrangements tie his selection to any other person.Hepion Pharmaceuticals, Inc. 8-K (2026-08-20) https://aibio.space/news/tuhura-biosciences-inc-stockholders-approve-1-878-287-loan-fee-shares/https://aibio.space/news/tuhura-biosciences-inc-stockholders-approve-1-878-287-loan-fee-shares/Wed, 19 Aug 2026 12:00:00 GMTFinancingsTuHURA Biosciences' stockholders approved on August 18, 2026 the issue of 1,878,287 shares to its lender, Parkview Holdings One LLC, as a fee for a $50 million revolving credit facility. The company's cash stood at $995,977 on June 30, 2026, according to its quarterly report.TuHURA Biosciences, Inc./NV Form 8-K filed August 19, 2026 (SEC EDGAR) https://aibio.space/news/mereo-biopharma-faces-securities-class-action-naming-ceo-chief/https://aibio.space/news/mereo-biopharma-faces-securities-class-action-naming-ceo-chief/Wed, 19 Aug 2026 12:00:00 GMTLegalDodge v. Mereo Biopharma Group PLC (1:26-cv-988) was filed Feb. 4, 2026 in the Southern District of New York. The lead plaintiff filed an amended complaint on July 13, 2026.Mereo BioPharma 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/innate-pharma-files-subscription-agreement-new-shares-1-70-each/https://aibio.space/news/innate-pharma-files-subscription-agreement-new-shares-1-70-each/Wed, 19 Aug 2026 12:00:00 GMTFinancingsInnate Pharma is issuing new shares at a fixed €1.70 each through Stifel and BTIG. Year-end cash fell to €28.1 million at December 31, 2025, from €66.4 million a year earlier.Innate Pharma SA 6-K (2026-08-19) https://aibio.space/news/mereo-biopharma-gets-second-nasdaq-bid-price-period-february-16-2027/https://aibio.space/news/mereo-biopharma-gets-second-nasdaq-bid-price-period-february-16-2027/Wed, 19 Aug 2026 12:00:00 GMTListingsNasdaq said on August 18, 2026 that the ADSs are still below $1.00 but the company is eligible for 180 more calendar days.Mereo BioPharma Group plc 8-K (2026-08-19) https://aibio.space/news/skye-bioscience-gets-nasdaq-notice-stockholders-equity-was-497-307/https://aibio.space/news/skye-bioscience-gets-nasdaq-notice-stockholders-equity-was-497-307/Wed, 19 Aug 2026 12:00:00 GMTListingsNasdaq said on August 18, 2026 that Skye Bioscience's stockholders' equity was a deficit of $497,307 at June 30, 2026, below the $2,500,000 minimum. The company has until October 2, 2026 to submit a plan to regain compliance.Skye Bioscience, Inc. 8-K (2026-08-19) https://aibio.space/news/silo-pharma-issues-165-000-shares-software-domain-names/https://aibio.space/news/silo-pharma-issues-165-000-shares-software-domain-names/Tue, 18 Aug 2026 12:00:00 GMTCompany UpdatesSilo agreed on August 18, 2026 to buy software, technology and domain names from Parkview Consulting LLC, paying with shares subject to a lock-up of up to twelve months.Silo Pharma, Inc. 8-K (2026-08-19) https://aibio.space/news/genprex-signs-cdmo-deal-scale-up-diabetes-gene-therapy-manufacturing/https://aibio.space/news/genprex-signs-cdmo-deal-scale-up-diabetes-gene-therapy-manufacturing/Tue, 18 Aug 2026 12:00:00 GMTCompany UpdatesThe contract manufacturer will make drug product for IND-enabling preclinical studies and future clinical trials of the company's AAV-based diabetes gene therapy.Genprex, Inc. 8-K (2026-08-18) https://aibio.space/news/cocrystal-appoints-carol-l-brosgart-board-directors/https://aibio.space/news/cocrystal-appoints-carol-l-brosgart-board-directors/Tue, 18 Aug 2026 12:00:00 GMTCompany UpdatesCocrystal Pharma's board appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately, according to a Form 8-K filed August 18, 2026.Cocrystal Pharma, Inc. 8-K (2026-08-18) https://aibio.space/news/bullfrog-ai-granted-nasdaq-second-compliance-period-bid-price/https://aibio.space/news/bullfrog-ai-granted-nasdaq-second-compliance-period-bid-price/Tue, 18 Aug 2026 12:00:00 GMTListingsNasdaq gave BullFrog AI until February 8, 2027 to regain the $1.00 minimum bid price. Stockholders approved a reverse stock split at a ratio of not less than 1-to-2 and not more than 1-to-15.BullFrog AI Holdings, Inc. 8-K (2026-08-20) https://aibio.space/news/icon-plc-issues-2-15-billion-senior-unsecured-notes/https://aibio.space/news/icon-plc-issues-2-15-billion-senior-unsecured-notes/Tue, 18 Aug 2026 12:00:00 GMTDebt FinancingThe notes mature in 2029, 2031 and 2036 and carry rates of 5.064%, 5.421% and 5.995%. Proceeds repaid term loans, a bridge facility and 2027 secured notes.ICON PLC 8-K (2026-08-18) https://aibio.space/news/baxter-raises-note-tender-offer-cap-600-million-after-early-results/https://aibio.space/news/baxter-raises-note-tender-offer-cap-600-million-after-early-results/Tue, 18 Aug 2026 12:00:00 GMTDebt FinancingHolders tendered $756,712,000 of the 2.539% notes due 2032 by the early tender time. The offer cap rose from $500 million to $600 million.SEC Form 8-K exhibit (press release) https://aibio.space/news/liminatus-pharma-sets-1-50-reverse-stock-split-meet-nasdaq-minimum-bid/https://aibio.space/news/liminatus-pharma-sets-1-50-reverse-stock-split-meet-nasdaq-minimum-bid/Tue, 18 Aug 2026 12:00:00 GMTListingsLiminatus will cut its shares 50 to 1 at the close of trading on August 20, 2026. The Nasdaq Panel now requires a $1.00 closing bid for ten consecutive trading days by September 3, after notices on market value and bid price.Liminatus Pharma, Inc. Form 8-K filed August 18, 2026 (SEC EDGAR) https://aibio.space/news/outlook-therapeutics-faces-securities-class-action-stayed-derivative/https://aibio.space/news/outlook-therapeutics-faces-securities-class-action-stayed-derivative/Tue, 18 Aug 2026 12:00:00 GMTLegalThe New Jersey court dismissed the second amended complaint in part on Dec. 23, 2025, and plaintiffs refiled. Outlook and certain unnamed officers are defendants; a Delaware derivative suit is stayed.Outlook Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/amylyx-pharmaceuticals-launches-350-000-000-common-stock-offering/https://aibio.space/news/amylyx-pharmaceuticals-launches-350-000-000-common-stock-offering/Tue, 18 Aug 2026 12:00:00 GMTFinancingsAmylyx's final supplement prices 14,090,000 shares at $35.500 for $500,195,000 before costs, above the $350,000,000 in the first filing. The company announced Phase 3 topline results the same day.Amylyx Pharmaceuticals, Inc. 424B5 (2026-08-18) https://aibio.space/news/scisparc-unit-neurothera-labs-completes-c-5-4-million-private/https://aibio.space/news/scisparc-unit-neurothera-labs-completes-c-5-4-million-private/Tue, 18 Aug 2026 12:00:00 GMTFinancingsSciSparc put in C$2.7 million, half the total, and says it will hold approximately 44.6% of NeuroThera afterward. NeuroThera plans to use the money for general working capital.SciSparc Ltd. 6-K (2026-08-18) https://aibio.space/news/revelation-grants-ceo-cfo-restricted-stock-tied-market-value/https://aibio.space/news/revelation-grants-ceo-cfo-restricted-stock-tied-market-value/Mon, 17 Aug 2026 12:00:00 GMTCompany UpdatesJames Rolke and Chester Zygmont each received restricted stock awards that vest in four tranches tied to market capitalization milestones of $30 million to $120 million.Revelation Biosciences, Inc. 8-K (2026-08-19) https://aibio.space/news/endra-reports-second-quarter-2026-results-merger-progress/https://aibio.space/news/endra-reports-second-quarter-2026-results-merger-progress/Mon, 17 Aug 2026 12:00:00 GMTMergersENDRA reported net income of approximately $160,000 for the second quarter of 2026 and said it expects the Noble Africa merger to close in the fourth quarter of 2026.ENDRA Life Sciences Inc. 8-K (2026-08-17) https://aibio.space/news/dermata-agrees-3-4-million-private-placement-warrants/https://aibio.space/news/dermata-agrees-3-4-million-private-placement-warrants/Mon, 17 Aug 2026 12:00:00 GMTFinancingsDermata Therapeutics agreed to sell 2,293,608 shares, or pre-funded warrants, at $1.46 per share, with Series E and Series F warrants attached. Gross proceeds are expected to be about $3.4 million before offering expenses.Dermata Therapeutics, Inc. 8-K (2026-08-17) https://aibio.space/news/coherus-oncology-takes-55-000-000-senior-secured-term-loan-refinance/https://aibio.space/news/coherus-oncology-takes-55-000-000-senior-secured-term-loan-refinance/Mon, 17 Aug 2026 12:00:00 GMTDebt FinancingInnovatus Life Sciences Lending Fund I, LP, is collateral agent on a loan that replaces an existing term loan and runs to August 2031, with interest-only payments for an initial 36 months.SEC Form 8-K https://aibio.space/news/outlook-therapeutics-files-nt-10-q-june-quarter-cites-finance-staff/https://aibio.space/news/outlook-therapeutics-files-nt-10-q-june-quarter-cites-finance-staff/Mon, 17 Aug 2026 12:00:00 GMTDistressOutlook says it cannot file its quarterly report on time because of its size, finance department turnover and work on a public offering that closed on August 14, 2026. It has a going concern warning in its last annual report.Outlook Therapeutics, Inc. Form NT 10-Q filed August 17, 2026 (SEC EDGAR) https://aibio.space/news/bright-minds-biosciences-reports-c-307-828-515-cash-after-public/https://aibio.space/news/bright-minds-biosciences-reports-c-307-828-515-cash-after-public/Mon, 17 Aug 2026 12:00:00 GMTFinancingsCash and cash equivalents reached CAD 307,828,515 at June 30, 2026, after a January 2026 public offering at US$90 a share. Over the nine months the company used CAD 23,402,489 in operations and reported no revenue.Bright Minds Biosciences Inc. 6-K (2026-08-17) https://aibio.space/news/fulcrum-therapeutics-agrees-all-stock-merger-slate-medicines/https://aibio.space/news/fulcrum-therapeutics-agrees-all-stock-merger-slate-medicines/Mon, 17 Aug 2026 12:00:00 GMTMergersFulcrum's holders would own 5.0% of the combined company, after an estimated $270.0 million cash dividend paid before closing. The release reports no efficacy data for Slate's lead drug, whose first readout in mid-2027 covers safety and pharmacokinetics in healthy volunteers.Fulcrum Therapeutics, Inc. 8-K (2026-08-17) https://aibio.space/news/lexaria-bioscience-regains-nasdaq-bid-price-compliance-hearing/https://aibio.space/news/lexaria-bioscience-regains-nasdaq-bid-price-compliance-hearing/Mon, 17 Aug 2026 12:00:00 GMTListingsThe Hearings Advisor told the company on August 17, 2026 that staff confirmed compliance with Listing Rule 5550(a)(2), and the requested hearing was cancelled.Lexaria Bioscience Corp. 8-K (2026-08-17) https://aibio.space/news/xortx-reports-994-045-cash-going-concern-note-first-half-2026/https://aibio.space/news/xortx-reports-994-045-cash-going-concern-note-first-half-2026/Mon, 17 Aug 2026 12:00:00 GMTListingsXORTX ended June 30, 2026 with $994,045 in cash after a $5,000,000 public offering, and the going-concern note stays. Operations used $3,768,993 in the six months.XORTX Therapeutics Inc. 6-K (2026-08-17) https://aibio.space/news/bioforce-nanosciences-names-interim-ceo-adds-general-counsel-advisers/https://aibio.space/news/bioforce-nanosciences-names-interim-ceo-adds-general-counsel-advisers/Fri, 14 Aug 2026 12:00:00 GMTCompany UpdatesAn August 14, 2026 filing lists officers, directors and advisory board members, including Richard Kaiser as interim chief executive officer and Scott Mager as general counsel and director.Form 8-K (SEC EDGAR) https://aibio.space/news/quoin-reports-second-quarter-2026-results-qrx003-progress/https://aibio.space/news/quoin-reports-second-quarter-2026-results-qrx003-progress/Fri, 14 Aug 2026 12:00:00 GMTCompany UpdatesQuoin said it had about $10.8 million in cash, cash equivalents and marketable securities as of June 30, 2026, and that it expects that position to fund operations into 2027.Quoin Pharmaceuticals, Ltd. 8-K (2026-08-14) https://aibio.space/news/traws-pharma-reports-q2-2026-results-updated-mhra-timeline/https://aibio.space/news/traws-pharma-reports-q2-2026-results-updated-mhra-timeline/Fri, 14 Aug 2026 12:00:00 GMTCompany UpdatesTraws reports $5.0 million in cash at June 30, 2026, and says existing cash plus expected at-the-market proceeds fund planned operations into the first quarter of 2027.Traws Pharma, Inc. SEC filing (Form 8-K) https://aibio.space/news/adagio-medical-receives-nasdaq-notice-stockholders-equity/https://aibio.space/news/adagio-medical-receives-nasdaq-notice-stockholders-equity/Fri, 14 Aug 2026 12:00:00 GMTListingsThe company reported stockholders' equity of negative $415,000 at June 30, 2026, below Nasdaq's $2,500,000 minimum, and must submit a compliance plan by September 28, 2026.Adagio Medical Holdings, Inc. 8-K (2026-08-14) https://aibio.space/news/retractable-technologies-reports-second-quarter-net-sales-7-2-million/https://aibio.space/news/retractable-technologies-reports-second-quarter-net-sales-7-2-million/Fri, 14 Aug 2026 12:00:00 GMTCompany UpdatesNet sales fell from $10.4 million a year earlier, and the quarter's net income of $2.8 million includes a $6.4 million gain on the sale of equity securities.Retractable Technologies Inc. 8-K (2026-08-14) https://aibio.space/news/lifeward-reports-second-quarter-2026-revenue-up-16-percent-6-6-million/https://aibio.space/news/lifeward-reports-second-quarter-2026-revenue-up-16-percent-6-6-million/Fri, 14 Aug 2026 12:00:00 GMTCompany UpdatesLifeward reported a net loss of $11.5 million for the quarter and said a July 6, 2026 financing could provide up to $11.2 million in growth capital.Lifeward Ltd. 8-K (2026-08-14) https://aibio.space/news/leonabio-reports-second-quarter-2026-results-elaine-3-update/https://aibio.space/news/leonabio-reports-second-quarter-2026-results-elaine-3-update/Fri, 14 Aug 2026 12:00:00 GMTCompany UpdatesLeonaBio reported cash, cash equivalents and investments of $51.1 million at June 30, 2026, and said it has enrolled 495 patients in its Phase 3 ELAINE-3 trial.LeonaBio, Inc. 8-K (2026-08-14) https://aibio.space/news/pavmed-reports-second-quarter-2026-results-lucid-coverage-policy/https://aibio.space/news/pavmed-reports-second-quarter-2026-results-lucid-coverage-policy/Fri, 14 Aug 2026 12:00:00 GMTCompany UpdatesLucid Diagnostics recognized $1.5 million in EsoGuard revenue in the second quarter, and PAVmed reported cash of $3.8 million at June 30, 2026.PAVmed 8-K https://aibio.space/news/vycor-medical-reports-second-quarter-2026-results/https://aibio.space/news/vycor-medical-reports-second-quarter-2026-results/Fri, 14 Aug 2026 12:00:00 GMTCompany UpdatesRevenue for the three months ended June 30, 2026 was $418,264, a decrease of 16% from the 2025 period. The company said most of the decline came from international markets.VYCOR MEDICAL INC 8-K (2026-08-14) https://aibio.space/news/enveric-reports-second-quarter-2026-net-loss-3-0-million/https://aibio.space/news/enveric-reports-second-quarter-2026-net-loss-3-0-million/Fri, 14 Aug 2026 12:00:00 GMTCompany UpdatesThe company reported cash-on-hand of $8.3 million as of June 30, 2026, and an update on its lead candidate EB-003 ahead of an IND submission.Enveric Biosciences 8-K, Exhibit 99.1 https://aibio.space/news/scienture-reports-second-quarter-2026-revenue-343-639/https://aibio.space/news/scienture-reports-second-quarter-2026-revenue-343-639/Fri, 14 Aug 2026 12:00:00 GMTCompany UpdatesRevenue rose from $56,325 in the first quarter, gross margin was approximately 97.7% and the net loss narrowed to about $2.8 million. The company began commercial launch of REZENOPY during the quarter.Scienture Holdings, Inc. 8-K (2026-08-20) https://aibio.space/news/trinity-biotech-amends-perceptive-term-loan-adding-about-2-5-million/https://aibio.space/news/trinity-biotech-amends-perceptive-term-loan-adding-about-2-5-million/Fri, 14 Aug 2026 12:00:00 GMTDebt FinancingThe amendment provides approximately $2.5 million of new debt funding and approximately $4.5 million of capitalized interest, for a total investment of approximately $7.0 million.TRINITY BIOTECH PLC 8-K (2026-08-14) https://aibio.space/news/senti-biosciences-unit-sells-4-0-million-convertible-notes-celadon/https://aibio.space/news/senti-biosciences-unit-sells-4-0-million-convertible-notes-celadon/Fri, 14 Aug 2026 12:00:00 GMTDebt FinancingThe notes were issued under an April 27, 2026 purchase agreement. The filing also ties the company to a potential merger with a contingent value right that could pay up to $60.0 million in cash.Senti Biosciences Holdings, Inc. 8-K (2026-08-20) https://aibio.space/news/dare-prices-6-0m-registered-direct-warrants-twice-shares/https://aibio.space/news/dare-prices-6-0m-registered-direct-warrants-twice-shares/Fri, 14 Aug 2026 12:00:00 GMTFinancingsDaré Bioscience sold 4.38M shares at $1.37 and gave buyers two warrant series covering 8.76M more, while Nasdaq reviews its listing and cash runs into Q4.Daré Bioscience press release (SEC Form 8-K, Exhibit 99.1) https://aibio.space/news/curanex-flags-going-concern-doubt-2-94-million-cash-june-30/https://aibio.space/news/curanex-flags-going-concern-doubt-2-94-million-cash-june-30/Fri, 14 Aug 2026 12:00:00 GMTDistressCuranex says its cash will not last twelve months, a reversal of the no-doubt finding in its first-quarter report. Prepaid research payments have so far held cash use well below its losses.Curanex 10-Q https://aibio.space/news/silexion-had-2-2-million-cash-june-30-flags-going-concern-doubt/https://aibio.space/news/silexion-had-2-2-million-cash-june-30-flags-going-concern-doubt/Fri, 14 Aug 2026 12:00:00 GMTDistressManagement said cash would last through the fourth quarter of 2026. The company has leaned on at-the-market sales and small offerings, and a Nasdaq delisting notice followed on August 18.SEC EDGAR: Silexion 10-Q https://aibio.space/news/exicures-class-action-derivative-suits-end-court-approved-settlements/https://aibio.space/news/exicures-class-action-derivative-suits-end-court-approved-settlements/Fri, 14 Aug 2026 12:00:00 GMTLegalExicure's securities class action and its shareholder derivative suits are over, according to a quarterly report filed August 14, 2026. The class action settled for $5.625 million, funded by insurers, and the derivative suits were dismissed in June 2026 after court approval.Exicure 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/neumora-ipo-class-action-navacaprant-disclosures-awaits-ruling/https://aibio.space/news/neumora-ipo-class-action-navacaprant-disclosures-awaits-ruling/Fri, 14 Aug 2026 12:00:00 GMTLegalA Securities Act suit in New York names Neumora, certain executive officers and certain underwriters. Defendants' reply on their motion to dismiss the second amended complaint is due August 24, 2026.Neumora Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/gt-biopharma-sued-four-convertible-note-holders-undelivered-conversion/https://aibio.space/news/gt-biopharma-sued-four-convertible-note-holders-undelivered-conversion/Fri, 14 Aug 2026 12:00:00 GMTLegalGT Biopharma is the only defendant named in New York suits by Z-One, Silberfein, DiPietro and the Werthman Trust. Z-One's claims were dismissed and appealed. The other three are in settlement talks.GT Biopharma 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/vistagen-faces-securities-class-action-two-derivative-suits-palisade-3/https://aibio.space/news/vistagen-faces-securities-class-action-two-derivative-suits-palisade-3/Fri, 14 Aug 2026 12:00:00 GMTLegalA Northern District of California class action names Vistagen, CEO Shawn Singh and COO Joshua Prince. Two derivative suits are stayed behind it, and a separate pro se case was dismissed with prejudice on August 12.Vistagen Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/hcw-biologics-faces-december-jury-trial-florida-mechanics-lien/https://aibio.space/news/hcw-biologics-faces-december-jury-trial-florida-mechanics-lien/Fri, 14 Aug 2026 12:00:00 GMTLegalBE&K Building Group sued HCW Biologics, Cogent Bank and subcontractors in Broward County over unpaid renovation invoices. Fisk Electric's suit was consolidated, and Cogent Bank has demanded the liens be cleared.HCW Biologics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/scilex-loses-ztlido-patent-appeal-federal-circuit-affirms-non/https://aibio.space/news/scilex-loses-ztlido-patent-appeal-federal-circuit-affirms-non/Fri, 14 Aug 2026 12:00:00 GMTLegalThe Federal Circuit affirmed on Aug. 4, 2026 that Aveva's generic does not infringe Scilex's ZTlido patents. Defendants were Aveva Drug Delivery Systems, Apotex Corp. and Apotex, Inc.Scilex Holding Company 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/scilex-semnur-named-sorrento-equity-holders-suit-now-stayed-california/https://aibio.space/news/scilex-semnur-named-sorrento-equity-holders-suit-now-stayed-california/Fri, 14 Aug 2026 12:00:00 GMTLegalMevi et al. v. Ji et al. names Scilex, Semnur and others not listed in the 10-Q. The court stayed the case on June 25, 2026; Scilex's filings do not identify the other defendants.Scilex Holding Company 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/capricor-discloses-new-securities-class-action-derivative-suit-fda/https://aibio.space/news/capricor-discloses-new-securities-class-action-derivative-suit-fda/Fri, 14 Aug 2026 12:00:00 GMTLegalDefendants: Capricor and unnamed officers in the new July 30 class action, and Capricor and CEO Linda Marbán in the 2025 one. The FDA also moved the deramiocel date to November 22, 2026.Capricor Therapeutics 10-Q (SEC EDGAR) https://aibio.space/news/adlai-nortye-reports-us-231-9-million-cash-after-two-2026-private/https://aibio.space/news/adlai-nortye-reports-us-231-9-million-cash-after-two-2026-private/Fri, 14 Aug 2026 12:00:00 GMTFinancingsAdlai Nortye reports $231.9 million in cash and short-term investments at June 30, 2026, up from $8.1 million six months earlier, after two private placements of $140 million and $150 million before fees, and it has de-prioritized AN4005 as a monotherapy.Adlai Nortye Group Ltd. 6-K (2026-08-14) https://aibio.space/news/casi-pharmaceuticals-reports-3-8-million-cash-details-nasdaq-delisting/https://aibio.space/news/casi-pharmaceuticals-reports-3-8-million-cash-details-nasdaq-delisting/Fri, 14 Aug 2026 12:00:00 GMTListingsCASI Pharmaceuticals had $3.8 million of cash at June 30, 2026, after its ordinary shares left Nasdaq and began quoting on the OTCQB. Its first-half release says recurring operating losses have raised substantial doubt about its ability to continue as a going concern.CASI Pharmaceuticals, Inc. 6-K (2026-08-14) https://aibio.space/news/inflarx-registers-up-65-000-000-more-shares-sales-program/https://aibio.space/news/inflarx-registers-up-65-000-000-more-shares-sales-program/Fri, 14 Aug 2026 12:00:00 GMTFinancingsSales run through Leerink Partners under an agreement dated June 28, 2024. The commission is up to 3.0% of gross proceeds.InflaRx N.V. 424B5 (2026-08-14) https://aibio.space/news/nutra-pharma-files-late-filing-notice-june-30-2026-quarterly-report/https://aibio.space/news/nutra-pharma-files-late-filing-notice-june-30-2026-quarterly-report/Fri, 14 Aug 2026 12:00:00 GMTDistressNutra Pharma filed a Form 12b-25 notice on August 14, 2026, saying its quarterly report for the period ended June 30, 2026 would be late. Its cash at December 31, 2025 was $12,181.Nutra Pharma Corp. NT 10-Q (2026-08-14) https://aibio.space/news/protokinetix-files-late-filing-notice-june-30-2026-quarterly-report/https://aibio.space/news/protokinetix-files-late-filing-notice-june-30-2026-quarterly-report/Fri, 14 Aug 2026 12:00:00 GMTDistressThe notice also says its 2025 Form 10-K and its March 31, 2026 Form 10-Q have not been filed. The company cites delays in finishing its financial statements and an auditor review.ProtoKinetix, Inc. NT 10-Q (2026-08-14) https://aibio.space/news/skye-bioscience-outlines-redx-pharma-deal-august-14-2026-investor-deck/https://aibio.space/news/skye-bioscience-outlines-redx-pharma-deal-august-14-2026-investor-deck/Fri, 14 Aug 2026 12:00:00 GMTListingsSkye Bioscience's investor deck describes a U.K. scheme of arrangement to combine with Redx Pharma, a concurrent financing totaling $125 million, and a contingent value right for former Skye holders. The deck says Skye is discontinuing its CBeyond trial of nimacimab.Skye Bioscience, Inc. 8-K (2026-08-14) https://aibio.space/news/lifeloc-reports-second-quarter-2026-revenue-up-10-percent/https://aibio.space/news/lifeloc-reports-second-quarter-2026-revenue-up-10-percent/Thu, 13 Aug 2026 12:00:00 GMTCompany UpdatesNet revenue rose to $2.445 million for the quarter ended June 30, 2026, and the company said it is targeting a limited commercial launch of SpinDetect in the first quarter of 2027.Lifeloc Technologies, Inc 8-K (2026-08-14) https://aibio.space/news/dogwood-reports-second-quarter-2026-results-halneuron-update/https://aibio.space/news/dogwood-reports-second-quarter-2026-results-halneuron-update/Thu, 13 Aug 2026 12:00:00 GMTCompany UpdatesDogwood reported a second quarter net loss of $11.5 million, including a $6.7 million non-cash impairment, and $9.6 million in cash that it says funds operations through the Phase 2b readout.Dogwood Therapeutics, Inc. 8-K (2026-08-13) https://aibio.space/news/nuwellis-reports-14-percent-second-quarter-revenue-growth-76-percent/https://aibio.space/news/nuwellis-reports-14-percent-second-quarter-revenue-growth-76-percent/Thu, 13 Aug 2026 12:00:00 GMTCompany UpdatesNet sales were $2.0 million in the quarter, and the company says recent financings extend its cash runway through the second quarter of 2027.Nuwellis, Inc. 8-K (2026-08-13) https://aibio.space/news/mink-reports-second-quarter-2026-results-early-trial-observations/https://aibio.space/news/mink-reports-second-quarter-2026-results-early-trial-observations/Thu, 13 Aug 2026 12:00:00 GMTCompany UpdatesMiNK said its cash and cash equivalents were $8.8 million as of June 30, 2026, and its second quarter net loss was $3.1 million. The company also reported Day 28 observations from its randomized Phase 2 trial in acute lung injury.MiNK Therapeutics, Inc. 8-K (2026-08-13) https://aibio.space/news/equillium-expects-eq504-phase-1-start-q4-2026-cash-2029/https://aibio.space/news/equillium-expects-eq504-phase-1-start-q4-2026-cash-2029/Thu, 13 Aug 2026 12:00:00 GMTCompany UpdatesEquillium reported a second-quarter net loss of $4.7 million and cash and cash equivalents of $57.2 million at June 30, 2026, which it says can fund planned operations into 2029.Equillium, Inc. 8-K (2026-08-13) https://aibio.space/news/bluejay-reports-q2-2026-results-9-6-million-cash/https://aibio.space/news/bluejay-reports-q2-2026-results-9-6-million-cash/Thu, 13 Aug 2026 12:00:00 GMTFinancingsThe company says its June 2026 private placement brought in about $7.6 million in net proceeds and that its cash should fund operations through the second quarter of 2027.Bluejay Diagnostics, Inc. 8-K (2026-08-13) https://aibio.space/news/tenon-medical-reports-second-quarter-2026-revenue-1-3-million/https://aibio.space/news/tenon-medical-reports-second-quarter-2026-revenue-1-3-million/Thu, 13 Aug 2026 12:00:00 GMTCompany UpdatesRevenue rose 127% from a year earlier and gross margin reached 64%. Cash was $1.7 million at June 30, 2026, before a $4.2 million offering that closed on July 1.Tenon Medical, Inc. 8-K (2026-08-13) https://aibio.space/news/biofrontera-reports-second-quarter-2026-net-product-revenue-12-0/https://aibio.space/news/biofrontera-reports-second-quarter-2026-net-product-revenue-12-0/Thu, 13 Aug 2026 12:00:00 GMTCompany UpdatesNet product revenue rose 32.9% from a year earlier, and gross margin reached 80%. The net loss was $0.6 million, compared with $5.3 million in the prior-year quarter.Biofrontera Inc. Form 8-K https://aibio.space/news/co-diagnostics-reports-second-quarter-2026-results-flu-rsv-test/https://aibio.space/news/co-diagnostics-reports-second-quarter-2026-results-flu-rsv-test/Thu, 13 Aug 2026 12:00:00 GMTCompany UpdatesThe net loss was $6.3 million, or $1.46 per share, and cash and cash equivalents were $3.6 million at June 30, 2026. The company said it submitted a 510(k) for its flu A/B and RSV test.Co-Diagnostics, Inc. 8-K (2026-08-13) https://aibio.space/news/ensysce-completes-cy-biopharma-acquisition-38-6-million-placements/https://aibio.space/news/ensysce-completes-cy-biopharma-acquisition-38-6-million-placements/Thu, 13 Aug 2026 12:00:00 GMTFinancingsEnsysce Biosciences said the Cy Biopharma acquisition closed on August 6, 2026, with private placement financings of $38.6 million and cash runway into late 2027.Ensysce Biosciences, Inc. 8-K (2026-08-13) https://aibio.space/news/aethlon-reports-first-quarter-fiscal-2027-results-third-cohort-dosing/https://aibio.space/news/aethlon-reports-first-quarter-fiscal-2027-results-third-cohort-dosing/Thu, 13 Aug 2026 12:00:00 GMTCompany UpdatesThe company reported cash of approximately $4.9 million at June 30, 2026, after raising about $4.0 million in gross proceeds after quarter-end, and operating expenses down 11.9%.AETHLON MEDICAL INC 8-K (2026-08-13) https://aibio.space/news/opko-issues-125-000-000-additional-senior-secured-notes/https://aibio.space/news/opko-issues-125-000-000-additional-senior-secured-notes/Thu, 13 Aug 2026 12:00:00 GMTDebt FinancingThe notes mature in July 2044 and are secured by royalty payments that EirGen Pharma Limited receives on mazdutide. HCR Injection SPV, LLC serves as agent.OPKO HEALTH, INC. 8-K (2026-08-14) https://aibio.space/news/positron-arranges-2-000-000-line-credit-12-percent-investor-george/https://aibio.space/news/positron-arranges-2-000-000-line-credit-12-percent-investor-george/Thu, 13 Aug 2026 12:00:00 GMTDebt FinancingThe note matures on August 13, 2028 and bears fixed interest at 12%. Cash is payable only on demand after maturity or while an event of default continues.POSITRON CORP 8-K (2026-08-18) https://aibio.space/news/sangamo-bankruptcy-auction-brings-163-55-million-ptc-lilly/https://aibio.space/news/sangamo-bankruptcy-auction-brings-163-55-million-ptc-lilly/Thu, 13 Aug 2026 12:00:00 GMTDistressWinning bids yield about $163.55 million in cash at closing and up to $100 million in milestones. Every sale still needs court approval, and the company is still selling other assets.Sangamo Therapeutics (SEC Form 8-K and press release) https://aibio.space/news/maplight-agrees-150-million-private-placement-shares-pre-funded/https://aibio.space/news/maplight-agrees-150-million-private-placement-shares-pre-funded/Thu, 13 Aug 2026 12:00:00 GMTFinancingsMapLight agreed to sell 9,197,887 voting shares at $11.38 and pre-funded warrants for 3,983,168 more shares, for about $150.0 million gross before fees.MPLT 8-K https://aibio.space/news/maplight-reports-351-3-million-cash-investments-sees-funding-through/https://aibio.space/news/maplight-reports-351-3-million-cash-investments-sees-funding-through/Thu, 13 Aug 2026 12:00:00 GMTFinancingsMapLight reported $351.3 million in cash and investments at June 30, 2026 and cited funding through 2028. It also agreed to a private placement of about $150.0 million at $11.38 a share. Six-month operating cash use was $96.0 million.MPLT 10-Q https://aibio.space/news/polaryx-reports-11-5-million-cash-funding-early-2027-going-concern/https://aibio.space/news/polaryx-reports-11-5-million-cash-funding-early-2027-going-concern/Thu, 13 Aug 2026 12:00:00 GMTDistressThe company says its cash lasts through the first quarter of 2027 and it will need more capital after that. SOTERIA is due to start in the second half of 2026.PLYX 10-Q https://aibio.space/news/silexion-raises-2-5-million-public-offering-shares-warrants-0-65/https://aibio.space/news/silexion-raises-2-5-million-public-offering-shares-warrants-0-65/Thu, 13 Aug 2026 12:00:00 GMTFinancingsThe best-efforts deal closed August 13, 2026. Silexion also converted $750,001 of debt owed to its former SPAC sponsor into shares at the offering price.SEC EDGAR: Silexion 8-K https://aibio.space/news/turn-issues-579-664-shares-gem-exercises-warrant-cashless-basis/https://aibio.space/news/turn-issues-579-664-shares-gem-exercises-warrant-cashless-basis/Thu, 13 Aug 2026 12:00:00 GMTFinancingsThe warrant covered 1,192,207 shares at $5.03. Because GEM used the cashless option, Turn received no cash and issued fewer shares than the warrant allowed it to buy.SEC EDGAR: Turn Therapeutics 8-K https://aibio.space/news/pelthos-therapeutics-says-first-quarter-2026-financials-can-no-longer/https://aibio.space/news/pelthos-therapeutics-says-first-quarter-2026-financials-can-no-longer/Thu, 13 Aug 2026 12:00:00 GMTDistressPelthos Therapeutics said on August 13, 2026 that its first-quarter 2026 financial statements can no longer be relied on. The restatement adds $14.8 million to the accumulated deficit, and the company reports a material weakness in its controls over convertible debt.Pelthos Therapeutics Inc. Form 8-K filed August 13, 2026 (SEC EDGAR) https://aibio.space/news/cytokinetics-sues-bristol-myers-squibb-myokardia-delaware-patent-suit/https://aibio.space/news/cytokinetics-sues-bristol-myers-squibb-myokardia-delaware-patent-suit/Thu, 13 Aug 2026 12:00:00 GMTLegalCytokinetics (Nasdaq: CYTK) filed a complaint on August 13, 2026, seeking a declaratory judgment that it does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The defendants are Bristol-Myers Squibb and MyoKardia.CYTOKINETICS INC Form 8-K filed August 13, 2026 (SEC EDGAR) https://aibio.space/news/aptevo-therapeutics-closes-warrant-inducement-private-placement-about/https://aibio.space/news/aptevo-therapeutics-closes-warrant-inducement-private-placement-about/Thu, 13 Aug 2026 12:00:00 GMTFinancingsAptevo Therapeutics (Nasdaq: APVO) closed deals that cut warrant exercise prices to $4.03 per share and sold shares or pre-funded warrants in a private placement. Roth Capital Partners was placement agent.Aptevo Therapeutics Inc. Form 8-K filed August 13, 2026 (SEC EDGAR) https://aibio.space/news/kyntra-bio-accrues-7-0-million-indemnity-tied-sec-case-against-ex-cmo/https://aibio.space/news/kyntra-bio-accrues-7-0-million-indemnity-tied-sec-case-against-ex-cmo/Thu, 13 Aug 2026 12:00:00 GMTLegalKyntra Bio, formerly FibroGen, says it must advance legal costs for an SEC case against its former chief medical officer and may have to cover some costs and judgments. It had accrued about $7.0 million for those obligations at June 30, 2026, up from an amount it called not material three months earlier.Kyntra Bio 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/calidi-faces-suits-two-former-finance-staff-investors-securities-fraud/https://aibio.space/news/calidi-faces-suits-two-former-finance-staff-investors-securities-fraud/Thu, 13 Aug 2026 12:00:00 GMTLegalCalidi, director and ex-CEO Allan Camaisa and ex-officer Ms. Pizarro are defendants in San Diego employment suits. Investor Yian Zeng's federal case against Calidi had a summary judgment hearing set for Aug 24, 2026.Calidi Biotherapeutics, Inc. 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/cormedix-faces-defencath-securities-class-action-derivative-settlement/https://aibio.space/news/cormedix-faces-defencath-securities-class-action-derivative-settlement/Thu, 13 Aug 2026 12:00:00 GMTLegalThe class action names CorMedix and six officers, including Khoso Baluch. A settlement of derivative suits naming 12 individuals had a final approval hearing set for September 23, 2026.CorMedix 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/alumis-carries-acelyrin-securities-class-action-izokibep-trial/https://aibio.space/news/alumis-carries-acelyrin-securities-class-action-izokibep-trial/Thu, 13 Aug 2026 12:00:00 GMTLegalAlumis (Nasdaq: ALMS) inherited Boukadoum v. Acelyrin in its May 2025 merger. The filing names ACELYRIN and unnamed officers and directors; ACELYRIN's 2024 signers are listed.Alumis 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/ars-pharmaceuticals-details-aptar-trade-secret-suit-own-antitrust/https://aibio.space/news/ars-pharmaceuticals-details-aptar-trade-secret-suit-own-antitrust/Thu, 13 Aug 2026 12:00:00 GMTLegalAptarGroup and Aptar France sued ARS Pharmaceuticals and ARS Pharmaceuticals Operations in March 2025. The company's separate antitrust suit against AptarGroup was moved to New York in July 2026.ARS Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/ars-pharmaceuticals-faces-securities-class-action-neffy-insurance/https://aibio.space/news/ars-pharmaceuticals-faces-securities-class-action-neffy-insurance/Thu, 13 Aug 2026 12:00:00 GMTLegalA stockholder sued the company and unnamed current and former officers in the Southern District of California on August 5, 2026. A pharmacy filed a separate fax-advertising class action in July.ARS Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/fate-therapeutics-faces-securities-class-action-three-derivative-suits/https://aibio.space/news/fate-therapeutics-faces-securities-class-action-three-derivative-suits/Thu, 13 Aug 2026 12:00:00 GMTLegalThe 10-Q says Fate and unnamed officers are defendants in a Southern District of California class action. The derivative suits are captioned against Wolchko; board lists come from Fate's 2023 and 2026 proxies.Fate Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/biovie-securities-class-certified-nevada-three-derivative-suits-stayed/https://aibio.space/news/biovie-securities-class-certified-nevada-three-derivative-suits-stayed/Thu, 13 Aug 2026 12:00:00 GMTLegalThe 10-K says the court certified the class on June 18, 2026 in In re BioVie Inc. Securities Litigation. BioVie and unnamed officers are defendants; insurance carries a $2 million deductible.BioVie 10-K for the fiscal year ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/gossamer-bio-faces-securities-class-action-lead-plaintiff-named/https://aibio.space/news/gossamer-bio-faces-securities-class-action-lead-plaintiff-named/Thu, 13 Aug 2026 12:00:00 GMTLegalKinnamon v. Gossamer Bio names the company and unnamed executive officers and directors over a June 16, 2025 to February 20, 2026 class period. The 10-Q gives no loss estimate.Gossamer Bio 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/satellos-reports-47-251-thousand-net-equity-proceeds-first-half-2026/https://aibio.space/news/satellos-reports-47-251-thousand-net-equity-proceeds-first-half-2026/Thu, 13 Aug 2026 12:00:00 GMTListingsCash and short-term investments stood at $7,393 thousand and $54,446 thousand at June 30, 2026. The shares were consolidated twelve-for-one in January.Satellos Bioscience Inc 6-K (2026-08-13) https://aibio.space/news/nervgen-reports-c-86-789-698-cash-after-may-2026-public-offering/https://aibio.space/news/nervgen-reports-c-86-789-698-cash-after-may-2026-public-offering/Thu, 13 Aug 2026 12:00:00 GMTFinancingsNervGen's cash rose to C$86,789,698 after a May 2026 offering of 24,000,000 units. Its warrant liability climbed to C$68,625,899, and a related party bought 800,000 of the units.NervGen Pharma Corp. 6-K (2026-08-13) https://aibio.space/news/proqr-reports-59-2-million-june-financing-117-1-million-cash/https://aibio.space/news/proqr-reports-59-2-million-june-financing-117-1-million-cash/Thu, 13 Aug 2026 12:00:00 GMTFinancingsProQR raised about $59.2 million in June, through a $50.0 million underwritten registered direct offering and a $9.2 million private placement to Eli Lilly and Company. The release names no underwriter, and says cash of €117.1 million covers runway into mid-2028.ProQR Therapeutics N.V. 6-K (2026-08-13) https://aibio.space/news/regen-biopharma-files-late-filing-notice-june-30-2026-quarterly-report/https://aibio.space/news/regen-biopharma-files-late-filing-notice-june-30-2026-quarterly-report/Thu, 13 Aug 2026 12:00:00 GMTDistressRegen Biopharma says a delay in its public accountant's review kept it from finishing the Form 10-Q for the period ended June 30, 2026. It says it will file within five calendar days of the due date.Regen Biopharma, Inc. NT 10-Q (2026-08-13) https://aibio.space/news/aprea-reports-second-quarter-2026-results-41-2-million-cash/https://aibio.space/news/aprea-reports-second-quarter-2026-results-41-2-million-cash/Wed, 12 Aug 2026 12:00:00 GMTCompany UpdatesAprea Therapeutics reported a net loss of $3.6 million for the quarter ended June 30, 2026, and said its cash should last into the first quarter of 2028. The company is also expanding enrollment in its lead WEE1 inhibitor trial.Aprea Therapeutics, Inc. 8-K (2026-08-12) https://aibio.space/news/ptc-named-winning-bidder-sangamos-fabry-gene-therapy-st-920/https://aibio.space/news/ptc-named-winning-bidder-sangamos-fabry-gene-therapy-st-920/Wed, 12 Aug 2026 12:00:00 GMTDistressPTC says the ST-920 rolling BLA will be completed in the fourth quarter of 2026, with a potential commercial launch in 2027 if the acquisition closes.PTC Therapeutics, Inc. 8-K (2026-08-13) https://aibio.space/news/ispecimen-signs-2-000-000-investor-relations-consulting-agreement/https://aibio.space/news/ispecimen-signs-2-000-000-investor-relations-consulting-agreement/Wed, 12 Aug 2026 12:00:00 GMTCompany UpdatesIR Agency LLC will provide news distribution for up to ten releases over a three-month term, and the fee is fully earned on receipt.Form 8-K https://aibio.space/news/aditxt-completes-sale-pearsanta-mdna-holdings/https://aibio.space/news/aditxt-completes-sale-pearsanta-mdna-holdings/Wed, 12 Aug 2026 12:00:00 GMTCompany UpdatesAditxt, Inc. said that on August 12, 2026 MDNA Holdings Inc. acquired substantially all of the outstanding shares of its majority-owned subsidiary, Pearsanta, Inc. Pearsanta agreed to pay Aditxt royalties on Net Revenue and two milestone payments of $250,000 each.Aditxt, Inc. 8-K (2026-08-19) https://aibio.space/news/mannatech-reports-second-quarter-2026-net-income-1-0-million/https://aibio.space/news/mannatech-reports-second-quarter-2026-net-income-1-0-million/Wed, 12 Aug 2026 12:00:00 GMTCompany UpdatesNet sales rose to $26.7 million for the quarter ended June 30, 2026, and the company reported net income after a net loss a year earlier.MANNATECH INC 8-K (2026-08-12) https://aibio.space/news/envue-medical-agrees-50-million-committed-equity-facility/https://aibio.space/news/envue-medical-agrees-50-million-committed-equity-facility/Wed, 12 Aug 2026 12:00:00 GMTFinancingsThe company can sell up to $50.0 million of common stock to one institutional investor, and the same day it amended a Series H preferred stock agreement with that investor.ENvue Medical, Inc. 8-K (2026-08-12) https://aibio.space/news/bio-green-med-reports-second-quarter-results-updates-future-nrg-deal/https://aibio.space/news/bio-green-med-reports-second-quarter-results-updates-future-nrg-deal/Wed, 12 Aug 2026 12:00:00 GMTMergersNet loss was $0.4 million for the quarter ended June 30, 2026, while the company advances a share exchange that would make Future NRG Sdn. Bhd. a wholly owned subsidiary.Bio Green Med Solution, Inc. 8-K (2026-08-14) https://aibio.space/news/aeon-reports-second-quarter-2026-results-15-3-million-financing/https://aibio.space/news/aeon-reports-second-quarter-2026-results-15-3-million-financing/Wed, 12 Aug 2026 12:00:00 GMTCompany UpdatesAEON Biopharma reported $3.4 million in cash at June 30, 2026, and said upfront proceeds from its July offering extend its runway into the first quarter of 2027. The company also regained NYSE American compliance on August 3, 2026.AEON Biopharma, Inc. 8-K (2026-08-12) https://aibio.space/news/alkermes-amends-term-loan-credit-agreement-cutting-interest-spreads/https://aibio.space/news/alkermes-amends-term-loan-credit-agreement-cutting-interest-spreads/Wed, 12 Aug 2026 12:00:00 GMTDebt FinancingJPMorgan Chase Bank, N.A. is administrative agent. The amendment cuts the spread on term loan A by 0.75% and on term loan B by 0.50%.SEC Form 8-K https://aibio.space/news/agenus-extends-ocean-1181-loan-maturity-november-2029/https://aibio.space/news/agenus-extends-ocean-1181-loan-maturity-november-2029/Wed, 12 Aug 2026 12:00:00 GMTDebt FinancingThe loan principal stays at $24,750,000 and the rate stays at 13.0%. The $247,500 extension fee is paid half in cash and half in shares.Agenus Inc. 8-K (2026-08-18) https://aibio.space/news/profusa-issues-714-285-72-senior-secured-convertible-note/https://aibio.space/news/profusa-issues-714-285-72-senior-secured-convertible-note/Wed, 12 Aug 2026 12:00:00 GMTDebt FinancingThe note has a $650,000.00 purchase price and matures in August 2027. The filing names no placement agent or advisor.Profusa, Inc. 8-K (2026-08-21) https://aibio.space/news/turn-therapeutics-ends-june-10-3-million-going-concern-warning/https://aibio.space/news/turn-therapeutics-ends-june-10-3-million-going-concern-warning/Wed, 12 Aug 2026 12:00:00 GMTDistressManagement says June 30 cash covers GX-03 work in atopic dermatitis into the third quarter of 2027, but the 10-Q also raises substantial doubt that Turn can continue as a going concern.SEC EDGAR: Turn Therapeutics 10-Q https://aibio.space/news/alto-neuroscience-ipo-securities-class-action-dismissed-leave-amend/https://aibio.space/news/alto-neuroscience-ipo-securities-class-action-dismissed-leave-amend/Wed, 12 Aug 2026 12:00:00 GMTLegalA federal court in California dismissed the securities class action over Alto Neuroscience's ALTO-100 disclosures on August 7, 2026, and gave the plaintiffs leave to file a third amended complaint. A related derivative action has been stayed.Alto Neuroscience 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/inovios-supply-contract-suit-against-vgxi-geneone-set-trial-october/https://aibio.space/news/inovios-supply-contract-suit-against-vgxi-geneone-set-trial-october/Wed, 12 Aug 2026 12:00:00 GMTLegalInovio sued VGXI, Inc. and GeneOne Life Science, Inc. in a Pennsylvania state court in 2020 over a supply agreement. The defendants counterclaimed. A seven-day trial was scheduled to begin October 13, 2026.Inovio Pharmaceuticals, Inc. 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/spero-says-sec-closed-investigation-without-action-against-two-ex/https://aibio.space/news/spero-says-sec-closed-investigation-without-action-against-two-ex/Wed, 12 Aug 2026 12:00:00 GMTLegalThe SEC fined former CEO Ankit Mahadevia $112,500 and former CFO Satyavrat Shukla $75,000 in a settled January 2026 order. Spero's letter of Jan 20, 2026 says the SEC does not intend to recommend action against it.Spero Therapeutics, Inc. 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/humacyte-securities-suit-symvess-safety-enters-discovery-four/https://aibio.space/news/humacyte-securities-suit-symvess-safety-enters-discovery-four/Wed, 12 Aug 2026 12:00:00 GMTLegalThe North Carolina class action names Humacyte and certain officers. Derivative suits name current or former directors and officers, and Ayabudge LLC in two cases. Product safety claims survived dismissal.Humacyte 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/atara-biotherapeutics-faces-securities-class-action-tab-cel-allele/https://aibio.space/news/atara-biotherapeutics-faces-securities-class-action-tab-cel-allele/Wed, 12 Aug 2026 12:00:00 GMTLegalKuang v. Atara, filed in Central District of California, names the company and unnamed current and former officers. An amended complaint came on August 10, and defendants must respond by October 9.Atara Biotherapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/lakefront-biotherapeutics-reports-241-904-shares-bought-back-under-eur/https://aibio.space/news/lakefront-biotherapeutics-reports-241-904-shares-bought-back-under-eur/Wed, 12 Aug 2026 12:00:00 GMTFinancingsRepurchases run no later than December 31, 2026. The company expects year-end 2026 cash and financial investments of EUR 1.975 billion to EUR 2.050 billion, including the buyback.Lakefront Biotherapeutics 6-K (2026-08-12) https://aibio.space/news/pharvaris-reports-318-million-cash-after-132-3-million-offering/https://aibio.space/news/pharvaris-reports-318-million-cash-after-132-3-million-offering/Wed, 12 Aug 2026 12:00:00 GMTFinancingsPharvaris reported €318 million of cash at June 30, 2026, after a $132.3 million underwritten offering it closed in May. The company says the money extends its runway into 2028, while its quarterly loss reached €47.8 million and its key pivotal trial has yet to report.Pharvaris N.V. 6-K (2026-08-12) https://aibio.space/news/vogenx-prices-ipo-6-250-000-shares-13-00-nasdaq/https://aibio.space/news/vogenx-prices-ipo-6-250-000-shares-13-00-nasdaq/Wed, 12 Aug 2026 12:00:00 GMTFinancingsVogenx priced 6,250,000 shares at $13.00, for $81,250,000 before underwriting discounts. The prospectus shows $251 thousand of cash at March 31, 2026 and a going-concern warning.Vogenx Inc 424B4 (2026-08-12) https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/Tue, 11 Aug 2026 12:00:00 GMTFinancingsThe company extended its runway into the second half of 2028. Lilly's stake carries no rights to the ABS-201 antibody.Absci https://aibio.space/news/silence-therapeutics-raises-175-million-after-divesiran-phase-2-win/https://aibio.space/news/silence-therapeutics-raises-175-million-after-divesiran-phase-2-win/Tue, 11 Aug 2026 12:00:00 GMTFinancingsThe upsized offering priced at $13.50 per ADS a day after the SANRECO results, adding to $72.1 million in cash at the end of June.Silence Therapeutics https://aibio.space/news/theriva-biologics-doses-first-virage2-patients-reports-cash-q1-2027/https://aibio.space/news/theriva-biologics-doses-first-virage2-patients-reports-cash-q1-2027/Tue, 11 Aug 2026 12:00:00 GMTCompany UpdatesThe NYSE American company reported $11.3 million of cash at June 30, 2026, after first patients were dosed in a Phase 2a trial of more frequent VCN-01 dosing in pancreatic cancer.Theriva Biologics, Inc. 8-K (2026-08-11) https://aibio.space/news/bolt-biotherapeutics-reports-second-quarter-results-cash-2027/https://aibio.space/news/bolt-biotherapeutics-reports-second-quarter-results-cash-2027/Tue, 11 Aug 2026 12:00:00 GMTCompany UpdatesThe company had $18.1 million in cash, cash equivalents and marketable securities on June 30, 2026. It expects to report initial clinical data from its lead antibody conjugate, BDC-4182, with its third-quarter results.Bolt Biotherapeutics press release (Form 8-K, Exhibit 99.1) https://aibio.space/news/eloxx-reports-second-quarter-results-after-66-0-million-offering/https://aibio.space/news/eloxx-reports-second-quarter-results-after-66-0-million-offering/Tue, 11 Aug 2026 12:00:00 GMTListingsThe company said its June offering and move to the Nasdaq Capital Market strengthened its balance sheet. Cash of $62.0 million is expected to fund operations into mid-2028.Eloxx Pharmaceuticals Form 8-K, Exhibit 99.1 https://aibio.space/news/dermata-reports-second-quarter-2026-results-4-4-million-cash/https://aibio.space/news/dermata-reports-second-quarter-2026-results-4-4-million-cash/Tue, 11 Aug 2026 12:00:00 GMTCompany UpdatesDermata Therapeutics reported $4.4 million in cash and cash equivalents at June 30, 2026, and said it expects to launch Tome Foundational Treatment on August 25, 2026. Cash is expected to fund operations into the fourth quarter of 2026.Dermata Therapeutics, Inc. 8-K (2026-08-11) https://aibio.space/news/intensity-therapeutics-reports-q2-2026-results-trial-updates/https://aibio.space/news/intensity-therapeutics-reports-q2-2026-results-trial-updates/Tue, 11 Aug 2026 12:00:00 GMTCompany UpdatesCash and cash equivalents were $9.5 million at June 30, 2026. The company began activities to resume enrollment in its INVINCIBLE-3 study and restarted treatment in INVINCIBLE-4.Intensity Therapeutics, Inc. 8-K (2026-08-11) https://aibio.space/news/enlivex-amends-21-0-million-lind-note-resets-conversion-price/https://aibio.space/news/enlivex-amends-21-0-million-lind-note-resets-conversion-price/Tue, 11 Aug 2026 12:00:00 GMTDebt FinancingEnlivex deleted a market capitalization default from its Lind note and revised conversion and prepayment terms. Outstanding principal rose to $19.2 million.Enlivex Ltd. 6-K (2026-08-11) https://aibio.space/news/veradermics-reports-819-9-million-cash-securities-sees-funding-2030/https://aibio.space/news/veradermics-reports-819-9-million-cash-securities-sees-funding-2030/Tue, 11 Aug 2026 12:00:00 GMTFinancingsVeradermics reported $819.9 million in cash and securities at June 30 and says the money lasts into 2030. That runway depends on Phase 3 readouts, the first of them due in the second half of 2026.SEC EDGAR: Veradermics 10-Q https://aibio.space/news/kyverna-faces-ipo-securities-class-action-consolidated-derivative-suit/https://aibio.space/news/kyverna-faces-ipo-securities-class-action-consolidated-derivative-suit/Tue, 11 Aug 2026 12:00:00 GMTLegalKyverna Therapeutics is defending a Securities Act class action over its February 2024 IPO, which names the company, certain officers and directors, and the underwriters. A second amended complaint is under a motion to dismiss, with a hearing set for September 3, 2026. Two derivative suits filed in May 2025 were later consolidated.Kyverna Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/taysha-derivative-suit-2023-private-placement-faces-termination-motion/https://aibio.space/news/taysha-derivative-suit-2023-private-placement-faces-termination-motion/Tue, 11 Aug 2026 12:00:00 GMTLegalStockholders sued in Delaware Chancery over the August 2023 private placement. A special litigation committee moved on March 3, 2026 to end the case, and the lead plaintiff does not oppose.Taysha Gene Therapies 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/therapeuticsmds-mayne-pharma-suit-stayed-imvexxy-patent-cases-against/https://aibio.space/news/therapeuticsmds-mayne-pharma-suit-stayed-imvexxy-patent-cases-against/Tue, 11 Aug 2026 12:00:00 GMTLegalTherapeuticsMD (Nasdaq: TXMD) sued Mayne Pharma LLC in Delaware over net working capital allowances and faces a countersuit. Teva and Sun Pharma are defendants in New Jersey patent cases over generic IMVEXXY.TherapeuticsMD 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/erasca-faces-securities-class-action-eras-0015-derivative-suit/https://aibio.space/news/erasca-faces-securities-class-action-eras-0015-derivative-suit/Tue, 11 Aug 2026 12:00:00 GMTLegalErasca (Nasdaq: ERAS) is named in a June class action in San Diego federal court. An August derivative suit names its current directors and CFO. The 10-Q names no officers in the class action.Erasca 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/bicara-biocon-face-y-trap-inventorship-suit-ficerafusp-alfa-patents/https://aibio.space/news/bicara-biocon-face-y-trap-inventorship-suit-ficerafusp-alfa-patents/Tue, 11 Aug 2026 12:00:00 GMTLegalY-Trap, Inc. sued Bicara Therapeutics and Biocon Ltd in Massachusetts federal court in October 2024. Discovery is ongoing, and a patent office review Bicara requested was instituted on July 15, 2026.Bicara Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/gain-therapeutics-ceo-gene-mack-sued-delaware-warrant-exercise-price/https://aibio.space/news/gain-therapeutics-ceo-gene-mack-sued-delaware-warrant-exercise-price/Tue, 11 Aug 2026 12:00:00 GMTLegalWarrant holder Andrew Schwartzberg seeks more than $3.1 million from Gain and Gene Mack for breach of contract, fraudulent inducement and promissory estoppel. Gain's 10-Q reports going concern doubt.Gain Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/abcellera-launches-200-000-000-share-offering-then-prices-9-75/https://aibio.space/news/abcellera-launches-200-000-000-share-offering-then-prices-9-75/Tue, 11 Aug 2026 12:00:00 GMTFinancingsA later announcement prices 17,435,897 common shares and pre-funded warrants for 3,076,926 shares, for expected gross proceeds of about $200.0 million. The offering is expected to close on August 14, 2026.AbCellera Biologics Inc. 424B5 (2026-08-11) https://aibio.space/news/aura-biosciences-cuts-about-20-percent-workforce-expects-cash-runway/https://aibio.space/news/aura-biosciences-cuts-about-20-percent-workforce-expects-cash-runway/Tue, 11 Aug 2026 12:00:00 GMTDistressThe company is refocusing on ocular oncology and minimizing resources for its bladder cancer program. Its Phase 3 CoMpass trial is fully enrolled with 108 patients.Aura Biosciences, Inc. 8-K (2026-08-11) https://aibio.space/news/tango-therapeutics-files-up-400-000-000-market-stock-program/https://aibio.space/news/tango-therapeutics-files-up-400-000-000-market-stock-program/Tue, 11 Aug 2026 12:00:00 GMTFinancingsTango Therapeutics filed to sell up to $400,000,000 of stock through Leerink Partners, replacing a $100,000,000 program of which about $64,389,566 had been sold. Its early response rates come from a small group of patients treated in combination.Tango Therapeutics, Inc. 424B5 (2026-08-11) https://aibio.space/news/adial-expects-ceo-cfo-leave-after-september-annual-meeting/https://aibio.space/news/adial-expects-ceo-cfo-leave-after-september-annual-meeting/Mon, 10 Aug 2026 12:00:00 GMTCompany UpdatesAdial anticipates that Cary Claiborne and Vinay Shah will leave after stockholders approve the proposals at the annual meeting, and that Matthew Davidson will become president and chief executive officer.Adial Pharmaceuticals, Inc 8-K (2026-08-13) https://aibio.space/news/palisade-bio-reports-second-quarter-2026-results-phase-2-plans-pali/https://aibio.space/news/palisade-bio-reports-second-quarter-2026-results-phase-2-plans-pali/Mon, 10 Aug 2026 12:00:00 GMTCompany UpdatesThe company reported a net loss of $10.6 million for the quarter and cash of $125.2 million at June 30, 2026. It expects to start the Phase 2 ASCENTRA-UC trial in the second half of 2026.Palisade Bio, Inc. 8-K (2026-08-10) https://aibio.space/news/bionano-reports-second-quarter-2026-revenue-8-2-million/https://aibio.space/news/bionano-reports-second-quarter-2026-revenue-8-2-million/Mon, 10 Aug 2026 12:00:00 GMTCompany UpdatesConsumables revenue rose 31%, and the company completed the retirement of its senior secured convertible debentures.Bionano Genomics, Inc. 8-K (2026-08-10) https://aibio.space/news/interpace-biosciences-reports-second-quarter-revenue-9-1-million/https://aibio.space/news/interpace-biosciences-reports-second-quarter-revenue-9-1-million/Mon, 10 Aug 2026 12:00:00 GMTCompany UpdatesRevenue was $9.1 million, down slightly from the prior-year quarter as reported, while income from continuing operations was $0.3 million and thyroid revenue rose 9%.Form 8-K, Exhibit 99.1 (SEC EDGAR) https://aibio.space/news/bioxcel-amends-oaktree-credit-agreement-sets-august-21-deadline/https://aibio.space/news/bioxcel-amends-oaktree-credit-agreement-sets-august-21-deadline/Mon, 10 Aug 2026 12:00:00 GMTDebt FinancingOaktree Fund Administration, LLC is administrative agent. The amendment requires definitive transaction agreements by August 21, 2026 and sets the minimum liquidity amount at $3,000,000 from August 10, 2026.SEC Form 8-K https://aibio.space/news/os-therapies-sells-up-10-000-000-senior-secured-convertible-notes/https://aibio.space/news/os-therapies-sells-up-10-000-000-senior-secured-convertible-notes/Mon, 10 Aug 2026 12:00:00 GMTDebt FinancingThe first closing on August 10, 2026 covered $5,000,000 of units, including a bridge note conversion, and the second tranche is optional for each purchaser.SEC Form 8-K https://aibio.space/news/aspire-closes-30-0-million-cash-acquisition-enters-22-5-million/https://aibio.space/news/aspire-closes-30-0-million-cash-acquisition-enters-22-5-million/Mon, 10 Aug 2026 12:00:00 GMTDebt FinancingThe senior secured revolving credit facility will help fund the cash price for Dura Driver Control Systems, along with cash on hand. The release names no lender.Company press release (Exhibit 99.1) https://aibio.space/news/anavex-life-sciences-files-nt-10-q-says-june-quarter-report-late-amid/https://aibio.space/news/anavex-life-sciences-files-nt-10-q-says-june-quarter-report-late-amid/Mon, 10 Aug 2026 12:00:00 GMTDistressAnavex (Nasdaq: AVXL) cannot file its 10-Q for the quarter ended June 30, 2026 on time. The company also lists its 10-Q for the quarter ended March 31, 2026 as not yet filed.ANAVEX LIFE SCIENCES CORP. Form NT 10-Q filed August 10, 2026 (SEC EDGAR) https://aibio.space/news/veru-faces-securities-class-action-five-derivative-suits-sabizabulin/https://aibio.space/news/veru-faces-securities-class-action-five-derivative-suits-sabizabulin/Mon, 10 Aug 2026 12:00:00 GMTLegalVeru, Chairman and CEO Mitchell Steiner and CFO Michele Greco are defendants in a Florida class action. Five derivative suits name seven officers and directors. Veru says it cannot estimate losses.Veru Inc. 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/veru-faces-fraud-warranty-suit-buyer-fc2-business/https://aibio.space/news/veru-faces-fraud-warranty-suit-buyer-fc2-business/Mon, 10 Aug 2026 12:00:00 GMTLegalClear Future, Inc. sued Veru Inc. in Delaware Superior Court after buying the FC2 female condom business for $18.0 million in cash. Veru is the defendant named in the 10-Q and says it cannot estimate losses.Veru Inc. 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/sana-biotechnology-securities-class-action-stayed-after-second-amended/https://aibio.space/news/sana-biotechnology-securities-class-action-stayed-after-second-amended/Mon, 10 Aug 2026 12:00:00 GMTLegalThe Washington federal suit names Sana (Nasdaq: SANA), CEO Steven D. Harr and former CFO Nathan Hardy over SC291 statements. A second amended complaint was filed May 26, 2026, and the case is stayed.Sana Biotechnology 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/rocket-pharmaceuticals-faces-securities-class-action-derivative-suit/https://aibio.space/news/rocket-pharmaceuticals-faces-securities-class-action-derivative-suit/Mon, 10 Aug 2026 12:00:00 GMTLegalHo and Yankov complaints named Rocket, CEO Gaurav Shah and former CFO Aaron Ondrey. Rocket's motion to dismiss the consolidated complaint is pending, and a derivative suit is stayed.Rocket Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/metagenomis-ipo-class-action-moderna-collaboration-disclosures-moves/https://aibio.space/news/metagenomis-ipo-class-action-moderna-collaboration-disclosures-moves/Mon, 10 Aug 2026 12:00:00 GMTLegalVreeland v. Metagenomi names the company, unnamed officers and directors under Section 11. The court partly denied dismissal on March 24, 2026; the S-1 shows who signed.Metagenomi Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/axsome-derivative-suit-dismissed-delaware-new-york-case-awaits-ruling/https://aibio.space/news/axsome-derivative-suit-dismissed-delaware-new-york-case-awaits-ruling/Mon, 10 Aug 2026 12:00:00 GMTLegalStockholders sued Axsome's directors and officers in New York and Delaware over AXS-07 statements. Delaware dismissed with prejudice on July 9, 2026. The New York motion to dismiss is fully briefed.Axsome Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/axsome-resolves-all-sunosi-patent-suits-symbravo-case-against-apotex/https://aibio.space/news/axsome-resolves-all-sunosi-patent-suits-symbravo-case-against-apotex/Mon, 10 Aug 2026 12:00:00 GMTLegalAxsome's 10-Q says it has settled with every current Sunosi ANDA filer, the last being Aurobindo on June 2, 2026. Its Symbravo patent suit against Apotex Inc. is in fact discovery.Axsome Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/moonlake-faces-securities-class-action-sonelokimab-motion-dismiss/https://aibio.space/news/moonlake-faces-securities-class-action-sonelokimab-motion-dismiss/Mon, 10 Aug 2026 12:00:00 GMTLegalThe Peters suit names MoonLake and its chief executive, chief financial and chief scientific officers. The class period runs March 10, 2024 through September 29, 2025.MoonLake Immunotherapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/anavex-life-sciences-says-cannot-file-june-quarter-report-time/https://aibio.space/news/anavex-life-sciences-says-cannot-file-june-quarter-report-time/Mon, 10 Aug 2026 12:00:00 GMTDistressThe company cites a special committee's review of matters tied to the April 30, 2026 termination of its chief executive. Its quarterly report for the period ended March 31, 2026 is also listed as not filed.Anavex Life Sciences Corp. NT 10-Q (2026-08-10) https://aibio.space/news/cogent-biosciences-files-up-400-000-000-market-stock-sales/https://aibio.space/news/cogent-biosciences-files-up-400-000-000-market-stock-sales/Mon, 10 Aug 2026 12:00:00 GMTFinancingsGuggenheim Securities may act as agent or principal and is entitled to a 3.0% commission. The last reported sale price on August 7, 2026 was $42.39 per share, and the supplement puts dilution to new buyers at $37.68 per share.Cogent Biosciences, Inc. 424B5 (2026-08-10) https://aibio.space/news/lakewood-amedex-biotherapeutics-sets-vote-share-increase-100-000-000/https://aibio.space/news/lakewood-amedex-biotherapeutics-sets-vote-share-increase-100-000-000/Mon, 10 Aug 2026 12:00:00 GMTListingsHolders will vote on September 22, 2026 on raising authorized common stock from 12,500,000 shares and on a reverse split of up to 1-for-20.Lakewood-Amedex Biotherapeutics Inc. DEF 14A (2026-08-10) https://aibio.space/news/wave-life-sciences-ltd-now-wave-life-sciences-inc-files-form-15-end/https://aibio.space/news/wave-life-sciences-ltd-now-wave-life-sciences-inc-files-form-15-end/Mon, 10 Aug 2026 12:00:00 GMTListingsThe notice lists one holder of record of the ordinary shares and is dated August 7, 2026. Wave Life Sciences Ltd. reported a net loss of $204.4 million for 2025.Wave Life Sciences, Inc. 15-12G (2026-08-10) https://aibio.space/news/minerva-neurosciences-reports-second-quarter-2026-results-c19-trial/https://aibio.space/news/minerva-neurosciences-reports-second-quarter-2026-results-c19-trial/Fri, 07 Aug 2026 12:00:00 GMTCompany UpdatesMinerva reported GAAP net income of $17.5 million for the quarter, driven by a non-cash warrant gain, and cash, cash equivalents, marketable securities and restricted cash of approximately $75.4 million at June 30, 2026.Minerva Neurosciences, Inc 8-K (2026-08-07) https://aibio.space/news/osr-health-says-nasdaq-did-not-endorse-loyalty-cvr-program/https://aibio.space/news/osr-health-says-nasdaq-did-not-endorse-loyalty-cvr-program/Fri, 07 Aug 2026 12:00:00 GMTCompany UpdatesThe company said a July 31 statement should not be read as Nasdaq approval of the Shareholder Loyalty CVR Program, and the August 14, 2026 record date is unchanged.OSR Health, Inc. 8-K (2026-08-07) https://aibio.space/news/kiora-reports-second-quarter-2026-results-cash-runway-late-2028/https://aibio.space/news/kiora-reports-second-quarter-2026-results-cash-runway-late-2028/Fri, 07 Aug 2026 12:00:00 GMTCompany UpdatesKiora ended the quarter with about $16.8 million in cash and short-term investments. The company also reported a private placement for up to $24.0 million, with $5.0 million received upfront.Kiora Pharmaceuticals, Inc. 8-K (2026-08-07) https://aibio.space/news/glucotrack-amends-white-lion-equity-line-commitment-shares/https://aibio.space/news/glucotrack-amends-white-lion-equity-line-commitment-shares/Fri, 07 Aug 2026 12:00:00 GMTFinancingsGlucotrack amended its July 14, 2026 common stock purchase agreement with White Lion Capital, LLC, agreeing to issue 2,505,513 commitment shares and to pay a true-up amount if the commitment fee price falls below the minimum price.Glucotrack, Inc. 8-K (2026-08-10) https://aibio.space/news/biorestorative-suspends-orders-shipments-two-biocosmeceutical-lines/https://aibio.space/news/biorestorative-suspends-orders-shipments-two-biocosmeceutical-lines/Fri, 07 Aug 2026 12:00:00 GMTCompany UpdatesThe company paused its ExoCR and BioX products on August 7, 2026 while it reviews documentation, sourcing and regulatory status. It has not decided to discontinue them.BioRestorative Therapies, Inc. 8-K (2026-08-14) https://aibio.space/news/tuhura-biosciences-draws-650-000-more-parkview-credit-line/https://aibio.space/news/tuhura-biosciences-draws-650-000-more-parkview-credit-line/Fri, 07 Aug 2026 12:00:00 GMTDebt FinancingThe draw is part of a revolving credit facility of up to $50 million with Parkview Holdings One LLC that matures in April 2031.SEC Form 8-K https://aibio.space/news/cervomed-discloses-ex-ceos-2014-suit-narrowed-march-trial-set-october/https://aibio.space/news/cervomed-discloses-ex-ceos-2014-suit-narrowed-march-trial-set-october/Fri, 07 Aug 2026 12:00:00 GMTLegalPaul Feller sued RestorGenex, Pro Sports & Entertainment, ProElite and Stratus Media Group, GmbH in Los Angeles. The court dismissed some claims on March 26, 2026. CervoMed says it is defending itself vigorously.CervoMed Inc. 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/natera-appeals-guardant-false-advertising-judgment-after-292-5-million/https://aibio.space/news/natera-appeals-guardant-false-advertising-judgment-after-292-5-million/Fri, 07 Aug 2026 12:00:00 GMTLegalA jury found Natera liable in November 2024 in the Northern District of California. Final judgment came in June 2026 and Natera is appealing to the Ninth Circuit.Natera 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/agenus-securities-class-action-dismissed-plaintiff-appeals-sec-closes/https://aibio.space/news/agenus-securities-class-action-dismissed-plaintiff-appeals-sec-closes/Fri, 07 Aug 2026 12:00:00 GMTLegalThe District of Massachusetts dismissed In re Agenus Inc. Securities Litigation on March 24, 2026. The lead plaintiff appealed to the First Circuit, where briefing began in June. Derivative suits remain stayed.Agenus 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/ani-loses-post-trial-motions-cg-oncology-royalty-case-defends-acella/https://aibio.space/news/ani-loses-post-trial-motions-cg-oncology-royalty-case-defends-acella/Fri, 07 Aug 2026 12:00:00 GMTLegalA Delaware court denied ANI's bid for a new trial against CG Oncology on July 16, and ANI plans to appeal. In Minnesota, ANI is defending Acella's Lanham Act suit, with summary judgment argument set for August 25.ANI Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/ani-novitium-face-two-generic-drug-patent-suits-antitrust/https://aibio.space/news/ani-novitium-face-two-generic-drug-patent-suits-antitrust/Fri, 07 Aug 2026 12:00:00 GMTLegalOrphalan sued Novitium, and Xeris and Strongbridge sued Novitium and ANI. In a Harmony patent case against AET and Sandoz entities, the defendants counterclaim against Harmony and Novitium.ANI Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/merck-faces-securities-class-action-gardasil-demand-china-derivative/https://aibio.space/news/merck-faces-securities-class-action-gardasil-demand-china-derivative/Fri, 07 Aug 2026 12:00:00 GMTLegalCronin v. Merck in New Jersey names Merck and unnamed officers. The 10-Q gives no individual defendants; Merck's filings show its CEO, CFO and 13 director nominees.Merck & Co., Inc. 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/atyr-pharma-moves-dismiss-amended-class-action-efzofitimod-statements/https://aibio.space/news/atyr-pharma-moves-dismiss-amended-class-action-efzofitimod-statements/Fri, 07 Aug 2026 12:00:00 GMTLegalDefendants: aTyr Pharma, CEO Sanjay Shukla and, since May, CFO Jill M. Broadfoot. The July 17 motion to dismiss targets the amended complaint; aTyr committed on August 7 to cut 60% of staff.aTyr Pharma 10-Q (SEC EDGAR) https://aibio.space/news/blossomhill-prices-ipo-9-375-000-shares-16-00-150-000-000-total/https://aibio.space/news/blossomhill-prices-ipo-9-375-000-shares-16-00-150-000-000-total/Fri, 07 Aug 2026 12:00:00 GMTFinancingsBlossomHill priced 9,375,000 shares at $16.00 for $150,000,000 before costs, with delivery expected on or about August 10, 2026. The auditor's report on the 2025 financial statements includes a going-concern paragraph.BlossomHill Therapeutics, Inc. 424B4 (2026-08-07) https://aibio.space/news/corbus-pharmaceuticals-sets-up-sales-program-up-127-500-000/https://aibio.space/news/corbus-pharmaceuticals-sets-up-sales-program-up-127-500-000/Fri, 07 Aug 2026 12:00:00 GMTFinancingsCorbus can sell up to $127,500,000 of common stock through Jefferies LLC, which earns a fixed 3% commission on each share. At the $9.40 price the filing uses, new buyers would see $2.46 a share of immediate dilution.Corbus Pharmaceuticals Holdings, Inc. 424B5 (2026-08-07) https://aibio.space/news/latigo-biotherapeutics-prices-ipo-19-200-000-shares-18-00/https://aibio.space/news/latigo-biotherapeutics-prices-ipo-19-200-000-shares-18-00/Fri, 07 Aug 2026 12:00:00 GMTFinancingsThe offering totals $345,600,000 before underwriting discounts, and the company's auditors have raised going-concern doubt.Latigo Biotherapeutics, Inc. 424B4 (2026-08-07) https://aibio.space/news/aptorum-group-now-niki-biosolutions-regains-nasdaq-bid-price/https://aibio.space/news/aptorum-group-now-niki-biosolutions-regains-nasdaq-bid-price/Fri, 07 Aug 2026 12:00:00 GMTListingsNasdaq's August 4, 2026 letter says the closing bid price held at $1.00 or more for ten straight business days. The 8-K gives no share price, and the company's latest annual report shows $3.5 million of cash and a material weakness in its controls.Niki BioSolutions, Inc. 8-K (2026-08-07) https://aibio.space/news/roivant-posts-290-6m-quarterly-loss-3-9b-cash-keeps-buying-back-stock/https://aibio.space/news/roivant-posts-290-6m-quarterly-loss-3-9b-cash-keeps-buying-back-stock/Thu, 06 Aug 2026 12:00:00 GMTFinancingsThe holding company's June quarter showed higher research spending, almost no product revenue and a $950 million Moderna payment that arrived after quarter end.Roivant Sciences (SEC 8-K) https://aibio.space/news/scholar-rock-files-new-200-million-market-stock-program/https://aibio.space/news/scholar-rock-files-new-200-million-market-stock-program/Thu, 06 Aug 2026 12:00:00 GMTFinancingsThe Jefferies program replaces a November 2025 prospectus and has raised about $257.7 million in net proceeds to date. The filing came the day the company reported second-quarter results.Scholar Rock (Form 8-K) https://aibio.space/news/celldex-holds-717-6-million-before-phase-3-readout-cfo-sam-martin/https://aibio.space/news/celldex-holds-717-6-million-before-phase-3-readout-cfo-sam-martin/Thu, 06 Aug 2026 12:00:00 GMTFinancingsAn April stock sale lifted cash, and Celldex guides to funding through 2028. Its finance chief of nine years plans to leave by March 31, 2027.Celldex Therapeutics (SEC Form 8-K exhibit) https://aibio.space/news/theriva-doses-first-patient-virage2-pancreatic-cancer-trial/https://aibio.space/news/theriva-doses-first-patient-virage2-pancreatic-cancer-trial/Thu, 06 Aug 2026 12:00:00 GMTCompany UpdatesThe Phase 2a study will test more frequent repeated dosing of VCN-01 with standard chemotherapy in first-line metastatic pancreatic cancer.Theriva Biologics, Inc. 8-K (2026-08-06) https://aibio.space/news/metavia-reports-second-quarter-2026-net-loss-5-3-million/https://aibio.space/news/metavia-reports-second-quarter-2026-net-loss-5-3-million/Thu, 06 Aug 2026 12:00:00 GMTCompany UpdatesMetaVia reported a net loss of $5.3 million for the quarter ended June 30, 2026, with cash and cash equivalents of $12.6 million, and said all active Part 3 patients reached their highest planned doses.MetaVia Inc. 8-K (2026-08-06) https://aibio.space/news/vivosim-labs-reports-regained-equity-compliance-after-july-cash-events/https://aibio.space/news/vivosim-labs-reports-regained-equity-compliance-after-july-cash-events/Thu, 06 Aug 2026 12:00:00 GMTCompany UpdatesVivoSim Labs said Nasdaq told it on August 4, 2026 that it met the $2.5M stockholders' equity minimum, after a $5.0 million milestone payment, an escrow release and a $4.0 million financing in July.VivoSim Labs, INC. 8-K (2026-08-06) https://aibio.space/news/in8bio-reports-second-quarter-2026-results-glioblastoma-survival-data/https://aibio.space/news/in8bio-reports-second-quarter-2026-results-glioblastoma-survival-data/Thu, 06 Aug 2026 12:00:00 GMTCompany UpdatesIN8bio reported cash of $18.0 million at June 30, 2026 and a net loss of $4.8 million for the quarter, along with updates on its glioblastoma and gamma-delta T cell engager programs.IN8bio, Inc. 8-K (2026-08-06) https://aibio.space/news/revelation-reports-second-quarter-2026-results-cash-early-2027/https://aibio.space/news/revelation-reports-second-quarter-2026-results-cash-early-2027/Thu, 06 Aug 2026 12:00:00 GMTCompany UpdatesRevelation reported a net loss of $3.3 million for the quarter and $11.5 million in cash at June 30, 2026, which it says can fund operations through the first quarter of 2027.Revelation Biosciences, Inc. 8-K (2026-08-06) https://aibio.space/news/ispecimen-prices-5-million-public-offering-1-30-share/https://aibio.space/news/ispecimen-prices-5-million-public-offering-1-30-share/Thu, 06 Aug 2026 12:00:00 GMTFinancingsE.F. Hutton & Co. is the exclusive placement agent, and the offering is expected to close on August 7, 2026.Press release (SEC Exhibit 99.1) https://aibio.space/news/biovie-reports-topline-results-phase-2-sunrise-pd-trial-parkinsons/https://aibio.space/news/biovie-reports-topline-results-phase-2-sunrise-pd-trial-parkinsons/Thu, 06 Aug 2026 12:00:00 GMTCompany UpdatesBioVie said bezisterim met its prespecified endpoints in early-stage Parkinson's disease, with improved blood inflammatory markers and better composite clinical outcomes than placebo.BioVie Inc. 8-K (2026-08-06) https://aibio.space/news/aquabounty-widens-ohio-strategic-review-power-infrastructure/https://aibio.space/news/aquabounty-widens-ohio-strategic-review-power-infrastructure/Thu, 06 Aug 2026 12:00:00 GMTCompany UpdatesAquaBounty said on August 6, 2026 that its review of the Pioneer, Ohio property now covers power infrastructure and energy development, alongside its aquaculture sale talks.AquaBounty Technologies, Inc. 8-K (2026-08-06) https://aibio.space/news/icon-plc-subsidiary-prices-senior-notes-repay-bridge-term-loans/https://aibio.space/news/icon-plc-subsidiary-prices-senior-notes-repay-bridge-term-loans/Thu, 06 Aug 2026 12:00:00 GMTDebt FinancingICON plc said its subsidiary priced three series of senior unsecured notes. Proceeds are meant to repay its bridge facility, senior secured term loans and 2027 notes.ICON plc 6-K (2026-08-06) https://aibio.space/news/spyglass-ends-june-234-2-million-says-cash-lasts-through-2028/https://aibio.space/news/spyglass-ends-june-234-2-million-says-cash-lasts-through-2028/Thu, 06 Aug 2026 12:00:00 GMTFinancingsSecond-quarter net loss was $19.9 million. SpyGlass says its IPO proceeds and cash will fund operations through 2028 and that it will need substantial additional funding after that.SEC EDGAR: SpyGlass Pharma 10-Q https://aibio.space/news/tarsus-agrees-buy-alkeus-270-000-000-cash-180-000-000-stock/https://aibio.space/news/tarsus-agrees-buy-alkeus-270-000-000-cash-180-000-000-stock/Thu, 06 Aug 2026 12:00:00 GMTFinancingsThe merger agreement signed July 31, 2026 also provides milestone payments of up to $350,000,000. Closing needs Hart-Scott-Rodino clearance, and Tarsus expects to complete the deal in 2026.Tarsus Pharmaceuticals, Inc. Form 8-K filed August 6, 2026 (SEC EDGAR) https://aibio.space/news/ensysce-biosciences-buys-cy-biopharma-agrees-two-tranche-private/https://aibio.space/news/ensysce-biosciences-buys-cy-biopharma-agrees-two-tranche-private/Thu, 06 Aug 2026 12:00:00 GMTMergersEnsysce completed its acquisition of Cy Biopharma on August 5, 2026 and agreed to a Series C private placement of about $43 million in two tranches. After the deal, Cy's former holders would own about 73.86% of Ensysce on a fully diluted basis, and the second tranche depends on a clinical milestone.Ensysce Biosciences, Inc. Form 8-K filed August 6, 2026 (SEC EDGAR) https://aibio.space/news/ardelyx-securities-suit-xphozah-ends-after-appeal-withdrawn/https://aibio.space/news/ardelyx-securities-suit-xphozah-ends-after-appeal-withdrawn/Thu, 06 Aug 2026 12:00:00 GMTLegalYarborough v. Ardelyx named the company and executives Michael Raab, Susan Rodriguez, Laura Williams and Elizabeth Grammer. The First Circuit appeal was dismissed on March 26, 2026.Ardelyx 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/gilead-hiv-antitrust-appeal-awaits-ruling-after-october-2025-argument/https://aibio.space/news/gilead-hiv-antitrust-appeal-awaits-ruling-after-october-2025-argument/Thu, 06 Aug 2026 12:00:00 GMTLegalGilead, Bristol-Myers Squibb, Johnson & Johnson and Teva are defendants in consolidated federal suits over HIV drugs. Gilead paid $525 million in 2023 to settle with the direct purchaser class and retailer opt-out plaintiffs.Gilead Sciences 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/gilead-cites-august-2026-ruling-hiv-drug-injury-suits-about-23-000/https://aibio.space/news/gilead-cites-august-2026-ruling-hiv-drug-injury-suits-about-23-000/Thu, 06 Aug 2026 12:00:00 GMTLegalThe 10-Q names Gilead as defendant, with no co-defendants listed, in a putative class action and product liability suits over Viread, Truvada, Atripla, Complera and Stribild. A federal bellwether trial is set for March 2027.Gilead Sciences 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/iovance-faces-securities-class-action-three-derivative-suits-2025/https://aibio.space/news/iovance-faces-securities-class-action-three-derivative-suits-2025/Thu, 06 Aug 2026 12:00:00 GMTLegalIovance (Nasdaq: IOVA) and unnamed officers are defendants in a California class action over 2025 revenue guidance. Derivative suits against Frederick Vogt, Jean-Marc Bellemin and others are stayed. Iovance has moved to dismiss.Iovance Biotherapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/iovance-defends-two-delaware-derivative-suits-director-pay-2024-stock/https://aibio.space/news/iovance-defends-two-delaware-derivative-suits-director-pay-2024-stock/Thu, 06 Aug 2026 12:00:00 GMTLegalIovance (Nasdaq: IOVA) is a nominal defendant in two Court of Chancery suits against its directors. A 2020 pay suit is consolidated and a 2024 offering suit is in motion-to-dismiss briefing.Iovance Biotherapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/intellia-says-court-dismissed-securities-class-action-director-pay/https://aibio.space/news/intellia-says-court-dismissed-securities-class-action-director-pay/Thu, 06 Aug 2026 12:00:00 GMTLegalA Massachusetts court fully granted dismissal of the Gonzalez suit against Intellia (Nasdaq: NTLA) and unnamed officers on June 18, 2026. A Delaware suit against directors and BlueAllele's patent suit remain open.Intellia Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/viatris-faces-indore-plant-securities-class-action-derivative-suits/https://aibio.space/news/viatris-faces-indore-plant-securities-class-action-derivative-suits/Thu, 06 Aug 2026 12:00:00 GMTLegalViatris (Nasdaq: VTRS) and unnamed current and former officers are defendants in a Pennsylvania class action over Indore disclosures. Derivative suits name officers and directors in Pennsylvania and Delaware.Viatris 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/relay-therapeutics-nominal-defendant-delaware-derivative-suit-2021/https://aibio.space/news/relay-therapeutics-nominal-defendant-delaware-derivative-suit-2021/Thu, 06 Aug 2026 12:00:00 GMTLegalHayes v. Borisy, filed December 2024, names Borisy and other directors and officers of Relay (Nasdaq: RLAY) that the 10-Q does not list. The case is in discovery and Relay cannot predict the outcome or any loss.Relay Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/federal-circuit-affirms-invalidity-puma-licensed-patents-tagrisso-suit/https://aibio.space/news/federal-circuit-affirms-invalidity-puma-licensed-patents-tagrisso-suit/Thu, 06 Aug 2026 12:00:00 GMTLegalThe Federal Circuit affirmed on July 9, 2026 that the asserted patent claims are invalid. Wyeth, the Pfizer subsidiary and co-plaintiff, had won a $107.5 million jury award against AstraZeneca Pharmaceuticals LP and AstraZeneca AB.Puma Biotechnology 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/pumas-malpractice-suit-against-former-law-firm-waits-north-carolina/https://aibio.space/news/pumas-malpractice-suit-against-former-law-firm-waits-north-carolina/Thu, 06 Aug 2026 12:00:00 GMTLegalPuma is suing Hedrick Gardner Kincheloe & Garofalo, L.L.P. and attorney David L. Levy over its defense in the Eshelman case. The Court of Appeals revived the claim on Sept. 3, 2025.Puma Biotechnology 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/ocugen-awaits-third-circuit-ruling-dismissed-securities-suit/https://aibio.space/news/ocugen-awaits-third-circuit-ruling-dismissed-securities-suit/Thu, 06 Aug 2026 12:00:00 GMTLegalThe 10-Q says the defendants in the Pennsylvania class action are the company and "certain of its agents" and names none. Derivative suits in two courts are stayed, and a Delaware class action over the charter was dismissed as moot.Ocugen 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/arcturus-sues-abbvie-capstan-trade-secrets-capstan-counterclaims/https://aibio.space/news/arcturus-sues-abbvie-capstan-trade-secrets-capstan-counterclaims/Thu, 06 Aug 2026 12:00:00 GMTLegalArcturus filed in the Southern District of California on September 23, 2025. Capstan Therapeutics answered with counterclaims against the company and two employees, and no trial date is set.Arcturus Therapeutics Holdings 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/pepgen-reports-securities-class-action-shareholder-demand/https://aibio.space/news/pepgen-reports-securities-class-action-shareholder-demand/Thu, 06 Aug 2026 12:00:00 GMTLegalThe 10-Q says the Karam suit against PepGen, its CEO and its CFO was voluntarily dismissed on Nov. 18, 2025. The filing does not name the officers; the 2023 annual report shows McArthur and Donnelly.PepGen Inc. 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/verrica-agrees-principle-settle-2022-securities-class-action-ycanth/https://aibio.space/news/verrica-agrees-principle-settle-2022-securities-class-action-ycanth/Thu, 06 Aug 2026 12:00:00 GMTLegalDefendants: Verrica and unnamed current and former officers and directors. A July term sheet would end a case certified in March; Verrica accrued $4.0 million and needs court approval.Verrica Pharmaceuticals 10-Q (SEC EDGAR) https://aibio.space/news/agomab-therapeutics-nv-reports-252-0-million-cash-after-208-million/https://aibio.space/news/agomab-therapeutics-nv-reports-252-0-million-cash-after-208-million/Thu, 06 Aug 2026 12:00:00 GMTFinancingsCash of €252.0 million compares with a six-month net loss of €31.0 million and €29,917 thousand used in operating activities. The release gives no efficacy figures for either of the two drugs.AgomAb Therapeutics NV 6-K (2026-08-06) https://aibio.space/news/artiva-biotherapeutics-files-400-000-000-shelf-100-000-000-atm-program/https://aibio.space/news/artiva-biotherapeutics-files-400-000-000-shelf-100-000-000-atm-program/Thu, 06 Aug 2026 12:00:00 GMTFinancingsThe at-the-market program would run through Leerink Partners as sales agent. The company's stock last sold at $11.59 per share on August 5, 2026.Artiva Biotherapeutics, Inc. S-3 (2026-08-06) https://aibio.space/news/braveheart-bio-prices-ipo-21-250-000-shares-18-00/https://aibio.space/news/braveheart-bio-prices-ipo-21-250-000-shares-18-00/Thu, 06 Aug 2026 12:00:00 GMTFinancingsBraveheart Bio's final prospectus, dated August 5, 2026, prices 21,250,000 shares at $18.00 each. Net proceeds are estimated at $351.2 million, and the company's accumulated deficit was $80.3 million at March 31, 2026.Braveheart Bio, Inc. 424B4 (2026-08-06) https://aibio.space/news/gh-research-reports-111-2-million-net-proceeds-april-2026-share/https://aibio.space/news/gh-research-reports-111-2-million-net-proceeds-april-2026-share/Thu, 06 Aug 2026 12:00:00 GMTFinancingsThe April offering sold 6,527,779 shares at $18.00. The interim report does not name the underwriters, and the six-month loss rose to $34,113 thousand.GH Research PLC 6-K (2026-08-06) https://aibio.space/news/oculis-reports-chf-47-775-thousand-market-share-sales-first-half/https://aibio.space/news/oculis-reports-chf-47-775-thousand-market-share-sales-first-half/Thu, 06 Aug 2026 12:00:00 GMTFinancingsOculis sold 2,250,000 shares under its ATM program for CHF 47,775 thousand in the first half of 2026. Cash and cash equivalents fell to CHF 61,614 thousand at June 30, 2026.Oculis Holding AG 6-K (2026-08-06) https://aibio.space/news/relay-therapeutics-adds-212-978-049-market-stock-program/https://aibio.space/news/relay-therapeutics-adds-212-978-049-market-stock-program/Thu, 06 Aug 2026 12:00:00 GMTFinancingsRelay Therapeutics amended its stock sales agreement on August 6, 2026 to add $212,978,049 of at-the-market sales, raising the program to $462,978,049. The prospectus puts immediate dilution at $14.22 a share for investors who buy in the offering.Relay Therapeutics, Inc. 8-K (2026-08-06) https://aibio.space/news/solid-biosciences-adds-sales-program-up-200-000-000-jefferies/https://aibio.space/news/solid-biosciences-adds-sales-program-up-200-000-000-jefferies/Thu, 06 Aug 2026 12:00:00 GMTFinancingsSolid Biosciences filed a prospectus supplement for up to $200,000,000 of at-the-market stock sales through Jefferies, replacing a prior $85,000,000 program. The filing says buyers would face dilution of about $4.30 per share at an assumed $8.73 price.Solid Biosciences Inc. 424B5 (2026-08-06) https://aibio.space/news/zhengye-biotechnology-regains-nasdaq-bid-price-compliance/https://aibio.space/news/zhengye-biotechnology-regains-nasdaq-bid-price-compliance/Thu, 06 Aug 2026 12:00:00 GMTListingsNasdaq's August 5, 2026 letter says the Class A ordinary shares closed at $1.00 or more for ten straight business days. The shares stay on the Nasdaq Capital Market.Zhengye Biotechnology Holding Limited 6-K (2026-08-06) https://aibio.space/news/arcus-ends-last-tigit-phase-3-gilead-gives-up-three-board-seats/https://aibio.space/news/arcus-ends-last-tigit-phase-3-gilead-gives-up-three-board-seats/Wed, 05 Aug 2026 12:00:00 GMTFinancingsArcus and AstraZeneca will stop PACIFIC-8 in stage III lung cancer. Second-quarter cash was $775 million, with runway guided to at least the second half of 2028.Arcus Biosciences (SEC Form 8-K exhibit) https://aibio.space/news/q32-bio-reports-q2-2026-net-loss-8-9-million-106-3-million-cash/https://aibio.space/news/q32-bio-reports-q2-2026-net-loss-8-9-million-106-3-million-cash/Wed, 05 Aug 2026 12:00:00 GMTCompany UpdatesThe company reported positive 36-week topline results for bempikibart and completed a $200.0 million public offering in July 2026.Q32 Bio Inc. 8-K (2026-08-05) https://aibio.space/news/genprex-regains-nasdaq-bid-price-compliance-panel-oversight-runs/https://aibio.space/news/genprex-regains-nasdaq-bid-price-compliance-panel-oversight-runs/Wed, 05 Aug 2026 12:00:00 GMTListingsNasdaq's Hearings Panel confirmed on August 4, 2026 that Genprex regained the $1.00 minimum bid price, but the panel keeps jurisdiction until December 7, 2026.Genprex, Inc. 8-K (2026-08-05) https://aibio.space/news/dermata-sets-august-25-2026-sale-date-tome-foundational-treatment/https://aibio.space/news/dermata-sets-august-25-2026-sale-date-tome-foundational-treatment/Wed, 05 Aug 2026 12:00:00 GMTCompany UpdatesDermata Therapeutics expects its first commercial product, Tome Foundational Treatment, to be available for sale starting August 25, 2026. The set of four once-weekly treatments sells for $178, about $45 per treatment.Dermata Therapeutics, Inc. 8-K (2026-08-05) https://aibio.space/news/eton-pharmaceuticals-licenses-asn-001-auson-3-0-million-upfront/https://aibio.space/news/eton-pharmaceuticals-licenses-asn-001-auson-3-0-million-upfront/Wed, 05 Aug 2026 12:00:00 GMTMergersEton (Nasdaq: ETON) signed a license agreement for ASN-001, a late-stage infantile hemangioma gel. It owes milestone payments after FDA approval and tiered royalties of 10% to 15% on net sales.Eton Pharmaceuticals, Inc. Form 8-K filed August 5, 2026 (SEC EDGAR) https://aibio.space/news/vistagen-gets-180-day-nasdaq-extension-until-february-1-2027-minimum/https://aibio.space/news/vistagen-gets-180-day-nasdaq-extension-until-february-1-2027-minimum/Wed, 05 Aug 2026 12:00:00 GMTListingsNasdaq gave Vistagen until February 1, 2027 to restore a $1.00 minimum bid, while its 10-K says its lead Phase 3 study missed the primary endpoint. It used $42.1 million in operations in its last fiscal year.Vistagen Therapeutics, Inc. Form 8-K filed August 5, 2026 (SEC EDGAR) https://aibio.space/news/perrigo-faces-new-york-securities-class-action-infant-formula/https://aibio.space/news/perrigo-faces-new-york-securities-class-action-infant-formula/Wed, 05 Aug 2026 12:00:00 GMTLegalThe 10-Q names Perrigo, CFO Eduardo Bezerra and former CEOs Patrick Lockwood-Taylor and Murray Kessler in French v. Perrigo. A Teamsters pension fund is lead plaintiff and filed an amended complaint on May 1, 2026.Perrigo 10-Q for the quarter ended June 27, 2026 (SEC EDGAR) https://aibio.space/news/bioage-faces-ninth-circuit-appeal-dismissed-ipo-securities-class/https://aibio.space/news/bioage-faces-ninth-circuit-appeal-dismissed-ipo-securities-class/Wed, 05 Aug 2026 12:00:00 GMTLegalBioAge Labs' 10-Q says a federal court dismissed the IPO securities class action with prejudice on March 2, 2026, and the plaintiff has appealed to the Ninth Circuit. The defendants are BioAge, its directors and certain officers, and the filings do not name the officers.BioAge Labs 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/geron-faces-rytelo-securities-class-action-four-derivative-suits/https://aibio.space/news/geron-faces-rytelo-securities-class-action-four-derivative-suits/Wed, 05 Aug 2026 12:00:00 GMTLegalGeron is a defendant in a consolidated securities class action over statements about RYTELO, and four derivative suits repeat the claims. The class action was dismissed without prejudice on March 30, 2026, and a second amended complaint is now under a motion to dismiss.Geron Corporation 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/revolution-medicines-reports-final-judgment-delaware-suit-eqrx-merger/https://aibio.space/news/revolution-medicines-reports-final-judgment-delaware-suit-eqrx-merger/Wed, 05 Aug 2026 12:00:00 GMTLegalThe Court of Chancery dismissed Nemeth v. Casdin with prejudice on June 18, 2026 after a settlement. Revolution was named only as successor to EQRx, alongside its director Alexis Borisy and others.Revolution Medicines, Inc. 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/context-therapeutics-closes-delaware-suit-three-year-director-terms/https://aibio.space/news/context-therapeutics-closes-delaware-suit-three-year-director-terms/Wed, 05 Aug 2026 12:00:00 GMTLegalThe Vladimir Gusinsky Revocable Trust sued Context and its directors on February 4, 2026. A consent judgment voided two charter provisions, and a third party paid plaintiff's counsel $850,000.Context Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/amgen-agrees-settle-roofers-securities-class-action-irs-tax/https://aibio.space/news/amgen-agrees-settle-roofers-securities-class-action-irs-tax/Wed, 05 Aug 2026 12:00:00 GMTLegalAmgen, CEO Robert Bradway and CFO Peter Griffith agreed to settle the New York class action, subject to court approval. Derivative suits against directors are stayed.Amgen 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/amgens-chemocentryx-securities-class-action-settlement-gets/https://aibio.space/news/amgens-chemocentryx-securities-class-action-settlement-gets/Wed, 05 Aug 2026 12:00:00 GMTLegalHomyk v. ChemoCentryx named ChemoCentryx and its CEO over TAVNEOS statements. A California federal court preliminarily approved a class settlement on June 12, 2026; final hearing is October 29.Amgen 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/biocryst-sues-annora-hetero-camber-delaware-generic-orladeyo/https://aibio.space/news/biocryst-sues-annora-hetero-camber-delaware-generic-orladeyo/Wed, 05 Aug 2026 12:00:00 GMTLegalBioCryst filed the patent suit on March 10, 2025 after Paragraph IV notices from Annora Pharma. The 10-Q says the case is in early stages and no estimate of loss is possible.BioCryst Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/recursion-lab-landlord-remain-utah-court-lease-construction-claims/https://aibio.space/news/recursion-lab-landlord-remain-utah-court-lease-construction-claims/Wed, 05 Aug 2026 12:00:00 GMTLegalIndustry Office SLC sued Recursion in 2023 for breach of contract; Recursion counterclaimed for breach and fraudulent misrepresentation. Both sides are in discovery. An Exscientia class action ended in December 2025.Recursion Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/acadia-awaits-federal-circuit-ruling-nuplazid-patent-suits-zydus-trial/https://aibio.space/news/acadia-awaits-federal-circuit-ruling-nuplazid-patent-suits-zydus-trial/Wed, 05 Aug 2026 12:00:00 GMTLegalAcadia is the plaintiff against Aurobindo, MSN, Teva and Zydus entities. A June 2025 judgment for Acadia is on appeal, and a new Zydus case goes to trial November 2, 2026.Acadia Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/mirum-sues-sandoz-hetero-biophore-zydus-delaware-generic-livmarli/https://aibio.space/news/mirum-sues-sandoz-hetero-biophore-zydus-delaware-generic-livmarli/Wed, 05 Aug 2026 12:00:00 GMTLegalMirum, Satiogen and Shire Human Genetic Therapies are plaintiffs in four consolidated cases. A 30-month FDA stay runs through March 29, 2029, and the Markman hearing is April 21, 2027.Mirum Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/attovia-therapeutics-prices-ipo-17-000-000-shares-17-00/https://aibio.space/news/attovia-therapeutics-prices-ipo-17-000-000-shares-17-00/Wed, 05 Aug 2026 12:00:00 GMTFinancingsThe offering totals $289,000,000 before fees. The shares have been approved for listing on the Nasdaq Global Market as ATTO.Attovia Therapeutics, Inc. 424B4 (2026-08-05) https://aibio.space/news/aura-biosciences-holders-approve-raising-authorized-shares-500-000-000/https://aibio.space/news/aura-biosciences-holders-approve-raising-authorized-shares-500-000-000/Wed, 05 Aug 2026 12:00:00 GMTListingsAuthorized common shares rise from 150,000,000. The August 5, 2026 special meeting also approved an amendment to the 2021 Stock Option and Incentive Plan.Aura Biosciences, Inc. 8-K (2026-08-05) https://aibio.space/news/emergent-biosolutions-posts-180-2-million-q2-loss-cuts-about-90-roles/https://aibio.space/news/emergent-biosolutions-posts-180-2-million-q2-loss-cuts-about-90-roles/Wed, 05 Aug 2026 12:00:00 GMTDistressA $191.3 million non-cash impairment charge drove the loss. The company expects annualized savings of approximately $40 million from the restructuring.Emergent BioSolutions Inc. 8-K (2026-08-05) https://aibio.space/news/faeth-therapeutics-reports-186-4-million-cash-securities-after-sensei/https://aibio.space/news/faeth-therapeutics-reports-186-4-million-cash-securities-after-sensei/Tue, 04 Aug 2026 12:00:00 GMTCompany UpdatesFaeth reported a net loss of $16.0 million for the quarter ended June 30, 2026, and said topline data from its Phase 2 PIK-201 trial in endometrial cancer are expected by year-end.Faeth Therapeutics, Inc. 8-K (2026-08-04) https://aibio.space/news/glucotrack-adds-3-500-000-secured-convertible-bridge-financing/https://aibio.space/news/glucotrack-adds-3-500-000-secured-convertible-bridge-financing/Tue, 04 Aug 2026 12:00:00 GMTDebt FinancingGlucotrack issued follow-on senior secured convertible notes with a $4,487,179 face amount and sold pre-funded warrants in an interim private placement.Glucotrack, Inc. 8-K (2026-08-05) https://aibio.space/news/60-degrees-pharmaceuticals-closes-private-placement-about-1-0-million/https://aibio.space/news/60-degrees-pharmaceuticals-closes-private-placement-about-1-0-million/Tue, 04 Aug 2026 12:00:00 GMTFinancings60 Degrees sold shares at $1.74 for approximately $1.0 million gross, with H.C. Wainwright & Co. as exclusive placement agent, after its annual report carried a going-concern warning.60 DEGREES PHARMACEUTICALS, INC. Form 8-K filed August 4, 2026 (SEC EDGAR) https://aibio.space/news/bio-rad-starts-restructuring-plan-80-90-million-pre-tax-charges/https://aibio.space/news/bio-rad-starts-restructuring-plan-80-90-million-pre-tax-charges/Tue, 04 Aug 2026 12:00:00 GMTDistressBio-Rad Laboratories said on August 4, 2026 that the plan includes position eliminations and facility closures worldwide and is expected to be substantially completed by the end of fiscal year 2027. Second-quarter net sales were $651.0 million.BIO-RAD LABORATORIES, INC. Form 8-K filed August 4, 2026 (SEC EDGAR) https://aibio.space/news/camp4-completes-second-closing-private-placement-50-1-million-gross/https://aibio.space/news/camp4-completes-second-closing-private-placement-50-1-million-gross/Tue, 04 Aug 2026 12:00:00 GMTFinancingsCAMP4 Therapeutics sold 10,756,498 shares and pre-funded warrants for 21,925,368 shares on August 3, 2026, after the trigger for the second closing was satisfied.Camp4 Therapeutics Corp Form 8-K filed August 4, 2026 (SEC EDGAR) https://aibio.space/news/niagen-bioscience-details-consumer-class-actions-thorne-suit-elysium/https://aibio.space/news/niagen-bioscience-details-consumer-class-actions-thorne-suit-elysium/Tue, 04 Aug 2026 12:00:00 GMTLegalNiagen and its ChromaDex subsidiary are sued in two consumer class actions and a Thorne patent case. A Federal Circuit ruling on a $9.2 million fee award to Elysium is pending.Niagen Bioscience 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/arrowhead-still-defending-ionis-patent-suit-plozasiran-after-delaware/https://aibio.space/news/arrowhead-still-defending-ionis-patent-suit-plozasiran-after-delaware/Tue, 04 Aug 2026 12:00:00 GMTLegalIonis sued Arrowhead in California on Sept. 11, 2025 over the '333 patent. Arrowhead, the only named defendant, disputes the claim; its Delaware declaratory action was dismissed Dec. 23, 2025.Arrowhead Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/onkure-says-plaintiffs-have-not-pursued-two-new-york-suits-reneo/https://aibio.space/news/onkure-says-plaintiffs-have-not-pursued-two-new-york-suits-reneo/Tue, 04 Aug 2026 12:00:00 GMTLegalThomas and Kent v. Reneo name Reneo and unnamed individual defendants. The 10-Q says plaintiffs have not pursued the claims; the 2024 proxy lists Reneo's board.OnKure Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/onkure-files-100-000-000-market-stock-sale-supplement/https://aibio.space/news/onkure-files-100-000-000-market-stock-sale-supplement/Tue, 04 Aug 2026 12:00:00 GMTFinancingsThe company says it is no longer subject to a Form S-3 sales limit. It had not sold any Class A shares under the program as of August 4, 2026.OnKure Therapeutics, Inc. 424B5 (2026-08-04) https://aibio.space/news/tyra-biosciences-sold-full-150-000-000-under-sales-program-raises/https://aibio.space/news/tyra-biosciences-sold-full-150-000-000-under-sales-program-raises/Tue, 04 Aug 2026 12:00:00 GMTFinancingsTyra Biosciences has sold the full $150,000,000 under its May 2025 at-the-market agreement and has raised the ceiling to $250,000,000. The filing also shows a 2025 net loss of $119.9 million and cash used in operations of $95.1 million.Tyra Biosciences, Inc. 424B5 (2026-08-04) https://aibio.space/news/logicmark-agrees-1-31-share-cash-merger-langham-project/https://aibio.space/news/logicmark-agrees-1-31-share-cash-merger-langham-project/Mon, 03 Aug 2026 12:00:00 GMTMergersThe agreement dated July 31, 2026 would convert LogicMark into a wholly owned subsidiary of Langham Project, LLC, subject to a shareholder vote and other conditions.LogicMark, Inc. 8-K (2026-08-03) https://aibio.space/news/alzamend-neuro-sells-7-5-million-series-d-preferred-affiliate-ault/https://aibio.space/news/alzamend-neuro-sells-7-5-million-series-d-preferred-affiliate-ault/Mon, 03 Aug 2026 12:00:00 GMTFinancingsThe agreement allows up to $25 million of Series D convertible preferred stock, and the first tranche closed July 31, 2026.Alzamend Neuro, Inc. 8-K (2026-08-03) https://aibio.space/news/cocrystal-sells-5-million-stock-opko-health/https://aibio.space/news/cocrystal-sells-5-million-stock-opko-health/Mon, 03 Aug 2026 12:00:00 GMTFinancingsOPKO Health, a longtime shareholder, buys 5,474,053 shares at $0.9134 each in a private placement with no warrants attached.Cocrystal Pharma, Inc. 8-K (2026-08-03) https://aibio.space/news/qhslab-reports-second-quarter-2026-revenue-up-40-1-percent/https://aibio.space/news/qhslab-reports-second-quarter-2026-revenue-up-40-1-percent/Mon, 03 Aug 2026 12:00:00 GMTCompany UpdatesTotal revenue rose 40.1% to $847,490 in the quarter ended June 30, 2026, and ISP revenue rose 86.4%, the company said in unaudited results.QHSLab, Inc. 8-K (2026-08-03) https://aibio.space/news/aeon-regains-nyse-american-compliance-after-july-offering/https://aibio.space/news/aeon-regains-nyse-american-compliance-after-july-offering/Mon, 03 Aug 2026 12:00:00 GMTListingsNYSE Regulation confirmed that AEON resolved the stockholders' equity deficiencies it had reported, after an offering that closed on July 15, 2026. The company expects the below-compliance indicator to be removed from its trading symbol.AEON Biopharma, Inc. 8-K (2026-08-03) https://aibio.space/news/supernus-indivior-plan-merger-backed-650-million-citibank-loan/https://aibio.space/news/supernus-indivior-plan-merger-backed-650-million-citibank-loan/Mon, 03 Aug 2026 12:00:00 GMTDebt FinancingSupernus and Indivior agreed to an all-stock merger that includes a $1.0 billion cash dividend to Indivior stockholders. The companies say a $650 million Citibank term loan commitment will help fund it, and they expect the deal to close in the fourth quarter of 2026.Supernus Pharmaceuticals, Inc., Exhibit 99.1 merger announcement (2026-08-03) https://aibio.space/news/amneal-reprices-2-039-billion-term-loan-adds-45-2-million/https://aibio.space/news/amneal-reprices-2-039-billion-term-loan-adds-45-2-million/Mon, 03 Aug 2026 12:00:00 GMTDebt FinancingAmneal's subsidiary converted $2.039 billion of term loans into new loans with a lower interest margin and added a $45.2 million term loan. The company estimates about $12 million of annual cash interest savings, and the maturity stays at August 1, 2032.Amneal Pharmaceuticals, Inc. Form 8-K (2026-08-03) https://aibio.space/news/autolus-issues-first-75-million-under-up-250-million-perceptive/https://aibio.space/news/autolus-issues-first-75-million-under-up-250-million-perceptive/Mon, 03 Aug 2026 12:00:00 GMTDebt FinancingAutolus issued an initial $75 million of notes to Perceptive Advisors on July 30, 2026 under a five-year, interest-only credit facility of up to $250 million. The company's outlook for cash into the second quarter of 2028 counts the first two tranches totaling $100 million.Autolus Therapeutics plc, Exhibit 99.1 second quarter 2026 results (2026-08-11) https://aibio.space/news/lisata-cuts-72-percent-staff-after-failed-kuva-buyout-then-merges/https://aibio.space/news/lisata-cuts-72-percent-staff-after-failed-kuva-buyout-then-merges/Mon, 03 Aug 2026 12:00:00 GMTDistressKuva Labs could not raise the money to complete its $4.00 tender offer for Lisata. Lisata then cut about 72% of its staff, and on Sept 17 it bought Marea with a $225 million private placement that heavily dilutes existing holders.Lisata Therapeutics (SEC Form 8-K) https://aibio.space/news/krystal-biotech-reports-doj-subpoenas-vyjuvek-testing-program-director/https://aibio.space/news/krystal-biotech-reports-doj-subpoenas-vyjuvek-testing-program-director/Mon, 03 Aug 2026 12:00:00 GMTLegalThe company and certain employees received Justice Department subpoenas in early 2025. A Delaware derivative suit over non-employee director pay has a fairness hearing set for September 14, 2026.Krystal Biotech 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/krystal-biotech-sued-delaware-inventorship-two-kb407-cystic-fibrosis/https://aibio.space/news/krystal-biotech-sued-delaware-inventorship-two-kb407-cystic-fibrosis/Mon, 03 Aug 2026 12:00:00 GMTLegalJonathan Forman says he conceived of inventions claimed in two U.S. patents and was wrongly left off as an inventor. Krystal is the named defendant and says the claims are without merit.Krystal Biotech 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/supernus-faces-january-2027-apokyn-antitrust-trial-related-insurance/https://aibio.space/news/supernus-faces-january-2027-apokyn-antitrust-trial-related-insurance/Mon, 03 Aug 2026 12:00:00 GMTLegalSage Chemical and TruPharma sued Supernus, Britannia, US WorldMeds and others in Delaware. Four individuals were dismissed in 2024. Insurance coverage suits tied to an unnamed Delaware action are open.Supernus Pharmaceuticals 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/ocular-therapeutix-faces-eyepoint-defamation-suit-injunction-ruling/https://aibio.space/news/ocular-therapeutix-faces-eyepoint-defamation-suit-injunction-ruling/Mon, 03 Aug 2026 12:00:00 GMTLegalEyePoint, Inc. sued Ocular in Massachusetts state court on March 20, 2026 over alleged false statements about DURAVYU. The court denied a restraining order on April 13 and has not ruled on a preliminary injunction.Ocular Therapeutix 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/autolus-issues-75-0-million-notes-under-up-250-0-million-perceptive/https://aibio.space/news/autolus-issues-75-0-million-notes-under-up-250-0-million-perceptive/Mon, 03 Aug 2026 12:00:00 GMTFinancingsThe senior secured notes mature July 30, 2031. Perceptive also received a warrant for up to 3,500,000 American Depositary Shares at $1.9314 each.Autolus Therapeutics plc 8-K (2026-08-03) https://aibio.space/news/stoke-therapeutics-files-new-200-000-000-market-stock-program/https://aibio.space/news/stoke-therapeutics-files-new-200-000-000-market-stock-program/Mon, 03 Aug 2026 12:00:00 GMTFinancingsStoke filed a $200,000,000 at-the-market supplement with Cantor Fitzgerald & Co. as sales agent, which can be paid up to 3.0% of gross proceeds. It replaces an earlier supplement under which the company sold about 4.7 million shares for net proceeds of $146.4 million.Stoke Therapeutics, Inc. 424B5 (2026-08-03) https://aibio.space/news/nuwellis-prices-3-4-million-registered-direct-offering-2-59-share/https://aibio.space/news/nuwellis-prices-3-4-million-registered-direct-offering-2-59-share/Fri, 31 Jul 2026 12:00:00 GMTFinancingsLadenburg Thalmann & Co. Inc. is the exclusive placement agent, and the deal includes warrants to buy up to 1,310,890 shares.Nuwellis, Inc. 8-K (2026-08-03) https://aibio.space/news/nasdaq-tells-osr-health-loyalty-cvr-program-will-not-adjust-price/https://aibio.space/news/nasdaq-tells-osr-health-loyalty-cvr-program-will-not-adjust-price/Fri, 31 Jul 2026 12:00:00 GMTCompany UpdatesIn a verbal communication, Nasdaq said the Shareholder Loyalty CVR program will not trigger a mechanical price adjustment, OSR Health said on July 31, 2026.OSR Health, Inc. 8-K (2026-07-31) https://aibio.space/news/co-diagnostics-warrant-inducement-expected-raise-about-2-67-million/https://aibio.space/news/co-diagnostics-warrant-inducement-expected-raise-about-2-67-million/Fri, 31 Jul 2026 12:00:00 GMTFinancingsHolders of existing warrants agreed to exercise at $1.571 per share in exchange for new warrants at $1.56. Maxim Group LLC is the exclusive placement agent.Co-Diagnostics, Inc. 8-K (2026-07-31) https://aibio.space/news/hepion-closes-3-055-000-private-placement-matching-warrants/https://aibio.space/news/hepion-closes-3-055-000-private-placement-matching-warrants/Fri, 31 Jul 2026 12:00:00 GMTFinancingsAgreements dated July 31, 2026 cover 61,100,000 shares at $0.05 per share. The offering closed on August 3, 2026, and the filing names no underwriter.Hepion Pharmaceuticals, Inc. 8-K (2026-08-04) https://aibio.space/news/aethlon-effects-1-5-reverse-stock-split-effective-july-31/https://aibio.space/news/aethlon-effects-1-5-reverse-stock-split-effective-july-31/Fri, 31 Jul 2026 12:00:00 GMTListingsThe split takes effect at 10:00 a.m. Eastern Time on July 31, 2026, and shares are expected to trade split-adjusted on August 4, 2026 under AEMD.AETHLON MEDICAL INC 8-K (2026-07-31) https://aibio.space/news/bioxcel-amends-oaktree-credit-agreement-defers-payment/https://aibio.space/news/bioxcel-amends-oaktree-credit-agreement-defers-payment/Fri, 31 Jul 2026 12:00:00 GMTDebt FinancingBioXcel's Eleventh Amendment moves a $9,016,914.47 payment to August 31, 2026, lowers the minimum liquidity amount to $6,250,000 and requires definitive transaction agreements by August 10, 2026.BioXcel Therapeutics, Inc. 8-K (2026-08-03) https://aibio.space/news/cdt-equity-raises-j-j-astor-note-2-266-650-19-percent-interest/https://aibio.space/news/cdt-equity-raises-j-j-astor-note-2-266-650-19-percent-interest/Fri, 31 Jul 2026 12:00:00 GMTDebt FinancingCDT Equity and J.J. Astor & Co. signed a second amendment on July 31, 2026 that raised the note's principal to $2,266,650 at 19% interest. Weekly installments of $104,187.65 start August 19, 2026, and the lender may convert part of the balance into common stock.SEC Form 8-K https://aibio.space/news/prophase-labs-issues-2-085-000-senior-secured-convertible-note/https://aibio.space/news/prophase-labs-issues-2-085-000-senior-secured-convertible-note/Fri, 31 Jul 2026 12:00:00 GMTDebt FinancingProPhase Labs signed a senior secured convertible loan with J.J. Astor & Co. on July 31, 2026. The note has an original principal of $2,085,000, a funding amount of $1,440,000 and a final maturity of July 31, 2027.ProPhase Labs, Inc. 8-K (2026-08-06) https://aibio.space/news/aiforia-signs-eur-20-million-venture-debt-eib/https://aibio.space/news/aiforia-signs-eur-20-million-venture-debt-eib/Fri, 31 Jul 2026 12:00:00 GMTDebt FinancingThe binding agreement with the European Investment Bank has three tranches and covenants tied to management changes.Aiforia Technologies Plc release (2026-07-31) https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-bid-price-deficiency-notice-deadline/https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-bid-price-deficiency-notice-deadline/Fri, 31 Jul 2026 12:00:00 GMTListingsNasdaq told Mira Pharmaceuticals on July 27, 2026 that its common stock no longer meets the $1 minimum bid price. The company has until January 25, 2027 to regain compliance, and it reported a 2025 net loss of $10.4 million on cash used in operations of $4.7 million.MIRA PHARMACEUTICALS, INC. Form 8-K filed July 31, 2026 (SEC EDGAR) https://aibio.space/news/pds-biotechnology-gets-nasdaq-minimum-bid-price-deficiency-letter-has/https://aibio.space/news/pds-biotechnology-gets-nasdaq-minimum-bid-price-deficiency-letter-has/Fri, 31 Jul 2026 12:00:00 GMTListingsNasdaq said PDS Biotechnology's common stock closed below $1.00 for 30 consecutive business days. The letter has no immediate effect on its Nasdaq Capital Market listing, and the company names a reverse stock split as one option.PDS Biotechnology Corp Form 8-K filed July 31, 2026 (SEC EDGAR) https://aibio.space/news/organon-faces-securities-class-action-dividend-statements-merger-proxy/https://aibio.space/news/organon-faces-securities-class-action-dividend-statements-merger-proxy/Fri, 31 Jul 2026 12:00:00 GMTLegalTeamsters Local 710 leads a consolidated New Jersey class action against Organon and unnamed officers. Two derivative suits are stayed, and a July 6 suit against the board and Sun Pharma entities challenges the merger proxy.Organon & Co. 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/apnimed-prices-ipo-12-000-000-shares-16-00/https://aibio.space/news/apnimed-prices-ipo-12-000-000-shares-16-00/Fri, 31 Jul 2026 12:00:00 GMTFinancingsApnimed priced 12,000,000 shares at $16.00 for $192,000,000 before fees. The company has no approved drug, a secured term loan, and a going-concern warning in its prospectus.Apnimed, Inc. 424B4 (2026-07-31) https://aibio.space/news/evogene-calls-september-4-meeting-director-slates-share-capital/https://aibio.space/news/evogene-calls-september-4-meeting-director-slates-share-capital/Fri, 31 Jul 2026 12:00:00 GMTListingsEvogene's board backs its own seven-person slate over a rival four-person slate at a September 4 meeting, and asks for 120,000,000 more authorized shares and a reverse split of 1-for-2 to 1-for-15. Year-end cash fell to $13.0 million in 2025.Evogene Ltd. 6-K (2026-07-31) https://aibio.space/news/northwest-biotherapeutics-registers-40-325-000-shares-tied-4-9-million/https://aibio.space/news/northwest-biotherapeutics-registers-40-325-000-shares-tied-4-9-million/Fri, 31 Jul 2026 12:00:00 GMTFinancingsNorthwest Biotherapeutics signed a $4.9 million convertible note with a Yorkville fund on July 29, 2026. Net proceeds after original issue discount, a facility commitment fee and expenses are $4,655,000.Northwest Biotherapeutics, Inc. 424B5 (2026-07-31) https://aibio.space/news/ptc-raises-2026-product-revenue-guidance-after-second-quarter/https://aibio.space/news/ptc-raises-2026-product-revenue-guidance-after-second-quarter/Thu, 30 Jul 2026 12:00:00 GMTCompany UpdatesPTC reported second quarter 2026 total revenue of $361 million, including $239 million of product revenue, and raised full-year product revenue guidance to $850 to $950 million.PTC Therapeutics, Inc. 8-K (2026-07-30) https://aibio.space/news/nasdaq-panel-grants-genprex-exception-1-00-bid-price-rule/https://aibio.space/news/nasdaq-panel-grants-genprex-exception-1-00-bid-price-rule/Thu, 30 Jul 2026 12:00:00 GMTListingsThe panel's July 29, 2026 decision lets Genprex stay listed on the Nasdaq Capital Market while it keeps a closing bid of at least $1.00 each trading day until December 7, 2026.Genprex, Inc. 8-K (2026-07-30) https://aibio.space/news/annexon-secures-credit-facility-up-200-million-oxford-finance/https://aibio.space/news/annexon-secures-credit-facility-up-200-million-oxford-finance/Thu, 30 Jul 2026 12:00:00 GMTDebt FinancingAnnexon drew $50 million at closing on a credit facility of up to $200 million from Oxford Finance LLC. Another $100 million depends on registrational milestones, and $50 million needs lender approval.Company press release (Exhibit 99.1) https://aibio.space/news/novo-holdings-cuts-maplight-stake-below-5-percent-after-july-30-share/https://aibio.space/news/novo-holdings-cuts-maplight-stake-below-5-percent-after-july-30-share/Thu, 30 Jul 2026 12:00:00 GMTFinancingsThe Danish investor sold 1.6 million shares in open-market trades at $12.00 to $15.00 and reported 2,086,622 shares left, about 4.9%.MPLT SCHEDULE 13D/A https://aibio.space/news/bristol-myers-squibb-details-texas-plavix-suit-arkansas-340b-complaint/https://aibio.space/news/bristol-myers-squibb-details-texas-plavix-suit-arkansas-340b-complaint/Thu, 30 Jul 2026 12:00:00 GMTLegalBristol Myers Squibb's 10-Q says the company and certain Sanofi entities are defendants in a Texas state suit over Plavix labeling, sales and promotion. Arkansas has sued BMS over 340B contract pharmacy policies, and a Celgene securities class action settled with final approval in May 2026.Bristol Myers Squibb 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/bristol-myers-squibb-sues-seven-generic-drugmakers-delaware-camzyos/https://aibio.space/news/bristol-myers-squibb-sues-seven-generic-drugmakers-delaware-camzyos/Thu, 30 Jul 2026 12:00:00 GMTLegalBristol Myers Squibb's 10-Q says it sued seven generic drugmakers in the U.S. District Court for the District of Delaware over Camzyos patents. The defendants are Aurobindo, Zenara, Micro Labs, Dr. Reddy's, Annora, Apotex and MSN. The filing gives no case numbers, filing dates or rulings.Bristol Myers Squibb 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/baxter-faces-two-securities-class-actions-derivative-suit-novum-lvp/https://aibio.space/news/baxter-faces-two-securities-class-actions-derivative-suit-novum-lvp/Thu, 30 Jul 2026 12:00:00 GMTLegalSuits in Illinois federal court allege misleading statements about Baxter's Novum LVP pump. The 10-Q names Baxter and unnamed officers; the derivative captions name Jose E. Almeida.Baxter International 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/baxters-hillrom-unit-faces-linet-antitrust-suit-bed-buyer-appeal-two/https://aibio.space/news/baxters-hillrom-unit-faces-linet-antitrust-suit-bed-buyer-appeal-two/Thu, 30 Jul 2026 12:00:00 GMTLegalLinet Americas sued Hill-Rom Holdings, Hill-Rom Company and Hill-Rom Services in 2021. A dismissed class action is on appeal, and a DOJ demand and subpoena remain open.Baxter International 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/alterity-reports-37-3-million-cash-after-1-50-share-consolidation/https://aibio.space/news/alterity-reports-37-3-million-cash-after-1-50-share-consolidation/Thu, 30 Jul 2026 12:00:00 GMTListingsThe quarterly cash flow report also shows an A$3,982,992 tax incentive refund and says the company is evaluating strategic and funding alternatives.Alterity Therapeutics Ltd. 6-K (2026-07-30) https://aibio.space/news/lexaria-sets-1-15-reverse-split-august-3-2026-meet-nasdaq-bid-rule/https://aibio.space/news/lexaria-sets-1-15-reverse-split-august-3-2026-meet-nasdaq-bid-rule/Thu, 30 Jul 2026 12:00:00 GMTListingsShares outstanding will drop from 24,787,446 to 1,652,518. The company expects to seek a Nasdaq hearing if it gets a delisting notice.Lexaria Bioscience Corp. 8-K (2026-07-30) https://aibio.space/news/dyne-therapeutics-has-898-5-million-cash-runway-2028-after-july/https://aibio.space/news/dyne-therapeutics-has-898-5-million-cash-runway-2028-after-july/Wed, 29 Jul 2026 12:00:00 GMTFinancingsThe company sold 21,045,000 shares at $20.50 in July and expanded a loan facility to $400 million as it prepares a possible Duchenne launch.Dyne Therapeutics https://aibio.space/news/traws-pharma-receives-nasdaq-notice-1-00-minimum-bid-price/https://aibio.space/news/traws-pharma-receives-nasdaq-notice-1-00-minimum-bid-price/Wed, 29 Jul 2026 12:00:00 GMTListingsNasdaq says Traws has until January 25, 2027 to regain compliance with the minimum bid price requirement, and that its listing remains fully effective for now.Traws Pharma, Inc. SEC filing (Form 8-K) https://aibio.space/news/synlogic-merge-caldera-therapeutics-all-stock-deal/https://aibio.space/news/synlogic-merge-caldera-therapeutics-all-stock-deal/Wed, 29 Jul 2026 12:00:00 GMTMergersThe combined company would operate as Caldera Therapeutics. A concurrent private placement of approximately $278 million is expected to close alongside the merger, which is expected to close by early 2027.Form 8-K, SEC EDGAR https://aibio.space/news/processa-acquires-vidya-therapeutics-200-million-placement/https://aibio.space/news/processa-acquires-vidya-therapeutics-200-million-placement/Wed, 29 Jul 2026 12:00:00 GMTMergersProcessa said it acquired Vidya Therapeutics, whose lead asset is the BTK inhibitor VT-7208, alongside a concurrent private placement of approximately $200 million.Processa Pharmaceuticals, Inc. 8-K (2026-07-29) https://aibio.space/news/vector-biosource-agrees-buy-four-blood-collection-centers/https://aibio.space/news/vector-biosource-agrees-buy-four-blood-collection-centers/Wed, 29 Jul 2026 12:00:00 GMTCompany UpdatesFOXO subsidiary Vector BioSource, Inc. signed a definitive agreement to acquire four U.S. blood collection centers from Grifols Bio Supplies, Inc. The company expects the deal to close in the third or fourth quarter of 2026.FOXO TECHNOLOGIES INC. 8-K (2026-07-29) https://aibio.space/news/hcw-biologics-prices-1-6-million-private-placement-insiders/https://aibio.space/news/hcw-biologics-prices-1-6-million-private-placement-insiders/Wed, 29 Jul 2026 12:00:00 GMTFinancingsThe company agreed to sell 618,682 units at $2.585 per unit, including shares to its founder, chairman and an officer, and the common warrants need stockholder approval.HCW Biologics press release, July 29, 2026 https://aibio.space/news/glucotrack-unit-advances-lt-100-toward-single-injection-dosing/https://aibio.space/news/glucotrack-unit-advances-lt-100-toward-single-injection-dosing/Wed, 29 Jul 2026 12:00:00 GMTCompany UpdatesLokahi Therapeutics, a wholly owned subsidiary of Glucotrack, said nonclinical results support testing one subcutaneous injection in place of up to 15 intradermal injections, with clinical evaluation possibly starting in the fourth quarter of 2026.Glucotrack, Inc. 8-K (2026-07-30) https://aibio.space/news/trafalgar-adds-three-new-officers-three-incoming-directors/https://aibio.space/news/trafalgar-adds-three-new-officers-three-incoming-directors/Wed, 29 Jul 2026 12:00:00 GMTMergersThe board of The Greater Cannabis Company, Inc. named Carlos Septién, Michelle Cervantes Vivanco and Ernesto Gómez Berjón on July 29, 2026, and they join the board after a notice period.TRAFALGAR INTERNATIONAL, INC. 8-K (2026-07-31) https://aibio.space/news/accuray-gets-lender-waiver-defaults-under-financing-agreement/https://aibio.space/news/accuray-gets-lender-waiver-defaults-under-financing-agreement/Wed, 29 Jul 2026 12:00:00 GMTDebt FinancingAccuray's lenders waived two defaults under its financing agreement, and the same amendment exchanges converted debt for preferred shares and penny warrants, subject to shareholder approval.ACCURAY INC 8-K (2026-07-29) https://aibio.space/news/china-resources-pharmaceutical-issues-rmb1-billion-second-tranche/https://aibio.space/news/china-resources-pharmaceutical-issues-rmb1-billion-second-tranche/Wed, 29 Jul 2026 12:00:00 GMTDebt FinancingA wholly owned subsidiary completed the second 2026 tranche of medium term notes, RMB1 billion at 1.52% per annum over three years.China Resources Pharmaceutical Group Limited announcement (2026-07-29) https://aibio.space/news/celularity-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until/https://aibio.space/news/celularity-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until/Wed, 29 Jul 2026 12:00:00 GMTListingsCelularity (Nasdaq: CELU) was told on July 23, 2026 that its Class A common stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on its listing, the company says.Celularity Inc Form 8-K filed July 29, 2026 (SEC EDGAR) https://aibio.space/news/ra-capital-exchanges-18-030-000-inhibikase-therapeutics-shares-pre/https://aibio.space/news/ra-capital-exchanges-18-030-000-inhibikase-therapeutics-shares-pre/Wed, 29 Jul 2026 12:00:00 GMTFinancingsOn July 29, 2026, RA Capital Healthcare Fund exchanged 18,030,000 Inhibikase common shares for a pre-funded warrant on the same number of shares. The warrant carries a 9.99% ownership limit, and the filing does not say why the exchange was made.Inhibikase Therapeutics, Inc. Form 8-K filed July 29, 2026 (SEC EDGAR) https://aibio.space/news/earth-science-tech-ask-holders-advisory-vote-reverse-split-uplisting/https://aibio.space/news/earth-science-tech-ask-holders-advisory-vote-reverse-split-uplisting/Wed, 29 Jul 2026 12:00:00 GMTListingsEarth Science Tech's board wants a non-binding stockholder signal on a reverse split to meet the bid price test for an uplisting. The company says it is not currently a listed issuer, and the proxy's notice gives no split ratio.Earth Science Tech, Inc. DEF 14A (2026-07-29) https://aibio.space/news/inventiva-says-cash-covers-operations-end-q2-2027-after-june/https://aibio.space/news/inventiva-says-cash-covers-operations-end-q2-2027-after-june/Wed, 29 Jul 2026 12:00:00 GMTFinancingsInventiva reported preliminary first-half 2026 figures showing €166.1 million in cash and €67.8 million in short-term deposits. The company says current cash does not cover operations for the next 12 months.Inventiva SA 6-K (2026-07-29) https://aibio.space/news/lb-pharmaceuticals-agrees-150-million-private-placement-34-94-share/https://aibio.space/news/lb-pharmaceuticals-agrees-150-million-private-placement-34-94-share/Wed, 29 Jul 2026 12:00:00 GMTFinancingsThe company is selling 3,577,560 shares and pre-funded warrants for up to 715,513 shares to institutional investors. The deal is expected to close on or about July 30, 2026, and the 2025 10-K filed in March 2026 shows net loss of $25.2 million for the year.LB Pharmaceuticals Inc 8-K (2026-07-29) https://aibio.space/news/onconetix-sells-30-249-600-series-f-preferred-pipe-financing/https://aibio.space/news/onconetix-sells-30-249-600-series-f-preferred-pipe-financing/Tue, 28 Jul 2026 12:00:00 GMTFinancingsThe securities purchase agreement covers 37,812 shares of Series F convertible preferred stock with an initial conversion price of $0.9767 per share.Onconetix 8-K https://aibio.space/news/american-shared-hospital-services-signs-forbearance-fifth-third-bank/https://aibio.space/news/american-shared-hospital-services-signs-forbearance-fifth-third-bank/Tue, 28 Jul 2026 12:00:00 GMTDebt FinancingA third amendment to the credit agreement with Fifth Third Bank, National Association, sets a standstill period that runs to June 30, 2027.American Shared Hospital Services 8-K (2026-07-28) https://aibio.space/news/bionexus-advances-vitaguard-rollout-southeast-asia/https://aibio.space/news/bionexus-advances-vitaguard-rollout-southeast-asia/Tue, 28 Jul 2026 12:00:00 GMTCompany UpdatesAfter a working visit to China, BioNexus says it is preparing the VitaGuard platform for ten licensed Southeast Asian markets.BioNexus Gene Lab Corp 8-K (2026-07-28) https://aibio.space/news/grifols-refinances-all-2027-maturities-about-3-billion-term-loan/https://aibio.space/news/grifols-refinances-all-2027-maturities-about-3-billion-term-loan/Tue, 28 Jul 2026 12:00:00 GMTDebt FinancingGrifols says it refinanced all of its 2027 maturities with an upsized Term Loan B of about €3 billion equivalent and lifted its revolving credit commitment to over $2 billion. Net leverage was 4.2x at the end of June.Grifols, S.A. Form 6-K, half-year 2026 results (2026-07-29) https://aibio.space/news/tuhura-biosciences-draws-1-500-000-parkview-revolving-credit-facility/https://aibio.space/news/tuhura-biosciences-draws-1-500-000-parkview-revolving-credit-facility/Tue, 28 Jul 2026 12:00:00 GMTDebt FinancingTuHURA Biosciences borrowed $1,500,000 more under its $50 million revolving facility with Parkview Holdings One LLC. The filing gives no interest rate for the draw and flags conflicts of interest tied to the lender.SEC Form 8-K https://aibio.space/news/alkermes-sues-teva-apotex-msn-proposed-generic-lybalvi/https://aibio.space/news/alkermes-sues-teva-apotex-msn-proposed-generic-lybalvi/Tue, 28 Jul 2026 12:00:00 GMTLegalTwo Alkermes subsidiaries filed Hatch-Waxman patent suits in New Jersey and Delaware against Teva Pharmaceuticals, Apotex and MSN entities. FDA approval of each generic application is stayed for up to 30 months.Alkermes 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/alkermes-faces-direct-purchaser-antitrust-class-action-vivitrol-patent/https://aibio.space/news/alkermes-faces-direct-purchaser-antitrust-class-action-vivitrol-patent/Tue, 28 Jul 2026 12:00:00 GMTLegalValue Drug Company sued Alkermes, Inc. and Alkermes Pharma Ireland Limited in Massachusetts in October 2025. A December 2025 motion to dismiss is the latest step the 10-Q reports.Alkermes 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/bgm-group-regains-nasdaq-compliance-after-filing-late-20/https://aibio.space/news/bgm-group-regains-nasdaq-compliance-after-filing-late-20/Tue, 28 Jul 2026 12:00:00 GMTListingsBGM Group filed the annual report for the year ended September 30, 2025 on July 21, 2026, and Nasdaq said the filing cured the lapse on July 24. The same report shows a net loss of $19.9 million, up from $1.4 million.BGM Group Ltd. 6-K (2026-07-28) https://aibio.space/news/entera-bio-closes-275-0-million-private-placement-2-04-share/https://aibio.space/news/entera-bio-closes-275-0-million-private-placement-2-04-share/Tue, 28 Jul 2026 12:00:00 GMTFinancingsBVF Partners-affiliated funds are among the buyers and gain the right to name two directors. Entera says it will use the money to support a Phase 3 study of EB613.Entera Bio Ltd. 8-K (2026-07-28) https://aibio.space/news/aptevo-files-patent-application-nectin-4-x-pd-l1-dual-targeting/https://aibio.space/news/aptevo-files-patent-application-nectin-4-x-pd-l1-dual-targeting/Mon, 27 Jul 2026 12:00:00 GMTCompany UpdatesAptevo filed a patent application covering a Nectin-4 x PD-L1 dual-targeting backbone that it says could support radiopharmaceuticals, T-cell engagers and other immune-based approaches.Aptevo Therapeutics Inc. 8-K (2026-07-27) https://aibio.space/news/calidi-biotherapeutics-effects-1-16-reverse-stock-split/https://aibio.space/news/calidi-biotherapeutics-effects-1-16-reverse-stock-split/Mon, 27 Jul 2026 12:00:00 GMTListingsThe split became effective July 30, 2026, and the common stock began trading split-adjusted on July 31 under the existing CLDI symbol.Calidi Biotherapeutics, Inc. 8-K (2026-07-31) https://aibio.space/news/profusa-expects-about-7-million-convertible-note-alongside-diagnostics/https://aibio.space/news/profusa-expects-about-7-million-convertible-note-alongside-diagnostics/Mon, 27 Jul 2026 12:00:00 GMTDebt FinancingProfusa signed a non-binding term sheet to acquire a private diagnostics company that it says had about $111 million of 2025 revenue. The deal would come with an estimated $7 million convertible note at a 7% rate and a 9% original issue discount.Profusa, Inc. 8-K (2026-07-27) https://aibio.space/news/biomx-extends-1-250-000-note-november-1-2026/https://aibio.space/news/biomx-extends-1-250-000-note-november-1-2026/Mon, 27 Jul 2026 12:00:00 GMTDebt FinancingBiomX extended a $1,250,000 promissory note held by Water IO Ltd. to November 1, 2026, after a $250,000 payment. The remaining principal is due in four monthly installments of $250,000, and accrued interest is to be settled in 800,000 shares of common stock if approvals arrive.BiomX Inc. 8-K (2026-07-28) https://aibio.space/news/scribe-therapeutics-prices-ipo-8-580-000-shares-15-00/https://aibio.space/news/scribe-therapeutics-prices-ipo-8-580-000-shares-15-00/Mon, 27 Jul 2026 12:00:00 GMTFinancingsScribe sold 8,580,000 shares at $15.00 with a going concern warning in its prospectus. The company had $49.7 million in cash and marketable securities at March 31, 2026, against $40.5 million in outstanding indebtedness.Scribe Therapeutics Inc. 424B4 (2026-07-27) https://aibio.space/news/vivosim-labs-gets-nasdaq-equity-notice-cites-july-warrant-exercises/https://aibio.space/news/vivosim-labs-gets-nasdaq-equity-notice-cites-july-warrant-exercises/Fri, 24 Jul 2026 12:00:00 GMTListingsNasdaq said VivoSim Labs no longer met the $2,500,000 stockholders' equity minimum on July 20, 2026, and the company said its equity exceeded $2.5 million after July transactions.VivoSim Labs, INC. 8-K (2026-07-24) https://aibio.space/news/apimeds-pharmaceuticals-reverse-stock-split-took-effect-july-24/https://aibio.space/news/apimeds-pharmaceuticals-reverse-stock-split-took-effect-july-24/Fri, 24 Jul 2026 12:00:00 GMTListingsThe one-for-ten split took effect on July 24, 2026, and the stock trades on NYSE American under APUS on a split-adjusted basis, with par value cut to $0.001.Apimeds Pharmaceuticals US, Inc. 8-K (2026-09-23) https://aibio.space/news/btig-terminates-matinas-market-sales-agreement/https://aibio.space/news/btig-terminates-matinas-market-sales-agreement/Fri, 24 Jul 2026 12:00:00 GMTFinancingsBTIG, LLC ended the 2020 at-the-market sales agreement with Matinas BioPharma, effective July 23, 2026, and the company says it owes no termination penalties.Matinas Biopharma Holdings, Inc. 8-K (2026-07-24) https://aibio.space/news/mannkind-closes-50-0-million-private-placement-led-frazier-life/https://aibio.space/news/mannkind-closes-50-0-million-private-placement-led-frazier-life/Fri, 24 Jul 2026 12:00:00 GMTFinancingsMannKind sold 10,440,838 shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88. The company names a $45.0 million contingent value rights payment, triggered by an FDA approval, among the uses of the money.MANNKIND CORP Form 8-K filed July 24, 2026 (SEC EDGAR) https://aibio.space/news/standard-biotools-gets-nasdaq-minimum-bid-price-notice-has-until/https://aibio.space/news/standard-biotools-gets-nasdaq-minimum-bid-price-notice-has-until/Fri, 24 Jul 2026 12:00:00 GMTListingsNasdaq told Standard BioTools on July 22, 2026 that its shares closed below $1.00 for 30 days. The company has until January 19, 2027 to regain compliance, and its own filing says it cannot be sure it will.STANDARD BIOTOOLS INC. Form 8-K filed July 24, 2026 (SEC EDGAR) https://aibio.space/news/oncolytics-biotech-gets-nasdaq-minimum-bid-price-deficiency-notice-has/https://aibio.space/news/oncolytics-biotech-gets-nasdaq-minimum-bid-price-deficiency-notice-has/Fri, 24 Jul 2026 12:00:00 GMTListingsNasdaq told Oncolytics its stock closed below $1.00 for 30 consecutive business days. The letter does not change the listing for now, but the company's annual report says its $5.2 million of cash cannot fund planned operations for 12 months, and that doubt about its ability to continue as a going concern is substantial.ONCOLYTICS BIOTECH INC Form 8-K filed July 24, 2026 (SEC EDGAR) https://aibio.space/news/fibrobiologics-gets-nasdaq-delisting-determination-1-00-minimum-bid/https://aibio.space/news/fibrobiologics-gets-nasdaq-delisting-determination-1-00-minimum-bid/Fri, 24 Jul 2026 12:00:00 GMTListingsNasdaq staff says the bid price closed below $1.00 for 30 consecutive business days and that FibroBiologics gets no 180-day compliance period after a reverse stock split. The company intends to request a hearing.FibroBiologics, Inc. Form 8-K filed July 24, 2026 (SEC EDGAR) https://aibio.space/news/summit-files-380-million-stock-program-10-q-flags-going-concern-doubt/https://aibio.space/news/summit-files-380-million-stock-program-10-q-flags-going-concern-doubt/Thu, 23 Jul 2026 12:00:00 GMTDistressCash and short-term investments were $690.7 million at June 30. The company sold $230.8 million of stock in the second quarter through its ATM.Summit Therapeutics (SEC 424B5) https://aibio.space/news/neuphoria-scancell-agree-all-share-merger-up-89-million-financing/https://aibio.space/news/neuphoria-scancell-agree-all-share-merger-up-89-million-financing/Thu, 23 Jul 2026 12:00:00 GMTMergersScancell will acquire Neuphoria in an all-share deal that would create a combined company listed on Nasdaq, alongside a financing of up to $89 million.Neuphoria Therapeutics Inc. 8-K (2026-07-24) https://aibio.space/news/bone-biologics-completes-3-0-million-private-placement-warrants/https://aibio.space/news/bone-biologics-completes-3-0-million-private-placement-warrants/Thu, 23 Jul 2026 12:00:00 GMTCompany UpdatesA single healthcare-focused institutional investor bought the shares. The company says the financing extends its runway through Q2 2027, and warrants could add up to about $6.0 million more if exercised for cash.Bone Biologics press release (Form 8-K, Exhibit 99.1) https://aibio.space/news/nexgel-signs-new-employment-agreement-ceo-adam-levy/https://aibio.space/news/nexgel-signs-new-employment-agreement-ceo-adam-levy/Thu, 23 Jul 2026 12:00:00 GMTCompany UpdatesThe July 23, 2026 agreement sets a $375,000 base salary, EBITDA-linked bonus tiers and an option grant of 160,000 shares at $0.647 per share.NEXGEL, INC. 8-K (2026-07-29) https://aibio.space/news/aeon-reports-partial-allotment-exercise-july-offering/https://aibio.space/news/aeon-reports-partial-allotment-exercise-july-offering/Thu, 23 Jul 2026 12:00:00 GMTFinancingsThe underwriters bought 4,696,102 additional shares on July 23, 2026, for about $1.5 million in gross proceeds. Lake Street Capital Markets, LLC acted as representative of the underwriters.AEON Biopharma, Inc. 8-K (2026-07-23) https://aibio.space/news/summit-therapeutics-derivative-suit-520-million-duggan-notes-ends/https://aibio.space/news/summit-therapeutics-derivative-suit-520-million-duggan-notes-ends/Thu, 23 Jul 2026 12:00:00 GMTLegalRainaldi Revocable Trust sued certain current and former Summit directors in Delaware Chancery in 2025, with Summit a nominal defendant. The parties stipulated to dismissal on May 27, 2026.Summit Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR) https://aibio.space/news/radiopharm-theranostics-sets-9-300-000-atm-limit-prices-4-050-001-36/https://aibio.space/news/radiopharm-theranostics-sets-9-300-000-atm-limit-prices-4-050-001-36/Thu, 23 Jul 2026 12:00:00 GMTFinancingsRadiopharm amended its at-the-market program to $9,300,000 on July 23, 2026. The next day it announced a $4.1 million registered direct offering at $3.16 per ADS, below the $4.29 last sale price on July 21.Radiopharm Theranostics Limited 424B5 (2026-07-23) https://aibio.space/news/china-pharma-prices-5-million-registered-direct-offering/https://aibio.space/news/china-pharma-prices-5-million-registered-direct-offering/Wed, 22 Jul 2026 12:00:00 GMTFinancingsChina Pharma Holdings, Inc. priced a registered direct offering of 2.5 million common shares at $2 per share, for gross proceeds of $5 million before placement agent fees and other expenses. FT Global Capital, Inc. is the exclusive placement agent.China Pharma Holdings, Inc. 8-K (2026-07-22) https://aibio.space/news/kairos-pharma-announces-bayer-collaboration-test-env-105-xofigo/https://aibio.space/news/kairos-pharma-announces-bayer-collaboration-test-env-105-xofigo/Wed, 22 Jul 2026 12:00:00 GMTCompany UpdatesThe collaboration will evaluate ENV-105 with Bayer's XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer involving bone, and the company cites a $570M to $1.3B addressable global market.Kairos Pharma, Ltd. 8-K (2026-07-22) https://aibio.space/news/first-choice-healthcare-amends-deal-florida-pharmacy-companies/https://aibio.space/news/first-choice-healthcare-amends-deal-florida-pharmacy-companies/Wed, 22 Jul 2026 12:00:00 GMTDistressThe amended agreement sets a maximum price of $21,306,000 for companies bought from seller Gary C. Bernard, M.D., and it depends on a related business combination that has not closed.First Choice Healthcare Solutions, Inc. 8-K (2026-08-19) https://aibio.space/news/china-resources-pharmaceutical-issues-rmb1-billion-medium-term-notes/https://aibio.space/news/china-resources-pharmaceutical-issues-rmb1-billion-medium-term-notes/Wed, 22 Jul 2026 12:00:00 GMTDebt FinancingA wholly owned subsidiary completed the first tranche of its 2026 medium term notes on 21 July 2026, at 1.53% per annum over 3 years.China Resources Pharmaceutical Group Limited announcement (2026-07-22) https://aibio.space/news/bluejay-completes-symon-ii-enrollment-750-patients-ahead-plan/https://aibio.space/news/bluejay-completes-symon-ii-enrollment-750-patients-ahead-plan/Tue, 21 Jul 2026 12:00:00 GMTCompany UpdatesPreliminary observations show an approximately 17% 28-day mortality rate in the enrolled population. The company expects to complete data cleaning, statistical analysis and clinical reporting over the coming months.Bluejay Diagnostics, Inc. 8-K (2026-07-22) https://aibio.space/news/phio-adds-dermatologist-r-todd-plott-board/https://aibio.space/news/phio-adds-dermatologist-r-todd-plott-board/Tue, 21 Jul 2026 12:00:00 GMTCompany UpdatesPhio Pharmaceuticals increased its board to six members and appointed R. Todd Plott, M.D., effective July 20, 2026, to serve until the 2026 annual meeting of stockholders.Phio Pharmaceuticals Corp. 8-K (2026-07-21) https://aibio.space/news/xtl-biopharmaceuticals-regains-nasdaq-compliance-faces-one-year-panel/https://aibio.space/news/xtl-biopharmaceuticals-regains-nasdaq-compliance-faces-one-year-panel/Tue, 21 Jul 2026 12:00:00 GMTListingsNasdaq staff confirmed on July 20, 2026 that XTL meets four listing rules. Another equity shortfall within the year would lead to a delist determination.XTL Biopharmaceuticals Ltd. 6-K (2026-07-21) https://aibio.space/news/60-degrees-describes-babesiosis-plan-2028-profitability-target/https://aibio.space/news/60-degrees-describes-babesiosis-plan-2028-profitability-target/Mon, 20 Jul 2026 12:00:00 GMTCompany UpdatesA July 2026 corporate presentation says the company targets profitability in 2028, based on malaria prevention sales and a supplemental indication for babesiosis.60 Degrees Pharmaceuticals, Inc. 8-K (2026-07-20) https://aibio.space/news/sunshine-biopharma-sets-up-4-000-000-market-stock-sale-aegis-capital/https://aibio.space/news/sunshine-biopharma-sets-up-4-000-000-market-stock-sale-aegis-capital/Mon, 20 Jul 2026 12:00:00 GMTFinancingsSunshine Biopharma Inc. signed an at-the-market sales agreement with Aegis Capital Corp. under which it may sell up to $4,000,000 of common stock, with Aegis as exclusive sales agent.Sunshine Biopharma Inc. 8-K (2026-07-20) https://aibio.space/news/okyo-pharma-files-annual-report-cites-22-million-offering-20-6-million/https://aibio.space/news/okyo-pharma-files-annual-report-cites-22-million-offering-20-6-million/Mon, 20 Jul 2026 12:00:00 GMTFinancingsThe company says it raised approximately $25 million in the fiscal year ended March 31, 2026. It says its cash funds the planned Phase 3 trial of urcosimod.OKYO Pharma Limited 6-K (2026-07-20) https://aibio.space/news/rockwell-medical-regains-nasdaq-bid-price-compliance-matter-closed/https://aibio.space/news/rockwell-medical-regains-nasdaq-bid-price-compliance-matter-closed/Mon, 20 Jul 2026 12:00:00 GMTListingsNasdaq told Rockwell Medical on July 16, 2026 that the company had regained compliance with the $1.00 minimum bid price, and closed the matter. The 8-K does not give the closing prices behind that finding.Rockwell Medical, Inc. 8-K (2026-07-20) https://aibio.space/news/healthy-extracts-issues-258-750-promissory-note-labrys-fund-ii/https://aibio.space/news/healthy-extracts-issues-258-750-promissory-note-labrys-fund-ii/Fri, 17 Jul 2026 12:00:00 GMTDebt FinancingHealthy Extracts Inc. issued a one-year promissory note with a principal amount of $258,750 to LABRYS FUND II, L.P. under an agreement dated July 17, 2026. The company received a net amount of $225,000, minus expenses.HEALTHY EXTRACTS INC. 8-K (2026-07-24) https://aibio.space/news/damora-completes-move-delaware-cayman-islands/https://aibio.space/news/damora-completes-move-delaware-cayman-islands/Fri, 17 Jul 2026 12:00:00 GMTCompany UpdatesDamora Therapeutics completed its redomestication effective July 16, 2026. Its ordinary shares trade on Nasdaq under a new CUSIP from July 20, 2026.Form 8-K, SEC EDGAR https://aibio.space/news/dare-bioscience-gets-nasdaq-notice-stockholders-equity-plans-hearing/https://aibio.space/news/dare-bioscience-gets-nasdaq-notice-stockholders-equity-plans-hearing/Fri, 17 Jul 2026 12:00:00 GMTListingsNasdaq told Daré Bioscience (Nasdaq: DARE) on July 13, 2026 that it no longer meets Listing Rule 5550(b). The company intends to request a hearing, which would stay delisting while the panel decides.Dare Bioscience, Inc. Form 8-K filed July 17, 2026 (SEC EDGAR) https://aibio.space/news/blossomhill-therapeutics-files-ipo-plans-nasdaq-listing-blsm/https://aibio.space/news/blossomhill-therapeutics-files-ipo-plans-nasdaq-listing-blsm/Fri, 17 Jul 2026 12:00:00 GMTFinancingsBlossomHill's S-1 leaves the share count, the price range and the proceeds blank. The prospectus also says the auditor's report on the 2025 financial statements carries a going-concern paragraph.BlossomHill Therapeutics, Inc. S-1 (2026-07-17) https://aibio.space/news/latigo-biotherapeutics-files-ipo-plans-nasdaq-listing-ltgo/https://aibio.space/news/latigo-biotherapeutics-files-ipo-plans-nasdaq-listing-ltgo/Fri, 17 Jul 2026 12:00:00 GMTFinancingsLatigo Biotherapeutics, Inc. filed a Form S-1 on July 17, 2026. The filing leaves the share count and price range blank, and the auditors have raised going-concern doubt.Latigo Biotherapeutics, Inc. S-1 (2026-07-17) https://aibio.space/news/xeris-completes-note-exchange-conversion-no-2028-convertible-notes/https://aibio.space/news/xeris-completes-note-exchange-conversion-no-2028-convertible-notes/Fri, 17 Jul 2026 12:00:00 GMTDebt FinancingHolders swapped about $23 million of 8.00% notes for about 5.0 million shares and about $23 million in cash. A separate holder converted $10.5 million of notes into about 3.6 million shares.Xeris Biopharma Holdings, Inc. 8-K (2026-07-17) https://aibio.space/news/vivosim-labs-prices-4-0-million-private-placement-0-85-warrants/https://aibio.space/news/vivosim-labs-prices-4-0-million-private-placement-0-85-warrants/Thu, 16 Jul 2026 12:00:00 GMTFinancingsVivoSim Labs agreed to sell 4,705,883 shares and warrants to one healthcare investor, with A.G.P./Alliance Global Partners as sole placement agent.VivoSim Labs, INC. 8-K (2026-07-17) https://aibio.space/news/raphael-pharmaceutical-chairman-cfo-resign-uri-tadelis-named-cfo/https://aibio.space/news/raphael-pharmaceutical-chairman-cfo-resign-uri-tadelis-named-cfo/Thu, 16 Jul 2026 12:00:00 GMTCompany UpdatesAjay Kumar Dhadha resigned as chairman effective June 30, 2026. Guy Ofir resigned as chief financial officer and general counsel effective July 16, 2026, and the company appointed Uri Tadelis as CFO.Raphael Pharmaceutical Form 8-K (Item 5.02) https://aibio.space/news/cdt-equity-do-1-10-reverse-stock-split-effective-july-17/https://aibio.space/news/cdt-equity-do-1-10-reverse-stock-split-effective-july-17/Thu, 16 Jul 2026 12:00:00 GMTListingsThe split takes effect July 17, 2026 and trades on a split-adjusted basis from July 20, reducing outstanding shares to approximately 631,077.CDT Equity Inc. 8-K (2026-07-16) https://aibio.space/news/bio-path-sells-small-regulation-lots-hires-strategic-advisor/https://aibio.space/news/bio-path-sells-small-regulation-lots-hires-strategic-advisor/Thu, 16 Jul 2026 12:00:00 GMTFinancingsBio-Path reports two small share sales under its Regulation A offering and an advisory engagement to find a buyer, partner or licensor.Bio-Path Holdings, Inc. 8-K (2026-07-16) https://aibio.space/news/aditxt-amends-secured-note-purchase-deal-ignite-proteomics/https://aibio.space/news/aditxt-amends-secured-note-purchase-deal-ignite-proteomics/Thu, 16 Jul 2026 12:00:00 GMTDebt FinancingAditxt signed Amendment No. 2 to its secured note purchase agreement with Ignite Proteomics investors on July 16, 2026. The amendment adds an investor, cancels one note and issues two new notes, and leaves the total senior secured principal unchanged.Aditxt, Inc. 8-K (2026-07-17) https://aibio.space/news/inhibrx-expands-oxford-finance-facility-500-0-million/https://aibio.space/news/inhibrx-expands-oxford-finance-facility-500-0-million/Thu, 16 Jul 2026 12:00:00 GMTDebt FinancingInhibrx's Oxford Finance facility now totals up to $500.0 million. The company funded $100.0 million at signing, and up to $225.0 million more depends on the lenders' discretion.Inhibrx Biosciences, Inc. release (2026-07-16) https://aibio.space/news/arbutus-expects-return-up-approximately-230m-shareholders/https://aibio.space/news/arbutus-expects-return-up-approximately-230m-shareholders/Thu, 16 Jul 2026 12:00:00 GMTDistressArbutus said it expects to begin returning up to about $230 million to shareholders in Q3 2026, but the form is not set, the board must approve it, and repurchases cannot start until a dividend from Genevant's parent arrives. The company received about $178 million from Moderna on July 8, 2026.Arbutus Biopharma Corporation 8-K (2026-07-16) https://aibio.space/news/helus-pharma-cybin-inc-closes-us-50-million-share-offering-us-4-85/https://aibio.space/news/helus-pharma-cybin-inc-closes-us-50-million-share-offering-us-4-85/Thu, 16 Jul 2026 12:00:00 GMTFinancingsHelus Pharma sold 10,309,280 shares at US$4.85 in an underwritten offering that closed on June 25, 2026. The proceeds are meant partly for a Phase 3 depression program whose data are not due until the fourth quarter.Helus Pharma Inc. 6-K (2026-07-16) https://aibio.space/news/inhibrx-expands-oxford-finance-credit-facility-up-500-0-million/https://aibio.space/news/inhibrx-expands-oxford-finance-credit-facility-up-500-0-million/Thu, 16 Jul 2026 12:00:00 GMTDebt FinancingA second amendment adds a tranche of up to $325.0 million, of which $100.0 million was funded at signing. The lenders received warrants for 21,457 shares at $93.21 per share.Inhibrx Biosciences, Inc. 8-K (2026-07-16) https://aibio.space/news/regenxbio-prices-100-million-stock-offering-9-00-share/https://aibio.space/news/regenxbio-prices-100-million-stock-offering-9-00-share/Thu, 16 Jul 2026 12:00:00 GMTFinancingsREGENXBIO launched a $100 million stock offering on July 16, 2026 at $9.00 a share, below the $11.20 close. Its own preliminary estimate puts cash, cash equivalents and marketable securities at about $105.5 million on June 30, down from $150.5 million on March 31.REGENXBIO Inc. 424B5 (2026-07-16) https://aibio.space/news/kairos-pharma-reports-interim-phase-1-safety-data-env-105-lung-cancer/https://aibio.space/news/kairos-pharma-reports-interim-phase-1-safety-data-env-105-lung-cancer/Wed, 15 Jul 2026 12:00:00 GMTCompany UpdatesThe company reports no serious adverse events, defined as Grade 3 or higher, in 13 patients treated with ENV-105 and osimertinib, and says the safety profile supports progression toward an early efficacy readout.Kairos Pharma, Ltd. 8-K (2026-07-15) https://aibio.space/news/azitra-reports-ex-vivo-skin-data-filaggrin-cosmetic-ingredient/https://aibio.space/news/azitra-reports-ex-vivo-skin-data-filaggrin-cosmetic-ingredient/Wed, 15 Jul 2026 12:00:00 GMTCompany UpdatesTwo ex vivo human skin studies of ATR-COSF showed deeper protein penetration and higher skin elasticity, according to a July 15, 2026 release. A human study is planned next.Azitra Inc 8-K (2026-07-15) https://aibio.space/news/ensysce-chief-operating-officer-jeffrey-millard-resigns/https://aibio.space/news/ensysce-chief-operating-officer-jeffrey-millard-resigns/Wed, 15 Jul 2026 12:00:00 GMTCompany UpdatesEnsysce Biosciences disclosed in an 8-K that Jeffrey Millard resigned as chief operating officer, effective July 10, 2026, with no reason or successor given.Ensysce Biosciences, Inc. 8-K (2026-07-15) https://aibio.space/news/polomar-health-names-douglas-beck-chief-financial-officer/https://aibio.space/news/polomar-health-names-douglas-beck-chief-financial-officer/Wed, 15 Jul 2026 12:00:00 GMTCompany UpdatesDouglas Beck became chief financial officer and treasurer effective July 15, 2026, and serves as principal financial and accounting officer. He is a licensed certified public accountant.Polomar Health Services, Inc. 8-K (2026-07-20) https://aibio.space/news/prestige-brands-sells-400-0-million-6-250-percent-senior-notes-due/https://aibio.space/news/prestige-brands-sells-400-0-million-6-250-percent-senior-notes-due/Wed, 15 Jul 2026 12:00:00 GMTDebt FinancingPrestige Brands, a subsidiary of Prestige Consumer Healthcare, issued $400.0 million of 6.250% senior notes due 2034. The 8-K names no placement agent, underwriter or advisor and does not say how the proceeds will be used. The parent's annual report says Walmart and Amazon were its only customers above 10% of gross revenues during 2026.SEC filing (Form 8-K) https://aibio.space/news/bayer-places-5-billion-u-s-dollars-bonds-five-tranches/https://aibio.space/news/bayer-places-5-billion-u-s-dollars-bonds-five-tranches/Wed, 15 Jul 2026 12:00:00 GMTDebt FinancingBayer US Finance LLC issues the notes, guaranteed by Bayer AG, with maturities between 5 and 30 years.Bayer AG release (2026-07-15) https://aibio.space/news/medincell-secures-28-million-non-dilutive-loans/https://aibio.space/news/medincell-secures-28-million-non-dilutive-loans/Wed, 15 Jul 2026 12:00:00 GMTDebt FinancingThe €28 million of bank loans has a five-year maturity and no covenants, and €20 million of the EIB facility is being repaid early, though the remaining EIB balance still comes due in July 2028.Medincell SA release (2026-07-15) https://aibio.space/news/neurotech-secures-3-15-million-secured-loan/https://aibio.space/news/neurotech-secures-3-15-million-secured-loan/Wed, 15 Jul 2026 12:00:00 GMTDebt FinancingThe loan is secured against refundable R&D tax incentive offsets for FY2026 and FY2027 and will help fund Phase III studies in ASD.Neurotech International Limited release (2026-07-15) https://aibio.space/news/senti-biosciences-signs-merger-agreement-celadon-affiliate-cvrs-tied/https://aibio.space/news/senti-biosciences-signs-merger-agreement-celadon-affiliate-cvrs-tied/Wed, 15 Jul 2026 12:00:00 GMTMergersSenti Biosciences agreed on July 14, 2026 to move most of its business, including lead candidate SENTI-202, to an affiliate of its largest stockholder. Holders would receive contingent value rights worth up to $60 million that pay only if milestones are met, while the company used $43.4 million in operations in 2025.Senti Biosciences Holdings, Inc. Form 8-K filed July 15, 2026 (SEC EDGAR) https://aibio.space/news/braveheart-bio-files-ipo-plans-nasdaq-global-market-listing-brve/https://aibio.space/news/braveheart-bio-files-ipo-plans-nasdaq-global-market-listing-brve/Wed, 15 Jul 2026 12:00:00 GMTFinancingsBraveheart Bio, Inc. filed a Form S-1 on July 15, 2026 for an initial public offering on The Nasdaq Global Market under the symbol BRVE. The preliminary prospectus leaves the share count and price blank, and names Goldman Sachs & Co. LLC and Jefferies as joint bookrunners.Braveheart Bio, Inc. S-1 (2026-07-15) https://aibio.space/news/proqr-registers-resale-up-3-030-303-shares-selling-shareholder/https://aibio.space/news/proqr-registers-resale-up-3-030-303-shares-selling-shareholder/Wed, 15 Jul 2026 12:00:00 GMTFinancingsProQR is registering 3,030,303 shares for resale by a holder the prospectus calls Ginkgo, issued in April 2026 under a share purchase agreement tied to a services contract. ProQR receives none of the proceeds, and the prospectus gives no per-share price for the shares.ProQR Therapeutics N.V. 424B5 (2026-07-15) https://aibio.space/news/vogenx-files-ipo-plans-nasdaq-capital-market-listing-vogx/https://aibio.space/news/vogenx-files-ipo-plans-nasdaq-capital-market-listing-vogx/Wed, 15 Jul 2026 12:00:00 GMTFinancingsVogenx filed a Form S-1 on July 15, 2026 for an initial public offering with the share count and price still blank. The filing reports $251 thousand of cash on March 31, 2026, and its financial statements carry going-concern doubt.Vogenx Inc S-1 (2026-07-15) https://aibio.space/news/q32-bio-enters-underwriting-agreement-public-offering-18-25-share/https://aibio.space/news/q32-bio-enters-underwriting-agreement-public-offering-18-25-share/Tue, 14 Jul 2026 12:00:00 GMTFinancingsMorgan Stanley, Jefferies, Cantor Fitzgerald and Oppenheimer are the representatives of the underwriters. The offering is expected to close on July 16, 2026.Q32 Bio Inc. 8-K (2026-07-15) https://aibio.space/news/genprex-plans-1-22-reverse-stock-split-effective-july-16/https://aibio.space/news/genprex-plans-1-22-reverse-stock-split-effective-july-16/Tue, 14 Jul 2026 12:00:00 GMTListingsThe split, approved by the board on July 2, 2026, moves shares outstanding from 11,108,577 to approximately 504,936, and the company released an investor presentation the same day.Genprex, Inc. 8-K (2026-07-14) https://aibio.space/news/cero-therapeutics-expands-srx-global-convertible-note-2-085-200/https://aibio.space/news/cero-therapeutics-expands-srx-global-convertible-note-2-085-200/Tue, 14 Jul 2026 12:00:00 GMTDebt FinancingCERo Therapeutics expanded its convertible note with SRX Global to $2,085,200. The note carries 10% interest, matures May 28, 2027, and converts at the lesser of $0.05 and 80% of recent trading lows.SEC Form 8-K https://aibio.space/news/nextcure-signs-merger-agreement-avere-therapeutics-alongside-320/https://aibio.space/news/nextcure-signs-merger-agreement-avere-therapeutics-alongside-320/Tue, 14 Jul 2026 12:00:00 GMTMergersNextCure (Nasdaq: NXTC) agreed to an all-stock merger with Avere Therapeutics. The 8-K puts pre-merger Avere holders at about 98.11% of the combined company, which would take the Avere Therapeutics name.NextCure, Inc. Form 8-K filed July 14, 2026 (SEC EDGAR) https://aibio.space/news/apollomics-regains-nasdaq-compliance-35-million-market-value-rule/https://aibio.space/news/apollomics-regains-nasdaq-compliance-35-million-market-value-rule/Tue, 14 Jul 2026 12:00:00 GMTListingsNasdaq said on July 8, 2026 that the matter is closed. The company had been notified of the shortfall on June 18, 2026.Apollomics, Inc. 6-K (2026-07-14) https://aibio.space/news/attovia-therapeutics-files-ipo-plans-nasdaq-listing-atto/https://aibio.space/news/attovia-therapeutics-files-ipo-plans-nasdaq-listing-atto/Tue, 14 Jul 2026 12:00:00 GMTFinancingsAttovia Therapeutics, Inc. filed a Form S-1 on July 14, 2026. The cover leaves the share count and price range blank.Attovia Therapeutics, Inc. S-1 (2026-07-14) https://aibio.space/news/apimeds-pharmaceuticals-sets-reverse-split-date-july-24/https://aibio.space/news/apimeds-pharmaceuticals-sets-reverse-split-date-july-24/Mon, 13 Jul 2026 12:00:00 GMTListingsThe company said on July 13, 2026 that its one-for-ten reverse split would take effect on July 24, after a March 2026 target passed without a filing.Apimeds Pharmaceuticals US, Inc. 8-K (2026-07-13) https://aibio.space/news/matinas-plans-gh-power-combination-sells-mat2203-azurity/https://aibio.space/news/matinas-plans-gh-power-combination-sells-mat2203-azurity/Mon, 13 Jul 2026 12:00:00 GMTMergersMatinas BioPharma agreed to combine with GH Power in a business combination expected to close in the fourth quarter of 2026, and to sell its MAT2203 and LNC business to Azurity Pharmaceuticals for $4.0 million upfront.Matinas Biopharma Holdings, Inc. 8-K (2026-07-13) https://aibio.space/news/aeon-prices-upsized-13-75-million-offering-milestone-warrants/https://aibio.space/news/aeon-prices-upsized-13-75-million-offering-milestone-warrants/Mon, 13 Jul 2026 12:00:00 GMTFinancingsThe offering was priced at $0.3221 per share and accompanying warrants. Lake Street Capital Markets, LLC is sole bookrunner, and Laidlaw & Company (UK) Ltd. is lead manager.AEON Biopharma, Inc. 8-K (2026-07-15) https://aibio.space/news/cumberland-pharmaceuticals-declares-1-50-special-dividend-authorizes-5/https://aibio.space/news/cumberland-pharmaceuticals-declares-1-50-special-dividend-authorizes-5/Mon, 13 Jul 2026 12:00:00 GMTFinancingsCumberland will pay a $1.50 special dividend and has authorized up to $5 million of buybacks. The board acted after the Apotex sale produced more net cash than the company had projected.Cumberland Pharmaceuticals Inc. 8-K (2026-07-13) https://aibio.space/news/erasca-launches-500-000-000-stock-offering-then-prices-31-428-572/https://aibio.space/news/erasca-launches-500-000-000-stock-offering-then-prices-31-428-572/Mon, 13 Jul 2026 12:00:00 GMTFinancingsErasca's final terms are 31,428,572 shares at $17.50, a total of $550,000,010.00, above the $500,000,000 first announced. Its two clinical-stage programs are early, and the annual report shows a net loss of $124.5 million for 2025.Erasca, Inc. 424B5 (2026-07-13) https://aibio.space/news/traws-pharma-sets-5-575-709-market-sales-limit-citizens-jmp/https://aibio.space/news/traws-pharma-sets-5-575-709-market-sales-limit-citizens-jmp/Fri, 10 Jul 2026 12:00:00 GMTFinancingsCitizens JMP Securities, LLC may sell up to $5,575,709 of Traws common stock under a July 10, 2026 prospectus supplement, the amount the company's current baby shelf limit allows.Traws Pharma, Inc. SEC filing (Form 8-K) https://aibio.space/news/revelation-adopts-stockholder-rights-plan-10-percent-trigger/https://aibio.space/news/revelation-adopts-stockholder-rights-plan-10-percent-trigger/Fri, 10 Jul 2026 12:00:00 GMTCompany UpdatesThe board adopted a rights plan on July 10, 2026 and declared a dividend of one right per share, payable to stockholders of record on July 21, 2026.Revelation Biosciences, Inc. 8-K (2026-07-13) https://aibio.space/news/silo-prices-up-11-7-million-private-placement/https://aibio.space/news/silo-prices-up-11-7-million-private-placement/Fri, 10 Jul 2026 12:00:00 GMTFinancingsSilo agreed to sell 619,965 shares and warrants at $6.452 per share, with H.C. Wainwright & Co. as exclusive placement agent. The company expects about $4 million upfront.Silo Pharma, Inc. 8-K (2026-07-13) https://aibio.space/news/nomad-power-solutions-raises-voyager-energy-storage-up-56-percent/https://aibio.space/news/nomad-power-solutions-raises-voyager-energy-storage-up-56-percent/Fri, 10 Jul 2026 12:00:00 GMTCompany UpdatesThe third-generation Voyager series raises standard usable storage to 2.025 MWh on the Eagle and Falcon and to 1.0 MWh on the Hawk, with power ratings and footprint unchanged.NOMAD POWER SOLUTIONS, INC. 8-K (2026-07-10) https://aibio.space/news/calidi-biotherapeutics-signs-new-san-diego-lease/https://aibio.space/news/calidi-biotherapeutics-signs-new-san-diego-lease/Fri, 10 Jul 2026 12:00:00 GMTCompany UpdatesThe company signed a 44-month lease for Suite 120 at 5580 Morehouse Drive and agreed to terminate its existing lease, effective September 30, 2026.Calidi Biotherapeutics, Inc. 8-K (2026-07-16) https://aibio.space/news/international-stem-cell-agrees-sell-lifeline-cell-technology-25-0/https://aibio.space/news/international-stem-cell-agrees-sell-lifeline-cell-technology-25-0/Fri, 10 Jul 2026 12:00:00 GMTCompany UpdatesThe buyer is American Type Culture Collection, Inc., and the company expects the sale to close in the third fiscal quarter of 2026, subject to closing conditions.International Stem Cell CORP 8-K (2026-07-16) https://aibio.space/news/anika-therapeutics-amends-50-0-million-bank-america-revolving-credit/https://aibio.space/news/anika-therapeutics-amends-50-0-million-bank-america-revolving-credit/Fri, 10 Jul 2026 12:00:00 GMTDebt FinancingAnika Therapeutics signed a fifth amendment to its Bank of America revolving credit line, now maturing July 10, 2031. The filing names no amount drawn, and the line carries a first-priority lien on most of the company's assets.SEC filing (Form 8-K) https://aibio.space/news/kestra-medical-draws-75-0-million-up-200-0-million-term-loan/https://aibio.space/news/kestra-medical-draws-75-0-million-up-200-0-million-term-loan/Fri, 10 Jul 2026 12:00:00 GMTDebt FinancingKestra Medical drew $75.0 million from a facility of up to $200.0 million. The Tranche A loan funded on July 10, 2026, and repaid a prior loan from Perceptive Credit Holdings IV, LP.SEC filing (Form 8-K) https://aibio.space/news/cue-biopharma-agrees-50-0-million-private-placement-led-cormorant/https://aibio.space/news/cue-biopharma-agrees-50-0-million-private-placement-led-cormorant/Fri, 10 Jul 2026 12:00:00 GMTFinancingsCue will sell 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for gross proceeds of about $50.0 million. Cormorant Asset Management led. The 8-K also reports RSU grants to officers and directors.Cue Biopharma, Inc. Form 8-K filed July 10, 2026 (SEC EDGAR) https://aibio.space/news/apnimed-files-ipo-plans-nasdaq-global-market-listing-apmd/https://aibio.space/news/apnimed-files-ipo-plans-nasdaq-global-market-listing-apmd/Fri, 10 Jul 2026 12:00:00 GMTFinancingsApnimed, Inc. filed a Form S-1 with a preliminary prospectus dated July 10, 2026. The cover leaves the share count and price range blank, and the company has no approved drug yet.Apnimed, Inc. S-1 (2026-07-10) https://aibio.space/news/cue-biopharma-agrees-50-0-million-private-placement-33-21-share/https://aibio.space/news/cue-biopharma-agrees-50-0-million-private-placement-33-21-share/Fri, 10 Jul 2026 12:00:00 GMTFinancingsCue Biopharma is selling 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for about $50.0 million in gross proceeds. Its release says the lead candidate is advancing toward Phase 1, while its annual report calls that candidate preclinical.Cue Biopharma, Inc. 8-K (2026-07-10) https://aibio.space/news/niagen-bioscience-sets-up-50-000-000-share-sales-program/https://aibio.space/news/niagen-bioscience-sets-up-50-000-000-share-sales-program/Fri, 10 Jul 2026 12:00:00 GMTFinancingsCanaccord Genuity and Roth Capital Partners are the sales agents under a June 26, 2026 agreement, for a 3% commission. The supplement puts net tangible book value at $0.97 a share against a $3.37 reference price.Niagen Bioscience, Inc. 424B5 (2026-07-10) https://aibio.space/news/metavia-completes-dose-titration-phase-1-part-3-study-da-1726/https://aibio.space/news/metavia-completes-dose-titration-phase-1-part-3-study-da-1726/Thu, 09 Jul 2026 12:00:00 GMTCompany UpdatesAll active patients in both Part 3 cohorts of the DA-1726 obesity study reached target doses of 48 mg and 64 mg, and topline data remains on track for the fourth quarter of 2026.MetaVia Inc. 8-K (2026-07-09) https://aibio.space/news/endra-regains-nasdaq-stockholders-equity-compliance/https://aibio.space/news/endra-regains-nasdaq-stockholders-equity-compliance/Thu, 09 Jul 2026 12:00:00 GMTListingsNasdaq told ENDRA on July 8, 2026 that it regained compliance with the $2,500,000 minimum stockholders' equity requirement, but the company will be under a one-year panel monitor.ENDRA Life Sciences Inc. 8-K (2026-07-09) https://aibio.space/news/bone-biologics-closes-private-placement-pre-funded-warrants-about-2-7/https://aibio.space/news/bone-biologics-closes-private-placement-pre-funded-warrants-about-2-7/Thu, 09 Jul 2026 12:00:00 GMTFinancingsBone Biologics sold pre-funded warrants for 2,112,677 shares at a combined $1.419 each, with Series F and G warrants at $1.42, through H.C. Wainwright & Co. Net proceeds were about $2.7 million, and the 10-K carries a going-concern warning.Bone Biologics Corp Form 8-K filed July 9, 2026 (SEC EDGAR) https://aibio.space/news/zyversa-director-resigns-company-explores-cost-cuts/https://aibio.space/news/zyversa-director-resigns-company-explores-cost-cuts/Wed, 08 Jul 2026 12:00:00 GMTCompany UpdatesZyVersa said a director has resigned and that it is considering cost reductions, pay cuts for two officers and possible sales of its VAR 200 or IC 100 candidates while it seeks to raise capital.ZyVersa Therapeutics, Inc. 8-K (2026-07-10) https://aibio.space/news/biorestoratives-ceo-cfo-resign-claim-severance-new-ceo-named/https://aibio.space/news/biorestoratives-ceo-cfo-resign-claim-severance-new-ceo-named/Wed, 08 Jul 2026 12:00:00 GMTCompany UpdatesTwo executives gave notice on July 13, 2026 and asserted about $2.85 million in aggregate cash severance. The board does not accept the claims, and it named Katharyn Field chief executive officer.BioRestorative Therapies, Inc. 8-K (2026-07-16) https://aibio.space/news/aquabountys-board-declines-reverse-stock-split-now/https://aibio.space/news/aquabountys-board-declines-reverse-stock-split-now/Wed, 08 Jul 2026 12:00:00 GMTListingsAquaBounty's board decided on July 6, 2026 not to carry out a reverse split of 1-for-5 to 1-for-20 that stockholders approved, and that authority expires July 31, 2026.AquaBounty Technologies, Inc. 8-K (2026-07-08) https://aibio.space/news/kyverna-amends-150-million-oxford-finance-loan-facility/https://aibio.space/news/kyverna-amends-150-million-oxford-finance-loan-facility/Wed, 08 Jul 2026 12:00:00 GMTDebt FinancingKyverna extended availability of $15.0 million in remaining Term A Loans to December 31, 2026, for a $187,500 upfront fee. Further changes to the facility apply only if the company draws the full $15.0 million.Kyverna Therapeutics, Inc. 8-K (2026-07-09) https://aibio.space/news/evofem-biosciences-issues-706-304-subordinated-note-hub-cyber-security/https://aibio.space/news/evofem-biosciences-issues-706-304-subordinated-note-hub-cyber-security/Wed, 08 Jul 2026 12:00:00 GMTDebt FinancingEvofem issued a $706,304 subordinated note to HUB Cyber Security, Ltd. The 12% note matures eleven months after July 8, 2026, and accrues a $2,000 weekly monitoring fee plus a one-time administration fee of $14,126.SEC filing (Form 8-K) https://aibio.space/news/evommune-cfo-agrees-return-10-160-short-swing-profit-after-july-share/https://aibio.space/news/evommune-cfo-agrees-return-10-160-short-swing-profit-after-july-share/Wed, 08 Jul 2026 12:00:00 GMTLegalEvommune's chief financial officer disclosed a purchase that matches a May sale under the short-swing rule, and agreed to pay the company $10,160.EVMN 4 https://aibio.space/news/theriva-receives-spanish-authorization-virage2-trial/https://aibio.space/news/theriva-receives-spanish-authorization-virage2-trial/Tue, 07 Jul 2026 12:00:00 GMTCompany UpdatesSpain's AEMPS cleared the Phase 2a study of more frequent VCN-01 dosing in first-line metastatic pancreatic cancer.Theriva Biologics, Inc. 8-K (2026-07-07) https://aibio.space/news/semnur-signs-binding-term-sheet-100-million-investment-iholding/https://aibio.space/news/semnur-signs-binding-term-sheet-100-million-investment-iholding/Tue, 07 Jul 2026 12:00:00 GMTFinancingsSemnur, a majority-owned subsidiary of Scilex, said iHolding Group LLP would buy $100,000,000 of newly issued common stock at an expected $10.00 per share. The proposal remains subject to due diligence and definitive agreements.Semnur Pharmaceuticals press release, Exhibit 99.1 to Form 8-K https://aibio.space/news/macrogenics-completes-sale-cdmo-manufacturing-business-bora-122-5/https://aibio.space/news/macrogenics-completes-sale-cdmo-manufacturing-business-bora-122-5/Tue, 07 Jul 2026 12:00:00 GMTMergersBora Pharmaceuticals and Bora Biologics USA paid $122.5 million, before transaction fees and expenses, for MacroGenics' GMP manufacturing operations. The sale closed effective June 30, 2026 and is subject to post-closing adjustments.MACROGENICS INC Form 8-K filed July 7, 2026 (SEC EDGAR) https://aibio.space/news/macrogenics-completes-sale-manufacturing-operations-bora-122-5-million/https://aibio.space/news/macrogenics-completes-sale-manufacturing-operations-bora-122-5-million/Tue, 07 Jul 2026 12:00:00 GMTMergersBora Pharmaceuticals took over MacroGenics' Rockville manufacturing site and hired about 140 former employees. The $122.5 million price is before fees, and the 8-K says extra post-closing payments may not be earned or received.MacroGenics, Inc. 8-K (2026-07-07) https://aibio.space/news/meiragtx-agrees-up-400-million-oberland-capital-investment-135-million/https://aibio.space/news/meiragtx-agrees-up-400-million-oberland-capital-investment-135-million/Tue, 07 Jul 2026 12:00:00 GMTFinancingsMeiraGTx will receive up to $400 million from Oberland Capital, starting with $135 million that includes $125 million of royalty funding and a $10 million equity investment. The release does not state the cap multiple on the royalties or the price of the new shares.MeiraGTx Holdings plc 8-K (2026-07-07) https://aibio.space/news/bioxcel-amends-credit-agreement-forms-strategic-process-committee/https://aibio.space/news/bioxcel-amends-credit-agreement-forms-strategic-process-committee/Mon, 06 Jul 2026 12:00:00 GMTDebt FinancingThe Tenth Amendment, entered July 3, 2026, defers a principal payment to July 31, 2026, lowers the minimum liquidity covenant to $7.5 million and requires definitive agreements by that date.BioXcel Therapeutics, Inc. 8-K (2026-07-06) https://aibio.space/news/oragenics-names-john-spencer-cfo-reports-annual-meeting-votes/https://aibio.space/news/oragenics-names-john-spencer-cfo-reports-annual-meeting-votes/Mon, 06 Jul 2026 12:00:00 GMTListingsOragenics appointed John Spencer, its Senior Controller, as Chief Financial Officer effective July 1, 2026. The company's June 29, 2026 annual meeting included a vote on authority for a reverse stock split of one-for-two to one-for-fifty.Oragenics Inc. 8-K (2026-07-06) https://aibio.space/news/foxo-ceo-gives-mid-year-2026-update-says-uplisting-under-consideration/https://aibio.space/news/foxo-ceo-gives-mid-year-2026-update-says-uplisting-under-consideration/Mon, 06 Jul 2026 12:00:00 GMTListingsIn a letter to shareholders, CEO Seamus Lagan reported first quarter 2026 net revenues of about $5.1 million, completed a 1:3,000 reverse stock split, and said FOXO is considering an uplisting to a recognized exchange before the end of 2026.FOXO TECHNOLOGIES INC. 8-K (2026-07-06) https://aibio.space/news/polomar-health-reconstitutes-board-amends-equity-plan/https://aibio.space/news/polomar-health-reconstitutes-board-amends-equity-plan/Mon, 06 Jul 2026 12:00:00 GMTCompany UpdatesFour directors were elected effective July 1, 2026, George Hornig became executive chairman and Terrence M. Tierney became interim chief executive officer. The annual evergreen increase falls from 10% to 3%.Polomar Health Services, Inc. 8-K (2026-07-06) https://aibio.space/news/aethlon-prices-4-0-million-follow-offering-0-7101-share/https://aibio.space/news/aethlon-prices-4-0-million-follow-offering-0-7101-share/Mon, 06 Jul 2026 12:00:00 GMTFinancingsMaxim Group LLC is sole placement agent for 5,633,009 shares or pre-funded warrants, each sold with a warrant for the same number of shares.AETHLON MEDICAL INC 8-K (2026-07-08) https://aibio.space/news/aspira-womens-health-takes-1-050-000-secured-subordinated-loan/https://aibio.space/news/aspira-womens-health-takes-1-050-000-secured-subordinated-loan/Mon, 06 Jul 2026 12:00:00 GMTDebt FinancingAspira Women's Health signed a $1,050,000 secured subordinated note with Agile Lending, LLC as lead lender. The note matures January 26, 2027, and the company will use it to refinance an earlier January loan.SEC filing (Form 8-K) https://aibio.space/news/cynata-takes-600-000-loan-secured-against-r-d-ti-rebate/https://aibio.space/news/cynata-takes-600-000-loan-secured-against-r-d-ti-rebate/Mon, 06 Jul 2026 12:00:00 GMTDebt FinancingThe $600,000 loan is secured against an expected R&D tax rebate of approximately $1.7m and the company's assets, and falls due by 30 September 2026 unless extended.Cynata Therapeutics Limited release (2026-07-06) https://aibio.space/news/prestige-consumer-healthcare-draws-95-0-million-term-loan-fund/https://aibio.space/news/prestige-consumer-healthcare-draws-95-0-million-term-loan-fund/Mon, 06 Jul 2026 12:00:00 GMTDebt FinancingThe company's subsidiary drew $95,000,000 on July 1, 2026. The 8-K also notes a $400,000,000 private offering of senior unsecured notes due 2034 whose pricing a July 6, 2026 press release announced.Prestige Consumer Healthcare Inc. Form 8-K filed July 6, 2026 (SEC EDGAR) https://aibio.space/news/nuvation-bio-issues-37-5-million-more-convertible-notes-offering/https://aibio.space/news/nuvation-bio-issues-37-5-million-more-convertible-notes-offering/Mon, 06 Jul 2026 12:00:00 GMTDebt FinancingNuvation Bio issued $37.5 million more of its 0.75% convertible senior notes due 2032 on July 6, 2026, after underwriters exercised their option in full. The offering now totals $287.5 million, with estimated net proceeds of about $277.6 million, and the notes can be settled in cash, shares or both at the company's choice.Nuvation Bio Inc. Form 8-K filed July 6, 2026 (SEC EDGAR) https://aibio.space/news/cosciens-biopharma-files-form-15-end-sec-reporting-duties/https://aibio.space/news/cosciens-biopharma-files-form-15-end-sec-reporting-duties/Mon, 06 Jul 2026 12:00:00 GMTListingsThe July 6, 2026 notice lists approximately 153 holders of record of its common shares.COSCIENS Biopharma Inc. 15-12G (2026-07-06) https://aibio.space/news/gelteq-closes-second-debt-tranche-receiving-2-5-million-net-discount/https://aibio.space/news/gelteq-closes-second-debt-tranche-receiving-2-5-million-net-discount/Mon, 06 Jul 2026 12:00:00 GMTListingsShareholders approved the second tranche on June 18, 2026, and the investor now holds a $2.875 million note convertible at 93% of recent trading prices.Gelteq Limited 6-K (2026-07-06) https://aibio.space/news/mindwalk-added-russell-3000e-index-then-files-250-000-000-shelf/https://aibio.space/news/mindwalk-added-russell-3000e-index-then-files-250-000-000-shelf/Mon, 06 Jul 2026 12:00:00 GMTFinancingsThe index change took effect after the U.S. market close on June 26, 2026. A Form F-3 filed on July 13, 2026 replaces an older shelf and includes a $50,000,000 at-the-market program.MindWalk Holdings Corp. 6-K (2026-07-06) https://aibio.space/news/igc-pharma-issues-shares-two-officers-0-27-settle-1-154-210-owed-them/https://aibio.space/news/igc-pharma-issues-shares-two-officers-0-27-settle-1-154-210-owed-them/Mon, 06 Jul 2026 12:00:00 GMTFinancingsThe CEO and the principal financial officer paid for the shares by cancelling amounts the company owed them, including personal cash advances. IGC Pharma paid no cash.IGC Pharma, Inc. 8-K (2026-07-06) https://aibio.space/news/nuvation-bios-convertible-notes-offering-reaches-287-5-million-after/https://aibio.space/news/nuvation-bios-convertible-notes-offering-reaches-287-5-million-after/Mon, 06 Jul 2026 12:00:00 GMTDebt FinancingNuvation Bio's underwriters exercised in full an option for $37.5 million more of 0.75% convertible senior notes due 2032, lifting the offering to $287.5 million. Net proceeds are estimated at $277.6 million, and the capped calls bought with them cost about $2.2 million.Nuvation Bio Inc. 8-K (2026-07-06) https://aibio.space/news/metavia-files-prospectus-supplement-up-4-000-000-share-sales/https://aibio.space/news/metavia-files-prospectus-supplement-up-4-000-000-share-sales/Thu, 02 Jul 2026 12:00:00 GMTFinancingsMetaVia filed a prospectus supplement for up to $4,000,000 of common stock under its at-the-market sales agreement with Ladenburg Thalmann & Co. Inc., dated November 6, 2025.MetaVia Inc. 8-K (2026-07-02) https://aibio.space/news/lixte-completes-merger-nomad-transportable-power-systems/https://aibio.space/news/lixte-completes-merger-nomad-transportable-power-systems/Thu, 02 Jul 2026 12:00:00 GMTMergersLIXTE is issuing 2,992,041 common shares and 50,366.07 Series D preferred shares to NOMAD stockholders, and has changed its name to NOMAD Power Solutions effective July 3, 2026.NOMAD POWER SOLUTIONS, INC. 8-K (2026-07-02) https://aibio.space/news/cns-pharmaceuticals-lays-out-oncology-neurology-asset-search/https://aibio.space/news/cns-pharmaceuticals-lays-out-oncology-neurology-asset-search/Thu, 02 Jul 2026 12:00:00 GMTCompany UpdatesThe July 2026 investor presentation describes a formal asset search after a $22.5 million financing and a leadership rebuild.CNS Pharmaceuticals, Inc. 8-K (2026-07-02) https://aibio.space/news/omeros-expects-close-16-0-million-note-repurchase-agrees-14-5-million/https://aibio.space/news/omeros-expects-close-16-0-million-note-repurchase-agrees-14-5-million/Thu, 02 Jul 2026 12:00:00 GMTDebt FinancingOmeros expects to close a $16.0 million principal repurchase of its 9.50% convertible notes due 2029, and agreed to buy up to $14.5 million more. The repurchases would leave about $40.3 million of notes outstanding, and the company may replace the cash with debt that is not convertible into equity.SEC Form 8-K https://aibio.space/news/ardelyx-draws-50-0-million-term-f-loan-under-slr-investment-corp-loan/https://aibio.space/news/ardelyx-draws-50-0-million-term-f-loan-under-slr-investment-corp-loan/Thu, 02 Jul 2026 12:00:00 GMTDebt FinancingArdelyx received the funds on June 29, 2026 under its 2022 loan and security agreement. The loan bears interest of 4.55% plus the greater of 1-month SOFR or 3.5%, with interest-only payments until July 1, 2030.ARDELYX, INC. Form 8-K filed July 2, 2026 (SEC EDGAR) https://aibio.space/news/creative-medical-technology-gets-4-5-million-warrant-exercise-reduced/https://aibio.space/news/creative-medical-technology-gets-4-5-million-warrant-exercise-reduced/Thu, 02 Jul 2026 12:00:00 GMTFinancingsHolders of warrants for 2,790,340 shares exercised after the price fell from $2.86 to $1.60 and received new warrants for 5,580,680 shares. Roth Capital Partners acted as financial advisor.CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Form 8-K filed July 2, 2026 (SEC EDGAR) https://aibio.space/news/pyxis-oncology-agrees-sell-about-50-million-stock-warrants-private/https://aibio.space/news/pyxis-oncology-agrees-sell-about-50-million-stock-warrants-private/Thu, 02 Jul 2026 12:00:00 GMTFinancingsPyxis Oncology agreed to sell 19,600,153 shares at $2.551 and warrants at $3.289 to investors led by BVF Partners L.P. The press release says the upfront money extends cash into the second quarter of 2027, while the company's annual report carried a going-concern warning and said cash would fund operations only into the fourth quarter of 2026.Pyxis Oncology, Inc. Form 8-K filed July 2, 2026 (SEC EDGAR) https://aibio.space/news/enanta-pharmaceuticals-files-up-75-000-000-market-stock-sales/https://aibio.space/news/enanta-pharmaceuticals-files-up-75-000-000-market-stock-sales/Thu, 02 Jul 2026 12:00:00 GMTFinancingsThe company signed an Open Market Sale Agreement with Jefferies LLC on July 2, 2026. Jefferies is entitled to a commission of up to 3.0% of gross sales.Enanta Pharmaceuticals, Inc. 424B5 (2026-07-02) https://aibio.space/news/integrated-biopharma-extends-pnc-revolving-credit-line-april-14-2027/https://aibio.space/news/integrated-biopharma-extends-pnc-revolving-credit-line-april-14-2027/Thu, 02 Jul 2026 12:00:00 GMTDistressThe $4,000,000.00 PNC line now runs to April 14, 2027, and a new Convertible ELOC of up to $250,000.00 replaces a matured $500,000.00 equipment note.Integrated BioPharma, Inc. 8-K (2026-07-02) https://aibio.space/news/scribe-therapeutics-files-ipo-plans-nasdaq-listing-sctx/https://aibio.space/news/scribe-therapeutics-files-ipo-plans-nasdaq-listing-sctx/Thu, 02 Jul 2026 12:00:00 GMTFinancingsScribe Therapeutics filed an S-1 on July 2, 2026 with blank share and price terms. Management and its auditor have raised substantial doubt about its ability to continue as a going concern.Scribe Therapeutics Inc. S-1 (2026-07-02) https://aibio.space/news/bridgebio-raises-up-1-billion-convertible-preferred-sixth-street-kkr/https://aibio.space/news/bridgebio-raises-up-1-billion-convertible-preferred-sixth-street-kkr/Wed, 01 Jul 2026 12:00:00 GMTFinancingsThe 7% preferred converts at $137.79 a share and is aimed at supporting present and upcoming launches. $933.9 million was funded at close.BridgeBio Pharma https://aibio.space/news/bioforce-nanosciences-receives-nevada-oil-gas-lease-assignment-pending/https://aibio.space/news/bioforce-nanosciences-receives-nevada-oil-gas-lease-assignment-pending/Wed, 01 Jul 2026 12:00:00 GMTCompany UpdatesA July 1, 2026 filing says the company received an assignment of eleven federal leases covering approximately 19,957 acres in Nye County, Nevada, subject to Bureau of Land Management approval.Form 8-K (SEC EDGAR) https://aibio.space/news/foxo-completes-1-3-000-reverse-stock-split/https://aibio.space/news/foxo-completes-1-3-000-reverse-stock-split/Wed, 01 Jul 2026 12:00:00 GMTListingsThe reverse split of FOXO's Class A common stock took effect at 4:01 p.m. ET on June 30, 2026. Shares trade on a split-adjusted basis under the temporary symbol FOXOD until the symbol reverts to FOXO on or about July 20, 2026.FOXO TECHNOLOGIES INC. 8-K (2026-07-01) https://aibio.space/news/hepion-adds-two-directors-including-son-interim-ceo/https://aibio.space/news/hepion-adds-two-directors-including-son-interim-ceo/Wed, 01 Jul 2026 12:00:00 GMTCompany UpdatesDanina Fisher and Gary S. Stetz, II joined the board on July 1, 2026. The filing notes that Mr. Stetz is the son of Gary Stetz, the interim chief executive.Hepion Pharmaceuticals, Inc. 8-K (2026-07-02) https://aibio.space/news/viatris-closes-40-000-000-000-unsecured-term-loan-mizuho-bank/https://aibio.space/news/viatris-closes-40-000-000-000-unsecured-term-loan-mizuho-bank/Wed, 01 Jul 2026 12:00:00 GMTDebt FinancingViatris signed a ¥40,000,000,000 senior unsecured term loan with Mizuho Bank, Ltd. as administrative agent. The proceeds may repay a 2021 loan of the same size, and the company reported a net loss of $3.51 billion for 2025.SEC filing (Form 8-K) https://aibio.space/news/alvotech-secures-75-million-term-loan-goldentree-funds/https://aibio.space/news/alvotech-secures-75-million-term-loan-goldentree-funds/Wed, 01 Jul 2026 12:00:00 GMTDebt FinancingAlvotech amended its credit agreement to add up to $75 million in term debt at 12.50% interest, maturing December 31, 2027. Its secured loan facility already had $1,031.6 million outstanding at the end of 2025.Alvotech 6-K (2026-07-01) https://aibio.space/news/fresenius-issues-1-billion-dual-tranche-bonds/https://aibio.space/news/fresenius-issues-1-billion-dual-tranche-bonds/Wed, 01 Jul 2026 12:00:00 GMTDebt FinancingTwo €500 million tranches, due in 2031 and 2034, will fund general corporate purposes, including refinancing.Fresenius SE & Co. KGaA release (2026-07-01) https://aibio.space/news/cadrenal-therapeutics-raises-3-0-million-private-placement-priced/https://aibio.space/news/cadrenal-therapeutics-raises-3-0-million-private-placement-priced/Wed, 01 Jul 2026 12:00:00 GMTFinancingsCadrenal (Nasdaq: CVKD) received gross proceeds of approximately $3.0 million from one institutional investor. Warrants could add about $5.8 million if exercised in full for cash, the company says.Cadrenal Therapeutics, Inc. Form 8-K filed July 1, 2026 (SEC EDGAR) https://aibio.space/news/cumberland-pharmaceuticals-closes-100-million-asset-sale-apotex/https://aibio.space/news/cumberland-pharmaceuticals-closes-100-million-asset-sale-apotex/Wed, 01 Jul 2026 12:00:00 GMTMergersCumberland sold six branded products for $100 million in cash and repaid about $5.3 million owed to Pinnacle Bank. It kept ifetroban, whose data so far come from early-stage studies, and its filings do not split out revenue for the products it sold.CUMBERLAND PHARMACEUTICALS INC Form 8-K filed July 1, 2026 (SEC EDGAR) https://aibio.space/news/cumberland-pharmaceuticals-closes-100-million-branded-product-deal/https://aibio.space/news/cumberland-pharmaceuticals-closes-100-million-branded-product-deal/Wed, 01 Jul 2026 12:00:00 GMTMergersApotex paid $100 million in cash to close the branded-products deal after shareholders approved it. Cumberland now says it will focus on ifetroban, but its release gives no trial figures for any of the programs.Cumberland Pharmaceuticals Inc. 8-K (2026-07-01) https://aibio.space/news/lifeward-amends-senior-secured-convertible-notes-tied-oramed/https://aibio.space/news/lifeward-amends-senior-secured-convertible-notes-tied-oramed/Tue, 30 Jun 2026 12:00:00 GMTDebt FinancingThe notes carry 8.0% interest and a $5.40 conversion price. The second tranche depends on ReWalk sales growth or a share price of $13.80 or higher.Lifeward Ltd. 8-K (2026-07-07) https://aibio.space/news/aptevo-receives-1-5-million-grant-advance-apvo451/https://aibio.space/news/aptevo-receives-1-5-million-grant-advance-apvo451/Tue, 30 Jun 2026 12:00:00 GMTCompany UpdatesAptevo was awarded a $1.5 million non-dilutive research grant from the Andy Hill CARE Fund to support IND-enabling work for APVO451, its nectin-4-targeted trispecific candidate.Aptevo Therapeutics Inc. 8-K (2026-06-30) https://aibio.space/news/tenon-medical-prices-4-2-million-public-offering-warrants/https://aibio.space/news/tenon-medical-prices-4-2-million-public-offering-warrants/Tue, 30 Jun 2026 12:00:00 GMTFinancingsThe offering is priced at $0.38 per share and common warrants. WallachBeth Capital LLC is the sole placement agent, and part of the proceeds will repay convertible notes.Tenon Medical, Inc. 8-K (2026-07-02) https://aibio.space/news/bespoke-extracts-extends-senior-secured-notes-august-14-2026/https://aibio.space/news/bespoke-extracts-extends-senior-secured-notes-august-14-2026/Tue, 30 Jun 2026 12:00:00 GMTDebt FinancingThe amendment moves the maturity of $410,000 in notes from June 30 to August 14, 2026, raises the rate to 17% from July 1 and requires extension shares.Bespoke Extracts, Inc. 8-K (2026-07-06) https://aibio.space/news/moleculin-calls-first-45-patient-miracle-results-positive-but-gives-no/https://aibio.space/news/moleculin-calls-first-45-patient-miracle-results-positive-but-gives-no/Tue, 30 Jun 2026 12:00:00 GMTCompany UpdatesThe company says both Annamycin arms showed favorable efficacy trends against the control arm in relapsed or refractory AML, on a full intent-to-treat basis.Moleculin Biotech, Inc. 8-K (2026-06-30) https://aibio.space/news/cosmos-health-authorizes-share-repurchase-up-5-million/https://aibio.space/news/cosmos-health-authorizes-share-repurchase-up-5-million/Tue, 30 Jun 2026 12:00:00 GMTCompany UpdatesThe program expires December 31, 2026 and may be renewed at the company's discretion.Cosmos Health Inc. 8-K (2026-07-06) https://aibio.space/news/tuhura-biosciences-borrows-1-900-000-more-under-parkview-credit-line/https://aibio.space/news/tuhura-biosciences-borrows-1-900-000-more-under-parkview-credit-line/Tue, 30 Jun 2026 12:00:00 GMTDebt FinancingTuHURA Biosciences drew an additional $1,900,000 under its revolving credit facility with Parkview Holdings One LLC. The facility matures April 21, 2031 and allows up to $50 million in borrowing, and the filing does not describe its interest rate or collateral.SEC filing (Form 8-K) https://aibio.space/news/os-therapies-signs-10-million-secured-convertible-note-leonite-fund/https://aibio.space/news/os-therapies-signs-10-million-secured-convertible-note-leonite-fund/Tue, 30 Jun 2026 12:00:00 GMTDebt FinancingThe company calls it a line of credit backed by UK tax credits. It drew $1.6 million first, mainly for OST-HER2 manufacturing.Company press release (Form 8-K, Exhibit 99.1) https://aibio.space/news/cdt-equity-closes-second-tranche-1-460-000-convertible-loan/https://aibio.space/news/cdt-equity-closes-second-tranche-1-460-000-convertible-loan/Tue, 30 Jun 2026 12:00:00 GMTDebt FinancingJ.J. Astor & Co. is the lender on a senior secured convertible note with a principal amount of $1,971,000, amended on June 30, 2026. The company receives $1,460,000 in two tranches, and repays the loan in weekly installments of $82,125 starting July 10, 2026.SEC filing (Form 8-K) https://aibio.space/news/hcw-biologics-regains-nasdaq-bid-price-compliance-faces-monitor-until/https://aibio.space/news/hcw-biologics-regains-nasdaq-bid-price-compliance-faces-monitor-until/Tue, 30 Jun 2026 12:00:00 GMTListingsA Nasdaq Hearings Panel found HCW Biologics (Nasdaq: HCWB) back in compliance with the minimum bid price rule. The company faces a mandatory panel monitor and will effect a one-for-six reverse stock split on June 30, 2026.HCW Biologics Inc. Form 8-K filed June 30, 2026 (SEC EDGAR) https://aibio.space/news/abivax-launches-600-000-000-offering-american-depositary-shares/https://aibio.space/news/abivax-launches-600-000-000-offering-american-depositary-shares/Tue, 30 Jun 2026 12:00:00 GMTFinancingsAbivax's preliminary supplement of June 30, 2026 described a $600,000,000 offering. The final supplement priced 6,400,000 ADSs at $125.0000 each, $800,000,000 in all, one day after the company announced Phase 3 maintenance results.Abivax SA 424B5 (2026-06-30) https://aibio.space/news/biocryst-close-birmingham-discovery-center-cuts-2026-spending-outlook/https://aibio.space/news/biocryst-close-birmingham-discovery-center-cuts-2026-spending-outlook/Mon, 29 Jun 2026 12:00:00 GMTFinancingsThe HAE drugmaker will stop internal drug discovery and look outside for new programs. A later 8-K/A put severance at $6.2 million to $7.5 million, and a state WARN notice listed 47 jobs at the site.BioCryst Pharmaceuticals (SEC Form 8-K, Exhibit 99.1) https://aibio.space/news/alaunos-reports-body-fat-adjusted-liver-weight-analysis-aln1003/https://aibio.space/news/alaunos-reports-body-fat-adjusted-liver-weight-analysis-aln1003/Mon, 29 Jun 2026 12:00:00 GMTCompany UpdatesAlaunos says a body-fat-adjusted analysis of liver weight in a 48-day mouse study supports further preclinical work on ALN1003.Alaunos Therapeutics, Inc. 8-K (2026-06-29) https://aibio.space/news/trafalgar-asset-management-gains-voting-control-cancels-company-debt/https://aibio.space/news/trafalgar-asset-management-gains-voting-control-cancels-company-debt/Mon, 29 Jun 2026 12:00:00 GMTCompany UpdatesTrafalgar Asset Management, LLC bought all the Series A and Series B preferred stock on June 29, 2026, and certain company debts were settled and canceled the same day.TRAFALGAR INTERNATIONAL, INC. 8-K (2026-07-06) https://aibio.space/news/agenus-extends-maturity-5-09-million-notes/https://aibio.space/news/agenus-extends-maturity-5-09-million-notes/Mon, 29 Jun 2026 12:00:00 GMTDebt FinancingAgenus pushed back the maturity of $5.09 million of 2015 notes by eight months, to February 18, 2027, and extended the expiration of earlier warrants to June 25, 2031. The filing does not describe new cash from the deal.Agenus Inc. 8-K (2026-07-06) https://aibio.space/news/celularity-takes-1-000-000-secured-loan-barach-family-trust/https://aibio.space/news/celularity-takes-1-000-000-secured-loan-barach-family-trust/Mon, 29 Jun 2026 12:00:00 GMTDebt FinancingCelularity signed a $1,000,000 secured loan with the Philip & Daniele Barach Family Trust at 4.0%. The loan matures at the earlier of 30 days after closing or receipt of certain financing proceeds, and it rises to 18.0% after a default.SEC filing (Form 8-K) https://aibio.space/news/ardelyx-draws-50-0-million-term-loan-slr-investment-corp/https://aibio.space/news/ardelyx-draws-50-0-million-term-loan-slr-investment-corp/Mon, 29 Jun 2026 12:00:00 GMTDebt FinancingArdelyx drew a $50.0 million Term F Loan from SLR Investment Corp. on June 29, 2026. The loan matures July 1, 2030 at 4.55% plus the greater of 1-month SOFR or 3.5%, and in a default the agent can reach the company's cash.Ardelyx, Inc. (2026-06-29) https://aibio.space/news/rockwell-medical-sets-1-10-reverse-stock-split-july-1-2026/https://aibio.space/news/rockwell-medical-sets-1-10-reverse-stock-split-july-1-2026/Mon, 29 Jun 2026 12:00:00 GMTListingsRockwell Medical's one-for-ten reverse split takes effect at 12:01 a.m. Eastern Time on July 1, 2026. The certificate was filed June 24, and the company says fractional shares will be paid in cash at the June 30 closing price, adjusted by the company.Rockwell Medical, Inc. 8-K (2026-06-29) https://aibio.space/news/zymeworks-agrees-buy-theravance-biopharma-17-share-about-929-million/https://aibio.space/news/zymeworks-agrees-buy-theravance-biopharma-17-share-about-929-million/Mon, 29 Jun 2026 12:00:00 GMTMergersZymeworks will pay $17.00 per share in cash, financed mainly by a $350 million non-recourse note from OMERS Life Sciences. The release says 75% of the YUPELRI profit-share cash flows are assigned to OMERS to service the note.Zymeworks Inc. 8-K (2026-06-29) https://aibio.space/news/soligenix-adds-2-500-000-market-sales-agreement/https://aibio.space/news/soligenix-adds-2-500-000-market-sales-agreement/Fri, 26 Jun 2026 12:00:00 GMTFinancingsSoligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,500,000.Soligenix, Inc. 8-K (2026-06-26) https://aibio.space/news/matinas-biopharma-receives-nyse-american-equity-notice-plan-accepted/https://aibio.space/news/matinas-biopharma-receives-nyse-american-equity-notice-plan-accepted/Fri, 26 Jun 2026 12:00:00 GMTListingsNYSE American says Matinas BioPharma fell short of two stockholders' equity standards and accepted its compliance plan, with a plan period through October 2, 2027.Matinas Biopharma Holdings, Inc. 8-K (2026-06-26) https://aibio.space/news/shoulder-innovations-takes-15-0-million-stifel-term-loan-repays/https://aibio.space/news/shoulder-innovations-takes-15-0-million-stifel-term-loan-repays/Fri, 26 Jun 2026 12:00:00 GMTDebt FinancingShoulder Innovations signed a $15.0 million senior secured term loan with Stifel Bank on June 26, 2026, and used it to repay Trinity Capital. The $30.0 million asset-based revolver was undrawn at closing.SEC filing (Form 8-K) https://aibio.space/news/china-resources-pharmaceutical-unit-issues-rmb2-billion-corporate/https://aibio.space/news/china-resources-pharmaceutical-unit-issues-rmb2-billion-corporate/Fri, 26 Jun 2026 12:00:00 GMTDebt FinancingA non-wholly owned subsidiary completed the third tranche of its 2026 corporate bonds, RMB2 billion at 1.59% per annum over three years.China Resources Pharmaceutical Group Limited announcement (2026-06-26) https://aibio.space/news/aquabounty-sells-2-250-000-series-b-preferred-stock/https://aibio.space/news/aquabounty-sells-2-250-000-series-b-preferred-stock/Thu, 25 Jun 2026 12:00:00 GMTFinancingsThe private placement closed June 25, 2026, with Univest Securities, LLC as placement agent. The shares carry an 18.0% annual dividend and a $1.03 conversion price.AquaBounty Technologies, Inc. 8-K (2026-06-30) https://aibio.space/news/alx-oncology-closes-up-50-000-000-hsbc-term-loan-facility/https://aibio.space/news/alx-oncology-closes-up-50-000-000-hsbc-term-loan-facility/Thu, 25 Jun 2026 12:00:00 GMTDebt FinancingALX Oncology borrowed $10,000,000 at closing from HSBC Ventures USA and used it to refinance its Oxford Finance and Silicon Valley Bank loan. The facility can reach $50,000,000, but $10,000,000 of that is uncommitted and the rest depends on draw dates and milestones.ALX Oncology Holdings Inc. 8-K (2026-06-26) https://aibio.space/news/disc-medicine-draws-30-000-000-extends-hercules-loan-draw-periods/https://aibio.space/news/disc-medicine-draws-30-000-000-extends-hercules-loan-draw-periods/Thu, 25 Jun 2026 12:00:00 GMTDebt FinancingA First Amendment to the Hercules loan splits the remaining $50,000,000 tranche and extends later draw deadlines into 2027 and 2028.SEC filing (Form 8-K) https://aibio.space/news/nuvation-bio-proposes-200-0-million-convertible-notes-offering/https://aibio.space/news/nuvation-bio-proposes-200-0-million-convertible-notes-offering/Thu, 25 Jun 2026 12:00:00 GMTDebt FinancingNuvation Bio plans $200.0 million of notes due 2032 and expects to use the proceeds to repay its senior secured loan and pay for capped calls. The rate and conversion price are not set until pricing.Nuvation Bio Inc. 8-K (2026-06-30) https://aibio.space/news/ligand-pharmaceuticals-completes-700-0-million-0-00-percent/https://aibio.space/news/ligand-pharmaceuticals-completes-700-0-million-0-00-percent/Thu, 25 Jun 2026 12:00:00 GMTDebt FinancingLigand closed $700.0 million of 0.00% convertible senior notes due 2031 after the initial purchasers exercised their option in full. Net proceeds were approximately $678.2 million, with about $72.9 million going to note hedges and approximately $60 million to a share repurchase. The initial conversion price is approximately $334.27 per share.LIGAND PHARMACEUTICALS INC Form 8-K filed June 25, 2026 (SEC EDGAR) https://aibio.space/news/cellectis-shareholders-approve-share-issuance-authorizations-including/https://aibio.space/news/cellectis-shareholders-approve-share-issuance-authorizations-including/Thu, 25 Jun 2026 12:00:00 GMTFinancingsVoting results filed June 25, 2026 show resolutions 13 to 24 carried with 95.25% to 99.73% of votes cast. Resolution 30, a savings-plan share issue, drew 14.81% support, yet the filing labels it carried.Cellectis S.A. 6-K (2026-06-25) https://aibio.space/news/absci-raises-100-million-7-41-share-eli-lilly-among-buyers/https://aibio.space/news/absci-raises-100-million-7-41-share-eli-lilly-among-buyers/Wed, 24 Jun 2026 12:00:00 GMTFinancingsThe offering followed interim phase 1 data for ABS-201. Proceeds fund the antibody's hair loss and endometriosis programs.Absci https://aibio.space/news/revelation-amends-ceo-cfo-employment-agreements-bylaws/https://aibio.space/news/revelation-amends-ceo-cfo-employment-agreements-bylaws/Wed, 24 Jun 2026 12:00:00 GMTCompany UpdatesThe amended agreements raise change-in-control severance and set a three-year initial term, and the board amended the bylaws on proxy nominations, the definition of Cause and emergency succession.Revelation Biosciences, Inc. 8-K (2026-06-24) https://aibio.space/news/4d-molecular-therapeutics-signs-up-200-0-million-hercules-loan/https://aibio.space/news/4d-molecular-therapeutics-signs-up-200-0-million-hercules-loan/Wed, 24 Jun 2026 12:00:00 GMTDebt FinancingHercules Capital, Inc. is the lender on senior secured term loans that mature in 2031, and most of the money is milestone-based or at the lender's discretion. The filing does not say how the company will use the proceeds.4D Molecular Therapeutics, Inc. 8-K (2026-06-29) https://aibio.space/news/calcimedica-agrees-private-placement-expected-upfront-gross-proceeds/https://aibio.space/news/calcimedica-agrees-private-placement-expected-upfront-gross-proceeds/Wed, 24 Jun 2026 12:00:00 GMTFinancingsInvestors agreed to buy 18,673,429 units at $0.8033 or $0.8032. Series A and B warrants could add up to approximately $34 million if fully exercised for cash. Closing is expected on or about June 25, 2026.CalciMedica, Inc. Form 8-K filed June 24, 2026 (SEC EDGAR) https://aibio.space/news/fda-conditionally-accepts-qyleki-brand-name-qrx003/https://aibio.space/news/fda-conditionally-accepts-qyleki-brand-name-qrx003/Tue, 23 Jun 2026 12:00:00 GMTCompany UpdatesThe FDA conditionally accepted QYLEKI as the proposed brand name for QRX003 in Netherton Syndrome, and the company says a pivotal Phase 3 study is expected to start in the second half of 2026.Quoin Pharmaceuticals, Ltd. 8-K (2026-06-23) https://aibio.space/news/nuwellis-effect-one-thirty-five-reverse-stock-split-june-25/https://aibio.space/news/nuwellis-effect-one-thirty-five-reverse-stock-split-june-25/Tue, 23 Jun 2026 12:00:00 GMTListingsThe split takes effect at 5:00 p.m. Eastern Time on June 25, 2026, and NUWE shares trade split-adjusted from June 26.Nuwellis, Inc. 8-K (2026-06-24) https://aibio.space/news/calidi-biotherapeutics-appoints-corsee-sanders-board/https://aibio.space/news/calidi-biotherapeutics-appoints-corsee-sanders-board/Tue, 23 Jun 2026 12:00:00 GMTCompany UpdatesDr. Corsee Sanders, a former Genentech/Roche and Celgene executive, joined the board as an independent director effective June 17, 2026.Calidi Biotherapeutics, Inc. 8-K (2026-06-23) https://aibio.space/news/sangamo-files-chapter-11-dip-financing-northridge-atm/https://aibio.space/news/sangamo-files-chapter-11-dip-financing-northridge-atm/Tue, 23 Jun 2026 12:00:00 GMTDebt FinancingSangamo filed for Chapter 11 in Delaware on June 23, 2026 and seeks court approval of DIP financing from Northridge ATM, LLC. Eli Lilly and Astellas have signed stalking horse bids for its assets.Sangamo Therapeutics, Inc. 8-K (2026-06-23) https://aibio.space/news/calcimedica-pushes-avenue-loan-maturity-2029-cuts-warrant-price/https://aibio.space/news/calcimedica-pushes-avenue-loan-maturity-2029-cuts-warrant-price/Tue, 23 Jun 2026 12:00:00 GMTDebt FinancingAvenue Venture Opportunities Fund II, L.P. is the lender on a $10,000,000 loan. The amendment moves maturity to September 1, 2029, expands the lender's conversion right to up to $3,000,000 and cuts the warrant price to $1.00.SEC Form 8-K https://aibio.space/news/cero-therapeutics-amends-1-413-600-promissory-note-srx-health/https://aibio.space/news/cero-therapeutics-amends-1-413-600-promissory-note-srx-health/Tue, 23 Jun 2026 12:00:00 GMTDebt FinancingCERo Therapeutics amended a note with SRX Health Solutions, Inc. that converts into common stock at a price set by recent trading. The maximum is $1,413,600, of which $663,600 was funded on June 23, 2026.CERo Therapeutics Holdings, Inc. 8-K (2026-06-26) https://aibio.space/news/boundless-bio-signs-merger-agreement-serapha-bio-cuts-workforce/https://aibio.space/news/boundless-bio-signs-merger-agreement-serapha-bio-cuts-workforce/Tue, 23 Jun 2026 12:00:00 GMTDistressBoundless Bio agreed to an all-stock merger with privately held Serapha Bio and said it would cut about 75% of its workforce. After closing, Boundless holders would own about 3.69% of the combined company, and most of the early data behind the deal come from a trial in Shanghai.Boundless Bio, Inc. Form 8-K filed June 23, 2026 (SEC EDGAR) https://aibio.space/news/traws-pharma-prepares-updated-mhra-data-package-third-quarter/https://aibio.space/news/traws-pharma-prepares-updated-mhra-data-package-third-quarter/Mon, 22 Jun 2026 12:00:00 GMTCompany UpdatesTraws says MHRA feedback has led it to add preclinical safety information to the tivoxavir marboxil data package, which it expects to resubmit in the third quarter of 2026.Traws Pharma, Inc. SEC filing (Form 8-K) https://aibio.space/news/genprex-receives-canadian-notice-allowance-reqorsa-combination-patent/https://aibio.space/news/genprex-receives-canadian-notice-allowance-reqorsa-combination-patent/Mon, 22 Jun 2026 12:00:00 GMTCompany UpdatesThe Canadian Intellectual Property Office issued a notice of allowance for a patent covering REQORSA with PD-1 or PD-L1 antibodies in lung cancer.Genprex, Inc. 8-K (2026-06-22) https://aibio.space/news/ligand-plans-550-million-convertible-notes-due-2031/https://aibio.space/news/ligand-plans-550-million-convertible-notes-due-2031/Mon, 22 Jun 2026 12:00:00 GMTDebt FinancingLigand plans a private offering of $550.0 million of notes due 2031 to fund note hedges, a repurchase of up to $75 million of stock and general purposes, including a pending deal for Xoma Royalty Corporation.SEC Form 8-K https://aibio.space/news/aditxt-adds-769-230-77-senior-secured-convertible-notes/https://aibio.space/news/aditxt-adds-769-230-77-senior-secured-convertible-notes/Mon, 22 Jun 2026 12:00:00 GMTDebt FinancingAditxt sold $769,230.77 of additional senior secured convertible notes for $500,000.00 in cash, and it reported $268,852 of cash at March 31, 2026. The filing does not name the investors.SEC Form 8-K https://aibio.space/news/betterlife-closes-cad-2-000-000-convertible-debenture-financing/https://aibio.space/news/betterlife-closes-cad-2-000-000-convertible-debenture-financing/Mon, 22 Jun 2026 12:00:00 GMTDebt FinancingBetterLife Pharma closed a CAD $2,000,000 convertible debenture on June 22, 2026, and a director and insider subscribed for the full amount. The conversion price compares with $0.07 per unit in an April 2026 private placement.BetterLife Pharma Inc. 6-K (2026-06-25) https://aibio.space/news/neogenomics-completes-316-25-million-convertible-notes-offering/https://aibio.space/news/neogenomics-completes-316-25-million-convertible-notes-offering/Mon, 22 Jun 2026 12:00:00 GMTDebt FinancingNeoGenomics completed $316.25 million of 0.75% convertible senior notes due 2032 under an indenture with U.S. Bank Trust Company, National Association, as trustee. It used about $28.7 million of the proceeds on capped calls.NeoGenomics, Inc. (2026-06-16) https://aibio.space/news/former-spac-sponsor-sues-silexion-tel-aviv-note-conversions/https://aibio.space/news/former-spac-sponsor-sues-silexion-tel-aviv-note-conversions/Mon, 22 Jun 2026 12:00:00 GMTLegalDefendants: Silexion, chairman and CEO Ilan Hadar, and CFO Mirit Horenshtein Hadar. Moringa Sponsor disputes how Silexion converted part of a $3,433 thousand note into shares and alternatively demands cash; Silexion says it complied with the note.SEC EDGAR: Silexion 10-Q https://aibio.space/news/akebia-stockholders-approve-raising-authorized-common-shares-500-000/https://aibio.space/news/akebia-stockholders-approve-raising-authorized-common-shares-500-000/Mon, 22 Jun 2026 12:00:00 GMTListingsStockholders approved raising authorized common stock from 350,000,000 to 500,000,000 at a June 17, 2026 meeting, with 88,853,129 votes against. The 8-K does not say how many shares are outstanding or planned for issue.Akebia Therapeutics, Inc. 8-K (2026-06-22) https://aibio.space/news/allogene-holders-approve-800-000-000-shares-files-atm-supplement-up/https://aibio.space/news/allogene-holders-approve-800-000-000-shares-files-atm-supplement-up/Mon, 22 Jun 2026 12:00:00 GMTListingsStockholders approved raising authorized common stock from 400,000,000 to 800,000,000 at the June 18, 2026 meeting; 345,024,351 shares were outstanding on the April 20 record date. A sales supplement filed June 22 covers up to $135.0 million of stock sales through TD Securities (U.S.A.) LLC.Allogene Therapeutics, Inc. 8-K (2026-06-22) https://aibio.space/news/allogene-therapeutics-registers-up-135-000-000-share-sales-td-cowen/https://aibio.space/news/allogene-therapeutics-registers-up-135-000-000-share-sales-td-cowen/Mon, 22 Jun 2026 12:00:00 GMTFinancingsThe sales agreement dates to 2019 and was amended in 2022 and 2023. TD Cowen can receive up to 3.0% of gross proceeds, and the prospectus lists 100,200,000 shares issued in April at $2.00 a share.Allogene Therapeutics, Inc. 424B5 (2026-06-22) https://aibio.space/news/cytomx-holders-approve-600-000-000-authorized-shares-larger-equity/https://aibio.space/news/cytomx-holders-approve-600-000-000-authorized-shares-larger-equity/Mon, 22 Jun 2026 12:00:00 GMTListingsStockholders voted on June 17, 2026 to raise authorized common stock from 300,000,000 to 600,000,000 shares. The 8-K does not say what the company plans to do with the extra shares.CytomX Therapeutics, Inc. 8-K (2026-06-22) https://aibio.space/news/definium-launches-500-million-offering-then-prices-20-588-236-shares/https://aibio.space/news/definium-launches-500-million-offering-then-prices-20-588-236-shares/Mon, 22 Jun 2026 12:00:00 GMTFinancingsDefinium sold 20,588,236 common shares at $34.00, or $700,000,024 before discounts, on the same day it reported that its Emerge depression trial met its primary endpoint. The prospectus supplement names eight underwriters, and its underwriting terms name no counsel.Definium Therapeutics, Inc. 424B5 (2026-06-22) https://aibio.space/news/eledon-holders-approve-raising-authorized-common-shares-450-000-000/https://aibio.space/news/eledon-holders-approve-raising-authorized-common-shares-450-000-000/Mon, 22 Jun 2026 12:00:00 GMTListingsThe annual meeting on June 18, 2026 approved the increase from 300,000,000 shares. The amendment is effective June 22, 2026.Eledon Pharmaceuticals, Inc. 8-K (2026-06-22) https://aibio.space/news/provectus-holders-authorize-reverse-split-between-1-10-1-50/https://aibio.space/news/provectus-holders-authorize-reverse-split-between-1-10-1-50/Mon, 22 Jun 2026 12:00:00 GMTListingsProvectus holders authorized a reverse split of between 1-for-10 and 1-for-50, with the ratio left to the board, and a matching cut in authorized shares. The company had $251,291 of cash at December 31, 2025, and its net loss widened to $5.4 million.Provectus Biopharmaceuticals, Inc. 8-K (2026-06-22) https://aibio.space/news/uniqure-launches-150-000-000-offering-then-prices-upsized-225-million/https://aibio.space/news/uniqure-launches-150-000-000-offering-then-prices-upsized-225-million/Mon, 22 Jun 2026 12:00:00 GMTFinancingsuniQure filed a $150,000,000 offering on June 22, 2026 and priced an upsized deal on June 23. The FDA has said its Huntington's data are not sufficient evidence for a marketing application, and the proceeds are partly earmarked for a launch.uniQure N.V. 424B5 (2026-06-22) https://aibio.space/news/petros-names-robert-weinstein-chief-accounting-officer/https://aibio.space/news/petros-names-robert-weinstein-chief-accounting-officer/Thu, 18 Jun 2026 12:00:00 GMTCompany UpdatesPetros appointed Robert Weinstein as chief accounting officer and principal financial officer on June 18, 2026, the day it separated Mitchell Arnold from his finance roles.Petros Pharmaceuticals, Inc. 8-K (2026-06-18) https://aibio.space/news/silo-pharma-regains-nasdaq-minimum-bid-price-compliance/https://aibio.space/news/silo-pharma-regains-nasdaq-minimum-bid-price-compliance/Thu, 18 Jun 2026 12:00:00 GMTListingsNasdaq told Silo it regained compliance with the minimum closing bid price requirement as of June 17, 2026, and the matter is now closed.Silo Pharma, Inc. 8-K (2026-06-18) https://aibio.space/news/kiora-reports-preclinical-epilepsy-data-ion-channel-modulator-kio-300/https://aibio.space/news/kiora-reports-preclinical-epilepsy-data-ion-channel-modulator-kio-300/Thu, 18 Jun 2026 12:00:00 GMTCompany UpdatesKIO-300 significantly suppressed seizure-associated activity in an ex vivo mouse temporal lobe epilepsy model, Kiora said. The poster was presented at the Epilepsy Foundation Pipeline Conference on June 18-19, 2026.Kiora Pharmaceuticals, Inc. 8-K (2026-06-18) https://aibio.space/news/lixte-lend-6-5-million-nomad-before-acquisition-closes/https://aibio.space/news/lixte-lend-6-5-million-nomad-before-acquisition-closes/Thu, 18 Jun 2026 12:00:00 GMTCompany UpdatesThe loan funds long-lead components and working capital ahead of an acquisition that the companies expect to close on or about July 1, 2026.NOMAD POWER SOLUTIONS, INC. 8-K (2026-06-18) https://aibio.space/news/sonoma-pharmaceuticals-lifts-market-offering-ceiling-3-641-703/https://aibio.space/news/sonoma-pharmaceuticals-lifts-market-offering-ceiling-3-641-703/Thu, 18 Jun 2026 12:00:00 GMTCompany UpdatesA prospectus supplement filed June 18, 2026 raises the aggregate offering price under the company's sales agreement with Ladenburg Thalmann to $3,641,703.Sonoma Pharmaceuticals, Inc. 8-K (2026-06-18) https://aibio.space/news/gri-bio-receives-fda-orphan-drug-designation-gri-0621-ipf/https://aibio.space/news/gri-bio-receives-fda-orphan-drug-designation-gri-0621-ipf/Thu, 18 Jun 2026 12:00:00 GMTCompany UpdatesThe FDA granted orphan drug designation to GRI-0621 for idiopathic pulmonary fibrosis, a designation that could bring seven years of U.S. market exclusivity if the drug is approved.GRI Bio, Inc. 8-K (2026-06-18) https://aibio.space/news/ptc-therapeutics-closes-550-000-000-convertible-notes-offering/https://aibio.space/news/ptc-therapeutics-closes-550-000-000-convertible-notes-offering/Thu, 18 Jun 2026 12:00:00 GMTDebt FinancingPTC Therapeutics sold $550,000,000 of 0.0% convertible senior notes due 2031 through Morgan Stanley & Co. LLC as representative of the initial purchasers. The initial conversion price is about $107.48 a share.PTC Therapeutics, Inc. 8-K (2026-06-18) https://aibio.space/news/viatris-completes-650-000-000-public-offering-4-250-percent-senior/https://aibio.space/news/viatris-completes-650-000-000-public-offering-4-250-percent-senior/Thu, 18 Jun 2026 12:00:00 GMTDebt FinancingViatris completed a €650,000,000 offering of 4.250% senior notes due 2033 on June 17, 2026. The proceeds first repay June revolver borrowings used to pay off $1.675 billion of 2026 notes, and the company reported a 2025 net loss of $3.51 billion. The 8-K names no underwriter.Viatris Inc Form 8-K filed June 18, 2026 (SEC EDGAR) https://aibio.space/news/dyadic-international-gets-nasdaq-delisting-notice-bid-price-plans/https://aibio.space/news/dyadic-international-gets-nasdaq-delisting-notice-bid-price-plans/Thu, 18 Jun 2026 12:00:00 GMTListingsNasdaq started a process that could lead to delisting after Dyadic missed the June 17, 2026 deadline to meet the $1.00 minimum bid price. The company plans to request a hearing, and the request automatically stays any delisting action until the panel decides.DYADIC INTERNATIONAL INC Form 8-K filed June 18, 2026 (SEC EDGAR) https://aibio.space/news/iovance-biotherapeutics-files-automatic-shelf-89-650-167-atm/https://aibio.space/news/iovance-biotherapeutics-files-automatic-shelf-89-650-167-atm/Thu, 18 Jun 2026 12:00:00 GMTFinancingsThe sale agreement supplement covers up to $89,650,167 of stock sold through Jefferies. Iovance's last reported sale price was $3.93 on June 17, 2026, and its 2025 net loss was $391.0 million.Iovance Biotherapeutics, Inc. S-3ASR (2026-06-18) https://aibio.space/news/kardigan-prices-ipo-25-000-000-shares-16-00/https://aibio.space/news/kardigan-prices-ipo-25-000-000-shares-16-00/Thu, 18 Jun 2026 12:00:00 GMTFinancingsKardigan priced 25,000,000 shares at $16.00 for $400,000,000 before fees. The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern.Kardigan, Inc. 424B4 (2026-06-18) https://aibio.space/news/prf-technologies-signs-15-0-million-equity-line-yorkville/https://aibio.space/news/prf-technologies-signs-15-0-million-equity-line-yorkville/Thu, 18 Jun 2026 12:00:00 GMTFinancingsThe Standby Equity Purchase Agreement lets PRF sell up to $15.0 million of shares over 36 months at 97% of recent prices. Its 2026 going-concern paragraph and $3.1 million year-end cash sit beside the new line.PRF Technologies Ltd. 6-K (2026-06-18) https://aibio.space/news/redhill-biopharma-signs-6-million-private-placement-up-19-4-million/https://aibio.space/news/redhill-biopharma-signs-6-million-private-placement-up-19-4-million/Thu, 18 Jun 2026 12:00:00 GMTFinancingsRedhill Biopharma agreed on June 18, 2026 to sell 8,571,429 ADSs at $0.70 each with two series of warrants. The upfront money is about $6 million, and the warrants add about $13.4 million only if they are exercised for cash, which the company says is not assured.Redhill Biopharma Ltd. 6-K (2026-06-18) https://aibio.space/news/sl-science-closes-horizon-space-acquisition-ii-deal-files-shell/https://aibio.space/news/sl-science-closes-horizon-space-acquisition-ii-deal-files-shell/Thu, 18 Jun 2026 12:00:00 GMTDistressSL Science Holding completed its merger with Horizon Space Acquisition II on June 12, 2026. Its shell company report says its three product candidates are still in preclinical testing, and that its financial statements carry a going-concern warning.SL Science Holding Limited 20-F (2026-06-18) https://aibio.space/news/xencor-holders-approve-4-000-000-share-increase-2023-equity-plan/https://aibio.space/news/xencor-holders-approve-4-000-000-share-increase-2023-equity-plan/Thu, 18 Jun 2026 12:00:00 GMTListingsThe annual meeting on June 16, 2026 also elected nine directors and ratified KPMG LLP as auditor.Xencor, Inc. 8-K (2026-06-18) https://aibio.space/news/aspira-womens-health-names-interim-ceo-after-buhle-exit/https://aibio.space/news/aspira-womens-health-names-interim-ceo-after-buhle-exit/Wed, 17 Jun 2026 12:00:00 GMTCompany UpdatesChairman John Fraser takes over as interim chief executive effective June 17, 2026, while the board searches for a permanent CEO. Terms of Michael Buhle's separation agreement are not yet final.Aspira Women's Health Inc. 8-K (2026-06-22) https://aibio.space/news/protokinetix-names-keith-brunt-president-adds-two-directors/https://aibio.space/news/protokinetix-names-keith-brunt-president-adds-two-directors/Wed, 17 Jun 2026 12:00:00 GMTCompany UpdatesProtoKinetix appointed Keith Brunt as a director and president and added Michael Jones and Jason Lamp to its board on June 17, 2026, after a March 31, 2026 resignation.ProtoKinetix, Inc. 8-K (2026-06-17) https://aibio.space/news/azitra-pauses-netherton-trial-moves-capital-cosmetics-proteins/https://aibio.space/news/azitra-pauses-netherton-trial-moves-capital-cosmetics-proteins/Wed, 17 Jun 2026 12:00:00 GMTCompany UpdatesIn a letter to shareholders issued June 17, 2026, CEO Francisco Salva said the company will redirect funds from ATR-12 enrollment to a filaggrin cosmetic ingredient and recombinant protein work.Azitra Inc 8-K (2026-06-17) https://aibio.space/news/jaguar-health-amends-streeterville-uptown-royalty-deals-extends-note/https://aibio.space/news/jaguar-health-amends-streeterville-uptown-royalty-deals-extends-note/Wed, 17 Jun 2026 12:00:00 GMTDebt FinancingJaguar Health's monthly royalty minimums of $750,000.00 now start October 1, 2026 under both royalty interests, and a Streeterville note matures October 1, 2026 instead of July 1. Streeterville also received common stock for Series Q preferred shares.SEC Form 8-K https://aibio.space/news/adaptive-biotechnologies-prices-upsized-300-million-convertible-notes/https://aibio.space/news/adaptive-biotechnologies-prices-upsized-300-million-convertible-notes/Wed, 17 Jun 2026 12:00:00 GMTDebt FinancingAdaptive Biotechnologies priced $300 million of 0% convertible senior notes due 2031, upsized from $250 million. J. Wood Capital Advisors LLC, its financial advisor on the offering, agreed to purchase about $10 million of shares.Adaptive Biotechnologies Corporation 8-K (2026-06-22) https://aibio.space/news/omeros-agrees-repurchase-up-16-0-million-convertible-notes/https://aibio.space/news/omeros-agrees-repurchase-up-16-0-million-convertible-notes/Wed, 17 Jun 2026 12:00:00 GMTDebt FinancingOmeros agreed to repurchase up to about $16.0 million of 9.50% convertible notes due 2029 for a total of up to about $34.0 million. The final price depends on the stock's trading in an averaging period that began June 18, 2026.SEC Form 8-K https://aibio.space/news/gossamer-bio-completes-exchange-2027-convertible-notes-secured-notes/https://aibio.space/news/gossamer-bio-completes-exchange-2027-convertible-notes-secured-notes/Wed, 17 Jun 2026 12:00:00 GMTDebt FinancingGossamer Bio's exchange of 2027 convertible notes drew $181,052,000 of tenders, and $18,948,000 of the old notes remain outstanding under a supplemental indenture that strips most covenants. The new notes are secured first-lien debt.SEC Form 8-K https://aibio.space/news/rigel-pharmaceuticals-completes-vepdegestrant-license-pays-70-0/https://aibio.space/news/rigel-pharmaceuticals-completes-vepdegestrant-license-pays-70-0/Wed, 17 Jun 2026 12:00:00 GMTMergersThe license for VEPPANU (vepdegestrant) became effective after the Hart-Scott-Rodino waiting period ended early. Rigel paid the licensors, Arvinas and Pfizer, a one-time upfront payment of $70.0 million.RIGEL PHARMACEUTICALS INC Form 8-K filed June 17, 2026 (SEC EDGAR) https://aibio.space/news/lakewood-amedex-biotherapeutics-sets-1-10-reverse-split-trading-june/https://aibio.space/news/lakewood-amedex-biotherapeutics-sets-1-10-reverse-split-trading-june/Wed, 17 Jun 2026 12:00:00 GMTListingsOutstanding shares will fall from about 17,506,577 to about 1,750,789. The stock stays on the Nasdaq Capital Market as LABT.Lakewood-Amedex Biotherapeutics Inc. 8-K (2026-06-17) https://aibio.space/news/legend-biotech-launches-225-000-000-ads-offering-then-prices-7-700-000/https://aibio.space/news/legend-biotech-launches-225-000-000-ads-offering-then-prices-7-700-000/Wed, 17 Jun 2026 12:00:00 GMTFinancingsThe offering totals $225,995,000 before underwriting discounts. Underwriters hold a 30-day option for 1,155,000 more ADSs, and closing was expected on June 23, 2026. The shares priced below the last sale price of $33.52.Legend Biotech Corporation 424B5 (2026-06-17) https://aibio.space/news/rigel-completes-vepdegestrant-license-arvinas-pfizer-pays-70-0-million/https://aibio.space/news/rigel-completes-vepdegestrant-license-arvinas-pfizer-pays-70-0-million/Wed, 17 Jun 2026 12:00:00 GMTMergersRigel paid the licensors a one-time upfront payment of $70.0 million after the antitrust waiting period ended early. The 8-K describes no milestones, royalties or clinical details for the drug.Rigel Pharmaceuticals, Inc. 8-K (2026-06-17) https://aibio.space/news/nuwellis-appoints-mike-mccormick-chief-executive-officer/https://aibio.space/news/nuwellis-appoints-mike-mccormick-chief-executive-officer/Tue, 16 Jun 2026 12:00:00 GMTCompany UpdatesJohn Erb steps back from the executive role and remains Chairman of the Board, and the new chief executive takes over on June 30, 2026.Nuwellis, Inc. 8-K (2026-06-18) https://aibio.space/news/dyne-therapeutics-draws-50-0-million-more-under-hercules-facility/https://aibio.space/news/dyne-therapeutics-draws-50-0-million-more-under-hercules-facility/Tue, 16 Jun 2026 12:00:00 GMTDebt FinancingDyne Therapeutics' Hercules facility now totals up to $400.0 million, with $200.0 million outstanding after a $50.0 million draw on June 16, 2026. Hercules Capital, Inc. is administrative agent and collateral agent for the lenders.Dyne Therapeutics, Inc. 8-K (2026-06-17) https://aibio.space/news/prestige-consumer-healthcare-closes-1-045-billion-breathe-right/https://aibio.space/news/prestige-consumer-healthcare-closes-1-045-billion-breathe-right/Tue, 16 Jun 2026 12:00:00 GMTMergersPrestige Consumer Healthcare (NYSE: PBH) completed the Breathe Right purchase for $1.045 billion in cash and entered a Term Loan Credit Agreement. It also raised its asset-based revolver commitments to $225 million.Prestige Consumer Healthcare Inc. Form 8-K filed June 16, 2026 (SEC EDGAR) https://aibio.space/news/lifeloc-completes-spindetect-disk-tooling-sets-staged-rollout/https://aibio.space/news/lifeloc-completes-spindetect-disk-tooling-sets-staged-rollout/Mon, 15 Jun 2026 12:00:00 GMTCompany UpdatesLifeloc completed production tooling for its SpinDetect test disks, commissioned a cleanroom, and expects a commercial launch in late 2026 or early 2027.Lifeloc Technologies, Inc 8-K (2026-06-16) https://aibio.space/news/global-innovative-platforms-updates-shareholders-studies-board/https://aibio.space/news/global-innovative-platforms-updates-shareholders-studies-board/Mon, 15 Jun 2026 12:00:00 GMTCompany UpdatesThe June 2026 letter reports an eight-month heartworm study begun April 1, 2026, a FINRA application submitted June 12, 2026, and a collaboration paying approximately $15,000 to $18,000 a month.Form 8-K, Exhibit 99.1 (SEC EDGAR) https://aibio.space/news/aim-immunotech-regains-nyse-american-stockholders-equity-compliance/https://aibio.space/news/aim-immunotech-regains-nyse-american-stockholders-equity-compliance/Mon, 15 Jun 2026 12:00:00 GMTListingsThe NYSE American said on June 12, 2026 that AIM had resolved its stockholders' equity deficiencies after a series of share sales and warrant exercises in May and June.AIM ImmunoTech Inc. 8-K (2026-06-15) https://aibio.space/news/polomar-health-ends-altanine-merger-patent-license/https://aibio.space/news/polomar-health-ends-altanine-merger-patent-license/Mon, 15 Jun 2026 12:00:00 GMTDistressPolomar and Altanine terminated their merger agreement as of June 12, 2026, and ended a related patent license. Polomar has until September 7, 2026, to sell remaining inventory under that license.Polomar Health Services, Inc. 8-K (2026-06-15) https://aibio.space/news/pds-biotechnology-closes-6-000-000-note-ya-ii-pn/https://aibio.space/news/pds-biotechnology-closes-6-000-000-note-ya-ii-pn/Mon, 15 Jun 2026 12:00:00 GMTDebt FinancingPDS Biotechnology's $6,000,000 note carries a 10% rate, a warrant for 2,158,274 shares and a twelve-month term. Yorkville Securities, an affiliate of the investor, is one of two sales agents for a $50,000,000 at-the-market program.PDS Biotechnology Corporation 8-K (2026-06-15) https://aibio.space/news/adaptive-biotechnologies-plans-250-million-convertible-notes/https://aibio.space/news/adaptive-biotechnologies-plans-250-million-convertible-notes/Mon, 15 Jun 2026 12:00:00 GMTDebt FinancingAdaptive Biotechnologies plans a $250 million offering of convertible senior notes due 2031 and expects to use up to $25 million of the proceeds to repurchase common stock. The interest rate and conversion terms will be set only at pricing.SEC Form 8-K https://aibio.space/news/neumora-cut-workforce-about-35-percent-end-navacaprant-after-phase-3/https://aibio.space/news/neumora-cut-workforce-about-35-percent-end-navacaprant-after-phase-3/Mon, 15 Jun 2026 12:00:00 GMTDistressNeumora Therapeutics is ending development of navacaprant after its two Phase 3 KOASTAL trials in major depressive disorder missed statistical significance. It cut about 35% of its workforce and amended a loan with K2 HealthVentures, and it says its cash will last into the third quarter of 2027.Neumora Therapeutics, Inc. Form 8-K filed June 15, 2026 (SEC EDGAR) https://aibio.space/news/engene-therapeutics-cuts-workforce-about-50-percent-restructuring/https://aibio.space/news/engene-therapeutics-cuts-workforce-about-50-percent-restructuring/Mon, 15 Jun 2026 12:00:00 GMTDistressenGene Therapeutics is cutting about 50% of its workforce and expects restructuring costs of $5.7 million to $6.4 million. It reported $285.2 million of cash at April 30, 2026, while its key trial data are interim and its FDA path depends on durability data not yet in hand.enGene Therapeutics Inc. Form 8-K filed June 15, 2026 (SEC EDGAR) https://aibio.space/news/alvotech-launches-125-million-share-sale-then-prices-22-666-667-shares/https://aibio.space/news/alvotech-launches-125-million-share-sale-then-prices-22-666-667-shares/Mon, 15 Jun 2026 12:00:00 GMTFinancingsAlvotech priced 22,666,667 shares at $3.750, below its $4.24 Nasdaq close on June 15, and a private placement of 17,826,666 shares to European investors is set to add about $66.85 million.Alvotech 424B5 (2026-06-15) https://aibio.space/news/engene-cuts-about-50-percent-workforce-reports-285-2-million-cash/https://aibio.space/news/engene-cuts-about-50-percent-workforce-reports-285-2-million-cash/Mon, 15 Jun 2026 12:00:00 GMTDistressThe bladder cancer gene therapy developer stopped enrollment in three study cohorts to conserve cash. It plans to start its BLA filing in the second half of 2026.enGene Therapeutics Inc. 8-K (2026-06-15) https://aibio.space/news/rockwell-medical-holders-approve-reverse-stock-split-amendment/https://aibio.space/news/rockwell-medical-holders-approve-reverse-stock-split-amendment/Mon, 15 Jun 2026 12:00:00 GMTListingsHolders cast 16,993,038 votes for the reverse split and 6,597,036 against it at the June 12, 2026 annual meeting. The 8-K reports the result but gives no split ratio and no effective date.Rockwell Medical, Inc. 8-K (2026-06-15) https://aibio.space/news/adagio-medical-gets-nasdaq-bid-price-notice-has-until-december-9/https://aibio.space/news/adagio-medical-gets-nasdaq-bid-price-notice-has-until-december-9/Fri, 12 Jun 2026 12:00:00 GMTListingsThe company's common stock traded below $1.00 for 30 consecutive business days, and it has 180 calendar days to regain compliance.Adagio Medical Holdings, Inc. 8-K (2026-06-12) https://aibio.space/news/traws-pharma-defers-txm-challenge-study-after-negative-mhra-review/https://aibio.space/news/traws-pharma-defers-txm-challenge-study-after-negative-mhra-review/Fri, 12 Jun 2026 12:00:00 GMTCompany UpdatesTraws says a negative review by the UK regulator has deferred its planned Phase 2a influenza challenge study, and that it is advancing backup influenza compounds.Traws Pharma, Inc. SEC filing (Form 8-K) https://aibio.space/news/nasdaq-staff-says-genprex-not-eligible-bid-price-compliance-period/https://aibio.space/news/nasdaq-staff-says-genprex-not-eligible-bid-price-compliance-period/Fri, 12 Jun 2026 12:00:00 GMTListingsA June 10, 2026 Nasdaq letter said Genprex would be delisted unless it requested a hearing, because its stock closed under $1.00 for 30 consecutive business days and it had a reverse split on October 21, 2025.Genprex, Inc. 8-K (2026-06-12) https://aibio.space/news/lipellas-bankruptcy-court-approves-sale-substantially-all-assets/https://aibio.space/news/lipellas-bankruptcy-court-approves-sale-substantially-all-assets/Fri, 12 Jun 2026 12:00:00 GMTDistressA bankruptcy court approved the sale of substantially all of Lipella's assets to XRAIY LLC under an agreement dated May 14, 2026, in a chapter 11 case filed on March 30, 2026.Lipella Pharmaceuticals Inc. 8-K (2026-07-15) https://aibio.space/news/viatris-offers-650-000-000-4-250-percent-senior-notes-due-2033/https://aibio.space/news/viatris-offers-650-000-000-4-250-percent-senior-notes-due-2033/Fri, 12 Jun 2026 12:00:00 GMTDebt FinancingViatris is offering €650,000,000 of 4.250% senior notes due 2033 to repay revolving credit borrowings drawn to retire its 2026 notes. Its 2025 net loss was $3.51 billion.SEC Form 8-K https://aibio.space/news/clearmind-sells-1-000-000-convertible-notes-90-percent-principal/https://aibio.space/news/clearmind-sells-1-000-000-convertible-notes-90-percent-principal/Fri, 12 Jun 2026 12:00:00 GMTDebt FinancingClearmind Medicine will issue $1,000,000 of convertible notes for $900,000 in cash, under a one-time exception to its own $2,500,000 quarterly limit. The agreement also amends the conversion price and sets a $1.875 floor price per share.SEC Form 8-K https://aibio.space/news/rocket-pharmaceuticals-closes-180-million-sale-priority-review-voucher/https://aibio.space/news/rocket-pharmaceuticals-closes-180-million-sale-priority-review-voucher/Fri, 12 Jun 2026 12:00:00 GMTMergersRocket received $180.0 million in gross proceeds from a large pharmaceutical company. It says pro forma cash of approximately $322.6 million should fund operations into the second quarter of 2028.ROCKET PHARMACEUTICALS, INC. Form 8-K filed June 12, 2026 (SEC EDGAR) https://aibio.space/news/soligenix-gets-nasdaq-minimum-bid-price-notice-ends-hybryte-program/https://aibio.space/news/soligenix-gets-nasdaq-minimum-bid-price-notice-ends-hybryte-program/Fri, 12 Jun 2026 12:00:00 GMTListingsNasdaq told Soligenix on June 10, 2026 that its stock has closed below the $1.00 minimum bid price, and the company has until December 7, 2026 to regain compliance. Its board then ended the HyBryte development program, after an interim analysis in a Phase 3 trial recommended stopping it for futility.SOLIGENIX, INC. Form 8-K filed June 12, 2026 (SEC EDGAR) https://aibio.space/news/biocardia-believes-regained-nasdaq-stockholders-equity-compliance-2/https://aibio.space/news/biocardia-believes-regained-nasdaq-stockholders-equity-compliance-2/Fri, 12 Jun 2026 12:00:00 GMTListingsNasdaq granted BioCardia until October 7, 2026 to regain compliance. The company says at-the-market sales with H.C. Wainwright & Co. brought net proceeds of $4.9 million and that it believes equity now exceeds $2.5 million.BioCardia, Inc. Form 8-K filed June 12, 2026 (SEC EDGAR) https://aibio.space/news/celularity-gets-nasdaq-notice-market-value-listed-securities-has-until/https://aibio.space/news/celularity-gets-nasdaq-notice-market-value-listed-securities-has-until/Fri, 12 Jun 2026 12:00:00 GMTListingsNasdaq told Celularity on June 9, 2026 that its market value of listed securities was below the $35 million minimum for 30 consecutive business days. The notice does not delist the stock.Celularity Inc Form 8-K filed June 12, 2026 (SEC EDGAR) https://aibio.space/news/annexon-holders-approve-raising-authorized-common-shares-500-000-000/https://aibio.space/news/annexon-holders-approve-raising-authorized-common-shares-500-000-000/Fri, 12 Jun 2026 12:00:00 GMTListingsAnnexon's stockholders approved raising authorized common stock from 300,000,000 to 500,000,000 shares on June 11, 2026, with 8,795,454 abstentions and no reason given for the increase.Annexon, Inc. 8-K (2026-06-12) https://aibio.space/news/cuprina-holdings-regains-nasdaq-compliance-july-7-2026-hearing/https://aibio.space/news/cuprina-holdings-regains-nasdaq-compliance-july-7-2026-hearing/Fri, 12 Jun 2026 12:00:00 GMTListingsCuprina said Nasdaq staff told its hearings department the bid price shortfall was cured, and a July 7, 2026 panel hearing was cancelled. The release does not say what moved the share price, and year-end cash was $2.4 million against cash used in operations of $7.1 million.Cuprina Holdings (Cayman) Limited 6-K (2026-06-12) https://aibio.space/news/theriva-reports-phase-1-head-neck-cancer-results-journal/https://aibio.space/news/theriva-reports-phase-1-head-neck-cancer-results-journal/Thu, 11 Jun 2026 12:00:00 GMTCompany UpdatesClinical Cancer Research published the Phase 1 study of VCN-01 with durvalumab in patients whose cancer was refractory to immunotherapy.Theriva Biologics, Inc. 8-K (2026-06-11) https://aibio.space/news/adial-acquires-azora-therapeutics-announces-up-64-million-financing/https://aibio.space/news/adial-acquires-azora-therapeutics-announces-up-64-million-financing/Thu, 11 Jun 2026 12:00:00 GMTMergersThe deal adds AT177, a colon-targeted AhR agonist for ulcerative colitis, to Adial's pipeline, with about $32 million in initial gross proceeds and up to $32 million more tied to Phase 1 initiation.Adial Pharmaceuticals, Inc 8-K (2026-06-11) https://aibio.space/news/iqvia-issues-950-000-000-4-625-percent-senior-notes-due-2033/https://aibio.space/news/iqvia-issues-950-000-000-4-625-percent-senior-notes-due-2033/Thu, 11 Jun 2026 12:00:00 GMTDebt FinancingIQVIA's €950,000,000 of 4.625% senior notes due 2033 are governed by a June 11, 2026 indenture with U.S. Bank Trust Company, National Association as trustee. Its 2025 net income of $1.36 billion was slightly below 2024.IQVIA HOLDINGS INC. 8-K (2026-06-11) https://aibio.space/news/cdt-equity-repays-legacy-notes-signs-1-460-000-jj-astor-loan/https://aibio.space/news/cdt-equity-repays-legacy-notes-signs-1-460-000-jj-astor-loan/Thu, 11 Jun 2026 12:00:00 GMTDebt FinancingCDT Equity agreed to pay off its Alliance Global Partners and Ascent Partners loans and signed a loan of up to $1,460,000 with JJ Astor & Co, which it says is now its only loan facility. Its 2025 net loss was $39.2 million.CDT Equity Inc. 8-K (2026-06-16) https://aibio.space/news/xeris-exchanges-23-million-2028-convertible-notes-cash-stock/https://aibio.space/news/xeris-exchanges-23-million-2028-convertible-notes-cash-stock/Thu, 11 Jun 2026 12:00:00 GMTDebt FinancingXeris will retire about $23 million of its 8.00% convertible notes due 2028 for about $23 million in cash plus common stock, with Morgan Stanley as placement agent. About $10.5 million of the notes will remain outstanding.SEC Form 8-K https://aibio.space/news/parabilis-medicines-closes-private-placement-4-166-666-shares/https://aibio.space/news/parabilis-medicines-closes-private-placement-4-166-666-shares/Thu, 11 Jun 2026 12:00:00 GMTFinancingsParabilis Medicines (Nasdaq: PBLS) sold shares to Regeneron at 90% of the $20.00 IPO price under a Stock Purchase Agreement dated June 9, 2026. The placement closed June 11, 2026.Parabilis Medicines, Inc. Form 8-K filed June 11, 2026 (SEC EDGAR) https://aibio.space/news/enliven-therapeutics-launches-250-000-000-offering-then-prices-upsized/https://aibio.space/news/enliven-therapeutics-launches-250-000-000-offering-then-prices-upsized/Thu, 11 Jun 2026 12:00:00 GMTFinancingsThe final terms total $399,998,279.17 in shares and pre-funded warrants before underwriting discounts. The offering was expected to close on or about June 15, 2026.Enliven Therapeutics, Inc. 424B5 (2026-06-11) https://aibio.space/news/veraxa-biotech-closes-voyager-spac-merger-nasdaq-trading-starts-june/https://aibio.space/news/veraxa-biotech-closes-voyager-spac-merger-nasdaq-trading-starts-june/Thu, 11 Jun 2026 12:00:00 GMTMergersVeraxa Biotech says its business combination with Voyager Acquisition Corp. has closed, and its shares and warrants were due to start trading on the Nasdaq Capital Market on June 11, 2026. The company cites a $27.5 million senior secured note and a share purchase agreement for up to $50 million.Veraxa Biotech AG 6-K (2026-06-11) https://aibio.space/news/bio-green-med-sells-1-103-338-shares-foreign-investors-794-403/https://aibio.space/news/bio-green-med-sells-1-103-338-shares-foreign-investors-794-403/Wed, 10 Jun 2026 12:00:00 GMTFinancingsThe sale at $0.72 per share closed on June 10, 2026 under Regulation S, and the filing names no underwriter, placement agent or financial advisor.Bio Green Med Solution, Inc. 8-K (2026-06-10) https://aibio.space/news/palisade-bio-adds-jordan-zwick-board-raises-authorized-shares/https://aibio.space/news/palisade-bio-adds-jordan-zwick-board-raises-authorized-shares/Wed, 10 Jun 2026 12:00:00 GMTCompany UpdatesThe annual meeting on June 10, 2026 approved raising authorized common stock from 300,000,000 to 450,000,000 shares. Stockholders also approved two amended equity plans.Palisade Bio, Inc. 8-K (2026-06-11) https://aibio.space/news/aethlon-medical-reports-fiscal-2026-results-enters-third-cohort/https://aibio.space/news/aethlon-medical-reports-fiscal-2026-results-enters-third-cohort/Wed, 10 Jun 2026 12:00:00 GMTCompany UpdatesAethlon Medical reported a net loss of $7.2 million for the fiscal year ended March 31, 2026, and said its Australian oncology study has entered its third and final dosing cohort.Aethlon Medical 8-K (2026-06-10) https://aibio.space/news/biorestorative-sets-up-1-000-000-revolving-loan-bowery-group/https://aibio.space/news/biorestorative-sets-up-1-000-000-revolving-loan-bowery-group/Wed, 10 Jun 2026 12:00:00 GMTDebt FinancingBioRestorative Therapies can borrow up to $1,000,000 from Bowery Group LLC at 12%, and the same agreement brought three director resignations and three new directors designated by the lender. Its cash use in 2025 was $10.8 million.SEC Form 8-K https://aibio.space/news/precision-biosciences-extends-banc-california-term-loan/https://aibio.space/news/precision-biosciences-extends-banc-california-term-loan/Wed, 10 Jun 2026 12:00:00 GMTDebt FinancingPrecision BioSciences has moved the maturity of its Banc of California term loan from June 30, 2027 to December 31, 2029. The company used $65.8 million in operations in 2025 and ended 2024 with $85.9 million in cash and cash equivalents.Precision BioSciences, Inc. 8-K (2026-06-16) https://aibio.space/news/aptorum-group-now-niki-biosolutions-shareholders-approve-diamir-merger/https://aibio.space/news/aptorum-group-now-niki-biosolutions-shareholders-approve-diamir-merger/Wed, 10 Jun 2026 12:00:00 GMTListingsShareholders of both companies approved the all-stock merger on June 9, 2026. The release gives no exchange ratio, and the company's 2025 research spending was $352,879, down from $2.2 million.Niki BioSolutions, Inc. 6-K (2026-06-10) https://aibio.space/news/parabilis-medicines-prices-ipo-33-500-000-shares-20-00-670-000-000/https://aibio.space/news/parabilis-medicines-prices-ipo-33-500-000-shares-20-00-670-000-000/Wed, 10 Jun 2026 12:00:00 GMTFinancingsParabilis Medicines priced 33,500,000 shares at $20.00 each, and Regeneron agreed to buy $75.0 million of stock at 90% of the IPO price, as the company's net loss reached $145,889 thousand in 2025.Parabilis Medicines, Inc. 424B4 (2026-06-10) https://aibio.space/news/solid-biosciences-holders-approve-doubling-authorized-shares-480-000/https://aibio.space/news/solid-biosciences-holders-approve-doubling-authorized-shares-480-000/Wed, 10 Jun 2026 12:00:00 GMTListingsSolid Biosciences stockholders voted at the June 10, 2026 annual meeting to double authorized common stock to 480,000,000 shares. The vote drew 893,360 votes against, and the say-on-pay vote drew 6,203,634 against.Solid Biosciences Inc. 8-K (2026-06-10) https://aibio.space/news/voyager-therapeutics-holders-approve-doubling-common-stock-240-000-000/https://aibio.space/news/voyager-therapeutics-holders-approve-doubling-common-stock-240-000-000/Wed, 10 Jun 2026 12:00:00 GMTListingsVoyager Therapeutics' stockholders approved on June 9, 2026 an increase in authorized common stock from 120,000,000 to 240,000,000 shares, and in total authorized capital stock from 125,000,000 to 245,000,000. The 8-K gives no reason for the increase.Voyager Therapeutics, Inc. 8-K (2026-06-10) https://aibio.space/news/bluejay-stockholders-approve-reverse-split-authority/https://aibio.space/news/bluejay-stockholders-approve-reverse-split-authority/Tue, 09 Jun 2026 12:00:00 GMTListingsStockholders approved a reverse split at a fixed ratio between 1-for-2 and 1-for-20, but the board has no present intention to carry it out in the next 12 months.Bluejay Diagnostics, Inc. 8-K (2026-06-09) https://aibio.space/news/aditxt-signs-deal-take-ignite-proteomics-public-150-million-value/https://aibio.space/news/aditxt-signs-deal-take-ignite-proteomics-public-150-million-value/Tue, 09 Jun 2026 12:00:00 GMTMergersAditxt, Inc. signed a definitive business combination agreement for Ignite Proteomics, LLC, its 100%-owned subsidiary, at an implied equity value of approximately $150 million. Ignite would become an independent public company through a newly formed holding company.Aditxt, Inc. 8-K (2026-06-10) https://aibio.space/news/cocrystal-names-james-sapirstein-chief-executive-officer/https://aibio.space/news/cocrystal-names-james-sapirstein-chief-executive-officer/Tue, 09 Jun 2026 12:00:00 GMTCompany UpdatesAn 8-K filed June 9, 2026 sets out the offer letter for the new chief executive, who replaces two co-chief executives.Cocrystal Pharma, Inc. 8-K (2026-06-09) https://aibio.space/news/enveric-files-2-425-000-market-offering-supplement-h-c-wainwright/https://aibio.space/news/enveric-files-2-425-000-market-offering-supplement-h-c-wainwright/Tue, 09 Jun 2026 12:00:00 GMTFinancingsThe prospectus supplement adds $2,425,000 of common stock to an at-the-market agreement with H.C. Wainwright & Co., LLC, following $4,483,711.04 already sold under it.Enveric Biosciences 8-K https://aibio.space/news/idorsia-takes-up-chf-250-million-senior-secured-term-loan/https://aibio.space/news/idorsia-takes-up-chf-250-million-senior-secured-term-loan/Tue, 09 Jun 2026 12:00:00 GMTDebt FinancingThe first CHF 150 million tranche will refinance the existing New Money Facility, of which CHF 105 million has been drawn.Idorsia Ltd (2026-06-09) https://aibio.space/news/jasper-therapeutics-receives-nasdaq-minimum-bid-price-notice-has-until/https://aibio.space/news/jasper-therapeutics-receives-nasdaq-minimum-bid-price-notice-has-until/Tue, 09 Jun 2026 12:00:00 GMTListingsNasdaq notified Jasper (JSPR) on June 3, 2026 that its voting common stock closed below $1.00 for thirty consecutive business days. The notice has no immediate effect on trading; a reverse stock split is among the options named.Jasper Therapeutics, Inc. Form 8-K filed June 9, 2026 (SEC EDGAR) https://aibio.space/news/bgm-group-closes-us-12-000-000-private-placement-200-000-000-shares/https://aibio.space/news/bgm-group-closes-us-12-000-000-private-placement-200-000-000-shares/Tue, 09 Jun 2026 12:00:00 GMTFinancingsBGM Group sold 200,000,000 Class A ordinary shares at US$0.06 each, with warrants for up to another 200,000,000 shares, for gross proceeds of US$12,000,000. The private placement closed on June 8, 2026.BGM Group Ltd. 6-K (2026-06-09) https://aibio.space/news/relay-therapeutics-holders-approve-raising-authorized-shares-450-000/https://aibio.space/news/relay-therapeutics-holders-approve-raising-authorized-shares-450-000/Tue, 09 Jun 2026 12:00:00 GMTListingsCommon stock authorized rises from 300,000,000 shares. Relay filed the amendment in Delaware on June 9, 2026.Relay Therapeutics, Inc. 8-K (2026-06-09) https://aibio.space/news/metavia-shareholders-approve-reverse-split-range-1-5-1-22/https://aibio.space/news/metavia-shareholders-approve-reverse-split-range-1-5-1-22/Mon, 08 Jun 2026 12:00:00 GMTListingsAt its June 8, 2026 annual meeting, MetaVia stockholders approved a reverse split of 5 to 22 shares into one, with the ratio left to the board, and 200,000 more shares for the equity plan.MetaVia Inc. 8-K (2026-06-08) https://aibio.space/news/ptc-director-alethia-young-steps-down-stays-advisor/https://aibio.space/news/ptc-director-alethia-young-steps-down-stays-advisor/Mon, 08 Jun 2026 12:00:00 GMTCompany UpdatesAlethia Young resigned from the PTC Therapeutics board effective June 8, 2026, and will remain an advisor under a consulting agreement running through June 8, 2027.PTC Therapeutics, Inc. 8-K (2026-06-09) https://aibio.space/news/nuwellis-closes-6-0-million-public-offering-priced-0-30-share/https://aibio.space/news/nuwellis-closes-6-0-million-public-offering-priced-0-30-share/Mon, 08 Jun 2026 12:00:00 GMTFinancingsLadenburg Thalmann & Co. Inc. was sole book-running manager, and the deal included Series C warrants for up to 60,000,000 shares.Nuwellis, Inc. 8-K (2026-06-10) https://aibio.space/news/vivos-therapeutics-issues-convertible-note-up-5-000-000/https://aibio.space/news/vivos-therapeutics-issues-convertible-note-up-5-000-000/Mon, 08 Jun 2026 12:00:00 GMTDebt FinancingVivos Therapeutics can draw up to $5,000,000 under a note from V-CO Investors 4 LLC, which adds a 10% bridge fee to each amount advanced and converts into the equity of a planned financing. The lender may call the note on demand once the June 30, 2026 Outside Date has passed.SEC filing exhibit 4.1 https://aibio.space/news/celcuity-completes-575-000-000-convertible-notes-offering-repays/https://aibio.space/news/celcuity-completes-575-000-000-convertible-notes-offering-repays/Mon, 08 Jun 2026 12:00:00 GMTDebt FinancingCelcuity issued $575,000,000 of 0.250% convertible senior notes due 2032 on June 8, 2026, with net proceeds of approximately $557.0 million. It repaid its loan agreement in full the same day.Celcuity Inc. Form 8-K filed June 8, 2026 (SEC EDGAR) https://aibio.space/news/atyr-pharma-gets-180-more-days-nasdaq-meet-1-00-minimum-bid-price/https://aibio.space/news/atyr-pharma-gets-180-more-days-nasdaq-meet-1-00-minimum-bid-price/Mon, 08 Jun 2026 12:00:00 GMTListingsNasdaq gave aTyr Pharma until November 30, 2026 to regain the $1.00 minimum bid price, and the company says it may use a reverse stock split. Its lead drug missed the primary endpoint of its Phase 3 trial in September 2025.aTYR PHARMA INC Form 8-K filed June 8, 2026 (SEC EDGAR) https://aibio.space/news/biontech-starts-buyback-up-usd-1-0-billion-adss-running-may-6-2027/https://aibio.space/news/biontech-starts-buyback-up-usd-1-0-billion-adss-running-may-6-2027/Mon, 08 Jun 2026 12:00:00 GMTFinancingsBioNTech is buying back American Depositary Shares worth up to USD 1.0 billion, with the buyback period running from June 8, 2026 to May 6, 2027. The program rests on a May 17, 2024 shareholder authorization capped at 24.9 million shares, and a credit institution the company has mandated runs the purchases.BioNTech SE 6-K (2026-06-08) https://aibio.space/news/savara-holders-approve-doubling-authorized-shares-600-000-000/https://aibio.space/news/savara-holders-approve-doubling-authorized-shares-600-000-000/Mon, 08 Jun 2026 12:00:00 GMTListingsSavara stockholders approved doubling authorized common stock to 600,000,000 shares. The 8-K gives no reason for the increase, and it also reports a new CFO and COO effective July 15, 2026, after the current CFO resigns for health reasons.Savara, Inc. 8-K (2026-06-08) https://aibio.space/news/aspira-womens-health-closes-1-485-million-private-placement/https://aibio.space/news/aspira-womens-health-closes-1-485-million-private-placement/Fri, 05 Jun 2026 12:00:00 GMTFinancingsThe June 5, 2026 deal sold 3,300,000 shares at $0.45 each, with warrants to buy up to 4,455,000 more shares. The filing names no underwriter or placement agent.Aspira Women's Health Inc. 8-K (2026-06-09) https://aibio.space/news/theriva-special-meeting-fails-reach-quorum-warrant-approval/https://aibio.space/news/theriva-special-meeting-fails-reach-quorum-warrant-approval/Fri, 05 Jun 2026 12:00:00 GMTCompany UpdatesToo few shares were present for the June 5, 2026 special meeting on share issuance for warrants, and the company must call another meeting.Theriva Biologics, Inc. 8-K (2026-06-05) https://aibio.space/news/petros-grants-7-000-000-restricted-shares-directors-officers/https://aibio.space/news/petros-grants-7-000-000-restricted-shares-directors-officers/Fri, 05 Jun 2026 12:00:00 GMTCompany UpdatesThe board approved restricted share awards on June 5, 2026, to the chairman, two directors and the president and chief commercial officer.Petros Pharmaceuticals, Inc. 8-K (2026-06-05) https://aibio.space/news/osr-health-postpones-2026-annual-meeting-no-new-date-set/https://aibio.space/news/osr-health-postpones-2026-annual-meeting-no-new-date-set/Fri, 05 Jun 2026 12:00:00 GMTCompany UpdatesThe board postponed the annual stockholder meeting that had been scheduled for June 18, 2026, and said it has not yet set a new date.OSR Health, Inc. 8-K (2026-06-11) https://aibio.space/news/igc-pharma-extends-12-000-000-bank-credit-facility-o-bank/https://aibio.space/news/igc-pharma-extends-12-000-000-bank-credit-facility-o-bank/Fri, 05 Jun 2026 12:00:00 GMTDebt FinancingIGC Pharma has extended its $12,000,000 bank facility with O-Bank, and the facility fee rises from $48,000 to $60,000. The filing gives no amount drawn and no interest rate.SEC EDGAR https://aibio.space/news/cerus-takes-up-65-0-million-secured-term-loan-midcap/https://aibio.space/news/cerus-takes-up-65-0-million-secured-term-loan-midcap/Fri, 05 Jun 2026 12:00:00 GMTDebt FinancingCerus has restated its two MidCap credit agreements, borrowing a first $35.0 million on a term loan that can reach $65.0 million. Its revolver had $29.9 million outstanding at closing, and the term loan is priced at Term SOFR plus 5.50%.SEC Form 8-K https://aibio.space/news/inotiv-enters-65-5-million-dip-credit-agreement-after-chapter-11/https://aibio.space/news/inotiv-enters-65-5-million-dip-credit-agreement-after-chapter-11/Fri, 05 Jun 2026 12:00:00 GMTDebt FinancingInotiv's $65.5 million debtor-in-possession facility includes $25,000,000 of new money and rolls up $40,521,753.47 of prepetition bridge loans into superpriority term loans. Both tranches pay interest in kind at Adjusted Term SOFR plus 11.5%.Inotiv, Inc. 8-K (2026-06-08) https://aibio.space/news/solid-biosciences-updates-resale-prospectus-add-selling-stockholders/https://aibio.space/news/solid-biosciences-updates-resale-prospectus-add-selling-stockholders/Fri, 05 Jun 2026 12:00:00 GMTFinancingsSolid Biosciences filed a prospectus supplement on June 5, 2026 that adds holders who bought shares from existing selling stockholders. Several holders in the table are offering their entire stake, and the company says it does not know when or in what amounts they will sell.Solid Biosciences Inc. 424B7 (2026-06-05) https://aibio.space/news/kairos-pharma-signs-cl-741-term-sheet-lists-milestones-2026/https://aibio.space/news/kairos-pharma-signs-cl-741-term-sheet-lists-milestones-2026/Thu, 04 Jun 2026 12:00:00 GMTCompany UpdatesKairos Pharma has signed a term sheet to acquire worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor, from privately held Celyn Therapeutics, Inc., and has listed the milestones it expects for the rest of 2026.Kairos Pharma, Ltd. 8-K (2026-06-04) https://aibio.space/news/aim-immunotech-releases-video-segment-ebola-ampligen/https://aibio.space/news/aim-immunotech-releases-video-segment-ebola-ampligen/Thu, 04 Jun 2026 12:00:00 GMTCompany UpdatesThe company said on June 4, 2026 that its virtual investor video discusses Ampligen's Ebola research, and that an updated Ebola-focused presentation is available on its website.AIM ImmunoTech Inc. 8-K (2026-06-04) https://aibio.space/news/bio-green-med-agrees-all-stock-deal-acquire-future-nrg/https://aibio.space/news/bio-green-med-agrees-all-stock-deal-acquire-future-nrg/Thu, 04 Jun 2026 12:00:00 GMTMergersA Business Combination Agreement would make Future NRG Sdn. Bhd., a Malaysian medical waste treatment company, a wholly owned subsidiary of Bio Green Med Solution, with closing expected in the fourth quarter of 2026.Bio Green Med Solution, Inc. 8-K (2026-06-04) https://aibio.space/news/imunon-raise-10-million-through-preferred-stock-secured-notes/https://aibio.space/news/imunon-raise-10-million-through-preferred-stock-secured-notes/Thu, 04 Jun 2026 12:00:00 GMTDebt FinancingIMUNON has sold $10 million of preferred stock and two secured notes to Streeterville Capital, with half placed in a collateral account, to fund its Phase 3 OVATION 3 trial. The company used $13.9 million in operations in 2025.SEC EDGAR https://aibio.space/news/luye-pharma-issue-us-180-000-000-bonds-due-2031/https://aibio.space/news/luye-pharma-issue-us-180-000-000-bonds-due-2031/Thu, 04 Jun 2026 12:00:00 GMTDebt FinancingLuye Pharma plans US$180,000,000 of 5.25% convertible bonds due 2031 and a concurrent repurchase of its 6.25% convertible bonds due 2028 at US$1,031.25 per US$1,000 of principal. The announcement says the two transactions may or may not complete.Luye Pharma Group Ltd. announcement (2026-06-04) https://aibio.space/news/syndax-agrees-250-0-million-private-placement-2-25-percent-convertible/https://aibio.space/news/syndax-agrees-250-0-million-private-placement-2-25-percent-convertible/Thu, 04 Jun 2026 12:00:00 GMTDebt FinancingSyndax Pharmaceuticals agreed on June 3, 2026 to issue $250.0 million of 2.25% convertible notes due 2031 in a private placement, with about $243 million of net proceeds expected. J. Wood Capital Advisors LLC is the sole placement agent, and the company's 2025 net loss was $285.4 million.Syndax Pharmaceuticals Inc Form 8-K filed June 4, 2026 (SEC EDGAR) https://aibio.space/news/fulcrum-therapeutics-cut-workforce-approximately-85-percent-reviews/https://aibio.space/news/fulcrum-therapeutics-cut-workforce-approximately-85-percent-reviews/Thu, 04 Jun 2026 12:00:00 GMTDistressThe restructuring follows the discontinuation of pociredir for sickle cell disease and carries expected charges of approximately $4.2 million. Leerink Partners LLC is advising the board.Fulcrum Therapeutics, Inc. Form 8-K filed June 4, 2026 (SEC EDGAR) https://aibio.space/news/onkure-therapeutics-holders-approve-equity-plan-adding-3-231-638/https://aibio.space/news/onkure-therapeutics-holders-approve-equity-plan-adding-3-231-638/Thu, 04 Jun 2026 12:00:00 GMTListingsThe amended 2024 plan also drops a cap on its annual share increase. The vote came at the June 3, 2026 annual meeting.OnKure Therapeutics, Inc. 8-K (2026-06-04) https://aibio.space/news/syndax-agrees-sell-250-0-million-2-25-percent-convertible-notes-due/https://aibio.space/news/syndax-agrees-sell-250-0-million-2-25-percent-convertible-notes-due/Thu, 04 Jun 2026 12:00:00 GMTDebt FinancingSyndax estimates net proceeds of about $243 million from the notes after the placement agent's fees and expenses. The 2.25% notes mature on June 15, 2031, and the conversion price is about $24.76 per share.Syndax Pharmaceuticals, Inc. 8-K (2026-06-04) https://aibio.space/news/trevi-therapeutics-holders-approve-doubling-authorized-shares-400-000/https://aibio.space/news/trevi-therapeutics-holders-approve-doubling-authorized-shares-400-000/Thu, 04 Jun 2026 12:00:00 GMTListingsTrevi stockholders voted to double authorized common stock to 400,000,000 shares and to add 8,000,000 shares to the stock incentive plan. The lead cough drug has no Phase 3 results yet, and the 2025 net loss was $42.8 million.Trevi Therapeutics, Inc. 8-K (2026-06-04) https://aibio.space/news/valneva-registers-resale-up-31-787-634-ordinary-shares-selling-holders/https://aibio.space/news/valneva-registers-resale-up-31-787-634-ordinary-shares-selling-holders/Thu, 04 Jun 2026 12:00:00 GMTFinancingsValneva filed a Form F-3 on June 4, 2026 to register the resale of up to 31,787,634 ordinary shares tied to its April 29 private placement. Valneva says it will receive no proceeds from the resale.Valneva SE F-3 (2026-06-04) https://aibio.space/news/minerva-stockholders-approve-charter-changes-officer-liability-forum/https://aibio.space/news/minerva-stockholders-approve-charter-changes-officer-liability-forum/Wed, 03 Jun 2026 12:00:00 GMTCompany UpdatesAt its June 3, 2026 annual meeting, Minerva's stockholders approved two charter amendments, and the board adopted amended bylaws the same day.Minerva Neurosciences, Inc 8-K (2026-06-04) https://aibio.space/news/cocrystal-appoints-james-sapirstein-chief-executive-officer/https://aibio.space/news/cocrystal-appoints-james-sapirstein-chief-executive-officer/Wed, 03 Jun 2026 12:00:00 GMTCompany UpdatesThe antiviral developer names a former biopharma chief executive with 23 product launches to lead the company, effective immediately.Cocrystal Pharma, Inc. 8-K (2026-06-03) https://aibio.space/news/conmed-agrees-buy-back-2-250-percent-convertible-notes-due-2027-cash/https://aibio.space/news/conmed-agrees-buy-back-2-250-percent-convertible-notes-due-2027-cash/Wed, 03 Jun 2026 12:00:00 GMTDebt FinancingCONMED will repurchase its 2.250% convertible notes due 2027 for cash under a purchase agreement dated June 3, 2026, with closing set for June 15, 2026. The principal and cash amounts sit in an exhibit the filing does not show.CONMED Corp 8-K (2026-06-04) https://aibio.space/news/fonar-closes-merger-20-million-term-loan-15-million-revolver/https://aibio.space/news/fonar-closes-merger-20-million-term-loan-15-million-revolver/Wed, 03 Jun 2026 12:00:00 GMTDebt FinancingFONAR's merger closed on June 3, 2026, and the company is now a wholly owned subsidiary of FONAR, LLC. As a borrower and guarantor under a new OceanFirst Bank credit agreement, it is bound by a $20 million term loan facility and a $15 million revolving facility secured by substantially all assets.FONAR CORP 8-K (2026-06-03) https://aibio.space/news/aditxt-issues-senior-secured-convertible-notes-35-percent-discount/https://aibio.space/news/aditxt-issues-senior-secured-convertible-notes-35-percent-discount/Wed, 03 Jun 2026 12:00:00 GMTDebt FinancingAditxt has issued senior secured convertible notes that combine about $725,000 in new cash with earlier notes consolidated into them, at a 35% original issue discount. The company held $268,852 in cash at March 31, 2026.SEC Form 8-K https://aibio.space/news/gossamer-bio-exchanges-181-052-000-2027-convertible-notes/https://aibio.space/news/gossamer-bio-exchanges-181-052-000-2027-convertible-notes/Wed, 03 Jun 2026 12:00:00 GMTDebt FinancingGossamer Bio says holders of 90.526% of its 2027 convertible notes tendered early, and the company expects to issue $65,174,000 of new 7.50% secured convertible notes due 2030 at early settlement. The exchange also strips most covenants from the old indenture.SEC EDGAR https://aibio.space/news/celcuity-prices-upsized-500-000-000-convertible-notes-offering/https://aibio.space/news/celcuity-prices-upsized-500-000-000-convertible-notes-offering/Wed, 03 Jun 2026 12:00:00 GMTDebt FinancingCelcuity priced $500,000,000 of 0.250% convertible senior notes due 2032, upsized from $400,000,000, with a 30-day option for $75,000,000 more. The company plans to use the proceeds first to repay its Oxford Finance loan.Celcuity Inc. (2026-06-03) https://aibio.space/news/helix-biopharma-closes-c-3-673-000-convertible-debenture-placement/https://aibio.space/news/helix-biopharma-closes-c-3-673-000-convertible-debenture-placement/Wed, 03 Jun 2026 12:00:00 GMTDebt FinancingThe unsecured debentures carry 25.00% simple interest, mature 14 months after closing and can convert at C$1.42 per share.Helix BioPharma Corp. release (2026-06-03) https://aibio.space/news/briacell-closes-best-efforts-offering-1-449-300-shares-3-25-raising-4/https://aibio.space/news/briacell-closes-best-efforts-offering-1-449-300-shares-3-25-raising-4/Wed, 03 Jun 2026 12:00:00 GMTFinancingsBriaCell sold 1,449,300 common shares at $3.25 in a best efforts offering for gross proceeds of $4.71 million. ThinkEquity LLC was sole placement agent, with a 7.5% cash fee and warrants for 72,465 shares, and the company's 10-K carries a going-concern warning.BriaCell Therapeutics Corp. Form 8-K filed June 3, 2026 (SEC EDGAR) https://aibio.space/news/regenxbio-starts-stock-option-exchange-offer-non-executive-employees/https://aibio.space/news/regenxbio-starts-stock-option-exchange-offer-non-executive-employees/Wed, 03 Jun 2026 12:00:00 GMTMergersREGENXBIO opened an option exchange offer for non-executive employees on June 3, 2026, after stockholders approved it. Stockholders rejected a similar program for executives, and the company's 2025 annual report says the year's $193.9 million net loss and a going-concern doubt sit alongside $240.9 million of cash.REGENXBIO Inc. Form 8-K filed June 3, 2026 (SEC EDGAR) https://aibio.space/news/celcuity-proposes-400-000-000-convertible-notes-then-prices-500-000/https://aibio.space/news/celcuity-proposes-400-000-000-convertible-notes-then-prices-500-000/Wed, 03 Jun 2026 12:00:00 GMTDebt FinancingThe notes mature on August 1, 2032, carry an initial conversion price of approximately $124.53 a share, and will repay the Oxford Finance and Innovatus loan in full. The last reported sale price on June 2, 2026 was $91.42.Celcuity Inc. 424B5 (2026-06-03) https://aibio.space/news/mineralys-prices-150-million-stock-offering-26-50-fund-tanabe-royalty/https://aibio.space/news/mineralys-prices-150-million-stock-offering-26-50-fund-tanabe-royalty/Wed, 03 Jun 2026 12:00:00 GMTFinancingsMineralys sold 5,660,378 shares at $26.50, below the $28.85 last sale on June 2, 2026. The proceeds fund part of a $200.0 million upfront payment to buy back a royalty owed to Tanabe Pharma Corporation.Mineralys Therapeutics, Inc. 424B5 (2026-06-03) https://aibio.space/news/regenxbio-starts-stock-option-exchange-non-executive-employees/https://aibio.space/news/regenxbio-starts-stock-option-exchange-non-executive-employees/Wed, 03 Jun 2026 12:00:00 GMTMergersREGENXBIO started a stock option exchange for non-executive employees on June 3, 2026, after stockholders approved it at the May 29 annual meeting. Stockholders rejected a similar exchange for executives, with 21,021,531 votes against to 14,097,815 for.REGENXBIO Inc. 8-K (2026-06-03) https://aibio.space/news/bluejay-announces-u-s-manufacturing-partnership-argonaut/https://aibio.space/news/bluejay-announces-u-s-manufacturing-partnership-argonaut/Tue, 02 Jun 2026 12:00:00 GMTCompany UpdatesThe strategic partnership with Argonaut Manufacturing Services aims to build U.S.-based manufacturing for the Symphony platform and reduce reliance on overseas sourcing.Bluejay Diagnostics, Inc. 8-K (2026-06-02) https://aibio.space/news/inotiv-plans-326-million-debt-cut-through-prepackaged-chapter-11/https://aibio.space/news/inotiv-plans-326-million-debt-cut-through-prepackaged-chapter-11/Tue, 02 Jun 2026 12:00:00 GMTDebt FinancingInotiv's prepackaged Chapter 11 plan would cut about $326 million of funded debt, convert a substantial portion of it into equity and cancel existing equity interests.Inotiv, Inc. 8-K (2026-06-03) https://aibio.space/news/mineralys-signs-up-500-0-million-senior-secured-term-loan/https://aibio.space/news/mineralys-signs-up-500-0-million-senior-secured-term-loan/Tue, 02 Jun 2026 12:00:00 GMTDebt FinancingMineralys can draw $100.0 million at closing on a $500.0 million loan, while the next $150.0 million depends on FDA approval of lorundrostat, and it owes Tanabe a $200.0 million cash payment.SEC EDGAR https://aibio.space/news/sensus-healthcare-signs-15-000-000-revolving-note-city-national-bank/https://aibio.space/news/sensus-healthcare-signs-15-000-000-revolving-note-city-national-bank/Tue, 02 Jun 2026 12:00:00 GMTDebt FinancingCity National Bank of Florida will lend up to $15,000,000 under a revolving note that matures June 5, 2027.Sensus Healthcare, Inc. 8-K (2026-06-05) https://aibio.space/news/maravai-lifesciences-signs-150-0-million-term-loan-30-0-million/https://aibio.space/news/maravai-lifesciences-signs-150-0-million-term-loan-30-0-million/Tue, 02 Jun 2026 12:00:00 GMTDebt FinancingA new credit agreement refinances a 2020 facility, with BSP Agency, LLC as administrative and collateral agent.MARAVAI LIFESCIENCES HOLDINGS, INC. 8-K (2026-06-03) https://aibio.space/news/delaware-court-holds-heron-cinvanti-patent-claims-invalid-heron-plans/https://aibio.space/news/delaware-court-holds-heron-cinvanti-patent-claims-invalid-heron-plans/Tue, 02 Jun 2026 12:00:00 GMTLegalThe court ruled June 1, 2026 in Heron's patent suit against Azurity Pharmaceuticals and Slayback Pharma entities. Heron says it will appeal to the Federal Circuit and that the ruling does not affect a prior settlement.HERON THERAPEUTICS, INC. /DE/ Form 8-K filed June 2, 2026 (SEC EDGAR) https://aibio.space/news/silo-pharma-completes-1-15-reverse-stock-split/https://aibio.space/news/silo-pharma-completes-1-15-reverse-stock-split/Mon, 01 Jun 2026 12:00:00 GMTListingsThe Nevada certificate took effect on June 2, 2026, and shares began trading split-adjusted on Nasdaq on June 3. The ticker stays SILO under a new CUSIP number.Silo Pharma, Inc. 8-K (2026-06-03) https://aibio.space/news/teleflex-prices-500-0-million-5-875-percent-senior-notes-due-2032/https://aibio.space/news/teleflex-prices-500-0-million-5-875-percent-senior-notes-due-2032/Mon, 01 Jun 2026 12:00:00 GMTDebt FinancingTeleflex will use the proceeds, with cash on hand, to redeem its outstanding 4.625% Senior Notes due 2027. The notes are being sold in a private offering.TELEFLEX INC 8-K (2026-06-02) https://aibio.space/news/clearmind-issue-1-500-000-convertible-promissory-notes/https://aibio.space/news/clearmind-issue-1-500-000-convertible-promissory-notes/Mon, 01 Jun 2026 12:00:00 GMTDebt FinancingThe notes carry a $1,500,000 principal amount and a cash purchase price of 90% of principal. The sale falls under an investor agreement amended in April 2026.SEC filing https://aibio.space/news/nutriband-extends-5-million-related-party-credit-line-tied-kindeva/https://aibio.space/news/nutriband-extends-5-million-related-party-credit-line-tied-kindeva/Mon, 01 Jun 2026 12:00:00 GMTDebt FinancingNutriband amended its $5 million credit line with TII Jet Services, a lender in Portugal. Advances carry 7% interest and may be used only for work with Kindeva toward the fentanyl NDA.NTRB 8-K https://aibio.space/news/fulcrum-therapeutics-drops-pociredir-starts-strategic-review-after-fda/https://aibio.space/news/fulcrum-therapeutics-drops-pociredir-starts-strategic-review-after-fda/Mon, 01 Jun 2026 12:00:00 GMTDistressFulcrum ends pociredir, its lead sickle cell program, after FDA concerns about malignancy risk, and sets no timeline for its strategic review. It reported $333.3 million in cash, cash equivalents and marketable securities as of March 31, 2026.Fulcrum Therapeutics, Inc. 8-K (2026-06-01) https://aibio.space/news/american-shared-hospital-services-discloses-lender-default-notice/https://aibio.space/news/american-shared-hospital-services-discloses-lender-default-notice/Fri, 29 May 2026 12:00:00 GMTDistressFifth Third Bank's May 29, 2026 notice cites four specified events of default under the credit agreement and raises the interest rate to the default rate.American Shared Hospital Services 8-K (2026-06-04) https://aibio.space/news/enveric-stockholders-vote-reverse-split-range-larger-authorized-share/https://aibio.space/news/enveric-stockholders-vote-reverse-split-range-larger-authorized-share/Fri, 29 May 2026 12:00:00 GMTListingsThe 8-K reports the May 28, 2026 annual meeting vote counts, including a reverse split ratio of 1-for-5 to 1-for-15 set at the Board's discretion.Enveric Biosciences 8-K https://aibio.space/news/nuo-therapeutics-closes-675-000-interim-loan-12-percent-interest/https://aibio.space/news/nuo-therapeutics-closes-675-000-interim-loan-12-percent-interest/Fri, 29 May 2026 12:00:00 GMTDebt FinancingFive lenders, including a director and a holder of more than 5% of the stock, joined the interim tranche. The notes pay 12% interest in warrants rather than cash and mature December 31, 2028.Nuo Therapeutics, Inc. 8-K (2026-06-03) https://aibio.space/news/china-resources-pharmaceutical-plans-rmb5-billion-medium-term-notes/https://aibio.space/news/china-resources-pharmaceutical-plans-rmb5-billion-medium-term-notes/Fri, 29 May 2026 12:00:00 GMTDebt FinancingA wholly owned subsidiary received registration for up to RMB5 billion of medium term notes, valid for two years, with no issue announced yet.China Resources Pharmaceutical Group Limited announcement (2026-05-29) https://aibio.space/news/calidi-biotherapeutics-amends-warrant-up-17-391-304-shares-0-23-adds/https://aibio.space/news/calidi-biotherapeutics-amends-warrant-up-17-391-304-shares-0-23-adds/Fri, 29 May 2026 12:00:00 GMTFinancingsCalidi Biotherapeutics replaced a May 6 warrant for up to 17,391,304 shares at $0.23 with one that cannot be exercised until stockholders approve it. The minimum vesting amount doubles to $1,000,000 and the vesting deadline moves to September 30, 2026.Calidi Biotherapeutics, Inc. Form 8-K filed May 29, 2026 (SEC EDGAR) https://aibio.space/news/cardiff-oncology-disputes-nervianos-termination-2017-license-agreement/https://aibio.space/news/cardiff-oncology-disputes-nervianos-termination-2017-license-agreement/Fri, 29 May 2026 12:00:00 GMTLegalNerviano Medical Sciences told Cardiff on May 27, 2026 it was ending the License Agreement over a patent inventorship dispute. Cardiff, which sued NMS as defendant on May 19, says the notice is legally ineffective.Cardiff Oncology, Inc. Form 8-K filed May 29, 2026 (SEC EDGAR) https://aibio.space/news/soligenix-adds-2-956-000-market-sales-agreement/https://aibio.space/news/soligenix-adds-2-956-000-market-sales-agreement/Thu, 28 May 2026 12:00:00 GMTFinancingsSoligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,956,000.Soligenix, Inc. 8-K (2026-05-28) https://aibio.space/news/endra-expects-3-8-million-private-placement-stock-warrants/https://aibio.space/news/endra-expects-3-8-million-private-placement-stock-warrants/Thu, 28 May 2026 12:00:00 GMTFinancingsENDRA agreed on May 27, 2026 to sell 578,387 shares or prefunded warrants, with common warrants for up to 1,156,774 shares, through sole placement agent Lucid Capital Markets, LLC.ENDRA Life Sciences Inc. 8-K (2026-05-28) https://aibio.space/news/vyome-reports-first-quarter-2026-results-licensing-agreement/https://aibio.space/news/vyome-reports-first-quarter-2026-results-licensing-agreement/Thu, 28 May 2026 12:00:00 GMTCompany UpdatesVyome reported a net loss attributable to common shareholders of approximately $963,000 for the quarter ended March 31, 2026, and cash of approximately $8.8 million, while announcing an in-licensing agreement with Impetis Biosciences Limited, a TATA Enterprise.Vyome Holdings, Inc. 8-K (2026-05-29) https://aibio.space/news/nasdaq-council-upholds-abpro-holdings-delisting-otc-pink-quotation/https://aibio.space/news/nasdaq-council-upholds-abpro-holdings-delisting-otc-pink-quotation/Thu, 28 May 2026 12:00:00 GMTListingsAbpro Holdings said Nasdaq's Listing and Hearing Review Council reaffirmed the panel's decision to delist its common stock and public warrants.Abpro Holdings Form 8-K (Item 3.01) https://aibio.space/news/cdt-equity-gets-nasdaq-notice-late-first-quarter-10/https://aibio.space/news/cdt-equity-gets-nasdaq-notice-late-first-quarter-10/Thu, 28 May 2026 12:00:00 GMTListingsThe company did not file its quarterly report for the period ended March 31, 2026 on time, and it has until July 20, 2026 to submit a plan to regain compliance.CDT Equity Inc. 8-K (2026-05-28) https://aibio.space/news/foxo-licenses-epigenetics-technology-longevityfp/https://aibio.space/news/foxo-licenses-epigenetics-technology-longevityfp/Thu, 28 May 2026 12:00:00 GMTCompany UpdatesFOXO Technologies and LongevityFP Technologies, LLC signed an exclusive license on May 28, 2026. LongevityFP will pay a royalty of three percent of its net revenues, capped at $1.3 million.FOXO TECHNOLOGIES INC. 8-K (2026-05-28) https://aibio.space/news/pelthos-ceo-present-jefferies-global-healthcare-conference-june-4-2026/https://aibio.space/news/pelthos-ceo-present-jefferies-global-healthcare-conference-june-4-2026/Thu, 28 May 2026 12:00:00 GMTCompany UpdatesScott Plesha will present and hold one-on-one investor meetings in New York. The company furnished its May 28, 2026 press release and a company presentation.Pelthos Therapeutics Form 8-K https://aibio.space/news/medline-sells-1-250-0-million-750-0-million-senior-secured-notes/https://aibio.space/news/medline-sells-1-250-0-million-750-0-million-senior-secured-notes/Thu, 28 May 2026 12:00:00 GMTDebt FinancingMedline issued $1,250.0 million of 2031 notes and $750.0 million of 2033 notes, then refinanced part of its 2030 term loan into an approximately $2,750.0 million loan due 2033. The new debt is secured on substantially all assets.Medline Inc. 8-K (2026-06-02) https://aibio.space/news/cero-therapeutics-issues-937-500-convertible-note-srx-health-solutions/https://aibio.space/news/cero-therapeutics-issues-937-500-convertible-note-srx-health-solutions/Thu, 28 May 2026 12:00:00 GMTDebt FinancingThe note was sold for $750,000 and bears 10% interest, with conversion at the lesser of $0.05 or a discount to recent trading prices.SEC EDGAR https://aibio.space/news/polaryx-closes-10-million-private-placement-about-35-investors/https://aibio.space/news/polaryx-closes-10-million-private-placement-about-35-investors/Thu, 28 May 2026 12:00:00 GMTFinancingsPrices ran from $3.70 to $4.10 a share depending on commitment size. MStone Partners, the largest holder, bought $360,000 of stock.PLYX 8-K https://aibio.space/news/silexion-completes-1-10-reverse-split-third-since-late-2024/https://aibio.space/news/silexion-completes-1-10-reverse-split-third-since-late-2024/Thu, 28 May 2026 12:00:00 GMTListingsSilexion's 1-for-10 reverse share split took effect after the close of trading on May 28, 2026, and the company's warrants were repriced ten-fold with it. By autumn the company was asking shareholders for another split.SEC EDGAR: Silexion 8-K https://aibio.space/news/royalty-pharma-signs-new-1-8-billion-revolving-credit-facility/https://aibio.space/news/royalty-pharma-signs-new-1-8-billion-revolving-credit-facility/Thu, 28 May 2026 12:00:00 GMTDebt FinancingRoyalty Pharma signed a $1.8 billion unsecured revolving credit facility maturing May 22, 2031, and repaid its 2021 facility in full. The covenants cap funded debt at 4.00 times Adjusted EBITDA, and the exhibit names a different borrower from the 8-K.Royalty Pharma plc Form 8-K filed May 28, 2026 (SEC EDGAR) https://aibio.space/news/sol-gel-says-33-1-million-march-offering-52-8-million-balance-fund/https://aibio.space/news/sol-gel-says-33-1-million-march-offering-52-8-million-balance-fund/Thu, 28 May 2026 12:00:00 GMTFinancingsSol-Gel's first-quarter 2026 report shows $52.8 million in cash and securities at March 31 after a March offering of about $33.1 million, with revenue of $0.1 million and a net loss of $3.7 million. The company says the funds support operations into 2028.Sol-Gel Technologies Ltd. 6-K (2026-05-28) https://aibio.space/news/biorestorative-files-lance-alstodts-employment-agreement-terms/https://aibio.space/news/biorestorative-files-lance-alstodts-employment-agreement-terms/Wed, 27 May 2026 12:00:00 GMTCompany UpdatesThe agreement, dated May 27, 2026, sets a three-year initial term and a bonus of up to 50% of salary. Severance equals two times salary plus bonus if he is terminated without cause or resigns for good reason.BioRestorative Therapies, Inc. 8-K (2026-05-29) https://aibio.space/news/traws-pharma-unveils-dual-strike-antiviral-aimed-hantavirus-ebola/https://aibio.space/news/traws-pharma-unveils-dual-strike-antiviral-aimed-hantavirus-ebola/Wed, 27 May 2026 12:00:00 GMTCompany UpdatesTraws says a proprietary combination antiviral may have activity against hantavirus, Ebola and Lassa, and that it plans to work with the U.S. CDC and regional regulators in Africa.Traws Pharma, Inc. SEC filing (Form 8-K) https://aibio.space/news/metavia-reports-da-1726-mean-weight-reduction-9-1-percent-48-mg/https://aibio.space/news/metavia-reports-da-1726-mean-weight-reduction-9-1-percent-48-mg/Wed, 27 May 2026 12:00:00 GMTCompany UpdatesIn a late-breaking poster at the EASL Congress 2026, the company reported a 9.1% mean body-weight reduction at Day 54 in the 48 mg cohort, with no serious adverse events up to that dose.MetaVia Inc. 8-K (2026-05-27) https://aibio.space/news/aptevo-niowave-launch-50-50-radiopharmaceutical-collaboration/https://aibio.space/news/aptevo-niowave-launch-50-50-radiopharmaceutical-collaboration/Wed, 27 May 2026 12:00:00 GMTFinancingsAptevo and Niowave agreed to a 50/50 collaboration to develop up to three radiopharmaceutical oncology programs, with Niowave making an at-the-market equity investment at closing.Aptevo Therapeutics Inc. 8-K (2026-05-27) https://aibio.space/news/minerva-sets-up-75-million-market-stock-sale-leerink-partners/https://aibio.space/news/minerva-sets-up-75-million-market-stock-sale-leerink-partners/Wed, 27 May 2026 12:00:00 GMTFinancingsMinerva signed a sales agreement with Leerink Partners LLC for up to $75.0 million of common stock, and its filing also says the roluperidone Phase 3 relapse phase now runs 52 weeks.Minerva Neurosciences, Inc 8-K (2026-05-27) https://aibio.space/news/nasdaq-letter-says-aditxt-falls-below-2-500-000-equity-minimum/https://aibio.space/news/nasdaq-letter-says-aditxt-falls-below-2-500-000-equity-minimum/Wed, 27 May 2026 12:00:00 GMTListingsAditxt, Inc. received a Nasdaq letter on May 27, 2026 citing stockholders' equity of $(35,174,386) for the period ended March 31, 2026. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 11, 2026.Aditxt, Inc. 8-K (2026-05-29) https://aibio.space/news/osr-health-agrees-buy-vxm01-assets-vaximm-30-000-000/https://aibio.space/news/osr-health-agrees-buy-vxm01-assets-vaximm-30-000-000/Wed, 27 May 2026 12:00:00 GMTCompany UpdatesThe $30,000,000 price is due in full on completion of a Phase 2 study of VXM01, and the company may make voluntary partial payments before then.OSR Health, Inc. 8-K (2026-06-02) https://aibio.space/news/dermata-shareholders-approve-warrant-repricing-larger-equity-plan/https://aibio.space/news/dermata-shareholders-approve-warrant-repricing-larger-equity-plan/Wed, 27 May 2026 12:00:00 GMTListingsAt its May 27, 2026 annual meeting, Dermata Therapeutics shareholders approved raising the share reserve of its 2021 equity plan to 402,214 shares and repricing warrants for up to 120,734 shares. Three Class II directors were elected.Dermata Therapeutics, Inc. 8-K (2026-05-27) https://aibio.space/news/medicus-pharma-closes-secured-notes-streeterville-capital/https://aibio.space/news/medicus-pharma-closes-secured-notes-streeterville-capital/Wed, 27 May 2026 12:00:00 GMTDebt FinancingThe lender paid $12 million at closing and deposited $10 million in a subsidiary's account under a deposit account control agreement. The notes carry monthly cash redemptions and trigger-based increases.SEC EDGAR https://aibio.space/news/teleflex-enters-new-credit-agreement-jpmorgan-chase-agent/https://aibio.space/news/teleflex-enters-new-credit-agreement-jpmorgan-chase-agent/Wed, 27 May 2026 12:00:00 GMTDebt FinancingThe credit agreement names JPMorgan Chase Bank, N.A. as administrative agent. The company's Form 8-K describes a revolver and two term loan facilities that refinance its earlier agreement.TELEFLEX INC 8-K (2026-05-27) https://aibio.space/news/conmed-amends-jpmorgan-credit-agreement-add-delayed-draw-term-loan/https://aibio.space/news/conmed-amends-jpmorgan-credit-agreement-add-delayed-draw-term-loan/Wed, 27 May 2026 12:00:00 GMTDebt FinancingThe first omnibus amendment adds Term A-2 commitments of $450,000,000 under the company's existing credit agreement, with JPMorgan Chase Bank, N.A. as administrative agent.CONMED Corp 8-K (2026-06-01) https://aibio.space/news/biophytis-changes-hexagon-bond-facility-make-revolving/https://aibio.space/news/biophytis-changes-hexagon-bond-facility-make-revolving/Wed, 27 May 2026 12:00:00 GMTDebt FinancingBiophytis amended its straight bond financing with Hexagon Capital Fund a second time, making the facility revolving and reducing its cost.Biophytis SA release (2026-05-27) https://aibio.space/news/sintx-technologies-gets-nasdaq-stockholders-equity-deficiency-notice/https://aibio.space/news/sintx-technologies-gets-nasdaq-stockholders-equity-deficiency-notice/Wed, 27 May 2026 12:00:00 GMTListingsSINTX Technologies received a Nasdaq notice on May 22, 2026 that its stockholders' equity, about $904,000 at March 31, 2026, is below the $2.5 million minimum. It has until July 6, 2026 to submit a plan to regain compliance, and its 2025 annual report carries a going-concern paragraph.Sintx Technologies, Inc. Form 8-K filed May 27, 2026 (SEC EDGAR) https://aibio.space/news/aspira-womens-health-expands-cleveland-clinic-collaboration-ai/https://aibio.space/news/aspira-womens-health-expands-cleveland-clinic-collaboration-ai/Tue, 26 May 2026 12:00:00 GMTCompany UpdatesThe master collaboration and license agreement covers biomarker discovery, validation and analytical models for women's health diagnostics. The release states no financial terms.Aspira Women's Health Inc. 8-K (2026-05-26) https://aibio.space/news/alaunos-combines-two-aln1003-mouse-studies-one-preclinical-readout/https://aibio.space/news/alaunos-combines-two-aln1003-mouse-studies-one-preclinical-readout/Tue, 26 May 2026 12:00:00 GMTCompany UpdatesAlaunos says early, non-GLP mouse data for ALN1003 span weight, insulin resistance, adipose signaling and liver pathology.Alaunos Therapeutics, Inc. 8-K (2026-05-26) https://aibio.space/news/genprex-reports-asco-abstract-trop-2-pten-biomarkers-reqorsa/https://aibio.space/news/genprex-reports-asco-abstract-trop-2-pten-biomarkers-reqorsa/Tue, 26 May 2026 12:00:00 GMTCompany UpdatesA Genprex-supported abstract at the 2026 ASCO Annual Meeting linked Trop-2 and PTEN protein levels to progression-free survival in non-small cell lung cancer, but not in small cell lung cancer.Genprex, Inc. 8-K (2026-05-26) https://aibio.space/news/cocrystal-reports-pan-viral-inhibitors-active-against-hantavirus/https://aibio.space/news/cocrystal-reports-pan-viral-inhibitors-active-against-hantavirus/Tue, 26 May 2026 12:00:00 GMTCompany UpdatesThe company says its novel direct-acting antivirals show pan-viral activity in early in vitro work against hantavirus, bunyavirus and influenza.Cocrystal Pharma, Inc. 8-K (2026-05-26) https://aibio.space/news/scienture-cfo-resigns-narasimhan-mani-named-interim-cfo/https://aibio.space/news/scienture-cfo-resigns-narasimhan-mani-named-interim-cfo/Tue, 26 May 2026 12:00:00 GMTCompany UpdatesEric Sherb resigned as chief financial officer on May 26, 2026. Dr. Narasimhan Mani, already a director and Co-Chief Executive Officer, took the interim role the same day.Scienture Holdings, Inc. 8-K (2026-05-29) https://aibio.space/news/bio-path-cancels-planned-reverse-split-approves-treasury-plan/https://aibio.space/news/bio-path-cancels-planned-reverse-split-approves-treasury-plan/Tue, 26 May 2026 12:00:00 GMTCompany UpdatesThe company canceled a previously approved 1-30 reverse split and its board approved a digital asset treasury and a share of a court judgment held by its chief executive.Bio-Path Holdings, Inc. 8-K (2026-05-26) https://aibio.space/news/tuhura-takes-first-1-700-000-draw-parkview-revolving-credit-facility/https://aibio.space/news/tuhura-takes-first-1-700-000-draw-parkview-revolving-credit-facility/Tue, 26 May 2026 12:00:00 GMTDebt FinancingThe $50 million revolving facility from Parkview Holdings One LLC matures in April 2031. The company expects to use the first draw for general corporate purposes.SEC EDGAR https://aibio.space/news/kardigan-files-ipo-plans-nasdaq-global-market-listing-kard/https://aibio.space/news/kardigan-files-ipo-plans-nasdaq-global-market-listing-kard/Tue, 26 May 2026 12:00:00 GMTFinancingsKardigan filed an S-1 for an IPO that would list on the Nasdaq Global Market as KARD. The filing leaves the share count and price range blank, reports $287.1 million of cash and investments, and still says there is substantial doubt about its ability to continue as a going concern.Kardigan, Inc. S-1 (2026-05-26) https://aibio.space/news/cartesian-therapeutics-signs-term-loan-up-150-0-million-k2/https://aibio.space/news/cartesian-therapeutics-signs-term-loan-up-150-0-million-k2/Tue, 26 May 2026 12:00:00 GMTDebt FinancingCartesian drew $50.0 million at closing under a senior secured loan that can reach $150.0 million, with the lenders able to convert up to $15.0 million into common stock at $8.2526 a share. The loan carries a minimum cash covenant starting April 1, 2027, and the 8-K does not name the individual lenders.Cartesian Therapeutics, Inc. 8-K (2026-05-26) https://aibio.space/news/ensysce-receives-nasdaq-notice-stockholders-equity-requirement/https://aibio.space/news/ensysce-receives-nasdaq-notice-stockholders-equity-requirement/Fri, 22 May 2026 12:00:00 GMTListingsNasdaq said Ensysce Biosciences must submit a plan by July 6, 2026, to regain compliance with its $2.5 million stockholders' equity requirement, or face delisting.Ensysce Biosciences, Inc. 8-K (2026-05-22) https://aibio.space/news/foxo-settles-j-h-darbie-fees-seeks-reverse-stock-split/https://aibio.space/news/foxo-settles-j-h-darbie-fees-seeks-reverse-stock-split/Fri, 22 May 2026 12:00:00 GMTFinancingsFOXO settled amounts owed to J.H. Darbie & Co., Inc. with preferred stock and $175,000 in installments. Its majority holder approved a reverse split at a ratio of 1:1,000 to 1:10,000.FOXO TECHNOLOGIES INC. 8-K (2026-05-22) https://aibio.space/news/cartesian-therapeutics-signs-up-150-0-million-senior-secured-term/https://aibio.space/news/cartesian-therapeutics-signs-up-150-0-million-senior-secured-term/Fri, 22 May 2026 12:00:00 GMTDebt FinancingThe loans carry a variable rate of at least 8.95% and mature on June 1, 2030. Only the first $50.0 million was funded at closing, and the two later tranches depend on milestones.Cartesian Therapeutics, Inc. (2026-05-26) https://aibio.space/news/spyglass-countersues-glaukos-trade-secret-case-trial-moved-january/https://aibio.space/news/spyglass-countersues-glaukos-trade-secret-case-trial-moved-january/Fri, 22 May 2026 12:00:00 GMTLegalDefendants are SpyGlass Pharma and employee Long Doan. SpyGlass countersued Glaukos on May 22 over contract interference, and the court moved trial to January 2027.SEC EDGAR: SpyGlass Pharma 10-Q https://aibio.space/news/transcode-therapeutics-gets-nasdaq-stockholders-equity-deficiency/https://aibio.space/news/transcode-therapeutics-gets-nasdaq-stockholders-equity-deficiency/Fri, 22 May 2026 12:00:00 GMTListingsNasdaq told TransCode on May 19, 2026 that its stockholders' equity of $1,251,427 is below the $2,500,000 minimum. The company has until July 3, 2026 to submit a plan to regain compliance, and its equity had been $10,335,466 at December 31, 2025.Transcode Therapeutics, Inc. Form 8-K filed May 22, 2026 (SEC EDGAR) https://aibio.space/news/tempest-therapeutics-gets-nasdaq-notice-stockholders-equity-flags/https://aibio.space/news/tempest-therapeutics-gets-nasdaq-notice-stockholders-equity-flags/Fri, 22 May 2026 12:00:00 GMTListingsTempest reported $822,000 of stockholders' equity against Nasdaq's $2,500,000 minimum, and two director resignations leave it short of several board rules. Its 10-K already carried a going-concern warning.Tempest Therapeutics, Inc. Form 8-K filed May 22, 2026 (SEC EDGAR) https://aibio.space/news/cosmos-health-reports-first-quarter-2026-revenue-17-93-million/https://aibio.space/news/cosmos-health-reports-first-quarter-2026-revenue-17-93-million/Thu, 21 May 2026 12:00:00 GMTCompany UpdatesRevenue rose 30.7% and total liabilities fell 9.6% in the quarter, and the company said its momentum continued into the second quarter.Cosmos Health Inc. 8-K (2026-05-22) https://aibio.space/news/hcw-biologics-prices-about-4-0-million-private-placement-e-f-hutton/https://aibio.space/news/hcw-biologics-prices-about-4-0-million-private-placement-e-f-hutton/Thu, 21 May 2026 12:00:00 GMTFinancingsThe company priced 2,846,975 units at $1.405 each to a group of healthcare investors, and the warrants are exercisable at $1.28 per share.HCW Biologics press release and Form 8-K, May 21, 2026 https://aibio.space/news/senti-biosciences-issues-10-0-million-senior-secured-convertible-notes/https://aibio.space/news/senti-biosciences-issues-10-0-million-senior-secured-convertible-notes/Wed, 20 May 2026 12:00:00 GMTDebt FinancingCeladon Partners SPV 24 bought the notes, and Acquiom Agency Services LLC was named collateral agent.SEC EDGAR https://aibio.space/news/optimi-health-prices-us-ipo-2-400-000-shares-us-6-25/https://aibio.space/news/optimi-health-prices-us-ipo-2-400-000-shares-us-6-25/Wed, 20 May 2026 12:00:00 GMTFinancingsThe offering totals US$15,000,000 before fees. Optimi has been approved to list on the Nasdaq Capital Market under the symbol OPTH.Optimi Health Corp. 424B4 (2026-05-20) https://aibio.space/news/purple-biotech-files-200-000-000-replacement-shelf-atm-limited-824-331/https://aibio.space/news/purple-biotech-files-200-000-000-replacement-shelf-atm-limited-824-331/Wed, 20 May 2026 12:00:00 GMTFinancingsThe F-3 caps the Wainwright ATM at $824,331 because the public float is below $75.0 million. The filing puts the float at $4.9 million, and the ADS last traded at $3.78 on May 18, 2026.Purple Biotech Ltd. F-3 (2026-05-20) https://aibio.space/news/inmed-agrees-all-stock-merger-mentari-therapeutics/https://aibio.space/news/inmed-agrees-all-stock-merger-mentari-therapeutics/Tue, 19 May 2026 12:00:00 GMTMergersInMed and privately held Mentari Therapeutics signed a definitive merger agreement, alongside a concurrent US$290 million private placement for the combined company.InMed Pharmaceuticals Inc. 8-K (2026-05-19) https://aibio.space/news/onconetix-effect-1-10-reverse-stock-split-may-21-2026/https://aibio.space/news/onconetix-effect-1-10-reverse-stock-split-may-21-2026/Tue, 19 May 2026 12:00:00 GMTListingsThe Board fixed the ratio under a stockholder authority approved April 30, 2026, to help keep the stock above Nasdaq's $1.00 minimum bid price.Onconetix press release https://aibio.space/news/aim-immunotech-pushes-streeterville-note-maturity-june-2027/https://aibio.space/news/aim-immunotech-pushes-streeterville-note-maturity-june-2027/Tue, 19 May 2026 12:00:00 GMTDebt FinancingThe note is now due June 30, 2027. The balance is about $1.68 million after the amendment and the extension fee.AIM ImmunoTech press release (Form 8-K) https://aibio.space/news/clearmind-medicine-announces-1-10-reverse-split-effective-may-21-2026/https://aibio.space/news/clearmind-medicine-announces-1-10-reverse-split-effective-may-21-2026/Tue, 19 May 2026 12:00:00 GMTListingsThe split is part of the company's plan to regain compliance with Nasdaq's minimum bid price rule. Issued shares fall from 10,190,337 to about 1,019,033.Clearmind Medicine Inc. 6-K (2026-05-19) https://aibio.space/news/larimar-therapeutics-holders-approve-raising-authorized-shares-215-000/https://aibio.space/news/larimar-therapeutics-holders-approve-raising-authorized-shares-215-000/Tue, 19 May 2026 12:00:00 GMTListingsAuthorized common stock rises from 115,000,000 to 215,000,000 shares, against 103,882,937 shares outstanding at the March 25, 2026 record date.Larimar Therapeutics, Inc. 8-K (2026-05-19) https://aibio.space/news/parabilis-medicines-files-ipo-regeneron-agrees-buy-about-75-0-million/https://aibio.space/news/parabilis-medicines-files-ipo-regeneron-agrees-buy-about-75-0-million/Tue, 19 May 2026 12:00:00 GMTFinancingsParabilis Medicines filed its IPO registration on May 19, 2026, with a $75.0 million Regeneron private placement tied to a collaboration, while its net loss grew to $145,889 thousand in 2025.Parabilis Medicines, Inc. S-1 (2026-05-19) https://aibio.space/news/regencell-bioscience-agrees-20-0-million-registered-direct-offering-20/https://aibio.space/news/regencell-bioscience-agrees-20-0-million-registered-direct-offering-20/Tue, 19 May 2026 12:00:00 GMTFinancingsRegencell Bioscience agreed on May 19, 2026 to sell 985,222 ordinary shares at $20.30 each in a registered direct offering, about $20.0 million gross. Univest Securities, LLC is the sole placement agent and is also buying shares for its own account.Regencell Bioscience Holdings Limited 6-K (2026-05-19) https://aibio.space/news/metavia-present-three-late-breaking-abstracts-ada-2026/https://aibio.space/news/metavia-present-three-late-breaking-abstracts-ada-2026/Mon, 18 May 2026 12:00:00 GMTCompany UpdatesThree posters, one on DA-1726 and two on vanoglipel, were accepted for the American Diabetes Association Scientific Sessions in New Orleans, June 5 to 8, 2026.MetaVia Inc. 8-K (2026-05-18) https://aibio.space/news/alaunos-reports-updated-aln1003-mouse-data-insulin-liver-markers/https://aibio.space/news/alaunos-reports-updated-aln1003-mouse-data-insulin-liver-markers/Mon, 18 May 2026 12:00:00 GMTCompany UpdatesAlaunos reported non-GLP mouse data for ALN1003 on insulin resistance, adipose signaling and liver histology, and said its cash runway extends into the second quarter of 2026.Alaunos Therapeutics, Inc. 8-K (2026-05-18) https://aibio.space/news/evofem-reports-first-quarter-2026-net-loss-5-5-million/https://aibio.space/news/evofem-reports-first-quarter-2026-net-loss-5-5-million/Mon, 18 May 2026 12:00:00 GMTCompany UpdatesNet sales were $0.9 million, up from $0.8 million a year earlier. The CEO said the company looks forward to non-dilutive capital from ex-U.S. partnerships in 2026.Evofem Biosciences, Inc. 8-K (2026-05-18) https://aibio.space/news/scienture-reports-q1-2026-revenue-56-thousand-95-6-percent-gross/https://aibio.space/news/scienture-reports-q1-2026-revenue-56-thousand-95-6-percent-gross/Mon, 18 May 2026 12:00:00 GMTCompany UpdatesRevenue rose 449% from a year earlier on more Arbli orders. The company also reported $11.0 million of non-dilutive debt financing.Scienture Holdings, Inc. 8-K (2026-05-22) https://aibio.space/news/sunshine-biopharma-prices-6-0-million-public-offering-units-series/https://aibio.space/news/sunshine-biopharma-prices-6-0-million-public-offering-units-series/Mon, 18 May 2026 12:00:00 GMTFinancingsThe reasonable best efforts offering of 12,000,000 common units at $0.50 per unit is expected to close on or about May 19, 2026, with Aegis Capital Corp. as exclusive placement agent.Sunshine Biopharma Inc. 8-K (2026-05-19) https://aibio.space/news/assertios-23-50-cash-merger-would-give-2027-convertible-noteholders/https://aibio.space/news/assertios-23-50-cash-merger-would-give-2027-convertible-noteholders/Mon, 18 May 2026 12:00:00 GMTDebt FinancingThe merger with Zydus Worldwide DMCC would let noteholders require repurchase at 100% of principal plus accrued interest. Parent waived the requirement that Assertio launch a note offer.Assertio Holdings, Inc. 8-K (2026-05-18) https://aibio.space/news/gossamer-bio-launches-exchange-offer-5-00-percent-convertible-notes/https://aibio.space/news/gossamer-bio-launches-exchange-offer-5-00-percent-convertible-notes/Mon, 18 May 2026 12:00:00 GMTDebt FinancingThe offer would swap $200 million of 2027 notes for new 7.50% secured convertible notes due 2030, plus shares or prefunded warrants.SEC filing https://aibio.space/news/palatin-technologies-move-stock-listing-nyse-american-nasdaq-capital/https://aibio.space/news/palatin-technologies-move-stock-listing-nyse-american-nasdaq-capital/Mon, 18 May 2026 12:00:00 GMTListingsPalatin will switch from NYSE American to the Nasdaq Capital Market, with its last NYSE American trading day on May 28, 2026. The move needs no shareholder action, but the company's annual report carries a going-concern warning.PALATIN TECHNOLOGIES INC Form 8-K filed May 18, 2026 (SEC EDGAR) https://aibio.space/news/akari-therapeutics-files-nt-10-q-cites-public-offering-work-expected/https://aibio.space/news/akari-therapeutics-files-nt-10-q-cites-public-offering-work-expected/Mon, 18 May 2026 12:00:00 GMTDistressAkari Therapeutics says its quarterly report for the period ended March 31, 2026 will be late, partly because of work on an upcoming public offering. It also expects a material non-cash impairment charge, and its March 2026 annual report carried a going-concern paragraph.Akari Therapeutics Plc Form NT 10-Q filed May 18, 2026 (SEC EDGAR) https://aibio.space/news/nervgen-reports-16-6-million-cash-investments-after-nasdaq-listing/https://aibio.space/news/nervgen-reports-16-6-million-cash-investments-after-nasdaq-listing/Mon, 18 May 2026 12:00:00 GMTListingsNervGen's first-quarter net loss narrowed on a non-cash warrant gain, while its annual filing shows a 2025 net loss of CAD 44.1 million. The company says all its clinical plans remain subject to more funding.NervGen Pharma Corp. 6-K (2026-05-18) https://aibio.space/news/lifeloc-reports-first-quarter-2026-results-spindetect-milestone/https://aibio.space/news/lifeloc-reports-first-quarter-2026-results-spindetect-milestone/Fri, 15 May 2026 12:00:00 GMTCompany UpdatesNet revenue rose 1% to $2.294 million and the quarterly net loss narrowed. The company said production tooling for its SpinDetect drug analyzer is complete and first article disks have been delivered.Lifeloc Technologies, Inc 8-K (2026-05-19) https://aibio.space/news/healthy-extracts-acquires-adli-gummies-which-does-business-imarais/https://aibio.space/news/healthy-extracts-acquires-adli-gummies-which-does-business-imarais/Fri, 15 May 2026 12:00:00 GMTMergersHealthy Extracts Inc. acquired 100% of Adli Gummies Inc. under an agreement dated May 15, 2026. It issued secured promissory notes of $165,000 and $629,000 and shares equal to approximately 17.76% of its outstanding common stock.HEALTHY EXTRACTS INC. 8-K (2026-05-18) https://aibio.space/news/traws-pharma-reports-q1-2026-net-loss-7-1-million-financing/https://aibio.space/news/traws-pharma-reports-q1-2026-net-loss-7-1-million-financing/Fri, 15 May 2026 12:00:00 GMTCompany UpdatesTraws reports a net loss of $7.1 million for the quarter ended March 31, 2026, and says its private financing of up to $60 million supports operations into the first quarter of 2027.Traws Pharma, Inc. SEC filing (Form 8-K) https://aibio.space/news/bioxcel-reports-first-quarter-2026-results-engages-mts-health-partners/https://aibio.space/news/bioxcel-reports-first-quarter-2026-results-engages-mts-health-partners/Fri, 15 May 2026 12:00:00 GMTCompany UpdatesThe company said the FDA accepted its IGALMI at-home sNDA with a November 14, 2026 PDUFA date, and that it is reviewing strategic options. First quarter net loss was $12.7 million.BioXcel Therapeutics, Inc. 8-K (2026-05-15) https://aibio.space/news/retractable-technologies-reports-first-quarter-net-sales-7-2-million/https://aibio.space/news/retractable-technologies-reports-first-quarter-net-sales-7-2-million/Fri, 15 May 2026 12:00:00 GMTCompany UpdatesNet sales fell from $8.3 million a year earlier, the operating loss widened to $6.2 million, and the company cut its workforce by approximately 16% in April.Retractable Technologies Inc. 8-K (2026-05-15) https://aibio.space/news/mink-starts-randomized-phase-2-trial-acute-lung-injury/https://aibio.space/news/mink-starts-randomized-phase-2-trial-acute-lung-injury/Fri, 15 May 2026 12:00:00 GMTCompany UpdatesMiNK reported first quarter 2026 results and said cash and cash equivalents were approximately $9.5 million at March 31, 2026. Preliminary data from the trial are expected in the second half of 2026.MiNK Therapeutics, Inc. 8-K (2026-05-15) https://aibio.space/news/emmaus-reports-lower-first-quarter-revenue-wider-net-loss/https://aibio.space/news/emmaus-reports-lower-first-quarter-revenue-wider-net-loss/Fri, 15 May 2026 12:00:00 GMTCompany UpdatesNet revenues fell to $2.0 million as U.S. sales dropped 33%. The company reported a net loss of $3.3 million and cash of $1.1 million at March 31, 2026.Emmaus Life Sciences press release, Exhibit 99.1 to Form 8-K https://aibio.space/news/enveric-reports-first-quarter-2026-net-loss-1-6-million/https://aibio.space/news/enveric-reports-first-quarter-2026-net-loss-1-6-million/Fri, 15 May 2026 12:00:00 GMTCompany UpdatesThe company reported cash-on-hand of $4.9 million at March 31, 2026, and a cash balance of approximately $10.3 million as of May 15, 2026.Enveric Biosciences 8-K, Exhibit 99.1 https://aibio.space/news/pavmed-reports-first-quarter-2026-results-simpler-capital-structure/https://aibio.space/news/pavmed-reports-first-quarter-2026-results-simpler-capital-structure/Fri, 15 May 2026 12:00:00 GMTCompany UpdatesPAVmed ended the first quarter with $6.5 million in cash, and Lucid Diagnostics' underwritten offering netted about $17 million.PAVmed 8-K https://aibio.space/news/vycor-medical-reports-first-quarter-2026-results/https://aibio.space/news/vycor-medical-reports-first-quarter-2026-results/Fri, 15 May 2026 12:00:00 GMTCompany UpdatesRevenue for the three months ended March 31, 2026 was $458,540, an increase of $22,162, or 5%, over the 2025 period. The company said most of the growth came from international markets.VYCOR MEDICAL INC 8-K (2026-05-15) https://aibio.space/news/ensysce-reports-first-quarter-2026-results-starts-strategic-review/https://aibio.space/news/ensysce-reports-first-quarter-2026-results-starts-strategic-review/Fri, 15 May 2026 12:00:00 GMTCompany UpdatesEnsysce Biosciences reported first quarter 2026 results, said its PF614-301 Phase 3 trial reached 50% of its interim enrollment target, and began a review of strategic alternatives.Ensysce Biosciences, Inc. 8-K (2026-05-15) https://aibio.space/news/polomar-health-waives-altanine-merger-conditions-amends-ceo-pact/https://aibio.space/news/polomar-health-waives-altanine-merger-conditions-amends-ceo-pact/Fri, 15 May 2026 12:00:00 GMTDistressA May 11, 2026 consent and waiver letter sets aside several closing conditions and requires updated audited financial statements. A May 12 amendment cuts the chief executive's base salary to $19,000 a month.Polomar Health Services, Inc. 8-K (2026-05-15) https://aibio.space/news/pelthos-changes-auditor-sets-out-separation-terms-former-cfo/https://aibio.space/news/pelthos-changes-auditor-sets-out-separation-terms-former-cfo/Fri, 15 May 2026 12:00:00 GMTCompany UpdatesPelthos dismissed CBIZ CPAs P.C. and engaged Grant Thornton LLP for 2026. The filing names Francis Knuettel II, whose separation agreement provides 12 months of base salary, or $430,000.00.Pelthos Therapeutics Form 8-K https://aibio.space/news/wuxi-apptec-agrees-issue-rmb6-780-million-convertible-bonds/https://aibio.space/news/wuxi-apptec-agrees-issue-rmb6-780-million-convertible-bonds/Fri, 15 May 2026 12:00:00 GMTDebt FinancingWuXi AppTec signed a subscription agreement on May 14, 2026 for bonds with an initial conversion price of HK$153.00 per H share.WuXi AppTec Co., Ltd. announcement (2026-05-15) https://aibio.space/news/skye-bioscience-gets-nasdaq-notice-stockholders-equity-9-011-804-below/https://aibio.space/news/skye-bioscience-gets-nasdaq-notice-stockholders-equity-9-011-804-below/Fri, 15 May 2026 12:00:00 GMTListingsNasdaq says Skye's stockholders' equity of $9,011,804, reported for the quarter ended March 31, 2026, is below the $10,000,000 Global Market minimum. The company has until June 29, 2026 to submit a plan.Skye Bioscience, Inc. Form 8-K filed May 15, 2026 (SEC EDGAR) https://aibio.space/news/apimeds-pharmaceuticals-us-files-nt-10-q-says-quarterly-report-march/https://aibio.space/news/apimeds-pharmaceuticals-us-files-nt-10-q-says-quarterly-report-march/Fri, 15 May 2026 12:00:00 GMTDistressApimeds (APUS) says it needs more time to finalize financial statements for the quarter ended March 31, 2026 and expects to file within a five-calendar-day extension. Its latest 10-K carries a going concern paragraph.Apimeds Pharmaceuticals US, Inc. Form NT 10-Q filed May 15, 2026 (SEC EDGAR) https://aibio.space/news/exicure-files-nt-10-q-late-filing-notice-expects-1-827-911-first/https://aibio.space/news/exicure-files-nt-10-q-late-filing-notice-expects-1-827-911-first/Fri, 15 May 2026 12:00:00 GMTDistressExicure says it needs more time to finish its quarterly report and expects a net loss of approximately $1,827,911 for the quarter. Cash fell to about $2,504,054 by March 31, 2026, and its 10-K already carried a going-concern warning.EXICURE, INC. Form NT 10-Q filed May 15, 2026 (SEC EDGAR) https://aibio.space/news/oramed-pharmaceuticals-files-nt-10-q-says-march-31-2026-quarterly/https://aibio.space/news/oramed-pharmaceuticals-files-nt-10-q-says-march-31-2026-quarterly/Fri, 15 May 2026 12:00:00 GMTDistressOramed Pharmaceuticals says it needs more time to finish the financial statements for the quarter ended March 31, 2026, and expects to file within five calendar days of the due date. Its 2025 annual report showed a $7,675,000 Scilex note due March 31, 2026, and going-concern warnings at two companies it has invested in.ORAMED PHARMACEUTICALS INC. Form NT 10-Q filed May 15, 2026 (SEC EDGAR) https://aibio.space/news/scilex-files-nt-10-q-late-filing-notice-expects-first-quarter-10-q-may/https://aibio.space/news/scilex-files-nt-10-q-late-filing-notice-expects-first-quarter-10-q-may/Fri, 15 May 2026 12:00:00 GMTDistressScilex Holding Company says it needs more time to finish its first-quarter 2026 financial statements, including the consolidation of Vivasor Holding Company, and expects to file by May 20, 2026. Its 2025 annual report carries a going-concern warning and an accumulated deficit of about $921.8 million.Scilex Holding Co Form NT 10-Q filed May 15, 2026 (SEC EDGAR) https://aibio.space/news/os-therapies-files-nt-10-q-says-first-quarter-report-will-late-after/https://aibio.space/news/os-therapies-files-nt-10-q-says-first-quarter-report-will-late-after/Fri, 15 May 2026 12:00:00 GMTDistressOS Therapies will miss the May 15, 2026 deadline for its first-quarter 10-Q and says it expects to file within the five-day extension. The filing comes from a company whose annual report, filed March 31, 2026, carries a going-concern warning and reports $269,830 of cash at year-end.OS Therapies Inc Form NT 10-Q filed May 15, 2026 (SEC EDGAR) https://aibio.space/news/rani-therapeutics-gets-nasdaq-minimum-bid-price-notice-cfo-svai/https://aibio.space/news/rani-therapeutics-gets-nasdaq-minimum-bid-price-notice-cfo-svai/Fri, 15 May 2026 12:00:00 GMTListingsRani Therapeutics (Nasdaq: RANI) has until November 9, 2026, to regain bid price compliance. It also reported cash, cash equivalents and marketable securities of $43.4 million and a first quarter net loss of $8.0 million.Rani Therapeutics Holdings, Inc. Form 8-K filed May 15, 2026 (SEC EDGAR) https://aibio.space/news/conexeu-sciences-issues-4-342-648-shares-warrant-exercises-about-1-963/https://aibio.space/news/conexeu-sciences-issues-4-342-648-shares-warrant-exercises-about-1-963/Fri, 15 May 2026 12:00:00 GMTFinancingsWarrant holders paid approximately $1,963,967 in gross proceeds on May 12, 2026 under an incentive program. The company also raised its stockholder meeting quorum to one-third to match Nasdaq rules.Conexeu Sciences Inc. Form 8-K filed May 15, 2026 (SEC EDGAR) https://aibio.space/news/abvc-biopharma-files-nt-10-q-late-filing-notice-quarter-ended-march-31/https://aibio.space/news/abvc-biopharma-files-nt-10-q-late-filing-notice-quarter-ended-march-31/Fri, 15 May 2026 12:00:00 GMTDistressABVC says it could not finalize its Form 10-Q and XBRL exhibit before the deadline without unreasonable effort or expense. Management believes it can file within the extension period.ABVC BIOPHARMA, INC. Form NT 10-Q filed May 15, 2026 (SEC EDGAR) https://aibio.space/news/cumberland-pharmaceuticals-files-proxy-100-million-asset-sale-apotex/https://aibio.space/news/cumberland-pharmaceuticals-files-proxy-100-million-asset-sale-apotex/Fri, 15 May 2026 12:00:00 GMTMergersCumberland would receive $100 million in cash from Apotex and keep its ifetroban programs. Because Tennessee law may treat the sale as a sale of substantially all of its assets, shareholders are asked to approve it.Cumberland Pharmaceuticals Inc. PREM14A (2026-05-15) https://aibio.space/news/enlivex-gets-nasdaq-bid-price-notice-has-until-november-9-2026/https://aibio.space/news/enlivex-gets-nasdaq-bid-price-notice-has-until-november-9-2026/Fri, 15 May 2026 12:00:00 GMTListingsNasdaq said the ordinary shares closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing or trading.Enlivex Ltd. 6-K (2026-05-15) https://aibio.space/news/dogwood-reports-first-quarter-2026-results-sp16-ind-approval/https://aibio.space/news/dogwood-reports-first-quarter-2026-results-sp16-ind-approval/Thu, 14 May 2026 12:00:00 GMTCompany UpdatesDogwood reported a first quarter net loss of $5.0 million and cash on hand of $13.2 million, which it says runs into the fourth quarter of 2026.Dogwood Therapeutics, Inc. 8-K (2026-05-14) https://aibio.space/news/aditxt-plans-1-27-reverse-stock-split-effective-may-18/https://aibio.space/news/aditxt-plans-1-27-reverse-stock-split-effective-may-18/Thu, 14 May 2026 12:00:00 GMTListingsAditxt, Inc. said it will effect a 1-for-27 reverse split of its common stock at the opening of trading on May 18, 2026. The company says the split is primarily intended to bring it into compliance with Nasdaq's minimum bid price requirement.Aditxt, Inc. 8-K (2026-05-15) https://aibio.space/news/genprex-reports-preclinical-diabetes-gene-therapy-data-asgct/https://aibio.space/news/genprex-reports-preclinical-diabetes-gene-therapy-data-asgct/Thu, 14 May 2026 12:00:00 GMTCompany UpdatesResearch collaborators presented data showing the company's Pdx1 and MafA gene therapy reversed hyperglycemia in a type 2 diabetes mouse model at the 2026 ASGCT Annual Meeting in Boston.Genprex, Inc. 8-K (2026-05-14) https://aibio.space/news/biofrontera-reports-first-quarter-2026-results-regains-nasdaq-bid/https://aibio.space/news/biofrontera-reports-first-quarter-2026-results-regains-nasdaq-bid/Thu, 14 May 2026 12:00:00 GMTCompany UpdatesRevenue rose about 17% to $10.1 million in the first quarter. Nasdaq confirmed on May 6, 2026 that the company had regained compliance with its minimum bid price requirement.Biofrontera Inc. press release https://aibio.space/news/aim-immunotech-posts-kol-segment-ampligen-pancreatic-cancer/https://aibio.space/news/aim-immunotech-posts-kol-segment-ampligen-pancreatic-cancer/Thu, 14 May 2026 12:00:00 GMTCompany UpdatesThe company said the on-demand segment features an Erasmus MC surgeon who discusses named patient program results and interim data from the ongoing Phase 2 trial.AIM ImmunoTech Inc. 8-K (2026-05-14) https://aibio.space/news/co-diagnostics-reports-first-quarter-2026-results-8-2-million-cash/https://aibio.space/news/co-diagnostics-reports-first-quarter-2026-results-8-2-million-cash/Thu, 14 May 2026 12:00:00 GMTCompany UpdatesThe net loss was $9.1 million, or $4.06 per share, and cash and cash equivalents were $8.2 million at March 31, 2026. The company said enrollment in its upper respiratory test studies is complete.Co-Diagnostics, Inc. 8-K (2026-05-14) https://aibio.space/news/calidi-reports-first-quarter-2026-results-cld-401-progress/https://aibio.space/news/calidi-reports-first-quarter-2026-results-cld-401-progress/Thu, 14 May 2026 12:00:00 GMTCompany UpdatesCalidi reported a first quarter net loss of $4.4 million, a $1.0 million cut in general and administrative expenses and a CLD-401 IND goal of year end 2026.Calidi Biotherapeutics, Inc. 8-K (2026-05-14) https://aibio.space/news/preferred-stock-removed-nasdaq-bio-green-med-reports-first-quarter/https://aibio.space/news/preferred-stock-removed-nasdaq-bio-green-med-reports-first-quarter/Thu, 14 May 2026 12:00:00 GMTListingsThe 6% Convertible Exchangeable Preferred Stock, under the symbol BGMSP, stopped trading in March. The common stock, BGMS, remains listed, and first-quarter product revenue was $0.8 million.Bio Green Med Solution, Inc. 8-K (2026-05-14) https://aibio.space/news/hcw-biologics-reports-first-quarter-2026-net-income-trimmune-license/https://aibio.space/news/hcw-biologics-reports-first-quarter-2026-net-income-trimmune-license/Thu, 14 May 2026 12:00:00 GMTCompany UpdatesThe company reported $6.5 million in revenue and net income of $3.5 million for the quarter ended March 31, 2026, and it still states substantial doubt about going concern.HCW Biologics first-quarter 2026 results, Form 8-K filed May 14, 2026 https://aibio.space/news/gri-bio-reports-first-quarter-2026-results-new-gri-0621-data/https://aibio.space/news/gri-bio-reports-first-quarter-2026-results-new-gri-0621-data/Thu, 14 May 2026 12:00:00 GMTCompany UpdatesGRI Bio reported approximately $11.0 million in cash as of March 31, 2026, and added analyses from its Phase 2a trial of GRI-0621 in idiopathic pulmonary fibrosis.GRI Bio, Inc. 8-K (2026-05-14) https://aibio.space/news/pelthos-issues-first-quarter-2026-results-release-posts-company/https://aibio.space/news/pelthos-issues-first-quarter-2026-results-release-posts-company/Thu, 14 May 2026 12:00:00 GMTCompany UpdatesThe company furnished a press release summarizing results for the three months ended March 31, 2026, with an update on operations. The 8-K body does not repeat the figures in that release.Pelthos Therapeutics Form 8-K https://aibio.space/news/ocugen-closes-130-0-million-6-75-percent-convertible-notes/https://aibio.space/news/ocugen-closes-130-0-million-6-75-percent-convertible-notes/Thu, 14 May 2026 12:00:00 GMTDebt FinancingThe notes include the full exercise of a $15.0 million over-allotment option. Ocugen used approximately $32.7 million of the proceeds to repay its Avenue loan.Ocugen, Inc. 8-K (2026-05-14) https://aibio.space/news/inotiv-amends-credit-agreement-40-0-million-bridge-facility/https://aibio.space/news/inotiv-amends-credit-agreement-40-0-million-bridge-facility/Thu, 14 May 2026 12:00:00 GMTDebt FinancingInotiv borrowed $27.5 million under the bridge facility and used it to repay its revolving loans, which were then terminated. The amendment also excludes some covenant tests and adds strategic alternatives milestones.Inotiv, Inc. 8-K (2026-05-18) https://aibio.space/news/gilead-sells-senior-notes-due-2028-through-2034-public-offering/https://aibio.space/news/gilead-sells-senior-notes-due-2028-through-2034-public-offering/Thu, 14 May 2026 12:00:00 GMTDebt FinancingGilead sold four series of senior notes due 2028 through 2034 in a public offering, with coupons from 4.250% to 4.900%. Barclays, BofA Securities and Citigroup Global Markets are the representatives of the underwriters.SEC EDGAR https://aibio.space/news/senti-biosciences-signs-up-40-million-convertible-note-financing/https://aibio.space/news/senti-biosciences-signs-up-40-million-convertible-note-financing/Thu, 14 May 2026 12:00:00 GMTDebt FinancingAn affiliate of Celadon Partners SPV 24 may buy notes in two tranches. The first tranche is $10 million and is expected to close in May.SEC filing https://aibio.space/news/cell-sources-delayed-10-q-shows-1-240-cash-11-1-million-past-due-notes/https://aibio.space/news/cell-sources-delayed-10-q-shows-1-240-cash-11-1-million-past-due-notes/Thu, 14 May 2026 12:00:00 GMTDistressCell Source, an OTC Pink company, signed a 10-Q on May 14, 2026 for the quarter ended March 31, 2025. It reports $1,240 of cash, a going-concern warning, and notes past due, while it prepares a Nasdaq uplisting.SEC EDGAR: Cell Source 10-Q https://aibio.space/news/cuprina-shareholders-approve-share-consolidation-higher-class-b-voting/https://aibio.space/news/cuprina-shareholders-approve-share-consolidation-higher-class-b-voting/Thu, 14 May 2026 12:00:00 GMTListingsCuprina holders approved a share consolidation, raised Class B votes from 10 to 100 per share and allowed share issues of 20% or more of Class A shares. About 2.79% of the Class A votes were represented at the meeting.Cuprina Holdings (Cayman) Limited 6-K (2026-05-14) https://aibio.space/news/zymeworks-authorizes-125-0-million-share-repurchase-program-ends-2025/https://aibio.space/news/zymeworks-authorizes-125-0-million-share-repurchase-program-ends-2025/Thu, 14 May 2026 12:00:00 GMTFinancingsThe earlier program bought back shares at an average price of $24.36 for $102.3 million. Zymeworks had about 73.0 million common shares outstanding as of May 13, 2026.Zymeworks Inc. 8-K (2026-05-14) https://aibio.space/news/aprea-reports-first-quarter-2026-results-46-5-million-cash/https://aibio.space/news/aprea-reports-first-quarter-2026-results-46-5-million-cash/Wed, 13 May 2026 12:00:00 GMTCompany UpdatesAprea said its $30 million private placement closed on March 31, 2026, and reported $46.5 million in cash at March 31, 2026, with runway into the first quarter of 2028. The company also described two partial responses in its Phase 1 trial of APR-1051.Aprea Therapeutics, Inc. 8-K (2026-05-13) https://aibio.space/news/spruce-biosciences-details-50-0-million-avenue-capital-loan-facility/https://aibio.space/news/spruce-biosciences-details-50-0-million-avenue-capital-loan-facility/Wed, 13 May 2026 12:00:00 GMTDebt FinancingAvenue Capital Management II, L.P. is the lender under a term loan facility signed January 7, 2026. The first $15.0 million tranche funded after closing.Spruce Biosciences, Inc. 8-K (2026-05-13) https://aibio.space/news/aptevo-completes-ceo-transition-secures-60-million-equity-line/https://aibio.space/news/aptevo-completes-ceo-transition-secures-60-million-equity-line/Wed, 13 May 2026 12:00:00 GMTCompany UpdatesAptevo says its RAINIER trial of mipletamig remains on track for Phase 2 dose selection by year end, and that a $60 million standby equity purchase agreement extends its access to capital.Aptevo Therapeutics Inc. SEC filing (Form 8-K) https://aibio.space/news/equillium-names-snehal-naik-chief-development-officer-reports-q1-2026/https://aibio.space/news/equillium-names-snehal-naik-chief-development-officer-reports-q1-2026/Wed, 13 May 2026 12:00:00 GMTCompany UpdatesEquillium said cash and cash equivalents were $61.3 million at March 31, 2026, following a $35 million private placement with RA Capital Management completed in March 2026.Equillium, Inc. 8-K (2026-05-13) https://aibio.space/news/onconetix-reports-q1-2026-progress-proteomedix/https://aibio.space/news/onconetix-reports-q1-2026-progress-proteomedix/Wed, 13 May 2026 12:00:00 GMTCompany UpdatesThe Swiss unit added two peer-reviewed papers, began enrolling in a U.S. validation study with Labcorp and kept expanding sales in Europe. The release does not report quarterly revenue or cash.Onconetix, Inc. 8-K (2026-05-14) https://aibio.space/news/logicmark-revenue-rises-24-percent-first-quarter-2026/https://aibio.space/news/logicmark-revenue-rises-24-percent-first-quarter-2026/Wed, 13 May 2026 12:00:00 GMTListingsRevenue reached $3.2 million and gross margin 69.6%, while the operating loss narrowed to $1.5 million and cash and investments totaled $7.5 million.Press release (SEC Exhibit 99.1) https://aibio.space/news/bionano-reports-first-quarter-2026-revenue-6-7-million/https://aibio.space/news/bionano-reports-first-quarter-2026-revenue-6-7-million/Wed, 13 May 2026 12:00:00 GMTCompany UpdatesConsumables revenue grew 20%, and the company guided to full-year 2026 revenue of $30 to $33 million.Bionano Genomics, Inc. 8-K (2026-05-13) https://aibio.space/news/dermata-reports-first-quarter-2026-results-2-0-million-atm-proceeds/https://aibio.space/news/dermata-reports-first-quarter-2026-results-2-0-million-atm-proceeds/Wed, 13 May 2026 12:00:00 GMTFinancingsDermata Therapeutics said its at-the-market facility produced $2.0 million of net proceeds in the first quarter of 2026. Cash was $6.9 million at March 31, 2026, and the company expects its resources to fund operations into the first quarter of 2027.Dermata Therapeutics, Inc. 8-K (2026-05-13) https://aibio.space/news/intelligent-bio-solutions-reports-fiscal-third-quarter-revenue-up-46/https://aibio.space/news/intelligent-bio-solutions-reports-fiscal-third-quarter-revenue-up-46/Wed, 13 May 2026 12:00:00 GMTCompany UpdatesTotal revenue reached $1.06 million for the quarter ended March 31, 2026, and nine-month revenue reached $3.07 million, up 39% year over year.Intelligent Bio Solutions 8-K https://aibio.space/news/biomx-sets-up-2-000-000-credit-line-mandragola-12-percent-notes/https://aibio.space/news/biomx-sets-up-2-000-000-credit-line-mandragola-12-percent-notes/Wed, 13 May 2026 12:00:00 GMTDebt FinancingMandragola Ltd is the lender under a credit line that issues 12% convertible promissory notes for each advance. Mandragola also received a five-year warrant.BiomX Inc. 8-K (2026-06-05) https://aibio.space/news/armata-pharmaceuticals-takes-25-million-secured-loan-innoviva/https://aibio.space/news/armata-pharmaceuticals-takes-25-million-secured-loan-innoviva/Wed, 13 May 2026 12:00:00 GMTDebt FinancingThe 14.0% term loan matures in January 2029 and is secured by substantially all of the company's assets. The lender is a subsidiary of Innoviva, which the filing describes as a principal shareholder.Armata Pharmaceuticals, Inc. (2026-05-13) https://aibio.space/news/armata-pharmaceuticals-signs-25-million-secured-loan-innoviva-14-0/https://aibio.space/news/armata-pharmaceuticals-signs-25-million-secured-loan-innoviva-14-0/Wed, 13 May 2026 12:00:00 GMTDebt FinancingThe term loan from Innoviva Strategic Opportunities LLC matures January 11, 2029 and is secured by substantially all company assets. Armata reported about $4.8 million of unrestricted cash and cash equivalents at March 31, 2026.Armata Pharmaceuticals, Inc. Form 8-K filed May 13, 2026 (SEC EDGAR) https://aibio.space/news/whitehawk-therapeutics-agrees-87-5-million-private-placement-stock/https://aibio.space/news/whitehawk-therapeutics-agrees-87-5-million-private-placement-stock/Wed, 13 May 2026 12:00:00 GMTFinancingsWhitehawk agreed to sell 4,330,866 shares at $3.92 and 17,991,021 pre-funded warrants in a PIPE financing. The company expects gross proceeds of about $87.5 million and a May 14, 2026 closing.Whitehawk Therapeutics, Inc. Form 8-K filed May 13, 2026 (SEC EDGAR) https://aibio.space/news/allogene-cites-200-4-million-gross-proceeds-april-offering-runway-2029/https://aibio.space/news/allogene-cites-200-4-million-gross-proceeds-april-offering-runway-2029/Wed, 13 May 2026 12:00:00 GMTFinancingsAllogene had $266.9 million in cash and investments at March 31, 2026, after an April offering with $200.4 million gross proceeds. Its first-quarter net loss was $42.6 million, and its key ALPHA3 comparison rests on 12 patients per arm.Allogene Therapeutics, Inc. 8-K (2026-05-13) https://aibio.space/news/fractyl-posts-first-quarter-profit-warrant-revaluation-cash-falls-63/https://aibio.space/news/fractyl-posts-first-quarter-profit-warrant-revaluation-cash-falls-63/Tue, 12 May 2026 12:00:00 GMTFinancingsA $30.1 million gain on warrant liabilities turned a $20.8 million operating loss into $9.2 million of net income.Fractyl Health (press release via BiopharmaWatch) https://aibio.space/news/mirum-prices-600-million-0-percent-convertible-notes-refinances-2029/https://aibio.space/news/mirum-prices-600-million-0-percent-convertible-notes-refinances-2029/Tue, 12 May 2026 12:00:00 GMTDebt FinancingThe notes carry no interest and convert at about $138.94 a share, a 30% premium to the May 12 price. Mirum swapped $237.2 million of 4% notes due 2029 for cash and shares.Mirum Pharmaceuticals (press release in Form 8-K) https://aibio.space/news/nuwellis-reports-26-percent-first-quarter-revenue-growth-70-1-percent/https://aibio.space/news/nuwellis-reports-26-percent-first-quarter-revenue-growth-70-1-percent/Tue, 12 May 2026 12:00:00 GMTCompany UpdatesNet sales were $2.4 million, and the company reported about $2.2 million of cash and no debt at March 31, 2026.Nuwellis, Inc. 8-K (2026-05-12) https://aibio.space/news/bolt-biotherapeutics-reports-first-quarter-results-23-9-million-cash/https://aibio.space/news/bolt-biotherapeutics-reports-first-quarter-results-23-9-million-cash/Tue, 12 May 2026 12:00:00 GMTCompany UpdatesThe company said its cash should fund operations into 2027, including completion of the dose escalation part of the BDC-4182 study. It expects initial clinical data in the third quarter of 2026.Bolt Biotherapeutics press release (Form 8-K, Exhibit 99.1) https://aibio.space/news/therapeuticsmd-reports-first-quarter-2026-results-strategic-review/https://aibio.space/news/therapeuticsmd-reports-first-quarter-2026-results-strategic-review/Tue, 12 May 2026 12:00:00 GMTCompany UpdatesThe royalty company reported net income from continuing operations of $103 thousand and cash of $8.4 million as of March 31, 2026, and said it still evaluates strategic alternatives.TherapeuticsMD, Inc. 8-K (2026-05-12) https://aibio.space/news/palisade-bio-reports-first-quarter-2026-results-132-6-million-cash/https://aibio.space/news/palisade-bio-reports-first-quarter-2026-results-132-6-million-cash/Tue, 12 May 2026 12:00:00 GMTCompany UpdatesThe company reported cash and cash equivalents of $132.6 million at March 31, 2026. It said the Phase 2 ulcerative colitis trial of PALI-2108 is expected to start in the third quarter of 2026.Palisade Bio, Inc. 8-K (2026-05-12) https://aibio.space/news/interpace-biosciences-reports-first-quarter-revenue-9-0-million/https://aibio.space/news/interpace-biosciences-reports-first-quarter-revenue-9-0-million/Tue, 12 May 2026 12:00:00 GMTCompany UpdatesRevenue was $9.0 million, down 22% from the prior-year quarter as reported and up 14% on a pro forma basis, and the company reaffirmed its 2026 thyroid growth guidance.Form 8-K, Exhibit 99.1 (SEC EDGAR) https://aibio.space/news/mirum-proposes-600-0-million-convertible-notes-offering/https://aibio.space/news/mirum-proposes-600-0-million-convertible-notes-offering/Tue, 12 May 2026 12:00:00 GMTDebt FinancingMirum plans to sell $600.0 million of convertible senior notes due 2032, with an option for up to $90.0 million more. Part of the proceeds would go toward exchanges of its 2029 notes.Mirum Pharmaceuticals, Inc. 8-K (2026-05-18) https://aibio.space/news/aquestive-enters-150-million-debt-facility-oaktree/https://aibio.space/news/aquestive-enters-150-million-debt-facility-oaktree/Tue, 12 May 2026 12:00:00 GMTDebt FinancingThe facility refinances Aquestive's existing debt. It starts with $55.0 million at signing and adds tranches tied to FDA approval and sales milestones.Aquestive Therapeutics, Inc. 8-K (2026-05-13) https://aibio.space/news/foxo-exchanges-series-preferred-senior-unsecured-notes/https://aibio.space/news/foxo-exchanges-series-preferred-senior-unsecured-notes/Tue, 12 May 2026 12:00:00 GMTDebt FinancingTwo institutional holders swapped Series A preferred stock for non-convertible notes of $5,307,096.94 and $2,467,988.34, due May 12, 2027.FOXO TECHNOLOGIES INC. 8-K (2026-05-18) https://aibio.space/news/tempus-ai-completes-460-0-million-convertible-notes-offering/https://aibio.space/news/tempus-ai-completes-460-0-million-convertible-notes-offering/Tue, 12 May 2026 12:00:00 GMTDebt FinancingThe notes carry no regular interest and mature May 15, 2032, after the initial purchasers exercised their option in full.Tempus AI, Inc. (2026-05-12) https://aibio.space/news/collegium-completes-650-million-azstarys-acquisition-funded-cash-300/https://aibio.space/news/collegium-completes-650-million-azstarys-acquisition-funded-cash-300/Tue, 12 May 2026 12:00:00 GMTMergersCollegium paid about $650 million in cash for AZSTARYS, using about $350 million of cash on hand and a $300 million delayed draw term loan. Two senior executives are leaving, and the company may pay up to $135 million more if AZSTARYS hits milestones.COLLEGIUM PHARMACEUTICAL, INC Form 8-K filed May 12, 2026 (SEC EDGAR) https://aibio.space/news/collegium-completes-azstarys-purchase-about-650-million-raises-2026/https://aibio.space/news/collegium-completes-azstarys-purchase-about-650-million-raises-2026/Tue, 12 May 2026 12:00:00 GMTMergersCollegium paid about $650 million in cash for AZSTARYS, using $350 million of its own cash and a $300 million loan draw. Corium Therapeutics may receive up to $135 million more if milestones are met.Collegium Pharmaceutical, Inc. 8-K (2026-05-12) https://aibio.space/news/travere-sells-525-million-2032-convertible-notes-buy-back-221-million/https://aibio.space/news/travere-sells-525-million-2032-convertible-notes-buy-back-221-million/Mon, 11 May 2026 12:00:00 GMTDebt FinancingThe 0.50% notes would lift convertible principal to $619.9 million but cut the coupon. Travere said it would spend about $350.9 million to repurchase part of the older debt.Travere Therapeutics (SEC 8-K) https://aibio.space/news/viridian-raises-394-million-convertible-notes-stock-repays-hercules/https://aibio.space/news/viridian-raises-394-million-convertible-notes-stock-repays-hercules/Mon, 11 May 2026 12:00:00 GMTFinancingsThe company sold $250 million of 1.75% notes due 2032 and shares at $17.00 ahead of its first approval. It used part of the money to pay off about $55.1 million of term debt.Viridian Therapeutics (SEC Form 8-K) https://aibio.space/news/metavia-present-da-1726-data-late-breaking-poster-easl-2026/https://aibio.space/news/metavia-present-da-1726-data-late-breaking-poster-easl-2026/Mon, 11 May 2026 12:00:00 GMTCompany UpdatesA late-breaking abstract on the obesity candidate DA-1726 was accepted for a poster at the EASL Congress 2026 in Barcelona, scheduled for May 27, 2026.MetaVia Inc. 8-K (2026-05-11) https://aibio.space/news/adial-reports-first-quarter-2026-results-ad04-business-update/https://aibio.space/news/adial-reports-first-quarter-2026-results-ad04-business-update/Mon, 11 May 2026 12:00:00 GMTCompany UpdatesCash was $4.6 million at March 31, 2026, and Adial says it can fund operating expenses into the second half of 2026 on its committed development plans.Adial Pharmaceuticals, Inc press release (2026-05-11) https://aibio.space/news/functional-brands-lowers-series-c-preferred-conversion-price-0-1636/https://aibio.space/news/functional-brands-lowers-series-c-preferred-conversion-price-0-1636/Mon, 11 May 2026 12:00:00 GMTCompany UpdatesThe company agreed with all Series C holders to reset the conversion price to $0.1636 per share, the market price at signing.Functional Brands Inc. 8-K https://aibio.space/news/nexgel-issues-1-000-000-convertible-note-new-director-brian-j-kieser/https://aibio.space/news/nexgel-issues-1-000-000-convertible-note-new-director-brian-j-kieser/Mon, 11 May 2026 12:00:00 GMTDebt FinancingThe unsecured note converts at $0.60 a share and goes to Brian J. Kieser, a new director who runs Sequence LifeScience. Sequence bought $5,500,000 of notes in an earlier April financing.NEXGEL, INC. 8-K (2026-05-12) https://aibio.space/news/aurinia-completes-kezar-life-sciences-acquisition-after-tender-offer-6/https://aibio.space/news/aurinia-completes-kezar-life-sciences-acquisition-after-tender-offer-6/Mon, 11 May 2026 12:00:00 GMTMergersAurinia said on May 11, 2026 that it completed its acquisition of Kezar Life Sciences. Holders received $6.955 in cash plus one contingent value right per share, after a tender offer in which 5,927,580 Kezar shares, about 80.24% of those outstanding, were validly tendered.Aurinia Pharmaceuticals Inc. Form 8-K filed May 11, 2026 (SEC EDGAR) https://aibio.space/news/anavex-life-sciences-files-late-filing-notice-10-q-after-ceo/https://aibio.space/news/anavex-life-sciences-files-late-filing-notice-10-q-after-ceo/Mon, 11 May 2026 12:00:00 GMTDistressAnavex Life Sciences told the SEC on May 11, 2026 that it cannot file its first-quarter 10-Q on time. The delay follows the April 30 termination of CEO Christopher Missling, and the company says the review of that termination may take longer than it expects.ANAVEX LIFE SCIENCES CORP. Form NT 10-Q filed May 11, 2026 (SEC EDGAR) https://aibio.space/news/odyssey-therapeutics-sells-1-388-889-shares-tpg-affiliate-18-00/https://aibio.space/news/odyssey-therapeutics-sells-1-388-889-shares-tpg-affiliate-18-00/Mon, 11 May 2026 12:00:00 GMTFinancingsThe private placement closed alongside Odyssey's initial public offering. The Share Purchase Agreement is dated May 7, 2026 and names five placement agents.Odyssey Therapeutics, Inc. Form 8-K filed May 11, 2026 (SEC EDGAR) https://aibio.space/news/arrivent-biopharma-files-up-250-000-000-market-stock-sales/https://aibio.space/news/arrivent-biopharma-files-up-250-000-000-market-stock-sales/Mon, 11 May 2026 12:00:00 GMTFinancingsArriVent BioPharma, Inc. filed a prospectus supplement on May 11, 2026 under its existing sales agreement with Jefferies LLC. The last reported sale price was $29.50 per share on May 8, 2026.ArriVent BioPharma, Inc. 424B5 (2026-05-11) https://aibio.space/news/conexeu-sciences-registers-9-481-123-shares-resale-ahead-planned/https://aibio.space/news/conexeu-sciences-registers-9-481-123-shares-resale-ahead-planned/Mon, 11 May 2026 12:00:00 GMTFinancingsThe prospectus registers resale shares only, so the company gets no proceeds from those sales. It expects Nasdaq trading on or about May 21, 2026, and its own financials carry going-concern doubt.Conexeu Sciences Inc. 424B4 (2026-05-11) https://aibio.space/news/puretech-health-plc-files-form-25-delist-adss-nasdaq/https://aibio.space/news/puretech-health-plc-files-form-25-delist-adss-nasdaq/Mon, 11 May 2026 12:00:00 GMTListingsThe filing, dated May 11, 2026, relies on the SEC rule for a voluntary withdrawal by the issuer. It covers American Depositary Shares, each representing 10 ordinary shares.PureTech Health PLC 25 (2026-05-11) https://aibio.space/news/scisparc-gets-conditional-nasdaq-compliance-letter-stockholders-equity/https://aibio.space/news/scisparc-gets-conditional-nasdaq-compliance-letter-stockholders-equity/Mon, 11 May 2026 12:00:00 GMTListingsNasdaq staff said on May 7, 2026 that SciSparc now meets the $2,500,000 stockholders' equity standard, but the letter is conditional. Delisting is possible if the company's next periodic report does not show compliance.SciSparc Ltd. 6-K (2026-05-11) https://aibio.space/news/lifeloc-borrows-500-000-chairman-cfo/https://aibio.space/news/lifeloc-borrows-500-000-chairman-cfo/Fri, 08 May 2026 12:00:00 GMTDebt FinancingLifeloc Technologies entered into a $500,000 promissory note with Vern Kornelsen, its Chief Financial Officer and Chairman of the Board. The note carries 10.5% interest and is secured by its Wheat Ridge office and most of its assets.Lifeloc Technologies, Inc 8-K (2026-05-08) https://aibio.space/news/ispecimen-prices-2-5-million-private-placement-5-12-share/https://aibio.space/news/ispecimen-prices-2-5-million-private-placement-5-12-share/Fri, 08 May 2026 12:00:00 GMTListingsE.F. Hutton & Co. is the exclusive placement agent, and the company expects the offering to close on or about May 11, 2026.Press release (SEC Exhibit 99.1) https://aibio.space/news/kiora-reports-first-quarter-2026-results-runway-late-2028/https://aibio.space/news/kiora-reports-first-quarter-2026-results-runway-late-2028/Fri, 08 May 2026 12:00:00 GMTCompany UpdatesKiora ended the first quarter with $13.9 million in cash and short-term investments. It raised an additional $5.0 million in gross proceeds from a strategic equity investment after quarter end.Kiora Pharmaceuticals, Inc. 8-K (2026-05-08) https://aibio.space/news/humacyte-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until/https://aibio.space/news/humacyte-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until/Fri, 08 May 2026 12:00:00 GMTListingsNasdaq told Humacyte on May 4, 2026 that its common stock closed below $1.00 for 30 consecutive business days. The company has until November 2, 2026 to regain compliance, and the notice has no immediate effect on its listing.Humacyte, Inc. Form 8-K filed May 8, 2026 (SEC EDGAR) https://aibio.space/news/artiva-biotherapeutics-prices-300-0-million-offering-shares-warrants/https://aibio.space/news/artiva-biotherapeutics-prices-300-0-million-offering-shares-warrants/Fri, 08 May 2026 12:00:00 GMTFinancingsArtiva Biotherapeutics agreed to sell 23,871,526 shares at $11.52 each, plus pre-funded warrants for 2,170,138 shares. The company's last reported sale price was $12.52 on May 7, 2026.Artiva Biotherapeutics, Inc. 424B5 (2026-05-08) https://aibio.space/news/nektar-therapeutics-sets-up-150-000-000-market-stock-program/https://aibio.space/news/nektar-therapeutics-sets-up-150-000-000-market-stock-program/Fri, 08 May 2026 12:00:00 GMTFinancingsNektar will sell up to $150 million of stock through Guggenheim Securities and H.C. Wainwright at a 3.0% commission. The company used $208.5 million in operations in 2025, and its Phase 3 spending is set to rise.Nektar Therapeutics 8-K (2026-05-08) https://aibio.space/news/celldex-closes-345-million-raise-guides-funding-through-2028/https://aibio.space/news/celldex-closes-345-million-raise-guides-funding-through-2028/Thu, 07 May 2026 12:00:00 GMTFinancingsFirst-quarter cash was $451.5 million before the April offering. Celldex then expected phase 3 hives data in the fourth quarter of 2026.Celldex Therapeutics (SEC Form 8-K exhibit) https://aibio.space/news/ptc-raises-2026-product-revenue-guidance-after-first-quarter/https://aibio.space/news/ptc-raises-2026-product-revenue-guidance-after-first-quarter/Thu, 07 May 2026 12:00:00 GMTCompany UpdatesPTC reported first quarter 2026 total revenue of $273 million and a net loss of $2.8 million, and raised full-year product revenue guidance to $750 to $850 million.PTC Therapeutics, Inc. 8-K (2026-05-07) https://aibio.space/news/quoin-reports-first-quarter-2026-results-fda-meeting-outcome/https://aibio.space/news/quoin-reports-first-quarter-2026-results-fda-meeting-outcome/Thu, 07 May 2026 12:00:00 GMTCompany UpdatesQuoin said an FDA Type C meeting indicated a single Phase 3 study may be sufficient for U.S. approval of QRX003, and reported approximately $14 million in cash as of March 31, 2026.Quoin Pharmaceuticals, Ltd. 8-K (2026-05-07) https://aibio.space/news/leonabio-reports-first-quarter-2026-results-elaine-3-amendment/https://aibio.space/news/leonabio-reports-first-quarter-2026-results-elaine-3-amendment/Thu, 07 May 2026 12:00:00 GMTCompany UpdatesLeonaBio said it is increasing the ELAINE-3 sample size to up to 600 participants and expects to start a Phase 2 ALS study for ATH-1105 in the second half of 2026.LeonaBio, Inc. 8-K (2026-05-07) https://aibio.space/news/revelation-biosciences-reports-first-quarter-2026-net-loss-3-0-million/https://aibio.space/news/revelation-biosciences-reports-first-quarter-2026-net-loss-3-0-million/Thu, 07 May 2026 12:00:00 GMTCompany UpdatesCash stood at $14.1 million on March 31, 2026, which the company says covers operations through the first quarter of 2027.Revelation Biosciences, Inc. 8-K (2026-05-07) https://aibio.space/news/in8bio-reports-first-quarter-2026-results-glioblastoma-survival/https://aibio.space/news/in8bio-reports-first-quarter-2026-results-glioblastoma-survival/Thu, 07 May 2026 12:00:00 GMTCompany UpdatesIN8bio reported cash of $21.9 million at March 31, 2026 and a net loss of $5.1 million for the quarter, and it described updated glioblastoma data and its INB-619 engager program.IN8bio, Inc. 8-K (2026-05-07) https://aibio.space/news/bluejay-gives-first-quarter-2026-corporate-update/https://aibio.space/news/bluejay-gives-first-quarter-2026-corporate-update/Thu, 07 May 2026 12:00:00 GMTCompany UpdatesAbout 680 patients were enrolled in SYMON-II as of May 5, 2026, toward a target of 750, and the company reported a first-quarter net loss of approximately $1.9 million.Bluejay Diagnostics, Inc. 8-K (2026-05-07) https://aibio.space/news/oragenics-signs-letter-intent-license-cardiodialysis-tbi/https://aibio.space/news/oragenics-signs-letter-intent-license-cardiodialysis-tbi/Thu, 07 May 2026 12:00:00 GMTCompany UpdatesOragenics signed a non-binding letter of intent to license certain indications of CardioDialysis from Sigyn Therapeutics for traumatic brain injury. The proposed terms include 3,250,000 restricted preferred shares and a 3% royalty for six years.Oragenics Inc. 8-K (2026-05-07) https://aibio.space/news/aim-immunotech-arranges-warrant-inducement-through-ladenburg-thalmann/https://aibio.space/news/aim-immunotech-arranges-warrant-inducement-through-ladenburg-thalmann/Thu, 07 May 2026 12:00:00 GMTFinancingsExisting holders agreed to exercise warrants at $0.48 a share in exchange for new Class H warrants, with gross proceeds of approximately $4.20 million if all existing warrants are exercised.AIM ImmunoTech Inc. 8-K (2026-05-08) https://aibio.space/news/intensity-therapeutics-reports-q1-2026-results-enrollment-plans/https://aibio.space/news/intensity-therapeutics-reports-q1-2026-results-enrollment-plans/Thu, 07 May 2026 12:00:00 GMTCompany UpdatesCash and cash equivalents were $10.2 million at March 31, 2026. The company plans to resume enrollment in INVINCIBLE-3 at a limited number of U.S. sites by the third quarter of 2026.Intensity Therapeutics, Inc. 8-K (2026-05-07) https://aibio.space/news/gelteq-agrees-up-3-5-million-convertible-note-financing/https://aibio.space/news/gelteq-agrees-up-3-5-million-convertible-note-financing/Thu, 07 May 2026 12:00:00 GMTDebt FinancingAn institutional investor will fund up to $3.5 million in two tranches. The first note carries 7% interest, matures in eighteen months and converts at a price that cannot fall below $0.50.SEC filing https://aibio.space/news/capricor-sues-nippon-shinyaku-ns-pharma-deramiocel-u-s-distribution/https://aibio.space/news/capricor-sues-nippon-shinyaku-ns-pharma-deramiocel-u-s-distribution/Thu, 07 May 2026 12:00:00 GMTLegalCapricor Therapeutics filed a complaint in New Jersey seeking to rescind its January 24, 2022 distribution agreement and asking for a preliminary injunction. The FDA target action date for Deramiocel is August 22, 2026.CAPRICOR THERAPEUTICS, INC. Form 8-K filed May 7, 2026 (SEC EDGAR) https://aibio.space/news/arcturus-therapeutics-reports-213-4-million-cash-sees-runway-past-q2/https://aibio.space/news/arcturus-therapeutics-reports-213-4-million-cash-sees-runway-past-q2/Thu, 07 May 2026 12:00:00 GMTDistressOperating expenses fell to $31.0 million from $46.2 million, but revenue fell by $27.3 million and the net loss was approximately $27.0 million.Arcturus Therapeutics Holdings Inc. 8-K (2026-05-07) https://aibio.space/news/structure-therapeutics-raises-market-limit-400-000-000/https://aibio.space/news/structure-therapeutics-raises-market-limit-400-000-000/Thu, 07 May 2026 12:00:00 GMTFinancingsLeerink Partners LLC and Cantor Fitzgerald & Co. are the sales agents. About $58.5 million of ADSs had already been sold, leaving $341,478,784 of capacity after the supplement.Structure Therapeutics Inc. 424B5 (2026-05-07) https://aibio.space/news/tg-therapeutics-raises-briumvi-sales-guidance-widens-buyback-300/https://aibio.space/news/tg-therapeutics-raises-briumvi-sales-guidance-widens-buyback-300/Wed, 06 May 2026 12:00:00 GMTFinancingsFirst-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases.TG Therapeutics (SEC 8-K) https://aibio.space/news/inmed-reports-third-quarter-results-3-0-million-net-loss/https://aibio.space/news/inmed-reports-third-quarter-results-3-0-million-net-loss/Wed, 06 May 2026 12:00:00 GMTCompany UpdatesInMed reported a net loss of $3.0 million for the quarter ended March 31, 2026, and cash, cash equivalents and short-term investments of $5.2 million, as it winds down its commercial operations.InMed Pharmaceuticals Inc. 8-K (2026-05-07) https://aibio.space/news/aptevo-reports-87-percent-clinical-benefit-frontline-aml-through/https://aibio.space/news/aptevo-reports-87-percent-clinical-benefit-frontline-aml-through/Wed, 06 May 2026 12:00:00 GMTCompany UpdatesAptevo says mipletamig data from 31 evaluable frontline AML patients show continued activity, and that the RAINIER trial has entered its final dose-optimization stage.Aptevo Therapeutics Inc. SEC filing (Form 8-K) https://aibio.space/news/viridian-completes-250-000-000-convertible-notes-offering/https://aibio.space/news/viridian-completes-250-000-000-convertible-notes-offering/Wed, 06 May 2026 12:00:00 GMTDebt FinancingViridian's $250,000,000 offering of 1.75% convertible senior notes due 2032 includes the full $25.0 million over-allotment option. A concurrent sale of 7,352,942 shares was priced at $17.00 a share.Viridian Therapeutics, Inc. 8-K (2026-05-11) https://aibio.space/news/citius-oncology-prices-11-5-million-warrant-inducement-signs-avenue/https://aibio.space/news/citius-oncology-prices-11-5-million-warrant-inducement-signs-avenue/Wed, 06 May 2026 12:00:00 GMTDebt FinancingCitius Oncology signed a warrant inducement worth about $11.5 million and a loan of up to $25.0 million with Avenue. Existing warrants are repriced to $0.90, and the new warrants and conversion rights add to the share count.CITIUS ONCOLOGY, INC. Form 8-K filed May 6, 2026 (SEC EDGAR) https://aibio.space/news/citius-oncology-announces-up-36-5-million-loan-warrant-financing/https://aibio.space/news/citius-oncology-announces-up-36-5-million-loan-warrant-financing/Wed, 06 May 2026 12:00:00 GMTDebt FinancingCitius Oncology signed a loan of up to $25 million with an Avenue Capital fund and expects about $11.5 million gross from a warrant exercise. Only $10 million of the loan funds at closing, and the new warrants cannot be exercised until stockholders approve the shares.Citius Oncology, Inc. 8-K (2026-05-06) https://aibio.space/news/inflarx-prices-150-000-000-share-offering-2-00-closes-day-later/https://aibio.space/news/inflarx-prices-150-000-000-share-offering-2-00-closes-day-later/Wed, 06 May 2026 12:00:00 GMTFinancingsInflaRx N.V. sold 75,000,000 ordinary shares in an underwritten offering led by Guggenheim Securities. The offering closed on May 7, 2026.InflaRx N.V. 424B5 (2026-05-06) https://aibio.space/news/exelixis-authorizes-another-750-million-buyback-first-quarter-revenue/https://aibio.space/news/exelixis-authorizes-another-750-million-buyback-first-quarter-revenue/Tue, 05 May 2026 12:00:00 GMTFinancingsThe new program runs through Dec. 31, 2027. First-quarter net product revenue was $555.0 million and 2026 guidance was left unchanged.Exelixis 8-K (SEC) https://aibio.space/news/theriva-reports-q1-2026-results-fda-agreement-phase-3-design/https://aibio.space/news/theriva-reports-q1-2026-results-fda-agreement-phase-3-design/Tue, 05 May 2026 12:00:00 GMTCompany UpdatesThe company reported cash of $14.4 million at March 31, 2026, a runway into Q1 2027, and FDA general agreement on a pivotal Phase 3 design for VCN-01.Theriva Biologics, Inc. 8-K (2026-05-05) https://aibio.space/news/q32-bio-reports-q1-2026-results-first-patient-dosed-part-b-extension/https://aibio.space/news/q32-bio-reports-q1-2026-results-first-patient-dosed-part-b-extension/Tue, 05 May 2026 12:00:00 GMTCompany UpdatesCash and cash equivalents were $50.8 million at March 31, 2026. The company received $14.2 million of at-the-market proceeds after the quarter ended.Q32 Bio Inc. 8-K (2026-05-05) https://aibio.space/news/minerva-reports-first-quarter-2026-results-starts-phase-3-trial/https://aibio.space/news/minerva-reports-first-quarter-2026-results-starts-phase-3-trial/Tue, 05 May 2026 12:00:00 GMTCompany UpdatesThe company reported a GAAP net loss of $125.4 million for the quarter, including a $109.4 million non-cash warrant charge, and said the first patient was screened in March.Minerva Neurosciences, Inc 8-K (2026-05-05) https://aibio.space/news/apimeds-pharmaceuticals-appoints-sungjoon-chae-co-chief-executive/https://aibio.space/news/apimeds-pharmaceuticals-appoints-sungjoon-chae-co-chief-executive/Tue, 05 May 2026 12:00:00 GMTCompany UpdatesApimeds named Sungjoon Chae Co-Chief Executive Officer on May 4, 2026 on a stockholder's nomination. The Form 8-K, dated May 5, 2026, describes his background as an architect and urban designer.Apimeds Pharmaceuticals US, Inc. 8-K (2026-05-05) https://aibio.space/news/ocugen-plans-115-million-convertible-senior-notes-offering/https://aibio.space/news/ocugen-plans-115-million-convertible-senior-notes-offering/Tue, 05 May 2026 12:00:00 GMTDebt FinancingOcugen plans $115 million of 6.75% convertible senior notes due 2034, with an option that takes the total to $130 million. Proceeds include $32.7 million to retire Avenue debt at 12.5%.Ocugen first quarter 2026 results release (Exhibit 99.1) https://aibio.space/news/travere-proposes-400-million-convertible-notes-offering/https://aibio.space/news/travere-proposes-400-million-convertible-notes-offering/Tue, 05 May 2026 12:00:00 GMTDebt FinancingTravere plans to sell $400 million of convertible senior notes due 2032, with an option for up to $60 million more. It intends to use part of the proceeds to repurchase 2029 notes for cash.Travere Therapeutics, Inc. 8-K (2026-05-11) https://aibio.space/news/pasithea-names-kartik-krishnan-chief-medical-officer/https://aibio.space/news/pasithea-names-kartik-krishnan-chief-medical-officer/Mon, 04 May 2026 12:00:00 GMTCompany UpdatesKartik Krishnan, M.D., Ph.D., became chief medical officer on May 1, 2026, and will oversee clinical development and medical strategy for PAS-004.Pasithea Therapeutics Corp. 8-K (2026-05-04) https://aibio.space/news/lexicon-signs-up-100-million-loan-hercules-capital/https://aibio.space/news/lexicon-signs-up-100-million-loan-hercules-capital/Mon, 04 May 2026 12:00:00 GMTDebt FinancingLexicon signed a loan of up to $100 million from Hercules in three tranches. The first $55 million was funded at closing, and Hercules receives warrants at $1.59 a share.Lexicon Pharmaceuticals, Inc. 8-K (2026-05-06) https://aibio.space/news/cns-pharmaceuticals-agrees-about-22-5-million-private-placement-pre/https://aibio.space/news/cns-pharmaceuticals-agrees-about-22-5-million-private-placement-pre/Mon, 04 May 2026 12:00:00 GMTFinancingsCNS Pharmaceuticals priced a private placement of common stock at $2.30 per share and pre-funded warrants at $2.299, for approximately $22.5 million gross. Most of the shares are pre-funded warrants for 9,143,479 shares. Closing is expected May 5, 2026. A director resigned and a new one was named.CNS Pharmaceuticals, Inc. Form 8-K filed May 4, 2026 (SEC EDGAR) https://aibio.space/news/lisata-kuva-labs-delay-tender-offer-start-may-29-kuva-pay-up-1-1/https://aibio.space/news/lisata-kuva-labs-delay-tender-offer-start-may-29-kuva-pay-up-1-1/Mon, 04 May 2026 12:00:00 GMTMergersLisata and Kuva Labs signed an amendment and waiver on May 3, 2026 that moves the tender offer start from April 13, 2026 to May 29, 2026. Kuva will pay up to $1.1 million of Lisata's expenses until the offer starts, and the offer is $5.00 in cash plus a $1.00 contingent value right.LISATA THERAPEUTICS, INC. Form 8-K filed May 4, 2026 (SEC EDGAR) https://aibio.space/news/aura-biosciences-agrees-repurchase-matrix-capitals-6-922-870-shares-5/https://aibio.space/news/aura-biosciences-agrees-repurchase-matrix-capitals-6-922-870-shares-5/Mon, 04 May 2026 12:00:00 GMTMergersAura Biosciences agreed to buy back up to 6,922,870 shares from Matrix Capital at $5.64, the price of an equity offering it announced on May 4, 2026. The buyback comes out of the offering's proceeds, and the company put preliminary cash at $114.7 million as of March 31, 2026.Aura Biosciences, Inc. Form 8-K filed May 4, 2026 (SEC EDGAR) https://aibio.space/news/gyre-therapeutics-completes-all-stock-acquisition-cullgen-valued-about/https://aibio.space/news/gyre-therapeutics-completes-all-stock-acquisition-cullgen-valued-about/Mon, 04 May 2026 12:00:00 GMTMergersGyre closed its merger with Cullgen on May 4, 2026. Cullgen holders get Gyre common and Series B preferred stock, and Cullgen's former CEO Ying Luo becomes Gyre's CEO.GYRE THERAPEUTICS, INC. Form 8-K filed May 4, 2026 (SEC EDGAR) https://aibio.space/news/rallybio-receive-50-000-000-fee-after-candid-ends-merger/https://aibio.space/news/rallybio-receive-50-000-000-fee-after-candid-ends-merger/Sun, 03 May 2026 12:00:00 GMTMergersCandid terminated its merger agreement with Rallybio on May 3, 2026, and entered into a Permitted Alternative Agreement with UCB S.A. Rallybio intends to withdraw its Form S-4 registration statement.Rallybio Corporation 8-K (2026-05-04) https://aibio.space/news/cero-sells-convertible-note-500-000-face-value-keystone/https://aibio.space/news/cero-sells-convertible-note-500-000-face-value-keystone/Fri, 01 May 2026 12:00:00 GMTDebt FinancingCERo Therapeutics Holdings issued a convertible promissory note to Keystone Capital Partners, LLC on April 27, 2026, with a purchase price of $400,000 and a principal face value of $500,000.CERo Therapeutics Holdings, Inc. 8-K (2026-05-01) https://aibio.space/news/shuttle-pharmaceuticals-agrees-merge-united-dogecoin/https://aibio.space/news/shuttle-pharmaceuticals-agrees-merge-united-dogecoin/Fri, 01 May 2026 12:00:00 GMTMergersThe merger is backed by an $11 million private placement that Shuttle expected to close on May 4, 2026.Shuttle Pharmaceuticals Holdings, Inc. 8-K (2026-05-01) https://aibio.space/news/alphatec-signs-175-0-million-term-loan-125-0-million-revolver/https://aibio.space/news/alphatec-signs-175-0-million-term-loan-125-0-million-revolver/Fri, 01 May 2026 12:00:00 GMTDebt FinancingJPMorgan Chase Bank, N.A. is administrative agent on the $175.0 million term loan A and the $125.0 million revolver, which repaid older credit agreements.Alphatec Holdings, Inc. 8-K (2026-05-05) https://aibio.space/news/veradermics-raises-about-472-million-100-share-follow-warrant-sale/https://aibio.space/news/veradermics-raises-about-472-million-100-share-follow-warrant-sale/Fri, 01 May 2026 12:00:00 GMTFinancingsVeradermics closed an underwritten sale of 3,843,790 shares at $100.00 and a $30.0 million private placement of pre-funded warrants on May 1. Its pivotal hair-loss trials are still running against $70.0 million of annual losses.SEC EDGAR: Veradermics 8-K https://aibio.space/news/senti-biosciences-agrees-sell-10-0-million-secured-convertible-notes/https://aibio.space/news/senti-biosciences-agrees-sell-10-0-million-secured-convertible-notes/Fri, 01 May 2026 12:00:00 GMTMergersSenti Biosciences agreed to sell up to $40.0 million of secured convertible notes to an affiliate of its largest stockholder. If the notes are not converted, the company must pay 200% of principal in cash at maturity, and the second tranche depends on a related deal that could pay up to $60.0 million.Senti Biosciences Holdings, Inc. Form 8-K filed May 1, 2026 (SEC EDGAR) https://aibio.space/news/cue-biopharma-licenses-ascendant-221-ascendant-health-pay-15-0-million/https://aibio.space/news/cue-biopharma-licenses-ascendant-221-ascendant-health-pay-15-0-million/Fri, 01 May 2026 12:00:00 GMTFinancingsCue Biopharma agreed to pay a $15.0 million upfront for rights to Ascendant-221, an anti-IgE antibody still in a Phase 2 study run by the licensor's affiliate, and to issue pre-funded warrants for up to 551,724 shares. Milestones could reach $676.5 million, and the company's own release cites a current going concern determination.Cue Biopharma, Inc. Form 8-K filed May 1, 2026 (SEC EDGAR) https://aibio.space/news/hemab-therapeutics-holdings-prices-301-500-000-ipo-18-00-share/https://aibio.space/news/hemab-therapeutics-holdings-prices-301-500-000-ipo-18-00-share/Fri, 01 May 2026 12:00:00 GMTFinancingsThe company priced 16,750,000 shares at $18.00 each, with delivery expected on or about May 4, 2026. It had net losses of $63.9 million in 2025 and no approved products.Hemab Therapeutics Holdings, Inc. 424B4 (2026-05-01) https://aibio.space/news/regentis-biomaterials-files-sell-3-333-334-shares-assumed-3-00/https://aibio.space/news/regentis-biomaterials-files-sell-3-333-334-shares-assumed-3-00/Fri, 01 May 2026 12:00:00 GMTFinancingsRegentis Biomaterials Ltd. filed a Form F-1 on May 1, 2026 for a firm commitment offering through ThinkEquity. The $3.00 price is the April 28, 2026 NYSE American close.Regentis Biomaterials Ltd. F-1 (2026-05-01) https://aibio.space/news/seaport-therapeutics-prices-ipo-14-160-000-shares-18-00/https://aibio.space/news/seaport-therapeutics-prices-ipo-14-160-000-shares-18-00/Fri, 01 May 2026 12:00:00 GMTFinancingsThe offering totals $254,880,000 before fees, and Seaport expects net proceeds of about $233.9 million. Entities affiliated with General Atlantic, a holder of more than 5% of the stock, have indicated interest in up to $50 million of shares, which is not binding.Seaport Therapeutics, Inc. 424B4 (2026-05-01) https://aibio.space/news/enveric-corrects-reverse-split-maximum-proxy-materials-1-15/https://aibio.space/news/enveric-corrects-reverse-split-maximum-proxy-materials-1-15/Thu, 30 Apr 2026 12:00:00 GMTListingsA proxy supplement corrects a typographical error that showed a 1-for-50 maximum on the proxy card and notice before the May 28, 2026 annual meeting.Enveric Biosciences proxy supplement https://aibio.space/news/cocrystal-presents-cdi-988-norovirus-data-icar-2026/https://aibio.space/news/cocrystal-presents-cdi-988-norovirus-data-icar-2026/Thu, 30 Apr 2026 12:00:00 GMTCompany UpdatesThe company says the first cohort of its Phase 1b norovirus challenge study is fully enrolled, with prevention and treatment cohorts to follow.Cocrystal Pharma, Inc. 8-K (2026-04-30) https://aibio.space/news/pds-biotechnology-agrees-sell-6-000-000-promissory-note/https://aibio.space/news/pds-biotechnology-agrees-sell-6-000-000-promissory-note/Thu, 30 Apr 2026 12:00:00 GMTDebt FinancingThe 10% note matures in twelve months and is sold to YA II PN, LTD. for $5,760,000. It comes with a warrant for 2,158,274 shares at $1.1824 a share.PDS Biotechnology Corporation 8-K (2026-05-01) https://aibio.space/news/clearmind-amends-convertible-note-deal-leaving-10-million-available/https://aibio.space/news/clearmind-amends-convertible-note-deal-leaving-10-million-available/Thu, 30 Apr 2026 12:00:00 GMTDebt FinancingThe amendment raises the subscription amount so that $10,000,000 of capacity remains for future convertible promissory notes.Clearmind Medicine Form 6-K https://aibio.space/news/perrigo-completes-sale-dermacosmetics-business-karo-305-6-million-cash/https://aibio.space/news/perrigo-completes-sale-dermacosmetics-business-karo-305-6-million-cash/Thu, 30 Apr 2026 12:00:00 GMTMergersPerrigo (NYSE: PRGO) received €305.6 million at closing and may get up to €27.0 million more over three years. The company says net proceeds will be used primarily to reduce debt.PERRIGO Co plc Form 8-K filed April 30, 2026 (SEC EDGAR) https://aibio.space/news/addex-therapeutics-files-late-filing-notice-2025-annual-report-form-20/https://aibio.space/news/addex-therapeutics-files-late-filing-notice-2025-annual-report-form-20/Thu, 30 Apr 2026 12:00:00 GMTDistressAddex Therapeutics filed a Form NT 20-F on April 30, 2026, saying it will miss the deadline for its 2025 annual report. It reported a 2025 net loss of CHF 6.7 million, against a 2024 profit of CHF 7.1 million that the company ties to a sale of part of its business.Addex Therapeutics Ltd NT 20-F (2026-04-30) https://aibio.space/news/avalyn-pharma-prices-ipo-16-666-667-shares-18-00/https://aibio.space/news/avalyn-pharma-prices-ipo-16-666-667-shares-18-00/Thu, 30 Apr 2026 12:00:00 GMTFinancingsThe offering totals $300,000,006 before fees. The shares have been approved for listing on the Nasdaq Global Select Market as AVLN.Avalyn Pharma Inc. 424B4 (2026-04-30) https://aibio.space/news/rockwell-medical-put-reverse-stock-split-vote-june-12-2026-meeting/https://aibio.space/news/rockwell-medical-put-reverse-stock-split-vote-june-12-2026-meeting/Thu, 30 Apr 2026 12:00:00 GMTListingsDEK:Rockwell Medical's proxy asks holders to approve a reverse split at a virtual meeting on June 12, 2026. Approval needs a majority of the votes cast, and the company's 2025 net loss was $5.3 million.Rockwell Medical, Inc. DEF 14A (2026-04-30) https://aibio.space/news/tiziana-life-sciences-files-late-filing-notice-2025-annual-report-form/https://aibio.space/news/tiziana-life-sciences-files-late-filing-notice-2025-annual-report-form/Thu, 30 Apr 2026 12:00:00 GMTDistressThe company says compiling and reviewing the information has imposed time constraints. It undertakes to file no later than 15 days after the original due date.Tiziana Life Sciences Ltd NT 20-F (2026-04-30) https://aibio.space/news/valneva-prices-37-million-private-placement-shares-attached-warrants/https://aibio.space/news/valneva-prices-37-million-private-placement-shares-attached-warrants/Thu, 30 Apr 2026 12:00:00 GMTFinancingsValneva agreed on April 29, 2026 to sell 15,893,817 new shares, each with a warrant, for €37 million. The warrants could add about €47 million if every one is exercised, at €2.96 each.Valneva SE 6-K (2026-04-30) https://aibio.space/news/xtl-biopharmaceuticals-cannot-file-2025-form-20-f-citing-subsidiary/https://aibio.space/news/xtl-biopharmaceuticals-cannot-file-2025-form-20-f-citing-subsidiary/Thu, 30 Apr 2026 12:00:00 GMTDistressThe company says it lacks operational and financial data for its subsidiary The Social Proxy Ltd., which is in liquidation proceedings.XTL Biopharmaceuticals Ltd. NT 20-F (2026-04-30) https://aibio.space/news/osr-health-licenses-vxm01-bcm-europe-up-815-million/https://aibio.space/news/osr-health-licenses-vxm01-bcm-europe-up-815-million/Wed, 29 Apr 2026 12:00:00 GMTCompany UpdatesBCM Europe, the company's largest shareholder, holds an exclusive global license and has pledged its entire stake as collateral for milestone payments of up to $815 million.OSR Health, Inc. 8-K (2026-04-30) https://aibio.space/news/autolus-therapeutics-cut-about-13-percent-workforce-expects-about-8/https://aibio.space/news/autolus-therapeutics-cut-about-13-percent-workforce-expects-about-8/Wed, 29 Apr 2026 12:00:00 GMTDistressAutolus will cut about 13% of its workforce and expects about $8 million in severance and related charges, with savings of about $15 million a year from 2027. It reiterated 2026 AUCATZYL revenue guidance of $120 million to $135 million, while its 10-K reports a 2025 net loss of $287.5 million and cash used in operations of $283.6 million.Autolus Therapeutics plc Form 8-K filed April 29, 2026 (SEC EDGAR) https://aibio.space/news/autolus-therapeutics-cuts-about-13-percent-staff-targets-15-million/https://aibio.space/news/autolus-therapeutics-cuts-about-13-percent-staff-targets-15-million/Wed, 29 Apr 2026 12:00:00 GMTDistressThe company expects about $8 million in restructuring charges and continues to expect its cash to fund operations into the fourth quarter of 2027.Autolus Therapeutics plc 8-K (2026-04-29) https://aibio.space/news/cormedix-asks-holders-ratify-past-changes-preferred-stock-terms/https://aibio.space/news/cormedix-asks-holders-ratify-past-changes-preferred-stock-terms/Wed, 29 Apr 2026 12:00:00 GMTListingsCorMedix wants stockholders to ratify earlier changes to its Series E and Series C-3 preferred stock, and to let preferred holders alone approve future changes to those terms.CorMedix Inc. DEF 14A (2026-04-29) https://aibio.space/news/jyong-biotech-files-late-filing-notice-2025-annual-report-form-20/https://aibio.space/news/jyong-biotech-files-late-filing-notice-2025-annual-report-form-20/Wed, 29 Apr 2026 12:00:00 GMTDistressThe company says it needs more time to finalize its audited financial statements and expects to file within 15 calendar days of the due date.Jyong Biotech Ltd. NT 20-F (2026-04-29) https://aibio.space/news/puretech-delist-adss-nasdaq-keep-primary-london-listing/https://aibio.space/news/puretech-delist-adss-nasdaq-keep-primary-london-listing/Wed, 29 Apr 2026 12:00:00 GMTListingsPureTech will delist its American Depositary Shares from Nasdaq and keep its London listing. The Form 25 is expected around May 11, 2026, with the last Nasdaq trading day around May 20, and the company plans to deregister with the SEC afterward.PureTech Health PLC 6-K (2026-04-29) https://aibio.space/news/soligenix-flash-2-trial-recommended-halt-futility/https://aibio.space/news/soligenix-flash-2-trial-recommended-halt-futility/Tue, 28 Apr 2026 12:00:00 GMTCompany UpdatesAfter an interim efficacy analysis, the Data Monitoring Committee recommended stopping the Phase 3 HyBryte trial for futility, and Soligenix says it has approximately $5.9 million of cash.Soligenix, Inc. 8-K (2026-04-28) https://aibio.space/news/citius-oncology-gets-nasdaq-minimum-bid-price-deficiency-notice-has/https://aibio.space/news/citius-oncology-gets-nasdaq-minimum-bid-price-deficiency-notice-has/Tue, 28 Apr 2026 12:00:00 GMTListingsNasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until October 19, 2026 to cure, while its auditor has flagged going-concern doubt and its parent funds most operations.CITIUS ONCOLOGY, INC. Form 8-K filed April 28, 2026 (SEC EDGAR) https://aibio.space/news/avalo-therapeutics-agrees-pay-2-25-million-option-15-million-almatabio/https://aibio.space/news/avalo-therapeutics-agrees-pay-2-25-million-option-15-million-almatabio/Tue, 28 Apr 2026 12:00:00 GMTMergersAvalo can pay $5.125 million in cash or stock within 90 days instead of $15 million owed when a Phase 3 trial doses its first patient. If it does not, the milestone amount becomes $12.75 million.Avalo Therapeutics, Inc. Form 8-K filed April 28, 2026 (SEC EDGAR) https://aibio.space/news/inflarx-regains-nasdaq-bid-price-compliance/https://aibio.space/news/inflarx-regains-nasdaq-bid-price-compliance/Tue, 28 Apr 2026 12:00:00 GMTListingsNasdaq's notice dated April 27, 2026 says the ordinary shares closed at $1.00 or more for 10 consecutive business days. The matter is closed.InflaRx N.V. 6-K (2026-04-28) https://aibio.space/news/inmed-cuts-exercise-price-preferred-investment-options-0-80/https://aibio.space/news/inmed-cuts-exercise-price-preferred-investment-options-0-80/Mon, 27 Apr 2026 12:00:00 GMTFinancingsInMed agreed to amend the exercise prices on preferred investment options held by Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co., LLC to $0.80 per share.InMed Pharmaceuticals Inc. 8-K (2026-04-27) https://aibio.space/news/evofem-signs-exclusive-solosec-distribution-deal-sub-saharan-africa/https://aibio.space/news/evofem-signs-exclusive-solosec-distribution-deal-sub-saharan-africa/Mon, 27 Apr 2026 12:00:00 GMTCompany UpdatesClovis Davis Pharmaceuticals will lead distribution, promotion, marketing and sales of SOLOSEC in the territory. The release is dated April 27, 2026.Evofem Biosciences, Inc. 8-K (2026-04-30) https://aibio.space/news/scienture-closes-8-million-note-purchase-streeterville-capital/https://aibio.space/news/scienture-closes-8-million-note-purchase-streeterville-capital/Mon, 27 Apr 2026 12:00:00 GMTDebt FinancingThe April 27, 2026 agreement issued an A-1 note and a B note to Streeterville Capital, LLC. Maxim Group LLC served as placement agent.Scienture Holdings, Inc. 8-K (2026-05-01) https://aibio.space/news/ligand-pharmaceuticals-signs-merger-agreement-acquire-xoma-royalty-39/https://aibio.space/news/ligand-pharmaceuticals-signs-merger-agreement-acquire-xoma-royalty-39/Mon, 27 Apr 2026 12:00:00 GMTMergersLigand will pay about $739 million in equity value for XOMA Royalty, plus a contingent value right tied to litigation. The deal needs a XOMA Royalty stockholder vote and is expected to close in the third quarter of 2026.LIGAND PHARMACEUTICALS INC Form 8-K filed April 27, 2026 (SEC EDGAR) https://aibio.space/news/organon-agrees-acquired-sun-pharma-14-00-share-cash/https://aibio.space/news/organon-agrees-acquired-sun-pharma-14-00-share-cash/Mon, 27 Apr 2026 12:00:00 GMTMergersOrganon agreed on April 26, 2026 to be bought by Sun Pharma for $14.00 a share in cash, a 103% premium to an April 9 close set before a media report. The company's enterprise value is $11.75 billion, and it carries $8.6 billion of debt.Organon & Co. Form 8-K filed April 27, 2026 (SEC EDGAR) https://aibio.space/news/intellia-therapeutics-proposes-150-000-000-stock-offering-prices-10-75/https://aibio.space/news/intellia-therapeutics-proposes-150-000-000-stock-offering-prices-10-75/Mon, 27 Apr 2026 12:00:00 GMTFinancingsIntellia filed to sell $150 million of common stock on April 27, 2026 and priced 16,744,187 shares at $10.75 on April 28. Its preliminary cash at March 31 was $517.2 million, and its risk factors say the FDA has lifted a clinical hold on the nex-z Phase 3 trials.Intellia Therapeutics, Inc. 424B5 (2026-04-27) https://aibio.space/news/aspira-womens-health-names-john-strahley-chief-financial-officer/https://aibio.space/news/aspira-womens-health-names-john-strahley-chief-financial-officer/Sun, 26 Apr 2026 12:00:00 GMTCompany UpdatesJohn Strahley joins as a fractional CFO and chief accounting officer effective April 27, 2026, on a $167,000 base salary, after the consulting arrangement with Brian Hungerford ended.Aspira Women's Health Inc. 8-K (2026-04-30) https://aibio.space/news/onconetix-directors-oakley-meier-resign-dorf-named-chairman/https://aibio.space/news/onconetix-directors-oakley-meier-resign-dorf-named-chairman/Fri, 24 Apr 2026 12:00:00 GMTCompany UpdatesJosh Epstein joined the board on April 23, 2026 and chairs its Nominating and Corporate Governance Committee. The 8-K says neither resignation involved a disagreement with management.Onconetix, Inc. 8-K (2026-04-24) https://aibio.space/news/ispecimen-plans-1-40-reverse-stock-split-effective-april-27-2026/https://aibio.space/news/ispecimen-plans-1-40-reverse-stock-split-effective-april-27-2026/Fri, 24 Apr 2026 12:00:00 GMTListingsAfter the split, the company's 52,639,796 shares become 1,316,032 shares, and the stock trades split-adjusted from April 28, 2026.Press release (SEC Exhibit 99.1) https://aibio.space/news/telomir-pharmaceuticals-completes-acquisition-teli-pharmaceuticals-34/https://aibio.space/news/telomir-pharmaceuticals-completes-acquisition-teli-pharmaceuticals-34/Fri, 24 Apr 2026 12:00:00 GMTMergersTelomir acquired 100% of TELI on April 22, 2026 and now holds the global rights to Telomir-1. Bayshore Trust contributed $1 million at closing and entered an option to pay up to $4 million more if milestones are met.Telomir Pharmaceuticals, Inc. Form 8-K filed April 24, 2026 (SEC EDGAR) https://aibio.space/news/citius-pharmaceuticals-prices-5-million-registered-direct-offering-0/https://aibio.space/news/citius-pharmaceuticals-prices-5-million-registered-direct-offering-0/Fri, 24 Apr 2026 12:00:00 GMTFinancingsCitius Pharmaceuticals sold 4,730,457 shares at $0.985 and pre-funded warrants for 345,686 shares, and it will issue warrants at $0.86 a share. The prospectus supplement also reports substantial doubt about its ability to continue as a going concern.Citius Pharmaceuticals, Inc. 424B5 (2026-04-24) https://aibio.space/news/lakewood-amedex-files-prospectus-nasdaq-direct-listing-4-689-177/https://aibio.space/news/lakewood-amedex-files-prospectus-nasdaq-direct-listing-4-689-177/Thu, 23 Apr 2026 12:00:00 GMTFinancingsThe company will receive no proceeds from the resale. It also has agreements to sell 937,500 shares of Series C Preferred Stock for gross proceeds of $7,500,000, and its audited 2025 statements carry a going concern warning.Lakewood-Amedex Biotherapeutics Inc. 424B4 (2026-04-23) https://aibio.space/news/amneal-agrees-acquire-kashiv-biosciences-375-000-000-cash-28-942-108/https://aibio.space/news/amneal-agrees-acquire-kashiv-biosciences-375-000-000-cash-28-942-108/Wed, 22 Apr 2026 12:00:00 GMTFinancingsAmneal will pay $375 million in cash and issue 28,942,108 shares to buy Kashiv BioSciences, and some sellers are affiliates of the Amneal Group. Up to $350 million more depends on US regulatory milestones for Kashiv products.Amneal Pharmaceuticals, Inc. Form 8-K filed April 22, 2026 (SEC EDGAR) https://aibio.space/news/tevogen-bio-holdings-now-tevogen-inc-gets-two-nasdaq-deficiency/https://aibio.space/news/tevogen-bio-holdings-now-tevogen-inc-gets-two-nasdaq-deficiency/Wed, 22 Apr 2026 12:00:00 GMTListingsTevogen received two Nasdaq notices in April 2026 saying it no longer meets the $50 million listed-securities market value requirement or the $15 million publicly held shares requirement. It has until October 13 and October 14, 2026 to regain compliance with each.Tevogen Inc. Form 8-K filed April 22, 2026 (SEC EDGAR) https://aibio.space/news/apimeds-pharmaceuticals-gets-nyse-american-late-filing-notice-2025/https://aibio.space/news/apimeds-pharmaceuticals-gets-nyse-american-late-filing-notice-2025/Wed, 22 Apr 2026 12:00:00 GMTListingsNYSE Regulation told Apimeds Pharmaceuticals US on April 17, 2026 that it had not filed its 2025 annual report on time. The company has until October 15, 2026 to file, its stock carries a ".LF" tag, and a trading halt that began April 2 is still in effect.Apimeds Pharmaceuticals US, Inc. Form 8-K filed April 22, 2026 (SEC EDGAR) https://aibio.space/news/altimmune-launches-stock-warrant-offering-later-prices-3-00/https://aibio.space/news/altimmune-launches-stock-warrant-offering-later-prices-3-00/Wed, 22 Apr 2026 12:00:00 GMTFinancingsAltimmune sold 64,250,000 shares at $3.00 with a warrant for each share, against a last reported sale price of $3.47 on April 22, 2026.Altimmune, Inc. 424B5 (2026-04-22) https://aibio.space/news/cue-biopharma-sets-1-30-reverse-stock-split-april-23-2026/https://aibio.space/news/cue-biopharma-sets-1-30-reverse-stock-split-april-23-2026/Wed, 22 Apr 2026 12:00:00 GMTListingsCue Biopharma's 1-for-30 reverse split takes effect at 5:00 p.m. Eastern Time on April 23, 2026. The company says it is meant to restore compliance with Nasdaq's minimum bid price, and its filing still carries a going-concern determination.Cue Biopharma, Inc. 8-K (2026-04-22) https://aibio.space/news/maze-therapeutics-prices-150-million-stock-pre-funded-warrant-offering/https://aibio.space/news/maze-therapeutics-prices-150-million-stock-pre-funded-warrant-offering/Wed, 22 Apr 2026 12:00:00 GMTFinancingsMaze Therapeutics, Inc. is selling 5,540,000 shares at $23.50 each and pre-funded warrants for 850,000 shares. Leerink Partners LLC is sole underwriter, and dilution to new investors is $14.40 per share.Maze Therapeutics, Inc. 424B5 (2026-04-22) https://aibio.space/news/galera-obsidian-therapeutics-merger-moves-forward-gazelle-parent-s-4/https://aibio.space/news/galera-obsidian-therapeutics-merger-moves-forward-gazelle-parent-s-4/Wed, 22 Apr 2026 12:00:00 GMTMergersGazelle Parent, Inc. filed the registration statement on April 22, 2026. Galera has agreed to sell Series C preferred stock for about $350.0 million, less certain Obsidian financing proceeds, before the mergers close.Obsidian Therapeutics, Inc. S-4 (2026-04-22) https://aibio.space/news/hepion-raises-700-000-common-stock-private-placement/https://aibio.space/news/hepion-raises-700-000-common-stock-private-placement/Tue, 21 Apr 2026 12:00:00 GMTFinancingsThe agreements dated April 21, 2026 cover 17,500,000 shares at $0.04 per share, and the offering closed the same day. The filing names no underwriter or placement agent.Hepion Pharmaceuticals, Inc. 8-K (2026-04-22) https://aibio.space/news/casi-pharmaceuticals-says-2025-form-20-f-late-expects-going-concern/https://aibio.space/news/casi-pharmaceuticals-says-2025-form-20-f-late-expects-going-concern/Tue, 21 Apr 2026 12:00:00 GMTDistressCASI Pharmaceuticals filed a Form NT 20-F on April 21, 2026, saying its annual report on Form 20-F for 2025 will be late because its U.S. GAAP financial statements are not yet available. It expects that report to say there remains substantial doubt about its ability to continue as a going concern.CASI Pharmaceuticals, Inc. NT 20-F (2026-04-21) https://aibio.space/news/oruka-therapeutics-substitutes-selling-stockholder-resale-prospectus/https://aibio.space/news/oruka-therapeutics-substitutes-selling-stockholder-resale-prospectus/Tue, 21 Apr 2026 12:00:00 GMTFinancingsSILV Fund Ltd. replaces Point72 Associates, LLC for 531,670 shares. The resale prospectus still covers up to 39,425,806 shares, against 49,542,691 outstanding on February 28, 2026.Oruka Therapeutics, Inc. 424B7 (2026-04-21) https://aibio.space/news/lilly-end-rigel-ocadusertib-license-effective-june-15-2026/https://aibio.space/news/lilly-end-rigel-ocadusertib-license-effective-june-15-2026/Tue, 21 Apr 2026 12:00:00 GMTDistressEli Lilly gave notice on April 16, 2026 that it is terminating its license for ocadusertib, a RIPK1 inhibitor, effective June 15, 2026. Rigel expects to regain full rights and does not expect future milestones or royalties under the agreement.Rigel Pharmaceuticals, Inc. 8-K (2026-04-21) https://aibio.space/news/spruce-biosciences-announces-proposed-underwritten-public-offering/https://aibio.space/news/spruce-biosciences-announces-proposed-underwritten-public-offering/Mon, 20 Apr 2026 12:00:00 GMTFinancingsLeerink Partners, Guggenheim Securities and Oppenheimer & Co. are joint book-running managers, with Jones and Craig-Hallum as co-managers.Spruce Biosciences, Inc. 8-K (2026-04-22) https://aibio.space/news/semnur-terminates-two-share-purchase-agreements-tied-2025-merger/https://aibio.space/news/semnur-terminates-two-share-purchase-agreements-tied-2025-merger/Mon, 20 Apr 2026 12:00:00 GMTDistressSemnur ended a private placement agreement with JW Capital Securities Limited and a share purchase agreement with Biconomy PTE. Ltd. Neither agreement had produced any issued shares.Semnur Pharmaceuticals Form 8-K https://aibio.space/news/first-tracks-biotherapeutics-begins-nasdaq-trading-after-anaptysbio/https://aibio.space/news/first-tracks-biotherapeutics-begins-nasdaq-trading-after-anaptysbio/Mon, 20 Apr 2026 12:00:00 GMTMergersFirst Tracks Biotherapeutics began trading on Nasdaq as AnaptysBio completed the spin-off. The release says the company launches with $180 million in cash and a two-year cash runway that it calls a projection, while the 8-K allocates $100.0 million in cash to First Tracks.First Tracks Biotherapeutics, Inc. Form 8-K filed April 20, 2026 (SEC EDGAR) https://aibio.space/news/dare-bioscience-closes-sale-20-000-units-regulation-preferred-stock/https://aibio.space/news/dare-bioscience-closes-sale-20-000-units-regulation-preferred-stock/Mon, 20 Apr 2026 12:00:00 GMTFinancingsDaré issued 20,000 Investor Units at $5.00 each, with one Series A Convertible Preferred share and two warrants per unit. The offering is for up to 4,854,000 units, and the company's auditor has raised going concern doubt.Dare Bioscience, Inc. Form 8-K filed April 20, 2026 (SEC EDGAR) https://aibio.space/news/igc-pharma-sells-promissory-notes-firstfire-vanquish-funding-307-000/https://aibio.space/news/igc-pharma-sells-promissory-notes-firstfire-vanquish-funding-307-000/Mon, 20 Apr 2026 12:00:00 GMTDebt FinancingThe notes mature in 2027 and carry 12% interest. They can convert into common stock at 75% of the lowest trading price in the prior ten trading days, and only after an event of default.IGC Pharma, Inc. Form 8-K filed April 20, 2026 (SEC EDGAR) https://aibio.space/news/anaptysbio-completes-spin-off-first-tracks-biotherapeutics/https://aibio.space/news/anaptysbio-completes-spin-off-first-tracks-biotherapeutics/Mon, 20 Apr 2026 12:00:00 GMTMergersAnaptysBio completed the spin-off of First Tracks Biotherapeutics on April 20, 2026, one share for every share held on April 6. AnaptysBio keeps the royalty business and gives a range of $140-$145 million for its net cash, while the press release calls the spin-off taxable and cites an EBIT margin it does not reconcile to GAAP.ANAPTYSBIO, INC Form 8-K filed April 20, 2026 (SEC EDGAR) https://aibio.space/news/kailera-therapeutics-completes-ipo-718-8-million-gross-proceeds-16-00/https://aibio.space/news/kailera-therapeutics-completes-ipo-718-8-million-gross-proceeds-16-00/Mon, 20 Apr 2026 12:00:00 GMTFinancingsKailera Therapeutics (Nasdaq: KLRA) sold 44,921,875 shares in its initial public offering, including the underwriters' full option. A restated charter set up a classified board and exclusive forum rules.Kailera Therapeutics, Inc. Form 8-K filed April 20, 2026 (SEC EDGAR) https://aibio.space/news/anaptysbio-completes-spin-off-first-tracks-biotherapeutics/https://aibio.space/news/anaptysbio-completes-spin-off-first-tracks-biotherapeutics/Mon, 20 Apr 2026 12:00:00 GMTMergersShareholders received one First Tracks share for each AnaptysBio share held on April 6, 2026. AnaptysBio now manages two royalty collaborations and starts with about $140-$145 million in net cash.AnaptysBio, Inc. 8-K (2026-04-20) https://aibio.space/news/an2-therapeutics-sets-up-80-000-000-share-sales-program-jefferies/https://aibio.space/news/an2-therapeutics-sets-up-80-000-000-share-sales-program-jefferies/Mon, 20 Apr 2026 12:00:00 GMTFinancingsAN2 Therapeutics filed an $80,000,000 prospectus supplement dated April 20, 2026 for sales through Jefferies LLC, which will be deemed an underwriter, earns up to 3.0% of gross proceeds and is under no obligation to sell any set amount.AN2 Therapeutics, Inc. 424B5 (2026-04-20) https://aibio.space/news/first-tracks-biotherapeutics-begins-nasdaq-trading-trax-180-million/https://aibio.space/news/first-tracks-biotherapeutics-begins-nasdaq-trading-trax-180-million/Mon, 20 Apr 2026 12:00:00 GMTMergersThe company was spun off from AnaptysBio, Inc. on April 20, 2026. It says it has a two-year cash runway.First Tracks Biotherapeutics, Inc. 8-K (2026-04-20) https://aibio.space/news/theriva-present-virage-trial-biomarker-data-aacr-2026/https://aibio.space/news/theriva-present-virage-trial-biomarker-data-aacr-2026/Fri, 17 Apr 2026 12:00:00 GMTCompany UpdatesA poster on April 20, 2026 will report tumor response, biomarker and subgroup analyses from the VIRAGE Phase 2b trial of VCN-01.Theriva Biologics, Inc. 8-K (2026-04-17) https://aibio.space/news/emergent-biosolutions-closes-150-million-term-loan-orbimed-cuts-abl/https://aibio.space/news/emergent-biosolutions-closes-150-million-term-loan-orbimed-cuts-abl/Fri, 17 Apr 2026 12:00:00 GMTDebt FinancingEmergent drew a $150 million term loan with OrbiMed as administrative agent and repaid its prior credit agreement. Interest is Term SOFR plus 6.25%, with a 3.00% floor, and the loan matures as late as April 16, 2031. The asset-based revolver falls from $100 million to $50 million.Emergent BioSolutions Inc. Form 8-K filed April 17, 2026 (SEC EDGAR) https://aibio.space/news/alamar-biosciences-prices-ipo-11-250-000-shares-17-00-each/https://aibio.space/news/alamar-biosciences-prices-ipo-11-250-000-shares-17-00-each/Fri, 17 Apr 2026 12:00:00 GMTFinancingsAlamar priced 11,250,000 shares at $17.00 each, and the underwriters later exercised their option in full, bringing gross proceeds to about $219.9 million.Alamar Biosciences, Inc. 424B4 (2026-04-17) https://aibio.space/news/emergent-biosolutions-draws-150-million-orbimed-term-loan-repays-prior/https://aibio.space/news/emergent-biosolutions-draws-150-million-orbimed-term-loan-repays-prior/Fri, 17 Apr 2026 12:00:00 GMTDebt FinancingThe Credit Agreement also provides a $75 million delayed draw term loan, available for 24 months. Interest is Term SOFR plus 6.25% per annum, with a 3.00% floor.Emergent BioSolutions Inc. 8-K (2026-04-17) https://aibio.space/news/kailera-therapeutics-prices-ipo-39-062-500-shares-16-00/https://aibio.space/news/kailera-therapeutics-prices-ipo-39-062-500-shares-16-00/Fri, 17 Apr 2026 12:00:00 GMTFinancingsThe offering totals $625,000,000 before fees. Existing stockholders have indicated interest in buying up to approximately $225 million of shares.Kailera Therapeutics, Inc. 424B4 (2026-04-17) https://aibio.space/news/odyssey-therapeutics-files-ipo-plans-nasdaq-capital-market-listing/https://aibio.space/news/odyssey-therapeutics-files-ipo-plans-nasdaq-capital-market-listing/Fri, 17 Apr 2026 12:00:00 GMTFinancingsOdyssey Therapeutics, Inc. filed a Form S-1 on April 17, 2026. The cover leaves the share count and price range blank.Odyssey Therapeutics, Inc. S-1 (2026-04-17) https://aibio.space/news/emmaus-appoints-henry-du-board-audit-committee/https://aibio.space/news/emmaus-appoints-henry-du-board-audit-committee/Thu, 16 Apr 2026 12:00:00 GMTCompany UpdatesHenry H. Du, a certified public accountant and interim chief financial officer of Alpha Cognition, fills the board seat left by the resignation of Jon Kuwahara.Emmaus Life Sciences Form 8-K https://aibio.space/news/oncotelic-reports-249-0-million-2025-profit-non-cash-joint-venture/https://aibio.space/news/oncotelic-reports-249-0-million-2025-profit-non-cash-joint-venture/Thu, 16 Apr 2026 12:00:00 GMTCompany UpdatesThe result reflects a non-cash increase of approximately $365.4 million in the fair value of the company's GMP Biotechnology investment, partly offset by a tax provision.Oncotelic Therapeutics, Inc. 8-K (2026-04-16) https://aibio.space/news/enveric-announces-up-13-9-million-private-placement-priced-market/https://aibio.space/news/enveric-announces-up-13-9-million-private-placement-priced-market/Thu, 16 Apr 2026 12:00:00 GMTFinancingsThe company agreed to sell 2,222,223 shares at $2.25 per share with warrants, for about $5 million upfront, with H.C. Wainwright & Co. as placement agent.Enveric Biosciences 8-K, Exhibit 99.1 https://aibio.space/news/acurx-pharmaceuticals-prices-2-5-million-registered-direct-offering/https://aibio.space/news/acurx-pharmaceuticals-prices-2-5-million-registered-direct-offering/Thu, 16 Apr 2026 12:00:00 GMTFinancingsAcurx agreed to sell 816,068 shares at $3.03 and pre-funded warrants for 9,017 shares, plus Series H warrants at $2.78 in a concurrent private placement. H.C. Wainwright & Co., LLC is the placement agent, and the 10-K says existing resources will not fund operations for at least 12 months.Acurx Pharmaceuticals, Inc. Form 8-K filed April 16, 2026 (SEC EDGAR) https://aibio.space/news/achieve-life-sciences-agrees-180-million-private-placement-ceo-richard/https://aibio.space/news/achieve-life-sciences-agrees-180-million-private-placement-ceo-richard/Thu, 16 Apr 2026 12:00:00 GMTFinancingsAchieve Life Sciences agreed on April 15, 2026 to sell shares, pre-funded warrants and warrants for anticipated gross proceeds of about $180.0 million, with up to $173.8 million more if the warrants are exercised. Chief Executive Richard Stewart steps down on April 18, 2026.ACHIEVE LIFE SCIENCES, INC. Form 8-K filed April 16, 2026 (SEC EDGAR) https://aibio.space/news/meiragtx-buys-xlrp-gene-therapy-rights-janssen-25-000-000-upfront/https://aibio.space/news/meiragtx-buys-xlrp-gene-therapy-rights-janssen-25-000-000-upfront/Thu, 16 Apr 2026 12:00:00 GMTMergersMeiraGTx also agreed to a one-time $50,000,000 contingent payment and mid-teens royalties starting on or after July 1, 2029. The 8-K also reports an amendment with Hologen.MeiraGTx Holdings plc Form 8-K filed April 16, 2026 (SEC EDGAR) https://aibio.space/news/altimmune-holders-approve-doubling-authorized-shares-400-000-000/https://aibio.space/news/altimmune-holders-approve-doubling-authorized-shares-400-000-000/Thu, 16 Apr 2026 12:00:00 GMTListingsShareholders approved raising authorized common stock from 200,000,000 to 400,000,000 shares, against 130,105,177 shares outstanding at the March 13, 2026 record date.Altimmune, Inc. 8-K (2026-04-16) https://aibio.space/news/meiragtx-agrees-buy-bota-vec-johnson-johnson-25-million-upfront/https://aibio.space/news/meiragtx-agrees-buy-bota-vec-johnson-johnson-25-million-upfront/Thu, 16 Apr 2026 12:00:00 GMTMergersMeiraGTx will pay Johnson & Johnson $25 million in cash upfront for bota-vec, a gene therapy whose Phase 3 primary endpoint did not reach statistical significance. The company plans filings in the U.S., EU and Japan, with a potential launch in 2027.MeiraGTx Holdings plc 8-K (2026-04-16) https://aibio.space/news/trevi-therapeutics-prices-150-million-stock-offering-13-00-share/https://aibio.space/news/trevi-therapeutics-prices-150-million-stock-offering-13-00-share/Thu, 16 Apr 2026 12:00:00 GMTFinancingsTrevi sold 11,600,000 shares at $13.00 each, about $150 million, below the $14.54 last sale on April 16, 2026. Its two pivotal Phase 3 trials for Haduvio are not due to report until the second half of 2027 and the first half of 2028.Trevi Therapeutics, Inc. 424B5 (2026-04-16) https://aibio.space/news/traws-pharma-reports-2025-results-completes-up-60-million-pipe/https://aibio.space/news/traws-pharma-reports-2025-results-completes-up-60-million-pipe/Wed, 15 Apr 2026 12:00:00 GMTCompany UpdatesTraws says a $10 million upfront private placement, with up to $50 million more in warrants, supports operations into the first quarter of 2027, including a planned challenge trial of tivoxavir marboxil.Traws Pharma, Inc. SEC filing (Form 8-K) https://aibio.space/news/mustang-bio-receives-nasdaq-bid-price-deficiency-notice/https://aibio.space/news/mustang-bio-receives-nasdaq-bid-price-deficiency-notice/Wed, 15 Apr 2026 12:00:00 GMTListingsMustang Bio's common stock closed below $1.00 for 30 consecutive business days, and the company has until October 12, 2026 to regain compliance with the Nasdaq minimum bid price rule.Mustang Bio, Inc. 8-K (2026-04-17) https://aibio.space/news/cosmos-health-reports-2025-revenue-65-3-million-up-20-percent/https://aibio.space/news/cosmos-health-reports-2025-revenue-65-3-million-up-20-percent/Wed, 15 Apr 2026 12:00:00 GMTCompany UpdatesGross profit rose 83% to $7.90 million, and cash reached $3.46 million at December 31, 2025.Cosmos Health Inc. 8-K (2026-04-16) https://aibio.space/news/wave-life-sciences-plans-move-parent-company-singapore-delaware/https://aibio.space/news/wave-life-sciences-plans-move-parent-company-singapore-delaware/Wed, 15 Apr 2026 12:00:00 GMTMergersWave Life Sciences said on April 15, 2026 that its board approved moving the parent company from Singapore to Delaware. Shares would be exchanged one for one, and the company expects the change in mid-2026, subject to shareholder and Singapore High Court approval.Wave Life Sciences, Inc. 8-K (2026-04-15) https://aibio.space/news/pelthos-ceo-attend-investor-meetings-piper-sandler-symposium-boston/https://aibio.space/news/pelthos-ceo-attend-investor-meetings-piper-sandler-symposium-boston/Tue, 14 Apr 2026 12:00:00 GMTCompany UpdatesScott Plesha will hold one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026. The company also made a presentation available on its website.Pelthos Therapeutics Form 8-K https://aibio.space/news/telix-pharmaceuticals-prices-upsized-us-600-million-convertible-bonds/https://aibio.space/news/telix-pharmaceuticals-prices-upsized-us-600-million-convertible-bonds/Tue, 14 Apr 2026 12:00:00 GMTFinancingsTelix raised its convertible notes offering from US$550 million to US$600 million and will use most of the money to buy back its 2029 convertible bonds. The reference price for the conversion terms was set at an 8.0 per cent discount to the closing share price.Telix Pharmaceuticals Limited 6-K (2026-04-14) https://aibio.space/news/oragenics-doses-first-patient-phase-iia-concussion-trial/https://aibio.space/news/oragenics-doses-first-patient-phase-iia-concussion-trial/Mon, 13 Apr 2026 12:00:00 GMTCompany UpdatesThe first patient in the Phase IIa trial of ONP-002 was dosed at Mackay Hospital in Australia, the first site activated, with two more Australian sites expected to activate in the second quarter.Oragenics Inc. 8-K (2026-04-13) https://aibio.space/news/hepion-signs-separation-agreement-former-ceo-kaouthar-lbiati/https://aibio.space/news/hepion-signs-separation-agreement-former-ceo-kaouthar-lbiati/Mon, 13 Apr 2026 12:00:00 GMTCompany UpdatesThe April 13, 2026 agreement provides $225,000 and a pro-rata bonus of $30,625, plus six months of COBRA reimbursement. Dr. Lbiati also left the board that day.Hepion Pharmaceuticals, Inc. 8-K (2026-04-14) https://aibio.space/news/imagenebio-agrees-sell-pre-funded-warrants-about-30-million-private/https://aibio.space/news/imagenebio-agrees-sell-pre-funded-warrants-about-30-million-private/Mon, 13 Apr 2026 12:00:00 GMTFinancingsThe warrants cover up to 5,770,335 shares at $5.199 per warrant share, with closing expected on or about April 14, 2026. ImageneBio plans to use the proceeds for its IMG-007 programs.ImageneBio, Inc. Form 8-K filed April 13, 2026 (SEC EDGAR) https://aibio.space/news/cue-biopharma-holders-approve-reverse-split-range-1-30-1-50/https://aibio.space/news/cue-biopharma-holders-approve-reverse-split-range-1-30-1-50/Mon, 13 Apr 2026 12:00:00 GMTListingsCue Biopharma holders approved a reverse split at a ratio between 1-for-30 and 1-for-50. The board will pick the ratio and the timing without another stockholder vote, and the filing does not say why the split is wanted.Cue Biopharma, Inc. 8-K (2026-04-13) https://aibio.space/news/aim-immunotech-amends-market-sales-agreement-maxim-group/https://aibio.space/news/aim-immunotech-amends-market-sales-agreement-maxim-group/Fri, 10 Apr 2026 12:00:00 GMTFinancingsThe amendment names Maxim Group LLC as exclusive sales agent and removes the limit on the amount of shares that can be sold under the agreement.AIM ImmunoTech Inc. 8-K (2026-04-10) https://aibio.space/news/evofem-amends-adjuvant-convertible-note-terms-payment-date/https://aibio.space/news/evofem-amends-adjuvant-convertible-note-terms-payment-date/Fri, 10 Apr 2026 12:00:00 GMTDistressThe Fourth Amendment, dated April 10, 2026, makes the notes payable in full at the earliest of three events. It bars prepayment for six months without Adjuvant's consent.Evofem Biosciences, Inc. 8-K (2026-04-16) https://aibio.space/news/hemab-therapeutics-holdings-files-ipo-plans-nasdaq-listing-coag/https://aibio.space/news/hemab-therapeutics-holdings-files-ipo-plans-nasdaq-listing-coag/Fri, 10 Apr 2026 12:00:00 GMTFinancingsHemab Therapeutics Holdings, Inc. filed a Form S-1 on April 10, 2026, with the share count and price range left blank. Its lead drug has had serious thrombosis events, and the company reported a net loss of $63.9 million for 2025.Hemab Therapeutics Holdings, Inc. S-1 (2026-04-10) https://aibio.space/news/seaport-therapeutics-files-ipo-plans-nasdaq-listing-sptx/https://aibio.space/news/seaport-therapeutics-files-ipo-plans-nasdaq-listing-sptx/Fri, 10 Apr 2026 12:00:00 GMTFinancingsSeaport Therapeutics filed its Form S-1 on April 10, 2026 with the share count and price range still blank. The filing shows a 2025 net loss of $74,881 thousand and a stockholders' deficit of $92,545 thousand.Seaport Therapeutics, Inc. S-1 (2026-04-10) https://aibio.space/news/theriva-special-meeting-fails-quorum-new-meeting-called/https://aibio.space/news/theriva-special-meeting-fails-quorum-new-meeting-called/Thu, 09 Apr 2026 12:00:00 GMTCompany UpdatesA special meeting on share issuance for warrants did not convene because too few shares were present, and the company will call another meeting.Theriva Biologics, Inc. 8-K (2026-04-09) https://aibio.space/news/alaunos-receives-nasdaq-notice-stockholders-equity-requirement/https://aibio.space/news/alaunos-receives-nasdaq-notice-stockholders-equity-requirement/Thu, 09 Apr 2026 12:00:00 GMTListingsNasdaq says Alaunos does not meet its $2,500,000 minimum for stockholders' equity, and the company plans to submit a compliance plan.Alaunos Therapeutics, Inc. 8-K (2026-04-15) https://aibio.space/news/kyntra-bio-gets-nasdaq-deficiency-notice-50-million-total-assets/https://aibio.space/news/kyntra-bio-gets-nasdaq-deficiency-notice-50-million-total-assets/Thu, 09 Apr 2026 12:00:00 GMTListingsThe April 2, 2026 letter cites Listing Rule 5450(b)(3)(A) and revenue of FibroGen International held for sale. Kyntra Bio has 45 days, until May 18, 2026, to submit a plan to regain compliance.KYNTRA BIO, INC. Form 8-K filed April 9, 2026 (SEC EDGAR) https://aibio.space/news/gossamer-bio-receives-nasdaq-minimum-bid-price-deficiency-notice-has/https://aibio.space/news/gossamer-bio-receives-nasdaq-minimum-bid-price-deficiency-notice-has/Thu, 09 Apr 2026 12:00:00 GMTListingsGossamer Bio (Nasdaq: GOSS) says its stock did not maintain a $1.00 minimum bid price for 30 consecutive business days. It has 180 calendar days to regain compliance and may be eligible for an additional 180 days.Gossamer Bio, Inc. Form 8-K filed April 9, 2026 (SEC EDGAR) https://aibio.space/news/an2-therapeutics-sets-up-80-million-market-program-jefferies/https://aibio.space/news/an2-therapeutics-sets-up-80-million-market-program-jefferies/Thu, 09 Apr 2026 12:00:00 GMTFinancingsAN2 Therapeutics set up an $80 million at-the-market sales program with Jefferies LLC on April 9, 2026 and ended an earlier agreement with TD Securities, against a 2025 net loss of $35.2 million and cash used in operations of $29.8 million.AN2 Therapeutics, Inc. 8-K (2026-04-09) https://aibio.space/news/ensysce-biosciences-closes-2-million-series-b-preferred-stock-warrant/https://aibio.space/news/ensysce-biosciences-closes-2-million-series-b-preferred-stock-warrant/Wed, 08 Apr 2026 12:00:00 GMTFinancingsEnsysce Biosciences sold 2,000 shares of Series B preferred stock for $2 million on April 6, 2026, to 3i, LP. The deal comes with warrants for up to 8,727,273 common shares, all at $0.55, and the stated value of the preferred stock was raised from $1,100 to $1,200 a share.Ensysce Biosciences, Inc. Form 8-K filed April 8, 2026 (SEC EDGAR) https://aibio.space/news/avalyn-pharma-files-ipo-plans-nasdaq-global-market-listing-avln/https://aibio.space/news/avalyn-pharma-files-ipo-plans-nasdaq-global-market-listing-avln/Wed, 08 Apr 2026 12:00:00 GMTFinancingsAvalyn Pharma Inc. filed a Form S-1 on April 8, 2026. The cover leaves the share count and price range blank.Avalyn Pharma Inc. S-1 (2026-04-08) https://aibio.space/news/phio-pharmaceuticals-sets-up-6-360-000-market-program/https://aibio.space/news/phio-pharmaceuticals-sets-up-6-360-000-market-program/Wed, 08 Apr 2026 12:00:00 GMTFinancingsPhio set up an at-the-market program that lets it sell up to $6,360,000 of common stock through H.C. Wainwright & Co., LLC, with a 3.0% commission. The size is capped because its public float is only $19,080,217, and its auditors have raised a going concern doubt.Phio Pharmaceuticals Corp. 8-K (2026-04-08) https://aibio.space/news/adial-grants-restricted-stock-awards-executives-directors/https://aibio.space/news/adial-grants-restricted-stock-awards-executives-directors/Tue, 07 Apr 2026 12:00:00 GMTCompany UpdatesThe compensation committee approved restricted stock awards on April 7, 2026 for Cary Claiborne, Vinay Shah, Tony Goodman and other directors, vesting on the first anniversary or on a change of control.Adial Pharmaceuticals, Inc 8-K (2026-04-09) https://aibio.space/news/protagenic-end-chief-financial-officers-employment-april-30-2026/https://aibio.space/news/protagenic-end-chief-financial-officers-employment-april-30-2026/Tue, 07 Apr 2026 12:00:00 GMTCompany UpdatesThe board notified Alexander Arrow, MD, on March 31, 2026, that his employment will be terminated effective April 30, 2026. The filing gives no reason for the decision.Protagenic Therapeutics Form 8-K https://aibio.space/news/aquabounty-exchanges-4-000-000-senior-notes-preferred-stock/https://aibio.space/news/aquabounty-exchanges-4-000-000-senior-notes-preferred-stock/Tue, 07 Apr 2026 12:00:00 GMTFinancingsA note exchange and a $500,000 preferred sale both closed April 7, 2026. Univest Securities, LLC was the placement agent for the offering.AquaBounty Technologies, Inc. 8-K (2026-04-08) https://aibio.space/news/artelo-regains-nasdaq-listing-compliance-under-one-year-panel-monitor/https://aibio.space/news/artelo-regains-nasdaq-listing-compliance-under-one-year-panel-monitor/Tue, 07 Apr 2026 12:00:00 GMTListingsNasdaq confirmed that Artelo Biosciences has regained compliance with its equity and annual meeting rules. The company is now subject to a one-year panel monitor.Artelo Biosciences press release (Form 8-K, Exhibit 99.1) https://aibio.space/news/supernus-acquires-navitors-nv-5138-assets-study-pledge-up-350-million/https://aibio.space/news/supernus-acquires-navitors-nv-5138-assets-study-pledge-up-350-million/Tue, 07 Apr 2026 12:00:00 GMTMergersSupernus agreed on April 1, 2026 to buy the NV-5138 assets from Navitor. The price is an obligation to complete one Phase 2b study plus milestone payments of up to $350 million, and Supernus may stop pursuing the milestones if it judges the study unsuccessful.SUPERNUS PHARMACEUTICALS, INC. Form 8-K filed April 7, 2026 (SEC EDGAR) https://aibio.space/news/kiora-pharmaceuticals-closes-private-placement-up-24-million/https://aibio.space/news/kiora-pharmaceuticals-closes-private-placement-up-24-million/Tue, 07 Apr 2026 12:00:00 GMTFinancingsKiora Pharmaceuticals, Inc. closed the deal with Perceptive Advisors and ADAR1 Capital Management on April 6, 2026, with $5.0 million in upfront funding. Up to $19 million more could come if milestone-based warrants are exercised.Kiora Pharmaceuticals, Inc. 8-K (2026-04-07) https://aibio.space/news/northwest-biotherapeutics-reports-october-2025-closing-advent/https://aibio.space/news/northwest-biotherapeutics-reports-october-2025-closing-advent/Tue, 07 Apr 2026 12:00:00 GMTMergersThe company bought the UK manufacturer from a seller controlled by its chief executive. Payment is due in installments over two years.Northwest Biotherapeutics, Inc. 8-K (2026-04-07) https://aibio.space/news/sunshine-biopharma-reports-fiscal-2025-revenue-36-3-million/https://aibio.space/news/sunshine-biopharma-reports-fiscal-2025-revenue-36-3-million/Mon, 06 Apr 2026 12:00:00 GMTCompany UpdatesThe company says 2025 revenue rose 4.1% and its net loss was $5.98 million, which it attributes partly to a $1.75 million impairment charge, and it expects cost cuts of $2 million to $3 million in 2026.Sunshine Biopharma Inc. 8-K (2026-04-09) https://aibio.space/news/ensysce-director-curtis-rosebraugh-resigns-board/https://aibio.space/news/ensysce-director-curtis-rosebraugh-resigns-board/Fri, 03 Apr 2026 12:00:00 GMTCompany UpdatesEnsysce Biosciences said director Curtis Rosebraugh resigned effective April 1, 2026, and that he had served on the Nominating and Corporate Governance Committee.Ensysce Biosciences, Inc. 8-K (2026-04-03) https://aibio.space/news/matinas-biopharma-receives-nyse-american-notice-three-equity-standards/https://aibio.space/news/matinas-biopharma-receives-nyse-american-notice-three-equity-standards/Fri, 03 Apr 2026 12:00:00 GMTListingsNYSE American says Matinas BioPharma is out of compliance with three stockholders' equity standards, with equity of $4.83 million at December 31, 2025, and a plan due by May 2, 2026.Matinas Biopharma Holdings, Inc. 8-K (2026-04-03) https://aibio.space/news/lisata-kuva-labs-push-back-tender-offer-start-april-13-2026/https://aibio.space/news/lisata-kuva-labs-push-back-tender-offer-start-april-13-2026/Fri, 03 Apr 2026 12:00:00 GMTMergersLisata and Kuva Labs agreed on April 2, 2026 to move the tender offer start from April 3 to April 13, 2026, or a later agreed date. The offer pays $5.00 in cash plus a $1.00 contingent right, and Lisata's 10-K says its $16.0 million in cash does not cover twelve months of spending.LISATA THERAPEUTICS, INC. Form 8-K filed April 3, 2026 (SEC EDGAR) https://aibio.space/news/entera-bio-sells-7-827-789-units-bvf-affiliated-funds-1-2775-each/https://aibio.space/news/entera-bio-sells-7-827-789-units-bvf-affiliated-funds-1-2775-each/Fri, 03 Apr 2026 12:00:00 GMTFinancingsEntera Bio sold 7,827,789 units to funds affiliated with BVF Partners LP at $1.2775 a unit, with the closing on April 2, 2026. The 8-K names no placement agent or bank, and the company's 10-K says its cash covers operations only through the middle of the third quarter of 2026.Entera Bio Ltd. Form 8-K filed April 3, 2026 (SEC EDGAR) https://aibio.space/news/aurinia-unit-agrees-acquire-kezar-life-sciences-tender-offer-6-955/https://aibio.space/news/aurinia-unit-agrees-acquire-kezar-life-sciences-tender-offer-6-955/Fri, 03 Apr 2026 12:00:00 GMTMergersAn Aurinia subsidiary will buy Kezar Life Sciences for $6.955 in cash per share plus a CVR, but the offer depends on Kezar holding at least $50.0 million of net cash at closing. The deal is expected to close in the second quarter of 2026.Aurinia Pharmaceuticals Inc. Form 8-K filed April 3, 2026 (SEC EDGAR) https://aibio.space/news/aeon-biopharma-receives-additional-nyse-american-notice-stockholders/https://aibio.space/news/aeon-biopharma-receives-additional-nyse-american-notice-stockholders/Fri, 03 Apr 2026 12:00:00 GMTListingsThe notice cites a stockholders' deficit of approximately $55 million as of December 31, 2025. AEON keeps its listing and has until August 3, 2026 to regain compliance.AEON Biopharma, Inc. Form 8-K filed April 3, 2026 (SEC EDGAR) https://aibio.space/news/aardvark-therapeutics-sets-up-150-000-000-share-sales-program-piper/https://aibio.space/news/aardvark-therapeutics-sets-up-150-000-000-share-sales-program-piper/Fri, 03 Apr 2026 12:00:00 GMTFinancingsThe Equity Distribution Agreement is dated March 23, 2026. Piper Sandler's commission is 3.0% of the gross sales price per share, and the prospectus says the $4.07 share price is below net tangible book value per share.Aardvark Therapeutics, Inc. 424B5 (2026-04-03) https://aibio.space/news/kioras-chief-development-officer-eric-daniels-depart-april-17-2026/https://aibio.space/news/kioras-chief-development-officer-eric-daniels-depart-april-17-2026/Thu, 02 Apr 2026 12:00:00 GMTCompany UpdatesKiora said Eric J. Daniels, M.D., MBA, will leave his role as Chief Development Officer on April 17, 2026, and that the company has started a search for a successor. The company's ABACUS-2 and KLARITY trials continue.Kiora Pharmaceuticals, Inc. 8-K (2026-04-02) https://aibio.space/news/fda-grants-fast-track-designation-cdi-988-norovirus/https://aibio.space/news/fda-grants-fast-track-designation-cdi-988-norovirus/Thu, 02 Apr 2026 12:00:00 GMTCompany UpdatesThe oral antiviral candidate gains earlier FDA contact and a possible path to Priority Review, Cocrystal said in an April 2, 2026 release.Cocrystal Pharma, Inc. 8-K (2026-04-02) https://aibio.space/news/caris-life-sciences-takes-400-000-000-term-loan-blue-owl-blackstone/https://aibio.space/news/caris-life-sciences-takes-400-000-000-term-loan-blue-owl-blackstone/Thu, 02 Apr 2026 12:00:00 GMTDebt FinancingCaris Life Sciences took a $400,000,000 term loan from funds managed by Blue Owl and Blackstone to repay its 2023 credit agreement. The new deal also adds a $300,000,000 delayed draw facility for acquisitions, and the company already reported $796.3 million of cash at the end of 2025.Caris Life Sciences, Inc. Form 8-K filed April 2, 2026 (SEC EDGAR) https://aibio.space/news/adagene-prices-us-70-0-million-offering-18-666-000-adss-us-3-75/https://aibio.space/news/adagene-prices-us-70-0-million-offering-18-666-000-adss-us-3-75/Thu, 02 Apr 2026 12:00:00 GMTFinancingsAdagene Inc. priced 18,666,000 American depositary shares at $3.75 for about $70.0 million gross, below the $4.61 last sale price on April 1. Leerink Partners LLC and LifeSci Capital LLC are joint book-running managers, and cash stood at $74.5 million at the end of 2025.Adagene Inc. 424B5 (2026-04-02) https://aibio.space/news/cyclerion-now-korsana-biosciences-agrees-all-stock-merger-korsana-380/https://aibio.space/news/cyclerion-now-korsana-biosciences-agrees-all-stock-merger-korsana-380/Wed, 01 Apr 2026 12:00:00 GMTMergersCyclerion and private Korsana Biosciences signed a merger agreement on April 1, 2026. A concurrent private financing of approximately $380 million is expected to fund Korsana's operations into 2029.Korsana Biosciences, Inc. Form 8-K filed April 1, 2026 (SEC EDGAR) https://aibio.space/news/quince-therapeutics-now-irulya-therapeutics-files-nt-10-k-after-phase/https://aibio.space/news/quince-therapeutics-now-irulya-therapeutics-files-nt-10-k-after-phase/Wed, 01 Apr 2026 12:00:00 GMTDistressThe company says it needs more time to complete its 2025 annual report because of reduced headcount and negative Phase 3 results. It expects to file within the fifteen calendar day extension under Rule 12b-25.IRulya Therapeutics Inc. Form NT 10-K filed April 1, 2026 (SEC EDGAR) https://aibio.space/news/scilex-files-nt-10-k-needs-more-time-financial-statements-including/https://aibio.space/news/scilex-files-nt-10-k-needs-more-time-financial-statements-including/Wed, 01 Apr 2026 12:00:00 GMTDistressScilex Holding Company says it could not file its annual report by the March 31, 2026 due date and expects to file by April 15, 2026. It says it needs more time to finalize financial statements, including consolidating Vivasor Holding Company.Scilex Holding Co Form NT 10-K filed April 1, 2026 (SEC EDGAR) https://aibio.space/news/china-pharma-holdings-files-nt-10-k-late-annual-report-estimates-3-19/https://aibio.space/news/china-pharma-holdings-files-nt-10-k-late-annual-report-estimates-3-19/Wed, 01 Apr 2026 12:00:00 GMTDistressChina Pharma says it will file its 2025 annual report within fifteen calendar days after March 31, 2026. Its estimates show revenue of $4.1 million and a net loss of about $3.19 million, and its auditors have raised going-concern doubt before.CHINA PHARMA HOLDINGS, INC. Form NT 10-K filed April 1, 2026 (SEC EDGAR) https://aibio.space/news/apollomics-signs-2-0-million-convertible-note-chairman-ceo/https://aibio.space/news/apollomics-signs-2-0-million-convertible-note-chairman-ceo/Wed, 01 Apr 2026 12:00:00 GMTDebt FinancingApollomics signed a $2.0 million unsecured note with its chairman and chief executive, Hung-Wen (Howard) Chen, on March 30, 2026, at 0% interest, which converts into equity at a 20% discount if the company later raises at least $10.0 million.Apollomics, Inc. 6-K (2026-04-01) https://aibio.space/news/cardiol-therapeutics-reports-31-million-raised-cash-runway-q4-2027/https://aibio.space/news/cardiol-therapeutics-reports-31-million-raised-cash-runway-q4-2027/Wed, 01 Apr 2026 12:00:00 GMTFinancingsCardiol says $31 million of gross proceeds from an October 2025 private placement and a January 2026 bought deal funds it through its Phase III pericarditis trial. The release names no underwriter or placement agent.Cardiol Therapeutics Inc. 6-K (2026-04-01) https://aibio.space/news/therapeuticsmd-files-late-notice-after-printer-error-left-out-auditor/https://aibio.space/news/therapeuticsmd-files-late-notice-after-printer-error-left-out-auditor/Wed, 01 Apr 2026 12:00:00 GMTDistressTherapeuticsMD filed a Form 12b-25 notice on April 1, 2026 after a printer error left the predecessor auditor's report out of its 2025 annual report. The company reported a 2025 net loss of $569,000 and year-end cash of $7.5 million.TherapeuticsMD, Inc. NT 10-K (2026-04-01) https://aibio.space/news/greenwich-lifesciences-inc-files-nt-10-k-says-annual-report-will-late/https://aibio.space/news/greenwich-lifesciences-inc-files-nt-10-k-says-annual-report-will-late/Tue, 31 Mar 2026 12:00:00 GMTDistressGreenwich LifeSciences said on March 31, 2026 that its annual report for 2025 would be late. Its 2024 annual report already carried an auditor's going concern paragraph, with $4,091,990 in cash at year end against a $15,788,809 net loss.Greenwich LifeSciences, Inc. Form NT 10-K filed March 31, 2026 (SEC EDGAR) https://aibio.space/news/zenas-biopharma-closes-200-000-000-convertible-senior-notes-offering/https://aibio.space/news/zenas-biopharma-closes-200-000-000-convertible-senior-notes-offering/Tue, 31 Mar 2026 12:00:00 GMTDebt FinancingZenas BioPharma closed a $200 million offering of 2.50% convertible senior notes due 2032, with net proceeds of about $193.7 million and Jefferies, Evercore, Citigroup and Guggenheim as representatives. Its 10-K reports substantial doubt about going concern.Zenas BioPharma, Inc. Form 8-K filed March 31, 2026 (SEC EDGAR) https://aibio.space/news/geovax-labs-files-nt-10-k-says-2025-annual-report-will-late/https://aibio.space/news/geovax-labs-files-nt-10-k-says-2025-annual-report-will-late/Tue, 31 Mar 2026 12:00:00 GMTDistressGeoVax missed the March 31, 2026 deadline for its 2025 annual report and expects to file within 15 days. It expects a 2025 net loss of about $21.5 million, and its 2024 annual report carried a going-concern warning from the auditors.GeoVax Labs, Inc. Form NT 10-K filed March 31, 2026 (SEC EDGAR) https://aibio.space/news/oramed-closes-oratech-sale-lifeward-shares-warrants-revenue-share/https://aibio.space/news/oramed-closes-oratech-sale-lifeward-shares-warrants-revenue-share/Tue, 31 Mar 2026 12:00:00 GMTMergersOramed Pharmaceuticals closed the sale of its Oratech subsidiary to Lifeward Ltd. on March 25, 2026, for 1,250,363 Lifeward ordinary shares, pre-funded warrants, warrants and a 4% revenue share on ReWalk products. The same day it bought $9,000,000 of Lifeward convertible notes, and Lifeward carries a going-concern warning of its own.ORAMED PHARMACEUTICALS INC. Form 8-K filed March 31, 2026 (SEC EDGAR) https://aibio.space/news/traws-pharma-files-nt-10-k-cites-financing-efforts-going-concern/https://aibio.space/news/traws-pharma-files-nt-10-k-cites-financing-efforts-going-concern/Tue, 31 Mar 2026 12:00:00 GMTDistressTraws Pharma filed a Form NT 10-K on March 31, 2026, saying it has not yet signed any financing and needs time to assess how a deal would affect its going-concern evaluation. The notice also gives unaudited 2025 net income of about $9.2 million, driven by a $26.7 million warrant accounting gain.Traws Pharma, Inc. Form NT 10-K filed March 31, 2026 (SEC EDGAR) https://aibio.space/news/sunshine-biopharma-files-nt-10-k-says-annual-report-will-late/https://aibio.space/news/sunshine-biopharma-files-nt-10-k-says-annual-report-will-late/Tue, 31 Mar 2026 12:00:00 GMTDistressSunshine Biopharma filed a Form 12b-25 on March 31, 2026 for its 10-K for the year ended December 31, 2025. It cites time constraints and says it will file no later than fifteen days after the original due date. Its 2024 net loss was $5,134,116.Sunshine Biopharma Inc. Form NT 10-K filed March 31, 2026 (SEC EDGAR) https://aibio.space/news/transcode-therapeutics-files-nt-10-k-says-2025-annual-report-will-late/https://aibio.space/news/transcode-therapeutics-files-nt-10-k-says-2025-annual-report-will-late/Tue, 31 Mar 2026 12:00:00 GMTDistressTransCode blames the complexity of accounting for its October 2025 deal with DEFJ, LLC, including a roughly $25 million Series B preferred placement. It expects to file within the extension period.Transcode Therapeutics, Inc. Form NT 10-K filed March 31, 2026 (SEC EDGAR) https://aibio.space/news/scynexis-acquires-poxels-pxl-770-8-000-000-upfront-up-188-000-000/https://aibio.space/news/scynexis-acquires-poxels-pxl-770-8-000-000-upfront-up-188-000-000/Tue, 31 Mar 2026 12:00:00 GMTMergersUnder an asset purchase agreement dated March 30, 2026, SCYNEXIS acquired Poxel's AMP kinase activator assets, including PXL-770, now SCY-770, and received a worldwide license.SCYNEXIS INC Form 8-K filed March 31, 2026 (SEC EDGAR) https://aibio.space/news/northwest-biotherapeutics-says-10-k-late-advent-bioservices-accounting/https://aibio.space/news/northwest-biotherapeutics-says-10-k-late-advent-bioservices-accounting/Tue, 31 Mar 2026 12:00:00 GMTDistressThe company cites issues tied to its Advent BioServices acquisition, including differences between UK GAAP and US GAAP. The notice gives no date for the annual report.Northwest Biotherapeutics, Inc. NT 10-K (2026-03-31) https://aibio.space/news/silo-issues-2-100-000-shares-qwikagents-software-domains/https://aibio.space/news/silo-issues-2-100-000-shares-qwikagents-software-domains/Mon, 30 Mar 2026 12:00:00 GMTCompany UpdatesSilo filed an 8-K covering an asset purchase from Many Ads Inc. paid for with 2,100,000 shares of common stock. The filing names no underwriter or placement agent.Silo Pharma, Inc. 8-K (2026-04-02) https://aibio.space/news/inmed-pharmaceuticals-gets-nasdaq-minimum-bid-price-deficiency-notice/https://aibio.space/news/inmed-pharmaceuticals-gets-nasdaq-minimum-bid-price-deficiency-notice/Mon, 30 Mar 2026 12:00:00 GMTListingsNasdaq told InMed on March 27, 2026 that its shares closed below $1.00 for 30 consecutive trading days. The company has 180 calendar days to regain compliance and keeps trading as INM.InMed Pharmaceuticals Inc. Form 8-K filed March 30, 2026 (SEC EDGAR) https://aibio.space/news/dyadic-international-gets-nasdaq-deficiency-notice-under-rule-5550/https://aibio.space/news/dyadic-international-gets-nasdaq-deficiency-notice-under-rule-5550/Mon, 30 Mar 2026 12:00:00 GMTListingsDyadic received a Nasdaq notice on March 27, 2026 that it is out of compliance with Listing Rule 5550(b). It has until May 11, 2026 to submit a plan to regain compliance, and a separate bid price deadline of June 17, 2026 also stands.DYADIC INTERNATIONAL INC Form 8-K filed March 30, 2026 (SEC EDGAR) https://aibio.space/news/kazia-reports-aud-69-46-million-cash-after-us-46-51-million-pipe-half/https://aibio.space/news/kazia-reports-aud-69-46-million-cash-after-us-46-51-million-pipe-half/Mon, 30 Mar 2026 12:00:00 GMTListingsOrdinary shares rose to 5,667,995,734 from 809,418,734 in six months. Nasdaq confirmed on 18 December 2025 that the company had regained compliance with Listing Rule 5550(b).Kazia Therapeutics Limited 6-K (2026-03-30) https://aibio.space/news/onkure-therapeutics-agrees-150-0-million-private-placement-4-15-share/https://aibio.space/news/onkure-therapeutics-agrees-150-0-million-private-placement-4-15-share/Mon, 30 Mar 2026 12:00:00 GMTFinancingsOnKure Therapeutics, Inc. is selling 26,713,636 shares and pre-funded warrants for 9,430,959 shares to institutional accredited investors. AI Biotechnology LLC is lead investor and gets a board nominee right.OnKure Therapeutics, Inc. 8-K (2026-03-30) https://aibio.space/news/zivo-bioscience-delist-otc-markets-file-form-15-end-sec-reporting/https://aibio.space/news/zivo-bioscience-delist-otc-markets-file-form-15-end-sec-reporting/Mon, 30 Mar 2026 12:00:00 GMTListingsThe board says SEC reporting costs are no longer in the best interests of the company and its stockholders. ZIVO plans to file the form on or around March 30, 2026.Zivo Bioscience, Inc. 8-K (2026-03-30) https://aibio.space/news/palisade-bio-sells-3-0-million-stock-affiliate-iterative-health/https://aibio.space/news/palisade-bio-sells-3-0-million-stock-affiliate-iterative-health/Fri, 27 Mar 2026 12:00:00 GMTFinancingsThe company sold 1,536,885 shares at $1.952 per share, with the sale closing on March 27, 2026. It also signed an agreement with Iterative Health to help enroll patients in its planned Phase 2 ulcerative colitis study.Palisade Bio, Inc. 8-K (2026-04-02) https://aibio.space/news/alamar-biosciences-files-ipo-plans-nasdaq-listing-almr/https://aibio.space/news/alamar-biosciences-files-ipo-plans-nasdaq-listing-almr/Fri, 27 Mar 2026 12:00:00 GMTFinancingsAlamar Biosciences filed an S-1 on March 27, 2026, reporting a 2025 net loss of $29.8 million on revenue of $74.2 million. The cover leaves the share count and price range blank.Alamar Biosciences, Inc. S-1 (2026-03-27) https://aibio.space/news/anaptysbio-board-approves-first-tracks-spin-off-set-launch-180-million/https://aibio.space/news/anaptysbio-board-approves-first-tracks-spin-off-set-launch-180-million/Fri, 27 Mar 2026 12:00:00 GMTFinancingsAnaptysBio will spin off First Tracks Bio on April 20, 2026 with $180 million of cash, $100 million of it from AnaptysBio itself, and the release gives no results for the spun-off company's lead programs.AnaptysBio, Inc. 8-K (2026-03-27) https://aibio.space/news/kailera-therapeutics-files-ipo-plans-nasdaq-listing-klra/https://aibio.space/news/kailera-therapeutics-files-ipo-plans-nasdaq-listing-klra/Fri, 27 Mar 2026 12:00:00 GMTFinancingsKailera Therapeutics, Inc. filed a Form S-1 on March 27, 2026. The cover leaves the share count and price range blank.Kailera Therapeutics, Inc. S-1 (2026-03-27) https://aibio.space/news/satellos-bioscience-reports-us-57-2-million-february-offering-runway/https://aibio.space/news/satellos-bioscience-reports-us-57-2-million-february-offering-runway/Fri, 27 Mar 2026 12:00:00 GMTFinancingsSatellos Bioscience Inc closed the equity offering on February 9, 2026 and began trading on the Nasdaq Global Market under the ticker MSLE. Cash was $27.7 million at year end.Satellos Bioscience Inc 6-K (2026-03-27) https://aibio.space/news/quantum-biopharma-reports-2025-results-believes-cash-lasts-past/https://aibio.space/news/quantum-biopharma-reports-2025-results-believes-cash-lasts-past/Fri, 27 Mar 2026 12:00:00 GMTListingsQuantum BioPharma reports $11.3 million in cash and digital assets at the filing date and says cash lasts beyond January 2028. Its annual report shows year-end cash of $1.9 million, and the release does not split out the digital assets.Quantum Biopharma Ltd. 6-K (2026-03-27) https://aibio.space/news/maplight-annual-report-details-200-million-series-d-preferred/https://aibio.space/news/maplight-annual-report-details-200-million-series-d-preferred/Thu, 26 Mar 2026 12:00:00 GMTFinancingsThe 2025 financing closed in two parts before the IPO. Holders tied to board members were among the buyers, the proxy shows.MPLT 10-K https://aibio.space/news/meiragtx-extends-perceptive-notes-may-2027-agrees-redeem-25-000-000/https://aibio.space/news/meiragtx-extends-perceptive-notes-may-2027-agrees-redeem-25-000-000/Thu, 26 Mar 2026 12:00:00 GMTFinancingsMeiraGTx (Nasdaq: MGTX) moved the maturity of its Perceptive notes from August 2, 2026 to May 2, 2027. It will redeem $25,000,000 by June 30, 2026, and Perceptive's warrants are repriced to $8.00.MeiraGTx Holdings plc Form 8-K filed March 26, 2026 (SEC EDGAR) https://aibio.space/news/upstream-bio-sets-up-150-000-000-market-stock-program-leerink/https://aibio.space/news/upstream-bio-sets-up-150-000-000-market-stock-program-leerink/Thu, 26 Mar 2026 12:00:00 GMTFinancingsUpstream Bio signed a sales agreement with Leerink Partners LLC on March 26, 2026 that lets it sell up to $150,000,000 of common stock on the Nasdaq market. Leerink may earn a commission of up to 3.0% of gross proceeds, and cash used in operations rose to $133.3 million in 2025.Upstream Bio, Inc. 424B5 (2026-03-26) https://aibio.space/news/nkarta-sets-up-100-000-000-market-stock-program-stifel/https://aibio.space/news/nkarta-sets-up-100-000-000-market-stock-program-stifel/Wed, 25 Mar 2026 12:00:00 GMTFinancingsNkarta set up a $100 million at-the-market program with Stifel on March 25, 2026, with commissions of up to 3%. Its 2025 net loss was $104.1 million, and its operating cash use was $88.7 million.Nkarta, Inc. S-3 (2026-03-25) https://aibio.space/news/zhengye-biotechnology-shareholders-approve-share-reclassification/https://aibio.space/news/zhengye-biotechnology-shareholders-approve-share-reclassification/Wed, 25 Mar 2026 12:00:00 GMTListingsAll five resolutions passed at the March 24, 2026 annual meeting, including a share reclassification and a share consolidation.Zhengye Biotechnology Holding Limited 6-K (2026-03-25) https://aibio.space/news/indaptus-therapeutics-reports-change-control-lazar-sells-preferred/https://aibio.space/news/indaptus-therapeutics-reports-change-control-lazar-sells-preferred/Tue, 24 Mar 2026 12:00:00 GMTMergersFive buyers including Yun Yao and Sino Lion Ventures Limited bought preferred stock that could convert into 108,936,000 shares. The board appointed Junyi Dai chairman and chief executive officer, and four directors resigned on March 18, 2026.Indaptus Therapeutics, Inc. Form 8-K filed March 24, 2026 (SEC EDGAR) https://aibio.space/news/cytodyn-extends-two-28-5-million-convertible-notes-36-months-cuts/https://aibio.space/news/cytodyn-extends-two-28-5-million-convertible-notes-36-months-cuts/Tue, 24 Mar 2026 12:00:00 GMTDebt FinancingCytoDyn and the holders of two $28.5 million convertible notes agreed to extend both maturities by 36 months, to April 2029. In return, the company will pay $1,000,000 a month in common stock, and the interest rate falls to 5%.CytoDyn Inc. 8-K (2026-03-24) https://aibio.space/news/galapagos-now-lakefront-biotherapeutics-advanced-talks-gilead-ouro/https://aibio.space/news/galapagos-now-lakefront-biotherapeutics-advanced-talks-gilead-ouro/Tue, 24 Mar 2026 12:00:00 GMTMergersGilead agreed to buy Ouro Medicines for $1,675 million in cash plus up to $500 million in milestones. Galapagos said it would pay 50% of the upfront cost under proposed terms, and no agreement between the two companies had been signed.Lakefront Biotherapeutics 6-K (2026-03-24) https://aibio.space/news/turn-therapeutics-draws-7-million-25-million-secured-loan-avenue/https://aibio.space/news/turn-therapeutics-draws-7-million-25-million-secured-loan-avenue/Mon, 23 Mar 2026 12:00:00 GMTDebt FinancingTurn Therapeutics signed a term loan of up to $25.0 million with Avenue Venture Opportunities Fund II, L.P. It bears interest of at least 12.25%, is secured on the company's assets, and only $7.0 million is committed up front.SEC EDGAR: Turn Therapeutics 8-K https://aibio.space/news/renovorx-closes-private-placement-about-10-million-gross-proceeds/https://aibio.space/news/renovorx-closes-private-placement-about-10-million-gross-proceeds/Mon, 23 Mar 2026 12:00:00 GMTFinancingsRenovoRx (Nasdaq: RNXT) sold 8,438,790 shares, pre-funded warrants and revenue milestone warrants to 15 investors, five of them insiders. The deal closed March 20, 2026.RenovoRx, Inc. Form 8-K filed March 23, 2026 (SEC EDGAR) https://aibio.space/news/aardvark-therapeutics-sets-up-150-000-000-market-stock-program/https://aibio.space/news/aardvark-therapeutics-sets-up-150-000-000-market-stock-program/Mon, 23 Mar 2026 12:00:00 GMTFinancingsAardvark Therapeutics, Inc. signed an equity distribution agreement with Piper Sandler & Co. on March 23, 2026 and filed a Form S-3 shelf registration the same day. The company paused its main Phase 3 trial in February 2026 after cardiac observations in a healthy volunteer study.Aardvark Therapeutics, Inc. S-3 (2026-03-23) https://aibio.space/news/ernexa-therapeutics-gets-nasdaq-minimum-bid-price-notice-plans-request/https://aibio.space/news/ernexa-therapeutics-gets-nasdaq-minimum-bid-price-notice-plans-request/Fri, 20 Mar 2026 12:00:00 GMTListingsNasdaq staff says Ernexa's stock failed to maintain a $1.00 minimum bid price for 30 consecutive business days, and that the company is not eligible for a 180-calendar day compliance period because of a reverse stock split in the past year. The company plans to request a hearing.Ernexa Therapeutics Inc. Form 8-K filed March 20, 2026 (SEC EDGAR) https://aibio.space/news/xtl-biopharmaceuticals-change-ads-ratio-400-ordinary-shares-march-25/https://aibio.space/news/xtl-biopharmaceuticals-change-ads-ratio-400-ordinary-shares-march-25/Fri, 20 Mar 2026 12:00:00 GMTListingsThe change has the same effect as a one-for-four reverse ADS split. The ordinary shares are not affected.XTL Biopharmaceuticals Ltd. 6-K (2026-03-20) https://aibio.space/news/skye-bioscience-gets-nasdaq-bid-price-deficiency-notice-has-until/https://aibio.space/news/skye-bioscience-gets-nasdaq-bid-price-deficiency-notice-has-until/Thu, 19 Mar 2026 12:00:00 GMTListingsNasdaq told Skye Bioscience (Nasdaq: SKYE) its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance and says it will consider its options.Skye Bioscience, Inc. Form 8-K filed March 19, 2026 (SEC EDGAR) https://aibio.space/news/chemomab-reports-2025-results-cites-fda-alignment-partner-talks/https://aibio.space/news/chemomab-reports-2025-results-cites-fda-alignment-partner-talks/Thu, 19 Mar 2026 12:00:00 GMTListingsThe March 19, 2026 release recalls an August 2025 ADS ratio change that worked as a one-for-four reverse ADS split.Chemomab Therapeutics Ltd. 6-K (2026-03-19) https://aibio.space/news/niagen-bioscience-raises-share-buyback-authorization-20-million/https://aibio.space/news/niagen-bioscience-raises-share-buyback-authorization-20-million/Thu, 19 Mar 2026 12:00:00 GMTFinancingsThe board lifted the program from $10 million. The company had repurchased approximately $2.6 million of stock through March 17, 2026.Niagen Bioscience, Inc. 8-K (2026-03-19) https://aibio.space/news/nucana-says-24-3-million-cash-should-fund-operations-2029/https://aibio.space/news/nucana-says-24-3-million-cash-should-fund-operations-2029/Thu, 19 Mar 2026 12:00:00 GMTFinancingsNuCana's cash rose to £24.3 million after two 2025 raises, but its 2025 net loss was £29.4 million and net cash used in operating activities was £7,467 thousand. The melanoma data for NUC-7738 come from an expansion study the release does not size.NuCana plc 6-K (2026-03-19) https://aibio.space/news/biodexa-change-adr-ratio-500-000-shares-one-five-reverse-adr-split/https://aibio.space/news/biodexa-change-adr-ratio-500-000-shares-one-five-reverse-adr-split/Wed, 18 Mar 2026 12:00:00 GMTListingsThe change, aimed at Nasdaq's $1.00 minimum bid price, is expected on or about April 6, 2026. Holders must exchange five old ADRs for one new one, and the company says it cannot guarantee the change will work.Biodexa Pharmaceuticals plc 6-K (2026-03-18) https://aibio.space/news/stoke-therapeutics-files-automatic-shelf-150-000-000-atm-prospectus/https://aibio.space/news/stoke-therapeutics-files-automatic-shelf-150-000-000-atm-prospectus/Wed, 18 Mar 2026 12:00:00 GMTFinancingsStoke's shelf includes a $150,000,000 at-the-market program with Cantor Fitzgerald, which can be paid up to 3.0% of gross proceeds in commissions. The stock's last reported sale price was $33.96 on March 16, 2026.Stoke Therapeutics, Inc. S-3ASR (2026-03-18) https://aibio.space/news/purple-biotech-regains-nasdaq-minimum-bid-price-compliance/https://aibio.space/news/purple-biotech-regains-nasdaq-minimum-bid-price-compliance/Tue, 17 Mar 2026 12:00:00 GMTListingsThe ADSs held a closing bid of $1.00 or more for at least 10 consecutive business days, reached on March 13, 2026. The company is now compliant with applicable listing standards.Purple Biotech Ltd. 6-K (2026-03-17) https://aibio.space/news/fennec-pharmaceuticals-settles-pedmark-patent-litigation-cipla/https://aibio.space/news/fennec-pharmaceuticals-settles-pedmark-patent-litigation-cipla/Mon, 16 Mar 2026 12:00:00 GMTLegalUnder a license agreement, the lawsuit will be dismissed and Cipla will not sell a generic version in the U.S. until September 1, 2033, or earlier under specified circumstances. Each side bears its own costs.FENNEC PHARMACEUTICALS INC. Form 8-K filed March 16, 2026 (SEC EDGAR) https://aibio.space/news/talphera-closes-third-private-placement-tranche-approximately-4-1/https://aibio.space/news/talphera-closes-third-private-placement-tranche-approximately-4-1/Mon, 16 Mar 2026 12:00:00 GMTFinancingsTalphera (Nasdaq: TLPH) sold 639,931 shares at $0.586 and pre-funded warrants for up to 6,399,316 shares on March 13, 2026, to purchasers who did not join the earlier Optional Closing.TALPHERA, INC. Form 8-K filed March 16, 2026 (SEC EDGAR) https://aibio.space/news/acumen-pharmaceuticals-agrees-35-75-million-private-placement-3-30/https://aibio.space/news/acumen-pharmaceuticals-agrees-35-75-million-private-placement-3-30/Mon, 16 Mar 2026 12:00:00 GMTFinancingsAcumen Pharmaceuticals, Inc. entered into a securities purchase agreement with institutional and accredited investors. RA Capital Management, an existing investor, led the deal, and the release names no placement agent.Acumen Pharmaceuticals, Inc. 8-K (2026-03-16) https://aibio.space/news/amphastar-adds-50-million-share-buyback-program/https://aibio.space/news/amphastar-adds-50-million-share-buyback-program/Mon, 16 Mar 2026 12:00:00 GMTFinancingsAmphastar's board raised its buyback by $50 million on March 12, 2026, to offset dilution from equity compensation, while 2025 net income fell to $98.1 million and cash from operations dropped.Amphastar Pharmaceuticals, Inc. 8-K (2026-03-16) https://aibio.space/news/cytomx-files-250-000-000-stock-offering-prices-5-300-share/https://aibio.space/news/cytomx-files-250-000-000-stock-offering-prices-5-300-share/Mon, 16 Mar 2026 12:00:00 GMTFinancingsCytomX priced 45,990,567 shares and pre-funded warrants for 1,179,245 more at $5.300 a share, below the $5.45 last reported sale price on March 17, 2026. Its lead clinical data are interim, and the prospectus gives no patient count or response rate.CytomX Therapeutics, Inc. 424B5 (2026-03-16) https://aibio.space/news/innocan-pharma-files-us-ipo-3-750-000-units-nyse-american-listing/https://aibio.space/news/innocan-pharma-files-us-ipo-3-750-000-units-nyse-american-listing/Mon, 16 Mar 2026 12:00:00 GMTFinancingsThe filing assumes a $5.50 unit price, which would bring net proceeds of about $17.98 million. The financial statements carry a going-concern paragraph, and the accumulated deficit was $38,027,000 at September 30, 2025.InnoCan Pharma Corporation F-1 (2026-03-16) https://aibio.space/news/zevra-agrees-sell-sdx-portfolio-commave-therapeutics-50-million/https://aibio.space/news/zevra-agrees-sell-sdx-portfolio-commave-therapeutics-50-million/Mon, 16 Mar 2026 12:00:00 GMTDistressThe deal settles a Delaware lawsuit. Zevra says it repaid its $63 million term loan in full before signing.Zevra Therapeutics, Inc. 8-K (2026-03-16) https://aibio.space/news/corvus-pharmaceuticals-raises-market-program-200-000-000/https://aibio.space/news/corvus-pharmaceuticals-raises-market-program-200-000-000/Fri, 13 Mar 2026 12:00:00 GMTFinancingsCorvus had sold no shares under its $100,000,000 Jefferies program and had suspended it in January. The amendment doubles the ceiling to $200,000,000, with Jefferies paid up to 3.0% of gross proceeds.Corvus Pharmaceuticals, Inc. 424B5 (2026-03-13) https://aibio.space/news/scisparc-unit-neurothera-labs-buy-54-01-percent-cliniquantum-shares/https://aibio.space/news/scisparc-unit-neurothera-labs-buy-54-01-percent-cliniquantum-shares/Thu, 12 Mar 2026 12:00:00 GMTMergersNeuroThera would issue 56,600,000 of its own shares, valued at approximately $9,459,954.20, plus up to $2,500,000 in earn-out payments. The release does not say what the issuance would do to SciSparc's approximately 75% stake in NeuroThera.SciSparc Ltd. 6-K (2026-03-12) https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-bid-price/https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-bid-price/Wed, 11 Mar 2026 12:00:00 GMTListingsNasdaq granted VYNE an extra 180 calendar days, until September 7, 2026, to meet the $1.00 minimum bid price. Its 2025 net loss was $26,483 thousand, and the company says its cash is enough only through the closing of its planned merger with Yarrow Biosciences.Yarrow Bioscience, Inc. Form 8-K filed March 11, 2026 (SEC EDGAR) https://aibio.space/news/xenon-prices-650-million-stock-offering-57-after-epilepsy-data/https://aibio.space/news/xenon-prices-650-million-stock-offering-57-after-epilepsy-data/Tue, 10 Mar 2026 12:00:00 GMTFinancingsThe sale came a day after phase 3 X-TOLE2 results. Xenon ended March with $1.34 billion in cash and says it funds operations into 2029.Xenon Pharmaceuticals (SEC prospectus supplement) https://aibio.space/news/an2-therapeutics-agrees-about-40-million-private-placement-2-85-share/https://aibio.space/news/an2-therapeutics-agrees-about-40-million-private-placement-2-85-share/Tue, 10 Mar 2026 12:00:00 GMTFinancingsThe company is selling 8,245,611 shares and pre-funded warrants for up to 5,789,493 shares to institutional investors. Leerink Partners is the exclusive placement agent, and closing is expected March 10, 2026.AN2 Therapeutics, Inc. Form 8-K filed March 10, 2026 (SEC EDGAR) https://aibio.space/news/septerna-files-automatic-shelf-150-000-000-atm-sales-agreement/https://aibio.space/news/septerna-files-automatic-shelf-150-000-000-atm-sales-agreement/Tue, 10 Mar 2026 12:00:00 GMTFinancingsSepterna can sell up to $150,000,000 of stock through BofA Securities, at a fee of up to 3.0%. Its 2025 net loss was $48.9 million, yet cash from operations was positive at $110.2 million, a swing the shelf filing does not explain.Septerna, Inc. S-3ASR (2026-03-10) https://aibio.space/news/relmada-therapeutics-agrees-approximately-160-0-million-private/https://aibio.space/news/relmada-therapeutics-agrees-approximately-160-0-million-private/Mon, 09 Mar 2026 12:00:00 GMTFinancingsRelmada agreed to sell 29,474,569 shares and pre-funded warrants for up to 4,210,527 shares to institutional and accredited investors. It announced 12-month Phase 2 data for NDV-01 the same day, where the 12-month response rate rests on 25 patients.RELMADA THERAPEUTICS, INC. Form 8-K filed March 9, 2026 (SEC EDGAR) https://aibio.space/news/longeveron-tells-nasdaq-lacks-audit-committee-financial-expert-after/https://aibio.space/news/longeveron-tells-nasdaq-lacks-audit-committee-financial-expert-after/Mon, 09 Mar 2026 12:00:00 GMTListingsLongeveron told Nasdaq on March 4, 2026 that it was temporarily out of compliance after director Richard Kender resigned from its audit committee. The company had $19.2 million of cash at December 31, 2024, and its annual report projected that cash would last only into the fourth quarter of 2025.Longeveron Inc. Form 8-K filed March 9, 2026 (SEC EDGAR) https://aibio.space/news/dianthus-launches-400-000-000-stock-offering-then-prices-81-00-share/https://aibio.space/news/dianthus-launches-400-000-000-stock-offering-then-prices-81-00-share/Mon, 09 Mar 2026 12:00:00 GMTFinancingsDianthus priced 7,313,582 shares and pre-funded warrants for 402,468 shares at $81.00, for $624,999,648 in total, after launching a $400,000,000 offering. Its 2025 net loss was $162.3 million, and the supplement names no counsel.Dianthus Therapeutics, Inc. 424B5 (2026-03-09) https://aibio.space/news/engene-holdings-now-engene-therapeutics-sets-up-100-000-000-stock/https://aibio.space/news/engene-holdings-now-engene-therapeutics-sets-up-100-000-000-stock/Mon, 09 Mar 2026 12:00:00 GMTFinancingsThe company signed a sales agreement with Leerink Partners LLC on March 9, 2026. It ended an earlier agreement with Jefferies LLC under which no shares were sold.enGene Therapeutics Inc. 8-K (2026-03-09) https://aibio.space/news/korro-bio-agrees-85-million-private-placement-led-venrock-healthcare/https://aibio.space/news/korro-bio-agrees-85-million-private-placement-led-venrock-healthcare/Mon, 09 Mar 2026 12:00:00 GMTFinancingsKorro Bio, Inc. is selling 4,501,928 shares at $11.11 and pre-funded warrants for 3,148,836 shares. The company expects the money to extend cash runway into the second half of 2028.Korro Bio, Inc. 8-K (2026-03-09) https://aibio.space/news/genentech-end-xencor-collaboration-license-agreement-september-4-2026/https://aibio.space/news/genentech-end-xencor-collaboration-license-agreement-september-4-2026/Mon, 09 Mar 2026 12:00:00 GMTDistressGenentech elected to terminate the agreement for convenience. Xencor says it expected the move.Xencor, Inc. 8-K (2026-03-09) https://aibio.space/news/inmed-pharmaceuticals-wind-down-baymedica-only-revenue-generating/https://aibio.space/news/inmed-pharmaceuticals-wind-down-baymedica-only-revenue-generating/Fri, 06 Mar 2026 12:00:00 GMTDistressInMed's board approved exiting BayMedica's sales on March 4, 2026. The company calls BayMedica its only revenue-generating business, expects about $550,000 in severance costs and about $120,000 in other spending, and its annual report already carries a going-concern warning.InMed Pharmaceuticals Inc. Form 8-K filed March 6, 2026 (SEC EDGAR) https://aibio.space/news/eupraxia-pharmaceuticals-reports-closing-us-63-2-million-public/https://aibio.space/news/eupraxia-pharmaceuticals-reports-closing-us-63-2-million-public/Fri, 06 Mar 2026 12:00:00 GMTFinancingsEupraxia Pharmaceuticals Inc. sold 7,607,145 common shares at US$7.00 each, plus pre-funded warrants for 1,428,571 shares. The material change date is February 20, 2026.Eupraxia Pharmaceuticals, Inc. 6-K (2026-03-06) https://aibio.space/news/nurix-therapeutics-lifts-market-program-total-413-65-million/https://aibio.space/news/nurix-therapeutics-lifts-market-program-total-413-65-million/Fri, 06 Mar 2026 12:00:00 GMTFinancingsNurix raised its Piper Sandler at-the-market program to $413.65 million, of which $113.65 million has already been sold. Its fiscal 2025 net loss was $264.5 million and cash used in operations was $249.5 million.Nurix Therapeutics, Inc. 424B5 (2026-03-06) https://aibio.space/news/solid-biosciences-agrees-240-0-million-private-placement-5-61-share/https://aibio.space/news/solid-biosciences-agrees-240-0-million-private-placement-5-61-share/Fri, 06 Mar 2026 12:00:00 GMTFinancingsSolid Biosciences agreed to sell 14,973,257 shares at $5.61 and pre-funded warrants for 27,807,482 shares, for about $240.0 million gross. Its year-end 2025 cash figure is a preliminary, unaudited estimate, and the company says the deal extends runway into the first half of 2028.Solid Biosciences Inc. 8-K (2026-03-06) https://aibio.space/news/contineum-therapeutics-amends-share-sales-deal-registers-up-100/https://aibio.space/news/contineum-therapeutics-amends-share-sales-deal-registers-up-100/Thu, 05 Mar 2026 12:00:00 GMTFinancingsContineum can now sell up to $100 million of Class A stock through Leerink Partners LLC, and its dilution example shows $7.18 a share lost at a $15.34 price. The company has also deferred two programs until it obtains funding.Contineum Therapeutics, Inc. 424B5 (2026-03-05) https://aibio.space/news/evaxion-says-cash-funds-operations-second-half-2027/https://aibio.space/news/evaxion-says-cash-funds-operations-second-half-2027/Thu, 05 Mar 2026 12:00:00 GMTFinancingsEvaxion says its cash can fund operations into the second half of 2027, after a $7.5 million option exercise fee and a debt conversion with the European Investment Bank. The release reports a cash burn of about $14 million for 2026 and names no bank or agent for its amended at-the-market facility.Evaxion A/S 6-K (2026-03-05) https://aibio.space/news/mediwound-reports-53-6-million-cash-after-30-0-million-registered/https://aibio.space/news/mediwound-reports-53-6-million-cash-after-30-0-million-registered/Thu, 05 Mar 2026 12:00:00 GMTFinancingsMediWound ended 2025 with $53.6 million in cash, cash equivalents and deposits after a $30.0 million registered direct offering. Its net loss narrowed to $23.9 million mainly because of warrant revaluation, while revenue fell to $17.0 million.MediWound Ltd. 6-K (2026-03-05) https://aibio.space/news/regen-biopharma-issues-77-849-847-shares-settle-convertible-debt/https://aibio.space/news/regen-biopharma-issues-77-849-847-shares-settle-convertible-debt/Wed, 04 Mar 2026 12:00:00 GMTFinancingsRegen Biopharma issued 77,849,847 common shares between February 4 and February 27, 2026 to settle convertible debt and fees. The company had 212,318,424 shares outstanding on March 3, 2026, and its pipeline has not yet entered a clinical trial.Regen Biopharma, Inc. 8-K (2026-03-04) https://aibio.space/news/arbutus-genevant-settle-moderna-lnp-patent-litigation-950-0-million/https://aibio.space/news/arbutus-genevant-settle-moderna-lnp-patent-litigation-950-0-million/Tue, 03 Mar 2026 12:00:00 GMTLegalModerna agrees to pay a $950.0 million noncontingent lump sum and may owe a further $1.3 billion depending on a Federal Circuit appeal on 28 U.S.C. §1498. Arbutus is entitled to 20% of proceeds after litigation costs, or, if less, tiered low single-digit royalties.Arbutus Biopharma Corp Form 8-K filed March 3, 2026 (SEC EDGAR) https://aibio.space/news/china-pharma-issue-12-600-000-shares-6-93-million-patent-transfer/https://aibio.space/news/china-pharma-issue-12-600-000-shares-6-93-million-patent-transfer/Tue, 03 Mar 2026 12:00:00 GMTFinancingsChina Pharma's subsidiary Helpson agreed on February 26, 2026 to buy a sublingual tablet patent for $6.93 million, paid in 12,600,000 unregistered shares at $0.55 each. The company has a going-concern warning in its latest annual report.CHINA PHARMA HOLDINGS, INC. Form 8-K filed March 3, 2026 (SEC EDGAR) https://aibio.space/news/gt-biopharma-issues-non-reliance-notice-will-restate-june-september/https://aibio.space/news/gt-biopharma-issues-non-reliance-notice-will-restate-june-september/Mon, 02 Mar 2026 12:00:00 GMTDistressOn March 1, 2026 the audit committee concluded the quarterly reports contained an error: Greenshoe Rights from a May 2025 private placement required liability classification. GT Biopharma (Nasdaq: GTBP) will file Forms 10-Q/A.GT Biopharma, Inc. Form 8-K filed March 2, 2026 (SEC EDGAR) https://aibio.space/news/gyre-therapeutics-agrees-acquire-cullgen-all-stock-deal-valued-about/https://aibio.space/news/gyre-therapeutics-agrees-acquire-cullgen-all-stock-deal-valued-about/Mon, 02 Mar 2026 12:00:00 GMTFinancingsGyre Therapeutics agreed to buy privately held Cullgen in an all-stock deal valued at about $300 million, issuing common stock and Series B convertible preferred. Until stockholders approve the conversion, Gyre may not issue more than 19.99% of its stock, and Cullgen's lead drug has completed only a Phase 1 trial.GYRE THERAPEUTICS, INC. Form 8-K filed March 2, 2026 (SEC EDGAR) https://aibio.space/news/zymeworks-enters-250-million-royalty-backed-financing-royalty-pharma/https://aibio.space/news/zymeworks-enters-250-million-royalty-backed-financing-royalty-pharma/Mon, 02 Mar 2026 12:00:00 GMTFinancingsZymeworks sold 30% of its future Ziihera royalties to a subsidiary that borrowed $250 million from Royalty Pharma. The loan costs about $481 million by its 2042 maturity, and it is secured by the subsidiary's assets.Zymeworks Inc. Form 8-K filed March 2, 2026 (SEC EDGAR) https://aibio.space/news/acrivon-ends-akoya-companion-diagnostic-agreement-takes-testing-house/https://aibio.space/news/acrivon-ends-akoya-companion-diagnostic-agreement-takes-testing-house/Mon, 02 Mar 2026 12:00:00 GMTDistressThe February 25, 2026 termination involves no payments. Acrivon keeps full rights to its ACR-368 OncoSignature test.Acrivon Therapeutics, Inc. 8-K (2026-03-02) https://aibio.space/news/anebulo-pharmaceuticals-files-form-15-end-sec-reporting-duties/https://aibio.space/news/anebulo-pharmaceuticals-files-form-15-end-sec-reporting-duties/Mon, 02 Mar 2026 12:00:00 GMTListingsAnebulo's March 2, 2026 Form 15 puts its SEC reporting duties to an end and gives 71 holders of record for its common stock, while the company's last reported cash figure was $9.0 million at December 31, 2025.Anebulo Pharmaceuticals Inc 15-12G (2026-03-02) https://aibio.space/news/belite-bio-says-completed-402-million-public-offering-adss/https://aibio.space/news/belite-bio-says-completed-402-million-public-offering-adss/Mon, 02 Mar 2026 12:00:00 GMTFinancingsBelite Bio says its $402 million offering was completed with the overallotment option fully exercised. The same release reports a 2025 net loss of $77.6 million, up from $36.1 million, and cash of $352.9 million at year-end.Belite Bio, Inc 6-K (2026-03-02) https://aibio.space/news/geron-files-automatic-shelf-150-000-000-atm-prospectus-td-cowen/https://aibio.space/news/geron-files-automatic-shelf-150-000-000-atm-prospectus-td-cowen/Mon, 02 Mar 2026 12:00:00 GMTFinancingsThe sales agreement pays TD Securities (USA) LLC up to 3.0% of gross proceeds. Geron's stock last sold at $1.65 on February 26, 2026, and the company's 2025 net loss was $83.5 million.Geron Corporation S-3ASR (2026-03-02) https://aibio.space/news/sionna-therapeutics-files-automatic-shelf-250-000-000-atm-sales/https://aibio.space/news/sionna-therapeutics-files-automatic-shelf-250-000-000-atm-sales/Mon, 02 Mar 2026 12:00:00 GMTFinancingsSionna Therapeutics signed a sales agreement with Leerink Partners LLC on March 2, 2026 for up to $250,000,000 of common stock sold at the market. Leerink's commission is up to 3.0% of the gross sales price per share.Sionna Therapeutics, Inc. S-3ASR (2026-03-02) https://aibio.space/news/jupiter-neurosciences-gets-two-nasdaq-notices-minimum-bid-price-market/https://aibio.space/news/jupiter-neurosciences-gets-two-nasdaq-notices-minimum-bid-price-market/Fri, 27 Feb 2026 12:00:00 GMTListingsNasdaq says the stock closed below $1.00 for 30 consecutive business days and that its market value of listed securities stayed below $35 million. The company has until August 25, 2026 on both, and its auditor has raised going-concern doubt.JUPITER NEUROSCIENCES, INC. Form 8-K filed February 27, 2026 (SEC EDGAR) https://aibio.space/news/indaptus-stockholders-approve-preferred-stock-conversion-reverse-split/https://aibio.space/news/indaptus-stockholders-approve-preferred-stock-conversion-reverse-split/Fri, 27 Feb 2026 12:00:00 GMTMergersStockholders approved conversion of preferred stock that, once converted, would give David Lazar 111.0 million common shares, about 96.4% of the fully diluted common stock. They also approved up to two reverse stock splits and authorized shares rising to 1,000,000,000.Indaptus Therapeutics, Inc. Form 8-K filed February 27, 2026 (SEC EDGAR) https://aibio.space/news/atrium-therapeutics-completes-spin-off-avidity-biosciences-starts/https://aibio.space/news/atrium-therapeutics-completes-spin-off-avidity-biosciences-starts/Fri, 27 Feb 2026 12:00:00 GMTMergersAtrium Therapeutics became independent on February 26, 2026, when Avidity Biosciences distributed all of its shares at one Atrium share for every ten Avidity shares. Atrium began trading on Nasdaq as RNA on February 27, and it signed an amended license and a transition services agreement with Avidity the same day.Atrium Therapeutics, Inc. Form 8-K filed February 27, 2026 (SEC EDGAR) https://aibio.space/news/altamira-therapeutics-files-form-15-end-sec-reporting-duties/https://aibio.space/news/altamira-therapeutics-files-form-15-end-sec-reporting-duties/Fri, 27 Feb 2026 12:00:00 GMTListingsAltamira Therapeutics filed a Form 15 dated February 27, 2026, to terminate its registration or suspend its duty to file reports with the SEC. The form lists 48 holders of record, and the company's last business description, from April 2025, still calls its lead programs preclinical.Altamira Therapeutics Ltd. 15-12G (2026-02-27) https://aibio.space/news/generate-biomedicines-prices-ipo-25-000-000-shares-16-00/https://aibio.space/news/generate-biomedicines-prices-ipo-25-000-000-shares-16-00/Fri, 27 Feb 2026 12:00:00 GMTFinancingsThe offering totals $400,000,000 before costs, with net proceeds estimated at $368.8 million. The prospectus keeps the going-concern warning and says no pivotal trial has finished.Generate Biomedicines, Inc. 424B4 (2026-02-27) https://aibio.space/news/xortx-auditor-flags-going-concern-doubt-2025-financials-cash-was-864/https://aibio.space/news/xortx-auditor-flags-going-concern-doubt-2025-financials-cash-was-864/Fri, 27 Feb 2026 12:00:00 GMTDistressThe audit report says XORTX must finance its research or postpone it. The statements show an accumulated deficit of $23,824,557 at December 31, 2025.XORTX Therapeutics Inc. 6-K (2026-02-27) https://aibio.space/news/viatris-expects-700-million-850-million-restructuring-charges-plans-up/https://aibio.space/news/viatris-expects-700-million-850-million-restructuring-charges-plans-up/Thu, 26 Feb 2026 12:00:00 GMTDistressAfter an enterprise-wide strategic review, Viatris committed to restructuring that it expects to cut its global workforce by up to approximately 10%. It expects potential savings of between $600 million and $700 million.Viatris Inc Form 8-K filed February 26, 2026 (SEC EDGAR) https://aibio.space/news/lipocine-raises-market-program-50-000-000/https://aibio.space/news/lipocine-raises-market-program-50-000-000/Thu, 26 Feb 2026 12:00:00 GMTFinancingsLipocine Inc. filed a prospectus supplement on February 26, 2026 under its sales agreement with A.G.P./Alliance Global Partners. It had sold $10,615,576 of stock under the earlier registration.Lipocine Inc. 424B5 (2026-02-26) https://aibio.space/news/atrium-therapeutics-spin-off-avidity-give-holders-one-share-ten/https://aibio.space/news/atrium-therapeutics-spin-off-avidity-give-holders-one-share-ten/Thu, 26 Feb 2026 12:00:00 GMTMergersAvidity holders of record on February 12, 2026 would receive Atrium shares, but the distribution depends on Avidity's merger with Novartis and is taxable to holders. Avidity may instead sell Atrium to a third party, in which case no distribution would occur.Atrium Therapeutics, Inc. 8-K (2026-02-26) https://aibio.space/news/larimar-launches-75-0-million-stock-offering-then-prices-100-000-000/https://aibio.space/news/larimar-launches-75-0-million-stock-offering-then-prices-100-000-000/Wed, 25 Feb 2026 12:00:00 GMTFinancingsLargest stockholder Deerfield and some directors indicated interest in buying. The priced offering is 20,000,000 shares at $5.00, or $94,000,000 to the company before expenses.Larimar Therapeutics, Inc. 424B5 (2026-02-25) https://aibio.space/news/bicara-therapeutics-launches-150-000-000-offering-then-prices-16-00/https://aibio.space/news/bicara-therapeutics-launches-150-000-000-offering-then-prices-16-00/Tue, 24 Feb 2026 12:00:00 GMTFinancingsBicara priced 7,175,000 shares at $16.00 and pre-funded warrants for 2,200,000 more, with underwriting discounts of $9,000,000 on a total of $149,999,780.Bicara Therapeutics Inc. 424B5 (2026-02-24) https://aibio.space/news/regentis-biomaterials-discloses-going-concern-qualification-2025-audit/https://aibio.space/news/regentis-biomaterials-discloses-going-concern-qualification-2025-audit/Tue, 24 Feb 2026 12:00:00 GMTListingsRegentis Biomaterials said on February 24, 2026 that its auditor's opinion on the 2025 financial statements carries a going concern qualification. The company reported $7.4 million in cash at December 31, 2025, and its pivotal knee cartilage trial is still enrolling.Regentis Biomaterials Ltd. 6-K (2026-02-24) https://aibio.space/news/moonlake-amends-hercules-loan-draws-25-0-million-keeps-up-400-0/https://aibio.space/news/moonlake-amends-hercules-loan-draws-25-0-million-keeps-up-400-0/Mon, 23 Feb 2026 12:00:00 GMTDebt FinancingMoonLake drew $25.0 million under a Hercules loan totaling $500.0 million across six tranches. Most of the tranches still to come depend on Phase 3 results and FDA action for its lead drug, sonelokimab, and the company's 81% response figure comes from 26 patients with no comparison arm reported.MoonLake Immunotherapeutics Form 8-K filed February 23, 2026 (SEC EDGAR) https://aibio.space/news/fortress-subsidiary-cyprium-agrees-sell-priority-review-voucher-205/https://aibio.space/news/fortress-subsidiary-cyprium-agrees-sell-priority-review-voucher-205/Mon, 23 Feb 2026 12:00:00 GMTFinancingsCyprium, a majority-owned Fortress Biotech subsidiary, agreed on February 22, 2026 to sell a priority review voucher for $205 million in cash at closing. Fortress also amended its Oaktree credit agreement, with about $29.5 million outstanding.Fortress Biotech, Inc. Form 8-K filed February 23, 2026 (SEC EDGAR) https://aibio.space/news/adc-therapeutics-amends-hcr-royalty-deal-issues-warrants-9-834-776/https://aibio.space/news/adc-therapeutics-amends-hcr-royalty-deal-issues-warrants-9-834-776/Mon, 23 Feb 2026 12:00:00 GMTFinancingsThe February 18, 2026 amendment sets the change-of-control payment to HCR at $150 million or $200 million and revises a buyout option. HCR received warrants at $3.8130 per share.ADC Therapeutics SA Form 8-K filed February 23, 2026 (SEC EDGAR) https://aibio.space/news/vir-biotechnology-receive-335-million-astellas-vir-5500-licensing-deal/https://aibio.space/news/vir-biotechnology-receive-335-million-astellas-vir-5500-licensing-deal/Mon, 23 Feb 2026 12:00:00 GMTFinancingsVir Biotechnology agreed to co-develop VIR-5500 with Astellas for $335 million in upfront and near-term payments, plus up to $1.37 billion in later milestones. The drug is still in Phase 1, and the deal closes only after Hart-Scott-Rodino clearance.Vir Biotechnology, Inc. Form 8-K filed February 23, 2026 (SEC EDGAR) https://aibio.space/news/galapagos-now-lakefront-biotherapeutics-lowers-wind-down-cost-estimate/https://aibio.space/news/galapagos-now-lakefront-biotherapeutics-lowers-wind-down-cost-estimate/Mon, 23 Feb 2026 12:00:00 GMTDistressThe company lowered its expected cell therapy restructuring cash costs to €125 to €175 million. It expects to be a lean organization of about 35-40 employees by the end of 2026.Lakefront Biotherapeutics 6-K (2026-02-23) https://aibio.space/news/oric-pharmaceuticals-files-new-200-0-million-market-prospectus/https://aibio.space/news/oric-pharmaceuticals-files-new-200-0-million-market-prospectus/Mon, 23 Feb 2026 12:00:00 GMTFinancingsOric Pharmaceuticals, Inc. has sold 13,478,432 shares under the program for gross proceeds of approximately $139.7 million. The new supplement replaces the one from March 2024.Oric Pharmaceuticals, Inc. 424B5 (2026-02-23) https://aibio.space/news/vir-biotechnology-signs-335-million-astellas-deal-then-prices-stock/https://aibio.space/news/vir-biotechnology-signs-335-million-astellas-deal-then-prices-stock/Mon, 23 Feb 2026 12:00:00 GMTFinancingsVir Biotechnology will receive $335 million in upfront and near-term payments from Astellas for VIR-5500, a prostate cancer T-cell engager still in Phase 1. Its February 25 prospectus supplement priced a $150,000,002 stock offering at $8.50 per share.Vir Biotechnology, Inc. 8-K (2026-02-23) https://aibio.space/news/opus-genetics-closes-private-placement-series-b-preferred-stock/https://aibio.space/news/opus-genetics-closes-private-placement-series-b-preferred-stock/Thu, 19 Feb 2026 12:00:00 GMTFinancingsPurchasers paid $3.39 per share for 7,374,632 non-voting convertible preferred shares. Conversion into common stock depends on stockholder approval at the 2026 annual meeting. Preliminary cash was $45 million at year end.Opus Genetics, Inc. Form 8-K filed February 19, 2026 (SEC EDGAR) https://aibio.space/news/psyence-biomedical-shareholders-approve-share-consolidation-up-250-1/https://aibio.space/news/psyence-biomedical-shareholders-approve-share-consolidation-up-250-1/Thu, 19 Feb 2026 12:00:00 GMTListingsShareholders gave Psyence's board authority to consolidate the common shares at a ratio of up to 250:1, but the board has not set a ratio or timing, and the company says a consolidation may never happen.Psyence Biomedical Ltd. 6-K (2026-02-19) https://aibio.space/news/sensei-biotherapeutics-acquires-faeth-therapeutics-agrees-200-million/https://aibio.space/news/sensei-biotherapeutics-acquires-faeth-therapeutics-agrees-200-million/Wed, 18 Feb 2026 12:00:00 GMTMergersSensei Biotherapeutics closed its acquisition of Faeth Therapeutics on February 17, 2026, and agreed the same day to sell about $200 million of Series B preferred stock. The new investors would hold 54.3% of the company on an as-converted basis, and the lead drug's headline response rate comes from 15 patients.Faeth Therapeutics, Inc. Form 8-K filed February 18, 2026 (SEC EDGAR) https://aibio.space/news/outlook-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice/https://aibio.space/news/outlook-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice/Wed, 18 Feb 2026 12:00:00 GMTListingsNasdaq says Outlook's stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on its Nasdaq Capital Market listing, and a second 180-day period may be available.Outlook Therapeutics, Inc. Form 8-K filed February 18, 2026 (SEC EDGAR) https://aibio.space/news/atossa-therapeutics-regains-nasdaq-minimum-bid-price-compliance/https://aibio.space/news/atossa-therapeutics-regains-nasdaq-minimum-bid-price-compliance/Tue, 17 Feb 2026 12:00:00 GMTListingsAtossa Therapeutics received a Nasdaq letter on February 17, 2026 saying it regained the $1.00 minimum closing bid price. The stock met the test on February 13, 2026, the last trading day before the extended deadline, after a February 2025 notice and an extension granted in August 2025.ATOSSA THERAPEUTICS, INC. Form 8-K filed February 17, 2026 (SEC EDGAR) https://aibio.space/news/mereo-biopharma-gets-nasdaq-minimum-bid-price-deficiency-notice-adss/https://aibio.space/news/mereo-biopharma-gets-nasdaq-minimum-bid-price-deficiency-notice-adss/Tue, 17 Feb 2026 12:00:00 GMTListingsMereo BioPharma's American Depositary Shares failed to hold a $1.00 minimum bid price for 30 consecutive business days, and Nasdaq gave the company until August 17, 2026 to regain compliance. The company's 2024 annual report shows a net loss of $43.3 million and $69.8 million of cash.Mereo BioPharma Group plc Form 8-K filed February 17, 2026 (SEC EDGAR) https://aibio.space/news/geovax-closes-registered-direct-offering-2-31-share-net-proceeds-about/https://aibio.space/news/geovax-closes-registered-direct-offering-2-31-share-net-proceeds-about/Tue, 17 Feb 2026 12:00:00 GMTFinancingsGeoVax sold 402,000 shares and pre-funded warrants for up to 30,902 shares, plus Series A-1 and A-2 warrants in a concurrent private placement. H.C. Wainwright & Co., LLC was placement agent.GeoVax Labs, Inc. Form 8-K filed February 17, 2026 (SEC EDGAR) https://aibio.space/news/anebulo-pharmaceuticals-files-form-25-withdraw-stock-nasdaq/https://aibio.space/news/anebulo-pharmaceuticals-files-form-25-withdraw-stock-nasdaq/Tue, 17 Feb 2026 12:00:00 GMTListingsAnebulo filed a Form 25 on February 17, 2026 to withdraw its common stock from Nasdaq as a voluntary withdrawal, while its lead drug candidate remains at an early stage and its cash fell in the second half of 2025.Anebulo Pharmaceuticals Inc 25 (2026-02-17) https://aibio.space/news/nutriband-terminates-planned-5-million-sale-pocono-unit/https://aibio.space/news/nutriband-terminates-planned-5-million-sale-pocono-unit/Fri, 13 Feb 2026 12:00:00 GMTMergersNutriband said its board ended the deal after the buyer missed the December 31 closing and stopped paying late fees. The annual report puts the price at $5 million, and only $30,000 in late fees was received.NTRB 8-K https://aibio.space/news/citius-pharmaceuticals-gets-nasdaq-minimum-bid-price-notice-compliance/https://aibio.space/news/citius-pharmaceuticals-gets-nasdaq-minimum-bid-price-notice-compliance/Fri, 13 Feb 2026 12:00:00 GMTListingsNasdaq told Citius Pharmaceuticals on February 9, 2026 that its stock had closed below $1.00 for 30 consecutive business days, and the company has until August 10, 2026 to regain compliance. The same filing reports $3.9 million in first-quarter revenue from LYMPHIR, against $7.7 million in cash.Citius Pharmaceuticals, Inc. Form 8-K filed February 13, 2026 (SEC EDGAR) https://aibio.space/news/werewolf-therapeutics-cuts-64-percent-workforce-cfo-cmo-resign/https://aibio.space/news/werewolf-therapeutics-cuts-64-percent-workforce-cfo-cmo-resign/Fri, 13 Feb 2026 12:00:00 GMTDistressWerewolf expects a one-time charge of approximately $4.1 million in the first quarter of 2026. The filing also discloses the company's efforts to raise capital and a review of strategic partnerships for WTX-124 and WTX-330.Werewolf Therapeutics, Inc. Form 8-K filed February 13, 2026 (SEC EDGAR) https://aibio.space/news/evommune-sells-125-million-stock-privately-27-88-share/https://aibio.space/news/evommune-sells-125-million-stock-privately-27-88-share/Thu, 12 Feb 2026 12:00:00 GMTFinancingsEvommune's $125 million private placement was followed by a failed atopic dermatitis trial; the company says its 2026 raise brought net proceeds of $117.2 million.EVMN 8-K https://aibio.space/news/lunai-bioworks-receives-nasdaq-delisting-determination-minimum-bid/https://aibio.space/news/lunai-bioworks-receives-nasdaq-delisting-determination-minimum-bid/Thu, 12 Feb 2026 12:00:00 GMTListingsNasdaq staff decided on February 6, 2026 to delist Lunai Bioworks, saying a reverse stock split in September 2025 bars the company from the usual 180-day cure period. The company has asked for a hearing, which pauses a February 18 trading suspension.Lunai Bioworks Inc. Form 8-K filed February 12, 2026 (SEC EDGAR) https://aibio.space/news/regenxbio-registers-up-150-000-000-share-sales-through-leerink/https://aibio.space/news/regenxbio-registers-up-150-000-000-share-sales-through-leerink/Thu, 12 Feb 2026 12:00:00 GMTFinancingsREGENXBIO filed a prospectus supplement for up to $150 million of at-the-market stock sales through Leerink Partners. The filing warns of substantial doubt about its ability to continue as a going concern.REGENXBIO Inc. 424B5 (2026-02-12) https://aibio.space/news/spyglass-closes-172-5-million-ipo-after-underwriters-take-full-option/https://aibio.space/news/spyglass-closes-172-5-million-ipo-after-underwriters-take-full-option/Mon, 09 Feb 2026 12:00:00 GMTFinancingsSpyGlass Pharma closed a $172.5 million IPO with Jefferies, Leerink Partners, Citigroup and Stifel running the book. The money is meant to carry a glaucoma implant through two Phase 3 trials.SEC EDGAR: SpyGlass Pharma Filed issuer press release https://aibio.space/news/vistagen-gets-nasdaq-minimum-bid-price-deficiency-notice-until-august/https://aibio.space/news/vistagen-gets-nasdaq-minimum-bid-price-deficiency-notice-until-august/Fri, 06 Feb 2026 12:00:00 GMTListingsNasdaq told Vistagen on Feb 3, 2026, that its stock had closed below $1.00 for 30 consecutive business days. The company has until Aug 3, 2026, to regain compliance, and its last annual report carried a going-concern warning.Vistagen Therapeutics, Inc. Form 8-K filed February 6, 2026 (SEC EDGAR) https://aibio.space/news/agomab-therapeutics-prices-ipo-12-500-000-adss-16-00/https://aibio.space/news/agomab-therapeutics-prices-ipo-12-500-000-adss-16-00/Fri, 06 Feb 2026 12:00:00 GMTFinancingsAgomAb priced 12,500,000 ADSs at $16.00 for $200,000,000 and expects about $181 million in net proceeds. Its lead drug has shown only safety results in a Phase 2a Crohn's trial, and the prospectus reports an accumulated loss of €164.3 million.AgomAb Therapeutics NV 424B4 (2026-02-06) https://aibio.space/news/anebulo-pharmaceuticals-delist-nasdaq-deregister-sec/https://aibio.space/news/anebulo-pharmaceuticals-delist-nasdaq-deregister-sec/Fri, 06 Feb 2026 12:00:00 GMTListingsAnebulo's board approved leaving Nasdaq and ending SEC reporting, with a Form 25 due about February 17, 2026 and a Form 15 about February 27, while its lead drug candidate is still in early clinical work.Anebulo Pharmaceuticals Inc 8-K (2026-02-06) https://aibio.space/news/veradermics-completes-294-8-million-ipo-full-overallotment-exercise/https://aibio.space/news/veradermics-completes-294-8-million-ipo-full-overallotment-exercise/Thu, 05 Feb 2026 12:00:00 GMTFinancingsVeradermics closed its initial public offering of 15,077,647 shares at $17.00 a share on February 5, 2026. The underwriters later exercised in full their option on 2,261,647 more shares.SEC EDGAR: Veradermics 10-Q https://aibio.space/news/lb-pharmaceuticals-agrees-100-0-million-private-placement-21-17-share/https://aibio.space/news/lb-pharmaceuticals-agrees-100-0-million-private-placement-21-17-share/Thu, 05 Feb 2026 12:00:00 GMTFinancingsLB Pharmaceuticals agreed to sell 3,306,571 shares and pre-funded warrants for up to 1,417,107 shares to institutional investors. It plans to use the proceeds for a Phase 2 trial of LB-102 in major depressive disorder and for general corporate purposes.LB PHARMACEUTICALS INC Form 8-K filed February 5, 2026 (SEC EDGAR) https://aibio.space/news/eikon-therapeutics-prices-ipo-21-177-600-shares-18-00/https://aibio.space/news/eikon-therapeutics-prices-ipo-21-177-600-shares-18-00/Thu, 05 Feb 2026 12:00:00 GMTFinancingsThe offering totals $381,196,800. The stock is approved to list on Nasdaq under EIKN, and proceeds to the company are $354,513,024 before expenses.Eikon Therapeutics, Inc. 424B4 (2026-02-05) https://aibio.space/news/maze-therapeutics-draws-40-0-million-under-hercules-term-loan-facility/https://aibio.space/news/maze-therapeutics-draws-40-0-million-under-hercules-term-loan-facility/Wed, 04 Feb 2026 12:00:00 GMTDebt FinancingMaze received an initial $40.0 million term loan and says net proceeds were approximately $38.4 million. Up to $160.0 million more is available if conditions are met. It also ended its Banc of California loan.Maze Therapeutics, Inc. Form 8-K filed February 4, 2026 (SEC EDGAR) https://aibio.space/news/generate-biomedicines-files-ipo-plans-nasdaq-listing-genb/https://aibio.space/news/generate-biomedicines-files-ipo-plans-nasdaq-listing-genb/Wed, 04 Feb 2026 12:00:00 GMTFinancingsThe S-1 leaves the share count and price range blank. Management and the auditor say cash will not last twelve months, which raises going-concern doubt.Generate Biomedicines, Inc. S-1 (2026-02-04) https://aibio.space/news/maze-therapeutics-signs-hercules-loan-up-200-0-million-draws-40-0/https://aibio.space/news/maze-therapeutics-signs-hercules-loan-up-200-0-million-draws-40-0/Wed, 04 Feb 2026 12:00:00 GMTDistressThe senior secured facility matures February 1, 2031. Maze ended its Banc of California loan agreement in connection with the deal.Maze Therapeutics, Inc. 8-K (2026-02-04) https://aibio.space/news/replimune-amends-hercules-loan-draws-35-million-delays-repayment/https://aibio.space/news/replimune-amends-hercules-loan-draws-35-million-delays-repayment/Tue, 03 Feb 2026 12:00:00 GMTDebt FinancingThe Third Amendment raises the third tranche to $35 million, which was funded at closing, and sets the interest rate at the greater of 8.50% or Prime plus 1.75%. Replimune says its cash runway now reaches late into the first quarter of 2027.Replimune Group, Inc. Form 8-K filed February 3, 2026 (SEC EDGAR) https://aibio.space/news/amneal-cuts-term-loan-margin-50-basis-points-estimates-11-million/https://aibio.space/news/amneal-cuts-term-loan-margin-50-basis-points-estimates-11-million/Tue, 03 Feb 2026 12:00:00 GMTDebt FinancingAmneal Pharmaceuticals LLC cut the interest margin on its term loans by 50 basis points in an amendment dated February 2, 2026, with JPMorgan Chase Bank, N.A. as administrative agent. The company estimates annual cash interest savings of about $11 million, and the loans still mature on August 1, 2032.Amneal Pharmaceuticals, Inc. Form 8-K filed February 3, 2026 (SEC EDGAR) https://aibio.space/news/perspective-therapeutics-prices-175-million-stock-pre-funded-warrant/https://aibio.space/news/perspective-therapeutics-prices-175-million-stock-pre-funded-warrant/Tue, 03 Feb 2026 12:00:00 GMTFinancingsPerspective Therapeutics priced 39,576,088 shares at $3.79 each, plus pre-funded warrants for 6,598,046 shares, for gross proceeds of about $175 million. Piper Sandler & Co. is one of five joint book-running managers, and Hogan Lovells US LLP is counsel to the company.Perspective Therapeutics, Inc. 424B5 (2026-02-03) https://aibio.space/news/polaryx-begins-nasdaq-trading-through-direct-listing/https://aibio.space/news/polaryx-begins-nasdaq-trading-through-direct-listing/Mon, 02 Feb 2026 12:00:00 GMTListingsPolaryx began trading on Nasdaq on February 2, 2026 without an underwriter, and the company received no money from the listing.PLYX 424B4 https://aibio.space/news/umeworld-formerly-umeworld-limited-says-10-q-late-after-auditor/https://aibio.space/news/umeworld-formerly-umeworld-limited-says-10-q-late-after-auditor/Mon, 02 Feb 2026 12:00:00 GMTDistressUMeWorld filed a notice on February 2, 2026 that its quarterly report for the quarter ended December 31, 2025 will be late. Its auditor, J&S Associate PLT, resigned on December 31, 2025, and the company has not yet engaged a successor, so the review of its interim results has not started.UMeWorld Inc. NT 10-Q (2026-02-02) https://aibio.space/news/alx-oncology-raises-150-million-1-57-share-led-ra-capital-tcgx/https://aibio.space/news/alx-oncology-raises-150-million-1-57-share-led-ra-capital-tcgx/Fri, 30 Jan 2026 12:00:00 GMTFinancingsALX Oncology priced 76,979,112 shares and pre-funded warrants for 18,574,120 more, at $1.57 a share, after a year of failed or dropped combination trials and a narrower focus on its CD47 drug evorpacept.ALX Oncology Holdings https://aibio.space/news/tenaya-therapeutics-gets-nasdaq-minimum-bid-price-notice-has-until/https://aibio.space/news/tenaya-therapeutics-gets-nasdaq-minimum-bid-price-notice-has-until/Fri, 30 Jan 2026 12:00:00 GMTListingsNasdaq told Tenaya Therapeutics on January 28, 2026 that its shares had closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until July 27, 2026 to regain compliance, and an 8-K filed January 30 also adds 2,161,000 shares to its inducement equity plan.Tenaya Therapeutics, Inc. Form 8-K filed January 30, 2026 (SEC EDGAR) https://aibio.space/news/bgm-group-files-late-notice-20-f-xy-management-acquisition-accounting/https://aibio.space/news/bgm-group-files-late-notice-20-f-xy-management-acquisition-accounting/Fri, 30 Jan 2026 12:00:00 GMTDistressBGM Group Ltd. says it cannot file its annual report on Form 20-F for the year ended September 30, 2025 on time. It is still finishing the consolidation and acquisition accounting for its purchase of YX Management Company Limited.BGM Group Ltd. NT 20-F (2026-01-30) https://aibio.space/news/biomarin-prices-850-million-5-5-percent-notes-help-fund-4-8-billion/https://aibio.space/news/biomarin-prices-850-million-5-5-percent-notes-help-fund-4-8-billion/Thu, 29 Jan 2026 12:00:00 GMTFinancingsThe senior notes due 2034 priced at par and will sit in escrow until the deal closes. BioMarin also completed syndication of a $2 billion term loan B.BioMarin Pharmaceutical https://aibio.space/news/aprea-therapeutics-agrees-5-6-million-private-placement-priced-market/https://aibio.space/news/aprea-therapeutics-agrees-5-6-million-private-placement-priced-market/Thu, 29 Jan 2026 12:00:00 GMTFinancingsAprea expects gross proceeds of approximately $5.6 million from selling 6,288,857 shares, or pre-funded warrants, with common warrants for the same number of shares at $0.765. Maxim Group LLC is placement agent for a 7% fee. Closing is expected January 30, 2026.Aprea Therapeutics, Inc. Form 8-K filed January 29, 2026 (SEC EDGAR) https://aibio.space/news/altimmune-agrees-75-million-registered-direct-offering-one-new/https://aibio.space/news/altimmune-agrees-75-million-registered-direct-offering-one-new/Wed, 28 Jan 2026 12:00:00 GMTFinancingsAltimmune is selling 12,397,920 shares at $4.40 each, plus pre-funded warrants for 4,647,534 shares, to one investor, with Titan Partners Group LLC as sole placement agent.Altimmune, Inc. 424B5 (2026-01-28) https://aibio.space/news/savara-amends-hercules-loan-agreement-resets-draw-terms-up-75-million/https://aibio.space/news/savara-amends-hercules-loan-agreement-resets-draw-terms-up-75-million/Tue, 27 Jan 2026 12:00:00 GMTDebt FinancingAs amended, the loan agreement provides for up to $105 million of term loans, and the added draws depend on FDA approval of MOLBREEVI for aPAP. Two covenant compliance dates move to April 1, 2027 and September 30, 2027.Savara Inc Form 8-K filed January 27, 2026 (SEC EDGAR) https://aibio.space/news/vivani-medical-prices-4-5-million-stock-offering-chairmans-affiliate/https://aibio.space/news/vivani-medical-prices-4-5-million-stock-offering-chairmans-affiliate/Tue, 27 Jan 2026 12:00:00 GMTFinancingsVivani will sell 1,689,200 shares in a registered direct offering and 1,351,351 shares in a private placement at $1.48 each. ThinkEquity is sole placement agent for the registered part, and the company used $20,786 thousand in operations in 2024 against $19,690 thousand of year-end cash.Vivani Medical, Inc. Form 8-K filed January 27, 2026 (SEC EDGAR) https://aibio.space/news/indivior-plc-now-indivior-pharmaceuticals-inc-completes/https://aibio.space/news/indivior-plc-now-indivior-pharmaceuticals-inc-completes/Mon, 26 Jan 2026 12:00:00 GMTMergersThe company amended its November 4, 2024 note purchase agreement to reflect that Indivior U.S. now reports the financials. The board carries over, and a 2026 equity plan reserves 17,500,000 shares.Indivior Pharmaceuticals, Inc. Form 8-K filed January 26, 2026 (SEC EDGAR) https://aibio.space/news/4d-molecular-swaps-common-stock-pre-funded-warrants-ra-capital-bvf/https://aibio.space/news/4d-molecular-swaps-common-stock-pre-funded-warrants-ra-capital-bvf/Mon, 26 Jan 2026 12:00:00 GMTFinancingsRA Capital exchanged 4,850,000 shares and Biotechnology Value Fund exchanged 1,750,000 shares. The company had 51,007,874 shares outstanding as of January 23, 2026.4D Molecular Therapeutics, Inc. 8-K (2026-01-26) https://aibio.space/news/larimar-therapeutics-exchange-2-500-000-common-shares-series-preferred/https://aibio.space/news/larimar-therapeutics-exchange-2-500-000-common-shares-series-preferred/Thu, 22 Jan 2026 12:00:00 GMTFinancingsLarimar agreed with Blue Owl Healthcare Opportunities IV Public Investments LP to swap 2,500,000 common shares for 250,000 Series A convertible preferred shares. Each preferred share converts into 10 common shares, and closing is expected January 23, 2026.Larimar Therapeutics, Inc. Form 8-K filed January 22, 2026 (SEC EDGAR) https://aibio.space/news/larimar-swaps-2-500-000-common-shares-250-000-series-preferred-blue/https://aibio.space/news/larimar-swaps-2-500-000-common-shares-250-000-series-preferred-blue/Thu, 22 Jan 2026 12:00:00 GMTFinancingsEach share of Series A convertible preferred stock converts into 10 shares of common stock, subject to certain limitations. The exchange was expected to close on January 23, 2026.Larimar Therapeutics, Inc. 8-K (2026-01-22) https://aibio.space/news/bioage-sells-115-million-stock-19-50-after-nlrp3-pill-cuts-crp-86/https://aibio.space/news/bioage-sells-115-million-stock-19-50-after-nlrp3-pill-cuts-crp-86/Wed, 21 Jan 2026 12:00:00 GMTFinancingsBioAge Labs priced 5.9 million shares with Goldman Sachs, Piper Sandler and Citigroup nine days after new phase 1 data on BGE-102, its brain-penetrant NLRP3 inhibitor.BioAge Labs (SEC Form 8-K) https://aibio.space/news/aeon-biopharma-completes-daewoong-note-exchange-issuing-11-918-380/https://aibio.space/news/aeon-biopharma-completes-daewoong-note-exchange-issuing-11-918-380/Wed, 21 Jan 2026 12:00:00 GMTFinancingsAEON Biopharma exchanged its senior secured convertible notes held by Daewoong for new shares, pre-funded warrants and a smaller $1,500,000 note after stockholders approved the deal on January 21, 2026. The swap adds dilution, and the second closing of its private placement is still pending.AEON Biopharma, Inc. Form 8-K filed January 21, 2026 (SEC EDGAR) https://aibio.space/news/engene-holdings-now-engene-therapeutics-expands-hercules-loan-up-125/https://aibio.space/news/engene-holdings-now-engene-therapeutics-expands-hercules-loan-up-125/Wed, 21 Jan 2026 12:00:00 GMTDebt FinancingThe Second Amendment draws $25 million at closing to refinance existing term loans. Further tranches depend on milestones.enGene Therapeutics Inc. 8-K (2026-01-21) https://aibio.space/news/umeworld-begins-trading-otc-markets-umew-after-move-delaware/https://aibio.space/news/umeworld-begins-trading-otc-markets-umew-after-move-delaware/Wed, 21 Jan 2026 12:00:00 GMTListingsUMeWorld moved its legal home from the British Virgin Islands to Delaware, changed its name and began trading as UMEW on the OTC Markets on January 21, 2026. Its annual report for the year ended September 30, 2025 includes a going concern warning.UMeWorld Inc. 8-K (2026-01-21) https://aibio.space/news/gri-bio-says-nasdaq-found-conditionally-regained-stockholders-equity/https://aibio.space/news/gri-bio-says-nasdaq-found-conditionally-regained-stockholders-equity/Fri, 16 Jan 2026 12:00:00 GMTListingsNasdaq's staff found only conditional compliance with the $2.5 million equity rule after a December 2025 deficiency notice. The company's auditors had already raised going-concern doubt in its 2024 annual report.GRI Bio, Inc. Form 8-K filed January 16, 2026 (SEC EDGAR) https://aibio.space/news/agenus-completes-75-0-million-manufacturing-asset-sale-zydus-16-0/https://aibio.space/news/agenus-completes-75-0-million-manufacturing-asset-sale-zydus-16-0/Fri, 16 Jan 2026 12:00:00 GMTMergersAgenus received $75 million, less certain expenses, for its manufacturing operations, and sold 2,133,333 shares to a Zydus affiliate at $7.50 each. Up to $50 million in further payments depends on orders for its BOT+BAL drug product.AGENUS INC Form 8-K filed January 16, 2026 (SEC EDGAR) https://aibio.space/news/nrx-pharmaceuticals-gets-nasdaq-notice-missing-annual-meeting-deadline/https://aibio.space/news/nrx-pharmaceuticals-gets-nasdaq-notice-missing-annual-meeting-deadline/Fri, 16 Jan 2026 12:00:00 GMTListingsNasdaq said NRX Pharmaceuticals is out of compliance because it did not hold an annual meeting within twelve months of fiscal year end. The company set the 2025 Annual Meeting for March 23, 2026.NRX Pharmaceuticals, Inc. Form 8-K filed January 16, 2026 (SEC EDGAR) https://aibio.space/news/agomab-therapeutics-files-u-s-ipo-adss-seeks-nasdaq-listing-agmb/https://aibio.space/news/agomab-therapeutics-files-u-s-ipo-adss-seeks-nasdaq-listing-agmb/Fri, 16 Jan 2026 12:00:00 GMTFinancingsAgomAb Therapeutics filed to sell American depositary shares and list them on Nasdaq as AGMB. The price range and share count are blank, and the company has a Phase 2a Crohn's trial whose published results were on safety only.AgomAb Therapeutics NV F-1 (2026-01-16) https://aibio.space/news/tiziana-life-sciences-closes-8-8-million-registered-direct-offering-1/https://aibio.space/news/tiziana-life-sciences-closes-8-8-million-registered-direct-offering-1/Fri, 16 Jan 2026 12:00:00 GMTFinancingsTiziana Life Sciences Ltd sold 7,040,000 ordinary shares to senior management and existing shareholders without a placement agent. Each share came with a warrant at $1.50.Tiziana Life Sciences Ltd 6-K (2026-01-16) https://aibio.space/news/bridgebio-prices-550-million-0-75-percent-convertible-notes-refinance/https://aibio.space/news/bridgebio-prices-550-million-0-75-percent-convertible-notes-refinance/Thu, 15 Jan 2026 12:00:00 GMTDebt FinancingThe notes due 2033 carry a 45% conversion premium. Underwriters later took the full option, and BridgeBio bought back about 1.1 million shares alongside the sale.BridgeBio Pharma https://aibio.space/news/cell-source-closes-1-875-million-convertible-note-placement-plans/https://aibio.space/news/cell-source-closes-1-875-million-convertible-note-placement-plans/Thu, 15 Jan 2026 12:00:00 GMTDebt FinancingCell Source closed $1,875,000 of original issue discount convertible notes for $1,500,000 in gross proceeds. The notes convert at 90% of a recent low price, and buyers also received warrants at $.40.Cell Source via ACCESS Newswire Issuer press release https://aibio.space/news/briacell-prices-30-million-offering-units-warrants-through-thinkequity/https://aibio.space/news/briacell-prices-30-million-offering-units-warrants-through-thinkequity/Tue, 13 Jan 2026 12:00:00 GMTFinancingsBriaCell Therapeutics sold 5.4 million units at $5.59, each with a five-year warrant struck at $6.93. The best-efforts deal closed Jan. 15.BriaCell Therapeutics https://aibio.space/news/polaryx-completes-one-four-reverse-stock-split-ahead-nasdaq-listing/https://aibio.space/news/polaryx-completes-one-four-reverse-stock-split-ahead-nasdaq-listing/Mon, 12 Jan 2026 12:00:00 GMTListingsPolaryx's 1-for-4 reverse split took effect on January 12, 2026, ahead of a Nasdaq direct listing that raised no money for the company.PLYX 10-K https://aibio.space/news/ibio-raises-26-million-frazier-led-investors-push-obesity-antibodies/https://aibio.space/news/ibio-raises-26-million-frazier-led-investors-push-obesity-antibodies/Fri, 09 Jan 2026 12:00:00 GMTFinancingsThe AI-driven antibody company sold shares and pre-funded warrants at $2.35 in a private placement. It says the cash runs into calendar 2028 and that first human trials of IBIO-610 start in early 2027.iBio, Inc. (via GlobeNewswire) https://aibio.space/news/eikon-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-eikn/https://aibio.space/news/eikon-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-eikn/Fri, 09 Jan 2026 12:00:00 GMTFinancingsThe Delaware company applied to list on the Nasdaq Global Market. The share count and price range are blank in the preliminary prospectus.Eikon Therapeutics, Inc. S-1 (2026-01-09) https://aibio.space/news/monte-rosa-upsizes-stock-sale-300-million-after-oral-nek7-degrader/https://aibio.space/news/monte-rosa-upsizes-stock-sale-300-million-after-oral-nek7-degrader/Thu, 08 Jan 2026 12:00:00 GMTFinancingsMonte Rosa Therapeutics priced 12.5 million shares and pre-funded warrants at $24 the day after interim phase 1 data on MRT-8102, an oral molecular glue aimed at heart-disease inflammation.Monte Rosa Therapeutics https://aibio.space/news/genelux-sells-20-million-stock-3-share-fund-ovarian-cancer-phase-3/https://aibio.space/news/genelux-sells-20-million-stock-3-share-fund-ovarian-cancer-phase-3/Thu, 08 Jan 2026 12:00:00 GMTFinancingsGenelux sold 6,666,667 shares at $3.00 through Lucid Capital Markets, raising about $20.0 million gross. The oncolytic virus developer is running a phase 3 trial of Olvi-Vec in platinum-resistant ovarian cancer, and its China partner Newsoara holds the rights there.Genelux Corporation https://aibio.space/news/aktis-oncology-prices-upsized-ipo-18-raising-about-318-million/https://aibio.space/news/aktis-oncology-prices-upsized-ipo-18-raising-about-318-million/Thu, 08 Jan 2026 12:00:00 GMTFinancingsThe radiopharmaceutical developer sold 17.65 million shares on the Nasdaq, the first U.S. biotech IPO of 2026, after raising its offering size.Aktis Oncology (GlobeNewswire) https://aibio.space/news/alumis-raises-300-million-day-after-psoriasis-pill-beats-placebo/https://aibio.space/news/alumis-raises-300-million-day-after-psoriasis-pill-beats-placebo/Wed, 07 Jan 2026 12:00:00 GMTFinancingsAlumis sold 17.65 million shares at $17 after two phase 3 trials of its oral TYK2 inhibitor envudeucitinib met all endpoints. A prospectus had flagged going-concern doubt before the deal.Alumis Inc. https://aibio.space/news/curis-raises-20-2-million-up-front-pipe-could-bring-up-80-8-million/https://aibio.space/news/curis-raises-20-2-million-up-front-pipe-could-bring-up-80-8-million/Wed, 07 Jan 2026 12:00:00 GMTFinancingsThe emavusertib developer sold preferred stock with three warrant series at $0.75, one of them timed to an enrollment goal in its leukemia trial.Curis, Inc. https://aibio.space/news/propanc-biopharma-gets-nasdaq-minimum-bid-price-deficiency-notice-has/https://aibio.space/news/propanc-biopharma-gets-nasdaq-minimum-bid-price-deficiency-notice-has/Wed, 07 Jan 2026 12:00:00 GMTListingsPropanc Biopharma received a Nasdaq notice that its stock has been below the $1.00 minimum bid price, and it has until June 30, 2026 to regain compliance. Its latest annual report showed cash of $12,088 at June 30, 2025.Propanc Biopharma, Inc. Form 8-K filed January 7, 2026 (SEC EDGAR) https://aibio.space/news/arrowhead-pharmaceuticals-prices-625-000-000-0-00-percent-convertible/https://aibio.space/news/arrowhead-pharmaceuticals-prices-625-000-000-0-00-percent-convertible/Wed, 07 Jan 2026 12:00:00 GMTDebt FinancingArrowhead Pharmaceuticals raised the notes from $500,000,000 to $625,000,000 while selling common stock at the same time. The notes rank behind $254.9 million of secured borrowing.Arrowhead Pharmaceuticals, Inc. 424B5 (2026-01-07) https://aibio.space/news/phathom-pharmaceuticals-prices-stock-pre-funded-warrant-offering-16-00/https://aibio.space/news/phathom-pharmaceuticals-prices-stock-pre-funded-warrant-offering-16-00/Wed, 07 Jan 2026 12:00:00 GMTFinancingsPhathom priced 6,875,000 shares at $16.00 plus pre-funded warrants for 1,250,078 shares, for a public offering of $129,999,998. Its cash fell from $297.3 million at the end of 2024 to a preliminary $130 million at the end of 2025, and the company expects operating profit only in the second half of 2026, excluding stock-based compensation.Phathom Pharmaceuticals, Inc. 424B5 (2026-01-07) https://aibio.space/news/praxis-prices-575-million-stock-offering-260-share-ahead-two-nda/https://aibio.space/news/praxis-prices-575-million-stock-offering-260-share-ahead-two-nda/Tue, 06 Jan 2026 12:00:00 GMTFinancingsPraxis Precision Medicines sold 2.2 million shares to fund launch plans for two Breakthrough-designated drugs. Net proceeds later came to $621.2 million.Praxis Precision Medicines (via GlobeNewswire) https://aibio.space/news/immunic-gets-extra-180-days-nasdaq-bid-price-rule-after-transfer/https://aibio.space/news/immunic-gets-extra-180-days-nasdaq-bid-price-rule-after-transfer/Tue, 06 Jan 2026 12:00:00 GMTListingsNasdaq approved Immunic's move from the Global Select Market to the Capital Market, with trading there from January 7, 2026. The company now has until June 22, 2026 to regain compliance with the $1.00 minimum bid price and has told Nasdaq it would seek a reverse stock split if necessary.IMMUNIC, INC. Form 8-K filed January 6, 2026 (SEC EDGAR) https://aibio.space/news/galecto-now-damora-therapeutics-issues-warrant-up-628-302-shares-names/https://aibio.space/news/galecto-now-damora-therapeutics-issues-warrant-up-628-302-shares-names/Tue, 06 Jan 2026 12:00:00 GMTFinancingsThe December 31, 2025 warrant went to Paramora Holding LLC at $23.01 per share under an October 7, 2025 option agreement with Paragon Therapeutics. The board named Sherwin Sattarzadeh Chief Operating Officer.Damora Therapeutics, Inc. Form 8-K filed January 6, 2026 (SEC EDGAR) https://aibio.space/news/igc-pharma-agrees-sell-779-997-shares-0-30-direct-offering/https://aibio.space/news/igc-pharma-agrees-sell-779-997-shares-0-30-direct-offering/Tue, 06 Jan 2026 12:00:00 GMTFinancingsThe registered direct offering is expected to bring in about $234,000 before expenses. IGC Pharma says it will use the money for working capital and general corporate purposes.IGC Pharma, Inc. 424B5 (2026-01-06) https://aibio.space/news/salarius-pharmaceuticals-now-decoy-therapeutics-gets-nasdaq-delisting-2/https://aibio.space/news/salarius-pharmaceuticals-now-decoy-therapeutics-gets-nasdaq-delisting-2/Fri, 02 Jan 2026 12:00:00 GMTListingsNasdaq said on December 31, 2025 that the company missed the $1.00 minimum bid price and gets no grace period. Suspension is set for January 9, 2026 unless it appeals by January 7, 2026.Decoy Therapeutics Inc. Form 8-K filed January 2, 2026 (SEC EDGAR) https://aibio.space/news/zura-bio-issue-8-657-402-shares-pay-7-325-000-athanor-capital-ends/https://aibio.space/news/zura-bio-issue-8-657-402-shares-pay-7-325-000-athanor-capital-ends/Fri, 02 Jan 2026 12:00:00 GMTFinancingsZura Bio will issue 8,657,402 Class A shares to Athanor Capital and pay it a $7,325,000 upfront fee within 30 days, ending its Stone Peach and BAFFX17 arrangements. An internal audit subcommittee review found no issue that affected previously filed financial statements, and the Athanor deal adds a $25,000,000 milestone payment.Zura Bio Ltd Form 8-K filed January 2, 2026 (SEC EDGAR) https://aibio.space/news/fibrobiologics-gets-nasdaq-delisting-notice-bid-price-plans-request/https://aibio.space/news/fibrobiologics-gets-nasdaq-delisting-notice-bid-price-plans-request/Fri, 02 Jan 2026 12:00:00 GMTListingsNasdaq staff plans to delist FibroBiologics after its stock did not regain the $1.00 minimum bid price by December 29, 2025. The company will ask for a hearing and has asked stockholders to approve a reverse split of 1 for 5 to 1 for 30.FibroBiologics, Inc. Form 8-K filed January 2, 2026 (SEC EDGAR) https://aibio.space/news/bausch-lomb-closes-2-802-125-000-term-loan-refinancing/https://aibio.space/news/bausch-lomb-closes-2-802-125-000-term-loan-refinancing/Fri, 02 Jan 2026 12:00:00 GMTDebt FinancingBausch + Lomb closed a $2,802,125,000 term loan tranche maturing January 15, 2031, used to refinance its term B loans due 2028 and 2031. The margin on term SOFR loans is 3.75%, but the filing does not say how much of the tranche is new cash.Bausch & Lomb Corp Form 8-K filed January 2, 2026 (SEC EDGAR) https://aibio.space/news/eledon-pharmaceuticals-swaps-4-203-764-shares-pre-funded-warrant/https://aibio.space/news/eledon-pharmaceuticals-swaps-4-203-764-shares-pre-funded-warrant/Fri, 02 Jan 2026 12:00:00 GMTFinancingsThe exchange closed on December 30, 2025. The warrant has an initial exercise price of $0.001 per share.Eledon Pharmaceuticals, Inc. 8-K (2026-01-02) https://aibio.space/news/cybin-inc-now-helus-pharma-files-form-25-leave-nyse-american/https://aibio.space/news/cybin-inc-now-helus-pharma-files-form-25-leave-nyse-american/Fri, 02 Jan 2026 12:00:00 GMTListingsThe January 2, 2026 filing covers the company's common shares. It relies on the SEC rule for a voluntary withdrawal by the issuer.Helus Pharma Inc. 25 (2026-01-02) https://aibio.space/news/northwest-biotherapeutics-holders-approve-raising-authorized-shares-2/https://aibio.space/news/northwest-biotherapeutics-holders-approve-raising-authorized-shares-2/Fri, 02 Jan 2026 12:00:00 GMTListingsCommon stock authorized rises from 1,700,000,000 to 2,600,000,000 shares. The company filed the amendment in Delaware on December 30, 2025.Northwest Biotherapeutics, Inc. 8-K (2026-01-02) https://aibio.space/news/climb-bio-sues-alumis-acelyrin-3-million-budoprutug-milestone-payment/https://aibio.space/news/climb-bio-sues-alumis-acelyrin-3-million-budoprutug-milestone-payment/Wed, 31 Dec 2025 12:00:00 GMTLegalClimb Bio filed a complaint in Delaware Superior Court against Alumis Inc. and Acelyrin, Inc. It asks for a declaration that budoprutug is not a Product under a 2024 asset purchase agreement, and that Climb does not owe a $3 million milestone payment.Climb Bio, Inc. Form 8-K filed December 31, 2025 (SEC EDGAR) https://aibio.space/news/collegium-closes-980-million-syndicated-credit-facility-truist-bank/https://aibio.space/news/collegium-closes-980-million-syndicated-credit-facility-truist-bank/Tue, 30 Dec 2025 12:00:00 GMTDebt FinancingThe five-year facility has a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver, with Truist Bank as administrative agent. Collegium used the initial loan to repay its previous term loan in full, including its prepayment premium, which the filing does not size.COLLEGIUM PHARMACEUTICAL, INC Form 8-K filed December 30, 2025 (SEC EDGAR) https://aibio.space/news/arcturus-files-500-000-000-replacement-shelf-187-765-319-atm/https://aibio.space/news/arcturus-files-500-000-000-replacement-shelf-187-765-319-atm/Tue, 30 Dec 2025 12:00:00 GMTFinancingsThe at-the-market sales agreement names Cantor Fitzgerald, Wells Fargo Securities and William Blair. As of December 22, 2025, the company had sold 1,179,201 shares under it for about $12 million.Arcturus Therapeutics Holdings Inc. S-3 (2025-12-30) https://aibio.space/news/collegium-closes-980-million-syndicated-credit-facility-repays/https://aibio.space/news/collegium-closes-980-million-syndicated-credit-facility-repays/Tue, 30 Dec 2025 12:00:00 GMTDebt FinancingThe $980 million facility matures in 2030 and includes a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver. The initial term loan repaid about $581 million owed to Pharmakon, so it brought no new cash at closing.Collegium Pharmaceutical, Inc. 8-K (2025-12-30) https://aibio.space/news/mesoblast-registers-resale-up-500-000-adss-issuable-warrant-exercise/https://aibio.space/news/mesoblast-registers-resale-up-500-000-adss-issuable-warrant-exercise/Tue, 30 Dec 2025 12:00:00 GMTFinancingsHolders would receive all resale proceeds. Mesoblast would receive US$16.25 per ADS if the warrants are exercised.Mesoblast Limited F-3 (2025-12-30) https://aibio.space/news/silo-pharma-gets-second-180-days-nasdaq-meet-1-00-minimum-bid-price/https://aibio.space/news/silo-pharma-gets-second-180-days-nasdaq-meet-1-00-minimum-bid-price/Mon, 29 Dec 2025 12:00:00 GMTListingsSilo Pharma did not regain the $1.00 minimum bid price by December 24, 2025, and Nasdaq granted it a second 180-day period to June 22, 2026. The company has told Nasdaq it may use a reverse stock split to cure the deficiency, and its annual report shows an accumulated deficit of $15,264,691.Silo Pharma, Inc. Form 8-K filed December 29, 2025 (SEC EDGAR) https://aibio.space/news/immunitybio-adds-up-459-972-480-market-stock-program/https://aibio.space/news/immunitybio-adds-up-459-972-480-market-stock-program/Mon, 29 Dec 2025 12:00:00 GMTFinancingsThe company amended its sales agreement with Jefferies and filed a new prospectus supplement. It also confirmed a higher authorized share count.ImmunityBio, Inc. 424B5 (2025-12-29) https://aibio.space/news/cassava-sciences-now-filana-therapeutics-agrees-31-25-million-class/https://aibio.space/news/cassava-sciences-now-filana-therapeutics-agrees-31-25-million-class/Tue, 23 Dec 2025 12:00:00 GMTLegalCassava and Chief Financial Officer Eric J. Schoen accepted a mediator's recommendation to settle the consolidated securities class action for $31.25 million. Remi Barbier and Lindsay Burns did not sign the term sheet but would receive releases once the court approves.FILANA THERAPEUTICS, INC. Form 8-K filed December 23, 2025 (SEC EDGAR) https://aibio.space/news/anebulo-drops-reverse-split-plan-3-50-share-self-tender-up-300-000/https://aibio.space/news/anebulo-drops-reverse-split-plan-3-50-share-self-tender-up-300-000/Mon, 22 Dec 2025 12:00:00 GMTListingsAnebulo's board dropped a planned reverse split and will instead tender for up to 300,000 shares at $3.50, to keep its holder count below 300 for a go-private plan, while its lead drug rests on a Phase 2 study in healthy volunteers.Anebulo Pharmaceuticals Inc 8-K (2025-12-22) https://aibio.space/news/apollomics-interim-report-shows-4-398-thousand-shareholders-deficit/https://aibio.space/news/apollomics-interim-report-shows-4-398-thousand-shareholders-deficit/Mon, 22 Dec 2025 12:00:00 GMTListingsApollomics reports a $4,398 thousand shareholders' deficit at June 30, 2025, after cash fell to $2,094 thousand from $9,766 thousand at year-end and the six months produced a $12,536 thousand loss.Apollomics, Inc. 6-K (2025-12-22) https://aibio.space/news/biodexa-prices-10-million-best-efforts-offering-ads-units-warrants/https://aibio.space/news/biodexa-prices-10-million-best-efforts-offering-ads-units-warrants/Thu, 18 Dec 2025 12:00:00 GMTFinancingsBiodexa priced 157,000 units and 2,891,781 pre-funded units at $3.28 each, with two Series L warrants per unit. The last reported sale price of the ADSs was $6.50 on December 16, 2025.Biodexa Pharmaceuticals plc 6-K (2025-12-18) https://aibio.space/news/sl-science-holding-files-f-4-horizon-space-acquisition-ii-sl-bio/https://aibio.space/news/sl-science-holding-files-f-4-horizon-space-acquisition-ii-sl-bio/Thu, 18 Dec 2025 12:00:00 GMTMergersSL Science Holding's F-4 says the blank-check company's trust holds $69,000,000 and that its chairman would control about 58% of the voting power of the combined company. The target's main products include cancer drugs that the filing does not show as approved.SL Science Holding Limited F-4 (2025-12-18) https://aibio.space/news/larimar-therapeutics-swaps-blue-owl-funds-2-500-000-shares-series/https://aibio.space/news/larimar-therapeutics-swaps-blue-owl-funds-2-500-000-shares-series/Wed, 17 Dec 2025 12:00:00 GMTFinancingsLarimar Therapeutics agreed to swap 2,500,000 common shares held by a Blue Owl fund for 250,000 Series A convertible preferred shares, each convertible into 10 common shares. The filing calls the preferred "toothless," and the holder can raise its conversion blocker to 19.99%.Larimar Therapeutics, Inc. Form 8-K filed December 17, 2025 (SEC EDGAR) https://aibio.space/news/nyse-american-accepts-azitras-stockholders-equity-compliance-plan-sets/https://aibio.space/news/nyse-american-accepts-azitras-stockholders-equity-compliance-plan-sets/Wed, 17 Dec 2025 12:00:00 GMTListingsNYSE American accepted Azitra's plan to restore its $4.0 million minimum stockholders' equity and set April 1, 2027 as the deadline. The stock stays listed while the plan runs, but the company's 2024 annual report carried a going-concern warning.Azitra, Inc. Form 8-K filed December 17, 2025 (SEC EDGAR) https://aibio.space/news/cadrenal-therapeutics-agrees-2-2-million-registered-direct-offering/https://aibio.space/news/cadrenal-therapeutics-agrees-2-2-million-registered-direct-offering/Tue, 16 Dec 2025 12:00:00 GMTFinancingsCadrenal will sell 207,374 shares at $10.85 plus unregistered warrants for up to 414,748 shares at $10.60, for expected gross proceeds of about $2.2 million. H.C. Wainwright & Co., LLC is exclusive placement agent.Cadrenal Therapeutics, Inc. Form 8-K filed December 16, 2025 (SEC EDGAR) https://aibio.space/news/lexaria-closes-registered-direct-offering-warrant-placement-about-3-5/https://aibio.space/news/lexaria-closes-registered-direct-offering-warrant-placement-about-3-5/Tue, 16 Dec 2025 12:00:00 GMTFinancingsLexaria sold 2,661,600 shares at $1.315 in a registered direct offering and placed matching warrants at $1.19, for about $3.5 million gross. H.C. Wainwright & Co., LLC was placement agent. Its annual report says the company has substantial doubt about continuing as a going concern.Lexaria Bioscience Corp. Form 8-K filed December 16, 2025 (SEC EDGAR) https://aibio.space/news/geron-begins-restructuring-cutting-about-one-third-roughly-260/https://aibio.space/news/geron-begins-restructuring-cutting-about-one-third-roughly-260/Tue, 16 Dec 2025 12:00:00 GMTDistressGeron Corporation estimates about $18 million in restructuring charges, mostly severance and benefits, and expects the workforce reduction to be substantially complete in the first quarter of 2026.GERON CORP Form 8-K filed December 16, 2025 (SEC EDGAR) https://aibio.space/news/geron-begins-restructuring-cuts-about-one-third-roughly-260-employees/https://aibio.space/news/geron-begins-restructuring-cuts-about-one-third-roughly-260-employees/Tue, 16 Dec 2025 12:00:00 GMTDistressThe company estimates about $18 million in restructuring charges, mostly severance and benefits, hitting results in the fourth quarter of 2025 and the first quarter of 2026.Geron Corporation 8-K (2025-12-16) https://aibio.space/news/radiopharm-theranostics-files-50-000-000-ads-shelf-sets-18-900-000/https://aibio.space/news/radiopharm-theranostics-files-50-000-000-ads-shelf-sets-18-900-000/Tue, 16 Dec 2025 12:00:00 GMTFinancingsRadiopharm Theranostics filed a $50,000,000 shelf registration on December 16, 2025 and a sales agreement with Leerink Partners the same day. A prospectus supplement filed December 23 set up to $18,900,000 of at-the-market sales.Radiopharm Theranostics Limited F-3 (2025-12-16) https://aibio.space/news/therapeuticsmd-holders-approve-raising-authorized-common-stock-640-000/https://aibio.space/news/therapeuticsmd-holders-approve-raising-authorized-common-stock-640-000/Tue, 16 Dec 2025 12:00:00 GMTListingsTherapeuticsMD stockholders approved raising authorized common stock to 640,000,000 shares at the December 15, 2025 annual meeting. The company had 11,574,362 shares outstanding at the record date, and the increase drew 548,884 votes against.TherapeuticsMD, Inc. 8-K (2025-12-16) https://aibio.space/news/turn-completes-first-gem-equity-draw-4-1-million-about-3-29-share/https://aibio.space/news/turn-completes-first-gem-equity-draw-4-1-million-about-3-29-share/Mon, 15 Dec 2025 12:00:00 GMTFinancingsThe 10-K reports GEM bought 1,235,200 shares for about $4.07 million in 2025 under an $85.0 million agreement. The company has since drawn a $7.0 million term loan and flagged going-concern doubt.SEC EDGAR: Turn Therapeutics 10-Q https://aibio.space/news/pharmacyte-biotech-files-nt-10-q-quarter-ended-october-31-2025-citing/https://aibio.space/news/pharmacyte-biotech-files-nt-10-q-quarter-ended-october-31-2025-citing/Mon, 15 Dec 2025 12:00:00 GMTDistressPharmaCyte Biotech will miss the December 15, 2025 deadline for its quarterly report and says it will file within five calendar days. The company's latest annual report says its licensed patents have expired and that the know-how for its core technology sits with a partner, while it has cut program spending during a board review.PharmaCyte Biotech, Inc. Form NT 10-Q filed December 15, 2025 (SEC EDGAR) https://aibio.space/news/immunome-proposes-400-million-stock-offering-later-sets-21-50-price/https://aibio.space/news/immunome-proposes-400-million-stock-offering-later-sets-21-50-price/Mon, 15 Dec 2025 12:00:00 GMTFinancingsImmunome said on December 15, 2025 that it planned a $400 million stock offering, and priced it the next day at $21.50 a share.Immunome, Inc. 424B5 (2025-12-15) https://aibio.space/news/tiziana-life-sciences-files-best-efforts-share-offering-thinkequity/https://aibio.space/news/tiziana-life-sciences-files-best-efforts-share-offering-thinkequity/Fri, 12 Dec 2025 12:00:00 GMTFinancingsThe preliminary filing leaves the size and price blank. There is no minimum amount, so the company may sell fewer shares than offered.Tiziana Life Sciences Ltd 424B5 (2025-12-12) https://aibio.space/news/climb-bio-agrees-swap-20-440-000-ra-capital-shares-pre-funded-warrant/https://aibio.space/news/climb-bio-agrees-swap-20-440-000-ra-capital-shares-pre-funded-warrant/Thu, 11 Dec 2025 12:00:00 GMTFinancingsClimb Bio agreed on December 11, 2025 to take back 20,440,000 shares from an entity affiliated with RA Capital in exchange for a pre-funded warrant. After the exchange, RA Capital and its affiliates will hold about 23.0% of the voting power, and the filing describes no cash payment to the company.Climb Bio, Inc. Form 8-K filed December 11, 2025 (SEC EDGAR) https://aibio.space/news/tivic-health-systems-now-valion-bio-buys-scorpius-cdmo-assets-16-253/https://aibio.space/news/tivic-health-systems-now-valion-bio-buys-scorpius-cdmo-assets-16-253/Thu, 11 Dec 2025 12:00:00 GMTMergersTivic Health Systems bought the manufacturing and development assets of Scorpius Holdings at a public auction, paying $16,253,147.10 in cash funded by a senior secured convertible note sold to 3i. The note converts at a fixed price and at a discount to market, which can add shares.Valion Bio, Inc. Form 8-K filed December 11, 2025 (SEC EDGAR) https://aibio.space/news/addex-amends-h-c-wainwright-atm-deal-up-3-300-000-adss/https://aibio.space/news/addex-amends-h-c-wainwright-atm-deal-up-3-300-000-adss/Wed, 10 Dec 2025 12:00:00 GMTFinancingsAddex Therapeutics amended its at-the-market agreement with H.C. Wainwright and filed a prospectus supplement for up to $3,300,000 of ADSs. The company reported CHF 2.2 million of cash at September 30, 2025 and says it covers expenses through mid-June 2026.Addex Therapeutics Ltd 424B5 (2025-12-10) https://aibio.space/news/c4-therapeutics-registers-125-000-000-share-sales-through-td-cowen/https://aibio.space/news/c4-therapeutics-registers-125-000-000-share-sales-through-td-cowen/Wed, 10 Dec 2025 12:00:00 GMTFinancingsThe supplement covers $125,000,000 of a sales agreement that allows up to $200,000,000 in total. TD Securities (USA) LLC can earn up to a 3.0% commission, and the filing gives a November 20, 2025 closing price of $2.38.C4 Therapeutics, Inc. 424B5 (2025-12-10) https://aibio.space/news/evaxion-registers-up-45-527-824-ads-sales-after-public-float-passes-75/https://aibio.space/news/evaxion-registers-up-45-527-824-ads-sales-after-public-float-passes-75/Wed, 10 Dec 2025 12:00:00 GMTFinancingsEvaxion says its public float now passes $75.0 million, which lifts a sales cap and allows up to $45.52 million more in ADS sales through JonesTrading. The float figure uses an October share price, and the stock was $6.28 in early December.Evaxion A/S 424B5 (2025-12-10) https://aibio.space/news/dyne-therapeutics-borrows-50-0-million-second-tranche-under-amended/https://aibio.space/news/dyne-therapeutics-borrows-50-0-million-second-tranche-under-amended/Mon, 08 Dec 2025 12:00:00 GMTDebt FinancingThe First Amendment lets Dyne draw a $50.0 million tranche from Hercules Capital. Up to $75.0 million more depends on milestones, and the loan matures July 1, 2030 at prime plus 2.45% with a 7.50% floor.Dyne Therapeutics, Inc. Form 8-K filed December 8, 2025 (SEC EDGAR) https://aibio.space/news/fulcrum-proposes-150-0-million-stock-offering-later-upsized-175-0/https://aibio.space/news/fulcrum-proposes-150-0-million-stock-offering-later-upsized-175-0/Mon, 08 Dec 2025 12:00:00 GMTFinancingsThe $150.0 million offering priced on December 10, 2025 at $13.50 a share and was upsized to $175.0 million. Its lead drug data come from 12 patients in one dose cohort, and the dose comparison rests on six.Fulcrum Therapeutics, Inc. 424B5 (2025-12-08) https://aibio.space/news/wave-life-sciences-proposes-250-000-000-offering-then-prices-upsized/https://aibio.space/news/wave-life-sciences-proposes-250-000-000-offering-then-prices-upsized/Mon, 08 Dec 2025 12:00:00 GMTFinancingsWave Life Sciences filed a preliminary prospectus supplement on December 8, 2025 for a $250,000,000 offering. The pricing that followed on December 9 raised the deal to about $350 million at $19.00 per ordinary share.Wave Life Sciences, Inc. 424B5 (2025-12-08) https://aibio.space/news/pharmacyte-biotech-gets-nasdaq-minimum-bid-price-deficiency-notice-has/https://aibio.space/news/pharmacyte-biotech-gets-nasdaq-minimum-bid-price-deficiency-notice-has/Fri, 05 Dec 2025 12:00:00 GMTListingsNasdaq told PharmaCyte on December 1, 2025 that its stock had failed the $1.00 minimum bid price over 30 consecutive business days. The company has until June 1, 2026, and any reverse stock split would need shareholder approval. The filings give no share price or cash figure to show how far the company is from compliance.PharmaCyte Biotech, Inc. Form 8-K filed December 5, 2025 (SEC EDGAR) https://aibio.space/news/intensity-therapeutics-gets-second-180-days-meet-nasdaq-minimum-bid/https://aibio.space/news/intensity-therapeutics-gets-second-180-days-meet-nasdaq-minimum-bid/Fri, 05 Dec 2025 12:00:00 GMTListingsNasdaq gave Intensity until June 1, 2026 to restore a $1.00 closing bid price. The company says it may use a reverse stock split, and the notice has no immediate effect on its listing.INTENSITY THERAPEUTICS, INC. Form 8-K filed December 5, 2025 (SEC EDGAR) https://aibio.space/news/natera-closes-foresight-diagnostics-acquisition-agrees-issue-1-127-982/https://aibio.space/news/natera-closes-foresight-diagnostics-acquisition-agrees-issue-1-127-982/Fri, 05 Dec 2025 12:00:00 GMTMergersNatera closed the deal on December 4, 2025. The press release describes an all-stock transaction with a $275 million upfront and $175 million in earnouts tied to milestones.Natera, Inc. Form 8-K filed December 5, 2025 (SEC EDGAR) https://aibio.space/news/polyrizon-agrees-sell-552-269-shares-9-00-registered-direct-offering/https://aibio.space/news/polyrizon-agrees-sell-552-269-shares-9-00-registered-direct-offering/Fri, 05 Dec 2025 12:00:00 GMTListingsExpected gross proceeds are about $4.97 million. The company says the price is a premium to the Nasdaq Minimum Price.Polyrizon Ltd. 6-K (2025-12-05) https://aibio.space/news/crescent-biopharma-agrees-185-million-private-placement-kelun-biotech/https://aibio.space/news/crescent-biopharma-agrees-185-million-private-placement-kelun-biotech/Thu, 04 Dec 2025 12:00:00 GMTFinancingsCrescent agreed to sell 13,795,685 ordinary shares at $13.41 for about $185.0 million. Two license deals with Kelun-Biotech require Crescent to pay $80.0 million within 30 days of signing, while Kelun-Biotech pays it $20.0 million in the same period.CRESCENT BIOPHARMA, INC. Form 8-K filed December 4, 2025 (SEC EDGAR) https://aibio.space/news/baxter-closes-three-series-senior-notes-offering-about-1-99-billion/https://aibio.space/news/baxter-closes-three-series-senior-notes-offering-about-1-99-billion/Thu, 04 Dec 2025 12:00:00 GMTFinancingsBaxter closed a three-series senior notes offering on December 4, 2025 and used part of the proceeds to repay its term loan. The rest is earmarked for cash tender offers on older notes, so the company is swapping debt rather than shrinking it.BAXTER INTERNATIONAL INC Form 8-K filed December 4, 2025 (SEC EDGAR) https://aibio.space/news/immuron-issue-45-472-000-shares-aud-0-07910-placement/https://aibio.space/news/immuron-issue-45-472-000-shares-aud-0-07910-placement/Thu, 04 Dec 2025 12:00:00 GMTFinancingsThe 45,472,000 shares are sold to US investors through the company's at-the-market facility, according to a note in the filing. The filing names no lead manager or underwriter.Immuron Limited 6-K (2025-12-04) https://aibio.space/news/gri-bio-gets-nasdaq-deficiency-notice-minimum-stockholders-equity/https://aibio.space/news/gri-bio-gets-nasdaq-deficiency-notice-minimum-stockholders-equity/Tue, 02 Dec 2025 12:00:00 GMTListingsNasdaq told GRI Bio on November 26, 2025 that it does not meet the $2,500,000 stockholders' equity requirement for the Capital Market. The company has until January 10, 2026 to submit a compliance plan, and its annual report already carried a going-concern warning.GRI Bio, Inc. Form 8-K filed December 2, 2025 (SEC EDGAR) https://aibio.space/news/kazia-therapeutics-prices-50-0-million-private-placement-5-00-ads/https://aibio.space/news/kazia-therapeutics-prices-50-0-million-private-placement-5-00-ads/Tue, 02 Dec 2025 12:00:00 GMTFinancingsThe deal has no common warrant coverage but includes prefunded warrants. Kazia expects net proceeds of approximately $46.5 million and says its cash runway would extend into the second half of 2028.Kazia Therapeutics Limited 6-K (2025-12-02) https://aibio.space/news/omeros-closes-zaltenibart-sale-novo-nordisk-receives-240-0-million/https://aibio.space/news/omeros-closes-zaltenibart-sale-novo-nordisk-receives-240-0-million/Mon, 01 Dec 2025 12:00:00 GMTMergersOmeros got $240.0 million upfront and may earn up to $510 million in development and approval milestones and $1.3 billion in sales milestones. About $72.6 million retired its credit agreement and the board approved a buyback of up to $100.0 million.OMEROS CORP Form 8-K filed December 1, 2025 (SEC EDGAR) https://aibio.space/news/q32-bio-sells-adx-097-akebia-therapeutics-7-0-million-upfront/https://aibio.space/news/q32-bio-sells-adx-097-akebia-therapeutics-7-0-million-upfront/Mon, 01 Dec 2025 12:00:00 GMTMergersQ32 Bio closed the asset sale on November 28, 2025 and is eligible for up to $580 million in milestones plus royalties. It now expects cash to fund operations into the second half of 2027.Q32 Bio Inc. Form 8-K filed December 1, 2025 (SEC EDGAR) https://aibio.space/news/gt-biopharma-gets-nasdaq-minimum-bid-price-notice-has-until-may-19/https://aibio.space/news/gt-biopharma-gets-nasdaq-minimum-bid-price-notice-has-until-may-19/Wed, 26 Nov 2025 12:00:00 GMTListingsNasdaq told GT Biopharma on November 20, 2025 that its stock had closed below $1 for 30 consecutive business days. The company has until May 19, 2026 to regain compliance, and its last annual report carried a going-concern warning alongside a $13.2 million net loss.GT Biopharma, Inc. Form 8-K filed November 26, 2025 (SEC EDGAR) https://aibio.space/news/akari-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice-has/https://aibio.space/news/akari-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice-has/Wed, 26 Nov 2025 12:00:00 GMTListingsNasdaq told Akari Therapeutics on November 24, 2025 that its American Depositary Shares had closed below $1.00 for 30 consecutive business days. The company has until May 25, 2026 to regain compliance, and its 2024 annual report carries a going-concern warning.Akari Therapeutics Plc Form 8-K filed November 26, 2025 (SEC EDGAR) https://aibio.space/news/metavia-gets-180-day-nasdaq-extension-may-26-2026-minimum-bid-price/https://aibio.space/news/metavia-gets-180-day-nasdaq-extension-may-26-2026-minimum-bid-price/Wed, 26 Nov 2025 12:00:00 GMTListingsMetaVia Inc. (Nasdaq: MTVA) was granted more time to regain compliance after its stock closed below $1.00 for 30 consecutive trading days. It says a reverse stock split is an option.MetaVia Inc. Form 8-K filed November 26, 2025 (SEC EDGAR) https://aibio.space/news/mesoblast-holders-approve-convertible-notes-warrants-director-cova/https://aibio.space/news/mesoblast-holders-approve-convertible-notes-warrants-director-cova/Wed, 26 Nov 2025 12:00:00 GMTDebt FinancingAll resolutions passed by poll at the November 25, 2025 annual meeting. Shareholders also approved option grants and prior share issues.Mesoblast Limited 6-K (2025-11-26) https://aibio.space/news/polypid-raises-share-sales-program-limit-8-250-000-15-000-000/https://aibio.space/news/polypid-raises-share-sales-program-limit-8-250-000-15-000-000/Wed, 26 Nov 2025 12:00:00 GMTFinancingsPolyPid can now sell up to $15,000,000 of ordinary shares through Oppenheimer & Co. Inc., up from $8,250,000, paying a 3.0% commission. Its shares closed at $3.68 on November 25, 2025, and the supplement does not say how much cash the company has.PolyPid Ltd. 424B5 (2025-11-26) https://aibio.space/news/artelo-biosciences-gets-nasdaq-delisting-determination-stockholders/https://aibio.space/news/artelo-biosciences-gets-nasdaq-delisting-determination-stockholders/Tue, 25 Nov 2025 12:00:00 GMTListingsNasdaq's staff ruled that Artelo had not completed the capital raise it promised to fix its equity shortfall. Trading continues pending a hearing panel appeal, and the company's last annual report carried going-concern doubt.ARTELO BIOSCIENCES, INC. Form 8-K filed November 25, 2025 (SEC EDGAR) https://aibio.space/news/cumberland-pharmaceuticals-extends-pinnacle-bank-credit-line-october/https://aibio.space/news/cumberland-pharmaceuticals-extends-pinnacle-bank-credit-line-october/Mon, 24 Nov 2025 12:00:00 GMTDebt FinancingCumberland's amended Pinnacle Bank line has up to $15 million available, a right to request $10 million more, and a maturity of October 1, 2027. The filing does not say how much is drawn.CUMBERLAND PHARMACEUTICALS INC Form 8-K filed November 24, 2025 (SEC EDGAR) https://aibio.space/news/verrica-pharmaceuticals-agrees-about-50-million-private-placement/https://aibio.space/news/verrica-pharmaceuticals-agrees-about-50-million-private-placement/Mon, 24 Nov 2025 12:00:00 GMTFinancingsVerrica agreed to sell common stock, pre-funded warrants and Series C warrants for about $50 million, and will use $35.0 million to settle its OrbiMed credit agreement. The company says cash will last into mid-2027.Verrica Pharmaceuticals Inc. Form 8-K filed November 24, 2025 (SEC EDGAR) https://aibio.space/news/anaptysbio-sues-tesaro-gsk-delaware-chancery-court-jemperli/https://aibio.space/news/anaptysbio-sues-tesaro-gsk-delaware-chancery-court-jemperli/Fri, 21 Nov 2025 12:00:00 GMTLegalAnaptysBio's Verified Complaint of Nov 20, 2025 names Tesaro, Inc. and its parent GlaxoSmithKline and alleges breaches of the Jemperli collaboration. Tesaro sued AnaptysBio the same day, and the parties have agreed to ask for an expedited schedule.ANAPTYSBIO, INC Form 8-K filed November 21, 2025 (SEC EDGAR) https://aibio.space/news/moleculin-biotech-gets-nasdaq-delisting-determination-plans-hearing/https://aibio.space/news/moleculin-biotech-gets-nasdaq-delisting-determination-plans-hearing/Fri, 21 Nov 2025 12:00:00 GMTListingsNasdaq staff issued a delisting determination against Moleculin Biotech's common stock for failing the $2.5 million stockholders' equity rule. The company said it will ask a hearing panel to stay any suspension, and its last annual report showed $4.3 million of cash and a going-concern warning.Moleculin Biotech, Inc. Form 8-K filed November 21, 2025 (SEC EDGAR) https://aibio.space/news/cullinan-unit-ends-mit-license-cln-617-after-dropping-program/https://aibio.space/news/cullinan-unit-ends-mit-license-cln-617-after-dropping-program/Fri, 21 Nov 2025 12:00:00 GMTDistressCullinan Amber Corp. will return the licensed patent rights to MIT. The termination takes effect February 18, 2026.Cullinan Therapeutics, Inc. 8-K (2025-11-21) https://aibio.space/news/abbott-agrees-acquire-exact-sciences-105-share-cash-about-21-billion/https://aibio.space/news/abbott-agrees-acquire-exact-sciences-105-share-cash-about-21-billion/Thu, 20 Nov 2025 12:00:00 GMTMergersAbbott agreed on November 20, 2025 to buy Exact Sciences for $105 per share in cash, an equity value the companies put at about $21 billion. Abbott's commitment letter provides up to $20 billion of bridge loans, and the companies expect the deal to close in the second quarter of 2026, subject to a shareholder vote and antitrust review.ABBOTT LABORATORIES Form 8-K filed November 20, 2025 (SEC EDGAR) https://aibio.space/news/harrow-completes-melt-pharmaceuticals-acquisition-approximately-4-3/https://aibio.space/news/harrow-completes-melt-pharmaceuticals-acquisition-approximately-4-3/Tue, 18 Nov 2025 12:00:00 GMTMergersHarrow paid about $4.3 million in cash to close its purchase of Melt Pharmaceuticals on Nov 17, 2025. The contingent milestone payments are unchanged, and the MELT-300 sedation drug still needs an NDA, which the company plans for the first half of 2027.HARROW, INC. Form 8-K filed November 18, 2025 (SEC EDGAR) https://aibio.space/news/cogent-biosciences-completes-230-000-000-offering-1-625-percent/https://aibio.space/news/cogent-biosciences-completes-230-000-000-offering-1-625-percent/Tue, 18 Nov 2025 12:00:00 GMTDebt FinancingCogent Biosciences closed a $230,000,000 offering of 1.625% convertible notes due 2031 on November 18, 2025, including the full over-allotment option. The 8-K names no underwriters, and the company's 2024 annual report showed operating cash use of $207.8 million that year.Cogent Biosciences, Inc. Form 8-K filed November 18, 2025 (SEC EDGAR) https://aibio.space/news/bristol-myers-squibb-amends-cash-tender-offers-sets-early-settlement/https://aibio.space/news/bristol-myers-squibb-amends-cash-tender-offers-sets-early-settlement/Tue, 18 Nov 2025 12:00:00 GMTMergersBristol Myers Squibb amended its cash tender offers for its own notes after the November 17, 2025 early tender deadline. It cut the Pool 1 cap from $4,000,000,000 and raised the Pool 2 cap from $3,000,000,000, and it set early settlement for November 20. Accepted notes will be cancelled and retired.BRISTOL MYERS SQUIBB CO Form 8-K filed November 18, 2025 (SEC EDGAR) https://aibio.space/news/soligenix-regains-nasdaq-stockholders-equity-compliance-after-august/https://aibio.space/news/soligenix-regains-nasdaq-stockholders-equity-compliance-after-august/Tue, 18 Nov 2025 12:00:00 GMTListingsNasdaq told Soligenix on November 18, 2025 that the matter is closed. The company reported stockholders' equity of $7,597,976 for the quarter ended September 30, 2025, against a $2,500,000 requirement.SOLIGENIX, INC. Form 8-K filed November 18, 2025 (SEC EDGAR) https://aibio.space/news/shuttle-pharmaceuticals-believes-2-5-million-private-placement/https://aibio.space/news/shuttle-pharmaceuticals-believes-2-5-million-private-placement/Mon, 17 Nov 2025 12:00:00 GMTListingsShuttle reported stockholders' equity of $1,394,161 against Nasdaq's $2,500,000 minimum. Nasdaq staff will keep monitoring, and delisting is possible if compliance is not shown in the next periodic report.Shuttle Pharmaceuticals Holdings, Inc. Form 8-K filed November 17, 2025 (SEC EDGAR) https://aibio.space/news/biodexa-pharmaceuticals-plans-offering-up-3-377-110-ads-warrant-units/https://aibio.space/news/biodexa-pharmaceuticals-plans-offering-up-3-377-110-ads-warrant-units/Mon, 17 Nov 2025 12:00:00 GMTFinancingsThe best efforts sale would pair each ADS with a Series L warrant whose exercise price resets after issue. The company says it will likely receive no additional cash when those warrants are exercised.Biodexa Pharmaceuticals plc F-1 (2025-11-17) https://aibio.space/news/advanced-biomed-files-nt-10-q-says-review-september-30-2025-quarter/https://aibio.space/news/advanced-biomed-files-nt-10-q-says-review-september-30-2025-quarter/Fri, 14 Nov 2025 12:00:00 GMTDistressAdvanced Biomed, which carried a going-concern warning and a Nasdaq bid price notice in its last annual report, says the review of its September 30, 2025 quarter is not finished.Advanced Biomed Inc. Form NT 10-Q filed November 14, 2025 (SEC EDGAR) https://aibio.space/news/igc-pharma-subsidiary-closes-vancouver-facility-asset-sale-valued/https://aibio.space/news/igc-pharma-subsidiary-closes-vancouver-facility-asset-sale-valued/Fri, 14 Nov 2025 12:00:00 GMTMergersHoli Hemp LLC sold equipment, inventory and operating assets for an agreed fair value of about $2.7 million, but the consideration was supply rights and a contingent payout, with no cash. The pro forma statements show a non-cash gain of $1,051 thousand that narrows a reported quarterly loss to $548 thousand.IGC Pharma, Inc. Form 8-K filed November 14, 2025 (SEC EDGAR) https://aibio.space/news/nanoviricides-closes-registered-direct-offering-gross-proceeds-about-6/https://aibio.space/news/nanoviricides-closes-registered-direct-offering-gross-proceeds-about-6/Fri, 14 Nov 2025 12:00:00 GMTFinancingsThe company sold 1,970,000 shares at $1.68 per share and pre-funded warrants for up to 1,601,429 shares to one investor, and issued Series A and Series B warrants in a concurrent private placement.NANOVIRICIDES, INC. Form 8-K filed November 14, 2025 (SEC EDGAR) https://aibio.space/news/q-c-technologies-files-nt-10-q-late-filing-notice-september-2025/https://aibio.space/news/q-c-technologies-files-nt-10-q-late-filing-notice-september-2025/Fri, 14 Nov 2025 12:00:00 GMTDistressQ/C Technologies told the SEC on November 14, 2025 that it needs more time to finalize its quarterly report for the nine months ended September 30, 2025. The company filed its April 2025 annual report under the name TNF Pharmaceuticals, and that report carried a going-concern warning.Q/C TECHNOLOGIES, INC. Form NT 10-Q filed November 14, 2025 (SEC EDGAR) https://aibio.space/news/igc-pharma-unit-sold-vancouver-facility-assets-supply-rights-not-cash/https://aibio.space/news/igc-pharma-unit-sold-vancouver-facility-assets-supply-rights-not-cash/Fri, 14 Nov 2025 12:00:00 GMTMergersHoli Hemp LLC completed the disposition on September 29, 2025. IGC Pharma filed pro forma financial statements showing a $1,051 thousand gain.IGC Pharma, Inc. 8-K (2025-11-14) https://aibio.space/news/acumen-pharmaceuticals-registers-50-000-000-share-sales-three-agents/https://aibio.space/news/acumen-pharmaceuticals-registers-50-000-000-share-sales-three-agents/Thu, 13 Nov 2025 12:00:00 GMTFinancingsAcumen has sold $12.3 million of stock under its sales agreement so far, which leaves $37.7 million available. BofA Securities, Stifel and BTIG are the sales agents.Acumen Pharmaceuticals, Inc. 424B5 (2025-11-13) https://aibio.space/news/black-diamond-therapeutics-files-500-000-000-replacement-shelf-150-000/https://aibio.space/news/black-diamond-therapeutics-files-500-000-000-replacement-shelf-150-000/Thu, 13 Nov 2025 12:00:00 GMTFinancingsThe new shelf replaces one that expires on November 22, 2025. It carries forward $400,005,680.55 of securities that remain unsold under the earlier registration.Black Diamond Therapeutics, Inc. S-3 (2025-11-13) https://aibio.space/news/cassava-sciences-now-filana-therapeutics-files-200-000-000-shelf-50/https://aibio.space/news/cassava-sciences-now-filana-therapeutics-files-200-000-000-shelf-50/Thu, 13 Nov 2025 12:00:00 GMTFinancingsThe at-the-market supplement lets Cantor Fitzgerald sell up to $50,000,000 of stock for up to 3.0% in commissions. The company's lead drug failed its Phase 3 Alzheimer's study, and its share price closed at $3.11.Filana Therapeutics, Inc. S-3 (2025-11-13) https://aibio.space/news/korro-bio-cuts-approximately-34-percent-workforce-restructuring-pauses/https://aibio.space/news/korro-bio-cuts-approximately-34-percent-workforce-restructuring-pauses/Wed, 12 Nov 2025 12:00:00 GMTDistressKorro Bio cut about 34% of its workforce on November 12, 2025, paused its Novo Nordisk collaboration for 12 months, and said the moves extend its cash into the second half of 2027. Its chief medical officer also resigned, and its lead RNA editing candidate fell short of the protein levels the company had projected.Korro Bio, Inc. Form 8-K filed November 12, 2025 (SEC EDGAR) https://aibio.space/news/arcturus-therapeutics-files-nt-10-q-after-technical-error-delays-third/https://aibio.space/news/arcturus-therapeutics-files-nt-10-q-after-technical-error-delays-third/Wed, 12 Nov 2025 12:00:00 GMTDistressArcturus blamed a technical transmission error for missing the deadline on its September 30, 2025 quarterly report. The notice gives no results, and the company's 2024 annual report shows cash use rising sharply.Arcturus Therapeutics Holdings Inc. Form NT 10-Q filed November 12, 2025 (SEC EDGAR) https://aibio.space/news/annexon-proposes-75-000-000-stock-offering-prices-shares-2-60/https://aibio.space/news/annexon-proposes-75-000-000-stock-offering-prices-shares-2-60/Wed, 12 Nov 2025 12:00:00 GMTFinancingsAnnexon priced 25,096,153 shares at $2.60 for about $75 million on November 12, 2025, with pre-funded warrants for up to 3,750,000 more shares, and its two lead programs are still in late-stage trials.Annexon, Inc. 424B5 (2025-11-12) https://aibio.space/news/arcturus-therapeutics-10-q-gets-november-12-filing-date-after/https://aibio.space/news/arcturus-therapeutics-10-q-gets-november-12-filing-date-after/Wed, 12 Nov 2025 12:00:00 GMTDistressArcturus says a technical transmission error caused it to miss the 5:30 PM Eastern deadline on November 10, 2025 for its quarterly report. Its commercial product is KOSTAIVE, a COVID-19 vaccine sold in Japan.Arcturus Therapeutics Holdings Inc. NT 10-Q (2025-11-12) https://aibio.space/news/cosciens-biopharma-delisted-nasdaq-september-applies-otcqb-quotation/https://aibio.space/news/cosciens-biopharma-delisted-nasdaq-september-applies-otcqb-quotation/Wed, 12 Nov 2025 12:00:00 GMTListingsCOSCIENS plans to file a Form 15-F to end its U.S. reporting and has applied for OTCQB quotation. It had $8.5 million of cash on September 30, 2025, and its net loss narrowed to $1.8 million in the quarter.COSCIENS Biopharma Inc. 6-K (2025-11-12) https://aibio.space/news/precision-biosciences-prices-75-000-093-stock-warrant-offering/https://aibio.space/news/precision-biosciences-prices-75-000-093-stock-warrant-offering/Wed, 12 Nov 2025 12:00:00 GMTFinancingsGuggenheim Securities, LLC is the sole underwriter. The company sells 10,815,000 shares, each with half a warrant, at a combined $6.14. Proceeds are $70,500,087 before expenses, and the as adjusted net tangible book value would be $3.74 a share.Precision BioSciences, Inc. 424B5 (2025-11-12) https://aibio.space/news/korro-bio-cuts-about-34-percent-workforce-expects-cash-runway-second/https://aibio.space/news/korro-bio-cuts-about-34-percent-workforce-expects-cash-runway-second/Wed, 12 Nov 2025 12:00:00 GMTDistressThe RNA editing company ended the third quarter of 2025 with $102.5 million in cash and securities. Its AATD drug candidate KRRO-110 did not reach projected protein levels.Korro Bio, Inc. 8-K (2025-11-12) https://aibio.space/news/galecto-now-damora-therapeutics-buys-damora-agrees-about-285-million/https://aibio.space/news/galecto-now-damora-therapeutics-buys-damora-agrees-about-285-million/Mon, 10 Nov 2025 12:00:00 GMTMergersGalecto completed its acquisition of Damora Therapeutics on November 10, 2025. A concurrent private placement of Series C preferred stock for approximately $285 million is expected to close November 12.Damora Therapeutics, Inc. Form 8-K filed November 10, 2025 (SEC EDGAR) https://aibio.space/news/lyell-immunopharma-licenses-lyl273-car-t-candidate-40-million-1-9/https://aibio.space/news/lyell-immunopharma-licenses-lyl273-car-t-candidate-40-million-1-9/Mon, 10 Nov 2025 12:00:00 GMTFinancingsLyell Immunopharma agreed to pay $40 million in cash and issue 1.9 million shares for exclusive rights to LYL273, a CAR T candidate for colorectal cancer that has been tested in 12 patients. The deal also carries more shares, large milestone payments and tiered royalties, and the company says its cash lasts into 2027 once it closes.Lyell Immunopharma, Inc. Form 8-K filed November 10, 2025 (SEC EDGAR) https://aibio.space/news/evommune-closes-nyse-ipo-10-8-million-shares-16-nets-157-0-million/https://aibio.space/news/evommune-closes-nyse-ipo-10-8-million-shares-16-nets-157-0-million/Fri, 07 Nov 2025 12:00:00 GMTFinancingsEvommune sold 9,375,000 shares at $16.00 in its New York Stock Exchange listing, with a 30-day option on 1,406,250 more. Its most advanced drug's efficacy data come from a small Phase 2 study in a different condition than the one it is pursuing.EVMN 10-K https://aibio.space/news/biofrontera-sells-xepi-cream-assets-pelthos-therapeutics-gets-3/https://aibio.space/news/biofrontera-sells-xepi-cream-assets-pelthos-therapeutics-gets-3/Fri, 07 Nov 2025 12:00:00 GMTMergersOnly $3,000,000 was paid at closing on November 6, 2025. The rest of the $10,000,000 maximum depends on a $1,000,000 payment and up to $6 million in sales milestones, and Xepi had no sales in 2024.Biofrontera Inc. Form 8-K filed November 7, 2025 (SEC EDGAR) https://aibio.space/news/altimmune-expands-hercules-loan-facility-125-million-draws-20-million/https://aibio.space/news/altimmune-expands-hercules-loan-facility-125-million-draws-20-million/Thu, 06 Nov 2025 12:00:00 GMTDebt FinancingThe amendment raises term loan availability from $100.0 million to $125.0 million and extends the interest-only period to 30 months. Altimmune held $210.8 million in cash, cash equivalents and short-term investments at September 30, 2025.Altimmune, Inc. Form 8-K filed November 6, 2025 (SEC EDGAR) https://aibio.space/news/phio-pharmaceuticals-warrant-inducement-brings-approximately-12-6/https://aibio.space/news/phio-pharmaceuticals-warrant-inducement-brings-approximately-12-6/Thu, 06 Nov 2025 12:00:00 GMTFinancingsHolders exercised existing warrants, most at a reduced $2.05 per share, in return for new Series A Warrants. Phio expects total gross proceeds of approximately $13.4 million before fees.Phio Pharmaceuticals Corp. Form 8-K filed November 6, 2025 (SEC EDGAR) https://aibio.space/news/4d-molecular-therapeutics-prices-99-999-993-stock-offering-10-5100/https://aibio.space/news/4d-molecular-therapeutics-prices-99-999-993-stock-offering-10-5100/Thu, 06 Nov 2025 12:00:00 GMTFinancings4D Molecular Therapeutics priced an offering of about $100 million in shares and pre-funded warrants at $10.51 each, with Leerink Partners LLC and Evercore Group L.L.C. as joint bookrunners. Preliminary cash of $372.2 million is unaudited, and new buyers face immediate dilution of $1.36 per share.4D Molecular Therapeutics, Inc. 424B5 (2025-11-06) https://aibio.space/news/halozyme-expands-revolver-750-000-000-proposes-two-650-million/https://aibio.space/news/halozyme-expands-revolver-750-000-000-proposes-two-650-million/Wed, 05 Nov 2025 12:00:00 GMTDebt FinancingHalozyme amended its credit agreement to raise the revolver to $750,000,000, with nothing drawn. It also proposed two $650 million convertible note offerings, with terms to be set at pricing.HALOZYME THERAPEUTICS, INC. Form 8-K filed November 5, 2025 (SEC EDGAR) https://aibio.space/news/absci-totient-sellers-agree-final-milestone-payout-under-2021-merger/https://aibio.space/news/absci-totient-sellers-agree-final-milestone-payout-under-2021-merger/Tue, 04 Nov 2025 12:00:00 GMTMergersA letter agreement dated October 31, 2025 settles all potential milestone payments from Absci's 2021 Totient deal. Former Totient stockholders get about $7.6 million, and Absci gets about $8.7 million.Absci Corp Form 8-K filed November 4, 2025 (SEC EDGAR) https://aibio.space/news/prelude-therapeutics-signs-incyte-option-deal-get-35-million-cash-25/https://aibio.space/news/prelude-therapeutics-signs-incyte-option-deal-get-35-million-cash-25/Tue, 04 Nov 2025 12:00:00 GMTFinancingsPrelude Therapeutics gave Incyte an option on its preclinical JAK2V617F JH2 inhibitor program for a $35 million cash payment, plus a $25 million stock purchase. Exercising the option would cost Incyte $100 million, and the company is pausing a separate SMARCA2 degrader program.Prelude Therapeutics Inc Form 8-K filed November 4, 2025 (SEC EDGAR) https://aibio.space/news/taysha-gene-therapies-files-new-shelf-up-200-000-000-market-prospectus/https://aibio.space/news/taysha-gene-therapies-files-new-shelf-up-200-000-000-market-prospectus/Tue, 04 Nov 2025 12:00:00 GMTFinancingsTaysha filed an automatic shelf on November 4, 2025, with a sales agreement of up to $200,000,000 of common stock. As of November 3, 2025, it had sold $12,000,000 under the earlier agreement, while its third-quarter net loss was $32.7 million.Taysha Gene Therapies, Inc. 8-K (2025-11-04) https://aibio.space/news/tscan-therapeutics-cuts-about-30-percent-workforce-66-roles-extend/https://aibio.space/news/tscan-therapeutics-cuts-about-30-percent-workforce-66-roles-extend/Mon, 03 Nov 2025 12:00:00 GMTDistressTScan expects annual cost savings of $45.0 million in 2026 and 2027 and a one-time charge of up to approximately $2.3 million. It says its cash runway now extends into the second half of 2027.TScan Therapeutics, Inc. Form 8-K filed November 3, 2025 (SEC EDGAR) https://aibio.space/news/kyverna-signs-oxford-finance-loan-facility-up-150-0-million-expects/https://aibio.space/news/kyverna-signs-oxford-finance-loan-facility-up-150-0-million-expects/Mon, 03 Nov 2025 12:00:00 GMTDebt FinancingKyverna signed a loan facility of up to $150.0 million with Oxford Finance and drew $25.0 million at closing, secured by substantially all of its assets. The company says its runway still runs into 2027, the same guidance it gave before the loan.Kyverna Therapeutics, Inc. Form 8-K filed November 3, 2025 (SEC EDGAR) https://aibio.space/news/ardelyx-files-automatic-shelf-100-000-000-atm-sales-agreement/https://aibio.space/news/ardelyx-files-automatic-shelf-100-000-000-atm-sales-agreement/Mon, 03 Nov 2025 12:00:00 GMTFinancingsJefferies LLC is the sales agent for up to $100,000,000 of common stock. A second Jefferies program, dated January 18, 2023, may still sell up to approximately $80.0 million.Ardelyx, Inc. S-3ASR (2025-11-03) https://aibio.space/news/cytodyn-secures-30-million-stock-purchase-commitment-yorkville/https://aibio.space/news/cytodyn-secures-30-million-stock-purchase-commitment-yorkville/Mon, 03 Nov 2025 12:00:00 GMTFinancingsCytoDyn can sell up to $30 million of common stock to Yorkville Advisors Global over 36 months, at its own discretion and with no warrants attached. The release names no placement agent or counsel, and the annual report says the company will pursue non-dilutive financing in addition to traditional fundraising.CytoDyn Inc. 8-K (2025-11-03) https://aibio.space/news/gelteq-files-late-notice-20-f-says-needs-more-time-financials/https://aibio.space/news/gelteq-files-late-notice-20-f-says-needs-more-time-financials/Mon, 03 Nov 2025 12:00:00 GMTDistressThe company expects to file its annual report for the year ended June 30, 2025 within the fifteen-day grace period.Gelteq Limited NT 20-F (2025-11-03) https://aibio.space/news/calidi-biotherapeutics-sells-75-percent-nova-cell-stake-6-000-000/https://aibio.space/news/calidi-biotherapeutics-sells-75-percent-nova-cell-stake-6-000-000/Fri, 31 Oct 2025 12:00:00 GMTMergersNova Cell pays by cancelling a net $1,214,864 of debt Calidi owed it, plus $4,785,136 of deferred, contingent consideration. Nova Cell is no longer a subsidiary, and the company expects $0.5 million a year in expense cuts.Calidi Biotherapeutics, Inc. Form 8-K filed October 31, 2025 (SEC EDGAR) https://aibio.space/news/4d-molecular-therapeutics-licenses-4d-150-otsuka-asia-pacific-deal-85/https://aibio.space/news/4d-molecular-therapeutics-licenses-4d-150-otsuka-asia-pacific-deal-85/Fri, 31 Oct 2025 12:00:00 GMTFinancings4D Molecular Therapeutics agreed on October 31, 2025 to license 4D-150 to Otsuka for Asia-Pacific markets in exchange for an $85 million upfront payment. The company keeps leading global Phase 3 work, and Otsuka's expected cost sharing is at least $50 million over three years.4D Molecular Therapeutics, Inc. Form 8-K filed October 31, 2025 (SEC EDGAR) https://aibio.space/news/alterity-reports-54-56m-cash-after-20m-placement-quarter/https://aibio.space/news/alterity-reports-54-56m-cash-after-20m-placement-quarter/Fri, 31 Oct 2025 12:00:00 GMTFinancingsOperating cash outflows were A$5.34M for the quarter ended 30 September 2025. The company says the placement was led by healthcare-focused funds.Alterity Therapeutics Ltd. 6-K (2025-10-31) https://aibio.space/news/kazia-therapeutics-says-20-f-late-audit-procedures-not-complete/https://aibio.space/news/kazia-therapeutics-says-20-f-late-audit-procedures-not-complete/Fri, 31 Oct 2025 12:00:00 GMTDistressThe company expects to file its annual report for the year ended June 30, 2025 no later than the fifteenth calendar day after the due date.Kazia Therapeutics Limited NT 20-F (2025-10-31) https://aibio.space/news/lunai-bioworks-gets-nasdaq-deficiency-notice-35-million-market-value/https://aibio.space/news/lunai-bioworks-gets-nasdaq-deficiency-notice-35-million-market-value/Thu, 30 Oct 2025 12:00:00 GMTListingsLunai Bioworks received a Nasdaq notice that its market value of listed securities had been below the $35 million minimum for 30 consecutive business days. It has until April 27, 2026 to regain compliance, and the company says the notice has no immediate effect on trading.Lunai Bioworks Inc. Form 8-K filed October 30, 2025 (SEC EDGAR) https://aibio.space/news/savara-prices-130-0-million-stock-offering-4-20-share/https://aibio.space/news/savara-prices-130-0-million-stock-offering-4-20-share/Wed, 29 Oct 2025 12:00:00 GMTFinancingsSavara priced 23,809,524 shares at $4.20, below the $4.41 last sale price, and pre-funded warrants for 7,142,857 more. Jefferies, Piper Sandler and Guggenheim Securities are joint book-running managers, and Polsinelli PC is the company's counsel.Savara, Inc. 424B5 (2025-10-29) https://aibio.space/news/maplight-ipo-closes-additional-share-option-brings-gross-proceeds-288/https://aibio.space/news/maplight-ipo-closes-additional-share-option-brings-gross-proceeds-288/Tue, 28 Oct 2025 12:00:00 GMTFinancingsMapLight Therapeutics closed its initial public offering at $17.00 a share, and the underwriters exercised their option for more shares in full. Its lead drug has no Phase 2 results yet.MPLT 8-K https://aibio.space/news/biofrontera-inc-closes-purchase-u-s-ameluz-rhodoled-rights-sells-2-5/https://aibio.space/news/biofrontera-inc-closes-purchase-u-s-ameluz-rhodoled-rights-sells-2-5/Fri, 24 Oct 2025 12:00:00 GMTMergersBiofrontera Inc. closed its purchase of U.S. rights to Ameluz and RhodoLED from its former parent on October 24, 2025, paying an earnout of 12% or 15% of Ameluz revenue. The same day it closed a $2.5 million second tranche of Series C preferred, and the company says that closing and the deal together keep it above Nasdaq's equity requirement.Biofrontera Inc. Form 8-K filed October 24, 2025 (SEC EDGAR) https://aibio.space/news/enveric-biosciences-gets-nasdaq-delisting-notice-sets-1-12-reverse/https://aibio.space/news/enveric-biosciences-gets-nasdaq-delisting-notice-sets-1-12-reverse/Thu, 23 Oct 2025 12:00:00 GMTListingsNasdaq said Enveric's stock closed below $1.00 for 30 consecutive trading days and the company has no compliance period. It plans to request a hearing and will split its shares 1-for-12 on October 28, 2025.Enveric Biosciences, Inc. Form 8-K filed October 23, 2025 (SEC EDGAR) https://aibio.space/news/minerva-neurosciences-agrees-80-million-private-placement-up-200/https://aibio.space/news/minerva-neurosciences-agrees-80-million-private-placement-up-200/Wed, 22 Oct 2025 12:00:00 GMTFinancingsVivo Capital LLC led the deal, which brings $80 million upfront in Series A preferred stock. The rest comes from two warrant tranches, and the larger one is tied to a Phase 3 roluperidone trial meeting its primary endpoint.Minerva Neurosciences, Inc. Form 8-K filed October 22, 2025 (SEC EDGAR) https://aibio.space/news/alkermes-agrees-buy-avadel-18-50-share-plus-cvr-jpmorgan-bridge-loan/https://aibio.space/news/alkermes-agrees-buy-avadel-18-50-share-plus-cvr-jpmorgan-bridge-loan/Wed, 22 Oct 2025 12:00:00 GMTMergersAlkermes offers $18.50 a share in cash, plus a CVR that pays only if two conditions are met by December 31, 2028. The deal is funded with cash and a JPMorgan bridge loan, and it has not closed.Alkermes plc. Form 8-K filed October 22, 2025 (SEC EDGAR) https://aibio.space/news/alector-cuts-workforce-about-49-percent-after-latozinemab-phase-3/https://aibio.space/news/alector-cuts-workforce-about-49-percent-after-latozinemab-phase-3/Tue, 21 Oct 2025 12:00:00 GMTDistressAlector expects $7.7 million in restructuring charges and reports a preliminary $291.1 million in cash and short-term investments at September 30, 2025. Its head of research and development is resigning.Alector, Inc. Form 8-K filed October 21, 2025 (SEC EDGAR) https://aibio.space/news/oragenics-regains-nyse-american-equity-compliance-settles-ladenburg/https://aibio.space/news/oragenics-regains-nyse-american-equity-compliance-settles-ladenburg/Tue, 21 Oct 2025 12:00:00 GMTListingsNYSE American told Oragenics on October 20, 2025 that it again meets stockholders' equity standards. The company also paid Ladenburg Thalmann $700,000 to settle a dispute over a $2,500,000 fee claim.ORAGENICS INC Form 8-K filed October 21, 2025 (SEC EDGAR) https://aibio.space/news/biontech-opens-exchange-offer-curevac-15-061-575-new-adss-registered/https://aibio.space/news/biontech-opens-exchange-offer-curevac-15-061-575-new-adss-registered/Mon, 20 Oct 2025 12:00:00 GMTMergersBioNTech's offer documents register 15,061,575 new ADSs for CureVac shares, with the exchange ratio set by a $5.4641 formula and a collar. The offer opens October 21, 2025, and BioNTech's unaudited first-half figures show a net loss of €802.4 million.BioNTech SE 425 (2025-10-20) https://aibio.space/news/keros-therapeutics-starts-tender-offer-up-10-950-165-shares-17-75/https://aibio.space/news/keros-therapeutics-starts-tender-offer-up-10-950-165-shares-17-75/Mon, 20 Oct 2025 12:00:00 GMTFinancingsKeros Therapeutics, Inc. offers to buy back its stock for cash, for up to $194.4 million in total. The Schedule TO was filed October 20, 2025.Keros Therapeutics, Inc. SC TO-I (2025-10-20) https://aibio.space/news/lexeo-therapeutics-prices-public-offering-8-00-share-plus-10-million/https://aibio.space/news/lexeo-therapeutics-prices-public-offering-8-00-share-plus-10-million/Fri, 17 Oct 2025 12:00:00 GMTFinancingsLexeo agrees to sell 15,625,000 shares for expected gross proceeds of approximately $125 million. A concurrent private placement of pre-funded warrants is expected to bring approximately $10 million.Lexeo Therapeutics, Inc. Form 8-K filed October 17, 2025 (SEC EDGAR) https://aibio.space/news/medicus-pharma-sells-1-088-048-shares-yorkville-under-standby-equity/https://aibio.space/news/medicus-pharma-sells-1-088-048-shares-yorkville-under-standby-equity/Fri, 17 Oct 2025 12:00:00 GMTFinancingsMedicus Pharma (Nasdaq: MDCX) sold shares in eight transactions between September 8 and October 16, 2025 for approximate aggregate consideration of $2,526,364. It used part to prepay a Yorkville debenture.Medicus Pharma Ltd. Form 8-K filed October 17, 2025 (SEC EDGAR) https://aibio.space/news/aspire-biopharma-holdings-now-aspire-lakewood-holdings-seeks-nasdaq/https://aibio.space/news/aspire-biopharma-holdings-now-aspire-lakewood-holdings-seeks-nasdaq/Fri, 17 Oct 2025 12:00:00 GMTListingsNasdaq says Aspire's shares face delisting for missing the $50,000,000 market value rule and the $1.00 bid price rule. The company paid $20,000 to request a hearing, and its 2024 audit carried going-concern doubt.Aspire-Lakewood Holdings, Inc. Form 8-K filed October 17, 2025 (SEC EDGAR) https://aibio.space/news/hcw-biologics-wins-nasdaq-panel-extension-meet-equity-rule-december-31/https://aibio.space/news/hcw-biologics-wins-nasdaq-panel-extension-meet-equity-rule-december-31/Thu, 16 Oct 2025 12:00:00 GMTListingsA Nasdaq Hearings Panel granted HCW Biologics (Nasdaq: HCWB) continued listing on October 13, 2025. The company must show compliance with the Equity Rule by December 31, 2025 and with all other rules by February 16, 2026.HCW Biologics Inc. Form 8-K filed October 16, 2025 (SEC EDGAR) https://aibio.space/news/c4-therapeutics-prices-stock-warrant-offering-2-47-expects-117-0/https://aibio.space/news/c4-therapeutics-prices-stock-warrant-offering-2-47-expects-117-0/Thu, 16 Oct 2025 12:00:00 GMTFinancingsEach share or pre-funded warrant comes with two warrant classes, each covering 50,608,500 shares at $2.22. C4 says the net proceeds would extend its cash runway to the end of 2028, and the larger $341.7 million figure assumes every warrant is exercised for cash.C4 Therapeutics, Inc. 424B5 (2025-10-16) https://aibio.space/news/kura-oncology-files-amended-2023-inducement-option-plan-3-250-000/https://aibio.space/news/kura-oncology-files-amended-2023-inducement-option-plan-3-250-000/Thu, 16 Oct 2025 12:00:00 GMTListingsThe plan was amended by the board on October 15, 2025 and is filed as an exhibit. It is built around Nasdaq's inducement-grant exemption from shareholder approval.Kura Oncology, Inc. 8-K (2025-10-16) https://aibio.space/news/quoin-closes-16-6-million-private-placement-warrants-could-add-up-88-0/https://aibio.space/news/quoin-closes-16-6-million-private-placement-warrants-could-add-up-88-0/Wed, 15 Oct 2025 12:00:00 GMTFinancingsQuoin sold ADSs and pre-funded warrants with four series of warrants whose cash exercise depends on FDA and trial events that the filings do not report as having happened. Maxim Group LLC was the exclusive placement agent, and director Dennis Langer took part.Quoin Pharmaceuticals Ltd. Form 8-K filed October 15, 2025 (SEC EDGAR) https://aibio.space/news/keros-therapeutics-repurchase-10-176-595-shares-about-181-million/https://aibio.space/news/keros-therapeutics-repurchase-10-176-595-shares-about-181-million/Wed, 15 Oct 2025 12:00:00 GMTMergersKeros Therapeutics agreed on October 15, 2025 to buy 10,176,595 shares from two investors for about $181 million at $17.75 each, and plans a tender offer for up to $194 million at the same price. Two directors resigned under the Pontifax agreement, and the company's preliminary cash figure of about $693.5 million is unaudited.Keros Therapeutics, Inc. Form 8-K filed October 15, 2025 (SEC EDGAR) https://aibio.space/news/keros-agrees-buy-back-adar1-pontifax-shares-17-75-plans-tender-offer/https://aibio.space/news/keros-agrees-buy-back-adar1-pontifax-shares-17-75-plans-tender-offer/Wed, 15 Oct 2025 12:00:00 GMTMergersThe repurchases are part of a $375 million capital return program. Keros also plans to share 25% of certain net cash from its Takeda license with stockholders.Keros Therapeutics, Inc. 8-K (2025-10-15) https://aibio.space/news/allogene-discloses-factor-bioscience-patent-suit-against-licensor/https://aibio.space/news/allogene-discloses-factor-bioscience-patent-suit-against-licensor/Tue, 14 Oct 2025 12:00:00 GMTLegalFactor Bioscience sued Cellectis and AstraZeneca in Delaware federal court on Sept 26, 2025, over TALEN gene-editing technology. Allogene is not a party, but it licenses that technology from Cellectis and says Factor may still sue it directly.Allogene Therapeutics, Inc. Form 8-K filed October 14, 2025 (SEC EDGAR) https://aibio.space/news/candel-signs-trinity-capital-term-loan-up-130-0-million-draws-50-0/https://aibio.space/news/candel-signs-trinity-capital-term-loan-up-130-0-million-draws-50-0/Tue, 14 Oct 2025 12:00:00 GMTDebt FinancingCandel signed a five-year term loan with Trinity Capital Inc. for up to $130 million and drew $50 million at closing. The loan carries a 10.25% initial rate, a 4.25% exit fee and a minimum cash covenant that applies if the company's market value falls below $550 million.Candel Therapeutics, Inc. Form 8-K filed October 14, 2025 (SEC EDGAR) https://aibio.space/news/karyopharm-closes-recapitalization-9-00-percent-convertible-notes-12-5/https://aibio.space/news/karyopharm-closes-recapitalization-9-00-percent-convertible-notes-12-5/Tue, 14 Oct 2025 12:00:00 GMTDebt FinancingKaryopharm closed a recapitalization on October 10, 2025 that borrowed $12.5 million under its term loan, issued $15.0 million of 9.00% notes due 2028 and $103.5 million of 9.00% notes due 2029, and exchanged $100.978 million of older notes. Lenders also waived specified defaults under the loan.Karyopharm Therapeutics Inc. Form 8-K filed October 14, 2025 (SEC EDGAR) https://aibio.space/news/cellectar-biosciences-gets-about-5-8-million-gross-warrant-inducement/https://aibio.space/news/cellectar-biosciences-gets-about-5-8-million-gross-warrant-inducement/Fri, 10 Oct 2025 12:00:00 GMTFinancingsHolders exercised existing warrants at $5.25 per share and paid $0.125 per new warrant. Cellectar anticipates its cash and the net proceeds will fund operations into the third quarter of 2026.Cellectar Biosciences, Inc. Form 8-K filed October 10, 2025 (SEC EDGAR) https://aibio.space/news/cellectar-biosciences-raises-about-5-8-million-warrant-inducement-deal/https://aibio.space/news/cellectar-biosciences-raises-about-5-8-million-warrant-inducement-deal/Fri, 10 Oct 2025 12:00:00 GMTFinancingsHolders exercised warrants for 1,048,094 shares at $5.25 and received new warrants at $6.00. Cellectar says cash should last into the third quarter of 2026.Cellectar Biosciences, Inc. 8-K (2025-10-10) https://aibio.space/news/xenetic-biosciences-prices-4-5-million-offering-735-000-shares-6-12/https://aibio.space/news/xenetic-biosciences-prices-4-5-million-offering-735-000-shares-6-12/Fri, 10 Oct 2025 12:00:00 GMTFinancingsCanaccord Genuity is sole bookrunner. Xenetic plans to use net proceeds for working capital and general corporate purposes.Xenetic Biosciences, Inc. 424B5 (2025-10-10) https://aibio.space/news/agenus-takes-up-10-000-000-loan-zydus-pledges-822-910-mink-shares/https://aibio.space/news/agenus-takes-up-10-000-000-loan-zydus-pledges-822-910-mink-shares/Thu, 09 Oct 2025 12:00:00 GMTFinancingsThe note bears interest at 3.81% a year and is tied to the closing of an asset and stock purchase deal the companies signed on June 3, 2025.Agenus Inc. 8-K (2025-10-09) https://aibio.space/news/alzamend-neuro-issues-361-743-shares-conversion-series-b-preferred/https://aibio.space/news/alzamend-neuro-issues-361-743-shares-conversion-series-b-preferred/Thu, 09 Oct 2025 12:00:00 GMTFinancingsThe shares were issued between October 1, 2025 and October 8, 2025. The company had 3,801,604 common shares outstanding as of October 8, 2025.Alzamend Neuro, Inc. 8-K (2025-10-09) https://aibio.space/news/mindwalk-authorizes-buyback-up-2-3-million-shares/https://aibio.space/news/mindwalk-authorizes-buyback-up-2-3-million-shares/Thu, 09 Oct 2025 12:00:00 GMTFinancingsThe twelve-month program starts October 15, 2025. The company says it represents approximately 5% of the 46,154,188 common shares outstanding.MindWalk Holdings Corp. 6-K (2025-10-09) https://aibio.space/news/karyopharm-agrees-debt-equity-deals-says-give-100-million-flexibility/https://aibio.space/news/karyopharm-agrees-debt-equity-deals-says-give-100-million-flexibility/Wed, 08 Oct 2025 12:00:00 GMTFinancingsThe deals combine new loans and notes, payment deferrals, debt-for-equity exchanges and a private placement of about $8.75 million. Karyopharm expects about $36 million of gross proceeds and a cash runway into the second quarter of 2026.Karyopharm Therapeutics Inc. 8-K (2025-10-08) https://aibio.space/news/lenz-therapeutics-sells-1-748-634-shares-45-75-80-000-000-block-trade/https://aibio.space/news/lenz-therapeutics-sells-1-748-634-shares-45-75-80-000-000-block-trade/Wed, 08 Oct 2025 12:00:00 GMTFinancingsThe sale to a single investor was made under the company's at-the-market agreement with TD Securities (USA) LLC. LENZ reported the 1,748,634 shares sold at $45.75 in an 8-K filed October 8, 2025.LENZ Therapeutics, Inc. 8-K (2025-10-08) https://aibio.space/news/transcode-agrees-buy-polynoma-sell-ck-life-sciences-25-million/https://aibio.space/news/transcode-agrees-buy-polynoma-sell-ck-life-sciences-25-million/Wed, 08 Oct 2025 12:00:00 GMTMergersAfter the deal, CK Life Sciences would hold about 91% of TransCode on a fully diluted basis, and existing holders about 9%. Converting the preferred stock needs stockholder approval where Nasdaq rules apply, and up to $95 million in milestones may go to CK Life Sciences.TransCode Therapeutics, Inc. 8-K (2025-10-08) https://aibio.space/news/spruce-biosciences-agrees-50-0-million-private-placement-68-00-share/https://aibio.space/news/spruce-biosciences-agrees-50-0-million-private-placement-68-00-share/Wed, 08 Oct 2025 12:00:00 GMTFinancingsInstitutional investors are buying 502,181 shares at $68.00 and pre-funded warrants for 233,144 more, for expected gross proceeds of about $50.0 million. The 8-K contains no clinical data for tralesinidase alfa, the program Spruce plans to file in the first quarter of 2026.Spruce Biosciences, Inc. 8-K (2025-10-08) https://aibio.space/news/zenas-biopharma-licenses-orelabrutinib-innocare-announces-120-0/https://aibio.space/news/zenas-biopharma-licenses-orelabrutinib-innocare-announces-120-0/Wed, 08 Oct 2025 12:00:00 GMTFinancingsZenas gains global rights to the BTK inhibitor outside oncology plus two early autoimmune drugs. It also registered an at-the-market program for up to $200,000,000 of stock with Jefferies.Zenas BioPharma, Inc. 8-K (2025-10-08) https://aibio.space/news/elutia-closes-cied-business-sale-boston-scientific-puts-8-million/https://aibio.space/news/elutia-closes-cied-business-sale-boston-scientific-puts-8-million/Tue, 07 Oct 2025 12:00:00 GMTMergersThe sale closed October 1, 2025 for $88 million in cash, with $8 million held in escrow. Elutia used about $27.8 million to repay SWK Funding debt, and its 2024 annual report carried a going-concern warning after a net loss of $53.9 million.ELUTIA INC. Form 8-K filed October 7, 2025 (SEC EDGAR) https://aibio.space/news/adicet-bio-gets-until-april-6-2026-meet-nasdaq-bid-price-rule-moves/https://aibio.space/news/adicet-bio-gets-until-april-6-2026-meet-nasdaq-bid-price-rule-moves/Tue, 07 Oct 2025 12:00:00 GMTListingsNasdaq granted Adicet Bio an additional 180 calendar days. The stock moves from the Nasdaq Global Market to the Nasdaq Capital Market on October 9, 2025.Adicet Bio, Inc. 8-K (2025-10-07) https://aibio.space/news/elutia-closes-88-million-sale-bioenvelope-business-boston-scientific/https://aibio.space/news/elutia-closes-88-million-sale-bioenvelope-business-boston-scientific/Tue, 07 Oct 2025 12:00:00 GMTMergersElutia sold its EluPro and CanGaroo bioenvelopes for cash. It plans to bring its NXT-41x breast reconstruction product to market in the first half of 2027.Elutia, Inc. 8-K (2025-10-07) https://aibio.space/news/humacyte-prices-60-0-million-registered-direct-offering-stock-warrants/https://aibio.space/news/humacyte-prices-60-0-million-registered-direct-offering-stock-warrants/Tue, 07 Oct 2025 12:00:00 GMTFinancingsHumacyte is selling 28,436,018 shares, with warrants for the same number of shares, at $2.11 per share and warrant. The release does not say how the proceeds will be used.Humacyte, Inc. 8-K (2025-10-07) https://aibio.space/news/jade-biosciences-agrees-135-million-private-placement-9-14-share/https://aibio.space/news/jade-biosciences-agrees-135-million-private-placement-9-14-share/Tue, 07 Oct 2025 12:00:00 GMTFinancingsJade Biosciences agreed to a PIPE financing of about $135 million at $9.14 per share, with Jefferies, TD Cowen, Stifel and Wedbush named as placement agents, and says its cash will fund operations into the first half of 2028.Jade Biosciences, Inc. 8-K (2025-10-07) https://aibio.space/news/biomea-fusion-prices-24-999-898-offering-stock-warrants-2-05/https://aibio.space/news/biomea-fusion-prices-24-999-898-offering-stock-warrants-2-05/Mon, 06 Oct 2025 12:00:00 GMTFinancingsBiomea Fusion is issuing 11,195,121 shares and 1,000,000 pre-funded warrants under an October 6, 2025 prospectus supplement, for $24,999,898 before discounts. Jefferies is book-running manager and H.C. Wainwright & Co., LLC is lead manager.Biomea Fusion, Inc. 424B5 (2025-10-07) https://aibio.space/news/salarius-now-decoy-therapeutics-says-share-sales-lift-equity-above/https://aibio.space/news/salarius-now-decoy-therapeutics-says-share-sales-lift-equity-above/Mon, 06 Oct 2025 12:00:00 GMTListingsSalarius said $2.4 million from an at-the-market program and $3.8 million from C/M Capital Master Fund, LP lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The figure is preliminary, and Nasdaq has not yet confirmed compliance.Decoy Therapeutics Inc. 8-K (2025-10-06) https://aibio.space/news/entero-therapeutics-now-gridai-technologies-acquires-grid-ai-whose/https://aibio.space/news/entero-therapeutics-now-gridai-technologies-acquires-grid-ai-whose/Mon, 06 Oct 2025 12:00:00 GMTMergersGRID AI's former shareholders would own about 82.5% of Entero's fully diluted common stock, subject to shareholder approval, and could name two directors at closing.GridAI Technologies Corp. 8-K (2025-10-06) https://aibio.space/news/werewolf-therapeutics-breaks-nasdaq-audit-committee-rule-after/https://aibio.space/news/werewolf-therapeutics-breaks-nasdaq-audit-committee-rule-after/Mon, 06 Oct 2025 12:00:00 GMTListingsThe death of director Dr. Alon Lazarus on September 30, 2025 left Werewolf's audit committee with two members, one short of Nasdaq's three-member minimum. The company plans to appoint an independent director at its earliest opportunity.Werewolf Therapeutics, Inc. 8-K (2025-10-06) https://aibio.space/news/nasdaq-files-form-25-delist-zyversa-therapeutics-common-stock/https://aibio.space/news/nasdaq-files-form-25-delist-zyversa-therapeutics-common-stock/Mon, 06 Oct 2025 12:00:00 GMTListingsThe Nasdaq Stock Market LLC filed the notice with the SEC on October 6, 2025, citing the rule an exchange uses to remove a security.ZyVersa Therapeutics, Inc. 25-NSE (2025-10-06) https://aibio.space/news/halozyme-signs-merger-agreement-acquire-elektrofi-750-million-cash/https://aibio.space/news/halozyme-signs-merger-agreement-acquire-elektrofi-750-million-cash/Fri, 03 Oct 2025 12:00:00 GMTMergersHalozyme could also owe up to three $50 million milestone payments tied to product regulatory approvals. Closing requires the Hart-Scott-Rodino waiting period to expire or end, and a $36 million reverse termination fee applies in certain cases.HALOZYME THERAPEUTICS, INC. Form 8-K filed October 3, 2025 (SEC EDGAR) https://aibio.space/news/microbot-medical-holder-exercises-600-000-options-2-10-gets-series/https://aibio.space/news/microbot-medical-holder-exercises-600-000-options-2-10-gets-series/Fri, 03 Oct 2025 12:00:00 GMTFinancingsUnder a September 14, 2025 inducement agreement, a holder exercised 600,000 series H options and received 600,000 series J options. A separate exercise of 374,167 options produced gross proceeds of approximately $896,000.Microbot Medical Inc. Form 8-K filed October 3, 2025 (SEC EDGAR) https://aibio.space/news/ovid-therapeutics-agrees-pipe-financing-80-8-million-initial-gross/https://aibio.space/news/ovid-therapeutics-agrees-pipe-financing-80-8-million-initial-gross/Fri, 03 Oct 2025 12:00:00 GMTFinancingsOvid Therapeutics agreed to a private placement of convertible preferred stock and warrants with initial gross proceeds of about $80.8 million and up to $175.1 million in total. The preferred cannot convert until stockholders approve more shares, and the same day the company reported Phase 1 data from 68 healthy volunteers, with the CEO among the investors.Ovid Therapeutics Inc. Form 8-K filed October 3, 2025 (SEC EDGAR) https://aibio.space/news/xilio-therapeutics-moves-nasdaq-capital-market-gets-until-march-30/https://aibio.space/news/xilio-therapeutics-moves-nasdaq-capital-market-gets-until-march-30/Fri, 03 Oct 2025 12:00:00 GMTListingsXilio moved its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market after missing the $1.00 minimum bid price. The move does not cure the bid price problem, and the company's March annual report carried a going-concern warning.Xilio Therapeutics, Inc. Form 8-K filed October 3, 2025 (SEC EDGAR) https://aibio.space/news/azitra-gets-nyse-american-notice-minimum-stockholders-equity/https://aibio.space/news/azitra-gets-nyse-american-notice-minimum-stockholders-equity/Fri, 03 Oct 2025 12:00:00 GMTListingsNYSE American told Azitra on October 1, 2025 that its stockholders' equity of $2.2 million is below the $4.0 million required. The company has until October 31, 2025 to submit a plan, with compliance due by April 1, 2027. Its 2024 annual report carried a going-concern warning.Azitra, Inc. Form 8-K filed October 3, 2025 (SEC EDGAR) https://aibio.space/news/abpro-holdings-faces-nasdaq-delisting-after-missing-1-00-bid-price/https://aibio.space/news/abpro-holdings-faces-nasdaq-delisting-after-missing-1-00-bid-price/Fri, 03 Oct 2025 12:00:00 GMTListingsNasdaq told Abpro on September 30, 2025 that it had not regained compliance with the $1.00 minimum bid price. The company says it will ask an appeal panel for a hearing, which would stay the suspension, but the filing gives no assurance the panel will grant it more time.Abpro Holdings Inc. 8-K (2025-10-03) https://aibio.space/news/azitra-gets-nyse-american-notice-4-million-stockholders-equity/https://aibio.space/news/azitra-gets-nyse-american-notice-4-million-stockholders-equity/Fri, 03 Oct 2025 12:00:00 GMTListingsNYSE American says Azitra is below its $4 million stockholders' equity standard, and the company has until October 31, 2025 to file a plan to restore compliance.Azitra Inc 8-K (2025-10-03) https://aibio.space/news/onconetix-sells-convertible-preferred-warrants-approximately-6-25/https://aibio.space/news/onconetix-sells-convertible-preferred-warrants-approximately-6-25/Fri, 03 Oct 2025 12:00:00 GMTFinancingsInstitutional investors bought 7,813 shares of Series E convertible preferred stock and warrants for 2,025,223 common shares. The preferred converts at $3.8576.Onconetix, Inc. 8-K (2025-10-03) https://aibio.space/news/xilio-therapeutics-moves-nasdaq-capital-market-gets-180-more-days-1-00/https://aibio.space/news/xilio-therapeutics-moves-nasdaq-capital-market-gets-180-more-days-1-00/Fri, 03 Oct 2025 12:00:00 GMTListingsNasdaq approved the transfer from the Global Select Market effective October 6, 2025. Xilio now has until March 30, 2026 to regain compliance with the minimum bid price rule.Xilio Therapeutics, Inc. 8-K (2025-10-03) https://aibio.space/news/bolt-biotherapeutics-cuts-workforce-about-50-percent-extends-cash/https://aibio.space/news/bolt-biotherapeutics-cuts-workforce-about-50-percent-extends-cash/Thu, 02 Oct 2025 12:00:00 GMTDistressBolt will cut about 20 employees, roughly 50% of its workforce, with pre-tax charges of $1.5 million to $2.0 million. The company says the cut extends its cash runway into 2027. Initial BDC-4182 clinical data, now expected in the third quarter of 2026, will come later after a protocol change.Bolt Biotherapeutics, Inc. Form 8-K filed October 2, 2025 (SEC EDGAR) https://aibio.space/news/theriva-biologics-cuts-32-percent-workforce-expects-cash-runway-second/https://aibio.space/news/theriva-biologics-cuts-32-percent-workforce-expects-cash-runway-second/Thu, 02 Oct 2025 12:00:00 GMTDistressTheriva says cutting about seven employees, or 32% of its global workforce, and other cost cuts extend its cash runway into the second quarter of 2026. Its 2024 annual report carried a going-concern warning, and the company reported $11.6 million of cash and equivalents at December 31, 2024.Theriva Biologics, Inc. Form 8-K filed October 2, 2025 (SEC EDGAR) https://aibio.space/news/biocardia-regains-compliance-nasdaq-equity-rule/https://aibio.space/news/biocardia-regains-compliance-nasdaq-equity-rule/Thu, 02 Oct 2025 12:00:00 GMTListingsNasdaq staff told BioCardia in writing that it again meets the Equity Rule, but the 8-K gives no equity figure and does not say how the gap was closed.BioCardia, Inc. 8-K (2025-10-02) https://aibio.space/news/kala-bio-receives-oxford-finance-default-notice-lender-declares-29-1/https://aibio.space/news/kala-bio-receives-oxford-finance-default-notice-lender-declares-29-1/Wed, 01 Oct 2025 12:00:00 GMTDistressOxford Finance says an event of default under a Material Adverse Change clause is continuing and has accelerated all obligations under the 2021 loan agreement. The notice says interest began accruing at the Default Rate, and that $29.1 million is now payable.KALA BIO, Inc. Form 8-K filed October 1, 2025 (SEC EDGAR) https://aibio.space/news/jaguar-health-agrees-sell-shares-pre-funded-warrants-brown-stone-1-56/https://aibio.space/news/jaguar-health-agrees-sell-shares-pre-funded-warrants-brown-stone-1-56/Wed, 01 Oct 2025 12:00:00 GMTFinancingsJaguar agreed to sell 161,583 shares and 479,442 pre-funded warrants at $1.56 to Brown Stone Capital Limited. Two days later it issued 286,532 shares to cut a royalty balance by $600,000.Jaguar Health, Inc. 8-K (2025-10-01) https://aibio.space/news/edesa-biotech-amends-canada-funding-deal-first-repayment-moves-2032/https://aibio.space/news/edesa-biotech-amends-canada-funding-deal-first-repayment-moves-2032/Tue, 30 Sep 2025 12:00:00 GMTFinancingsEdesa and the Government of Canada amended a contribution agreement worth up to CAD $23 million ($17 million USD) in partially repayable funding. Repayment would begin only if the company earns gross revenue.Edesa Biotech, Inc. Form 8-K filed September 30, 2025 (SEC EDGAR) https://aibio.space/news/alpha-cognition-prices-34-999-052-public-offering-shares-6-25/https://aibio.space/news/alpha-cognition-prices-34-999-052-public-offering-shares-6-25/Tue, 30 Sep 2025 12:00:00 GMTFinancingsAlpha Cognition priced 4,651,516 common shares and pre-funded warrants for 948,484 shares at $6.25 and $6.249, for a total of $34,999,052 before fees. Titan Partners Group is the sole bookrunner, and the company says the money will fund a sales push for ZUNVEYL.Alpha Cognition Inc. 424B5 (2025-09-30) https://aibio.space/news/artelo-biosciences-prices-1-999-984-67-offering-4-40-share/https://aibio.space/news/artelo-biosciences-prices-1-999-984-67-offering-4-40-share/Tue, 30 Sep 2025 12:00:00 GMTFinancingsR.F. Lafferty & Co., Inc. is the sole book-running manager. The filing also cuts the company's at-the-market program to $0 after it sold all the remaining stock under it.Artelo Biosciences, Inc. 424B5 (2025-09-30) https://aibio.space/news/enanta-launches-50-000-000-stock-offering-later-prices-65-000-000/https://aibio.space/news/enanta-launches-50-000-000-stock-offering-later-prices-65-000-000/Tue, 30 Sep 2025 12:00:00 GMTFinancingsThe preliminary filing left price and share count blank. The final prospectus supplement, dated September 30, 2025, priced 6,500,000 shares at $10.00, with $61,100,000 going to the company before expenses.Enanta Pharmaceuticals, Inc. 424B5 (2025-09-30) https://aibio.space/news/mira-pharmaceuticals-closes-skny-acquisition-all-stock-deal/https://aibio.space/news/mira-pharmaceuticals-closes-skny-acquisition-all-stock-deal/Tue, 30 Sep 2025 12:00:00 GMTMergersSKNY contributed $5 million in marketable securities to MIRA as a closing condition. MIRA says it believes it has regained compliance with Nasdaq's $2,500,000 equity rule, but the filing gives no share count for the deal.MIRA Pharmaceuticals, Inc. 8-K (2025-09-30) https://aibio.space/news/kala-bio-cut-51-percent-workforce-ends-kpi-012-after-phase-2b-trial/https://aibio.space/news/kala-bio-cut-51-percent-workforce-ends-kpi-012-after-phase-2b-trial/Mon, 29 Sep 2025 12:00:00 GMTDistressKALA BIO will stop developing KPI-012 and its stem cell secretome platform, cut approximately 19 employees and talk with its secured lender while it explores strategic options.KALA BIO, Inc. Form 8-K filed September 29, 2025 (SEC EDGAR) https://aibio.space/news/sutro-biopharma-plans-cut-workforce-about-one-third-expects-cash/https://aibio.space/news/sutro-biopharma-plans-cut-workforce-about-one-third-expects-cash/Mon, 29 Sep 2025 12:00:00 GMTDistressSutro Biopharma (Nasdaq: STRO) plans a workforce reduction of approximately one-third to focus on three preclinical ADC programs. It estimates $4.1 million to $4.3 million in costs.SUTRO BIOPHARMA, INC. Form 8-K filed September 29, 2025 (SEC EDGAR) https://aibio.space/news/bon-natural-lifes-interim-results-reflect-1-25-share-consolidation/https://aibio.space/news/bon-natural-lifes-interim-results-reflect-1-25-share-consolidation/Mon, 29 Sep 2025 12:00:00 GMTListingsBon Natural Life's unaudited interim statements for the six months to March 31, 2025, filed in a Form 6-K on September 29, 2025, reflect a 1-for-25 share consolidation and net proceeds of $10,543,805 from a public offering of Class A ordinary shares. Cash rose from $80,466 to $8,894,053 over the period.Bon Natural Life Limited 6-K (2025-09-29) https://aibio.space/news/estrella-immunopharma-regains-nasdaq-compliance-bid-price-market-value/https://aibio.space/news/estrella-immunopharma-regains-nasdaq-compliance-bid-price-market-value/Mon, 29 Sep 2025 12:00:00 GMTListingsNasdaq sent two letters on September 23, 2025 closing both matters. The company had been notified of the deficiencies in April and August.Estrella Immunopharma, Inc. 8-K (2025-09-29) https://aibio.space/news/journey-medical-extends-swk-term-loan-maturity-june-2028-credit/https://aibio.space/news/journey-medical-extends-swk-term-loan-maturity-june-2028-credit/Fri, 26 Sep 2025 12:00:00 GMTDebt FinancingJourney Medical's $25.0 million SWK term loan now matures June 27, 2028. Principal repayments start in February 2026 unless trailing revenue tops $60.0 million at December 31, 2025.Journey Medical Corp Form 8-K filed September 26, 2025 (SEC EDGAR) https://aibio.space/news/tevogen-bio-holdings-inc-now-tevogen-inc-gets-nasdaq-minimum-bid-price/https://aibio.space/news/tevogen-bio-holdings-inc-now-tevogen-inc-gets-nasdaq-minimum-bid-price/Fri, 26 Sep 2025 12:00:00 GMTListingsNasdaq told Tevogen Bio Holdings on September 23, 2025 that its shares had closed below $1.00 for 30 consecutive business days, giving it until March 23, 2026 to regain compliance. Its 2024 annual report said the company was relying on $8.0 million of grant funding it had not yet received.Tevogen Inc. Form 8-K filed September 26, 2025 (SEC EDGAR) https://aibio.space/news/ani-pharmaceuticals-forces-conversion-last-series-preferred-482-320/https://aibio.space/news/ani-pharmaceuticals-forces-conversion-last-series-preferred-482-320/Fri, 26 Sep 2025 12:00:00 GMTFinancingsANI mandatorily converted the last 20,000 preferred shares into 482,320 common shares on September 26, 2025. The filing reports no cash proceeds, and no preferred shares remain outstanding.ANI PHARMACEUTICALS INC Form 8-K filed September 26, 2025 (SEC EDGAR) https://aibio.space/news/longeveron-gets-nasdaq-minimum-bid-price-notice-has-until-march-23/https://aibio.space/news/longeveron-gets-nasdaq-minimum-bid-price-notice-has-until-march-23/Fri, 26 Sep 2025 12:00:00 GMTListingsNasdaq notified Longeveron (LGVN) on September 22, 2025 that its Class A common stock missed the $1.00 minimum bid price. The notice does not cause immediate delisting; a second 180-day period may be available.Longeveron Inc. Form 8-K filed September 26, 2025 (SEC EDGAR) https://aibio.space/news/adaptimmune-gets-nasdaq-panel-exception-until-december-1-2025-fix-bid/https://aibio.space/news/adaptimmune-gets-nasdaq-panel-exception-until-december-1-2025-fix-bid/Fri, 26 Sep 2025 12:00:00 GMTListingsA Nasdaq Hearings Panel gave Adaptimmune until December 1, 2025 to meet the $1.00 minimum bid price, or its American Depositary Shares will be delisted. The 8-K gives no share price and no count of days below the floor.Adaptimmune Therapeutics plc 8-K (2025-09-26) https://aibio.space/news/fractyl-health-prices-60-million-stock-offering-1-00-share/https://aibio.space/news/fractyl-health-prices-60-million-stock-offering-1-00-share/Fri, 26 Sep 2025 12:00:00 GMTFinancingsFractyl is selling 60,000,000 shares through BofA Securities, Evercore ISI and Ladenburg Thalmann, after a $1.05 raise in August. The prospectus supplement carries going-concern language.Fractyl Health, Inc. 8-K (2025-09-26) https://aibio.space/news/longeveron-gets-nasdaq-notice-trading-below-1-00-minimum-bid-price/https://aibio.space/news/longeveron-gets-nasdaq-notice-trading-below-1-00-minimum-bid-price/Fri, 26 Sep 2025 12:00:00 GMTListingsThe company has until March 23, 2026 to bring its Class A common stock back above the threshold. The notice has no immediate effect on its listing.Longeveron Inc. 8-K (2025-09-26) https://aibio.space/news/q-c-technologies-formerly-tnf-pharmaceuticals-starts-trading-qcls/https://aibio.space/news/q-c-technologies-formerly-tnf-pharmaceuticals-starts-trading-qcls/Fri, 26 Sep 2025 12:00:00 GMTFinancingsThe former TNF Pharmaceuticals began trading on Nasdaq as QCLS on September 26, 2025, under a new name tied to a licensed laser computing technology. The filing does not state how much the September private placement raised.Q/C Technologies, Inc. 8-K (2025-09-26) https://aibio.space/news/alzamend-neuro-issues-300-000-shares-conversion-series-b-preferred/https://aibio.space/news/alzamend-neuro-issues-300-000-shares-conversion-series-b-preferred/Thu, 25 Sep 2025 12:00:00 GMTFinancingsBetween September 17 and September 25, 2025, 696 shares of Series B Convertible Preferred Stock converted into common stock. Alzamend had 3,439,861 common shares outstanding as of September 25, 2025.Alzamend Neuro, Inc. Form 8-K filed September 25, 2025 (SEC EDGAR) https://aibio.space/news/silexion-therapeutics-regains-nasdaq-equity-bid-price-compliance/https://aibio.space/news/silexion-therapeutics-regains-nasdaq-equity-bid-price-compliance/Thu, 25 Sep 2025 12:00:00 GMTListingsNasdaq's September 23, 2025 letter confirmed that Silexion meets its $2.5 million shareholders' equity rule and its $1.00 bid-price rule. The company is now under a mandatory panel monitor until September 23, 2026, and one more equity failure in that period would lead to a delisting determination.Silexion Therapeutics Corp 8-K (2025-09-25) https://aibio.space/news/curanex-repays-400-000-loans-ceos-wife-weeks-after-ipo/https://aibio.space/news/curanex-repays-400-000-loans-ceos-wife-weeks-after-ipo/Wed, 24 Sep 2025 12:00:00 GMTFinancingsCuranex paid $408,537.32 on two notes held by its secretary, Dian Ying Jing, the wife of its chief executive. The payments came on September 23 and 24, 2025, well before the notes matured in 2027.Curanex 8-K https://aibio.space/news/uniqure-amends-hercules-term-loan-draws-50-million-refinance-debt/https://aibio.space/news/uniqure-amends-hercules-term-loan-draws-50-million-refinance-debt/Wed, 24 Sep 2025 12:00:00 GMTDebt FinancinguniQure amended its Hercules term loan on September 22, 2025. The 2025 Term Loan is up to $175 million, $50 million was drawn at closing to refinance existing debt, and the balance depends on milestones tied to AMT-130.uniQure N.V. Form 8-K filed September 24, 2025 (SEC EDGAR) https://aibio.space/news/biocardia-believes-regained-nasdaq-stockholders-equity-compliance/https://aibio.space/news/biocardia-believes-regained-nasdaq-stockholders-equity-compliance/Wed, 24 Sep 2025 12:00:00 GMTListingsBioCardia says its stockholders' equity exceeds the $2.5 million Nasdaq minimum after two private placements, an offering with net proceeds of about $5.1 million and at-the-market sales. Nasdaq will keep monitoring the company.BioCardia, Inc. Form 8-K filed September 24, 2025 (SEC EDGAR) https://aibio.space/news/immuneering-prices-offering-9-23-share-sanofi-unit-buy-25-0-million/https://aibio.space/news/immuneering-prices-offering-9-23-share-sanofi-unit-buy-25-0-million/Wed, 24 Sep 2025 12:00:00 GMTFinancingsImmuneering is selling 18,959,914 shares at $9.23 and expects about $164.1 million in net proceeds, plus about $23.3 million from a Sanofi unit. The company's 2024 audit report carried a going-concern paragraph.Immuneering Corporation 8-K (2025-09-24) https://aibio.space/news/pepgen-prices-100-000-000-public-offering-31-250-000-shares-3-200/https://aibio.space/news/pepgen-prices-100-000-000-public-offering-31-250-000-shares-3-200/Wed, 24 Sep 2025 12:00:00 GMTFinancingsPepGen priced 31,250,000 shares at $3.200 for gross proceeds of $100,000,000, a price above the $2.66 close the filings report for September 24, 2025. The company says the proceeds plus its existing cash will not be enough to finish development of any product candidate.PepGen Inc. 424B5 (2025-09-24) https://aibio.space/news/allarity-therapeutics-agrees-2-5-million-private-placement-7-5-million/https://aibio.space/news/allarity-therapeutics-agrees-2-5-million-private-placement-7-5-million/Mon, 22 Sep 2025 12:00:00 GMTFinancingsAllarity agreed to sell 1,562,500 shares at $1.60 each, or pre-funded warrants, to one investor, closing September 23, 2025. The investor may buy $7.5 million more: within 90 days per the 8-K, 60 days per the purchase agreement.Allarity Therapeutics, Inc. Form 8-K filed September 22, 2025 (SEC EDGAR) https://aibio.space/news/cytokinetics-issues-750-0-million-1-75-percent-convertible-senior/https://aibio.space/news/cytokinetics-issues-750-0-million-1-75-percent-convertible-senior/Mon, 22 Sep 2025 12:00:00 GMTDebt FinancingCytokinetics issued $750.0 million of 1.75% convertible senior notes due 2031 on September 19, 2025, and expects to spend about $402.5 million of the net proceeds on the cash side of exchanges for its 2027 notes. The notes convert at about $68.42 a share. Neither the 8-K nor the release gives the company's cash balance.CYTOKINETICS INC Form 8-K filed September 22, 2025 (SEC EDGAR) https://aibio.space/news/allarity-therapeutics-agrees-2-5-million-private-placement-7-5-million/https://aibio.space/news/allarity-therapeutics-agrees-2-5-million-private-placement-7-5-million/Mon, 22 Sep 2025 12:00:00 GMTFinancingsThe buyer gets 1,562,500 shares or pre-funded warrants at $1.60 and can add $7.5 million more within 90 days, at a price set by Nasdaq's minimum-price rule.Allarity Therapeutics, Inc. 8-K (2025-09-22) https://aibio.space/news/bioatla-wins-nasdaq-panel-extension-deadlines-fix-price-equity-gaps/https://aibio.space/news/bioatla-wins-nasdaq-panel-extension-deadlines-fix-price-equity-gaps/Mon, 22 Sep 2025 12:00:00 GMTListingsA Nasdaq hearing panel let BioAtla stay listed on conditions: a transfer to the Nasdaq Capital Market by September 26, 2025, equity compliance by December 31, 2025 and bid price compliance by February 2, 2026.BioAtla, Inc. 8-K (2025-09-22) https://aibio.space/news/mbx-biosciences-files-10-000-000-share-offering-later-sells-11-108-055/https://aibio.space/news/mbx-biosciences-files-10-000-000-share-offering-later-sells-11-108-055/Mon, 22 Sep 2025 12:00:00 GMTFinancingsMBX Biosciences filed an S-1 on September 22, 2025 for 10,000,000 shares. The deal priced on September 24 at $18.00 for 11,108,055 shares and closed on September 26 with net proceeds of about $187.5 million.MBX Biosciences, Inc. S-1 (2025-09-22) https://aibio.space/news/oruka-therapeutics-announces-180-million-private-placement-led-viking/https://aibio.space/news/oruka-therapeutics-announces-180-million-private-placement-led-viking/Mon, 22 Sep 2025 12:00:00 GMTFinancingsThe company is selling 10,933,405 shares at $15.00 and pre-funded warrants for 1,066,666 more. Closing was expected on or about September 19, 2025.Oruka Therapeutics, Inc. 8-K (2025-09-22) https://aibio.space/news/equillium-expands-market-stock-program-up-75-000-000/https://aibio.space/news/equillium-expands-market-stock-program-up-75-000-000/Fri, 19 Sep 2025 12:00:00 GMTFinancingsEquillium's public float of about $93.7 million lifts it above Form S-3 sales limits. The company had sold $0.96 million of stock under the program so far, against the $21,950,000 covered by the earlier prospectus.Equillium, Inc. 424B5 (2025-09-19) https://aibio.space/news/igc-pharma-files-sell-up-11-309-229-stock-market/https://aibio.space/news/igc-pharma-files-sell-up-11-309-229-stock-market/Fri, 19 Sep 2025 12:00:00 GMTFinancingsIGC Pharma, Inc. set the amount under a $60,000,000 at-the-market sales agreement with A.G.P./Alliance Global Partners. The cap follows a rule that limits small companies to one-third of their public float.IGC Pharma, Inc. 424B5 (2025-09-19) https://aibio.space/news/longeveron-sets-up-10-700-000-market-stock-program-h-c-wainwright/https://aibio.space/news/longeveron-sets-up-10-700-000-market-stock-program-h-c-wainwright/Fri, 19 Sep 2025 12:00:00 GMTFinancingsThe size is capped by SEC limits for companies with a public float under $75,000,000. Longeveron's stock last sold at $0.77 on September 18, 2025.Longeveron Inc. 424B5 (2025-09-19) https://aibio.space/news/prelude-therapeutics-regains-compliance-nasdaq-1-00-minimum-bid-price/https://aibio.space/news/prelude-therapeutics-regains-compliance-nasdaq-1-00-minimum-bid-price/Fri, 19 Sep 2025 12:00:00 GMTListingsNasdaq told Prelude on September 18, 2025 that the bid-price matter is closed. The company had been out of compliance since a March 27, 2025 notice.Prelude Therapeutics Incorporated 8-K (2025-09-19) https://aibio.space/news/soligenix-prices-7-5-million-public-offering-shares-warrants-1-35/https://aibio.space/news/soligenix-prices-7-5-million-public-offering-shares-warrants-1-35/Fri, 19 Sep 2025 12:00:00 GMTFinancingsThe offering covers 5,555,560 shares or equivalents with matching five-year warrants. Soligenix also cut the exercise price on 1,162,064 older warrants to $1.35.Soligenix, Inc. S-1 (2025-09-19) https://aibio.space/news/vaxart-delisted-nasdaq-after-missing-hearings-panel-conditions/https://aibio.space/news/vaxart-delisted-nasdaq-after-missing-hearings-panel-conditions/Fri, 19 Sep 2025 12:00:00 GMTListingsNasdaq told Vaxart on September 19, 2025 that its common stock will be delisted after the company withdrew a reverse stock split proposal that a hearings panel had made a condition of continued listing. Trading on Nasdaq was suspended on July 8, 2025.Vaxart, Inc. 8-K (2025-09-19) https://aibio.space/news/jasper-therapeutics-prices-30-million-offering-stock-warrants/https://aibio.space/news/jasper-therapeutics-prices-30-million-offering-stock-warrants/Thu, 18 Sep 2025 12:00:00 GMTFinancingsJasper priced 11,670,707 shares and 675,000 pre-funded warrants, each with a common warrant, at $2.43, for about $30 million before costs. The prospectus also discloses an unresolved trial investigation and a going concern warning.Jasper Therapeutics, Inc. 424B5 (2025-09-18) https://aibio.space/news/medicus-pharma-issues-8-0-million-debenture-yorkville-fund/https://aibio.space/news/medicus-pharma-issues-8-0-million-debenture-yorkville-fund/Thu, 18 Sep 2025 12:00:00 GMTDebt FinancingThe 8% debenture matures in twelve months and refinances about $1.7 million of earlier Yorkville debentures. Medicus expects net proceeds of approximately $5.7 million, and the lender can require repayment from part of any equity raise.Medicus Pharma Ltd. 8-K (2025-09-18) https://aibio.space/news/nasdaq-complete-delisting-zyversa-therapeutics-stock-form-25-filing/https://aibio.space/news/nasdaq-complete-delisting-zyversa-therapeutics-stock-form-25-filing/Thu, 18 Sep 2025 12:00:00 GMTListingsNasdaq told ZyVersa it would announce the delisting on September 18, 2025. The shares have traded on the OTCQB Venture Market since July 28, 2025.ZyVersa Therapeutics, Inc. 8-K (2025-09-18) https://aibio.space/news/arvinas-cut-about-15-percent-staff-seek-vepdegestrant-partner-approves/https://aibio.space/news/arvinas-cut-about-15-percent-staff-seek-vepdegestrant-partner-approves/Wed, 17 Sep 2025 12:00:00 GMTDistressArvinas said on September 17, 2025 that it will cut its workforce by a further 15%, mainly in vepdegestrant commercialization roles, and that it will seek a third party to take over the drug with Pfizer. The same day its board authorized a buyback of up to $100 million, and the filing does not give the cash balance on which that depends.ARVINAS, INC. Form 8-K filed September 17, 2025 (SEC EDGAR) https://aibio.space/news/x4-pharmaceuticals-cuts-workforce-50-percent-restructuring-four-senior/https://aibio.space/news/x4-pharmaceuticals-cuts-workforce-50-percent-restructuring-four-senior/Wed, 17 Sep 2025 12:00:00 GMTDistressX4 is cutting about 50% of its workforce for annualized savings of about $13 million, with cash charges of about $3.3 million, after three executives were terminated and its chief medical officer resigned. Its 2024 annual report carried a going-concern warning tied to a loan covenant with Hercules.X4 Pharmaceuticals, Inc Form 8-K filed September 17, 2025 (SEC EDGAR) https://aibio.space/news/aquabounty-regains-compliance-nasdaq-1-00-minimum-bid-price-rule/https://aibio.space/news/aquabounty-regains-compliance-nasdaq-1-00-minimum-bid-price-rule/Wed, 17 Sep 2025 12:00:00 GMTListingsAquaBounty told the SEC on September 17, 2025 that Nasdaq closed its $1.00 bid price matter after a January 15, 2025 notice. The company no longer runs any salmon farm, and its 10-K puts 2024 impairments at $129.8 million.AquaBounty Technologies, Inc. 8-K (2025-09-17) https://aibio.space/news/arvinas-cuts-about-15-percent-staff-authorizes-100-million-buyback/https://aibio.space/news/arvinas-cuts-about-15-percent-staff-authorizes-100-million-buyback/Wed, 17 Sep 2025 12:00:00 GMTDistressThe company and Pfizer have agreed to out-license vepdegestrant commercialization rights and have begun looking for a partner. Arvinas expects about $4.5 million in workforce costs.Arvinas, Inc. 8-K (2025-09-17) https://aibio.space/news/neuphoria-therapeutics-gets-nasdaq-extension-december-29-2025-hold/https://aibio.space/news/neuphoria-therapeutics-gets-nasdaq-extension-december-29-2025-hold/Tue, 16 Sep 2025 12:00:00 GMTListingsNasdaq accepted Neuphoria's plan on September 10, 2025, after a July 18, 2025 notice that it had not held an annual meeting. The company has until December 29, 2025 and says it will file its Form 10-K on or before September 29, 2025.Neuphoria Therapeutics Inc. Form 8-K filed September 16, 2025 (SEC EDGAR) https://aibio.space/news/biocardia-files-best-efforts-stock-warrant-offering-later-prices-1-25/https://aibio.space/news/biocardia-files-best-efforts-stock-warrant-offering-later-prices-1-25/Tue, 16 Sep 2025 12:00:00 GMTFinancingsThe September 16 registration covered up to 2,800,000 shares at an assumed $2.27. On September 18 the final prospectus sold 4,800,000 shares with warrants at $1.25, for $6,000,000.BioCardia, Inc. S-1 (2025-09-16) https://aibio.space/news/bio-green-med-solution-preferred-stock-falls-short-nasdaq-1-million/https://aibio.space/news/bio-green-med-solution-preferred-stock-falls-short-nasdaq-1-million/Tue, 16 Sep 2025 12:00:00 GMTListingsNasdaq says the 6% Convertible Exchangeable Preferred Stock has been below the $1 million minimum for publicly held shares for 30 consecutive business days. The company has until March 10, 2026 to regain compliance, and its 8-K does not say how it will get there.Bio Green Med Solution, Inc. 8-K (2025-09-16) https://aibio.space/news/microbot-medical-expects-25-2-million-first-closing-option-exercises/https://aibio.space/news/microbot-medical-expects-25-2-million-first-closing-option-exercises/Tue, 16 Sep 2025 12:00:00 GMTFinancingsA second closing should add about $4 million. New series J options could bring about $63 million more if fully exercised.Microbot Medical Inc. 8-K (2025-09-16) https://aibio.space/news/ovid-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/https://aibio.space/news/ovid-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/Tue, 16 Sep 2025 12:00:00 GMTListingsNasdaq told Ovid on September 11, 2025 that it again meets the $1.00 minimum bid price, but the company's notice does not say how it got back above that level.Ovid Therapeutics Inc. 8-K (2025-09-16) https://aibio.space/news/relmada-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/https://aibio.space/news/relmada-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/Tue, 16 Sep 2025 12:00:00 GMTListingsRelmada Therapeutics said on September 16, 2025 that Nasdaq confirmed in a September 15 notice that it has regained compliance with the $1.00 minimum bid price. The stock stays on the Nasdaq Capital Market under RLMD, but the company's lead drug failed in late 2024.Relmada Therapeutics, Inc. 8-K (2025-09-16) https://aibio.space/news/revelation-biosciences-gets-9-6-million-gross-proceeds-warrant/https://aibio.space/news/revelation-biosciences-gets-9-6-million-gross-proceeds-warrant/Mon, 15 Sep 2025 12:00:00 GMTFinancingsHolders of 13,065,000 Class H warrants agreed to exercise at $2.20 per share and receive 13,065,000 new Class I warrants in a private placement. Roth Capital Partners advised.REVELATION BIOSCIENCES, INC. Form 8-K filed September 15, 2025 (SEC EDGAR) https://aibio.space/news/revelation-biosciences-agrees-9-6-million-immediate-warrant-exercise/https://aibio.space/news/revelation-biosciences-agrees-9-6-million-immediate-warrant-exercise/Mon, 15 Sep 2025 12:00:00 GMTFinancingsRevelation Biosciences said on September 11, 2025 that holders will exercise warrants for up to 4,355,000 shares at $2.20 each, about $9.6 million in gross proceeds. In return they receive new Class I warrants for up to 13,065,000 shares, which cannot be exercised until stockholders approve them.Revelation Biosciences, Inc. 8-K (2025-09-15) https://aibio.space/news/benitec-biopharma-says-two-quarterly-financial-reports-should-not/https://aibio.space/news/benitec-biopharma-says-two-quarterly-financial-reports-should-not/Fri, 12 Sep 2025 12:00:00 GMTDistressBenitec's Audit Committee found share-based compensation expense was understated in the quarters ended December 31, 2024 and March 31, 2025. The company expects to file its 2025 annual report on time.Benitec Biopharma Inc. Form 8-K filed September 12, 2025 (SEC EDGAR) https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-minimum-bid-price/https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-minimum-bid-price/Fri, 12 Sep 2025 12:00:00 GMTListingsNasdaq told the company on September 11, 2025 that its stock closed below $1.00 for 30 consecutive business days. It has until March 10, 2026 to regain compliance, and the Nasdaq Capital Market listing is unchanged for now.Yarrow Bioscience, Inc. Form 8-K filed September 12, 2025 (SEC EDGAR) https://aibio.space/news/traws-pharma-buys-antiviral-compound-assets-related-party-viriom-2-350/https://aibio.space/news/traws-pharma-buys-antiviral-compound-assets-related-party-viriom-2-350/Fri, 12 Sep 2025 12:00:00 GMTMergersTraws Pharma paid $2,350,000 in cash, in full, for assets tied to a pyrrolidine antiviral compound held by Viriom. The seller's executive chairman is Traws's own chief operating officer, and its 2024 annual report carries a going-concern warning.Traws Pharma, Inc. Form 8-K filed September 12, 2025 (SEC EDGAR) https://aibio.space/news/cocrystal-pharma-prices-4-7-million-direct-offering-1-70-share/https://aibio.space/news/cocrystal-pharma-prices-4-7-million-direct-offering-1-70-share/Fri, 12 Sep 2025 12:00:00 GMTFinancingsThe company agreed to sell 2,764,710 shares at $1.70 each, with warrants for up to 5,529,420 shares at $1.50 that could add approximately $8.3 million if fully exercised for cash. H.C. Wainwright & Co. is the placement agent.Cocrystal Pharma, Inc. 8-K (2025-09-12) https://aibio.space/news/curanex-pharmaceuticals-raises-2-250-000-more-ipo-underwriters/https://aibio.space/news/curanex-pharmaceuticals-raises-2-250-000-more-ipo-underwriters/Fri, 12 Sep 2025 12:00:00 GMTFinancingsDominari Securities bought 562,500 more shares at the $4.00 IPO price. Total gross proceeds from the offering reached $17,250,000.Curanex Pharmaceuticals Inc 8-K (2025-09-12) https://aibio.space/news/lb-pharmaceuticals-prices-ipo-19-000-000-shares-15-00/https://aibio.space/news/lb-pharmaceuticals-prices-ipo-19-000-000-shares-15-00/Fri, 12 Sep 2025 12:00:00 GMTFinancingsThe offering totals $285,000,000, and the shares are approved for listing on Nasdaq under LBRX. Proceeds to the company are $265,050,000 before expenses, and the company's lead drug has a Phase 3 trial still ahead.LB Pharmaceuticals Inc 424B4 (2025-09-12) https://aibio.space/news/nrx-pharmaceuticals-completes-acquisition-dura-medical-clinics-through/https://aibio.space/news/nrx-pharmaceuticals-completes-acquisition-dura-medical-clinics-through/Fri, 12 Sep 2025 12:00:00 GMTMergersNRx's subsidiary HOPE Therapeutics closed its purchase of Dura Medical, which runs two Florida clinics. The 8-K gives no purchase price, and part of the consideration is paid in later earn-outs and in interests that convert into HOPE shares.NRX Pharmaceuticals, Inc. 8-K (2025-09-12) https://aibio.space/news/pluri-regains-nasdaq-audit-committee-compliance-after-naming/https://aibio.space/news/pluri-regains-nasdaq-audit-committee-compliance-after-naming/Fri, 12 Sep 2025 12:00:00 GMTListingsNasdaq confirmed the matter is closed after Pluri elected Eitan Ajchenbaum as an independent director and Audit Committee chair. The gap began after the June 30, 2025 annual meeting.Pluri Inc. 8-K (2025-09-12) https://aibio.space/news/silexion-therapeutics-prices-6-0-million-offering-4-00-share-warrants/https://aibio.space/news/silexion-therapeutics-prices-6-0-million-offering-4-00-share-warrants/Fri, 12 Sep 2025 12:00:00 GMTFinancingsSilexion priced a $6.0 million public offering at $4.00 per share and warrants, with H.C. Wainwright as exclusive placement agent. Its prospectus says cash was $3.5 million at June 30, 2025 and carries a going-concern warning.Silexion Therapeutics Corp 424B4 (2025-09-12) https://aibio.space/news/traws-pharma-buys-antiviral-assets-viriom-2-350-000-related-party-deal/https://aibio.space/news/traws-pharma-buys-antiviral-assets-viriom-2-350-000-related-party-deal/Fri, 12 Sep 2025 12:00:00 GMTMergersTraws Pharma paid $2,350,000 in cash for intellectual property and other assets from Viriom, a company tied to its chief operating officer. The board and audit committee approved the deal and called the price fair and reasonable.Traws Pharma, Inc. 8-K (2025-09-12) https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-notice-sub-1-00/https://aibio.space/news/vyne-therapeutics-now-yarrow-bioscience-gets-nasdaq-notice-sub-1-00/Fri, 12 Sep 2025 12:00:00 GMTListingsVYNE Therapeutics, now Yarrow Bioscience, has until March 10, 2026 to lift its closing bid price back to at least $1.00 per share.Yarrow Bioscience, Inc. 8-K (2025-09-12) https://aibio.space/news/bausch-health-completes-durect-acquisition-after-tender-offer-draws/https://aibio.space/news/bausch-health-completes-durect-acquisition-after-tender-offer-draws/Thu, 11 Sep 2025 12:00:00 GMTMergersBHC Lyon accepted 19,984,767 DURECT shares and merged into DURECT on September 11, 2025. Holders get $1.75 per share in cash plus a contingent value right that pays only if net sales milestones are reached.Bausch Health Companies Inc. Form 8-K filed September 11, 2025 (SEC EDGAR) https://aibio.space/news/tuhura-biosciences-investors-agree-buy-3-2-million-deferred-stock-now/https://aibio.space/news/tuhura-biosciences-investors-agree-buy-3-2-million-deferred-stock-now/Thu, 11 Sep 2025 12:00:00 GMTFinancingsFour investors who could defer their purchases until December 31, 2025 agreed to buy now. In return, TuHURA extended warrants on 1.5 million shares to December 31, 2030.TuHURA Biosciences, Inc. 8-K (2025-09-11) https://aibio.space/news/sellas-life-sciences-expects-23-6-million-gross-investors-warrant/https://aibio.space/news/sellas-life-sciences-expects-23-6-million-gross-investors-warrant/Thu, 11 Sep 2025 12:00:00 GMTFinancingsSELLAS says an institutional investor will exercise January 2025 warrants for 19,685,040 shares, bringing about $23.6 million gross. The investor gets new unregistered warrants for the same number of shares at $1.88, so the dilution continues.SELLAS Life Sciences Group, Inc. 8-K (2025-09-11) https://aibio.space/news/anixa-biosciences-files-200-000-000-replacement-shelf-100-000-000-atm/https://aibio.space/news/anixa-biosciences-files-200-000-000-replacement-shelf-100-000-000-atm/Wed, 10 Sep 2025 12:00:00 GMTFinancingsAnixa Biosciences filed a $200,000,000 replacement shelf on September 10, 2025, with a $100,000,000 sales program through Cantor Fitzgerald & Co., because its current shelf expires on September 19, 2025 and its clinical programs are still in early trials.Anixa Biosciences, Inc. S-3 (2025-09-10) https://aibio.space/news/camp4-therapeutics-signs-private-placement-up-100-million-50-million/https://aibio.space/news/camp4-therapeutics-signs-private-placement-up-100-million-50-million/Wed, 10 Sep 2025 12:00:00 GMTFinancingsLeerink Partners is lead placement agent for the $50 million upfront, with Piper Sandler & Co., Cantor Fitzgerald and Wedbush & Co. as co-placement agents. The second $50 million depends on milestones, including clearance to start a trial of CMP-SYNGAP-01.CAMP4 Therapeutics Corporation 8-K (2025-09-10) https://aibio.space/news/celcuity-upsizes-term-loan-facility-500-million-innovatus-oxford/https://aibio.space/news/celcuity-upsizes-term-loan-facility-500-million-innovatus-oxford/Wed, 10 Sep 2025 12:00:00 GMTDebt FinancingCelcuity drew $30 million at closing, bringing the term loan to $130 million. The $170 million of new committed capital depends on FDA approval of gedatolisib or on commercial revenue milestones.Celcuity Inc. 8-K (2025-09-10) https://aibio.space/news/talphera-raises-about-17-million-private-placement-cormedix-investors/https://aibio.space/news/talphera-raises-about-17-million-private-placement-cormedix-investors/Wed, 10 Sep 2025 12:00:00 GMTFinancingsShares sold at $0.55 each. Investors other than CorMedix agreed to buy about $12 million more if the NEPHRO CRRT study meets its primary endpoint and the stock clears a price test.Talphera, Inc. 8-K (2025-09-10) https://aibio.space/news/actuate-therapeutics-prices-2-142-858-shares-7-00-15-000-006-gross/https://aibio.space/news/actuate-therapeutics-prices-2-142-858-shares-7-00-15-000-006-gross/Tue, 09 Sep 2025 12:00:00 GMTFinancingsActuate Therapeutics priced 2,142,858 shares at $7.00 for $15,000,006 in gross proceeds, below the $8.24 last sale price. Lucid Capital Markets is the sole underwriter, and the prospectus says the company's current liabilities exceeded its assets at June 30, 2025.Actuate Therapeutics, Inc. 424B5 (2025-09-09) https://aibio.space/news/osr-holdings-now-osr-health-gets-nasdaq-notice-after-30-days-below-1/https://aibio.space/news/osr-holdings-now-osr-health-gets-nasdaq-notice-after-30-days-below-1/Tue, 09 Sep 2025 12:00:00 GMTListingsThe company has until March 4, 2026 to regain compliance with the minimum bid price rule. Its shares keep trading on The Nasdaq Capital Market for now.OSR Health, Inc. 8-K (2025-09-09) https://aibio.space/news/rein-therapeutics-draws-second-1-0-million-advance-yorkville/https://aibio.space/news/rein-therapeutics-draws-second-1-0-million-advance-yorkville/Tue, 09 Sep 2025 12:00:00 GMTFinancingsRein received net proceeds of $0.95 million from the $1.0 million second advance on September 8, 2025. Yorkville buys each advance at 95% of face value, charges 8% interest and can require repayment in stock.Rein Therapeutics, Inc. 8-K (2025-09-09) https://aibio.space/news/abivax-expects-cash-q4-2027-after-747-5-million-gross-offering/https://aibio.space/news/abivax-expects-cash-q4-2027-after-747-5-million-gross-offering/Mon, 08 Sep 2025 12:00:00 GMTDistressAbivax reported a first-half net loss of EUR 100.8 million and negative shareholders' equity of EUR 48.3 million at June 30, 2025, before a July US offering and several note conversions. The company now says its cash lasts into the fourth quarter of 2027.Abivax SA 6-K (2025-09-08) https://aibio.space/news/coherus-oncology-regains-nasdaq-compliance-1-00-minimum-bid-price-rule/https://aibio.space/news/coherus-oncology-regains-nasdaq-compliance-1-00-minimum-bid-price-rule/Mon, 08 Sep 2025 12:00:00 GMTListingsNasdaq closed the matter on September 5, 2025, ahead of the December 29, 2025 deadline the company had been given.Coherus Oncology, Inc. 8-K (2025-09-08) https://aibio.space/news/nrx-pharmaceuticals-says-8-8-million-raise-had-no-warrants-repricing/https://aibio.space/news/nrx-pharmaceuticals-says-8-8-million-raise-had-no-warrants-repricing/Mon, 08 Sep 2025 12:00:00 GMTFinancingsThe $8.8 million combines an August registered direct offering with at-the-market sales since July 1, 2025. The company says none of it carried warrants, repricing or variable-rate terms, but the filing gives no share count, price or investor names.NRX Pharmaceuticals, Inc. 8-K (2025-09-08) https://aibio.space/news/pharvaris-signs-registration-rights-agreement-general-atlantic-ph/https://aibio.space/news/pharvaris-signs-registration-rights-agreement-general-atlantic-ph/Mon, 08 Sep 2025 12:00:00 GMTMergersPharvaris agreed to file a resale shelf registration within 30 calendar days for General Atlantic PH B.V., and the investor decides when to sell, how and at what price. The company may postpone the shelf only once in any twelve months, and the filing does not say how many shares the investor holds.Pharvaris N.V. 6-K (2025-09-08) https://aibio.space/news/rapport-therapeutics-prices-250-million-stock-offering-26-00-share/https://aibio.space/news/rapport-therapeutics-prices-250-million-stock-offering-26-00-share/Mon, 08 Sep 2025 12:00:00 GMTFinancingsRapport priced 9,615,385 shares at $26.00 the day after reporting Phase 2a epilepsy data for RAP-219, with net proceeds of about $234.7 million. The data came from 30 treated patients and were tested against fixed null rates, not a placebo group.Rapport Therapeutics, Inc. 424B5 (2025-09-08) https://aibio.space/news/dbv-technologies-sets-up-market-program-up-150-million-adss-nasdaq/https://aibio.space/news/dbv-technologies-sets-up-market-program-up-150-million-adss-nasdaq/Fri, 05 Sep 2025 12:00:00 GMTFinancingsDBV Technologies set up a $150 million at-the-market program for American Depositary Shares, sold through Citizens JMP Securities, LLC for a 3.0% commission. The prospectus supplement shows $3.86 per ADS of immediate dilution at a $9.18 reference price.DBV Technologies SA 424B5 (2025-09-05) https://aibio.space/news/fibrogen-now-kyntra-bio-completes-220-million-china-unit-sale/https://aibio.space/news/fibrogen-now-kyntra-bio-completes-220-million-china-unit-sale/Fri, 05 Sep 2025 12:00:00 GMTMergersFibroGen used part of the proceeds to repay about $81 million of Morgan Stanley Tactical Value term loans. Pro forma total equity turns positive only with minority interests counted, while the stockholders' deficit attributable to FibroGen remains.Kyntra Bio, Inc. 8-K (2025-09-05) https://aibio.space/news/nucana-says-nasdaq-confirmed-compliance-closed-listing-matter/https://aibio.space/news/nucana-says-nasdaq-confirmed-compliance-closed-listing-matter/Fri, 05 Sep 2025 12:00:00 GMTListingsThe company says Nasdaq closed its listing matter and that its cash lasts into 2029. The release gives no cash balance or burn figure and does not say what steps restored compliance.NuCana plc 6-K (2025-09-05) https://aibio.space/news/optimi-health-files-u-s-ipo-nasdaq-uplisting-canadian-exchange/https://aibio.space/news/optimi-health-files-u-s-ipo-nasdaq-uplisting-canadian-exchange/Fri, 05 Sep 2025 12:00:00 GMTFinancingsThe British Columbia company plans a reverse share split and has applied to list on the Nasdaq Capital Market. Titan Partners Group is the sole bookrunner.Optimi Health Corp. F-1 (2025-09-05) https://aibio.space/news/pharmacyte-biotech-adds-3-million-stake-tnf-pharmaceuticals/https://aibio.space/news/pharmacyte-biotech-adds-3-million-stake-tnf-pharmaceuticals/Fri, 05 Sep 2025 12:00:00 GMTMergersPharmaCyte says the money is meant to support TNF's license of a light-based computing platform for cryptocurrency mining. TNF plans to change its name and ticker.PharmaCyte Biotech, Inc. 8-K (2025-09-05) https://aibio.space/news/ac-immune-cut-about-30-percent-workforce-sees-chf-127-1-million/https://aibio.space/news/ac-immune-cut-about-30-percent-workforce-sees-chf-127-1-million/Thu, 04 Sep 2025 12:00:00 GMTDistressThe company is focusing on its late-stage active immunotherapy programs and two small molecule programs. It says near-term clinical milestones are unchanged.AC Immune SA 6-K (2025-09-04) https://aibio.space/news/bone-biologics-expects-cash-fund-operations-second-quarter-2026/https://aibio.space/news/bone-biologics-expects-cash-fund-operations-second-quarter-2026/Thu, 04 Sep 2025 12:00:00 GMTFinancingsBone Biologics says its June offering raised $5 million gross and that it expects cash to fund operations into the second quarter of 2026, while enrollment in its pilot study is slower than planned.Bone Biologics Corporation 8-K (2025-09-04) https://aibio.space/news/cyclacel-now-bio-green-med-solution-swaps-series-c-warrants-559-395/https://aibio.space/news/cyclacel-now-bio-green-med-solution-swaps-series-c-warrants-559-395/Thu, 04 Sep 2025 12:00:00 GMTFinancingsCyclacel Pharmaceuticals, now Bio Green Med Solution, agreed to exchange Series C warrants for 559,395 new common shares. The 8-K gives no exercise price and describes no cash payment.Bio Green Med Solution, Inc. 8-K (2025-09-04) https://aibio.space/news/cero-therapeutics-appeals-nasdaq-delisting-2-500-000-stockholders/https://aibio.space/news/cero-therapeutics-appeals-nasdaq-delisting-2-500-000-stockholders/Thu, 04 Sep 2025 12:00:00 GMTListingsNasdaq staff set a September 8, 2025 delisting date. CERo requested a hearing on September 3, 2025, which stays the suspension, and plans to present a compliance plan.CERo Therapeutics Holdings, Inc. 8-K (2025-09-04) https://aibio.space/news/equillium-regains-compliance-nasdaqs-1-00-minimum-bid-price-rule/https://aibio.space/news/equillium-regains-compliance-nasdaqs-1-00-minimum-bid-price-rule/Thu, 04 Sep 2025 12:00:00 GMTListingsNasdaq notified the company on August 29, 2025. Its shares closed at $1.00 or more for at least 10 consecutive business days.Equillium, Inc. 8-K (2025-09-04) https://aibio.space/news/mesoblast-signs-option-issue-up-us-50-million-convertible-notes/https://aibio.space/news/mesoblast-signs-option-issue-up-us-50-million-convertible-notes/Thu, 04 Sep 2025 12:00:00 GMTListingsThe notes carry a 5% coupon and convert at US$16.25 per ADR. Issuance depends on shareholder approval at the upcoming annual general meeting.Mesoblast Limited 6-K (2025-09-04) https://aibio.space/news/nutriband-reports-5-31-million-warrant-exercises-six-months-july-31/https://aibio.space/news/nutriband-reports-5-31-million-warrant-exercises-six-months-july-31/Wed, 03 Sep 2025 12:00:00 GMTFinancingsPrivate investors exercised warrants for 778,041 shares and public holders for 47,076 shares. Employee options added $44,206.NTRB 8-K https://aibio.space/news/precigen-draws-100-0-million-closing-pharmakon-senior-secured-term/https://aibio.space/news/precigen-draws-100-0-million-closing-pharmakon-senior-secured-term/Wed, 03 Sep 2025 12:00:00 GMTDebt FinancingPrecigen entered a five-year senior secured loan agreement with funds managed by Pharmakon Advisors. A $25.0 million delayed draw tranche is available until June 29, 2027, and the loans mature September 3, 2030.PRECIGEN, INC. Form 8-K filed September 3, 2025 (SEC EDGAR) https://aibio.space/news/adial-pharmaceuticals-gets-180-day-nasdaq-extension-1-00-bid-price/https://aibio.space/news/adial-pharmaceuticals-gets-180-day-nasdaq-extension-1-00-bid-price/Wed, 03 Sep 2025 12:00:00 GMTListingsAdial Pharmaceuticals has until March 2, 2026 to hold its shares at $1.00 or more for ten consecutive business days. Its 10-K for 2024 said current cash would not cover the next twelve months, and its accumulated deficit reached $82.0 million.Adial Pharmaceuticals, Inc 8-K (2025-09-03) https://aibio.space/news/celularity-regains-nasdaq-compliance-after-filing-two-late-quarterly/https://aibio.space/news/celularity-regains-nasdaq-compliance-after-filing-two-late-quarterly/Wed, 03 Sep 2025 12:00:00 GMTListingsNasdaq told Celularity on September 2, 2025 that it complies with Listing Rule 5250(c)(1) again, after the company filed its Form 10-Q reports for the periods ended March 31 and June 30, 2025.Celularity Inc. 8-K (2025-09-03) https://aibio.space/news/ironwood-pharmaceuticals-regains-compliance-nasdaq-1-00-bid-price-rule/https://aibio.space/news/ironwood-pharmaceuticals-regains-compliance-nasdaq-1-00-bid-price-rule/Wed, 03 Sep 2025 12:00:00 GMTListingsNasdaq told Ironwood on August 29, 2025 that the matter is closed. The company had received a deficiency notice on May 28, 2025.Ironwood Pharmaceuticals, Inc. 8-K (2025-09-03) https://aibio.space/news/medicus-pharma-completes-antev-acquisition-about-us-3-0-million-cash-1/https://aibio.space/news/medicus-pharma-completes-antev-acquisition-about-us-3-0-million-cash-1/Tue, 02 Sep 2025 12:00:00 GMTMergersMedicus closed its Antev deal on August 29, 2025 and could owe up to approximately $65 million more on milestones. It also sold 250,000 shares to Yorkville for approximately $490,535 and added Patrick J. Mahaffy to its board.Medicus Pharma Ltd. Form 8-K filed September 2, 2025 (SEC EDGAR) https://aibio.space/news/cormedix-completes-melinta-therapeutics-acquisition-300-million/https://aibio.space/news/cormedix-completes-melinta-therapeutics-acquisition-300-million/Tue, 02 Sep 2025 12:00:00 GMTMergersCorMedix paid $260 million in cash and $40 million in common shares to Melinta's owners. A contingent payment agreement adds up to $25 million tied to a rezafungin approval by June 30, 2029.CorMedix Inc. Form 8-K filed September 2, 2025 (SEC EDGAR) https://aibio.space/news/context-therapeutics-gets-nasdaq-extension-february-23-2026-minimum/https://aibio.space/news/context-therapeutics-gets-nasdaq-extension-february-23-2026-minimum/Tue, 02 Sep 2025 12:00:00 GMTListingsNasdaq gave Context Therapeutics until February 23, 2026 to regain compliance with the $1.00 minimum bid price rule. The company says it may need a reverse stock split and cannot promise it will regain compliance.Context Therapeutics Inc. Form 8-K filed September 2, 2025 (SEC EDGAR) https://aibio.space/news/zenas-biopharma-signs-royalty-financing-royalty-pharma-up-300-million/https://aibio.space/news/zenas-biopharma-signs-royalty-financing-royalty-pharma-up-300-million/Tue, 02 Sep 2025 12:00:00 GMTFinancingsZenas BioPharma sold Royalty Pharma a share of future obexelimab revenue for up to $300 million. It received $75 million at closing, and the other three $75 million payments depend on a Phase 3 milestone and two FDA approvals. The company says the cash lasts into the first quarter of 2027.Zenas BioPharma, Inc. Form 8-K filed September 2, 2025 (SEC EDGAR) https://aibio.space/news/context-therapeutics-gets-180-more-days-nasdaq-meet-1-00-bid-price/https://aibio.space/news/context-therapeutics-gets-180-more-days-nasdaq-meet-1-00-bid-price/Tue, 02 Sep 2025 12:00:00 GMTListingsThe new deadline is February 23, 2026. The company says a reverse stock split is an option if needed, and it gives no assurance it will regain compliance by then.Context Therapeutics Inc. 8-K (2025-09-02) https://aibio.space/news/mangoceuticals-sells-709-677-shares-1-55-1-100-000-private-placement/https://aibio.space/news/mangoceuticals-sells-709-677-shares-1-55-1-100-000-private-placement/Tue, 02 Sep 2025 12:00:00 GMTFinancingsFive accredited investors bought restricted stock under subscription agreements signed August 26, 2025 and August 29, 2025. No underwriters were used.Mangoceuticals, Inc. 8-K (2025-09-02) https://aibio.space/news/vtv-therapeutics-agrees-private-placement-about-80-million/https://aibio.space/news/vtv-therapeutics-agrees-private-placement-about-80-million/Tue, 02 Sep 2025 12:00:00 GMTFinancingsvTv Therapeutics agreed on August 29, 2025 to sell 5,243,732 units for expected gross proceeds of about $80 million before offering expenses. Each unit carries a warrant exercisable at $22.71, and the placement was expected to close initially on September 3, 2025.vTv Therapeutics Inc. 8-K (2025-09-02) https://aibio.space/news/zenas-biopharma-signs-royalty-pharma-funding-deal-worth-up-300-million/https://aibio.space/news/zenas-biopharma-signs-royalty-pharma-funding-deal-worth-up-300-million/Tue, 02 Sep 2025 12:00:00 GMTMergersRoyalty Pharma will pay $75 million upfront for a 5.5% royalty on worldwide net sales of obexelimab, with three more $75 million payments tied to milestones.Zenas BioPharma, Inc. 8-K (2025-09-02) https://aibio.space/news/envoy-medical-asks-nasdaq-panel-review-delisting-determination-market/https://aibio.space/news/envoy-medical-asks-nasdaq-panel-review-delisting-determination-market/Fri, 29 Aug 2025 12:00:00 GMTListingsNasdaq said Envoy did not regain compliance with its $35,000,000 market value of listed securities requirement. A hearing request filed August 29, 2025 stays any trading suspension.Envoy Medical, Inc. Form 8-K filed August 29, 2025 (SEC EDGAR) https://aibio.space/news/enveric-biosciences-gets-nasdaq-stockholders-equity-deficiency-notice/https://aibio.space/news/enveric-biosciences-gets-nasdaq-stockholders-equity-deficiency-notice/Fri, 29 Aug 2025 12:00:00 GMTListingsNasdaq says Enveric does not meet the $2,500,000 minimum stockholders' equity requirement. The company reported stockholders' equity of $2,184,769 in its latest 10-Q and has until October 10, 2025 to file a compliance plan.Enveric Biosciences, Inc. Form 8-K filed August 29, 2025 (SEC EDGAR) https://aibio.space/news/enveric-biosciences-falls-short-nasdaq-2-500-000-stockholders-equity/https://aibio.space/news/enveric-biosciences-falls-short-nasdaq-2-500-000-stockholders-equity/Fri, 29 Aug 2025 12:00:00 GMTListingsNasdaq's deficiency letter came after the company reported stockholders' equity of $2,184,769 at June 30, 2025, below the $2,500,000 minimum for the Nasdaq Capital Market. Enveric has until October 10, 2025 to submit a plan to regain compliance.Enveric Biosciences, Inc. 8-K (2025-08-29) https://aibio.space/news/century-therapeutics-gets-180-more-days-meet-nasdaq-bid-price-rule/https://aibio.space/news/century-therapeutics-gets-180-more-days-meet-nasdaq-bid-price-rule/Fri, 29 Aug 2025 12:00:00 GMTListingsNasdaq gave Century until February 23, 2026, to lift its closing bid price above $1.00, and moved its listing to the Nasdaq Capital Market. The company's own clinical data for its lead lymphoma program did not meet its bar for a transformational result.Century Therapeutics, Inc. 8-K (2025-08-29) https://aibio.space/news/moleculin-biotech-raise-up-6-0-million-through-warrant-inducement-deal/https://aibio.space/news/moleculin-biotech-raise-up-6-0-million-through-warrant-inducement-deal/Fri, 29 Aug 2025 12:00:00 GMTFinancingsHolders will exercise warrants for 16,216,216 shares at $0.37. They get new Series F warrants for 64,864,864 shares at $0.55, pending shareholder approval.Moleculin Biotech, Inc. 8-K (2025-08-29) https://aibio.space/news/purple-biotech-files-f-1-ads-offering-later-prices-6-million-deal-1-00/https://aibio.space/news/purple-biotech-files-f-1-ads-offering-later-prices-6-million-deal-1-00/Fri, 29 Aug 2025 12:00:00 GMTFinancingsThe August filing assumed $2.22 per ADS. The September 4 pricing set a combined $1.00 with short-term warrants, for about $6 million of gross proceeds before fees.Purple Biotech Ltd. F-1 (2025-08-29) https://aibio.space/news/rallybio-moves-nasdaq-capital-market-gets-180-more-days-bid-price/https://aibio.space/news/rallybio-moves-nasdaq-capital-market-gets-180-more-days-bid-price/Fri, 29 Aug 2025 12:00:00 GMTListingsRallybio moved its listing to the Nasdaq Capital Market on August 29, 2025 after missing its first bid-price deadline. It received 180 more days, to February 23, 2026, to bring its stock back to at least $1.00.Rallybio Corporation 8-K (2025-08-29) https://aibio.space/news/xilio-therapeutics-gets-nasdaq-notice-stockholders-equity-below-10-0/https://aibio.space/news/xilio-therapeutics-gets-nasdaq-notice-stockholders-equity-below-10-0/Thu, 28 Aug 2025 12:00:00 GMTListingsNasdaq says Xilio reported stockholders' equity of $7,069,000 at June 30, 2025, below the $10.0 million minimum for the Global Select Market. The company has until October 6, 2025 to submit a plan, and it remains out of compliance with the $1.00 minimum bid price rule.Xilio Therapeutics, Inc. Form 8-K filed August 28, 2025 (SEC EDGAR) https://aibio.space/news/imunon-regains-compliance-nasdaq-minimum-bid-price-requirement/https://aibio.space/news/imunon-regains-compliance-nasdaq-minimum-bid-price-requirement/Thu, 28 Aug 2025 12:00:00 GMTListingsImunon (Nasdaq: IMNN) says the Nasdaq Hearings Panel notified it on August 27, 2025 that it meets the $1.00 minimum closing bid price. The stock will continue trading on the Nasdaq Capital Market.Imunon, Inc. Form 8-K filed August 28, 2025 (SEC EDGAR) https://aibio.space/news/journey-medical-sets-up-new-market-program-3-750-000-shares/https://aibio.space/news/journey-medical-sets-up-new-market-program-3-750-000-shares/Thu, 28 Aug 2025 12:00:00 GMTFinancingsJourney Medical signed an at-the-market sales agreement with B. Riley Securities, Inc. and Lake Street Capital Markets, LLC for up to 3,750,000 shares. It ended an older B. Riley program under which it had sold 4,121,318 shares.Journey Medical Corporation 8-K (2025-08-28) https://aibio.space/news/imunon-regains-nasdaq-minimum-bid-price-compliance-after-hearings/https://aibio.space/news/imunon-regains-nasdaq-minimum-bid-price-compliance-after-hearings/Thu, 28 Aug 2025 12:00:00 GMTListingsThe Nasdaq Hearings Panel confirmed compliance, so Imunon common stock will keep trading on The Nasdaq Capital Market. The company also pointed to a recent 15% stock dividend.Imunon, Inc. 8-K (2025-08-28) https://aibio.space/news/curanex-raises-15-million-ipo-then-2-25-million-more-overallotment/https://aibio.space/news/curanex-raises-15-million-ipo-then-2-25-million-more-overallotment/Wed, 27 Aug 2025 12:00:00 GMTFinancingsCuranex closed its initial public offering of 3,750,000 shares at $4.00 a share on August 27, 2025. Dominari Securities led the underwriters, and the proceeds are earmarked for Phyto-N, a lead drug candidate for ulcerative colitis.Curanex 8-K https://aibio.space/news/grace-therapeutics-nda-acceptance-opens-window-up-7-6-million-warrants/https://aibio.space/news/grace-therapeutics-nda-acceptance-opens-window-up-7-6-million-warrants/Wed, 27 Aug 2025 12:00:00 GMTFinancingsThe FDA accepted the GTx-104 application on August 22, 2025, with an April 23, 2026 target date. Warrants from the September 2023 private placement, at $3.003 each, expire on the earlier of the 60th day after acceptance or September 25, 2028.Grace Therapeutics, Inc. 8-K (2025-08-27) https://aibio.space/news/veru-regains-compliance-nasdaq-minimum-bid-price-rule/https://aibio.space/news/veru-regains-compliance-nasdaq-minimum-bid-price-rule/Wed, 27 Aug 2025 12:00:00 GMTListingsA Nasdaq letter received August 26, 2025 says Veru has regained compliance with the $1.00 minimum bid price rule and that the matter is closed. Nasdaq first wrote to the company about the bid price on August 29, 2024.Veru Inc. 8-K (2025-08-27) https://aibio.space/news/indivior-plc-now-indivior-pharmaceuticals-inc-expects-39-50-million/https://aibio.space/news/indivior-plc-now-indivior-pharmaceuticals-inc-expects-39-50-million/Tue, 26 Aug 2025 12:00:00 GMTDistressIndivior says its Action Agenda initiative brings headcount reductions and real estate consolidations. It expects $27 million to $35 million of the charges to be cash and is exploring strategic alternatives for OPVEE and its non-U.S. business.Indivior Pharmaceuticals, Inc. Form 8-K filed August 26, 2025 (SEC EDGAR) https://aibio.space/news/briacell-plans-1-10-share-consolidation-meet-nasdaq-listing-rules/https://aibio.space/news/briacell-plans-1-10-share-consolidation-meet-nasdaq-listing-rules/Tue, 26 Aug 2025 12:00:00 GMTListingsBriaCell's board approved a one-for-ten share consolidation to keep its Nasdaq listing, expected to take effect August 25, 2025, subject to approval from Nasdaq and the Toronto Stock Exchange.BriaCell Therapeutics Corp 8-K (2025-08-26) https://aibio.space/news/cognition-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/https://aibio.space/news/cognition-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/Tue, 26 Aug 2025 12:00:00 GMTListingsNasdaq told Cognition Therapeutics on August 26, 2025 that the company again meets its listing requirements after the stock closed above $1.00 for more than ten trading days.Cognition Therapeutics, Inc. 8-K (2025-08-26) https://aibio.space/news/plus-therapeutics-now-cerenome-wins-nasdaq-equity-nod-more-time-1-00/https://aibio.space/news/plus-therapeutics-now-cerenome-wins-nasdaq-equity-nod-more-time-1-00/Tue, 26 Aug 2025 12:00:00 GMTListingsNasdaq confirmed compliance with both the $35 million market value standard and the $2.5 million equity standard. The bid price deadline moves to November 12, 2025.Cerenome, Inc. 8-K (2025-08-26) https://aibio.space/news/cosciens-biopharma-files-form-25-withdraw-shares-nasdaq/https://aibio.space/news/cosciens-biopharma-files-form-25-withdraw-shares-nasdaq/Tue, 26 Aug 2025 12:00:00 GMTListingsCOSCIENS marked the voluntary withdrawal box on its Nasdaq Form 25. The form gives no reason, and the company's April 2025 annual report describes a failed Phase 3 trial and a shift to natural-based products.COSCIENS Biopharma Inc. 25 (2025-08-26) https://aibio.space/news/bright-minds-biosciences-files-250-000-000-shelf-100-000-000-atm/https://aibio.space/news/bright-minds-biosciences-files-250-000-000-shelf-100-000-000-atm/Tue, 26 Aug 2025 12:00:00 GMTFinancingsPiper Sandler & Co. and Cantor Fitzgerald & Co. are the agents under an August 25, 2025 equity distribution agreement. The company's latest annual report shows cash used in operations of CAD 1.9 million for fiscal 2024.Bright Minds Biosciences Inc. F-3 (2025-08-26) https://aibio.space/news/evofem-signs-sixth-amendment-aditxt-merger-agreement/https://aibio.space/news/evofem-signs-sixth-amendment-aditxt-merger-agreement/Tue, 26 Aug 2025 12:00:00 GMTMergersEvofem's sixth amendment to its Aditxt merger agreement adds a new Series G-1 preferred stock to the deal and caps dissenting shares. Common holders share a total of $1,800,000, and the proxy says no fairness opinion was sought.Evofem Biosciences, Inc. 8-K (2025-08-26) https://aibio.space/news/shattuck-labs-closes-private-placement-up-103-million-led-orbimed/https://aibio.space/news/shattuck-labs-closes-private-placement-up-103-million-led-orbimed/Tue, 26 Aug 2025 12:00:00 GMTFinancingsShattuck says the placement could fund operations into 2029 if all warrants are exercised. Two new directors join the board, including OrbiMed's Mona Ashiya, and four directors leave.Shattuck Labs, Inc. 8-K (2025-08-26) https://aibio.space/news/liminatus-pharma-gets-nasdaq-deficiency-notice-late-form-10/https://aibio.space/news/liminatus-pharma-gets-nasdaq-deficiency-notice-late-form-10/Mon, 25 Aug 2025 12:00:00 GMTListingsLiminatus Pharma (Nasdaq: LIMN) has until October 21, 2025 to submit a plan to regain compliance after the delayed filing of its report for the period ended June 30, 2025. The stock keeps trading for now.Liminatus Pharma, Inc. Form 8-K filed August 25, 2025 (SEC EDGAR) https://aibio.space/news/dermata-therapeutics-regains-nasdaq-compliance-after-hearing-panel/https://aibio.space/news/dermata-therapeutics-regains-nasdaq-compliance-after-hearing-panel/Mon, 25 Aug 2025 12:00:00 GMTListingsNasdaq staff told Dermata on August 22, 2025 that the company again meets the $1.00 minimum bid price, which closes the matter. The company needed a hearing panel's exception to reach that point, and its 8-K gives no cash figure.Dermata Therapeutics, Inc. 8-K (2025-08-25) https://aibio.space/news/curis-gets-nasdaq-delisting-determination-market-value-rule-plans/https://aibio.space/news/curis-gets-nasdaq-delisting-determination-market-value-rule-plans/Fri, 22 Aug 2025 12:00:00 GMTListingsNasdaq staff said Curis did not regain compliance with the $35,000,000 market value requirement by August 20, 2025. Curis must request a hearing by August 28, 2025; the request keeps its stock listed during the appeal.CURIS INC Form 8-K filed August 22, 2025 (SEC EDGAR) https://aibio.space/news/curis-appeal-nasdaq-delisting-after-missing-35-000-000-market-value/https://aibio.space/news/curis-appeal-nasdaq-delisting-after-missing-35-000-000-market-value/Fri, 22 Aug 2025 12:00:00 GMTListingsCuris missed Nasdaq's $35 million market value rule and must ask for a hearing by August 28, 2025 to avoid delisting. It says it will ask, and its shares stay listed while a panel decides.Curis, Inc. 8-K (2025-08-22) https://aibio.space/news/iovance-restates-jefferies-market-deal-allowing-sales-up-350-0-million/https://aibio.space/news/iovance-restates-jefferies-market-deal-allowing-sales-up-350-0-million/Fri, 22 Aug 2025 12:00:00 GMTFinancingsIovance may sell up to $350.0 million of stock through Jefferies, which can take up to 3.0% of gross proceeds. The company is not obliged to sell any shares, and its stock last traded at $2.60 on August 19, 2025.Iovance Biotherapeutics, Inc. 424B5 (2025-08-22) https://aibio.space/news/protalix-renews-20-000-000-market-stock-program-h-c-wainwright/https://aibio.space/news/protalix-renews-20-000-000-market-stock-program-h-c-wainwright/Fri, 22 Aug 2025 12:00:00 GMTFinancingsAbout $15.7 million of stock remains available for sale after earlier sales of $4.3 million. The sales agent earns a 3.0% commission.Protalix BioTherapeutics, Inc. (DE) 424B5 (2025-08-22) https://aibio.space/news/novavax-agrees-issue-225-0-million-4-625-percent-convertible-senior/https://aibio.space/news/novavax-agrees-issue-225-0-million-4-625-percent-convertible-senior/Thu, 21 Aug 2025 12:00:00 GMTDebt FinancingAbout $49.7 million of the new convertible notes would be sold for cash, and about $175.3 million would be exchanged for 2027 notes. The exchange gives Novavax no cash. The company expects to close on or about August 27, 2025.NOVAVAX INC Form 8-K filed August 21, 2025 (SEC EDGAR) https://aibio.space/news/sarepta-agrees-swap-about-700-0-million-2027-convertible-notes-sell-20/https://aibio.space/news/sarepta-agrees-swap-about-700-0-million-2027-convertible-notes-sell-20/Thu, 21 Aug 2025 12:00:00 GMTFinancingsSarepta would swap about $700.0 million of 1.25% notes due 2027 for $602.0 million of new 4.875% notes due 2030, about $123.3 million in cash and new shares. It also agreed to a $20.0 million private placement, with J. Wood Capital Advisors LLC as financial advisor and subscriber.Sarepta Therapeutics, Inc. Form 8-K filed August 21, 2025 (SEC EDGAR) https://aibio.space/news/atossa-therapeutics-gets-180-more-days-meet-nasdaq-1-00-bid-price-rule/https://aibio.space/news/atossa-therapeutics-gets-180-more-days-meet-nasdaq-1-00-bid-price-rule/Thu, 21 Aug 2025 12:00:00 GMTListingsThe new deadline is February 17, 2026. Atossa said it may consider a reverse stock split if needed.Atossa Therapeutics, Inc. 8-K (2025-08-21) https://aibio.space/news/enanta-files-patent-infringement-suit-against-pfizer-paxlovid-eu/https://aibio.space/news/enanta-files-patent-infringement-suit-against-pfizer-paxlovid-eu/Wed, 20 Aug 2025 12:00:00 GMTLegalEnanta Pharmaceuticals says it sued Pfizer Inc. and certain of its subsidiaries in the Unified Patent Court on Aug 20, 2025, alleging infringement of a European patent through Paxlovid sales. The claim is untested, and no hearing date is given.ENANTA PHARMACEUTICALS INC Form 8-K filed August 20, 2025 (SEC EDGAR) https://aibio.space/news/genprex-gets-second-nasdaq-delisting-basis-stockholders-equity/https://aibio.space/news/genprex-gets-second-nasdaq-delisting-basis-stockholders-equity/Wed, 20 Aug 2025 12:00:00 GMTListingsNasdaq says Genprex's equity of $1,391,195 is below the $2.5 million minimum, adding a second basis for delisting to an unresolved bid price failure. A hearing request has stayed any delisting for now.Genprex, Inc. Form 8-K filed August 20, 2025 (SEC EDGAR) https://aibio.space/news/invivyd-prices-offering-74-811-404-shares-0-52-each/https://aibio.space/news/invivyd-prices-offering-74-811-404-shares-0-52-each/Wed, 20 Aug 2025 12:00:00 GMTFinancingsInvivyd sold 74,811,404 shares at $0.52 each and pre-funded warrants for up to 21,342,442 more shares, for a total public offering price of $49,997,865.68 before underwriting discounts.Invivyd, Inc. 424B5 (2025-08-20) https://aibio.space/news/i-mab-now-novabridge-biosciences-cites-61-2-million-net-august/https://aibio.space/news/i-mab-now-novabridge-biosciences-cites-61-2-million-net-august/Wed, 20 Aug 2025 12:00:00 GMTFinancingsPro-forma cash of about $226.8 million assumes the August offering, which added 76,666,659 ordinary shares. Reported cash and short-term investments were lower at June 30 than at the end of 2024, and the lead drug's efficacy data come from 10 of 12 patients.NovaBridge Biosciences 6-K (2025-08-20) https://aibio.space/news/windtree-therapeutics-delisted-nasdaq-shares-move-otc-market/https://aibio.space/news/windtree-therapeutics-delisted-nasdaq-shares-move-otc-market/Wed, 20 Aug 2025 12:00:00 GMTListingsNasdaq will suspend trading in Windtree's common stock at the open on August 21, 2025. The company has applied for the OTCID tier.Windtree Therapeutics, Inc. 8-K (2025-08-20) https://aibio.space/news/evogene-cuts-30-percent-workforce-reports-11-7-million-cash-18-71/https://aibio.space/news/evogene-cuts-30-percent-workforce-reports-11-7-million-cash-18-71/Tue, 19 Aug 2025 12:00:00 GMTDistressEvogene is cutting 30% of its workforce and says an $18.71 million asset sale and a $4.4 million share program give it an 18-month runway. The $11.7 million cash figure leaves out the sale proceeds, and the company's equity attributable to shareholders is negative.Evogene Ltd. 6-K (2025-08-19) https://aibio.space/news/hcw-biologics-faces-nasdaq-suspension-equity-rule-plans-request/https://aibio.space/news/hcw-biologics-faces-nasdaq-suspension-equity-rule-plans-request/Tue, 19 Aug 2025 12:00:00 GMTListingsNasdaq says HCW Biologics was out of compliance with its equity rule on June 30, 2025. The shares would be suspended on August 28 unless the company asks for a hearing by August 26.HCW Biologics Inc. 8-K (2025-08-19) https://aibio.space/news/unicycive-discloses-securities-class-action-oxylanthanum-carbonate/https://aibio.space/news/unicycive-discloses-securities-class-action-oxylanthanum-carbonate/Mon, 18 Aug 2025 12:00:00 GMTLegalUnicycive said a securities class action was filed in the Northern District of California against the company and certain of its officers, who are not named. The suit concerns statements about its oxylanthanum carbonate application. The company calls the claims meritless.Unicycive Therapeutics, Inc. Form 8-K filed August 18, 2025 (SEC EDGAR) https://aibio.space/news/genprex-gets-second-nasdaq-deficiency-notice-equity-1-391-195/https://aibio.space/news/genprex-gets-second-nasdaq-deficiency-notice-equity-1-391-195/Mon, 18 Aug 2025 12:00:00 GMTListingsStockholders' equity of $1,391,195 at June 30, 2025 is below the $2.5 million minimum. Genprex has asked for a Nasdaq Hearings Panel hearing, which pauses any delisting while the process runs.Genprex, Inc. 8-K (2025-08-18) https://aibio.space/news/pharmacyte-biotech-agrees-7-0-million-convertible-preferred-private/https://aibio.space/news/pharmacyte-biotech-agrees-7-0-million-convertible-preferred-private/Mon, 18 Aug 2025 12:00:00 GMTFinancingsPharmaCyte agreed to sell 7,000 shares of Series C convertible preferred stock, with a $1,000 stated value each, to existing investors for $7.0 million. The preferred converts at $1.00 a share, against $4.00 for the 2023 Series B, and it carries a 7.0% quarterly dividend payable in cash.PharmaCyte Biotech, Inc. 8-K (2025-08-18) https://aibio.space/news/propanc-biopharma-prices-4-million-offering-moves-nasdaq/https://aibio.space/news/propanc-biopharma-prices-4-million-offering-moves-nasdaq/Mon, 18 Aug 2025 12:00:00 GMTFinancingsPropanc sold 1,000,000 shares at $4.00 each, while its prospectus carries a going-concern warning and reports $50,760 of cash on March 31, 2025. The stock left the OTC Pink market for the Nasdaq Capital Market.Propanc Biopharma, Inc. 424B4 (2025-08-18) https://aibio.space/news/cingulate-files-nt-10-q-citing-management-changes-quarter-ended-june/https://aibio.space/news/cingulate-files-nt-10-q-citing-management-changes-quarter-ended-june/Fri, 15 Aug 2025 12:00:00 GMTDistressThe company says it needs more time to review its financial statements after recent changes in management. It expects to file its Form 10-Q within the five calendar day period under Rule 12b-25.Cingulate Inc. Form NT 10-Q filed August 15, 2025 (SEC EDGAR) https://aibio.space/news/os-therapies-files-nt-10-q-late-filing-notice-second-quarter-cites/https://aibio.space/news/os-therapies-files-nt-10-q-late-filing-notice-second-quarter-cites/Fri, 15 Aug 2025 12:00:00 GMTDistressOS Therapies could not file its quarterly report for the period ended June 30, 2025 by its August 14, 2025 due date. Its last annual report carried an auditor's going concern warning and showed $5,533,527 of cash at the end of 2024.OS Therapies Inc Form NT 10-Q filed August 15, 2025 (SEC EDGAR) https://aibio.space/news/heron-therapeutics-adopts-rights-plan-4-99-percent-trigger-protect-tax/https://aibio.space/news/heron-therapeutics-adopts-rights-plan-4-99-percent-trigger-protect-tax/Fri, 15 Aug 2025 12:00:00 GMTMergersHeron's board adopted a Tax Benefit Preservation Plan on August 13, 2025. A holder that reaches 4.99% without board approval would trigger rights, and the company says it had about $1.37 billion of U.S. federal NOLs at December 31, 2024.HERON THERAPEUTICS, INC. /DE/ Form 8-K filed August 15, 2025 (SEC EDGAR) https://aibio.space/news/agentix-corp-says-june-quarter-report-will-late/https://aibio.space/news/agentix-corp-says-june-quarter-report-will-late/Fri, 15 Aug 2025 12:00:00 GMTDistressAgentix has no meaningful revenue, and its lead drug candidate has animal efficacy data only in its annual report. It says it cannot finish its quarterly report on time and expects to file by August 19, 2025.Agentix Corp. NT 10-Q (2025-08-15) https://aibio.space/news/cero-therapeutics-delays-q2-report-estimates-18-5-million-quarterly/https://aibio.space/news/cero-therapeutics-delays-q2-report-estimates-18-5-million-quarterly/Fri, 15 Aug 2025 12:00:00 GMTDistressThe company needs more time to value marketable securities it received as part payment for Series D Preferred Stock. It estimates an $18.5 million net loss for the quarter and a $33.4 million loss attributable to common shareholders.CERo Therapeutics Holdings, Inc. NT 10-Q (2025-08-15) https://aibio.space/news/cingulate-delays-quarterly-report-after-management-changes/https://aibio.space/news/cingulate-delays-quarterly-report-after-management-changes/Fri, 15 Aug 2025 12:00:00 GMTDistressCingulate filed a late-filing notice for its report on the quarter ended June 30, 2025. It expects to file within the five-day extension period.Cingulate Inc. NT 10-Q (2025-08-15) https://aibio.space/news/calidi-biotherapeutics-prices-6-million-public-offering-units-2-00/https://aibio.space/news/calidi-biotherapeutics-prices-6-million-public-offering-units-2-00/Fri, 15 Aug 2025 12:00:00 GMTFinancingsThe offering combines common stock units and pre-funded warrant units, each with a Series I warrant exercisable at $2.00 for five years.Calidi Biotherapeutics, Inc. S-1 (2025-08-15) https://aibio.space/news/cosmos-health-files-late-notice-june-30-2025-quarterly-report/https://aibio.space/news/cosmos-health-files-late-notice-june-30-2025-quarterly-report/Fri, 15 Aug 2025 12:00:00 GMTDistressCosmos Health said it could not finish its June 30, 2025 Form 10-Q on time, blaming delays in obtaining and compiling information, including its XBRL filing. It does not expect a significant change in results from a year earlier.Cosmos Health Inc. NT 10-Q (2025-08-15) https://aibio.space/news/hcw-biologics-delays-quarterly-report-period-ended-june-30-2025/https://aibio.space/news/hcw-biologics-delays-quarterly-report-period-ended-june-30-2025/Fri, 15 Aug 2025 12:00:00 GMTDistressHCW Biologics says it needs more time to finish its June quarter 10-Q and expects to file within the five-day grace period. The notice gives no revenue, loss or cash figures.HCW Biologics Inc. NT 10-Q (2025-08-15) https://aibio.space/news/heron-therapeutics-adopts-rights-plan-protect-1-37-billion-tax-losses/https://aibio.space/news/heron-therapeutics-adopts-rights-plan-protect-1-37-billion-tax-losses/Fri, 15 Aug 2025 12:00:00 GMTMergersThe plan, effective August 14, 2025, aims to deter any investor or group from reaching 4.99% of the common stock. The release gives no current taxable income, net loss or cash figure.Heron Therapeutics, Inc. 8-K (2025-08-15) https://aibio.space/news/liminatus-pharma-files-late-notice-quarterly-report-june-30-2025/https://aibio.space/news/liminatus-pharma-files-late-notice-quarterly-report-june-30-2025/Fri, 15 Aug 2025 12:00:00 GMTDistressThe company said its financial statements could not be completed in time for review and signatures. It checked the box saying it will file within the grace period.Liminatus Pharma, Inc. NT 10-Q (2025-08-15) https://aibio.space/news/os-therapies-delays-quarterly-report-period-ended-june-30-2025/https://aibio.space/news/os-therapies-delays-quarterly-report-period-ended-june-30-2025/Fri, 15 Aug 2025 12:00:00 GMTDistressOS Therapies says it needs more time to finish its financial statement close for the quarter ended June 30, 2025, and expects to file within the five-day extension.OS Therapies Incorporated NT 10-Q (2025-08-15) https://aibio.space/news/sigyn-therapeutics-delays-quarterly-report-period-ended-june-30-2025/https://aibio.space/news/sigyn-therapeutics-delays-quarterly-report-period-ended-june-30-2025/Fri, 15 Aug 2025 12:00:00 GMTDistressSigyn Therapeutics filed a Form 12b-25 notice on August 15, 2025 saying it cannot file its quarterly report for the period ended June 30, 2025 on time. It promises to file no later than five days after the original due date.Sigyn Therapeutics Inc. NT 10-Q (2025-08-15) https://aibio.space/news/sol-gel-reports-24-2-million-cash-expects-runway-early-2027/https://aibio.space/news/sol-gel-reports-24-2-million-cash-expects-runway-early-2027/Fri, 15 Aug 2025 12:00:00 GMTListingsSol-Gel's second-quarter report shows $24.2 million in cash and securities at June 30, 2025, and net income of $11.6 million that came mostly from a one-time $16 million sale of U.S. product rights. The company's largest pipeline asset still has no results until the fourth quarter of 2026.Sol-Gel Technologies Ltd. 6-K (2025-08-15) https://aibio.space/news/soligenix-gets-nasdaq-notice-stockholders-equity-below-2-500-000/https://aibio.space/news/soligenix-gets-nasdaq-notice-stockholders-equity-below-2-500-000/Fri, 15 Aug 2025 12:00:00 GMTListingsSoligenix reported stockholders' equity of $1,828,951 at June 30, 2025 and has until September 29, 2025 to submit a plan to regain compliance with the Nasdaq minimum.Soligenix, Inc. 8-K (2025-08-15) https://aibio.space/news/cdt-equity-formerly-conduit-pharmaceuticals-says-q1-2025-financials/https://aibio.space/news/cdt-equity-formerly-conduit-pharmaceuticals-says-q1-2025-financials/Thu, 14 Aug 2025 12:00:00 GMTDistressThe company says $0.4 million of milestone payments to Sarborg Limited were booked as research and development expense but should have been an acquired diagnostic asset. It plans to amend its first-quarter Form 10-Q.CDT Equity Inc. Form 8-K filed August 14, 2025 (SEC EDGAR) https://aibio.space/news/allarity-therapeutics-files-nt-10-q-says-june-30-2025-quarterly-report/https://aibio.space/news/allarity-therapeutics-files-nt-10-q-says-june-30-2025-quarterly-report/Thu, 14 Aug 2025 12:00:00 GMTDistressAllarity says its auditors have not finished reviewing the quarter. It expects to file within five calendar days of the due date and does not anticipate a significant change in results from a year earlier.Allarity Therapeutics, Inc. Form NT 10-Q filed August 14, 2025 (SEC EDGAR) https://aibio.space/news/nrx-pharmaceuticals-files-nt-10-q-says-second-quarter-form-10-q-will/https://aibio.space/news/nrx-pharmaceuticals-files-nt-10-q-says-second-quarter-form-10-q-will/Thu, 14 Aug 2025 12:00:00 GMTDistressNRx Pharmaceuticals (Nasdaq: NRXP) told the SEC it needs more time to compile information for its June 30, 2025 quarterly report. It expects to file within five calendar days of the due date.NRX Pharmaceuticals, Inc. Form NT 10-Q filed August 14, 2025 (SEC EDGAR) https://aibio.space/news/allarity-therapeutics-delays-quarterly-report-while-auditors-finish/https://aibio.space/news/allarity-therapeutics-delays-quarterly-report-while-auditors-finish/Thu, 14 Aug 2025 12:00:00 GMTDistressThe company filed a late-filing notice on August 14, 2025 for its report on the quarter ended June 30, 2025. It expects to file within the extension period, but its auditors had not finished their review.Allarity Therapeutics, Inc. NT 10-Q (2025-08-14) https://aibio.space/news/apimeds-pharmaceuticals-delays-quarterly-report-period-ended-june-30/https://aibio.space/news/apimeds-pharmaceuticals-delays-quarterly-report-period-ended-june-30/Thu, 14 Aug 2025 12:00:00 GMTDistressApimeds says it cannot file its quarterly report for the period ended June 30, 2025 on time and expects to file within the five-day extension. Its lead drug, Apitox, rests on a prior Phase III trial that the company's own filing describes in conflicting terms.Apimeds Pharmaceuticals US, Inc. NT 10-Q (2025-08-14) https://aibio.space/news/aquestive-therapeutics-prices-85-000-000-stock-offering-4-00-share/https://aibio.space/news/aquestive-therapeutics-prices-85-000-000-stock-offering-4-00-share/Thu, 14 Aug 2025 12:00:00 GMTFinancingsAquestive sold 21,250,000 shares at $4.00 through Leerink Partners, Cantor and Oppenheimer, a day after agreeing to a conditional $75 million revenue-interest deal with an affiliate of RTW Investments. Anaphylm's approval is a condition of that deal.Aquestive Therapeutics, Inc. 424B5 (2025-08-14) https://aibio.space/news/eloxx-pharmaceuticals-lacks-funds-auditor-review-expects-0-6-million/https://aibio.space/news/eloxx-pharmaceuticals-lacks-funds-auditor-review-expects-0-6-million/Thu, 14 Aug 2025 12:00:00 GMTDistressThe company also has not filed its annual reports for 2023 and 2024. It expects to disclose substantial doubt about its ability to continue as a going concern.Eloxx Pharmaceuticals, Inc. NT 10-Q (2025-08-14) https://aibio.space/news/goldenwell-biotech-files-late-notice-june-quarter-report/https://aibio.space/news/goldenwell-biotech-files-late-notice-june-quarter-report/Thu, 14 Aug 2025 12:00:00 GMTDistressGoldenwell said it could not compile its financial information in time and expects to file by August 19, 2025. Its notice also says an annual report has not been filed, and its latest filed balance sheet is small.GOLDENWELL BIOTECH INC. NT 10-Q (2025-08-14) https://aibio.space/news/jupiter-neurosciences-delays-quarterly-report-period-ended-june-30/https://aibio.space/news/jupiter-neurosciences-delays-quarterly-report-period-ended-june-30/Thu, 14 Aug 2025 12:00:00 GMTDistressJupiter said it needs more time to complete the presentation and review of its financial statements. It expects to file within five calendar days of the deadline and says it anticipates no significant change in results.Jupiter Neurosciences, Inc. NT 10-Q (2025-08-14) https://aibio.space/news/nrx-pharmaceuticals-files-late-notice-quarterly-report-june-30-2025/https://aibio.space/news/nrx-pharmaceuticals-files-late-notice-quarterly-report-june-30-2025/Thu, 14 Aug 2025 12:00:00 GMTDistressNRx told the SEC it will miss the regular deadline for its June quarter report and needs more time to compile information. It expects to file within the form's five-day grace period, and the notice gives no figures.NRX Pharmaceuticals, Inc. NT 10-Q (2025-08-14) https://aibio.space/news/neonc-technologies-delays-quarterly-report-finish-review-stock-unit/https://aibio.space/news/neonc-technologies-delays-quarterly-report-finish-review-stock-unit/Thu, 14 Aug 2025 12:00:00 GMTDistressNeOnc needs more time to review non-cash expense charges tied to previously granted restricted stock units. It expects to file within five days.NeOnc Technologies Holdings, Inc. NT 10-Q (2025-08-14) https://aibio.space/news/ocean-biomedical-delays-quarterly-report-period-ended-june-30-2025/https://aibio.space/news/ocean-biomedical-delays-quarterly-report-period-ended-june-30-2025/Thu, 14 Aug 2025 12:00:00 GMTDistressThe company said it is working with its auditor to finish the review of its Form 10-Q. It expects to file within 5 calendar days of the due date.Ocean Biomediacal, Inc. NT 10-Q (2025-08-14) https://aibio.space/news/protagenic-therapeutics-delays-10-q-after-approving-move-virtual-model/https://aibio.space/news/protagenic-therapeutics-delays-10-q-after-approving-move-virtual-model/Thu, 14 Aug 2025 12:00:00 GMTDistressProtagenic Therapeutics said on August 14, 2025 that it cannot file its June quarter report on time, because its board approved a restructuring to a virtual operating model on August 8. The company expects to file by August 19, 2025, and the notice gives no cost or cash estimate for the restructuring.Protagenic Therapeutics, Inc. NT 10-Q (2025-08-14) https://aibio.space/news/tnf-pharmaceuticals-now-q-c-technologies-delays-june-quarter-report/https://aibio.space/news/tnf-pharmaceuticals-now-q-c-technologies-delays-june-quarter-report/Thu, 14 Aug 2025 12:00:00 GMTDistressTNF Pharmaceuticals says it needs more time to finish the financial statements for the six months ended June 30, 2025, and expects to file within the extension window. The notice does not say what is holding up the numbers.Q/C Technologies, Inc. NT 10-Q (2025-08-14) https://aibio.space/news/denali-capital-acquisition-corp-now-semnur-pharmaceuticals-delays-june/https://aibio.space/news/denali-capital-acquisition-corp-now-semnur-pharmaceuticals-delays-june/Thu, 14 Aug 2025 12:00:00 GMTDistressDenali Capital filed a Form 12b-25 notice on August 14, 2025 saying it cannot file its June 30, 2025 quarterly report on time, because it is still completing its financial statements. The notice says the report will come no later than the fifth calendar day after the due date.Semnur Pharmaceuticals Inc. NT 10-Q (2025-08-14) https://aibio.space/news/windtree-therapeutics-files-late-notice-quarterly-report-june-30-2025/https://aibio.space/news/windtree-therapeutics-files-late-notice-quarterly-report-june-30-2025/Thu, 14 Aug 2025 12:00:00 GMTDistressThe company said it needs more time to finalize its financial statements and related disclosures. It expects to file within five calendar days after the due date.Windtree Therapeutics, Inc. NT 10-Q (2025-08-14) https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics/https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics/Wed, 13 Aug 2025 12:00:00 GMTMergersBridgeBio Oncology Therapeutics, the former Helix Acquisition Corp. II, closed its merger on August 11, 2025 and reports gross proceeds of approximately $381.8 million. BBOT's unaudited statements show a net loss of $50,490 thousand and $42,892 thousand used in operations for the first half of 2025.BridgeBio Oncology Therapeutics, Inc. Form 8-K filed August 13, 2025 (SEC EDGAR) https://aibio.space/news/vivani-medical-agrees-sell-7-936-507-shares-1-26-private-placement/https://aibio.space/news/vivani-medical-agrees-sell-7-936-507-shares-1-26-private-placement/Wed, 13 Aug 2025 12:00:00 GMTFinancingsVivani's Share Purchase Agreement with an entity affiliated with a director and another investor is expected to close in stages through July 15, 2026. The company says the proceeds secure its financial position into the second half of 2026.Vivani Medical, Inc. Form 8-K filed August 13, 2025 (SEC EDGAR) https://aibio.space/news/enliven-therapeutics-files-automatic-shelf-200-0-million-atm/https://aibio.space/news/enliven-therapeutics-files-automatic-shelf-200-0-million-atm/Wed, 13 Aug 2025 12:00:00 GMTFinancingsThe Open Market Sale Agreement with Jefferies is dated June 23, 2023. Enliven's common stock is listed on the Nasdaq Global Select Market.Enliven Therapeutics, Inc. S-3ASR (2025-08-13) https://aibio.space/news/promis-neurosciences-files-50-000-000-shelf-up-17-988-524-share-sales/https://aibio.space/news/promis-neurosciences-files-50-000-000-shelf-up-17-988-524-share-sales/Wed, 13 Aug 2025 12:00:00 GMTFinancingsProMIS filed a $50,000,000 base shelf on Form S-3 and an at-the-market agreement with H.C. Wainwright & Co. for up to $17,988,524 of common shares, at a commission of up to 3.0%. The stock closed at $0.628 on August 11, 2025, and the supplement does not explain its float figures.ProMIS Neurosciences Inc. S-3 (2025-08-13) https://aibio.space/news/vivani-medical-agrees-10-0-million-private-placement-1-26-share/https://aibio.space/news/vivani-medical-agrees-10-0-million-private-placement-1-26-share/Wed, 13 Aug 2025 12:00:00 GMTFinancingsVivani sells 7,936,507 shares at $1.26 to two buyers, one of them tied to chairman Gregg Williams. Cash was $8.1 million at June 30, 2025, and the release presents the new money as securing its position into the second half of 2026.Vivani Medical, Inc. 8-K (2025-08-13) https://aibio.space/news/armata-pharmaceuticals-enters-15-million-secured-term-loan-innoviva-14/https://aibio.space/news/armata-pharmaceuticals-enters-15-million-secured-term-loan-innoviva-14/Tue, 12 Aug 2025 12:00:00 GMTDebt FinancingA $15 million loan from a unit of Armata's largest shareholder, Innoviva, carries a 14.0% rate, is secured by substantially all of the company's assets and matures in January 2029. Cash stood at $4.3 million on June 30, 2025.Armata Pharmaceuticals, Inc. Form 8-K filed August 12, 2025 (SEC EDGAR) https://aibio.space/news/cormedix-completes-150-000-000-convertible-senior-notes-offering-due/https://aibio.space/news/cormedix-completes-150-000-000-convertible-senior-notes-offering-due/Tue, 12 Aug 2025 12:00:00 GMTDebt FinancingCorMedix closed a $150,000,000 private placement of 4.00% convertible senior notes due 2030 on August 12, 2025. Each $1,000 of principal converts into 74.2515 common shares at the initial rate, and U.S. Bank Trust Company is trustee under the new indenture.CorMedix Inc. Form 8-K filed August 12, 2025 (SEC EDGAR) https://aibio.space/news/oric-pharmaceuticals-cuts-20-percent-workforce-closes-discovery/https://aibio.space/news/oric-pharmaceuticals-cuts-20-percent-workforce-closes-discovery/Tue, 12 Aug 2025 12:00:00 GMTDistressORIC expects a one-time cost of approximately $1.9 million for the workforce reduction. The company says cash and investments should fund its revised operating plan into 2H 2028, helped by $244 million in gross proceeds.Oric Pharmaceuticals, Inc. Form 8-K filed August 12, 2025 (SEC EDGAR) https://aibio.space/news/fate-therapeutics-approves-restructuring-12-percent-workforce/https://aibio.space/news/fate-therapeutics-approves-restructuring-12-percent-workforce/Tue, 12 Aug 2025 12:00:00 GMTDistressFate Therapeutics (Nasdaq: FATE) expects $0.9 million to $1.2 million in severance charges in the third quarter of 2025. The company says it has $249 million in cash and investments and a runway through the end of 2027.FATE THERAPEUTICS INC Form 8-K filed August 12, 2025 (SEC EDGAR) https://aibio.space/news/compass-therapeutics-prices-119-999-329-stock-warrant-offering-3-00/https://aibio.space/news/compass-therapeutics-prices-119-999-329-stock-warrant-offering-3-00/Tue, 12 Aug 2025 12:00:00 GMTFinancingsCompass is selling 33,290,000 shares and pre-funded warrants for 6,710,000 shares. Proceeds before expenses are $112,800,000.Compass Therapeutics, Inc. 424B5 (2025-08-12) https://aibio.space/news/mosaic-immunoengineering-delays-june-30-2025-quarterly-report/https://aibio.space/news/mosaic-immunoengineering-delays-june-30-2025-quarterly-report/Tue, 12 Aug 2025 12:00:00 GMTDistressMosaic ImmunoEngineering missed the 5:30 p.m. EDT August 14, 2025 deadline for its second-quarter report, citing financial reporting and close procedures. Its annual report warned it might have to cease operations if a deal with Oncotelic and note-holder waivers were not secured by June 30, 2025.Mosaic ImmunoEngineering Inc. NT 10-Q (2025-08-12) https://aibio.space/news/cormedix-completes-150-000-000-convertible-senior-notes-offering-due/https://aibio.space/news/cormedix-completes-150-000-000-convertible-senior-notes-offering-due/Tue, 12 Aug 2025 12:00:00 GMTDebt FinancingThe 4.00% notes were sold in a private placement. The initial conversion rate is 74.2515 shares of common stock per $1,000 principal amount.CorMedix Inc. 8-K (2025-08-12) https://aibio.space/news/diamedica-therapeutics-sets-up-100-0-million-market-share-program-td/https://aibio.space/news/diamedica-therapeutics-sets-up-100-0-million-market-share-program-td/Tue, 12 Aug 2025 12:00:00 GMTFinancingsDiaMedica agreed to sell up to $100.0 million of common shares through TD Securities (USA) LLC, which can earn up to 3.0% of gross proceeds. No sale can be made until the Form S-3 is declared effective, and the filings give no cash balance.DiaMedica Therapeutics Inc. S-3 (2025-08-12) https://aibio.space/news/intensity-therapeutics-regains-nasdaq-stockholders-equity-compliance/https://aibio.space/news/intensity-therapeutics-regains-nasdaq-stockholders-equity-compliance/Tue, 12 Aug 2025 12:00:00 GMTListingsNasdaq said on August 8, 2025 that Intensity meets the $2,500,000 stockholders' equity requirement. That finding rests partly on share sales made in July, and the company could still face delisting if its next periodic report does not show compliance.Intensity Therapeutics, Inc. 8-K (2025-08-12) https://aibio.space/news/oric-cuts-20-percent-staff-after-244-million-gross-financing-expects/https://aibio.space/news/oric-cuts-20-percent-staff-after-244-million-gross-financing-expects/Tue, 12 Aug 2025 12:00:00 GMTDistressThe company ended discovery research to focus on ORIC-944 and enozertinib. It does not expect to use its at-the-market facility for the foreseeable future.Oric Pharmaceuticals, Inc. 8-K (2025-08-12) https://aibio.space/news/veru-completes-1-10-reverse-stock-split-nasdaq/https://aibio.space/news/veru-completes-1-10-reverse-stock-split-nasdaq/Tue, 12 Aug 2025 12:00:00 GMTListingsVeru's 1-for-10 reverse stock split took effect at 11:59 p.m. Central time on August 8, 2025, and the stock trades split-adjusted from August 11. The 8-K gives no reason for the split and no pre-split share count.Veru Inc. 8-K (2025-08-12) https://aibio.space/news/verrica-pharmaceuticals-details-1-10-reverse-split-8-0-million-torii/https://aibio.space/news/verrica-pharmaceuticals-details-1-10-reverse-split-8-0-million-torii/Tue, 12 Aug 2025 12:00:00 GMTListingsVerrica's 1-for-10 reverse stock split took effect at the close of trading on July 24, 2025, cutting issued shares from 92,650,404 to 9,265,034. Second-quarter net income of $0.2 million depended on an $8.0 million Torii milestone.Verrica Pharmaceuticals Inc. 8-K (2025-08-12) https://aibio.space/news/x4-pharmaceuticals-agrees-60-million-private-placement-replaces-ceo/https://aibio.space/news/x4-pharmaceuticals-agrees-60-million-private-placement-replaces-ceo/Tue, 12 Aug 2025 12:00:00 GMTFinancingsStifel is sole placement agent for the PIPE, which Coastlands Capital led at $1.42 per share. Closing was expected on or about August 13, 2025.X4 Pharmaceuticals, Inc. 8-K (2025-08-12) https://aibio.space/news/biovie-closes-public-offering-units-warrants-net-proceeds-about-10-4/https://aibio.space/news/biovie-closes-public-offering-units-warrants-net-proceeds-about-10-4/Mon, 11 Aug 2025 12:00:00 GMTFinancingsThinkEquity was sole underwriter for 5,620,000 units and 380,000 pre-funded units. Warrants carry a $2.50 exercise price and trade as BIVIW; BioVie plans to use the money for working capital.BIOVIE INC. Form 8-K filed August 11, 2025 (SEC EDGAR) https://aibio.space/news/ocugen-agrees-sell-20-000-000-stock-warrants-janus-henderson-1-00/https://aibio.space/news/ocugen-agrees-sell-20-000-000-stock-warrants-janus-henderson-1-00/Mon, 11 Aug 2025 12:00:00 GMTFinancingsThe registered direct offering covers 20,000,000 shares and warrants for 20,000,000 more at $1.50. Full warrant exercise could bring up to $30 million more.Ocugen, Inc. 424B5 (2025-08-11) https://aibio.space/news/oragenics-says-series-h-preferred-raise-brought-16-5-million-gross/https://aibio.space/news/oragenics-says-series-h-preferred-raise-brought-16-5-million-gross/Mon, 11 Aug 2025 12:00:00 GMTFinancingsNet proceeds were about $15.2 million after fees and expenses. The company plans to start a Phase IIa concussion trial in Q3 2025.Oragenics Inc. 8-K (2025-08-11) https://aibio.space/news/immunitybio-gets-preliminary-court-approval-shareholder-derivative/https://aibio.space/news/immunitybio-gets-preliminary-court-approval-shareholder-derivative/Fri, 08 Aug 2025 12:00:00 GMTLegalA federal court preliminarily approved the settlement of three shareholder derivative suits naming ImmunityBio's current and former officers and directors. The company agrees to governance reforms and expects its insurer to pay the plaintiffs' attorneys' fees, which their counsel plans to ask the court to set at up to $1,400,000. The final hearing is November 4, 2025.ImmunityBio, Inc. Form 8-K filed August 8, 2025 (SEC EDGAR) https://aibio.space/news/biovie-prices-12-million-public-offering-units-2-00/https://aibio.space/news/biovie-prices-12-million-public-offering-units-2-00/Fri, 08 Aug 2025 12:00:00 GMTFinancingsBioVie priced 6,000,000 units, including pre-funded units, at $2.00 each for about $12 million. ThinkEquity is sole book-running manager, and the prospectus says the financial statements raise substantial doubt about the company's ability to continue as a going concern.BioVie Inc. 424B5 (2025-08-08) https://aibio.space/news/fibrobiologics-gets-nasdaq-notice-market-value-below-35-0-million/https://aibio.space/news/fibrobiologics-gets-nasdaq-notice-market-value-below-35-0-million/Fri, 08 Aug 2025 12:00:00 GMTListingsFibroBiologics received a Nasdaq notice that its market value of listed securities is below the $35.0 million minimum. It has until February 2, 2026 to close at or above that level for ten business days, and the 8-K gives no current market value or remedy.FibroBiologics, Inc. 8-K (2025-08-08) https://aibio.space/news/processa-pharmaceuticals-gets-second-180-day-nasdaq-period-fix-bid/https://aibio.space/news/processa-pharmaceuticals-gets-second-180-day-nasdaq-period-fix-bid/Fri, 08 Aug 2025 12:00:00 GMTListingsNasdaq has given Processa until February 2, 2026 to bring its share price back to at least $1, a second 180-day period. The company says it will consider a reverse stock split, and the filing gives no recent share price to show how far it is from the threshold.Processa Pharmaceuticals, Inc. 8-K (2025-08-08) https://aibio.space/news/estrella-immunopharma-gets-nasdaq-deficiency-notice-35-000-000-market/https://aibio.space/news/estrella-immunopharma-gets-nasdaq-deficiency-notice-35-000-000-market/Thu, 07 Aug 2025 12:00:00 GMTListingsNasdaq told Estrella on August 1, 2025 that its market value of listed securities fell below the $35,000,000 minimum. It has until January 28, 2026 to regain compliance, and its annual report for the year ended June 30, 2024 carried a going-concern warning.Estrella Immunopharma, Inc. Form 8-K filed August 7, 2025 (SEC EDGAR) https://aibio.space/news/ptc-therapeutics-pays-about-225-0-million-cancel-censa-sales-payments/https://aibio.space/news/ptc-therapeutics-pays-about-225-0-million-cancel-censa-sales-payments/Thu, 07 Aug 2025 12:00:00 GMTMergersFormer Censa securityholders holding about 90% of its equity gave up 8% to 12% net sales payments on sepiapterin. PTC will owe milestone payments of about $90.0 million each if sales reach set thresholds.PTC THERAPEUTICS, INC. Form 8-K filed August 7, 2025 (SEC EDGAR) https://aibio.space/news/processa-pharmaceuticals-sells-5-467-181-shares-1-3-million-private/https://aibio.space/news/processa-pharmaceuticals-sells-5-467-181-shares-1-3-million-private/Thu, 07 Aug 2025 12:00:00 GMTFinancingsProcessa says the private placement closed August 6, 2025, with LifeSci Capital LLC as exclusive placement agent. The company also says it is evaluating corporate cryptocurrency treasury strategies.Processa Pharmaceuticals, Inc. Form 8-K filed August 7, 2025 (SEC EDGAR) https://aibio.space/news/cormedix-buy-melinta-therapeutics-closing-targeted-early-september-1/https://aibio.space/news/cormedix-buy-melinta-therapeutics-closing-targeted-early-september-1/Thu, 07 Aug 2025 12:00:00 GMTMergersCorMedix said it will buy Melinta Therapeutics, with closing targeted as early as September 1, 2025. The company's August 7 release gives no price, no financing and no adviser for the deal.CorMedix Inc. 8-K (2025-08-07) https://aibio.space/news/ptc-therapeutics-pays-about-225-0-million-cancel-censa-sales-payments/https://aibio.space/news/ptc-therapeutics-pays-about-225-0-million-cancel-censa-sales-payments/Thu, 07 Aug 2025 12:00:00 GMTMergersPTC paid about $225.0 million in cash to former Censa holders who gave up their share of sepiapterin sales, and it is still obligated to make five milestone payments of about $90.0 million each. The filing does not say what the rights were worth.PTC Therapeutics, Inc. 8-K (2025-08-07) https://aibio.space/news/adma-biologics-enters-300-million-credit-agreement-led-j-p-morgan/https://aibio.space/news/adma-biologics-enters-300-million-credit-agreement-led-j-p-morgan/Wed, 06 Aug 2025 12:00:00 GMTDebt FinancingThe agreement provides a $75 million term loan and a $225 million revolving credit facility, both maturing August 5, 2028. ADMA used the proceeds to pay off its earlier facility with Ares Capital Corporation.ADMA BIOLOGICS, INC. Form 8-K filed August 6, 2025 (SEC EDGAR) https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-keeps-120-million/https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-keeps-120-million/Wed, 06 Aug 2025 12:00:00 GMTFinancingsHelix says about $120 million remains in trust after redemptions, and that a $261 million private placement led by Cormorant Asset Management would bring the merger with BBOT to about $382 million gross.BridgeBio Oncology Therapeutics, Inc. 8-K (2025-08-06) https://aibio.space/news/cosmos-health-signs-note-facility-up-300-million-ethereum-treasury/https://aibio.space/news/cosmos-health-signs-note-facility-up-300-million-ethereum-treasury/Wed, 06 Aug 2025 12:00:00 GMTFinancingsCosmos Health agreed to issue up to $300 million of senior secured convertible promissory notes, with at least 72.5% of each tranche's net proceeds going to an Ethereum reserve. Curvature Securities, LLC was the sole placement agent, and the release gives no note terms or investor name.Cosmos Health Inc. 8-K (2025-08-06) https://aibio.space/news/oncotelic-therapeutics-issues-560-000-secured-convertible-note-mast/https://aibio.space/news/oncotelic-therapeutics-issues-560-000-secured-convertible-note-mast/Wed, 06 Aug 2025 12:00:00 GMTDebt FinancingOncotelic's $560,000 note converts at a fixed $0.07 per share and carries 10% interest, and a separate equity purchase agreement with the same lender could add up to $25 million of stock sales.Oncotelic Therapeutics, Inc. 8-K (2025-08-06) https://aibio.space/news/sana-biotechnology-prices-75-0-million-offering-3-35-share/https://aibio.space/news/sana-biotechnology-prices-75-0-million-offering-3-35-share/Wed, 06 Aug 2025 12:00:00 GMTFinancingsSana sold 20,895,522 shares at $3.35 plus pre-funded warrants for 1,492,537 more, with about $70.0 million in estimated net proceeds. It reported about $90.1 million in cash at July 31, 2025 and estimates $40.0 million to $45.0 million in facility impairments.Sana Biotechnology, Inc. 424B5 (2025-08-06) https://aibio.space/news/nutriband-distributes-3-million-series-preferred-shares-convertible/https://aibio.space/news/nutriband-distributes-3-million-series-preferred-shares-convertible/Tue, 05 Aug 2025 12:00:00 GMTFinancingsHolders got one non-voting preferred share for every four common shares. The shares convert one-for-one only after FDA approval of an AVERSA-based product.NTRB 8-K https://aibio.space/news/bon-natural-life-says-nasdaq-closed-bid-price-matter-one-year-panel/https://aibio.space/news/bon-natural-life-says-nasdaq-closed-bid-price-matter-one-year-panel/Tue, 05 Aug 2025 12:00:00 GMTListingsBon Natural Life says Nasdaq has closed its bid price matter after the Hearings Panel decision, but the company stays under a one-year Discretionary Panel Monitor. The Nasdaq confirmation came on July 29, 2025, and the company reported it in a Form 6-K dated August 4, 2025.Bon Natural Life Limited 6-K (2025-08-05) https://aibio.space/news/ocean-biomedicals-nasdaq-delisting-becomes-final-after-board-declines/https://aibio.space/news/ocean-biomedicals-nasdaq-delisting-becomes-final-after-board-declines/Tue, 05 Aug 2025 12:00:00 GMTListingsNasdaq's board declined to review a May 15, 2025 Listing Council decision, making it Nasdaq's final action. The company's chief financial officer and a director have also resigned.Ocean Biomediacal, Inc. 8-K (2025-08-05) https://aibio.space/news/intensity-therapeutics-raises-6-6-million-july-2025-market-sales/https://aibio.space/news/intensity-therapeutics-raises-6-6-million-july-2025-market-sales/Mon, 04 Aug 2025 12:00:00 GMTFinancingsIntensity sold 19,868,658 shares at an average of $0.3323 each under its at-the-market program in July 2025. The company says its cash now reaches into the second half of 2026, but the release gives no cash balance.Intensity Therapeutics, Inc. 8-K (2025-08-04) https://aibio.space/news/exicure-regains-compliance-nasdaq-periodic-filing-rule/https://aibio.space/news/exicure-regains-compliance-nasdaq-periodic-filing-rule/Mon, 04 Aug 2025 12:00:00 GMTListingsExicure said it met Listing Rule 5250(c)(1) as of July 1, 2025, after filing its Form 10-Q for the quarter ended March 31, 2025.Exicure, Inc. 8-K (2025-08-04) https://aibio.space/news/protalix-says-delaware-stockholder-class-action-bylaws-dismissed-160/https://aibio.space/news/protalix-says-delaware-stockholder-class-action-bylaws-dismissed-160/Fri, 01 Aug 2025 12:00:00 GMTLegalA Delaware stockholder class action against Protalix BioTherapeutics and its board, Thomas v. Bashan, et al., was dismissed as to the plaintiff after the board amended the bylaws. Protalix agreed to pay $160,000 in fees and expenses to the plaintiff's counsel, and it denies the allegations.Protalix BioTherapeutics, Inc. Form 8-K filed August 1, 2025 (SEC EDGAR) https://aibio.space/news/celcuity-completes-201-250-000-offering-2-750-percent-convertible/https://aibio.space/news/celcuity-completes-201-250-000-offering-2-750-percent-convertible/Fri, 01 Aug 2025 12:00:00 GMTDebt FinancingCelcuity (Nasdaq: CELC) sold $201,250,000 of 2.750% convertible notes due 2031, including an over-allotment option the underwriters exercised on July 30, 2025. The notes convert at an initial price of about $51.30 per share, and the company sold stock and pre-funded warrants in a separate, concurrent offering.Celcuity Inc. Form 8-K filed August 1, 2025 (SEC EDGAR) https://aibio.space/news/alzamend-neuro-issues-243-429-shares-series-b-preferred-conversions/https://aibio.space/news/alzamend-neuro-issues-243-429-shares-series-b-preferred-conversions/Fri, 01 Aug 2025 12:00:00 GMTFinancingsAlzamend Neuro (Nasdaq: ALZN) issued 243,429 common shares between July 23 and July 30, 2025 on conversion of Series B Convertible Preferred Stock. It had 3,139,861 common shares outstanding on July 30.Alzamend Neuro, Inc. Form 8-K filed August 1, 2025 (SEC EDGAR) https://aibio.space/news/geovax-receives-nasdaq-bid-price-deficiency-notice-has-until-january/https://aibio.space/news/geovax-receives-nasdaq-bid-price-deficiency-notice-has-until-january/Fri, 01 Aug 2025 12:00:00 GMTListingsGeoVax's closing bid price was below $1.00 for 30 consecutive business days, according to a July 31, 2025 deficiency letter. The first deadline is January 27, 2026, and a second 180-day period is possible.GeoVax Labs, Inc. 8-K (2025-08-01) https://aibio.space/news/ibio-receives-nasdaq-notice-trading-below-1-00-minimum-bid-price/https://aibio.space/news/ibio-receives-nasdaq-notice-trading-below-1-00-minimum-bid-price/Fri, 01 Aug 2025 12:00:00 GMTListingsThe company has until January 26, 2026 to regain compliance. Its shares keep trading on The Nasdaq Capital Market under the symbol IBIO for now.iBio, Inc. 8-K (2025-08-01) https://aibio.space/news/neonc-technologies-signs-up-50-million-investment-deal-quazar-25-share/https://aibio.space/news/neonc-technologies-signs-up-50-million-investment-deal-quazar-25-share/Fri, 01 Aug 2025 12:00:00 GMTMergersQuazar Investment would buy 1.4 million shares and fund trials and infrastructure in the UAE and MENA region. Closing still depends on a capital formation round.NeOnc Technologies Holdings, Inc. 8-K (2025-08-01) https://aibio.space/news/supernus-completes-sage-therapeutics-acquisition-after-tender-offer-8/https://aibio.space/news/supernus-completes-sage-therapeutics-acquisition-after-tender-offer-8/Thu, 31 Jul 2025 12:00:00 GMTMergersSupernus completed its acquisition of Sage Therapeutics on July 31, 2025 after a tender offer, paying $8.50 in cash per share plus a contingent value right worth up to $3.50. The filing puts the cash consideration at about $561 million, and says no CVR payment is assured.SUPERNUS PHARMACEUTICALS, INC. Form 8-K filed July 31, 2025 (SEC EDGAR) https://aibio.space/news/adaptimmune-sells-cell-therapy-assets-us-worldmeds-55-million-upfront/https://aibio.space/news/adaptimmune-sells-cell-therapy-assets-us-worldmeds-55-million-upfront/Thu, 31 Jul 2025 12:00:00 GMTMergersAdaptimmune sold its TECELRA, lete-cel, afami-cel and uza-cel cell therapies to a US WorldMeds subsidiary for $55 million in cash at closing, with up to $30 million more on milestones. The $134 million gain is a pro forma estimate built on March 31, 2025 values.Adaptimmune Therapeutics plc 8-K (2025-07-31) https://aibio.space/news/veraxa-biotech-holding-ag-now-veraxa-biotech-ag-files-f-4-voyager-spac/https://aibio.space/news/veraxa-biotech-holding-ag-now-veraxa-biotech-ag-files-f-4-voyager-spac/Thu, 31 Jul 2025 12:00:00 GMTMergersThe Form F-4 for Veraxa Biotech Holding AG is dated July 16, 2025 and covers the business combination with Voyager Acquisition Corp. under an agreement dated April 22, 2025. The date of Voyager's shareholder meeting is still blank.Veraxa Biotech AG F-4 (2025-07-31) https://aibio.space/news/propanc-biopharma-sells-112-350-convertible-note-107-000-22-percent/https://aibio.space/news/propanc-biopharma-sells-112-350-convertible-note-107-000-22-percent/Wed, 30 Jul 2025 12:00:00 GMTDebt FinancingPropanc Biopharma sold a $112,350 convertible note to 1800 Diagonal Lending LLC for $107,000. The note bears 22% interest, matures April 30, 2026 and converts at a 25% discount after 180 days, in a stock its last annual report says was quoted at $0.0003.Propanc Biopharma, Inc. Form 8-K filed July 30, 2025 (SEC EDGAR) https://aibio.space/news/aim-immunotech-prices-8-0-million-unit-offering-works-fix-equity/https://aibio.space/news/aim-immunotech-prices-8-0-million-unit-offering-works-fix-equity/Wed, 30 Jul 2025 12:00:00 GMTFinancingsAIM ImmunoTech sold units at $4.00 with two warrants each, a month after a 1-for-100 reverse split, and its prospectus says there is likely substantial doubt about its ability to continue as a going concern. It must lift stockholders' equity to at least $6 million by June 11, 2026.AIM ImmunoTech Inc. 424B5 (2025-07-30) https://aibio.space/news/dyadic-international-prices-6-052-000-share-offering-0-95-below-last/https://aibio.space/news/dyadic-international-prices-6-052-000-share-offering-0-95-below-last/Wed, 30 Jul 2025 12:00:00 GMTFinancingsGross proceeds would be $5,749,400. The price compares with a last reported sale of $1.1750 on July 29, 2025. An executive agreed to buy 26,000 shares.Dyadic International, Inc. 424B5 (2025-07-30) https://aibio.space/news/prime-medicine-prices-38-000-000-share-offering-3-30-125-400-000-gross/https://aibio.space/news/prime-medicine-prices-38-000-000-share-offering-3-30-125-400-000-gross/Wed, 30 Jul 2025 12:00:00 GMTFinancingsPrime sold 38,000,000 shares at $3.30, below the $3.83 closing price on July 29, 2025. The estimated net proceeds are $120.2 million, and the auditor's 2024 report carries a going-concern paragraph.Prime Medicine, Inc. 424B5 (2025-07-30) https://aibio.space/news/ikena-oncology-now-imagenebio-completes-inmagene-merger-issues/https://aibio.space/news/ikena-oncology-now-imagenebio-completes-inmagene-merger-issues/Tue, 29 Jul 2025 12:00:00 GMTMergersIkena Oncology, now ImageneBio, closed its merger with Inmagene Biopharmaceuticals on July 25, 2025. It issued contingent value rights to both sets of shareholders, which pay only from proceeds of selected assets, and it took on a transition services deal with a company owned by Inmagene's legacy holders.ImageneBio, Inc. Form 8-K filed July 29, 2025 (SEC EDGAR) https://aibio.space/news/merck-approves-2025-restructuring-program-about-3-0-billion-pretax/https://aibio.space/news/merck-approves-2025-restructuring-program-about-3-0-billion-pretax/Tue, 29 Jul 2025 12:00:00 GMTDistressMerck expects to eliminate certain positions in sales, administrative and research and development organizations and expects annual savings of approximately $1.7 billion, substantially realized by the end of 2027.Merck & Co., Inc. Form 8-K filed July 29, 2025 (SEC EDGAR) https://aibio.space/news/splash-beverage-group-now-endovia-health-sciences-faces-nyse-american/https://aibio.space/news/splash-beverage-group-now-endovia-health-sciences-faces-nyse-american/Tue, 29 Jul 2025 12:00:00 GMTListingsThe exchange suspended trading in the company's $184.00 warrants because of their low trading price. The common stock is not affected.Endovia Health Sciences, Inc. 8-K (2025-07-29) https://aibio.space/news/immunoprecise-antibodies-now-mindwalk-holdings-reports-fiscal-2025/https://aibio.space/news/immunoprecise-antibodies-now-mindwalk-holdings-reports-fiscal-2025/Tue, 29 Jul 2025 12:00:00 GMTListingsRevenue was $24.5 million in both fiscal 2025 and fiscal 2024, and the net loss widened to $30.2 million from $26.1 million. The release gives no date for the regained Nasdaq compliance.MindWalk Holdings Corp. 6-K (2025-07-29) https://aibio.space/news/imagenebio-says-ikena-oncology-imagene-merger-completed-july-2025/https://aibio.space/news/imagenebio-says-ikena-oncology-imagene-merger-completed-july-2025/Tue, 29 Jul 2025 12:00:00 GMTMergersA July 2025 corporate overview says the merger closed and that the company has raised $140 million to date. Its lead drug, IMG-007, is in a Phase 2b trial in atopic dermatitis.ImageneBio, Inc. 8-K (2025-07-29) https://aibio.space/news/ocugen-regains-compliance-nasdaq-1-00-minimum-bid-price-rule/https://aibio.space/news/ocugen-regains-compliance-nasdaq-1-00-minimum-bid-price-rule/Tue, 29 Jul 2025 12:00:00 GMTListingsOcugen's stock closed at or above $1.00 for ten business days from July 8, 2025 to July 25, 2025. Nasdaq said on July 28, 2025, that the matter is closed.Ocugen, Inc. 8-K (2025-07-29) https://aibio.space/news/passage-bio-regains-compliance-nasdaq-minimum-bid-price-rule/https://aibio.space/news/passage-bio-regains-compliance-nasdaq-minimum-bid-price-rule/Tue, 29 Jul 2025 12:00:00 GMTListingsNasdaq confirmed on July 28, 2025 that Passage Bio's shares had closed at $1.00 or more for at least 10 consecutive business days, closing a matter that began in August 2024.Passage Bio, Inc. 8-K (2025-07-29) https://aibio.space/news/pharmacyte-biotech-delays-annual-report-year-ended-april-30-2025/https://aibio.space/news/pharmacyte-biotech-delays-annual-report-year-ended-april-30-2025/Tue, 29 Jul 2025 12:00:00 GMTDistressThe company said it needs more time to prepare and review its financial statements. It plans to file within 15 days of the July 29, 2025 due date.PharmaCyte Biotech, Inc. NT 10-K (2025-07-29) https://aibio.space/news/cingulate-reports-unregistered-share-issuances-lender-exchange-debt/https://aibio.space/news/cingulate-reports-unregistered-share-issuances-lender-exchange-debt/Fri, 25 Jul 2025 12:00:00 GMTFinancingsCingulate reported on July 25, 2025 that it issued common stock in three transactions with a lender, in exchange for part of the debt it owes, at $4.18 to $4.79 a share. The filing also covers a 7,538-share issuance to a service provider and a 30,000-share officer option grant. It names no bank or placement agent.Cingulate Inc. Form 8-K filed July 25, 2025 (SEC EDGAR) https://aibio.space/news/palisade-bio-sets-0-9047-warrant-inducement-about-3-9-million-gross/https://aibio.space/news/palisade-bio-sets-0-9047-warrant-inducement-about-3-9-million-gross/Fri, 25 Jul 2025 12:00:00 GMTFinancingsA holder will exercise 4,318,905 Palisade warrants at a reduced price and receive new warrants for up to 8,637,810 shares. Ladenburg Thalmann is the placement agent.PALISADE BIO, INC. Form 8-K filed July 25, 2025 (SEC EDGAR) https://aibio.space/news/anavex-signs-market-sales-agreement-td-cowen-up-150-million/https://aibio.space/news/anavex-signs-market-sales-agreement-td-cowen-up-150-million/Fri, 25 Jul 2025 12:00:00 GMTFinancingsThe company may sell common stock from time to time but is not obligated to sell any. TD Cowen can earn up to 3.0% in commissions.Anavex Life Sciences Corp. 424B5 (2025-07-25) https://aibio.space/news/chemomab-signs-market-agreement-lifesci-capital-up-7-258-687/https://aibio.space/news/chemomab-signs-market-agreement-lifesci-capital-up-7-258-687/Fri, 25 Jul 2025 12:00:00 GMTFinancingsThe Israeli company may sell American depositary shares from time to time and is not obligated to sell any. LifeSci Capital will earn a 3.0% commission.Chemomab Therapeutics Ltd. 424B5 (2025-07-25) https://aibio.space/news/cytodyn-files-100-000-000-shelf-registration-stock-warrants-units/https://aibio.space/news/cytodyn-files-100-000-000-shelf-registration-stock-warrants-units/Fri, 25 Jul 2025 12:00:00 GMTFinancingsCytoDyn filed a Form S-3 shelf that would let it offer up to $100,000,000 of stock, warrants, subscription rights and units. The stock is quoted on the OTCQB, where it closed at $0.29 on July 24, 2025, and the shelf cannot be used until it takes effect.CytoDyn Inc. S-3 (2025-07-25) https://aibio.space/news/lyell-immunopharma-signs-private-placement-up-100-million-13-32-share/https://aibio.space/news/lyell-immunopharma-signs-private-placement-up-100-million-13-32-share/Fri, 25 Jul 2025 12:00:00 GMTFinancingsLyell's private placement starts with about $50 million at $13.32 per share. A second $50 million at $25.61 per share depends on a milestone within 12 months.Lyell Immunopharma, Inc. 8-K (2025-07-25) https://aibio.space/news/omeros-prices-22-million-registered-direct-offering-4-10-share/https://aibio.space/news/omeros-prices-22-million-registered-direct-offering-4-10-share/Fri, 25 Jul 2025 12:00:00 GMTFinancingsPolar Asset Management Partners is buying 5,365,853 shares at a premium of approximately 14% to the closing price on the agreement date. Closing was expected on or about July 28, 2025.Omeros Corporation 424B5 (2025-07-25) https://aibio.space/news/processa-pharmaceuticals-registers-up-5-239-073-market-stock-sales/https://aibio.space/news/processa-pharmaceuticals-registers-up-5-239-073-market-stock-sales/Fri, 25 Jul 2025 12:00:00 GMTFinancingsProcessa filed a new prospectus supplement that lets it sell up to $5,239,073 of stock through its at-the-market program with A.G.P./Alliance Global Partners. Its shares closed at $0.2497 on July 22, 2025, down from $0.40 on June 11, 2025, the date its public float was measured.Processa Pharmaceuticals, Inc. 424B5 (2025-07-25) https://aibio.space/news/advanced-biomed-gets-nasdaq-bid-price-notice-has-until-january-14-2026/https://aibio.space/news/advanced-biomed-gets-nasdaq-bid-price-notice-has-until-january-14-2026/Thu, 24 Jul 2025 12:00:00 GMTListingsThe stock closed below $1.00 for 32 consecutive business days. Shares keep trading on the Nasdaq Capital Market under ADVB during the compliance period.Advanced Biomed Inc. 8-K (2025-07-24) https://aibio.space/news/incannex-healthcare-adds-up-100-000-000-market-stock-program/https://aibio.space/news/incannex-healthcare-adds-up-100-000-000-market-stock-program/Thu, 24 Jul 2025 12:00:00 GMTFinancingsIncannex had already sold about $63,469,250 of stock under the program. A week later it said it has no plans to use the full capacity in the near term.Incannex Healthcare Inc. 424B5 (2025-07-24) https://aibio.space/news/rocket-pharmaceuticals-starts-restructuring-workforce-reduction-about/https://aibio.space/news/rocket-pharmaceuticals-starts-restructuring-workforce-reduction-about/Wed, 23 Jul 2025 12:00:00 GMTDistressRocket says the plan, approved by its board on June 18, 2025, aims to extend its operational runway into the second quarter of 2027. The company expects about $3.5 million in charges in the second half of 2025, against a 2024 operating cash outflow of $209.7 million.ROCKET PHARMACEUTICALS, INC. Form 8-K filed July 23, 2025 (SEC EDGAR) https://aibio.space/news/adicet-bio-announces-workforce-reduction-about-30-percent-ends-adi-270/https://aibio.space/news/adicet-bio-announces-workforce-reduction-about-30-percent-ends-adi-270/Wed, 23 Jul 2025 12:00:00 GMTDistressAdicet's board approved a cut of about 30% of its workforce on July 22, 2025 and ended its ADI-270 cancer program. The company expects about $2.3 million in charges and a cash runway into the fourth quarter of 2026, after a $117.1 million net loss in 2024.Adicet Bio, Inc. Form 8-K filed July 23, 2025 (SEC EDGAR) https://aibio.space/news/oramed-gives-scilex-option-buy-back-warrants-27-000-000/https://aibio.space/news/oramed-gives-scilex-option-buy-back-warrants-27-000-000/Wed, 23 Jul 2025 12:00:00 GMTFinancingsScilex will pay a $1,500,000 option fee in two installments. If the buyback is completed and paid in full, the maturity of the Tranche A Note moves to March 31, 2026.Oramed Pharmaceuticals Inc. 8-K (2025-07-23) https://aibio.space/news/lantheus-completes-life-molecular-imaging-acquisition-350-million/https://aibio.space/news/lantheus-completes-life-molecular-imaging-acquisition-350-million/Tue, 22 Jul 2025 12:00:00 GMTMergersLantheus closed the acquisition on July 21, 2025 and named Dr. Ludger Dinkelborg Head of Research and Development, effective August 1, 2025. The deal adds the Alzheimer's PET imaging agent Neuraceq.Lantheus Holdings, Inc. Form 8-K filed July 22, 2025 (SEC EDGAR) https://aibio.space/news/diamedica-therapeutics-agrees-30-1-million-private-placement-existing/https://aibio.space/news/diamedica-therapeutics-agrees-30-1-million-private-placement-existing/Mon, 21 Jul 2025 12:00:00 GMTFinancingsDiaMedica will sell 8,606,426 common shares at $3.50 each, for expected gross proceeds of $30.1 million before fees. The 8-K names no placement agent, and the company used $22,076 thousand in operations in 2024 while its equity fell to $40,718 thousand.DiaMedica Therapeutics Inc. Form 8-K filed July 21, 2025 (SEC EDGAR) https://aibio.space/news/sab-biotherapeutics-agrees-175-million-private-placement-sanofi/https://aibio.space/news/sab-biotherapeutics-agrees-175-million-private-placement-sanofi/Mon, 21 Jul 2025 12:00:00 GMTFinancingsSAB Biotherapeutics expects about $175 million in gross proceeds from Series B preferred stock, convertible into 100,000,000 common shares at $1.75. Warrants could bring in up to $284 million more, and the conversion rights wait on a stockholder vote.SAB Biotherapeutics, Inc. Form 8-K filed July 21, 2025 (SEC EDGAR) https://aibio.space/news/sab-biotherapeutics-agrees-175-million-private-placement-sanofi/https://aibio.space/news/sab-biotherapeutics-agrees-175-million-private-placement-sanofi/Mon, 21 Jul 2025 12:00:00 GMTFinancingsSAB will issue convertible preferred stock convertible at $1.75 per share, plus warrants that could bring up to $284 million more if exercised in full. It expects cash to last into the middle of 2028.SAB Biotherapeutics, Inc. 8-K (2025-07-21) https://aibio.space/news/abeona-therapeutics-cuts-term-loan-rate-11-75-percent-issues-avenue/https://aibio.space/news/abeona-therapeutics-cuts-term-loan-rate-11-75-percent-issues-avenue/Fri, 18 Jul 2025 12:00:00 GMTDebt FinancingAbeona Therapeutics lowered the rate on its senior secured term loan from 13.5% to a fixed 11.75% and gave the Avenue lenders warrants for up to 16,474 shares at $6.07. Its 2024 net loss was $63.7 million, and its 10-K says $98.1 million in year-end cash and investments, plus later at-the-market proceeds, covers at least 12 months from issuance.ABEONA THERAPEUTICS INC. Form 8-K filed July 18, 2025 (SEC EDGAR) https://aibio.space/news/neuphoria-therapeutics-gets-nasdaq-notice-annual-meeting-requirement/https://aibio.space/news/neuphoria-therapeutics-gets-nasdaq-notice-annual-meeting-requirement/Fri, 18 Jul 2025 12:00:00 GMTListingsNeuphoria Therapeutics received a Nasdaq notice that it did not hold an annual meeting within a year of its June 30, 2024 fiscal year end. It has until September 1, 2025 to submit a plan, and its annual report for that year carries a going-concern warning with cash that, combined with an ATM facility, is expected to fund work into late in the first quarter of fiscal 2026.Neuphoria Therapeutics Inc. Form 8-K filed July 18, 2025 (SEC EDGAR) https://aibio.space/news/nasdaq-files-form-25-delist-avenue-therapeutics-common-stock/https://aibio.space/news/nasdaq-files-form-25-delist-avenue-therapeutics-common-stock/Fri, 18 Jul 2025 12:00:00 GMTListingsThe Nasdaq Stock Market LLC filed a Form 25-NSE on July 18, 2025, to remove Avenue Therapeutics common stock from listing and registration.Avenue Therapeutics, Inc. 25-NSE (2025-07-18) https://aibio.space/news/60-degrees-pharmaceuticals-prices-5-million-offering-warrants-5/https://aibio.space/news/60-degrees-pharmaceuticals-prices-5-million-offering-warrants-5/Fri, 18 Jul 2025 12:00:00 GMTFinancings60 Degrees Pharmaceuticals priced 2,631,578 shares at $1.90 with warrants. About $5 million comes in up front, and the short-term warrants could bring in about $5 million more only if fully exercised for cash.60 Degrees Pharmaceuticals, Inc. 8-K (2025-07-18) https://aibio.space/news/gain-therapeutics-prices-public-offering-shares-warrants-7-0-million/https://aibio.space/news/gain-therapeutics-prices-public-offering-shares-warrants-7-0-million/Thu, 17 Jul 2025 12:00:00 GMTFinancingsGain agreed to sell 4,501,640 shares and warrants for 2,250,820 shares at $3.11 per set through Newbridge Securities. It expects net proceeds of approximately $6.3 million, with closing expected on or about July 17, 2025.Gain Therapeutics, Inc. Form 8-K filed July 17, 2025 (SEC EDGAR) https://aibio.space/news/connect-biopharma-regains-compliance-nasdaq-1-00-minimum-bid-price/https://aibio.space/news/connect-biopharma-regains-compliance-nasdaq-1-00-minimum-bid-price/Thu, 17 Jul 2025 12:00:00 GMTListingsThe company's American Depositary Shares closed at $1.00 or more for 10 straight business days, ending a deficiency first flagged on March 24, 2025.Connect Biopharma Holdings Limited 8-K (2025-07-17) https://aibio.space/news/i-mab-now-novabridge-biosciences-buy-bridge-health-biotech-1-8-million/https://aibio.space/news/i-mab-now-novabridge-biosciences-buy-bridge-health-biotech-1-8-million/Thu, 17 Jul 2025 12:00:00 GMTMergersThe deal gives the company rights tied to the antibody in its lead drug candidate, givastomig, and removes royalties owed on it. The efficacy figure behind the program is early and comes from a dose escalation study of 17 patients.NovaBridge Biosciences 6-K (2025-07-17) https://aibio.space/news/windtree-agrees-60-million-preferred-stock-sale-fund-bnb-treasury/https://aibio.space/news/windtree-agrees-60-million-preferred-stock-sale-fund-bnb-treasury/Thu, 17 Jul 2025 12:00:00 GMTFinancingsWindtree agreed on July 16, 2025 to sell about 60,000 shares of Series E preferred stock with warrants, and to use the money to buy BNB. The deal cannot close until shareholders approve it, and it lapses if approval is not obtained within 120 days.Windtree Therapeutics, Inc. 8-K (2025-07-17) https://aibio.space/news/cell-source-keeps-filing-delayed-reports-after-july-2025-form-15/https://aibio.space/news/cell-source-keeps-filing-delayed-reports-after-july-2025-form-15/Wed, 16 Jul 2025 12:00:00 GMTListingsCell Source's July 16, 2025 Form 15 checked the rule for suspending reporting duties. Its later filing list shows more reports, and in January 2026 the company said it was preparing a Nasdaq uplist.SEC EDGAR: Cell Source 15-12G https://aibio.space/news/indaptus-therapeutics-regains-nasdaq-compliance-1-00-bid-price-rule/https://aibio.space/news/indaptus-therapeutics-regains-nasdaq-compliance-1-00-bid-price-rule/Wed, 16 Jul 2025 12:00:00 GMTListingsThe stock closed at $1.00 or higher for 10 consecutive business days from June 27, 2025 to July 11, 2025. Nasdaq considers the matter closed.Indaptus Therapeutics, Inc. 8-K (2025-07-16) https://aibio.space/news/onconetix-signs-merger-deal-ocuvex-ocuvex-holders-would-own-90-percent/https://aibio.space/news/onconetix-signs-merger-deal-ocuvex-ocuvex-holders-would-own-90-percent/Wed, 16 Jul 2025 12:00:00 GMTMergersOnconetix holders would keep 10% of the combined company. Closing was expected in the fourth quarter of 2025, subject to regulatory, stockholder and third-party approvals.Onconetix, Inc. 8-K (2025-07-16) https://aibio.space/news/imunon-gets-nasdaq-hearing-panel-exception-after-delisting/https://aibio.space/news/imunon-gets-nasdaq-hearing-panel-exception-after-delisting/Mon, 14 Jul 2025 12:00:00 GMTListingsThe panel granted the exception on July 11, 2025, so Imunon can regain compliance with the $1.00 minimum bid price and the stockholders' equity requirement. Stockholders also approved 2,000,000 more plan shares, bringing the plan's limit to 3,970,000.Imunon, Inc. Form 8-K filed July 14, 2025 (SEC EDGAR) https://aibio.space/news/prokidney-sets-up-market-program-up-200-000-000-stock-jefferies/https://aibio.space/news/prokidney-sets-up-market-program-up-200-000-000-stock-jefferies/Mon, 14 Jul 2025 12:00:00 GMTFinancingsJefferies earns up to 3.0% of gross proceeds on the new $200,000,000 program. The stock last sold at $4.54 on July 11, 2025, and the second dosing group in the Phase 2 REGEN-007 trial missed statistical significance.ProKidney Corp. 424B5 (2025-07-14) https://aibio.space/news/artelo-biosciences-updated-2024-statements-carry-auditor-going-concern/https://aibio.space/news/artelo-biosciences-updated-2024-statements-carry-auditor-going-concern/Fri, 11 Jul 2025 12:00:00 GMTDistressMaloneBailey said recurring losses and a net capital deficiency raise substantial doubt. Stockholders' equity fell to $2,857 thousand from $11,752 thousand.Artelo Biosciences, Inc. 8-K (2025-07-11) https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics-says-s-4/https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics-says-s-4/Fri, 11 Jul 2025 12:00:00 GMTMergersThe shell company says the registration statement for its merger with BBOT is effective and set a shareholder meeting for August 4, 2025, but the release gives no deal value or minimum cash figure.BridgeBio Oncology Therapeutics, Inc. 8-K (2025-07-11) https://aibio.space/news/nasdaq-files-form-25-remove-bio-path-holdings-common-stock-listing/https://aibio.space/news/nasdaq-files-form-25-remove-bio-path-holdings-common-stock-listing/Fri, 11 Jul 2025 12:00:00 GMTListingsNasdaq Stock Market LLC filed a Form 25 notification dated July 11, 2025 to strike Bio-Path Holdings' common stock from listing and registration. The notice cites Exchange Act Rule 12d2-2(b), which covers removals the exchange initiates, and it does not give the reason.Bio-Path Holdings, Inc. 25-NSE (2025-07-11) https://aibio.space/news/i-mab-now-novabridge-biosciences-lifts-ads-sale-limit-50-000-000/https://aibio.space/news/i-mab-now-novabridge-biosciences-lifts-ads-sale-limit-50-000-000/Fri, 11 Jul 2025 12:00:00 GMTFinancingsThe amendment raises the amount of American depositary shares the company may sell under a sales agreement with Leerink Partners. It has not sold any under the agreement so far.NovaBridge Biosciences 424B5 (2025-07-11) https://aibio.space/news/rani-therapeutics-registers-resale-13-160-172-series-d-warrant-shares/https://aibio.space/news/rani-therapeutics-registers-resale-13-160-172-series-d-warrant-shares/Fri, 11 Jul 2025 12:00:00 GMTFinancingsRani Therapeutics filed a resale prospectus on July 11, 2025 covering up to 13,160,172 Class A shares issuable on exercise of a Series D warrant. The company says it will receive no proceeds from the resale itself.Rani Therapeutics Holdings, Inc. 424B5 (2025-07-11) https://aibio.space/news/denali-capital-now-semnur-pharmaceuticals-extends-spac-deadline-august/https://aibio.space/news/denali-capital-now-semnur-pharmaceuticals-extends-spac-deadline-august/Fri, 11 Jul 2025 12:00:00 GMTMergersDenali Capital deposited $874.78 into its trust account to extend its deadline by one month, to August 11, 2025. The blank-check company's units, shares and warrants now trade on the Pink market and the OTCQB, and it remains a shell company that depends on monthly extensions.Semnur Pharmaceuticals Inc. 425 (2025-07-11) https://aibio.space/news/pacira-biosciences-announces-workforce-reduction-71-employees-about-8/https://aibio.space/news/pacira-biosciences-announces-workforce-reduction-71-employees-about-8/Thu, 10 Jul 2025 12:00:00 GMTDistressPacira is shutting down its 45-liter EXPAREL suite in San Diego and cutting 71 employees, about 8% of its workforce. It expects $2.4 million to $2.8 million of cash charges in the third quarter and about $13 million a year in lower operating expenses.Pacira BioSciences, Inc. Form 8-K filed July 10, 2025 (SEC EDGAR) https://aibio.space/news/jupiter-neurosciences-regains-compliance-nasdaq-1-00-minimum-bid-price/https://aibio.space/news/jupiter-neurosciences-regains-compliance-nasdaq-1-00-minimum-bid-price/Thu, 10 Jul 2025 12:00:00 GMTListingsNasdaq confirmed on July 9, 2025 that Jupiter's stock held an average closing price of at least $1.00 over 13 days. The company's last annual report still carries a going concern warning.Jupiter Neurosciences, Inc. 8-K (2025-07-10) https://aibio.space/news/pacira-biosciences-cuts-about-70-jobs-decommissions-45-liter-exparel/https://aibio.space/news/pacira-biosciences-cuts-about-70-jobs-decommissions-45-liter-exparel/Thu, 10 Jul 2025 12:00:00 GMTDistressPacira is closing its 45-liter EXPAREL manufacturing system and cutting about 70 Technical Operations jobs, and the employee note it filed says the larger 200-liter process in San Diego and Swindon now supplies the product.Pacira BioSciences, Inc. 8-K (2025-07-10) https://aibio.space/news/vor-bio-names-sandy-mahatme-cfo-grants-13-882-750-inducement-rsus/https://aibio.space/news/vor-bio-names-sandy-mahatme-cfo-grants-13-882-750-inducement-rsus/Thu, 10 Jul 2025 12:00:00 GMTListingsVor Bio appointed Sandy Mahatme as chief financial officer and chief business officer effective July 9, 2025, and granted him 13,882,750 restricted stock units under Nasdaq's inducement rule. The release gives no share count or grant value to compare that award with.Vor Biopharma Inc. 8-K (2025-07-10) https://aibio.space/news/jasper-therapeutics-cuts-workforce-about-50-percent-halts-other/https://aibio.space/news/jasper-therapeutics-cuts-workforce-about-50-percent-halts-other/Wed, 09 Jul 2025 12:00:00 GMTDistressJasper's board approved a corporate reorganization on July 8, 2025. The company will focus on briquilimab in chronic urticaria, expects $1.8 million to $2.2 million in severance cash costs, and its chief medical officer is leaving.Jasper Therapeutics, Inc. Form 8-K filed July 9, 2025 (SEC EDGAR) https://aibio.space/news/sensei-biotherapeutics-now-faeth-therapeutics-regains-nasdaq-bid-price/https://aibio.space/news/sensei-biotherapeutics-now-faeth-therapeutics-regains-nasdaq-bid-price/Wed, 09 Jul 2025 12:00:00 GMTListingsNasdaq staff found the stock closed at $1.00 or more for 10 consecutive business days, from June 17, 2025 to July 1, 2025.Faeth Therapeutics, Inc. 8-K (2025-07-09) https://aibio.space/news/galectin-therapeutics-gets-new-10-million-credit-line-chairman-richard/https://aibio.space/news/galectin-therapeutics-gets-new-10-million-credit-line-chairman-richard/Wed, 09 Jul 2025 12:00:00 GMTDebt FinancingThe new $10 million line covers spending through June 2026, and $81 million of earlier borrowings from the same investor now mature September 30, 2026. The lead drug's NAVIGATE composite endpoint did not reach statistical significance.Galectin Therapeutics Inc. 8-K (2025-07-09) https://aibio.space/news/nasus-pharma-files-1-000-000-share-nyse-american-ipo-expects-10-00-12/https://aibio.space/news/nasus-pharma-files-1-000-000-share-nyse-american-ipo-expects-10-00-12/Wed, 09 Jul 2025 12:00:00 GMTFinancingsNasus Pharma seeks to list 1,000,000 shares on NYSE American at $10.00 to $12.00. Its prospectus says current cash will not fund planned operations, which raises substantial doubt about going concern, and its epinephrine Phase 2 study included 12 patients.Nasus Pharma Ltd. F-1 (2025-07-09) https://aibio.space/news/rallybio-sells-50-percent-stake-enpp1-joint-venture-recursion-cash/https://aibio.space/news/rallybio-sells-50-percent-stake-enpp1-joint-venture-recursion-cash/Tue, 08 Jul 2025 12:00:00 GMTMergersRecursion issued 1,457,952 of its shares to Rallybio's selling subsidiary. Rallybio could receive more shares, development milestone payments and low single digit royalties later.Rallybio Corp Form 8-K filed July 8, 2025 (SEC EDGAR) https://aibio.space/news/recursion-buys-rallybios-50-percent-enpp1-venture-stake-paying-1-457/https://aibio.space/news/recursion-buys-rallybios-50-percent-enpp1-venture-stake-paying-1-457/Tue, 08 Jul 2025 12:00:00 GMTFinancingsRecursion issued 1,457,952 shares to Rallybio for its half of an ENPP1 venture, with more stock and cash due on milestones. The company's share issuance is capped at 19.9% of outstanding common stock, and the 8-K names no underwriter or placement agent.RECURSION PHARMACEUTICALS, INC. Form 8-K filed July 8, 2025 (SEC EDGAR) https://aibio.space/news/entero-therapeutics-now-gridai-technologies-regains-nasdaq-annual/https://aibio.space/news/entero-therapeutics-now-gridai-technologies-regains-nasdaq-annual/Tue, 08 Jul 2025 12:00:00 GMTListingsNasdaq closed the matter on July 3, 2025, after the company held its annual meeting on June 30, 2025. The April annual report said the planned rescission of the ImmunogenX merger needed shareholder approval.GridAI Technologies Corp. 8-K (2025-07-08) https://aibio.space/news/rallybio-sells-enpp1-joint-venture-stake-recursion-initial-7-500-000/https://aibio.space/news/rallybio-sells-enpp1-joint-venture-stake-recursion-initial-7-500-000/Tue, 08 Jul 2025 12:00:00 GMTMergersRallybio sold its 50% interest in the ENPP1 joint venture to a Recursion subsidiary on July 8, 2025. It received 1,457,952 Recursion shares for an initial $7,500,000, and it could receive $12,500,000 more in stock if milestones are met.Rallybio Corporation 8-K (2025-07-08) https://aibio.space/news/unicycive-regains-nasdaq-minimum-bid-price-compliance-after-reverse/https://aibio.space/news/unicycive-regains-nasdaq-minimum-bid-price-compliance-after-reverse/Tue, 08 Jul 2025 12:00:00 GMTListingsNasdaq confirmed on July 7, 2025 that Unicycive's shares had averaged at least $1.00 after a 1:10 reverse stock split took effect on June 20, 2025. The release does not say what the FDA has done on the company's lead candidate, which had a PDUFA date of June 28, 2025.Unicycive Therapeutics, Inc. 8-K (2025-07-08) https://aibio.space/news/pacira-biosciences-enters-300-0-million-revolving-credit-facility/https://aibio.space/news/pacira-biosciences-enters-300-0-million-revolving-credit-facility/Mon, 07 Jul 2025 12:00:00 GMTDebt FinancingThe July 3, 2025 credit agreement is a $300.0 million senior secured revolver maturing July 3, 2030, and Pacira used part of it to repay its term loan A without prepayment penalties or fees. Wells Fargo Bank is administrative agent, and Wells Fargo Securities, Citizens Bank and Truist Securities are joint bookrunners and lead arrangers.Pacira BioSciences, Inc. Form 8-K filed July 7, 2025 (SEC EDGAR) https://aibio.space/news/century-therapeutics-plans-about-51-percent-workforce-cut-cfo-chief/https://aibio.space/news/century-therapeutics-plans-about-51-percent-workforce-cut-cfo-chief/Mon, 07 Jul 2025 12:00:00 GMTDistressCentury Therapeutics (Nasdaq: IPSC) expects to cut headcount by approximately 51% and record about $3.7 million in severance charges. Its CFO and Chief Development Officer will leave in July 2025.Century Therapeutics, Inc. Form 8-K filed July 7, 2025 (SEC EDGAR) https://aibio.space/news/collegium-pharmaceutical-authorizes-buyback-up-150-million/https://aibio.space/news/collegium-pharmaceutical-authorizes-buyback-up-150-million/Mon, 07 Jul 2025 12:00:00 GMTFinancingsThe board approved the program on July 1, 2025. It runs through December 31, 2026 and will be funded from existing cash on hand, but the 8-K gives no cash balance to measure that against.Collegium Pharmaceutical, Inc. 8-K (2025-07-07) https://aibio.space/news/pacira-signs-300-0-million-revolving-credit-facility-repays-term-loan/https://aibio.space/news/pacira-signs-300-0-million-revolving-credit-facility-repays-term-loan/Mon, 07 Jul 2025 12:00:00 GMTDistressPacira signed a $300.0 million senior secured revolving credit facility with Wells Fargo as administrative agent, and used part of it to repay its 2023 term loan A. The filing does not say how much was drawn.Pacira BioSciences, Inc. 8-K (2025-07-07) https://aibio.space/news/promis-neurosciences-gets-second-180-day-period-meet-nasdaq-bid-price/https://aibio.space/news/promis-neurosciences-gets-second-180-day-period-meet-nasdaq-bid-price/Mon, 07 Jul 2025 12:00:00 GMTListingsProMIS now has until December 29, 2025 to lift its share price to at least $1.00. It said it may effect a reverse stock split if necessary.ProMIS Neurosciences Inc. 8-K (2025-07-07) https://aibio.space/news/coherus-oncology-gets-nasdaq-minimum-bid-price-deficiency-notice-has/https://aibio.space/news/coherus-oncology-gets-nasdaq-minimum-bid-price-deficiency-notice-has/Thu, 03 Jul 2025 12:00:00 GMTListingsNasdaq told Coherus on June 30, 2025 that its stock had closed below $1.00 for 30 consecutive business days. The company has until December 29, 2025 to regain compliance, while its cash, cash equivalents and marketable securities were $126.0 million at December 31, 2024 against $230.0 million of 2026 convertible notes.Coherus Oncology, Inc. Form 8-K filed July 3, 2025 (SEC EDGAR) https://aibio.space/news/pluri-gets-nasdaq-audit-committee-notice-after-director-doron-birger/https://aibio.space/news/pluri-gets-nasdaq-audit-committee-notice-after-director-doron-birger/Thu, 03 Jul 2025 12:00:00 GMTListingsPluri told Nasdaq it fell below the three-independent-director minimum for its audit committee after shareholders voted against director Doron Birger, who chaired it. The cure period ends no later than June 30, 2026, and the company says it will add an independent director.Pluri Inc. Form 8-K filed July 3, 2025 (SEC EDGAR) https://aibio.space/news/silo-pharma-gets-nasdaq-minimum-bid-price-notice-has-until-december-24/https://aibio.space/news/silo-pharma-gets-nasdaq-minimum-bid-price-notice-has-until-december-24/Thu, 03 Jul 2025 12:00:00 GMTListingsNasdaq notified Silo Pharma on June 27, 2025 that its common stock has not met the $1.00 minimum bid price. The company has until December 24, 2025 to regain compliance, and may consider a reverse stock split if needed.Silo Pharma, Inc. Form 8-K filed July 3, 2025 (SEC EDGAR) https://aibio.space/news/lantern-pharma-sets-up-15-530-000-market-stock-program-thinkequity/https://aibio.space/news/lantern-pharma-sets-up-15-530-000-market-stock-program-thinkequity/Thu, 03 Jul 2025 12:00:00 GMTFinancingsThinkEquity LLC will earn a 3.0% commission on shares sold. Lantern's public float was $46,607,112 as of July 3, 2025, which limits sales to one-third of that float in any 12-month period while the float stays below $75 million.Lantern Pharma Inc. 424B5 (2025-07-03) https://aibio.space/news/lexicon-pharmaceuticals-moves-nasdaq-capital-market-get-more-time-1/https://aibio.space/news/lexicon-pharmaceuticals-moves-nasdaq-capital-market-get-more-time-1/Thu, 03 Jul 2025 12:00:00 GMTListingsLexicon gets until December 30, 2025 to regain the $1 minimum bid price and moves to the Nasdaq Capital Market on July 7, 2025, with a reverse split on the table if needed.Lexicon Pharmaceuticals, Inc. 8-K (2025-07-03) https://aibio.space/news/silo-pharma-gets-nasdaq-bid-price-notice-has-until-december-24-2025/https://aibio.space/news/silo-pharma-gets-nasdaq-bid-price-notice-has-until-december-24-2025/Thu, 03 Jul 2025 12:00:00 GMTListingsNasdaq told Silo Pharma on June 27, 2025 that its common stock fell below the $1.00 minimum bid price, based on closing bids from May 14 to June 26. The company has until December 24, 2025 to regain compliance and says it may consider a reverse stock split.Silo Pharma, Inc. 8-K (2025-07-03) https://aibio.space/news/tevogen-bio-holdings-sets-up-50-000-000-market-stock-program/https://aibio.space/news/tevogen-bio-holdings-sets-up-50-000-000-market-stock-program/Thu, 03 Jul 2025 12:00:00 GMTFinancingsTevogen can sell up to $50,000,000 of common stock through A.G.P./Alliance Global Partners, which is paid 3.0% of gross proceeds. The company's net tangible book value was negative $7.72 million at March 31, 2025, and buyers at the $1.25 reference price would face $1.07 a share of dilution.Tevogen Inc. 424B5 (2025-07-03) https://aibio.space/news/universe-pharmaceuticals-reports-3-3-million-six-month-loss-cash-47/https://aibio.space/news/universe-pharmaceuticals-reports-3-3-million-six-month-loss-cash-47/Thu, 03 Jul 2025 12:00:00 GMTFinancingsThe net loss widened to $3.3 million as third-party sales fell. Cash rose to $47,272,851, mainly because of a $15,000,000 share issue and related-party borrowings.Universe Pharmaceuticals Inc 6-K (2025-07-03) https://aibio.space/news/channel-therapeutics-now-pelthos-therapeutics-closes-merger-50-1/https://aibio.space/news/channel-therapeutics-now-pelthos-therapeutics-closes-merger-50-1/Wed, 02 Jul 2025 12:00:00 GMTMergersThe July 1, 2025 closing included a one-for-ten reverse stock split, a name change and royalty sales to Nomis RoyaltyVest, Ligand and Madison Royalty LLC. The shares were to trade as PTHS.Pelthos Therapeutics Inc. Form 8-K filed July 2, 2025 (SEC EDGAR) https://aibio.space/news/alaunos-therapeutics-tells-nasdaq-falls-short-audit-committee-rule/https://aibio.space/news/alaunos-therapeutics-tells-nasdaq-falls-short-audit-committee-rule/Wed, 02 Jul 2025 12:00:00 GMTListingsAlaunos told Nasdaq on July 2, 2025 that its audit committee falls short of Listing Rule 5605(c). The shortfall came after chief executive Dale Curtis Hogue, Jr. resigned and director Holger Weis took over as CEO and left the committee. The company plans to use a 180-day grace period.Alaunos Therapeutics, Inc. Form 8-K filed July 2, 2025 (SEC EDGAR) https://aibio.space/news/oragenics-closes-public-offering-series-h-preferred-about-16-5-million/https://aibio.space/news/oragenics-closes-public-offering-series-h-preferred-about-16-5-million/Wed, 02 Jul 2025 12:00:00 GMTFinancingsOragenics closed a registered offering of 660,000 Series H preferred shares and warrants on July 2, 2025, for about $16.5 million gross. The preferred converts at $2.50 a share, the conversion price has no floor, and Dawson James Securities took 7.00% of gross proceeds as placement agent.ORAGENICS INC Form 8-K filed July 2, 2025 (SEC EDGAR) https://aibio.space/news/abeona-closes-155-million-sale-rare-pediatric-disease-priority-review/https://aibio.space/news/abeona-closes-155-million-sale-rare-pediatric-disease-priority-review/Wed, 02 Jul 2025 12:00:00 GMTFinancingsAbeona received gross proceeds of $155 million on June 27, 2025. The company says unaudited cash, cash equivalents, restricted cash and short-term investments were approximately $225 million as of June 30, 2025.ABEONA THERAPEUTICS INC. Form 8-K filed July 2, 2025 (SEC EDGAR) https://aibio.space/news/abeona-therapeutics-closes-155-million-sale-priority-review-voucher/https://aibio.space/news/abeona-therapeutics-closes-155-million-sale-priority-review-voucher/Wed, 02 Jul 2025 12:00:00 GMTMergersThe sale closed on June 27, 2025. Abeona says cash and investments were about $225 million as of June 30, 2025, a figure it labels unaudited, and the release again does not name the buyer.Abeona Therapeutics Inc. 8-K (2025-07-02) https://aibio.space/news/geovax-labs-sells-9-235-000-units-0-65-public-offering/https://aibio.space/news/geovax-labs-sells-9-235-000-units-0-65-public-offering/Wed, 02 Jul 2025 12:00:00 GMTFinancingsEach unit carried one share and two warrants exercisable at $0.65. Estimated net proceeds are $5,582,557.50, and the lead program is a COVID-19 vaccine whose key comparison trial is still ahead.GeoVax Labs, Inc. 424B4 (2025-07-02) https://aibio.space/news/channel-therapeutics-now-pelthos-sets-10-one-reverse-split-ahead/https://aibio.space/news/channel-therapeutics-now-pelthos-sets-10-one-reverse-split-ahead/Wed, 02 Jul 2025 12:00:00 GMTMergersChannel Therapeutics will cut its share count from about 6,485,007 to about 648,501 in a 10-for-one reverse split before its merger with LNHC and a roughly $50 million raise led by Murchinson. The company says the split is meant to help it meet NYSE American initial listing requirements.Pelthos Therapeutics Inc. 8-K (2025-07-02) https://aibio.space/news/ocugen-gets-180-more-days-nasdaq-meet-minimum-bid-price-until-december/https://aibio.space/news/ocugen-gets-180-more-days-nasdaq-meet-minimum-bid-price-until-december/Tue, 01 Jul 2025 12:00:00 GMTListingsNasdaq granted Ocugen (Nasdaq: OCGN) an additional 180 calendar days to regain compliance with the $1.00 minimum closing bid price requirement. The first period ended June 30, 2025.Ocugen, Inc. Form 8-K filed July 1, 2025 (SEC EDGAR) https://aibio.space/news/ikena-oncology-now-imagenebio-files-merger-partner-inmagenes-phase-2b/https://aibio.space/news/ikena-oncology-now-imagenebio-files-merger-partner-inmagenes-phase-2b/Tue, 01 Jul 2025 12:00:00 GMTMergersInmagene dosed the first patient in its ADAPTIVE trial of IMG-007 in atopic dermatitis, with topline results expected in the fourth quarter of 2026. Ikena filed the news as merger material.ImageneBio, Inc. 8-K (2025-07-01) https://aibio.space/news/tuhura-biosciences-completes-kineta-acquisition-paying-0-185298-tuhura/https://aibio.space/news/tuhura-biosciences-completes-kineta-acquisition-paying-0-185298-tuhura/Mon, 30 Jun 2025 12:00:00 GMTMergersTuHURA closed its merger with Kineta on June 30, 2025, issuing about 2,868,169 shares at closing, with about 1,129,885 more due after six months, subject to adjustment. The deal adds the antibody TBS-2025, for which the press release reports tolerability and receptor occupancy but no efficacy results.TuHURA Biosciences, Inc./NV Form 8-K filed June 30, 2025 (SEC EDGAR) https://aibio.space/news/aptevo-says-15-9-million-new-equity-puts-back-line-nasdaq-rule/https://aibio.space/news/aptevo-says-15-9-million-new-equity-puts-back-line-nasdaq-rule/Mon, 30 Jun 2025 12:00:00 GMTListingsAptevo says about $15.9 million of gross equity raised in the June quarter puts it back above Nasdaq's $2.5 million stockholders' equity minimum. The figure is the company's own belief, and it was still awaiting formal confirmation from Nasdaq.Aptevo Therapeutics Inc. 8-K (2025-06-30) https://aibio.space/news/biofrontera-agrees-11-0-million-preferred-stock-sale-fund-u-s-ameluz/https://aibio.space/news/biofrontera-agrees-11-0-million-preferred-stock-sale-fund-u-s-ameluz/Mon, 30 Jun 2025 12:00:00 GMTFinancingsThe company will sell up to 11,000 Series C preferred shares to fund the purchase of U.S. rights to Ameluz from its former parent. Its royalty falls to 12% or 15% of U.S. sales, while the parent takes a 10% post-money stake.Biofrontera Inc. 8-K (2025-07-01) https://aibio.space/news/tuhura-biosciences-completes-acquisition-kineta-all-stock-deal/https://aibio.space/news/tuhura-biosciences-completes-acquisition-kineta-all-stock-deal/Mon, 30 Jun 2025 12:00:00 GMTMergersEach Kineta share converts into 0.185298 TuHURA shares, or 2,868,169 shares in total, with 1,129,885 more due after six months. The release gives no cash balance or loss figure.TuHURA Biosciences, Inc. 8-K (2025-06-30) https://aibio.space/news/in8bio-regains-compliance-nasdaq-1-00-minimum-bid-price-rule/https://aibio.space/news/in8bio-regains-compliance-nasdaq-1-00-minimum-bid-price-rule/Mon, 30 Jun 2025 12:00:00 GMTListingsNasdaq notified IN8bio on June 24, 2025 that the company again meets Listing Rule 5550(a)(2). The exchange said the matter is now closed.IN8bio, Inc. 8-K (2025-06-30) https://aibio.space/news/inmed-pharmaceuticals-agrees-sell-shares-2-561-5-million-private/https://aibio.space/news/inmed-pharmaceuticals-agrees-sell-shares-2-561-5-million-private/Mon, 30 Jun 2025 12:00:00 GMTFinancingsA single institutional investor is buying 1,952,363 shares or pre-funded warrants plus options on the same number of shares. H.C. Wainwright is placement agent.InMed Pharmaceuticals Inc. 8-K (2025-06-30) https://aibio.space/news/inmune-bio-agrees-sell-3-000-000-shares-6-30-19-million-direct/https://aibio.space/news/inmune-bio-agrees-sell-3-000-000-shares-6-30-19-million-direct/Mon, 30 Jun 2025 12:00:00 GMTFinancingsThe prospectus puts the immediate dilution to new buyers at $4.97 per share. Cash was $19,377 thousand at March 31, 2025, against an accumulated deficit of $172,843 thousand.INmune Bio Inc. 424B5 (2025-06-30) https://aibio.space/news/medicus-pharma-agrees-buy-antev-2-666-600-shares-plus-up-us-65-million/https://aibio.space/news/medicus-pharma-agrees-buy-antev-2-666-600-shares-plus-up-us-65-million/Mon, 30 Jun 2025 12:00:00 GMTMergersAntev shareholders would receive about 17% of Medicus common shares, plus up to US$65 million in contingent payments tied to FDA milestones. Antev's lead drug missed a secondary endpoint in an earlier Phase 2a trial, and Medicus carries going-concern doubt.Medicus Pharma Ltd. 8-K (2025-06-30) https://aibio.space/news/bausch-lomb-closes-675-million-secured-notes-offering-refinances-2027/https://aibio.space/news/bausch-lomb-closes-675-million-secured-notes-offering-refinances-2027/Fri, 27 Jun 2025 12:00:00 GMTDebt FinancingThe notes mature January 15, 2031 and pay three-month EURIBOR plus 3.875%. The company also arranged a $2.325 billion term loan and an $800 million revolver, using the proceeds to repay and refinance existing debt.Bausch & Lomb Corp Form 8-K filed June 27, 2025 (SEC EDGAR) https://aibio.space/news/immunic-gets-nasdaq-notice-after-stock-falls-below-1-00-30-days/https://aibio.space/news/immunic-gets-nasdaq-notice-after-stock-falls-below-1-00-30-days/Fri, 27 Jun 2025 12:00:00 GMTListingsThe company has until December 24, 2025 to regain compliance. The notice has no immediate effect on its listing on The Nasdaq Global Select Market.Immunic, Inc. 8-K (2025-06-27) https://aibio.space/news/pasithea-therapeutics-gets-nasdaq-notice-trading-below-1-00-bid-price/https://aibio.space/news/pasithea-therapeutics-gets-nasdaq-notice-trading-below-1-00-bid-price/Fri, 27 Jun 2025 12:00:00 GMTListingsThe company has until December 22, 2025 to regain compliance. It may qualify for a second 180-day period and is considering its options.Pasithea Therapeutics Corp. 8-K (2025-06-27) https://aibio.space/news/moleculin-biotech-gets-nasdaq-bid-price-notice-has-until-december-24/https://aibio.space/news/moleculin-biotech-gets-nasdaq-bid-price-notice-has-until-december-24/Fri, 27 Jun 2025 12:00:00 GMTListingsThe stock closed below $1.00 for 30 straight business days. The company may consider a reverse stock split to regain compliance.Moleculin Biotech, Inc. 8-K (2025-06-27) https://aibio.space/news/nektar-therapeutics-regains-compliance-nasdaq-minimum-bid-price-rule/https://aibio.space/news/nektar-therapeutics-regains-compliance-nasdaq-minimum-bid-price-rule/Fri, 27 Jun 2025 12:00:00 GMTListingsNasdaq told Nektar on June 24, 2025 that it met the minimum bid rule after a $1.00 closing bid held for 10 consecutive business days. The 8-K gives no share price or financial figures, and the company's pipeline is still in mid-stage trials.Nektar Therapeutics 8-K (2025-06-27) https://aibio.space/news/zymeworks-issues-5-086-480-shares-ecor1-funds-exercise-pre-funded/https://aibio.space/news/zymeworks-issues-5-086-480-shares-ecor1-funds-exercise-pre-funded/Fri, 27 Jun 2025 12:00:00 GMTFinancingsThe warrant holders net exercised in full after Zymeworks removed a 19.99% ownership cap. Shares outstanding rose to 74,844,505.Zymeworks Inc. 8-K (2025-06-27) https://aibio.space/news/cell-source-auditor-marcum-resigns-after-cbiz-takes-attest-business/https://aibio.space/news/cell-source-auditor-marcum-resigns-after-cbiz-takes-attest-business/Thu, 26 Jun 2025 12:00:00 GMTLegalMarcum LLP resigned as Cell Source's auditor on June 26, 2025, after CBIZ CPAs took over its attest practice. Marcum's reports on 2022 and 2023 carried a going-concern paragraph.SEC EDGAR: Cell Source 8-K https://aibio.space/news/actuate-therapeutics-agrees-sell-666-497-shares-7-00-private-placement/https://aibio.space/news/actuate-therapeutics-agrees-sell-666-497-shares-7-00-private-placement/Thu, 26 Jun 2025 12:00:00 GMTFinancingsThe deal pairs each share with a $7.00 warrant and is expected to bring in approximately $4.7 million in gross proceeds. Bios 2024 Co-Invest, LP, a current stockholder, is among the purchasers, and the filing says Bios would be deemed to own about 49.9% of the company.ACTUATE THERAPEUTICS, INC. Form 8-K filed June 26, 2025 (SEC EDGAR) https://aibio.space/news/scynexis-gets-nasdaq-minimum-bid-price-notice-has-until-december-17/https://aibio.space/news/scynexis-gets-nasdaq-minimum-bid-price-notice-has-until-december-17/Thu, 26 Jun 2025 12:00:00 GMTListingsSCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market.SCYNEXIS INC Form 8-K filed June 26, 2025 (SEC EDGAR) https://aibio.space/news/achieve-life-sciences-prices-45-000-000-offering-stock-warrants-3-00/https://aibio.space/news/achieve-life-sciences-prices-45-000-000-offering-stock-warrants-3-00/Thu, 26 Jun 2025 12:00:00 GMTFinancingsAchieve priced 15,000,000 shares, each sold with a five-year warrant at $3.00, for $45,000,000 in gross proceeds, below the $3.51 last reported sale price on June 26, 2025. The company's 2024 annual report carried a going-concern warning.Achieve Life Sciences, Inc. 424B5 (2025-06-26) https://aibio.space/news/bone-biologics-regains-compliance-nasdaq-1-00-minimum-bid-price-rule/https://aibio.space/news/bone-biologics-regains-compliance-nasdaq-1-00-minimum-bid-price-rule/Thu, 26 Jun 2025 12:00:00 GMTListingsNasdaq says Bone Biologics has met the $1.00 bid price rule after a 10-day run, but the release gives no share price, and its lead product still needs FDA approval before sale.Bone Biologics Corporation 8-K (2025-06-26) https://aibio.space/news/rani-therapeutics-gets-nasdaq-notice-1-00-minimum-bid-price/https://aibio.space/news/rani-therapeutics-gets-nasdaq-notice-1-00-minimum-bid-price/Thu, 26 Jun 2025 12:00:00 GMTListingsRani Therapeutics received a Nasdaq notice on June 20, 2025 that its Class A shares had a closing bid price below $1.00 for 30 consecutive business days. Its deadline to regain compliance is December 17, 2025, and the notice gives no closing price.Rani Therapeutics Holdings, Inc. 8-K (2025-06-26) https://aibio.space/news/scynexis-receives-nasdaq-notice-stock-below-1-00-has-until-december-17/https://aibio.space/news/scynexis-receives-nasdaq-notice-stock-below-1-00-has-until-december-17/Thu, 26 Jun 2025 12:00:00 GMTListingsSCYNEXIS received a Nasdaq notice that its common stock closed below $1.00 for 30 consecutive business days. It has until December 17, 2025 to regain compliance, and the company says the letter has no immediate effect on its listing on the Nasdaq Global Market.SCYNEXIS, Inc. 8-K (2025-06-26) https://aibio.space/news/vor-bio-licenses-telitacicept-remegen-45-million-plus-80-million/https://aibio.space/news/vor-bio-licenses-telitacicept-remegen-45-million-plus-80-million/Thu, 26 Jun 2025 12:00:00 GMTFinancingsVor Bio agreed to pay RemeGen a $45 million upfront payment and $80 million in warrants for global rights to telitacicept, excluding Greater China. The only efficacy result cited is from a China Phase 3 study, and initial global results are expected in the first half of 2027.Vor Biopharma Inc. 8-K (2025-06-26) https://aibio.space/news/lipella-pharmaceuticals-ceo-says-company-will-seek-relisting-after/https://aibio.space/news/lipella-pharmaceuticals-ceo-says-company-will-seek-relisting-after/Wed, 25 Jun 2025 12:00:00 GMTListingsLipella's common stock was quoted on the OTC Pink Market under LIPO as of June 19, 2025. Nasdaq objected to securities paid to a placement agent and advisor.Lipella Pharmaceuticals Inc. 8-K (2025-06-25) https://aibio.space/news/sutro-biopharma-receives-nasdaq-notice-falling-below-1-00-bid-price/https://aibio.space/news/sutro-biopharma-receives-nasdaq-notice-falling-below-1-00-bid-price/Wed, 25 Jun 2025 12:00:00 GMTListingsSutro has until December 17, 2025 to bring its share price back above $1.00 for ten consecutive business days, or face a delisting process. The company says it plans a reverse stock split before that date if necessary, and its 10-K shows three partners that ended clinical work after Phase 1.Sutro Biopharma, Inc. 8-K (2025-06-25) https://aibio.space/news/amarin-licenses-vazkepa-europe-recordati-25-million-upfront-plans/https://aibio.space/news/amarin-licenses-vazkepa-europe-recordati-25-million-upfront-plans/Tue, 24 Jun 2025 12:00:00 GMTDistressAmarin will receive $25 million upfront and up to $150 million in milestones under a 59-country license. It also expects a global restructuring to cut operating costs by approximately $70 million annually.AMARIN CORP PLC\UK Form 8-K filed June 24, 2025 (SEC EDGAR) https://aibio.space/news/amarin-licenses-vazkepa-europe-recordati-25-million-upfront-plans/https://aibio.space/news/amarin-licenses-vazkepa-europe-recordati-25-million-upfront-plans/Tue, 24 Jun 2025 12:00:00 GMTDistressAmarin is licensing Vazkepa in Europe to Recordati for a $25 million upfront payment and starting a restructuring that targets about $70 million in cost savings over the next 12 months, while the release gives no loss or cash-flow figures.Amarin Corporation plc 8-K (2025-06-24) https://aibio.space/news/candel-therapeutics-agrees-sell-about-15-0-million-stock-direct/https://aibio.space/news/candel-therapeutics-agrees-sell-about-15-0-million-stock-direct/Tue, 24 Jun 2025 12:00:00 GMTFinancingsCandel Therapeutics agreed on June 24, 2025 to sell 3,221,395 shares at $4.67 each in a registered direct offering. The prospectus names no placement agent or underwriter, and some buyers are directors and executive officers.Candel Therapeutics, Inc. 424B5 (2025-06-24) https://aibio.space/news/aytu-biopharma-extends-eclipse-term-loan-revolver-2029-adds-1-5/https://aibio.space/news/aytu-biopharma-extends-eclipse-term-loan-revolver-2029-adds-1-5/Mon, 23 Jun 2025 12:00:00 GMTDebt FinancingAmendment No. 6 to Aytu's loan and security agreement moves both maturities to June 12, 2029 and raises the term loan principal to $13.0 million. The new advance carries SOFR plus 5.50%.AYTU BIOPHARMA, INC Form 8-K filed June 23, 2025 (SEC EDGAR) https://aibio.space/news/impact-biomedical-signs-reverse-merger-agreement-dr-ashleys-limited/https://aibio.space/news/impact-biomedical-signs-reverse-merger-agreement-dr-ashleys-limited/Mon, 23 Jun 2025 12:00:00 GMTMergersImpact BioMedical agreed on June 21, 2025 to a reverse merger with Dr Ashleys, after which Impact holders would own 4.80% of the combined company. Closing needs shareholder approval, an effective registration statement and NYSE American listing approvals.IMPACT BIOMEDICAL INC. Form 8-K filed June 23, 2025 (SEC EDGAR) https://aibio.space/news/caribou-biosciences-regains-compliance-nasdaq-1-00-bid-price-rule/https://aibio.space/news/caribou-biosciences-regains-compliance-nasdaq-1-00-bid-price-rule/Mon, 23 Jun 2025 12:00:00 GMTListingsCaribou's Nasdaq notice covers a window of about two weeks, from June 3 to June 17, 2025, when its closing bid was $1.00 or more. The 8-K does not say what the price did before or after that window.Caribou Biosciences, Inc. 8-K (2025-06-23) https://aibio.space/news/impact-biomedical-agrees-reverse-merger-hong-kong-drugmaker-dr-ashleys/https://aibio.space/news/impact-biomedical-agrees-reverse-merger-hong-kong-drugmaker-dr-ashleys/Mon, 23 Jun 2025 12:00:00 GMTMergersThe combined company would trade on the NYSE American as Dr Ashleys Limited. The deal needs Impact BioMedical shareholder approval.Impact BioMedical Inc. 8-K (2025-06-23) https://aibio.space/news/ocugen-unit-orthocellix-merge-carisma-alongside-planned-25-0-million/https://aibio.space/news/ocugen-unit-orthocellix-merge-carisma-alongside-planned-25-0-million/Mon, 23 Jun 2025 12:00:00 GMTMergersOrthoCellix's stockholder and the concurrent financing investors are expected to own about 90% of the combined company, with Carisma holders at about 10%. The deal is all stock and needs approval from both companies' stockholders.Ocugen, Inc. 8-K (2025-06-23) https://aibio.space/news/enzon-pharmaceuticals-now-viskase-holdings-agrees-all-stock-merger/https://aibio.space/news/enzon-pharmaceuticals-now-viskase-holdings-agrees-all-stock-merger/Mon, 23 Jun 2025 12:00:00 GMTMergersEnzon, which calls itself a public company acquisition vehicle, agreed on June 20, 2025 to merge with Viskase in an all-stock deal. Viskase holders would own about 84.1% of the combined company, and Enzon common holders about 2.06%. The 8-K and release give no Viskase revenue, debt or earnings.Viskase Holdings, Inc. 425 (2025-06-23) https://aibio.space/news/aim-immunotech-gets-new-nyse-american-notice-stockholders-deficit/https://aibio.space/news/aim-immunotech-gets-new-nyse-american-notice-stockholders-deficit/Fri, 20 Jun 2025 12:00:00 GMTListingsAIM ImmunoTech had a stockholders' deficit of negative $3.9 million at March 31, 2025, and its 2024 net loss was approximately $17,320,000. Its tax-loss sales are capped, and the exchange deadline to fix the deficit is June 11, 2026.AIM ImmunoTech Inc. 8-K (2025-06-20) https://aibio.space/news/an2-therapeutics-swaps-shares-pre-funded-warrants-two-coastlands/https://aibio.space/news/an2-therapeutics-swaps-shares-pre-funded-warrants-two-coastlands/Fri, 20 Jun 2025 12:00:00 GMTFinancingsAN2 Therapeutics swapped 2,500,000 and 300,000 common shares for pre-funded warrants held by Coastlands Capital Partners LP on June 17 and June 19, 2025, and the 8-K reports no cash to the company from either exchange.AN2 Therapeutics, Inc. 8-K (2025-06-20) https://aibio.space/news/nyse-accepts-annovis-bio-plan-regain-listing-compliance/https://aibio.space/news/nyse-accepts-annovis-bio-plan-regain-listing-compliance/Fri, 20 Jun 2025 12:00:00 GMTListingsThe NYSE accepted Annovis Bio's plan to regain compliance with its market capitalization and stockholders' equity standards, giving the company 18 months from a March 26, 2025 notice, quarterly progress reports and a warning that trading could still be suspended.Annovis Bio, Inc. 8-K (2025-06-20) https://aibio.space/news/theriva-biologics-files-sell-up-2-534-352-stock-through-market-program/https://aibio.space/news/theriva-biologics-files-sell-up-2-534-352-stock-through-market-program/Fri, 20 Jun 2025 12:00:00 GMTFinancingsTheriva Biologics filed to sell up to $2,534,352 of stock through A.G.P./Alliance Global Partners, under a cap set by its public float. Its auditor's report carries a going-concern paragraph, and the main survival result in its lead trial has a p-value of 0.0546.Theriva Biologics, Inc. 424B5 (2025-06-20) https://aibio.space/news/glycomimetics-now-crescent-biopharma-completes-merger-200-million/https://aibio.space/news/glycomimetics-now-crescent-biopharma-completes-merger-200-million/Wed, 18 Jun 2025 12:00:00 GMTMergersCrescent Biopharma completed its merger with GlycoMimetics, and the combined company began trading as CBIO on June 16, 2025. The $200 million financing includes $37.5 million of converted notes. GlycoMimetics's own 2024 10-K had raised going-concern doubt.CRESCENT BIOPHARMA, INC. Form 8-K filed June 18, 2025 (SEC EDGAR) https://aibio.space/news/prothena-cuts-workforce-about-63-percent-after-ending-birtamimab/https://aibio.space/news/prothena-cuts-workforce-about-63-percent-after-ending-birtamimab/Wed, 18 Jun 2025 12:00:00 GMTDistressProthena expects $16 to $20 million in severance and related charges from the workforce reduction. Its Chief Regulatory Officer and Chief People Officer will leave effective August 1, 2025.PROTHENA CORP PUBLIC LTD CO Form 8-K filed June 18, 2025 (SEC EDGAR) https://aibio.space/news/c4-therapeutics-holders-approve-doubling-authorized-shares-300-000-000/https://aibio.space/news/c4-therapeutics-holders-approve-doubling-authorized-shares-300-000-000/Wed, 18 Jun 2025 12:00:00 GMTListingsStockholders voted 39,547,136 for and 20,664,896 against the increase, with 95,178 abstentions. The company filed the amendment in Delaware the same day.C4 Therapeutics, Inc. 8-K (2025-06-18) https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-says-equity-tops-nasdaq-2-5/https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-says-equity-tops-nasdaq-2-5/Wed, 18 Jun 2025 12:00:00 GMTListingsReShape says sales under its at-the-market program and a June 9 offering have lifted its stockholders' equity above the $2.5 million Nasdaq minimum. The company says that does not guarantee it will stay listed.Vyome Holdings, Inc. 8-K (2025-06-18) https://aibio.space/news/jyong-biotech-prices-20-million-ipo-2-666-667-shares-7-50-nasdaq/https://aibio.space/news/jyong-biotech-prices-20-million-ipo-2-666-667-shares-7-50-nasdaq/Wed, 18 Jun 2025 12:00:00 GMTFinancingsJyong Biotech, a Taiwan-based drug developer, priced 2,666,667 shares at $7.50 with Joseph Stone Capital, LLC as sole underwriter. Its lead candidate failed its primary endpoint in a pivotal U.S. trial, its auditor has raised going-concern doubt, and a Chinese court judgment puts about USD 19.4 million at stake.Jyong Biotech Ltd. 424B4 (2025-06-18) https://aibio.space/news/prothena-cuts-about-63-percent-workforce-after-ending-birtamimab/https://aibio.space/news/prothena-cuts-about-63-percent-workforce-after-ending-birtamimab/Wed, 18 Jun 2025 12:00:00 GMTDistressProthena will cut about 63% of its workforce after ending birtamimab, and expects $16 to $20 million in charges, mostly cash. The 8-K gives no headcount, cash balance or savings figure.Prothena Corporation plc 8-K (2025-06-18) https://aibio.space/news/biontech-files-purchase-agreement-acquire-curevac-through-exchange/https://aibio.space/news/biontech-files-purchase-agreement-acquire-curevac-through-exchange/Tue, 17 Jun 2025 12:00:00 GMTListingsBioNTech and CureVac signed a purchase agreement dated June 12, 2025 for a share exchange offer. The number of BioNTech shares per CureVac share moves with BioNTech's price, and the offer depends on a minimum condition.BioNTech SE 6-K (2025-06-17) https://aibio.space/news/plus-therapeutics-now-cerenome-cancels-warrants-signs-50-million/https://aibio.space/news/plus-therapeutics-now-cerenome-cancels-warrants-signs-50-million/Tue, 17 Jun 2025 12:00:00 GMTFinancingsInvestors in a March 2025 private placement agreed to cancel all Series A warrants and cut Series B warrant shares to up to 35,536,380. Lincoln Park may buy up to $50.0 million of stock over 36 months.Cerenome, Inc. 8-K (2025-06-17) https://aibio.space/news/polypid-agrees-26-7-million-warrant-exercises-3-50-share/https://aibio.space/news/polypid-agrees-26-7-million-warrant-exercises-3-50-share/Tue, 17 Jun 2025 12:00:00 GMTFinancingsHolders of existing PolyPid warrants will exercise them for $26.7 million at $3.50 per share and receive new warrants at $4.50. The company ties the money to a Phase 3 trial whose effect size its release does not give.PolyPid Ltd. 6-K (2025-06-17) https://aibio.space/news/nextcure-licenses-sim0505-12-million-upfront-agrees-sell-2-0-million/https://aibio.space/news/nextcure-licenses-sim0505-12-million-upfront-agrees-sell-2-0-million/Mon, 16 Jun 2025 12:00:00 GMTFinancingsNextCure agreed to pay Hainan Simcere Zaiming $17 million, including a $12 million upfront payment, for rights to a Phase 1 antibody drug conjugate. A Zaiming affiliate agreed to buy 4,063,633 shares for $2.0 million, and the company now says its cash lasts into mid-2026, not the second half of 2026 that its March 6 annual report gave.NextCure, Inc. Form 8-K filed June 16, 2025 (SEC EDGAR) https://aibio.space/news/aptevo-files-stock-warrant-offering-signs-25-0-million-yorkville/https://aibio.space/news/aptevo-files-stock-warrant-offering-signs-25-0-million-yorkville/Mon, 16 Jun 2025 12:00:00 GMTFinancingsAptevo filed to sell up to 1,709,401 shares with five common warrants each and signed a $25.0 million equity line with Yorkville. Its auditor's report carries a going concern paragraph, and cash was $2,139 thousand at March 31, 2025.Aptevo Therapeutics Inc. S-1 (2025-06-16) https://aibio.space/news/rezolute-sells-1-295-383-shares-private-placement-4-209-994-75/https://aibio.space/news/rezolute-sells-1-295-383-shares-private-placement-4-209-994-75/Fri, 13 Jun 2025 12:00:00 GMTFinancingsAn 8-K filed June 13, 2025 reports the sale. Certain insiders had agreed in April to buy up to $10,000,000 of stock at $3.25 per share in the private placement.Rezolute, Inc. Form 8-K filed June 13, 2025 (SEC EDGAR) https://aibio.space/news/equillium-gets-180-more-days-nasdaq-meet-minimum-bid-price-requirement/https://aibio.space/news/equillium-gets-180-more-days-nasdaq-meet-minimum-bid-price-requirement/Fri, 13 Jun 2025 12:00:00 GMTListingsNasdaq extended Equillium's deadline to December 8, 2025. The company says it will consider options including a reverse stock split, and its stock keeps trading on the Nasdaq Capital Market as "EQ".Equillium, Inc. Form 8-K filed June 13, 2025 (SEC EDGAR) https://aibio.space/news/quince-therapeutics-now-irulya-agrees-11-5-million-private-placement/https://aibio.space/news/quince-therapeutics-now-irulya-agrees-11-5-million-private-placement/Fri, 13 Jun 2025 12:00:00 GMTFinancingsQuince Therapeutics agreed to sell about $11.5 million of stock and warrants to institutional investors and three executives, and up to $10.4 million more depends on holders paying $1.20 per share.IRulya Therapeutics Inc. 8-K (2025-06-13) https://aibio.space/news/incannex-healthcare-applies-move-listing-nasdaq-capital-market/https://aibio.space/news/incannex-healthcare-applies-move-listing-nasdaq-capital-market/Fri, 13 Jun 2025 12:00:00 GMTListingsThe transfer from the Nasdaq Global Market is part of the company's effort to meet Nasdaq continued listing requirements. Shares would keep trading as IXHL.Incannex Healthcare Inc. 8-K (2025-06-13) https://aibio.space/news/aim-immunotech-regains-nyse-american-compliance-1-100-reverse-stock/https://aibio.space/news/aim-immunotech-regains-nyse-american-compliance-1-100-reverse-stock/Thu, 12 Jun 2025 12:00:00 GMTListingsAIM ImmunoTech regained NYSE American compliance on its low selling price test after a 1-for-100 reverse split effective June 12, 2025, with trading under AIM due to resume June 17. Its 2024 annual report carries a going-concern warning and a working capital deficit, and a separate stockholders' equity notice from December 2024 is not covered by this filing.AIM ImmunoTech Inc. Form 8-K filed June 12, 2025 (SEC EDGAR) https://aibio.space/news/adc-therapeutics-plans-about-30-percent-workforce-cut-u-k-closure-100/https://aibio.space/news/adc-therapeutics-plans-about-30-percent-workforce-cut-u-k-closure-100/Thu, 12 Jun 2025 12:00:00 GMTDistressADC Therapeutics approved a restructuring on June 11, 2025 that closes its U.K. research facility and cuts about 30% of its global workforce. The same day it agreed to a $100 million private placement priced at $3.53 per share.ADC Therapeutics SA Form 8-K filed June 12, 2025 (SEC EDGAR) https://aibio.space/news/spruce-biosciences-wins-nasdaq-panel-appeal-bid-price-deadline-august/https://aibio.space/news/spruce-biosciences-wins-nasdaq-panel-appeal-bid-price-deadline-august/Thu, 12 Jun 2025 12:00:00 GMTListingsA Nasdaq panel accepted Spruce Biosciences' appeal, but the stock returns to the Capital Market only if it meets the minimum bid price by August 5, 2025. Trading had been suspended on April 29, 2025, and the 10-K carries a going-concern warning.SPRUCE BIOSCIENCES, INC. Form 8-K filed June 12, 2025 (SEC EDGAR) https://aibio.space/news/i-mab-now-novabridge-biosciences-regains-nasdaq-minimum-bid-price/https://aibio.space/news/i-mab-now-novabridge-biosciences-regains-nasdaq-minimum-bid-price/Thu, 12 Jun 2025 12:00:00 GMTListingsNasdaq notified the company on June 11, 2025. Its American Depositary Shares will stay listed and traded on Nasdaq.NovaBridge Biosciences 6-K (2025-06-12) https://aibio.space/news/scinai-immunotherapeutics-raises-1-38-million-through-yorkville-equity/https://aibio.space/news/scinai-immunotherapeutics-raises-1-38-million-through-yorkville-equity/Thu, 12 Jun 2025 12:00:00 GMTFinancingsThe sales were priced at about $3.03 per ADS, a 3% discount to market. Scinai also says a cost-cutting program will lower annual employment costs by about $815,000.Scinai Immunotherapeutics Ltd. 6-K (2025-06-12) https://aibio.space/news/spruce-biosciences-wins-nasdaq-appeal-must-meet-bid-price-rule-august/https://aibio.space/news/spruce-biosciences-wins-nasdaq-appeal-must-meet-bid-price-rule-august/Thu, 12 Jun 2025 12:00:00 GMTListingsSpruce's shares have traded over the counter since a Nasdaq suspension on April 29, 2025. The Hearings Panel accepted the company's appeal on June 9, 2025, but the stock returns to the Nasdaq Capital Market only if it meets the bid price requirement by August 5, 2025.Spruce Biosciences, Inc. 8-K (2025-06-12) https://aibio.space/news/tempest-therapeutics-prices-6-25-registered-direct-offering-expects-4/https://aibio.space/news/tempest-therapeutics-prices-6-25-registered-direct-offering-expects-4/Thu, 12 Jun 2025 12:00:00 GMTFinancingsTempest sold 405,000 shares and prefunded warrants for 334,000 shares to one institutional investor at $6.25 each, for about $4.1 million net. The company's cash estimate runs only into the second quarter of 2026, and it is exploring strategic alternatives.Tempest Therapeutics, Inc. 424B5 (2025-06-12) https://aibio.space/news/cogent-biosciences-draws-50-million-term-loan-facility-up-400-million/https://aibio.space/news/cogent-biosciences-draws-50-million-term-loan-facility-up-400-million/Wed, 11 Jun 2025 12:00:00 GMTDebt FinancingCogent drew $50 million of a term loan facility of up to $400 million from SLR credit funds on June 11, 2025. Most of the rest depends on pivotal trial results and a launch the company expects in 2026, and the debt falls due in 2030.Cogent Biosciences, Inc. Form 8-K filed June 11, 2025 (SEC EDGAR) https://aibio.space/news/salarius-now-decoy-therapeutics-cuts-valuation-2-31-million-merger/https://aibio.space/news/salarius-now-decoy-therapeutics-cuts-valuation-2-31-million-merger/Wed, 11 Jun 2025 12:00:00 GMTMergersSalarius cut its relative valuation in the Decoy merger from $4.6 million to $2.31 million, so its legacy holders would keep 7.6% of the combined company instead of 14.1%. The 8-K blames "substantial deterioration" in its share price.Decoy Therapeutics Inc. 8-K (2025-06-11) https://aibio.space/news/okyo-pharma-files-up-15-500-000-market-share-sales/https://aibio.space/news/okyo-pharma-files-up-15-500-000-market-share-sales/Wed, 11 Jun 2025 12:00:00 GMTFinancingsOKYO Pharma Limited says it sold $3,999,911 under an earlier $4,000,000 supplement and will make no more sales under it. The new program is with B. Riley Securities.OKYO Pharma Limited 424B5 (2025-06-11) https://aibio.space/news/tonix-sets-up-programs-sell-up-150-0-million-75-0-million-stock/https://aibio.space/news/tonix-sets-up-programs-sell-up-150-0-million-75-0-million-stock/Wed, 11 Jun 2025 12:00:00 GMTFinancingsTonix set up two ways to sell new stock on June 11, 2025: up to $150.0 million through A.G.P./Alliance Global Partners and up to $75.0 million to Lincoln Park Capital Fund. Its lead drug has an FDA decision date of August 15, 2025.Tonix Pharmaceuticals Holding Corp. 8-K (2025-06-11) https://aibio.space/news/integra-lifesciences-amends-credit-agreement-covenant-relief-leverage/https://aibio.space/news/integra-lifesciences-amends-credit-agreement-covenant-relief-leverage/Mon, 09 Jun 2025 12:00:00 GMTDebt FinancingIntegra LifeSciences' June 6, 2025 amendment lifts its maximum consolidated total leverage ratio to 5.00 to 1.00 through June 30, 2026, then steps it down. The company says total indebtedness does not rise, but the amendment also restricts investments, new borrowing and transfers of intellectual property until the relief period ends.INTEGRA LIFESCIENCES HOLDINGS CORP Form 8-K filed June 9, 2025 (SEC EDGAR) https://aibio.space/news/aytu-biopharma-signs-exxua-commercialization-deal-fabre-kramer-pays-3/https://aibio.space/news/aytu-biopharma-signs-exxua-commercialization-deal-fabre-kramer-pays-3/Fri, 06 Jun 2025 12:00:00 GMTMergersAytu paid Fabre-Kramer a $3,000,000 upfront on June 5, 2025 for U.S. rights to EXXUA and owes a second $3,000,000 tied to sales timing. Royalties start at 28% of net sales, and the annual report shows an accumulated deficit of $320.0 million.AYTU BIOPHARMA, INC Form 8-K filed June 6, 2025 (SEC EDGAR) https://aibio.space/news/bolt-biotherapeutics-sets-1-20-reverse-stock-split-trading-adjusted/https://aibio.space/news/bolt-biotherapeutics-sets-1-20-reverse-stock-split-trading-adjusted/Fri, 06 Jun 2025 12:00:00 GMTListingsBolt Biotherapeutics filed a one-for-twenty reverse stock split on June 6, 2025, with split-adjusted trading set for June 9. The 8-K gives no reason for the split, and the company's 2024 annual report already said there was substantial doubt about its ability to continue as a going concern.Bolt Biotherapeutics, Inc. Form 8-K filed June 6, 2025 (SEC EDGAR) https://aibio.space/news/aytu-biopharma-pays-3-000-000-upfront-u-s-rights-depression-drug-exxua/https://aibio.space/news/aytu-biopharma-pays-3-000-000-upfront-u-s-rights-depression-drug-exxua/Fri, 06 Jun 2025 12:00:00 GMTMergersAytu agreed to pay a $3,000,000 upfront for U.S. rights to EXXUA, with further payments and royalties of 28% to 39% of net sales that depend on sales.Aytu BioPharma, Inc. 8-K (2025-06-06) https://aibio.space/news/bolt-biotherapeutics-effects-1-20-reverse-stock-split/https://aibio.space/news/bolt-biotherapeutics-effects-1-20-reverse-stock-split/Fri, 06 Jun 2025 12:00:00 GMTListingsBolt Biotherapeutics filed a Certificate of Amendment on June 6, 2025 to effect a one-for-twenty reverse stock split. Split-adjusted trading on the Nasdaq Capital Market under the existing ticker BOLT was scheduled to begin June 9, 2025, under a new CUSIP number.Bolt Biotherapeutics, Inc. 8-K (2025-06-06) https://aibio.space/news/tango-therapeutics-holders-approve-doubling-authorized-shares-400-000/https://aibio.space/news/tango-therapeutics-holders-approve-doubling-authorized-shares-400-000/Fri, 06 Jun 2025 12:00:00 GMTListingsCommon stock authorized rises from 200,000,000 shares. The vote was 85,825,060 for and 11,001,501 against, and the 8-K gives no reason for the larger share count.Tango Therapeutics, Inc. 8-K (2025-06-06) https://aibio.space/news/fortress-biotech-receive-about-28-0-million-checkpoint-sale-sun-pharma/https://aibio.space/news/fortress-biotech-receive-about-28-0-million-checkpoint-sale-sun-pharma/Thu, 05 Jun 2025 12:00:00 GMTMergersCheckpoint Therapeutics became a wholly owned Sun Pharma subsidiary on May 30, 2025. Fortress may also get up to $4.8 million through CVRs and a 2.5% royalty on certain net sales.Fortress Biotech, Inc. Form 8-K filed June 5, 2025 (SEC EDGAR) https://aibio.space/news/cellectar-biosciences-agrees-warrant-inducement-deal-about-2-5-million/https://aibio.space/news/cellectar-biosciences-agrees-warrant-inducement-deal-about-2-5-million/Thu, 05 Jun 2025 12:00:00 GMTFinancingsHolders of warrants for 8,301,322 shares agreed to exercise at a reduced price of $0.3041 per share. Ladenburg Thalmann & Co. Inc. is placement agent, and closing is expected on or about June 6, 2025.Cellectar Biosciences, Inc. Form 8-K filed June 5, 2025 (SEC EDGAR) https://aibio.space/news/talphera-gets-second-180-day-nasdaq-bid-price-period-december-1-2025/https://aibio.space/news/talphera-gets-second-180-day-nasdaq-bid-price-period-december-1-2025/Thu, 05 Jun 2025 12:00:00 GMTListingsTalphera (TLPH) moved its listing to The Nasdaq Capital Market on May 30, 2025 and received an additional 180 days to regain the $1.00 minimum bid price. It has told Nasdaq it will use a reverse stock split, if necessary.TALPHERA, INC. Form 8-K filed June 5, 2025 (SEC EDGAR) https://aibio.space/news/harmony-biosciences-settles-wakix-patent-suit-lupin-generic-entry-set/https://aibio.space/news/harmony-biosciences-settles-wakix-patent-suit-lupin-generic-entry-set/Thu, 05 Jun 2025 12:00:00 GMTLegalLupin Limited gets a license to launch a generic WAKIX no earlier than January 2030, or July 2030 with pediatric exclusivity, and the Delaware case will be dismissed.Harmony Biosciences Holdings, Inc. Form 8-K filed June 5, 2025 (SEC EDGAR) https://aibio.space/news/avalo-therapeutics-sets-up-75-000-000-market-program-td-cowen/https://aibio.space/news/avalo-therapeutics-sets-up-75-000-000-market-program-td-cowen/Thu, 05 Jun 2025 12:00:00 GMTFinancingsAvalo ended an earlier $50.0 million sales agreement with Oppenheimer. Its stock last sold at $3.72 on May 29, 2025.Avalo Therapeutics, Inc. 424B5 (2025-06-05) https://aibio.space/news/fortress-biotech-receive-about-28-0-million-checkpoint-sale-sun-pharma/https://aibio.space/news/fortress-biotech-receive-about-28-0-million-checkpoint-sale-sun-pharma/Thu, 05 Jun 2025 12:00:00 GMTMergersFortress Biotech says it will receive about $28.0 million in cash from the sale of Checkpoint Therapeutics to Sun Pharma, with up to $4.8 million more if a milestone is met. The gain on deconsolidation is an accounting figure, and pro forma cash is lower than reported.Fortress Biotech, Inc. 8-K (2025-06-05) https://aibio.space/news/talphera-gets-second-180-day-nasdaq-period-until-december-1-2025-fix/https://aibio.space/news/talphera-gets-second-180-day-nasdaq-period-until-december-1-2025-fix/Thu, 05 Jun 2025 12:00:00 GMTListingsTalphera moved its stock to the Nasdaq Capital Market on May 30, 2025 to qualify. It told Nasdaq it would do a reverse stock split if necessary.Talphera, Inc. 8-K (2025-06-05) https://aibio.space/news/elicio-therapeutics-takes-10-million-secured-loan-investor-gkcc/https://aibio.space/news/elicio-therapeutics-takes-10-million-secured-loan-investor-gkcc/Wed, 04 Jun 2025 12:00:00 GMTDebt FinancingThe note carries interest of up to 12.5% and matures on June 3, 2028. Elicio expects the cash to fund operations into the first quarter of 2026.Elicio Therapeutics, Inc. 8-K (2025-06-04) https://aibio.space/news/nektar-sets-one-fifteen-reverse-split-effective-june-8-2025/https://aibio.space/news/nektar-sets-one-fifteen-reverse-split-effective-june-8-2025/Wed, 04 Jun 2025 12:00:00 GMTListingsNektar's board approved the split on May 23, 2025, and trading on a split-adjusted basis is set to begin June 9. The filings give no reason for the split, and a June 6 amendment raised authorized shares to 390,000,000.Nektar Therapeutics 8-K (2025-06-04) https://aibio.space/news/relay-therapeutics-agrees-end-binney-street-lease-early-move-smaller/https://aibio.space/news/relay-therapeutics-agrees-end-binney-street-lease-early-move-smaller/Wed, 04 Jun 2025 12:00:00 GMTDistressRelay paid a lease modification payment of approximately $2.5 million and a relocation payment of approximately $3.5 million. It says the changes cut rent expense by approximately $16 million.Relay Therapeutics, Inc. 8-K (2025-06-04) https://aibio.space/news/ironwood-pharmaceuticals-gets-nasdaq-minimum-bid-price-deficiency/https://aibio.space/news/ironwood-pharmaceuticals-gets-nasdaq-minimum-bid-price-deficiency/Tue, 03 Jun 2025 12:00:00 GMTListingsNasdaq said Ironwood's Class A stock closed below $1.00 for 30 consecutive business days. The company has until November 24, 2025 to regain compliance, and the letter has no immediate effect on its listing.IRONWOOD PHARMACEUTICALS INC Form 8-K filed June 3, 2025 (SEC EDGAR) https://aibio.space/news/alto-neuroscience-buys-depression-drug-candidates-chase-therapeutics/https://aibio.space/news/alto-neuroscience-buys-depression-drug-candidates-chase-therapeutics/Tue, 03 Jun 2025 12:00:00 GMTMergersAlto may owe up to $71,500,000 in milestone payments, payable in cash or restricted stock, and says its cash is still expected to fund operations into 2028.Alto Neuroscience, Inc. Form 8-K filed June 3, 2025 (SEC EDGAR) https://aibio.space/news/bon-natural-life-announces-share-buyback-up-1-0-million/https://aibio.space/news/bon-natural-life-announces-share-buyback-up-1-0-million/Tue, 03 Jun 2025 12:00:00 GMTFinancingsBon Natural Life's board approved a share repurchase of up to $1.0 million of its Class A ordinary shares, to be bought in the open market by TradeUp Securities as exclusive agent. The company says it is not obliged to buy any particular number of shares and may suspend the program at any time.Bon Natural Life Limited 6-K (2025-06-03) https://aibio.space/news/taysha-gene-therapies-holders-approve-raising-authorized-shares-700/https://aibio.space/news/taysha-gene-therapies-holders-approve-raising-authorized-shares-700/Tue, 03 Jun 2025 12:00:00 GMTListingsCommon stock authorized rises from 400,000,000 shares. The company filed the amendment in Delaware on June 2, 2025.Taysha Gene Therapies, Inc. 8-K (2025-06-03) https://aibio.space/news/actuate-therapeutics-presentation-repeats-going-concern-doubt-need/https://aibio.space/news/actuate-therapeutics-presentation-repeats-going-concern-doubt-need/Mon, 02 Jun 2025 12:00:00 GMTDistressActuate Therapeutics filed a corporate overview dated May 31, 2025 that repeats its going-concern warning and says it needs capital to fund operations beyond the second quarter of fiscal 2025. The deck's survival figures are draft, unaudited data, and its progression-free survival result is not statistically significant.Actuate Therapeutics, Inc. 8-K (2025-06-02) https://aibio.space/news/editas-medicine-holders-approve-doubling-authorized-common-stock-390/https://aibio.space/news/editas-medicine-holders-approve-doubling-authorized-common-stock-390/Mon, 02 Jun 2025 12:00:00 GMTListingsThe amended charter also lifts total authorized capital stock to 395,000,000 shares. Holders also approved a revised 2015 Stock Incentive Plan that removes its evergreen provision.Editas Medicine, Inc. 8-K (2025-06-02) https://aibio.space/news/adagene-files-sell-up-us-100-000-000-adss-market/https://aibio.space/news/adagene-files-sell-up-us-100-000-000-adss-market/Fri, 30 May 2025 12:00:00 GMTFinancingsAdagene Inc. filed a prospectus supplement for an at-the-market program of up to US$100 million of American depositary shares, sold through Leerink Partners. The filing repeats the warning that its auditor is in mainland China, where trading in its ADSs could be barred.Adagene Inc. 424B5 (2025-05-30) https://aibio.space/news/adlai-nortye-drops-buparlisib-after-phase-iii-miss-plans-workforce-cut/https://aibio.space/news/adlai-nortye-drops-buparlisib-after-phase-iii-miss-plans-workforce-cut/Fri, 30 May 2025 12:00:00 GMTDistressAdlai Nortye's Phase III BURAN trial of buparlisib missed its overall survival endpoint, the company is dropping the drug, and it plans to cut staff "to preserve cash," with the release giving no survival figures.Adlai Nortye Group Ltd. 6-K (2025-05-30) https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-sets-up-9-700-000-market/https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-sets-up-9-700-000-market/Fri, 30 May 2025 12:00:00 GMTFinancingsMaxim Group LLC is the exclusive sales agent for up to $9,700,000 of stock, for a 3.0% commission. Two days earlier, Nasdaq had determined to delist ReShape, whose stockholders' equity was $1.2 million at March 31, 2025.Vyome Holdings, Inc. 8-K (2025-05-30) https://aibio.space/news/metavia-gets-nasdaq-minimum-bid-price-notice-deadline-november-25-2025/https://aibio.space/news/metavia-gets-nasdaq-minimum-bid-price-notice-deadline-november-25-2025/Fri, 30 May 2025 12:00:00 GMTListingsThe company's stock closed below $1.00 for 30 consecutive business days. It may be eligible for a second period of 180 calendar days.MetaVia Inc. 8-K (2025-05-30) https://aibio.space/news/reviva-pharmaceuticals-sets-up-50-million-market-stock-program/https://aibio.space/news/reviva-pharmaceuticals-sets-up-50-million-market-stock-program/Fri, 30 May 2025 12:00:00 GMTFinancingsB. Riley Securities and Alliance Global Partners will act as sales agents for a 3% commission. The stock's last reported sale price was $1.10 on May 27, 2025.Reviva Pharmaceuticals Holdings, Inc. 8-K (2025-05-30) https://aibio.space/news/keros-therapeutics-plans-workforce-reduction-approximately-45-percent/https://aibio.space/news/keros-therapeutics-plans-workforce-reduction-approximately-45-percent/Thu, 29 May 2025 12:00:00 GMTDistressKeros's board approved a plan on May 28, 2025 to cut its overall workforce by about 45%, with about $3.2 million in severance charges and up to about $0.4 million in retention costs. The cuts follow the January 2025 early termination of the PAH trial over pericardial effusion events, though the company held $559.9 million in cash at the end of 2024.Keros Therapeutics, Inc. Form 8-K filed May 29, 2025 (SEC EDGAR) https://aibio.space/news/taysha-gene-therapies-prices-public-offering-46-868-687-shares-pre/https://aibio.space/news/taysha-gene-therapies-prices-public-offering-46-868-687-shares-pre/Thu, 29 May 2025 12:00:00 GMTLegalTaysha Gene Therapies agreed to sell 46,868,687 shares and pre-funded warrants for 25,858,586 more at $2.75 a share, with net proceeds estimated at $187.4 million. The company says that money and its existing cash will last into 2028, and the filing names no lawsuit or defendant.Taysha Gene Therapies, Inc. Form 8-K filed May 29, 2025 (SEC EDGAR) https://aibio.space/news/keros-therapeutics-drops-cibotercept-pah-cuts-about-45-percent-staff/https://aibio.space/news/keros-therapeutics-drops-cibotercept-pah-cuts-about-45-percent-staff/Thu, 29 May 2025 12:00:00 GMTDistressHeadcount will fall to 85 full-time employees, with average annualized savings of about $17 million. The strategic alternatives review is still under way.Keros Therapeutics, Inc. 8-K (2025-05-29) https://aibio.space/news/oric-pharmaceuticals-agrees-125-million-private-placement-led-sr-one/https://aibio.space/news/oric-pharmaceuticals-agrees-125-million-private-placement-led-sr-one/Wed, 28 May 2025 12:00:00 GMTFinancingsORIC Pharmaceuticals agreed to sell about 19.2 million shares or pre-funded warrants at $6.50 in a private placement with roughly $125 million in gross proceeds. The company says the cash funds operations into the second half of 2027, a runway tied to a Phase 3 readout it has not yet reported.Oric Pharmaceuticals, Inc. Form 8-K filed May 28, 2025 (SEC EDGAR) https://aibio.space/news/maia-biotechnology-agrees-695-000-private-placement-warrants/https://aibio.space/news/maia-biotechnology-agrees-695-000-private-placement-warrants/Wed, 28 May 2025 12:00:00 GMTFinancingsMAIA Biotechnology (NYSE American: MAIA) expects gross proceeds of approximately $695,000 from shares sold at $1.50 with warrants at $1.71. A director is among the buyers, and closing is expected May 29, 2025.MAIA Biotechnology, Inc. Form 8-K filed May 28, 2025 (SEC EDGAR) https://aibio.space/news/cytomx-therapeutics-regains-compliance-nasdaq-minimum-bid-price/https://aibio.space/news/cytomx-therapeutics-regains-compliance-nasdaq-minimum-bid-price/Wed, 28 May 2025 12:00:00 GMTListingsNasdaq closed the matter on May 27, 2025, after the stock closed at $1.00 or above for 10 consecutive trading days. The annual report put the lead programs in Phase 1, and the 8-K gives no cash figures.CytomX Therapeutics, Inc. 8-K (2025-05-28) https://aibio.space/news/immunic-launches-pre-funded-warrant-offering-final-terms-total-64-991/https://aibio.space/news/immunic-launches-pre-funded-warrant-offering-final-terms-total-64-991/Wed, 28 May 2025 12:00:00 GMTFinancingsImmunic began an underwritten warrant offering on May 28, 2025 and set final terms on May 30: $0.7499 a unit, $64,991,334 in total. Leerink Partners is sole bookrunner.Immunic, Inc. 8-K (2025-05-28) https://aibio.space/news/lexeo-therapeutics-agrees-80-million-private-placement-stock-warrants/https://aibio.space/news/lexeo-therapeutics-agrees-80-million-private-placement-stock-warrants/Tue, 27 May 2025 12:00:00 GMTFinancingsLexeo Therapeutics agreed to a private placement of 20,790,120 shares and pre-funded warrants for 6,963,556 more, with common warrants attached, for gross proceeds the company expects to be about $80 million. Part of that figure depends on warrants that have not been exercised, and the runway it cites depends on a 2027 readout.Lexeo Therapeutics, Inc. Form 8-K filed May 27, 2025 (SEC EDGAR) https://aibio.space/news/mind-medicine-now-definium-therapeutics-grants-new-cfo-inducement/https://aibio.space/news/mind-medicine-now-definium-therapeutics-grants-new-cfo-inducement/Tue, 27 May 2025 12:00:00 GMTListingsMindMed named Brandi L. Roberts chief financial officer effective June 2, 2025, with inducement awards of an option on 500,000 shares and 125,000 performance share units. The awards sit outside the company's equity plans, and the lead drug's pivotal trials have not yet reported.Definium Therapeutics, Inc. 8-K (2025-05-27) https://aibio.space/news/gt-biopharma-enlarges-preferred-stock-private-placement-5-950-000-00/https://aibio.space/news/gt-biopharma-enlarges-preferred-stock-private-placement-5-950-000-00/Tue, 27 May 2025 12:00:00 GMTFinancingsA new purchaser joined the Series L 10% Convertible Preferred deal, which now carries an aggregate purchase price of $5,950,000.00. Buyers also hold greenshoe rights for up to $21,616,514 more.GT Biopharma, Inc. 8-K (2025-05-27) https://aibio.space/news/lexeo-therapeutics-agrees-80-million-private-placement-2-8825-share/https://aibio.space/news/lexeo-therapeutics-agrees-80-million-private-placement-2-8825-share/Tue, 27 May 2025 12:00:00 GMTFinancingsLexeo expects gross proceeds of approximately $80 million from 20,790,120 shares or pre-funded warrants at $2.8825, with common warrants struck at $2.82.Lexeo Therapeutics, Inc. 8-K (2025-05-27) https://aibio.space/news/emergent-biosolutions-derivative-lawsuit-settlement-gets-preliminary/https://aibio.space/news/emergent-biosolutions-derivative-lawsuit-settlement-gets-preliminary/Fri, 23 May 2025 12:00:00 GMTLegalThe U.S. District Court for the District of Maryland granted preliminary approval on May 9, 2025 to a settlement of shareholder derivative suits against current and former Emergent directors and officers. The settlement provides a $15 million payment to the company from insurance and governance reforms, and final approval is set for August 6, 2025.Emergent BioSolutions Inc. Form 8-K filed May 23, 2025 (SEC EDGAR) https://aibio.space/news/artelo-biosciences-gets-nasdaq-notice-652-000-stockholders-equity/https://aibio.space/news/artelo-biosciences-gets-nasdaq-notice-652-000-stockholders-equity/Fri, 23 May 2025 12:00:00 GMTListingsThe May 22, 2025 letter cites Nasdaq Listing Rule 5550(b)(1). Artelo has until July 7, 2025 to submit a plan to regain compliance, and the stock stays listed in the meantime.ARTELO BIOSCIENCES, INC. Form 8-K filed May 23, 2025 (SEC EDGAR) https://aibio.space/news/boundless-bio-cuts-about-one-third-workforce-narrows-pipeline-sees/https://aibio.space/news/boundless-bio-cuts-about-one-third-workforce-narrows-pipeline-sees/Fri, 23 May 2025 12:00:00 GMTDistressBoundless Bio will drop current BBI-355 trial arms and test BBI-355 with BBI-825. The cut is expected to cost about $1.2 million. Cash and short-term investments were $138.3 million on March 31, 2025, with runway expected into the first half of 2028.Boundless Bio, Inc. Form 8-K filed May 23, 2025 (SEC EDGAR) https://aibio.space/news/plus-therapeutics-now-cerenome-gets-nasdaq-deficiency-notice-late-form/https://aibio.space/news/plus-therapeutics-now-cerenome-gets-nasdaq-deficiency-notice-late-form/Fri, 23 May 2025 12:00:00 GMTListingsNasdaq notified the company on May 21, 2025 that its late quarterly report breaks Listing Rule 5250(c)(1). It must submit an update to its compliance plan by July 21, 2025, and any exception could run until November 17, 2025.CERENOME, INC. Form 8-K filed May 23, 2025 (SEC EDGAR) https://aibio.space/news/biofrontera-falls-below-nasdaq-2-500-000-stockholders-equity/https://aibio.space/news/biofrontera-falls-below-nasdaq-2-500-000-stockholders-equity/Fri, 23 May 2025 12:00:00 GMTListingsBiofrontera reported stockholders' equity of $469,000 at March 31, 2025, far below the $2,500,000 Nasdaq requires. It has 45 calendar days to submit a plan to regain compliance.Biofrontera Inc. 8-K (2025-05-23) https://aibio.space/news/q32-bio-gets-nasdaq-notice-after-reporting-stockholders-deficit-4-0/https://aibio.space/news/q32-bio-gets-nasdaq-notice-after-reporting-stockholders-deficit-4-0/Fri, 23 May 2025 12:00:00 GMTListingsThe minimum stockholders' equity requirement is $2.5 million. Q32 Bio has 45 calendar days to submit a plan to regain compliance.Q32 Bio Inc. 8-K (2025-05-23) https://aibio.space/news/onconetix-gets-nasdaq-notice-unfiled-10-q-issues-294-117-65-note/https://aibio.space/news/onconetix-gets-nasdaq-notice-unfiled-10-q-issues-294-117-65-note/Thu, 22 May 2025 12:00:00 GMTListingsNasdaq flagged the missing quarterly report on May 20, 2025 as another basis for delisting, ahead of a Panel hearing set for May 27, 2025. Onconetix also issued a promissory note to Keystone Capital Partners for a $250,000.00 purchase price.Onconetix, Inc. Form 8-K filed May 22, 2025 (SEC EDGAR) https://aibio.space/news/aptevo-therapeutics-gets-nasdaq-stockholders-equity-notice-sets-1-20/https://aibio.space/news/aptevo-therapeutics-gets-nasdaq-stockholders-equity-notice-sets-1-20/Thu, 22 May 2025 12:00:00 GMTListingsAptevo reported a stockholders' deficit of $1,473,000 against a $2,500,000 minimum. It also filed an at-the-market prospectus supplement for up to $3,015,515 of stock, and it set a 1-for-20 reverse stock split for May 23, 2025.Aptevo Therapeutics Inc. Form 8-K filed May 22, 2025 (SEC EDGAR) https://aibio.space/news/sol-gel-technologies-regains-nasdaq-minimum-bid-price-compliance-after/https://aibio.space/news/sol-gel-technologies-regains-nasdaq-minimum-bid-price-compliance-after/Thu, 22 May 2025 12:00:00 GMTListingsNasdaq confirmed on May 22, 2025 that the bid price deficiency matter is closed. The stock closed at $1.00 or more for 13 consecutive business days.Sol-Gel Technologies Ltd. 6-K (2025-05-22) https://aibio.space/news/alumis-completes-acelyrin-merger-0-4814-alumis-shares-acelyrin-share/https://aibio.space/news/alumis-completes-acelyrin-merger-0-4814-alumis-shares-acelyrin-share/Wed, 21 May 2025 12:00:00 GMTMergersAlumis Inc. says the merger closed May 21, 2025, making ACELYRIN a wholly owned subsidiary. Alumis says its cash runway now extends into 2027, and Lynn Tetrault joined its board.ALUMIS INC. Form 8-K filed May 21, 2025 (SEC EDGAR) https://aibio.space/news/telomir-pharmaceuticals-raises-3-million-private-placement-largest/https://aibio.space/news/telomir-pharmaceuticals-raises-3-million-private-placement-largest/Wed, 21 May 2025 12:00:00 GMTFinancingsTelomir sold 1 million restricted shares at $3.00 each to The Bayshore Trust, an entity affiliated with its largest shareholder. The price is 18% above the $2.54 closing price on the day of signing, and an earlier insider purchase in December 2024 was made at $7.00 a share.Telomir Pharmaceuticals, Inc. Form 8-K filed May 21, 2025 (SEC EDGAR) https://aibio.space/news/alumis-completes-merger-acelyrin-0-4814-shares-acelyrin-share/https://aibio.space/news/alumis-completes-merger-acelyrin-0-4814-shares-acelyrin-share/Wed, 21 May 2025 12:00:00 GMTMergersThe closing release uses 0.4814 shares per ACELYRIN share, while the merger agreement and Alumis's annual report set 0.4274, and the release does not explain the gap.Alumis Inc. 8-K (2025-05-21) https://aibio.space/news/nasdaq-panel-moves-delist-petros-pharmaceuticals-trading-shift-otc/https://aibio.space/news/nasdaq-panel-moves-delist-petros-pharmaceuticals-trading-shift-otc/Wed, 21 May 2025 12:00:00 GMTListingsA Nasdaq Hearings Panel has decided to delist Petros, with trading suspended at the open on May 22, 2025, on four grounds that include equity and bid-price rules and concern over the February 2025 public offering. Petros will ask the Listing Council to review the decision.Petros Pharmaceuticals, Inc. 8-K (2025-05-21) https://aibio.space/news/intensity-therapeutics-gets-nasdaq-stockholders-equity-deficiency/https://aibio.space/news/intensity-therapeutics-gets-nasdaq-stockholders-equity-deficiency/Tue, 20 May 2025 12:00:00 GMTListingsNasdaq says the company, whose cash was $2,590 thousand at year-end 2024, fell short of the $2,500,000 stockholders' equity minimum and has until July 3, 2025 to submit a compliance plan.INTENSITY THERAPEUTICS, INC. Form 8-K filed May 20, 2025 (SEC EDGAR) https://aibio.space/news/rani-therapeutics-cuts-warrant-exercise-price-0-65-about-4-3-million/https://aibio.space/news/rani-therapeutics-cuts-warrant-exercise-price-0-65-about-4-3-million/Tue, 20 May 2025 12:00:00 GMTFinancingsRani Therapeutics cut the exercise price of two outstanding warrants from $3.08 and $3.00 to $0.65 so an existing institutional investor would exercise them, for gross proceeds of about $4.3 million before advisory fees. The investor also receives a new Series D warrant for up to 13,160,172 shares.Rani Therapeutics Holdings, Inc. Form 8-K filed May 20, 2025 (SEC EDGAR) https://aibio.space/news/acadia-pharmaceuticals-wins-delaware-ruling-nuplazid-formulation/https://aibio.space/news/acadia-pharmaceuticals-wins-delaware-ruling-nuplazid-formulation/Tue, 20 May 2025 12:00:00 GMTLegalA federal court in Delaware ruled for Acadia on infringement and validity of the '721 patent against Aurobindo and MSN entities. The company also signed a lease of 12 years and two months for new Princeton offices.ACADIA PHARMACEUTICALS INC Form 8-K filed May 20, 2025 (SEC EDGAR) https://aibio.space/news/regenxbio-receives-150-million-closing-royalty-bond-loan-healthcare/https://aibio.space/news/regenxbio-receives-150-million-closing-royalty-bond-loan-healthcare/Mon, 19 May 2025 12:00:00 GMTDebt FinancingA REGENXBIO subsidiary signed a limited recourse royalty bond with an affiliate of HealthCare Royalty Management, repaid only from royalties. The company says the $150 million received at closing extends its cash runway into early 2027.REGENXBIO Inc. Form 8-K filed May 19, 2025 (SEC EDGAR) https://aibio.space/news/royalty-pharma-completes-acquisition-rp-llc-200-000-000-cash-24-530/https://aibio.space/news/royalty-pharma-completes-acquisition-rp-llc-200-000-000-cash-24-530/Mon, 19 May 2025 12:00:00 GMTMergersRoyalty Pharma Holdings Ltd also assumed a $380 million term loan facility. The 8-K reports a loan amendment with Bank of America, N.A., an exchange agreement and amended articles of association.Royalty Pharma plc Form 8-K filed May 19, 2025 (SEC EDGAR) https://aibio.space/news/protagenic-therapeutics-combines-phytanix-bio-all-stock-deal/https://aibio.space/news/protagenic-therapeutics-combines-phytanix-bio-all-stock-deal/Mon, 19 May 2025 12:00:00 GMTMergersPhytanix Bio holders would own about 65% of the combined company before financing, on a fully diluted basis, and their preferred stock and warrants need Nasdaq stockholder approval before they can convert or be exercised. The release's count of six drug candidates includes five preclinical assets.Protagenic Therapeutics, Inc. 8-K (2025-05-19) https://aibio.space/news/china-sxt-sells-10-000-000-shares-warrants-5-100-000-gross/https://aibio.space/news/china-sxt-sells-10-000-000-shares-warrants-5-100-000-gross/Mon, 19 May 2025 12:00:00 GMTFinancingsChina SXT sold 10,000,000 shares with two warrants each for a combined $0.51 a share. The warrant exercise price resets to $0.24 on the seventh day, and the warrants could cover up to 100,000,000 shares. No placement agent or underwriter was used.China SXT Pharmaceuticals, Inc. 424B5 (2025-05-19) https://aibio.space/news/dermata-regains-nasdaq-stockholders-equity-compliance-but-gets-bid/https://aibio.space/news/dermata-regains-nasdaq-stockholders-equity-compliance-but-gets-bid/Fri, 16 May 2025 12:00:00 GMTListingsDermata said on May 16, 2025 that Nasdaq's staff has confirmed it regained compliance with the stockholders' equity requirement, but a bid price notice says its securities will be suspended on May 23, 2025 unless it requests a hearing by May 21. The company plans to request one.Dermata Therapeutics, Inc. Form 8-K filed May 16, 2025 (SEC EDGAR) https://aibio.space/news/neumora-gets-nasdaq-minimum-bid-price-notice-has-until-november-10/https://aibio.space/news/neumora-gets-nasdaq-minimum-bid-price-notice-has-until-november-10/Fri, 16 May 2025 12:00:00 GMTListingsNasdaq told Neumora Therapeutics on May 14, 2025 that it is below the $1.00 minimum bid price requirement. The company is weighing a reverse stock split, with a stockholder vote set for May 28, 2025.Neumora Therapeutics, Inc. Form 8-K filed May 16, 2025 (SEC EDGAR) https://aibio.space/news/neumora-therapeutics-gets-nasdaq-notice-stock-below-1-00-bid-price/https://aibio.space/news/neumora-therapeutics-gets-nasdaq-notice-stock-below-1-00-bid-price/Fri, 16 May 2025 12:00:00 GMTListingsThe company has until November 10, 2025 to regain compliance. Stockholders vote on a possible reverse stock split on May 28, 2025.Neumora Therapeutics, Inc. 8-K (2025-05-16) https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-files-nt-10-q-delaying-first/https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-files-nt-10-q-delaying-first/Thu, 15 May 2025 12:00:00 GMTDistressThe company says it needs more time to compile its financial statements for the quarter ended March 31, 2025, including to reflect the May 9, 2025 reverse stock split.Vyome Holdings, Inc Form NT 10-Q filed May 15, 2025 (SEC EDGAR) https://aibio.space/news/exicure-files-nt-10-q-late-filing-notice-needs-more-time-march-31-2025/https://aibio.space/news/exicure-files-nt-10-q-late-filing-notice-needs-more-time-march-31-2025/Thu, 15 May 2025 12:00:00 GMTDistressExicure told the SEC on May 15, 2025 that it cannot file its quarterly report for the period ended March 31, 2025 on time, because it has not finished the accounting for its acquisition of GPCR Therapeutics USA, Inc. The company expects to file within the five-day extension that Rule 12b-25 allows, and it says the acquisition will make the quarter's results hard to compare with last year.EXICURE, INC. Form NT 10-Q filed May 15, 2025 (SEC EDGAR) https://aibio.space/news/pulmatrix-says-cullgen-merger-registration-effective-plans-divest/https://aibio.space/news/pulmatrix-says-cullgen-merger-registration-effective-plans-divest/Thu, 15 May 2025 12:00:00 GMTMergersPulmatrix said the SEC declared effective the registration statement for its proposed merger with Cullgen, which it expects to close in June 2025. It plans to divest PUR3100 and its other assets as part of the deal. Its cash was $7.7 million on March 31, 2025.Pulmatrix, Inc. Form 8-K filed May 15, 2025 (SEC EDGAR) https://aibio.space/news/eloxx-pharmaceuticals-files-nt-10-q-cites-lack-funds-accountant-review/https://aibio.space/news/eloxx-pharmaceuticals-files-nt-10-q-cites-lack-funds-accountant-review/Thu, 15 May 2025 12:00:00 GMTDistressEloxx says it cannot afford to engage its auditor to review first quarter 2025 financials, and it expects to disclose substantial doubt about its ability to continue as a going concern. It expects cash of $0.4 million at March 31, 2025.Eloxx Pharmaceuticals, Inc. Form NT 10-Q filed May 15, 2025 (SEC EDGAR) https://aibio.space/news/omeros-exchanges-70-8-million-2026-convertible-notes-9-50-percent/https://aibio.space/news/omeros-exchanges-70-8-million-2026-convertible-notes-9-50-percent/Thu, 15 May 2025 12:00:00 GMTDebt FinancingThe one-for-one exchange also means Omeros no longer has to make a $20.0 million term loan prepayment. Separately, it agreed to convert $10 million of the old notes into common stock.OMEROS CORP Form 8-K filed May 15, 2025 (SEC EDGAR) https://aibio.space/news/plus-therapeutics-now-cerenome-says-first-quarter-10-q-will-late/https://aibio.space/news/plus-therapeutics-now-cerenome-says-first-quarter-10-q-will-late/Thu, 15 May 2025 12:00:00 GMTDistressThe company filed an NT 10-Q on May 15, 2025. It needs more time to account for warrants from a March 2025 private placement and expects lower stockholders' equity at March 31, 2025.CERENOME, INC. Form NT 10-Q filed May 15, 2025 (SEC EDGAR) https://aibio.space/news/atara-biotherapeutics-prices-about-16-0-million-registered-direct/https://aibio.space/news/atara-biotherapeutics-prices-about-16-0-million-registered-direct/Thu, 15 May 2025 12:00:00 GMTFinancingsThe deal includes 834,237 shares and pre-funded warrants for 1,587,108 more. Atara plans to use the money toward approval of tab-cel.Atara Biotherapeutics, Inc. 424B5 (2025-05-15) https://aibio.space/news/aspira-womens-health-delays-first-quarter-report-finish-debt-equity/https://aibio.space/news/aspira-womens-health-delays-first-quarter-report-finish-debt-equity/Thu, 15 May 2025 12:00:00 GMTDistressAspira says it needs more time to finish accounting for debt and equity deals from the first quarter, and it expects a smaller net loss helped by a milestone payment.Aspira Women's Health Inc. NT 10-Q (2025-05-15) https://aibio.space/news/plus-therapeutics-now-cerenome-delays-q1-report-warrant-accounting/https://aibio.space/news/plus-therapeutics-now-cerenome-delays-q1-report-warrant-accounting/Thu, 15 May 2025 12:00:00 GMTDistressThe company needs more time to finalize accounting for common stock purchase warrants issued in its March 2025 private placement. It expects a warrant liability that will lower stockholders' equity.Cerenome, Inc. NT 10-Q (2025-05-15) https://aibio.space/news/greenwich-lifesciences-delays-first-quarter-report-expects-file-may-20/https://aibio.space/news/greenwich-lifesciences-delays-first-quarter-report-expects-file-may-20/Thu, 15 May 2025 12:00:00 GMTDistressThe company filed a late-filing notice for its quarterly report for the three months ended March 31, 2025. Its lead candidate, GLSI-100, is in a Phase III trial that is still expanding.Greenwich LifeSciences, Inc. NT 10-Q (2025-05-15) https://aibio.space/news/hcw-biologics-closes-5-0-million-offering-671-140-units-7-45/https://aibio.space/news/hcw-biologics-closes-5-0-million-offering-671-140-units-7-45/Thu, 15 May 2025 12:00:00 GMTFinancingsEach unit carries two warrants exercisable at $7.45, and Maxim Group was sole placement agent. The prospectus carries going-concern doubt and a Nasdaq compliance warning.HCW Biologics Inc. 8-K (2025-05-15) https://aibio.space/news/hepion-pharmaceuticals-delays-quarterly-report-three-months-ended/https://aibio.space/news/hepion-pharmaceuticals-delays-quarterly-report-three-months-ended/Thu, 15 May 2025 12:00:00 GMTDistressHepion says it is still compiling information for its March quarter 10-Q and expects to file within five calendar days. The notice previews research and development spending of $22,235, down from $2.5 million.Hepion Pharmaceuticals, Inc. NT 10-Q (2025-05-15) https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-delays-first-quarter-10/https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-delays-first-quarter-10/Thu, 15 May 2025 12:00:00 GMTDistressReShape says a reverse stock split on May 9, 2025 is one reason its March quarter 10-Q needs more time. It expects to file within the five-day extension and says it does not expect a significant change in results.Vyome Holdings, Inc. NT 10-Q (2025-05-15) https://aibio.space/news/neuphoria-therapeutics-delays-quarterly-report-period-ended-march-31/https://aibio.space/news/neuphoria-therapeutics-delays-quarterly-report-period-ended-march-31/Thu, 15 May 2025 12:00:00 GMTDistressNeuphoria said it needs more time to compile supporting documents and let its auditor finish its review. It expects to file within the five-day extension period.Neuphoria Therapeutics Inc. NT 10-Q (2025-05-15) https://aibio.space/news/novelstem-international-delays-first-quarter-2025-report-auditors/https://aibio.space/news/novelstem-international-delays-first-quarter-2025-report-auditors/Thu, 15 May 2025 12:00:00 GMTDistressNovelStem says its auditors need more time to finish their review of the March quarter, and it expects to file within five calendar days after the due date. NewStem, in which it holds about 31%, ceased operations and began liquidation in October 2024.NovelStem International Corp. NT 10-Q (2025-05-15) https://aibio.space/news/osr-holdings-now-osr-health-delays-quarterly-report-expects-11-4/https://aibio.space/news/osr-holdings-now-osr-health-delays-quarterly-report-expects-11-4/Thu, 15 May 2025 12:00:00 GMTDistressThe company blamed a delay in finalizing its statements with its auditors after its February 14, 2025 business combination.OSR Health, Inc. NT 10-Q (2025-05-15) https://aibio.space/news/pulmatrix-says-cullgen-merger-filing-effective-expects-june-2025-close/https://aibio.space/news/pulmatrix-says-cullgen-merger-filing-effective-expects-june-2025-close/Thu, 15 May 2025 12:00:00 GMTMergersPulmatrix says the SEC has declared effective its Form S-4 for the Cullgen merger, and expects a June 2025 close while it seeks buyers for its own assets. It had $7.7 million of cash at March 31, 2025, which it says lasts through the anticipated closing.Pulmatrix, Inc. 8-K (2025-05-15) https://aibio.space/news/tivic-health-now-valion-bio-ends-quarter-669-000-cash-lines-up/https://aibio.space/news/tivic-health-now-valion-bio-ends-quarter-669-000-cash-lines-up/Thu, 15 May 2025 12:00:00 GMTListingsTivic reported $669,000 of cash at March 31, 2025 and a $1.5 million net loss for the quarter. It then lined up a $25 million equity line and a purchase agreement for up to $8.4 million of securities.Valion Bio, Inc. 8-K (2025-05-15) https://aibio.space/news/exicure-delays-first-quarter-report-gpcr-acquisition-accounting/https://aibio.space/news/exicure-delays-first-quarter-report-gpcr-acquisition-accounting/Thu, 15 May 2025 12:00:00 GMTDistressThe company said it needs more time on the purchase price allocation for GPCR Therapeutics USA, Inc. It expects results to change significantly from the March 31, 2024 quarter.Exicure, Inc. NT 10-Q (2025-05-15) https://aibio.space/news/metavia-closes-private-placement-about-10-0-million-gross-proceeds/https://aibio.space/news/metavia-closes-private-placement-about-10-0-million-gross-proceeds/Wed, 14 May 2025 12:00:00 GMTFinancingsMetaVia sold 9,479,345 shares at $0.71 each and pre-funded warrants for 4,605,162 shares. Ladenburg Thalmann was the exclusive placement agent, for a cash fee of 9.0% of gross proceeds.MetaVia Inc. Form 8-K filed May 14, 2025 (SEC EDGAR) https://aibio.space/news/jade-biosciences-files-q1-financials-after-aerovate-merger-334-2/https://aibio.space/news/jade-biosciences-files-q1-financials-after-aerovate-merger-334-2/Wed, 14 May 2025 12:00:00 GMTMergersJade Biosciences (Nasdaq: JBIO) reported a net loss of $38,169 thousand and cash of $49,929 thousand for the quarter ended March 31, 2025, a period that ended before the merger and pre-closing financing closed April 28.Jade Biosciences, Inc. Form 8-K filed May 14, 2025 (SEC EDGAR) https://aibio.space/news/citius-oncology-10-q-cites-auditors-going-concern-doubt/https://aibio.space/news/citius-oncology-10-q-cites-auditors-going-concern-doubt/Wed, 14 May 2025 12:00:00 GMTDistressCitius Oncology reported $112 in cash at March 31, 2025 and negative working capital of about $31.7 million. Its parent had sufficient capital to fund it only through May 2025, and Nasdaq gave it until October 20, 2025 to fix its bid price.Citius Oncology, Inc. 10-Q (2025-05-14) https://aibio.space/news/citius-pharmaceuticals-10-q-cites-going-concern-doubt-nasdaq/https://aibio.space/news/citius-pharmaceuticals-10-q-cites-going-concern-doubt-nasdaq/Wed, 14 May 2025 12:00:00 GMTDistressThe company had $26,410 in cash at March 31, 2025. Its own estimate says cash, including $1.735 million of net proceeds from an April offering, lasts only through May 2025, and it lost $21,792,751 in the six months to March 31.Citius Pharmaceuticals, Inc. 10-Q (2025-05-14) https://aibio.space/news/jade-biosciences-formerly-aerovate-details-334-2-million-pre-merger/https://aibio.space/news/jade-biosciences-formerly-aerovate-details-334-2-million-pre-merger/Wed, 14 May 2025 12:00:00 GMTMergersAerovate Therapeutics took the Jade Biosciences name when the deal closed on April 28, 2025. Pre-merger Jade's management team runs the combined company.Jade Biosciences, Inc. 8-K (2025-05-14) https://aibio.space/news/metavia-announces-10-0-million-private-placement-priced-market/https://aibio.space/news/metavia-announces-10-0-million-private-placement-priced-market/Wed, 14 May 2025 12:00:00 GMTFinancingsInvestors are buying 9,479,345 shares at $0.71 and 4,605,162 pre-funded warrants. Proceeds go mainly to development of obesity candidate DA-1726.MetaVia Inc. 8-K (2025-05-14) https://aibio.space/news/oncolytics-biotech-flags-going-concern-doubt-first-quarter-statements/https://aibio.space/news/oncolytics-biotech-flags-going-concern-doubt-first-quarter-statements/Wed, 14 May 2025 12:00:00 GMTFinancingsOncolytics had cash of 15,303 thousand Canadian dollars at March 31, 2025, and said it can fund operations through the third quarter of 2025.Oncolytics Biotech Inc. 6-K (2025-05-14) https://aibio.space/news/altimmune-draws-15-0-million-under-hercules-loan-agreement-up-100-0/https://aibio.space/news/altimmune-draws-15-0-million-under-hercules-loan-agreement-up-100-0/Tue, 13 May 2025 12:00:00 GMTDebt FinancingThe term loan has four tranches and matures June 1, 2029. The company reported $150 million in cash, cash equivalents and short-term investments as of March 31, 2025.Altimmune, Inc. Form 8-K filed May 13, 2025 (SEC EDGAR) https://aibio.space/news/sangamo-therapeutics-prices-23-0-million-offering-stock-warrants-0-50/https://aibio.space/news/sangamo-therapeutics-prices-23-0-million-offering-stock-warrants-0-50/Tue, 13 May 2025 12:00:00 GMTListingsSangamo's underwritten offering is expected to bring in about $23.0 million. The 46,633,393 purchase warrants in the deal outnumber the 12,235,000 common shares, and Cantor Fitzgerald & Co. represents the underwriters.Sangamo Therapeutics, Inc. 8-K (2025-05-13) https://aibio.space/news/united-therapeutics-files-patent-infringement-suit-against-liquidia/https://aibio.space/news/united-therapeutics-files-patent-infringement-suit-against-liquidia/Mon, 12 May 2025 12:00:00 GMTLegalThe complaint alleges Liquidia infringes U.S. Patent No. 11,357,782 and seeks to bar Liquidia from commercializing YUTREPIA if approved. Liquidia says the claims mirror a patent that the Patent Trial and Appeal Board held invalid.Liquidia Corp Form 8-K filed May 12, 2025 (SEC EDGAR) https://aibio.space/news/atara-biotherapeutics-cuts-workforce-about-30-percent-expects-1-4/https://aibio.space/news/atara-biotherapeutics-cuts-workforce-about-30-percent-expects-1-4/Mon, 12 May 2025 12:00:00 GMTDistressThe company will keep about 23 employees after the cut and expects about $1.4 million in severance. Its latest annual report said cash of $42.5 million would not last twelve months and that about $15 million more was needed to pursue US approval of its lead drug.Atara Biotherapeutics, Inc. Form 8-K filed May 12, 2025 (SEC EDGAR) https://aibio.space/news/abeona-therapeutics-agrees-sell-priority-review-voucher-155-million/https://aibio.space/news/abeona-therapeutics-agrees-sell-priority-review-voucher-155-million/Mon, 12 May 2025 12:00:00 GMTFinancingsAbeona received the voucher when the FDA approved ZEVASKYN on April 28, 2025. The company says the proceeds give it cash for more than two years of operating expenses, but the release does not name the buyer.Abeona Therapeutics Inc. 8-K (2025-05-12) https://aibio.space/news/cervomed-sets-up-market-program-up-50-000-000-leerink-partners/https://aibio.space/news/cervomed-sets-up-market-program-up-50-000-000-leerink-partners/Mon, 12 May 2025 12:00:00 GMTFinancingsLeerink Partners earns 3.0% of any gross proceeds, and CervoMed is not obliged to sell any shares. The prospectus supplement notes an auditor going-concern paragraph.CervoMed Inc. 8-K (2025-05-12) https://aibio.space/news/nasdaq-panel-delists-hepion-pharmaceuticals-company-expects-otc/https://aibio.space/news/nasdaq-panel-delists-hepion-pharmaceuticals-company-expects-otc/Mon, 12 May 2025 12:00:00 GMTListingsNasdaq's hearings panel decided to delist Hepion after it failed the $1.00 minimum bid price and Nasdaq said it believes the company is a public shell. Trading was set to stop on May 13, 2025, and Hepion expects its shares to quote on the OTC Markets.Hepion Pharmaceuticals, Inc. 8-K (2025-05-12) https://aibio.space/news/immunome-reports-317-3-million-cash-expects-runway-2027/https://aibio.space/news/immunome-reports-317-3-million-cash-expects-runway-2027/Mon, 12 May 2025 12:00:00 GMTListingsImmunome's cash total includes $161.7 million from a January 2025 financing, and the quarter ended with a $41.6 million net loss. Its lead drug's Phase 3 data are not due until the second half of 2025.Immunome, Inc. 8-K (2025-05-12) https://aibio.space/news/tango-therapeutics-files-400-000-000-replacement-shelf-100-000-000-atm/https://aibio.space/news/tango-therapeutics-files-400-000-000-replacement-shelf-100-000-000-atm/Mon, 12 May 2025 12:00:00 GMTFinancingsThe new shelf replaces one that expires on September 12, 2025. Jefferies LLC would earn up to 3.0% on ATM sales, and Tango's stock closed at $1.10 per share on May 8, 2025.Tango Therapeutics, Inc. S-3 (2025-05-12) https://aibio.space/news/zeo-scientifix-issues-100-000-shares-warrants-500-000-shares/https://aibio.space/news/zeo-scientifix-issues-100-000-shares-warrants-500-000-shares/Mon, 12 May 2025 12:00:00 GMTFinancingsThe company also granted fully vested options at $2.86 per share to its interim chief executive and directors.Zeo ScientifiX Inc. 8-K (2025-05-12) https://aibio.space/news/apimeds-pharmaceuticals-us-prices-13-5-million-ipo-4-00-share/https://aibio.space/news/apimeds-pharmaceuticals-us-prices-13-5-million-ipo-4-00-share/Fri, 09 May 2025 12:00:00 GMTFinancingsApimeds is selling 3,375,000 shares at $4.00 for $13.5 million gross and listing on the NYSE American as APUS. Its controlling holder stays above 54%, and the company carries a going-concern paragraph from its auditor.Apimeds Pharmaceuticals US, Inc. 424B4 (2025-05-09) https://aibio.space/news/nuvectis-pharma-sets-up-60-million-market-stock-program-leerink/https://aibio.space/news/nuvectis-pharma-sets-up-60-million-market-stock-program-leerink/Fri, 09 May 2025 12:00:00 GMTFinancingsNuvectis can sell up to $60 million of stock through Leerink. It ended an earlier $40 million program with H.C. Wainwright after selling about $18.6 million under it.Nuvectis Pharma, Inc. 424B5 (2025-05-09) https://aibio.space/news/vor-biopharma-winds-down-clinical-operations-cuts-147-jobs-explores/https://aibio.space/news/vor-biopharma-winds-down-clinical-operations-cuts-147-jobs-explores/Thu, 08 May 2025 12:00:00 GMTDistressVor estimates about $19.3 million in wind-down costs and plans to keep about 8 employees. Its chief financial officer and chief scientific officer were terminated without cause.Vor Biopharma Inc. Form 8-K filed May 8, 2025 (SEC EDGAR) https://aibio.space/news/elutia-issues-1-105-528-shares-ligand-settle-2-2-million-royalties/https://aibio.space/news/elutia-issues-1-105-528-shares-ligand-settle-2-2-million-royalties/Thu, 08 May 2025 12:00:00 GMTFinancingsElutia receives no cash from the issuance. In its first-quarter results it said the change reduces cash outflows by $2.2 million in H1 2025.Elutia, Inc. 8-K (2025-05-08) https://aibio.space/news/liquidia-files-2024-financials-going-concern-doubt-revised-debt/https://aibio.space/news/liquidia-files-2024-financials-going-concern-doubt-revised-debt/Thu, 08 May 2025 12:00:00 GMTDistressThe auditor's report cites recurring losses. Management also changed how it accounts for two amendments to a $100.0 million royalty-backed financing.Liquidia Corporation 8-K (2025-05-08) https://aibio.space/news/korro-bio-announces-20-percent-workforce-reduction-expects-cash-runway/https://aibio.space/news/korro-bio-announces-20-percent-workforce-reduction-expects-cash-runway/Wed, 07 May 2025 12:00:00 GMTDistressKorro Bio began a restructuring on May 7, 2025, cutting about 20% of its workforce and taking one-time charges of about $1.2 million. The company cut costs before its first interim data readout, and its net loss widened in the first quarter.Korro Bio, Inc. Form 8-K filed May 7, 2025 (SEC EDGAR) https://aibio.space/news/cosmos-health-gets-second-180-day-nasdaq-period-lift-stock-above-1-00/https://aibio.space/news/cosmos-health-gets-second-180-day-nasdaq-period-lift-stock-above-1-00/Wed, 07 May 2025 12:00:00 GMTListingsNasdaq gave the company until November 3, 2025 to lift its bid above $1.00 for 10 straight business days. The first 180-day period expired on May 5, 2025, and the release gives no plan beyond the CEO's stated confidence.Cosmos Health Inc. 8-K (2025-05-07) https://aibio.space/news/design-therapeutics-files-300-000-000-shelf-100-000-000-atm-sales/https://aibio.space/news/design-therapeutics-files-300-000-000-shelf-100-000-000-atm-sales/Wed, 07 May 2025 12:00:00 GMTFinancingsJefferies LLC is the sales agent under an Open Market Sale Agreement for the $100,000,000 at-the-market portion. The May 7, 2025 filing gives a last reported sale price of $4.36 on May 5, 2025 and does not state a cash balance.Design Therapeutics, Inc. S-3 (2025-05-07) https://aibio.space/news/cyclerion-therapeutics-now-korsana-biosciences-sets-up-atm-program/https://aibio.space/news/cyclerion-therapeutics-now-korsana-biosciences-sets-up-atm-program/Wed, 07 May 2025 12:00:00 GMTFinancingsThe agreement covers up to $20,000,000 of stock, but small-float limits cap current sales at $2,994,080.Korsana Biosciences, Inc. 424B5 (2025-05-07) https://aibio.space/news/nucana-plc-prices-best-efforts-offering-2-452-935-adss-warrants/https://aibio.space/news/nucana-plc-prices-best-efforts-offering-2-452-935-adss-warrants/Wed, 07 May 2025 12:00:00 GMTFinancingsThe combined price of $0.6454 per ADS is set below the $1.10 last sale price on May 5, 2025. Warrant terms and a zero exercise price option on the Series B warrants could issue far more ADSs than the 2,452,935 sold.NuCana plc 424B4 (2025-05-07) https://aibio.space/news/transcode-therapeutics-faces-nasdaq-delisting-no-grace-period-plans/https://aibio.space/news/transcode-therapeutics-faces-nasdaq-delisting-no-grace-period-plans/Wed, 07 May 2025 12:00:00 GMTListingsTransCode received a Nasdaq notice on May 6, 2025 that its stock would be delisted from the Nasdaq Capital Market unless it appeals. Earlier reverse splits left it with no compliance period, so it must request a hearing by May 13, 2025.TransCode Therapeutics, Inc. 8-K (2025-05-07) https://aibio.space/news/cogent-biosciences-files-50-000-000-market-stock-sales/https://aibio.space/news/cogent-biosciences-files-50-000-000-market-stock-sales/Tue, 06 May 2025 12:00:00 GMTFinancingsThe amount is what remains under a $75,000,000 sales agreement with Guggenheim Securities after $25,000,000 was sold earlier. Dilution to new buyers at the May 2 price is $4.05 per share, and the company has recorded net losses in every year since it was founded.Cogent Biosciences, Inc. 424B5 (2025-05-06) https://aibio.space/news/exicure-buys-about-3-125-million-convertible-bonds-south-korean/https://aibio.space/news/exicure-buys-about-3-125-million-convertible-bonds-south-korean/Tue, 06 May 2025 12:00:00 GMTFinancingsThe bonds of KC Creation Co., Ltd. mature on April 30, 2028 and yield 2.9% a year. KC Creation expects to use the money to buy stocks of other corporations.Exicure, Inc. 8-K (2025-05-06) https://aibio.space/news/evolus-signs-amended-loan-agreement-150-000-000-first-tranche/https://aibio.space/news/evolus-signs-amended-loan-agreement-150-000-000-first-tranche/Mon, 05 May 2025 12:00:00 GMTDebt FinancingEvolus signed term loans of up to $250,000,000 in three tranches, with $150,000,000 advanced at the effective date. The loans carry 3-month SOFR plus 5.0%, with a 3.50% floor, and mature five years after the first tranche. Early repayment carries an exit payment of 2% of principal prepaid.Evolus, Inc. Form 8-K filed May 5, 2025 (SEC EDGAR) https://aibio.space/news/palisade-bio-gets-nasdaq-minimum-bid-price-deficiency-notice-has-180/https://aibio.space/news/palisade-bio-gets-nasdaq-minimum-bid-price-deficiency-notice-has-180/Fri, 02 May 2025 12:00:00 GMTListingsPalisade Bio received a Nasdaq minimum bid price notice on April 30, 2025, after its stock closed below $1.00 for 30 consecutive trading days. It has 180 calendar days to regain compliance, and its 2024 annual report carries a going-concern warning alongside $9.8 million of cash.PALISADE BIO, INC. Form 8-K filed May 2, 2025 (SEC EDGAR) https://aibio.space/news/palisade-bio-gets-nasdaq-notice-trading-below-1-00-minimum-bid-price/https://aibio.space/news/palisade-bio-gets-nasdaq-notice-trading-below-1-00-minimum-bid-price/Fri, 02 May 2025 12:00:00 GMTListingsPalisade Bio has 180 calendar days from an April 30, 2025 Nasdaq notice to get its shares back above $1.00, and its lead candidate is still in a Phase 1 study.Palisade Bio, Inc. 8-K (2025-05-02) https://aibio.space/news/pds-biotechnology-sells-convertible-debentures-20-000-000-retire/https://aibio.space/news/pds-biotechnology-sells-convertible-debentures-20-000-000-retire/Fri, 02 May 2025 12:00:00 GMTDebt FinancingPDS Biotechnology sold $22,222,222 of senior secured convertible debentures for $20,000,000 on April 30, 2025, and used about $19 million to repay its Horizon Technology loan. The filing names no placement agent, underwriter, financial adviser or counsel.PDS Biotechnology Corporation 8-K (2025-05-02) https://aibio.space/news/arvinas-cuts-workforce-about-33-percent-drops-two-phase-3/https://aibio.space/news/arvinas-cuts-workforce-about-33-percent-drops-two-phase-3/Thu, 01 May 2025 12:00:00 GMTDistressArvinas expects about $10 million in severance and termination costs, mostly in the second quarter of 2025. It and Pfizer removed two planned Phase 3 combination trials from the joint development plan.ARVINAS, INC. Form 8-K filed May 1, 2025 (SEC EDGAR) https://aibio.space/news/aerovate-therapeutics-now-jade-biosciences-completes-merger-private/https://aibio.space/news/aerovate-therapeutics-now-jade-biosciences-completes-merger-private/Thu, 01 May 2025 12:00:00 GMTMergersAerovate Therapeutics, whose only drug candidate missed its Phase 2b primary endpoint, closed its merger with Jade Biosciences on April 28, 2025. Aerovate holders kept about 1.4% of the combined company, and the financing includes $95 million of converted notes.Jade Biosciences, Inc. Form 8-K filed May 1, 2025 (SEC EDGAR) https://aibio.space/news/pliant-therapeutics-cut-workforce-about-45-percent-expects-3-6-million/https://aibio.space/news/pliant-therapeutics-cut-workforce-about-45-percent-expects-3-6-million/Thu, 01 May 2025 12:00:00 GMTDistressPliant expects to substantially complete the reduction by the end of the second quarter of 2025, with about $3.6 million in severance and related benefits. The cut follows the discontinuation of its BEACON-IPF Phase 2b trial of bexotegrast.PLIANT THERAPEUTICS, INC. Form 8-K filed May 1, 2025 (SEC EDGAR) https://aibio.space/news/an2-therapeutics-reports-ebo-301-miss-projects-78-5-million-cash-lasts/https://aibio.space/news/an2-therapeutics-reports-ebo-301-miss-projects-78-5-million-cash-lasts/Thu, 01 May 2025 12:00:00 GMTDistressAN2 Therapeutics says the Phase 3 portion of its EBO-301 study missed its primary endpoint, and it projects $78.5 million in cash lasting into 2028 while it shifts to Chagas, melioidosis and oncology programs that have no human efficacy data yet.AN2 Therapeutics, Inc. 8-K (2025-05-01) https://aibio.space/news/armata-pharmaceuticals-flags-going-concern-paragraph-gets-4-65-million/https://aibio.space/news/armata-pharmaceuticals-flags-going-concern-paragraph-gets-4-65-million/Thu, 01 May 2025 12:00:00 GMTListingsThe audit opinion in Armata's 2024 annual report contains a going concern explanatory paragraph. The company also received $4.65 million of additional Department of Defense award funding.Armata Pharmaceuticals, Inc. 8-K (2025-05-01) https://aibio.space/news/pasithea-therapeutics-files-share-warrant-offering-later-prices-1-40/https://aibio.space/news/pasithea-therapeutics-files-share-warrant-offering-later-prices-1-40/Thu, 01 May 2025 12:00:00 GMTFinancingsThe May 1, 2025 registration statement covered up to 3,246,753 shares at an assumed $1.54. The deal priced on May 6, 2025 at $1.40 for 3,571,428 shares or pre-funded warrants.Pasithea Therapeutics Corp. S-1 (2025-05-01) https://aibio.space/news/nymox-says-20-f-late-citing-unfinished-work-slow-vendor-replies/https://aibio.space/news/nymox-says-20-f-late-citing-unfinished-work-slow-vendor-replies/Thu, 01 May 2025 12:00:00 GMTDistressThe company says it is still compiling required information for its annual report for the year ended December 31, 2024.Nymox Pharmaceutical Corp. NT 20-F (2025-05-01) https://aibio.space/news/xortx-therapeutics-files-late-filing-notice-2024-annual-report/https://aibio.space/news/xortx-therapeutics-files-late-filing-notice-2024-annual-report/Thu, 01 May 2025 12:00:00 GMTDistressThe company says it needs more time for financial reporting, closing procedures and other disclosure items.XORTX Therapeutics Inc. NT 20-F (2025-05-01) https://aibio.space/news/abvc-biopharma-gets-nasdaq-equity-notice-sells-724-372-shares-offshore/https://aibio.space/news/abvc-biopharma-gets-nasdaq-equity-notice-sells-724-372-shares-offshore/Wed, 30 Apr 2025 12:00:00 GMTListingsABVC reported stockholders' equity of $723,959, below the $2,500,000 Nasdaq minimum. It also sold shares to 15 non-U.S. buyers for a little more than $436,000.ABVC BioPharma, Inc. 8-K (2025-04-30) https://aibio.space/news/avenue-therapeutics-ends-aj201-license-transfers-program-back-annji/https://aibio.space/news/avenue-therapeutics-ends-aj201-license-transfers-program-back-annji/Wed, 30 Apr 2025 12:00:00 GMTMergersAnnJi will pay Avenue $2.0 million over 90 days, plus possible milestones and a 1.75% royalty.Avenue Therapeutics, Inc. 8-K (2025-04-30) https://aibio.space/news/quoin-pharmaceuticals-regains-compliance-nasdaq-1-00-minimum-bid-price/https://aibio.space/news/quoin-pharmaceuticals-regains-compliance-nasdaq-1-00-minimum-bid-price/Wed, 30 Apr 2025 12:00:00 GMTListingsNasdaq said on April 29, 2025 that Quoin's ADSs closed at $1.00 or more from April 9 to April 28, closing the minimum bid price matter. The company says it has no commercialized product and has generated no revenue to date.Quoin Pharmaceuticals, Ltd. 8-K (2025-04-30) https://aibio.space/news/scilex-holding-regains-compliance-nasdaq-minimum-bid-price-rule/https://aibio.space/news/scilex-holding-regains-compliance-nasdaq-minimum-bid-price-rule/Wed, 30 Apr 2025 12:00:00 GMTListingsScilex met the $1.00 minimum closing bid price requirement on April 30, 2025. Its common stock and public warrants stay on the Nasdaq Capital Market.Scilex Holding Company 8-K (2025-04-30) https://aibio.space/news/trisalus-agrees-sell-5-500-000-shares-4-00-22-0-million-private/https://aibio.space/news/trisalus-agrees-sell-5-500-000-shares-4-00-22-0-million-private/Wed, 30 Apr 2025 12:00:00 GMTMergersTriSalus agreed to sell 5,500,000 shares at $4.00 in a private placement of about $22.0 million. The same deal ties it to an exchange offer for its Series A preferred stock, and the filing says the preferred terms would change.TriSalus Life Sciences, Inc. 425 (2025-04-30) https://aibio.space/news/xtl-biopharmaceuticals-20-f-lists-going-concern-delisting-risks/https://aibio.space/news/xtl-biopharmaceuticals-20-f-lists-going-concern-delisting-risks/Wed, 30 Apr 2025 12:00:00 GMTDistressThe annual report for 2024 also lists dilution risk and the availability of capital for working capital needs.XTL Biopharmaceuticals Ltd. 20-F (2025-04-30) https://aibio.space/news/entrada-therapeutics-plans-workforce-reduction-about-20-percent-focus/https://aibio.space/news/entrada-therapeutics-plans-workforce-reduction-about-20-percent-focus/Tue, 29 Apr 2025 12:00:00 GMTDistressThe board approved a strategic plan on April 29, 2025 that expects about $2 million in charges, mostly severance. The company says its cash runway still reaches into the second quarter of 2027.Entrada Therapeutics, Inc. Form 8-K filed April 29, 2025 (SEC EDGAR) https://aibio.space/news/pfizer-expands-cost-realignment-program-adds-1-2-billion-expected/https://aibio.space/news/pfizer-expands-cost-realignment-program-adds-1-2-billion-expected/Tue, 29 Apr 2025 12:00:00 GMTDistressPfizer expects approximately $1.6 billion in one-time costs to deliver the added savings by the end of 2027. It now targets approximately $5.7 billion of total net cost savings from the program.PFIZER INC Form 8-K filed April 29, 2025 (SEC EDGAR) https://aibio.space/news/amarin-regains-compliance-nasdaq-minimum-bid-price-requirement/https://aibio.space/news/amarin-regains-compliance-nasdaq-minimum-bid-price-requirement/Tue, 29 Apr 2025 12:00:00 GMTListingsNasdaq confirmed on April 29, 2025 that the stock averaged at least $1.00 over 10 consecutive business days. Amarin will stay listed on Nasdaq.Amarin Corporation plc 8-K (2025-04-29) https://aibio.space/news/scinai-files-late-20-f-notice-accounting-29-million-loan-conversion/https://aibio.space/news/scinai-files-late-20-f-notice-accounting-29-million-loan-conversion/Tue, 29 Apr 2025 12:00:00 GMTDistressThe company cites the conversion of its European Investment Bank debt to preferred equity and personnel losses after year-end, and expects to file by May 15, 2025.Scinai Immunotherapeutics Ltd. NT 20-F (2025-04-29) https://aibio.space/news/entrada-therapeutics-cut-about-20-percent-workforce-strategic-plan/https://aibio.space/news/entrada-therapeutics-cut-about-20-percent-workforce-strategic-plan/Tue, 29 Apr 2025 12:00:00 GMTDistressEntrada Therapeutics will cut about 20% of its workforce, with charges of about $2 million mostly in the second quarter of 2025. The 8-K gives the cash runway as lasting into the second quarter of 2027 in one place and into the second half of 2027 in another.Entrada Therapeutics, Inc. 8-K (2025-04-29) https://aibio.space/news/zhengye-biotechnology-files-late-filing-notice-auditor-needs-more-time/https://aibio.space/news/zhengye-biotechnology-files-late-filing-notice-auditor-needs-more-time/Tue, 29 Apr 2025 12:00:00 GMTDistressThe company says it is still compiling information for its annual report for the year ended December 31, 2024.Zhengye Biotechnology Holding Limited NT 20-F (2025-04-29) https://aibio.space/news/in8bio-expects-about-1-9-million-reduced-price-warrant-exercises/https://aibio.space/news/in8bio-expects-about-1-9-million-reduced-price-warrant-exercises/Mon, 28 Apr 2025 12:00:00 GMTFinancingsHolders agreed to exercise Series A and Series B warrants for cash at $0.1784 to $0.1844 per share by May 2, 2025. Two holders will swap warrants for pre-funded warrants, and IN8bio will cut the price of certain other Series B warrants to $0.45.IN8BIO, INC. Form 8-K filed April 28, 2025 (SEC EDGAR) https://aibio.space/news/serina-therapeutics-sets-up-13-270-500-market-share-sales-program/https://aibio.space/news/serina-therapeutics-sets-up-13-270-500-market-share-sales-program/Mon, 28 Apr 2025 12:00:00 GMTFinancingsSerina can sell up to $13,270,500 of stock through JonesTrading, which earns up to a 3.0% commission. Its auditor has raised going concern doubt, its lead drug is still preclinical, and the program's size is capped by an SEC float rule.Serina Therapeutics, Inc. 424B5 (2025-04-28) https://aibio.space/news/tempest-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/https://aibio.space/news/tempest-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/Mon, 28 Apr 2025 12:00:00 GMTListingsNasdaq sent the company a formal notice of compliance on April 24, 2025. The 8-K does not say how the price was restored, and the lead drug's Phase 3 timeline is subject to funding.Tempest Therapeutics, Inc. 8-K (2025-04-28) https://aibio.space/news/salarius-pharmaceuticals-now-decoy-therapeutics-gets-nasdaq-delisting/https://aibio.space/news/salarius-pharmaceuticals-now-decoy-therapeutics-gets-nasdaq-delisting/Fri, 25 Apr 2025 12:00:00 GMTListingsNasdaq says the stock's bid price was below $1.00 for 30 consecutive business days and, after a recent reverse stock split, no compliance period applies. The company plans to appeal by April 30, 2025.Decoy Therapeutics Inc. Form 8-K filed April 25, 2025 (SEC EDGAR) https://aibio.space/news/incannex-healthcare-inc-gets-nasdaq-minimum-bid-price-notice-has-until/https://aibio.space/news/incannex-healthcare-inc-gets-nasdaq-minimum-bid-price-notice-has-until/Fri, 25 Apr 2025 12:00:00 GMTListingsNasdaq told Incannex on April 23, 2025 that its shares had closed below $1.00 for 30 consecutive trading days, giving it until October 20, 2025 to regain compliance. Its annual report for the year ended June 30, 2024 carries an auditor's going concern paragraph.Incannex Healthcare Inc. Form 8-K filed April 25, 2025 (SEC EDGAR) https://aibio.space/news/spruce-biosciences-gets-nasdaq-delisting-notice-suspension-set-april/https://aibio.space/news/spruce-biosciences-gets-nasdaq-delisting-notice-suspension-set-april/Fri, 25 Apr 2025 12:00:00 GMTListingsNasdaq will suspend trading on April 29, 2025, and the company's appeal will not stop it. The company is cutting 55% of staff to focus on a rare-disease therapy it has not yet filed for approval, with going-concern doubt on record.SPRUCE BIOSCIENCES, INC. Form 8-K filed April 25, 2025 (SEC EDGAR) https://aibio.space/news/verastem-agrees-75-million-private-placement-stock-pre-funded-warrants/https://aibio.space/news/verastem-agrees-75-million-private-placement-stock-pre-funded-warrants/Fri, 25 Apr 2025 12:00:00 GMTFinancingsVerastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.Verastem, Inc. Form 8-K filed April 25, 2025 (SEC EDGAR) https://aibio.space/news/nyse-american-accepts-aeon-biopharma-plan-sets-august-3-2026-deadline/https://aibio.space/news/nyse-american-accepts-aeon-biopharma-plan-sets-august-3-2026-deadline/Fri, 25 Apr 2025 12:00:00 GMTListingsNYSE American accepted AEON Biopharma's plan to regain compliance with three continued listing standards and gave the company until August 3, 2026. The 8-K does not say which financial measures the company missed, and the company's migraine trials failed their primary endpoints.AEON Biopharma, Inc. 8-K (2025-04-25) https://aibio.space/news/pluri-swaps-976-139-shares-held-directors-company-pre-funded-warrants/https://aibio.space/news/pluri-swaps-976-139-shares-held-directors-company-pre-funded-warrants/Fri, 25 Apr 2025 12:00:00 GMTFinancingsThe investor is a company wholly beneficially owned by director Alejandro Weinstein. The new warrants can be exercised only after shareholder approvals required by Nasdaq rules.Pluri Inc. 8-K (2025-04-25) https://aibio.space/news/verastem-oncology-announces-75-million-private-placement-led-rtw/https://aibio.space/news/verastem-oncology-announces-75-million-private-placement-led-rtw/Fri, 25 Apr 2025 12:00:00 GMTFinancingsVerastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.Verastem, Inc. 8-K (2025-04-25) https://aibio.space/news/caribou-biosciences-cuts-47-jobs-drops-programs-sees-cash-runway/https://aibio.space/news/caribou-biosciences-cuts-47-jobs-drops-programs-sees-cash-runway/Thu, 24 Apr 2025 12:00:00 GMTDistressCaribou will reduce its workforce by 47 employees, discontinue its lupus trial, a CB-012 trial and preclinical research, and focus on CB-010 and CB-011. It reported a preliminary $212.5 million in cash and securities at March 31, 2025.Caribou Biosciences, Inc. Form 8-K filed April 24, 2025 (SEC EDGAR) https://aibio.space/news/nucana-files-offering-up-16-049-383-adss-series-b-warrants/https://aibio.space/news/nucana-files-offering-up-16-049-383-adss-series-b-warrants/Thu, 24 Apr 2025 12:00:00 GMTFinancingsThe offering is a best-efforts deal placed by Laidlaw & Company (UK) Ltd. Warrant terms with a zero exercise price option and reset provisions could push the number of ADSs issued far above the 16,049,383 offered.NuCana plc F-1 (2025-04-24) https://aibio.space/news/rezolute-prices-registered-direct-offering-about-90-million-3-25-share/https://aibio.space/news/rezolute-prices-registered-direct-offering-about-90-million-3-25-share/Wed, 23 Apr 2025 12:00:00 GMTFinancingsRezolute will sell 20,786,923 shares at $3.25 and pre-funded warrants for up to 6,905,385 shares, through Guggenheim Securities as representative of the underwriters. Estimated net proceeds are $84.2 million, and insiders separately agreed to buy up to $10,000,000 of stock at the same price.Rezolute, Inc. Form 8-K filed April 23, 2025 (SEC EDGAR) https://aibio.space/news/cero-therapeutics-signs-up-8-million-series-d-convertible-preferred/https://aibio.space/news/cero-therapeutics-signs-up-8-million-series-d-convertible-preferred/Tue, 22 Apr 2025 12:00:00 GMTFinancingsAbout $5 million is expected at the first closing. The company said the money will also help address Nasdaq shareholders' equity deficiencies.CERo Therapeutics Holdings, Inc. 8-K (2025-04-22) https://aibio.space/news/pacira-biosciences-approves-new-buyback-up-300-0-million/https://aibio.space/news/pacira-biosciences-approves-new-buyback-up-300-0-million/Tue, 22 Apr 2025 12:00:00 GMTFinancingsPacira BioSciences says its board approved a $300.0 million repurchase program on April 17, 2025, replacing the program announced in May 2024, while EXPAREL still accounts for most of its revenue.Pacira BioSciences, Inc. 8-K (2025-04-22) https://aibio.space/news/invivyd-signs-term-loan-facility-up-30-million-silicon-valley-bank/https://aibio.space/news/invivyd-signs-term-loan-facility-up-30-million-silicon-valley-bank/Mon, 21 Apr 2025 12:00:00 GMTDebt FinancingSilicon Valley Bank, a division of First-Citizens Bank & Trust Company, can lend Invivyd up to $30 million in three tranches. Only the first $10 million is open without revenue milestones, and the loans are due March 1, 2029.Invivyd, Inc. Form 8-K filed April 21, 2025 (SEC EDGAR) https://aibio.space/news/mind-medicine-mindmed-inc-now-definium-therapeutics-inc-refinances-42/https://aibio.space/news/mind-medicine-mindmed-inc-now-definium-therapeutics-inc-refinances-42/Mon, 21 Apr 2025 12:00:00 GMTDebt FinancingThe company refinanced its K2 HealthVentures term loans with a $42.0 million first tranche, cut the interest rate and gave lenders the right to convert up to $7.0 million into shares. Up to $120.0 million is available in total, but the filing reports only the first tranche as funded.Definium Therapeutics, Inc. Form 8-K filed April 21, 2025 (SEC EDGAR) https://aibio.space/news/jazz-pharmaceuticals-completes-acquisition-chimerix-about-935-million/https://aibio.space/news/jazz-pharmaceuticals-completes-acquisition-chimerix-about-935-million/Mon, 21 Apr 2025 12:00:00 GMTMergersJazz paid $8.55 per share in cash after its tender offer for Chimerix expired on April 17, 2025. Chimerix is now a wholly owned subsidiary of Jazz.Jazz Pharmaceuticals plc Form 8-K filed April 21, 2025 (SEC EDGAR) https://aibio.space/news/mind-medicine-now-definium-therapeutics-amends-k2-loan-up-120-0/https://aibio.space/news/mind-medicine-now-definium-therapeutics-amends-k2-loan-up-120-0/Mon, 21 Apr 2025 12:00:00 GMTDebt FinancingThe amendment allows up to $120.0 million of term loans, with a $42.0 million first tranche that refinanced existing loans. Interest carries a floor of 10.25%, lenders can convert up to $7.0 million into shares, and the 8-K gives no cash balance or net loss.Definium Therapeutics, Inc. 8-K (2025-04-21) https://aibio.space/news/scilex-unit-semnur-amends-denali-merger-deal-moves-outside-date/https://aibio.space/news/scilex-unit-semnur-amends-denali-merger-deal-moves-outside-date/Mon, 21 Apr 2025 12:00:00 GMTMergersSemnur signed Amendment No. 1 on April 16, 2025, covering Denali's move from Nasdaq to OTC quotation and extending its deadlines.Scilex Holding Company 8-K (2025-04-21) https://aibio.space/news/citius-pharmaceuticals-sells-ceo-one-series-preferred-share-100-ahead/https://aibio.space/news/citius-pharmaceuticals-sells-ceo-one-series-preferred-share-100-ahead/Fri, 18 Apr 2025 12:00:00 GMTFinancingsCitius Pharmaceuticals sold one share of a newly designated Series A preferred stock for $100 to Chairman and CEO Leonard Mazur on April 17, 2025. The share carries 1,000,000,000 votes on a proposal to raise authorized common shares from 16,000,000 to 250,000,000, and the board also cut the quorum for stockholder meetings to one-third.Citius Pharmaceuticals, Inc. Form 8-K filed April 18, 2025 (SEC EDGAR) https://aibio.space/news/tempest-therapeutics-cuts-21-26-employees-explores-strategic/https://aibio.space/news/tempest-therapeutics-cuts-21-26-employees-explores-strategic/Fri, 18 Apr 2025 12:00:00 GMTDistressTempest Therapeutics will cut 21 of its 26 full-time employees as it explores strategic alternatives, with cuts effective April 30, 2025. It expects about $1.5 million in cash costs, mostly severance, and its 2024 10-K said cash of $30.3 million would last at least 12 months.Tempest Therapeutics, Inc. Form 8-K filed April 18, 2025 (SEC EDGAR) https://aibio.space/news/aspire-biopharma-now-aspire-lakewood-holdings-gets-two-nasdaq/https://aibio.space/news/aspire-biopharma-now-aspire-lakewood-holdings-gets-two-nasdaq/Fri, 18 Apr 2025 12:00:00 GMTListingsOne letter cites the $50,000,000 market value of listed securities rule, with a deadline of October 13, 2025. The other cites the $1.00 minimum bid price rule.Aspire-Lakewood Holdings, Inc. 8-K (2025-04-18) https://aibio.space/news/tenaya-therapeutics-gets-nasdaq-notice-trading-below-1-00/https://aibio.space/news/tenaya-therapeutics-gets-nasdaq-notice-trading-below-1-00/Fri, 18 Apr 2025 12:00:00 GMTListingsTenaya has until October 13, 2025 to regain compliance, and may get another 180 days if it moves to the Nasdaq Capital Market.Tenaya Therapeutics, Inc. 8-K (2025-04-18) https://aibio.space/news/zura-bio-swaps-shares-pre-funded-warrants-venrock-affiliates-ai/https://aibio.space/news/zura-bio-swaps-shares-pre-funded-warrants-venrock-affiliates-ai/Thu, 17 Apr 2025 12:00:00 GMTFinancingsShareholders will surrender 3.5 million and 3.0 million Class A ordinary shares for no consideration and receive pre-funded warrants with a $0.001 exercise price.Zura Bio Ltd Form 8-K filed April 17, 2025 (SEC EDGAR) https://aibio.space/news/atea-pharmaceuticals-authorizes-25-million-buyback-reaches-agreement/https://aibio.space/news/atea-pharmaceuticals-authorizes-25-million-buyback-reaches-agreement/Thu, 17 Apr 2025 12:00:00 GMTDistressThe Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going.Atea Pharmaceuticals, Inc. 8-K (2025-04-17) https://aibio.space/news/cuprina-holdings-files-late-notice-2024-annual-report-form-20/https://aibio.space/news/cuprina-holdings-files-late-notice-2024-annual-report-form-20/Thu, 17 Apr 2025 12:00:00 GMTDistressThe Singapore-based company says it needs more time to finalize the report and plans to file within the fifteen-day grace period.Cuprina Holdings (Cayman) Limited NT 20-F (2025-04-17) https://aibio.space/news/cadrenal-therapeutics-files-sell-up-2-169-272-more-stock-through-atm/https://aibio.space/news/cadrenal-therapeutics-files-sell-up-2-169-272-more-stock-through-atm/Thu, 17 Apr 2025 12:00:00 GMTFinancingsCadrenal can sell up to $2,169,272 of common stock through H.C. Wainwright & Co., LLC, after it has already sold $7,655,240 under the same agreement. The sales are capped by an SEC rule that applies because its public float is under $75 million.Cadrenal Therapeutics, Inc. 424B5 (2025-04-17) https://aibio.space/news/painreform-now-prf-technologies-says-nasdaq-found-compliant-rule-5550/https://aibio.space/news/painreform-now-prf-technologies-says-nasdaq-found-compliant-rule-5550/Thu, 17 Apr 2025 12:00:00 GMTListingsNasdaq found PainReform complies with Rule 5550(b)(1), but warned that delisting could follow if the next periodic report does not show compliance.PRF Technologies Ltd. 6-K (2025-04-17) https://aibio.space/news/nasdaq-panel-delists-aspira-womens-health-2-5-million-equity-rule/https://aibio.space/news/nasdaq-panel-delists-aspira-womens-health-2-5-million-equity-rule/Wed, 16 Apr 2025 12:00:00 GMTListingsNasdaq's hearings panel has decided to delist Aspira Women's Health, which says its shares will trade on OTC markets under the symbol AWH.Aspira Women's Health Inc. 8-K (2025-04-16) https://aibio.space/news/athira-pharma-now-leonabio-wins-nasdaq-capital-market-move-180-more/https://aibio.space/news/athira-pharma-now-leonabio-wins-nasdaq-capital-market-move-180-more/Wed, 16 Apr 2025 12:00:00 GMTListingsThe transfer takes effect April 17, 2025. Athira, now LeonaBio, has until October 13, 2025 to lift its stock to $1.00 and is seeking approval for a reverse split.LeonaBio, Inc. 8-K (2025-04-16) https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-closes-merger-tvardi-1-3/https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-closes-merger-tvardi-1-3/Tue, 15 Apr 2025 12:00:00 GMTMergersCara Therapeutics completed its merger with Tvardi on April 15, 2025 and took the Tvardi name after a 1-for-3 reverse stock split. Former Cara holders keep about 15.4% of the combined company, and the cash plan runs into the second half of 2026 on the strength of two Phase 2 readouts that have not yet been reported.Tvardi Therapeutics, Inc. Form 8-K filed April 15, 2025 (SEC EDGAR) https://aibio.space/news/abpro-holdings-restates-prior-statements-understated-license/https://aibio.space/news/abpro-holdings-restates-prior-statements-understated-license/Tue, 15 Apr 2025 12:00:00 GMTDistressThe company found it had understated liabilities under one of its license agreements and expects a $3.3 million increase in each affected period. Statements for three earlier periods should no longer be relied upon.Abpro Holdings Inc. 10-K (2025-04-15) https://aibio.space/news/os-therapies-completes-purchase-advaxis-immunotherapy-assets-ayala/https://aibio.space/news/os-therapies-completes-purchase-advaxis-immunotherapy-assets-ayala/Tue, 15 Apr 2025 12:00:00 GMTMergersOS Therapies says the purchase adds three clinical-stage and eight preclinical listeria-based cancer immunotherapy candidates, but the release gives neither the price nor the terms.OS Therapies Incorporated 8-K (2025-04-15) https://aibio.space/news/coherus-biosciences-now-coherus-oncology-completes-udenyca-sale-gets/https://aibio.space/news/coherus-biosciences-now-coherus-oncology-completes-udenyca-sale-gets/Mon, 14 Apr 2025 12:00:00 GMTMergersCoherus received $483.4 million in cash at the April 11, 2025 closing and says it has a $250 million post-close cash balance. It is eligible for milestone payments of up to $75 million.Coherus Oncology, Inc. Form 8-K filed April 14, 2025 (SEC EDGAR) https://aibio.space/news/coherus-now-coherus-oncology-completes-udenyca-sale-intas-483-4/https://aibio.space/news/coherus-now-coherus-oncology-completes-udenyca-sale-intas-483-4/Mon, 14 Apr 2025 12:00:00 GMTMergersCoherus can earn up to $75 million more in sales milestones and says it has $250 million in cash after closing, enough to fund work into 2027.Coherus Oncology, Inc. 8-K (2025-04-14) https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-notice-2-5-million-stockholders/https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-notice-2-5-million-stockholders/Fri, 11 Apr 2025 12:00:00 GMTListingsNasdaq says MIRA's stockholders' equity of $2,199,750 at December 31, 2024 is below the $2.5 million minimum. The company has until May 23, 2025 to submit a plan, and says a pending acquisition would bring a $5 million capital infusion.MIRA PHARMACEUTICALS, INC. Form 8-K filed April 11, 2025 (SEC EDGAR) https://aibio.space/news/nasdaq-closes-creative-medical-technology-clawback-policy-compliance/https://aibio.space/news/nasdaq-closes-creative-medical-technology-clawback-policy-compliance/Fri, 11 Apr 2025 12:00:00 GMTListingsNasdaq said the company had not adopted or disclosed a required clawback policy on time, but is now in compliance and the matter is closed.Creative Medical Technology Holdings, Inc. 8-K (2025-04-11) https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-notice-2-5-million-equity-rule/https://aibio.space/news/mira-pharmaceuticals-gets-nasdaq-notice-2-5-million-equity-rule/Fri, 11 Apr 2025 12:00:00 GMTListingsMIRA reported stockholders' equity of $2,199,750 as of December 31, 2024, below the $2.5 million Nasdaq minimum. It has until May 23, 2025 to submit a plan to regain compliance, and its main fix is an acquisition the release says it expects to complete.MIRA Pharmaceuticals, Inc. 8-K (2025-04-11) https://aibio.space/news/pulmatrix-cullgen-amend-merger-agreement-switching-one-step-merger/https://aibio.space/news/pulmatrix-cullgen-amend-merger-agreement-switching-one-step-merger/Thu, 10 Apr 2025 12:00:00 GMTMergersAmendment No. 1, dated April 7, 2025, drops the second merger so Cullgen survives the merger as a wholly owned Pulmatrix subsidiary. It also clarifies the fractional shares provision.Pulmatrix, Inc. Form 8-K filed April 10, 2025 (SEC EDGAR) https://aibio.space/news/palatin-technologies-gets-nyse-american-delisting-notice-plans-appeal/https://aibio.space/news/palatin-technologies-gets-nyse-american-delisting-notice-plans-appeal/Thu, 10 Apr 2025 12:00:00 GMTListingsNYSE Regulation said it will start proceedings to delist Palatin Technologies (NYSE American: PTN) after the company did not regain compliance within an 18-month plan period. Palatin intends to appeal.PALATIN TECHNOLOGIES INC Form 8-K filed April 10, 2025 (SEC EDGAR) https://aibio.space/news/pulmatrix-amends-cullgen-merger-agreement-one-step-merger/https://aibio.space/news/pulmatrix-amends-cullgen-merger-agreement-one-step-merger/Thu, 10 Apr 2025 12:00:00 GMTMergersPulmatrix and Cullgen signed Amendment No. 1 to their merger agreement on April 7, 2025, dropping the planned second merger. The 8-K gives no exchange ratio, share count or valuation, and does not say why the structure changed.Pulmatrix, Inc. 8-K (2025-04-10) https://aibio.space/news/immunic-inc-prices-5-1-million-registered-direct-offering-0-90-share/https://aibio.space/news/immunic-inc-prices-5-1-million-registered-direct-offering-0-90-share/Wed, 09 Apr 2025 12:00:00 GMTFinancingsImmunic agreed on April 9, 2025 to sell 5,666,667 shares at $0.90 each for about $5.1 million, with Titan Partners Group LLC as sole placement agent. The company's 2024 annual report carried a going concern doubt and reported $35.7 million in cash at year end.IMMUNIC, INC. Form 8-K filed April 9, 2025 (SEC EDGAR) https://aibio.space/news/amarin-sets-1-20-ads-ratio-change-april-11-keep-nasdaq-listing/https://aibio.space/news/amarin-sets-1-20-ads-ratio-change-april-11-keep-nasdaq-listing/Wed, 09 Apr 2025 12:00:00 GMTListingsEach American Depositary Share will represent twenty ordinary shares instead of one. The company says the aim is to meet Nasdaq's $1.00 minimum bid price.Amarin Corporation plc 8-K (2025-04-09) https://aibio.space/news/nasdaq-moves-delist-denali-capital-now-semnur-pharmaceuticals-semnur/https://aibio.space/news/nasdaq-moves-delist-denali-capital-now-semnur-pharmaceuticals-semnur/Wed, 09 Apr 2025 12:00:00 GMTListingsNasdaq staff said Denali Capital Acquisition Corp. had not regained compliance with its $50.0 million market value and total assets rules and also failed the public float rule. The blank-check company's securities will be delisted unless it appeals by April 9, 2025.Semnur Pharmaceuticals Inc. 8-K (2025-04-09) https://aibio.space/news/zevra-therapeutics-closes-150-million-sale-rare-pediatric-disease/https://aibio.space/news/zevra-therapeutics-closes-150-million-sale-rare-pediatric-disease/Mon, 07 Apr 2025 12:00:00 GMTMergersZevra received gross proceeds of $150.0 million at the April 1, 2025 closing. The press release puts net cash proceeds at $148.3 million and cash, cash equivalents and investments at approximately $68.7 million on March 31, 2025.ZEVRA THERAPEUTICS, INC. Form 8-K filed April 7, 2025 (SEC EDGAR) https://aibio.space/news/neogen-refinances-term-loan-revolver-450-million-term-loan-250-million/https://aibio.space/news/neogen-refinances-term-loan-revolver-450-million-term-loan-250-million/Mon, 07 Apr 2025 12:00:00 GMTDebt FinancingNeogen refinanced its term loan and revolving credit facility on April 4, 2025, with a new $450.0 million term loan and a $250.0 million revolver that matures April 4, 2030. The revolver had $100.0 million drawn at closing, and the company says the deal is leverage-neutral and cuts its rate, a claim the 8-K and the release do not test against the old terms.NEOGEN CORP Form 8-K filed April 7, 2025 (SEC EDGAR) https://aibio.space/news/aim-immunotech-gets-nyse-american-delisting-notice-low-stock-price/https://aibio.space/news/aim-immunotech-gets-nyse-american-delisting-notice-low-stock-price/Mon, 07 Apr 2025 12:00:00 GMTListingsNYSE American suspended trading in AIM ImmunoTech (NYSE American: AIM) and began delisting proceedings, citing the low selling price of the stock. The company plans to appeal and expects Pink Open Market trading on April 7, 2025.AIM ImmunoTech Inc. Form 8-K filed April 7, 2025 (SEC EDGAR) https://aibio.space/news/traws-pharma-sets-market-sales-limit-7-427-749-under-baby-shelf-cap/https://aibio.space/news/traws-pharma-sets-market-sales-limit-7-427-749-under-baby-shelf-cap/Mon, 07 Apr 2025 12:00:00 GMTFinancingsTraws Pharma raised its at-the-market limit to $7,427,749 under the baby shelf cap, after selling 42,100 shares for about $122,210. The float that sets the cap uses an $8.29 high close, while the stock closed at $1.96 on April 4, 2025.Traws Pharma, Inc. 424B5 (2025-04-07) https://aibio.space/news/xbiotech-tells-nasdaq-audit-committee-vacancy-after-director-retires/https://aibio.space/news/xbiotech-tells-nasdaq-audit-committee-vacancy-after-director-retires/Mon, 07 Apr 2025 12:00:00 GMTListingsW. Thorpe McKenzie retired from the board effective March 27, 2025. XBiotech will run one-member audit and compensation committees for now.XBiotech Inc. 8-K (2025-04-07) https://aibio.space/news/meiragtx-signs-new-new-york-lab-lease-ends-sublease-early/https://aibio.space/news/meiragtx-signs-new-new-york-lab-lease-ends-sublease-early/Fri, 04 Apr 2025 12:00:00 GMTDistressMeiraGTx will pay base rent of $111.00 per square foot a year on a new 14,235 square foot lab at 450 East 29th Street, and it moved to end its current sublease at the same address earlier than scheduled. The 8-K does not say what the total commitment will cost.MeiraGTx Holdings plc 8-K (2025-04-04) https://aibio.space/news/arbutus-says-court-moved-moderna-patent-trial-september-29-2025/https://aibio.space/news/arbutus-says-court-moved-moderna-patent-trial-september-29-2025/Thu, 03 Apr 2025 12:00:00 GMTLegalArbutus Biopharma and Genevant Sciences sued Moderna, Inc. and a Moderna affiliate, which the filing does not name, over patents tied to the MRNA-1273 COVID-19 vaccine. On March 31, 2025 the court moved the patent trial from September 24 to September 29, 2025.Arbutus Biopharma Corp Form 8-K filed April 3, 2025 (SEC EDGAR) https://aibio.space/news/moonlake-draws-75-0-million-hercules-capital-loan-facility-up-500-0/https://aibio.space/news/moonlake-draws-75-0-million-hercules-capital-loan-facility-up-500-0/Thu, 03 Apr 2025 12:00:00 GMTDebt FinancingMoonLake's subsidiary, MoonLake Immunotherapeutics AG, borrowed the first tranche on March 31, 2025. Most further tranches depend on trial and FDA milestones, and the facility matures April 1, 2030.MoonLake Immunotherapeutics Form 8-K filed April 3, 2025 (SEC EDGAR) https://aibio.space/news/dogwood-therapeutics-says-has-regained-nasdaq-stockholders-equity/https://aibio.space/news/dogwood-therapeutics-says-has-regained-nasdaq-stockholders-equity/Thu, 03 Apr 2025 12:00:00 GMTListingsDogwood says a $19.9 million debt exchange with Conjoint and a sale of about $4.8 million in common stock lifted its stockholders' equity above the $2.5 million minimum. Nasdaq had set a May 14, 2025 deadline, and the release does not include a Nasdaq decision.Dogwood Therapeutics, Inc. 8-K (2025-04-03) https://aibio.space/news/lantheus-completes-evergreen-theragnostics-acquisition-paying-about/https://aibio.space/news/lantheus-completes-evergreen-theragnostics-acquisition-paying-about/Tue, 01 Apr 2025 12:00:00 GMTMergersLantheus said on April 1, 2025 that it completed its acquisition of Evergreen Theragnostics, paying about $275 million in cash at closing. That is a $250 million upfront payment plus a $25 million milestone, and up to $727.5 million in further milestone payments remain possible.Lantheus Holdings, Inc. Form 8-K filed April 1, 2025 (SEC EDGAR) https://aibio.space/news/onconetix-files-nt-10-k-late-filing-notice-says-cash-fell-0-6-million/https://aibio.space/news/onconetix-files-nt-10-k-late-filing-notice-says-cash-fell-0-6-million/Tue, 01 Apr 2025 12:00:00 GMTDistressOnconetix needs more time to finalize its 2024 financial statements and expects to file within the fifteen-day grace period. It flagged lower cash, goodwill and intangibles, and new subscription and warrant liabilities.Onconetix, Inc. Form NT 10-K filed April 1, 2025 (SEC EDGAR) https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-files-nt-10-k-late-notice-2024/https://aibio.space/news/reshape-lifesciences-now-vyome-holdings-files-nt-10-k-late-notice-2024/Tue, 01 Apr 2025 12:00:00 GMTDistressReShape Lifesciences filed a Form NT 10-K on April 1, 2025, saying it needs more time to compile information for its 2024 annual report. The notice does not explain the delay, and the company's 2023 annual report set a cost reduction target of about 55.4% for 2024.Vyome Holdings, Inc Form NT 10-K filed April 1, 2025 (SEC EDGAR) https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-stockholders-approve-tvardi/https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-stockholders-approve-tvardi/Tue, 01 Apr 2025 12:00:00 GMTMergersCara stockholders approved the share issuance for the merger with Tvardi, a reverse split range of 1-for-2 to 1-for-4, and an increase in authorized shares to 150,000,000.Tvardi Therapeutics, Inc. Form 8-K filed April 1, 2025 (SEC EDGAR) https://aibio.space/news/lyell-immunopharma-close-west-hills-plant-cut-about-73-jobs-reiterates/https://aibio.space/news/lyell-immunopharma-close-west-hills-plant-cut-about-73-jobs-reiterates/Tue, 01 Apr 2025 12:00:00 GMTDistressLyell expects $3.0 million to $4.0 million in closure and severance costs and net cash use of $175 million - $185 million in 2025. Its Chief Business Officer is also resigning.Lyell Immunopharma, Inc. Form 8-K filed April 1, 2025 (SEC EDGAR) https://aibio.space/news/eloxx-pharmaceuticals-files-nt-10-k-cannot-fund-audit-expects-going/https://aibio.space/news/eloxx-pharmaceuticals-files-nt-10-k-cannot-fund-audit-expects-going/Tue, 01 Apr 2025 12:00:00 GMTDistressThe late filing covers the year ended December 31, 2024. Eloxx expects cash and cash equivalents of $0.1 million at year end and lists four periodic reports it has not filed.Eloxx Pharmaceuticals, Inc. Form NT 10-K filed April 1, 2025 (SEC EDGAR) https://aibio.space/news/abpro-holdings-delays-annual-report-fiscal-year-ended-december-31-2024/https://aibio.space/news/abpro-holdings-delays-annual-report-fiscal-year-ended-december-31-2024/Tue, 01 Apr 2025 12:00:00 GMTDistressThe company says it needs more time to prepare its financial statements and expects to file within the fifteen-day extension period.Abpro Holdings Inc. NT 10-K (2025-04-01) https://aibio.space/news/boundless-bio-files-400-0-million-shelf-14-5-million-jefferies-stock/https://aibio.space/news/boundless-bio-files-400-0-million-shelf-14-5-million-jefferies-stock/Tue, 01 Apr 2025 12:00:00 GMTFinancingsBoundless Bio filed a Form S-3 on April 1, 2025 covering up to $400.0 million of securities. The same day it signed an at-the-market sales agreement with Jefferies LLC for up to $14.5 million of common stock, which can start only after the SEC declares the registration effective.Boundless Bio, Inc. S-3 (2025-04-01) https://aibio.space/news/conduit-pharmaceuticals-now-cdt-equity-says-meets-nasdaq-equity/https://aibio.space/news/conduit-pharmaceuticals-now-cdt-equity-says-meets-nasdaq-equity/Tue, 01 Apr 2025 12:00:00 GMTListingsThe company reported pro forma stockholders' equity of $2.8 million as of March 31, 2025, against a $2.5 million minimum. It also said it meets the market value of publicly held securities rule.CDT Equity Inc. 8-K (2025-04-01) https://aibio.space/news/coherus-now-coherus-oncology-repurchase-about-170-million-convertible/https://aibio.space/news/coherus-now-coherus-oncology-repurchase-about-170-million-convertible/Tue, 01 Apr 2025 12:00:00 GMTFinancingsThe buyback depends on closing the sale of the UDENYCA franchise. Coherus plans to buy back the remaining $60 million after that deal closes.Coherus Oncology, Inc. 8-K (2025-04-01) https://aibio.space/news/emmaus-life-sciences-delays-2024-annual-report-sees-revenue-down-more/https://aibio.space/news/emmaus-life-sciences-delays-2024-annual-report-sees-revenue-down-more/Tue, 01 Apr 2025 12:00:00 GMTDistressThe company needs more time for the first audit by an accounting firm it retained in September 2024. It estimates a loss from operations of about $1.9 million for 2024.Emmaus Life Sciences, Inc. NT 10-K (2025-04-01) https://aibio.space/news/genprex-delays-2024-annual-report-finish-financial-statements-audit/https://aibio.space/news/genprex-delays-2024-annual-report-finish-financial-statements-audit/Tue, 01 Apr 2025 12:00:00 GMTDistressThe company says it needs more time on its 2024 financial statements and audit procedures. Its lead drug, REQORSA, has a Phase 2a trial whose enrollment rules changed twice in 2024 and 2025.Genprex, Inc. NT 10-K (2025-04-01) https://aibio.space/news/entero-therapeutics-now-gridai-technologies-delays-10-k-accounting/https://aibio.space/news/entero-therapeutics-now-gridai-technologies-delays-10-k-accounting/Tue, 01 Apr 2025 12:00:00 GMTDistressEntero says it is reviewing the accounting treatment of a significant transaction and needs more time for its 2024 annual report. The business section describes an ImmunogenX rescission that the company expects to close by June 30, 2025.GridAI Technologies Corp. NT 10-K (2025-04-01) https://aibio.space/news/onconetix-delays-10-k-cash-falls-0-6-million-year-end/https://aibio.space/news/onconetix-delays-10-k-cash-falls-0-6-million-year-end/Tue, 01 Apr 2025 12:00:00 GMTDistressThe company expects to file within the 15-day grace period. Its cash was about $4.6 million at the end of 2023.Onconetix, Inc. NT 10-K (2025-04-01) https://aibio.space/news/tevogen-bio-holdings-now-tevogen-delays-10-k-sees-2024-loss-about-13-7/https://aibio.space/news/tevogen-bio-holdings-now-tevogen-delays-10-k-sees-2024-loss-about-13-7/Tue, 01 Apr 2025 12:00:00 GMTDistressTevogen said a change in outside accounting providers in September 2024 left it needing more time. It will keep reporting material weaknesses in internal controls.Tevogen Inc. NT 10-K (2025-04-01) https://aibio.space/news/vaccinex-delays-annual-report-fiscal-year-ended-december-31-2024/https://aibio.space/news/vaccinex-delays-annual-report-fiscal-year-ended-december-31-2024/Tue, 01 Apr 2025 12:00:00 GMTDistressThe company cited delays in completing its financial statements. It expects to file within the extension period of up to fifteen calendar days under Rule 12b-25.Vaccinex, Inc. NT 10-K (2025-04-01) https://aibio.space/news/abvc-biopharma-files-nt-10-k-late-filing-notice-2024-annual-report/https://aibio.space/news/abvc-biopharma-files-nt-10-k-late-filing-notice-2024-annual-report/Mon, 31 Mar 2025 12:00:00 GMTDistressThe company says it is still completing its audit for the year ended December 31, 2024 and expects to file the 10-K within 15 calendar days of the due date. It does not expect a significant change in results.ABVC BIOPHARMA, INC. Form NT 10-K filed March 31, 2025 (SEC EDGAR) https://aibio.space/news/greenwich-lifesciences-files-nt-10-k-expects-late-annual-report-april/https://aibio.space/news/greenwich-lifesciences-files-nt-10-k-expects-late-annual-report-april/Mon, 31 Mar 2025 12:00:00 GMTDistressThe company says it cannot file its 2024 annual report on time and expects to use the 15-day extension. Research and development expenses rose to $12,952,029, and the Phase IIb data behind its lead trial carry unresolved record gaps.Greenwich LifeSciences, Inc. Form NT 10-K filed March 31, 2025 (SEC EDGAR) https://aibio.space/news/matinas-biopharma-files-nt-10-k-says-needs-more-time-complete-2024/https://aibio.space/news/matinas-biopharma-files-nt-10-k-says-needs-more-time-complete-2024/Mon, 31 Mar 2025 12:00:00 GMTDistressMatinas said it needs more time to review its financial statements for the year ended December 31, 2024 and plans to file its Form 10-K within the fifteen calendar day extension. It does not anticipate a significant change in results of operations.Matinas BioPharma Holdings, Inc. Form NT 10-K filed March 31, 2025 (SEC EDGAR) https://aibio.space/news/sunshine-biopharma-files-nt-10-k-late-filing-notice-2024-annual-report/https://aibio.space/news/sunshine-biopharma-files-nt-10-k-late-filing-notice-2024-annual-report/Mon, 31 Mar 2025 12:00:00 GMTDistressThe company says it needs additional time to complete its financial statements for the period ended December 31, 2024. It checked the box for filing within the fifteenth calendar day after the due date.Sunshine Biopharma Inc. Form NT 10-K filed March 31, 2025 (SEC EDGAR) https://aibio.space/news/renovorx-files-nt-10-k-says-annual-report-will-late/https://aibio.space/news/renovorx-files-nt-10-k-says-annual-report-will-late/Mon, 31 Mar 2025 12:00:00 GMTDistressRenovoRx (Nasdaq: RNXT) filed a late-filing notice for its 2024 annual report, citing technical accounting work with its current and former auditors. It expects to file within the 15-day grace period.RenovoRx, Inc. Form NT 10-K filed March 31, 2025 (SEC EDGAR) https://aibio.space/news/aspire-biopharma-holdings-now-aspire-lakewood-holdings-files-nt-10/https://aibio.space/news/aspire-biopharma-holdings-now-aspire-lakewood-holdings-files-nt-10/Mon, 31 Mar 2025 12:00:00 GMTDistressAspire Biopharma told the SEC on March 31, 2025 that it needs more time to finish its 2024 financial statements. The notice gives no reason beyond that, and its narrative refers to a 10-Q deadline that does not match the annual report it is about.Aspire-Lakewood Holdings, Inc. Form NT 10-K filed March 31, 2025 (SEC EDGAR) https://aibio.space/news/rein-therapeutics-formerly-aileron-files-nt-10-k-expects-37-0-million/https://aibio.space/news/rein-therapeutics-formerly-aileron-files-nt-10-k-expects-37-0-million/Mon, 31 Mar 2025 12:00:00 GMTDistressRein Therapeutics, formerly Aileron, filed a late-filing notice for its 2024 annual report and expects an impairment loss of about $37.0 million tied to a delay in developing LTI-01. The charge is non-cash, but the company's 2023 annual report already carried a going-concern warning.Rein Therapeutics, Inc. Form NT 10-K filed March 31, 2025 (SEC EDGAR) https://aibio.space/news/abvc-biopharma-delays-annual-report-fiscal-year-ended-december-31-2024/https://aibio.space/news/abvc-biopharma-delays-annual-report-fiscal-year-ended-december-31-2024/Mon, 31 Mar 2025 12:00:00 GMTDistressABVC said it is still completing its audit and other disclosures. It expects to file the Form 10-K within the 15-day extension period.ABVC BioPharma, Inc. NT 10-K (2025-03-31) https://aibio.space/news/akari-therapeutics-delays-2024-annual-report-merger-accounting/https://aibio.space/news/akari-therapeutics-delays-2024-annual-report-merger-accounting/Mon, 31 Mar 2025 12:00:00 GMTDistressThe company is still finishing the accounting for its November 14, 2024 business combination. It expects to file within the 15-day extension.Akari Therapeutics Plc NT 10-K (2025-03-31) https://aibio.space/news/aspire-biopharma-now-aspire-lakewood-holdings-delays-2024-annual/https://aibio.space/news/aspire-biopharma-now-aspire-lakewood-holdings-delays-2024-annual/Mon, 31 Mar 2025 12:00:00 GMTDistressThe company said it could not file by April 15, 2025, the original due date, because it needs more time for its financial statements.Aspire-Lakewood Holdings, Inc. NT 10-K (2025-03-31) https://aibio.space/news/cyclacel-now-bio-green-med-solution-delays-2024-annual-report/https://aibio.space/news/cyclacel-now-bio-green-med-solution-delays-2024-annual-report/Mon, 31 Mar 2025 12:00:00 GMTDistressCyclacel filed the notice on March 31, 2025, saying it needed more time to gather information. It expects to file within fifteen calendar days.Bio Green Med Solution, Inc. NT 10-K (2025-03-31) https://aibio.space/news/bioxytran-delays-annual-report-auditor-needs-more-time-2024-audit/https://aibio.space/news/bioxytran-delays-annual-report-auditor-needs-more-time-2024-audit/Mon, 31 Mar 2025 12:00:00 GMTDistressThe company filed a late notice for its Form 10-K for the year ended December 31, 2024. It expects to file within the fifteen-day grace period.Bioxytran, Inc. NT 10-K (2025-03-31) https://aibio.space/news/celularity-delays-2024-annual-report-citing-liquidity-staffing/https://aibio.space/news/celularity-delays-2024-annual-report-citing-liquidity-staffing/Mon, 31 Mar 2025 12:00:00 GMTDistressCelularity expects 2024 revenue of $54.2 million and a loss from operations of $37.3 million, figures it says are still under review.Celularity Inc. NT 10-K (2025-03-31) https://aibio.space/news/cns-pharmaceuticals-regains-nasdaq-bid-price-compliance-faces-one-year/https://aibio.space/news/cns-pharmaceuticals-regains-nasdaq-bid-price-compliance-faces-one-year/Mon, 31 Mar 2025 12:00:00 GMTListingsNasdaq told CNS Pharmaceuticals on March 31, 2025 that it meets the $1.00 bid price rule. For one year, a new lapse leads to a delisting determination, with no compliance plan or extra time.CNS Pharmaceuticals, Inc. 8-K (2025-03-31) https://aibio.space/news/dbv-technologies-delays-annual-report-while-works-private-placement/https://aibio.space/news/dbv-technologies-delays-annual-report-while-works-private-placement/Mon, 31 Mar 2025 12:00:00 GMTDistressDBV said talks on financing for its Viaskin Peanut program diverted management time. It plans to file the 10-K within the 15-day extension period.DBV Technologies SA NT 10-K (2025-03-31) https://aibio.space/news/emergent-biosolutions-authorizes-repurchase-up-50-million-stock/https://aibio.space/news/emergent-biosolutions-authorizes-repurchase-up-50-million-stock/Mon, 31 Mar 2025 12:00:00 GMTFinancingsThe board approved the Share Repurchase Program on March 31, 2025. The 8-K says the full terms are in a press release attached as Exhibit 99.1, and the 8-K body gives none of them.Emergent BioSolutions Inc. 8-K (2025-03-31) https://aibio.space/news/matinas-biopharma-delays-annual-report-year-ended-december-31-2024/https://aibio.space/news/matinas-biopharma-delays-annual-report-year-ended-december-31-2024/Mon, 31 Mar 2025 12:00:00 GMTDistressThe company needs more time to complete the review of its financial statements and plans to file within the fifteen calendar day extension.Matinas Biopharma Holdings, Inc. NT 10-K (2025-03-31) https://aibio.space/news/oncotelic-therapeutics-delays-2024-annual-report-expects-file-within/https://aibio.space/news/oncotelic-therapeutics-delays-2024-annual-report-expects-file-within/Mon, 31 Mar 2025 12:00:00 GMTDistressThe company said it was unable to compile the financial information needed for a complete filing. It does not expect a significant change in results from the prior year.Oncotelic Therapeutics, Inc. NT 10-K (2025-03-31) https://aibio.space/news/prokidney-files-move-incorporation-cayman-islands-delaware/https://aibio.space/news/prokidney-files-move-incorporation-cayman-islands-delaware/Mon, 31 Mar 2025 12:00:00 GMTMergersProKidney's plan would move a Cayman Islands company to Delaware and register up to 292,707,888 shares. Its Class B shares have no public market, and the new charter would bar shareholder action by written consent.ProKidney Corp. S-4 (2025-03-31) https://aibio.space/news/transcode-therapeutics-delays-2024-annual-report-account-direct/https://aibio.space/news/transcode-therapeutics-delays-2024-annual-report-account-direct/Mon, 31 Mar 2025 12:00:00 GMTDistressTransCode said it needs time to account for a registered direct offering that closed on March 25, 2025. It expects to file within the Rule 12b-25 extension period.TransCode Therapeutics, Inc. NT 10-K (2025-03-31) https://aibio.space/news/rein-therapeutics-delays-10-k-expects-37-0-million-impairment-lti-01/https://aibio.space/news/rein-therapeutics-delays-10-k-expects-37-0-million-impairment-lti-01/Mon, 31 Mar 2025 12:00:00 GMTDistressThe impairment follows a temporary delay of further clinical work on LTI-01. The company, formerly Aileron Therapeutics, needs more time to finish its impairment assessment.Rein Therapeutics, Inc. NT 10-K (2025-03-31) https://aibio.space/news/renovorx-files-late-notice-2024-annual-report-cites-auditor-accounting/https://aibio.space/news/renovorx-files-late-notice-2024-annual-report-cites-auditor-accounting/Mon, 31 Mar 2025 12:00:00 GMTDistressRenovoRx said it needs to complete technical accounting requirements with its current and former auditing firms. It expects to file within the fifteen-day grace period.RenovoRx, Inc. NT 10-K (2025-03-31) https://aibio.space/news/reviva-pharmaceuticals-delays-2024-annual-report-expects-report/https://aibio.space/news/reviva-pharmaceuticals-delays-2024-annual-report-expects-report/Mon, 31 Mar 2025 12:00:00 GMTDistressThe company said it needs more time to finalize its financial statements and audit. It plans to file within the fifteen-day extension.Reviva Pharmaceuticals Holdings, Inc. NT 10-K (2025-03-31) https://aibio.space/news/sunshine-biopharma-files-late-notice-annual-report-december-31-2024/https://aibio.space/news/sunshine-biopharma-files-late-notice-annual-report-december-31-2024/Mon, 31 Mar 2025 12:00:00 GMTDistressThe Fort Lauderdale company said it needs more time to complete its financial statements. It does not expect a significant change in results.Sunshine Biopharma Inc. NT 10-K (2025-03-31) https://aibio.space/news/skinvisible-delays-annual-report-year-ended-december-31-2024/https://aibio.space/news/skinvisible-delays-annual-report-year-ended-december-31-2024/Mon, 31 Mar 2025 12:00:00 GMTDistressThe company said it could not compile all the information for its financial statements in time. It expects to file within the fifteen-day grace period.Skinvisible, Inc. NT 10-K (2025-03-31) https://aibio.space/news/spruce-biosciences-delays-annual-report-flags-going-concern-doubt/https://aibio.space/news/spruce-biosciences-delays-annual-report-flags-going-concern-doubt/Mon, 31 Mar 2025 12:00:00 GMTDistressSpruce expects cash to be insufficient to fund research and development for at least 12 months without new financing. It expects collaboration revenue to fall about 50%.Spruce Biosciences, Inc. NT 10-K (2025-03-31) https://aibio.space/news/savara-ends-100-0-million-market-stock-program-evercore/https://aibio.space/news/savara-ends-100-0-million-market-stock-program-evercore/Mon, 31 Mar 2025 12:00:00 GMTDistressSavara told Evercore it is ending a $100.0 million at-the-market sales agreement, effective April 2, 2025. The company says it owes no termination penalty and has sold no shares under the agreement since December 31, 2024.Savara, Inc. 8-K (2025-03-31) https://aibio.space/news/instil-bio-sets-up-100-million-market-stock-sale-program-jefferies/https://aibio.space/news/instil-bio-sets-up-100-million-market-stock-sale-program-jefferies/Mon, 31 Mar 2025 12:00:00 GMTFinancingsInstil Bio signed a $100 million at-the-market sales agreement with Jefferies, which earns 3.0 percent of gross sales. The last reported sale price before the filing was $19.36, and the lead drug's clinical data come from a partner's small Chinese trial.Instil Bio, Inc. 424B5 (2025-03-31) https://aibio.space/news/surrozen-closes-first-tranche-private-placement-about-76-4-million/https://aibio.space/news/surrozen-closes-first-tranche-private-placement-about-76-4-million/Fri, 28 Mar 2025 12:00:00 GMTFinancingsSurrozen sold 6,586,415 units in a first closing on March 26, 2025, for about $76.4 million gross before fees. Placement agent Guggenheim Securities, LLC was named in the purchase agreement. A second closing of about $98.6 million depends on FDA clearance of the SZN-8141 IND by October 31, 2026.Surrozen, Inc./DE Form 8-K filed March 28, 2025 (SEC EDGAR) https://aibio.space/news/trisalus-life-sciences-files-nt-10-k-citing-errors-material-weaknesses/https://aibio.space/news/trisalus-life-sciences-files-nt-10-k-citing-errors-material-weaknesses/Fri, 28 Mar 2025 12:00:00 GMTDistressTriSalus says it cannot file its 2024 annual report on time after finding errors in stock-based compensation and clinical trial expenses. It expects to file by the fifteenth calendar day after the due date. Preliminary 2024 revenue was $29.4 million.TriSalus Life Sciences, Inc. Form NT 10-K filed March 28, 2025 (SEC EDGAR) https://aibio.space/news/acurx-pharmaceuticals-gets-nasdaq-stockholders-equity-deficiency/https://aibio.space/news/acurx-pharmaceuticals-gets-nasdaq-stockholders-equity-deficiency/Fri, 28 Mar 2025 12:00:00 GMTListingsAcurx Pharmaceuticals received a Nasdaq letter saying it no longer meets the $2,500,000 stockholders' equity minimum for the Capital Market. The company must submit a plan to regain compliance by May 9, 2025, and the notice rests on its 2024 annual report.Acurx Pharmaceuticals, Inc. 8-K (2025-03-28) https://aibio.space/news/cell-source-delays-annual-report-year-ended-december-31-2024/https://aibio.space/news/cell-source-delays-annual-report-year-ended-december-31-2024/Fri, 28 Mar 2025 12:00:00 GMTDistressThe company says it is still compiling information for the report. It expects to file no later than the fifteenth calendar day after the due date.Cell Source, Inc. NT 10-K (2025-03-28) https://aibio.space/news/dermata-therapeutics-expects-6-2-million-holders-exercise-warrants-1/https://aibio.space/news/dermata-therapeutics-expects-6-2-million-holders-exercise-warrants-1/Fri, 28 Mar 2025 12:00:00 GMTFinancingsDermata agreed with holders of warrants for 4,834,470 shares to exercise at a reduced $1.284 a share, for about $6.2 million before fees. In return they receive new Series A and Series B warrants for up to 4,980,806 and 4,688,134 shares.Dermata Therapeutics, Inc. 8-K (2025-03-28) https://aibio.space/news/kairos-pharma-delays-annual-report-2024/https://aibio.space/news/kairos-pharma-delays-annual-report-2024/Fri, 28 Mar 2025 12:00:00 GMTDistressThe company expects to file within the 15-day extension period after its accounting staff finalizes the statements.Kairos Pharma, Ltd. NT 10-K (2025-03-28) https://aibio.space/news/fibrogen-now-kyntra-bio-extends-fortis-merger-option-deadline-december/https://aibio.space/news/fibrogen-now-kyntra-bio-extends-fortis-merger-option-deadline-december/Fri, 28 Mar 2025 12:00:00 GMTMergersFibroGen, now Kyntra Bio, and Fortis Therapeutics amended their evaluation agreement and option and merger agreement, moving the option exercise deadline.Kyntra Bio, Inc. 8-K (2025-03-28) https://aibio.space/news/lipella-pharmaceuticals-files-register-5-617-259-shares-resale-then/https://aibio.space/news/lipella-pharmaceuticals-files-register-5-617-259-shares-resale-then/Fri, 28 Mar 2025 12:00:00 GMTFinancingsThe shares come from Series B and Series C preferred stock and placement agent warrants tied to its private offerings. On April 4, 2025 Lipella added an at-the-market program of up to $2,641,881.Lipella Pharmaceuticals Inc. S-3 (2025-03-28) https://aibio.space/news/trisalus-life-sciences-delays-10-k-after-finding-errors-material/https://aibio.space/news/trisalus-life-sciences-delays-10-k-after-finding-errors-material/Fri, 28 Mar 2025 12:00:00 GMTDistressThe company found errors in the timing of stock-based compensation and clinical trial expenses. It expects to file its annual report within fifteen calendar days of the due date.TriSalus Life Sciences, Inc. NT 10-K (2025-03-28) https://aibio.space/news/annovis-bio-gets-nyse-continued-listing-notice-will-submit-compliance/https://aibio.space/news/annovis-bio-gets-nyse-continued-listing-notice-will-submit-compliance/Thu, 27 Mar 2025 12:00:00 GMTListingsThe NYSE says Annovis's 30-day average market capitalization was approximately $37.9 million and its stockholders' equity was $9.3 million, both under the $50 million floor. The company's 10-K already carries a going-concern warning and says its cash lasts into the fourth quarter of 2025.Annovis Bio, Inc. Form 8-K filed March 27, 2025 (SEC EDGAR) https://aibio.space/news/ironwood-pharmaceuticals-gets-nasdaq-deficiency-notice-late-2024-form/https://aibio.space/news/ironwood-pharmaceuticals-gets-nasdaq-deficiency-notice-late-2024-form/Thu, 27 Mar 2025 12:00:00 GMTListingsIronwood (Nasdaq: IRWD) has until May 20, 2025, to submit a plan to regain compliance with Nasdaq's timely filing rule and says it plans to file the 2024 Form 10-K as soon as practicable.IRONWOOD PHARMACEUTICALS INC Form 8-K filed March 27, 2025 (SEC EDGAR) https://aibio.space/news/nkarta-cut-34-percent-workforce-restructuring-expects-cash-runway-2029/https://aibio.space/news/nkarta-cut-34-percent-workforce-restructuring-expects-cash-runway-2029/Wed, 26 Mar 2025 12:00:00 GMTDistressNkarta is cutting 53 positions, about 34% of its staff, at an expected cost of $5.5 million to $6.5 million. It says its $380.5 million of cash and investments can fund operations into 2029, while the first clinical data from its lead program are not due until the second half of 2025.Nkarta, Inc. Form 8-K filed March 26, 2025 (SEC EDGAR) https://aibio.space/news/relmada-licenses-ndv-01-trigone-agrees-pay-3-500-000-issue-3-017-420/https://aibio.space/news/relmada-licenses-ndv-01-trigone-agrees-pay-3-500-000-issue-3-017-420/Wed, 26 Mar 2025 12:00:00 GMTFinancingsRelmada Therapeutics agreed on March 24, 2025 to license NDV-01 from Trigone Pharma for a $3,500,000 upfront fee and 3,017,420 restricted shares, which the press release says is 10% of its outstanding stock. Milestones can reach $200 million, and from 2026 Relmada must spend at least $5,000,000 a year on the drug.RELMADA THERAPEUTICS, INC. Form 8-K filed March 26, 2025 (SEC EDGAR) https://aibio.space/news/whitehawk-therapeutics-formerly-aadi-bioscience-completes-102-4/https://aibio.space/news/whitehawk-therapeutics-formerly-aadi-bioscience-completes-102-4/Wed, 26 Mar 2025 12:00:00 GMTMergersKAKEN INVESTMENTS INC. paid $102.4 million in cash at closing on March 25, 2025, after purchase price adjustments, for 100% of the stock of Aadi Subsidiary, Inc.Whitehawk Therapeutics, Inc. Form 8-K filed March 26, 2025 (SEC EDGAR) https://aibio.space/news/savara-draws-30-million-under-hercules-capital-loan-agreement-repays/https://aibio.space/news/savara-draws-30-million-under-hercules-capital-loan-agreement-repays/Wed, 26 Mar 2025 12:00:00 GMTDebt FinancingSavara drew the first $30 million of a loan of up to $200 million from a group led by Hercules Capital, and used it to repay its Silicon Valley Bank term loan. Later draws depend on FDA approval of MOLBREEVI, a revenue milestone or lender approval.Savara Inc Form 8-K filed March 26, 2025 (SEC EDGAR) https://aibio.space/news/benitec-biopharma-prices-30-million-stock-sale-13-00-share/https://aibio.space/news/benitec-biopharma-prices-30-million-stock-sale-13-00-share/Wed, 26 Mar 2025 12:00:00 GMTFinancingsBenitec Biopharma is issuing 2,043,000 shares and 300,000 pre-funded warrants at $13.00 a share. The prospectus says 900,000 of the shares go directly to Averill funds that are affiliates of Suvretta Capital, while the pricing release names Suvretta Capital itself.Benitec Biopharma Inc. 8-K (2025-03-26) https://aibio.space/news/precision-biosciences-updates-stock-sales-limit-14-868-926/https://aibio.space/news/precision-biosciences-updates-stock-sales-limit-14-868-926/Wed, 26 Mar 2025 12:00:00 GMTFinancingsPrecision BioSciences, Inc. became subject to a one-third-of-float cap on shelf offerings on March 26, 2025, when it filed its 2024 annual report. It filed a supplement to its Jefferies at-the-market program to reflect that.Precision BioSciences, Inc. 424B5 (2025-03-26) https://aibio.space/news/maia-biotechnology-cuts-market-program-11-200-000-30-000-000/https://aibio.space/news/maia-biotechnology-cuts-market-program-11-200-000-30-000-000/Wed, 26 Mar 2025 12:00:00 GMTFinancingsThe smaller size reflects an SEC limit tied to MAIA's public float. The company has sold about $11,633,086 of stock under the agreement so far.MAIA Biotechnology, Inc. 424B5 (2025-03-26) https://aibio.space/news/nkarta-cuts-34-percent-workforce-53-positions-sees-380-5-million-cash/https://aibio.space/news/nkarta-cuts-34-percent-workforce-53-positions-sees-380-5-million-cash/Wed, 26 Mar 2025 12:00:00 GMTDistressNkarta is cutting 34% of its workforce and freezing some hires, and it says $380.5 million in cash will fund operations into 2029. Its release reports no efficacy data for NKX019, and the trials enroll small groups.Nkarta, Inc. 8-K (2025-03-26) https://aibio.space/news/whitehawk-therapeutics-completes-sale-aadi-subsidiary-kaken-102-4/https://aibio.space/news/whitehawk-therapeutics-completes-sale-aadi-subsidiary-kaken-102-4/Wed, 26 Mar 2025 12:00:00 GMTMergersThe buyer paid the cash on closing after purchase price adjustments. The deal was signed on December 19, 2024 under the company's former name, Aadi Bioscience.Whitehawk Therapeutics, Inc. 8-K (2025-03-26) https://aibio.space/news/dermata-therapeutics-gets-nasdaq-stockholders-equity-deficiency-notice/https://aibio.space/news/dermata-therapeutics-gets-nasdaq-stockholders-equity-deficiency-notice/Tue, 25 Mar 2025 12:00:00 GMTListingsDermata reported stockholders' equity of about $1.6 million against the $2.5 million Nasdaq minimum. It must regain compliance or submit a plan by May 9, 2025.Dermata Therapeutics, Inc. Form 8-K filed March 25, 2025 (SEC EDGAR) https://aibio.space/news/jupiter-neurosciences-gets-nasdaq-minimum-bid-price-deficiency-notice/https://aibio.space/news/jupiter-neurosciences-gets-nasdaq-minimum-bid-price-deficiency-notice/Tue, 25 Mar 2025 12:00:00 GMTListingsJupiter Neurosciences received a Nasdaq letter on March 21, 2025 saying its stock fails the $1.00 minimum bid price rule. The company has until September 17, 2025 to regain compliance.JUPITER NEUROSCIENCES, INC. Form 8-K filed March 25, 2025 (SEC EDGAR) https://aibio.space/news/climb-bio-sets-up-22-350-000-market-stock-program-oppenheimer/https://aibio.space/news/climb-bio-sets-up-22-350-000-market-stock-program-oppenheimer/Tue, 25 Mar 2025 12:00:00 GMTFinancingsThe sales agent earns up to 3.0% of gross sales. Climb Bio reported $212.5 million of cash and securities at year end and expects to fund operations through 2027.Climb Bio, Inc. 424B5 (2025-03-25) https://aibio.space/news/genelux-prices-10-5-million-underwritten-offering-3-000-000-shares-3/https://aibio.space/news/genelux-prices-10-5-million-underwritten-offering-3-000-000-shares-3/Tue, 25 Mar 2025 12:00:00 GMTFinancingsNet proceeds are about $9.1 million. The auditor has raised going-concern doubt, and preliminary year-end cash was $30.9 million.Genelux Corporation 8-K (2025-03-25) https://aibio.space/news/entero-now-gridai-technologies-signs-deal-unwind-immunogenx-merger/https://aibio.space/news/entero-now-gridai-technologies-signs-deal-unwind-immunogenx-merger/Tue, 25 Mar 2025 12:00:00 GMTMergersEntero Therapeutics, now GridAI Technologies, signed a rescission agreement with all former ImmunogenX shareholders. It still needs shareholder approval on or before June 30, 2025.GridAI Technologies Corp. 8-K (2025-03-25) https://aibio.space/news/gri-bio-prices-5-0-million-public-offering-3-60-three-warrant-series/https://aibio.space/news/gri-bio-prices-5-0-million-public-offering-3-60-three-warrant-series/Tue, 25 Mar 2025 12:00:00 GMTFinancingsThe prospectus puts gross proceeds at $4,999,878 and says auditors have raised going-concern doubt. Cash covers operations into the third quarter of 2025 with the money.GRI Bio, Inc. 8-K (2025-04-02) https://aibio.space/news/neonc-technologies-sets-nasdaq-direct-listing-registers-2-101-313/https://aibio.space/news/neonc-technologies-sets-nasdaq-direct-listing-registers-2-101-313/Tue, 25 Mar 2025 12:00:00 GMTFinancingsNeOnc's prospectus registers 2,101,313 shares for resale in a Nasdaq direct listing, and the company gets none of the proceeds. Its financial advisor RBW Capital Partners is also the placement agent for a $10 million private placement, and the auditor's report carries a going concern paragraph.NeOnc Technologies Holdings, Inc. 424B4 (2025-03-25) https://aibio.space/news/transcode-therapeutics-agrees-sell-10-250-000-shares-warrants-0-98/https://aibio.space/news/transcode-therapeutics-agrees-sell-10-250-000-shares-warrants-0-98/Tue, 25 Mar 2025 12:00:00 GMTFinancingsTransCode is selling 10,250,000 shares and warrants at $0.98 per share and warrant, through ThinkEquity LLC as exclusive placement agent, for a total offering price of $10,045,000 before fees. The prospectus shows an immediate dilution of $0.72 per share to new investors, and the auditor's report carries a going concern paragraph.TransCode Therapeutics, Inc. 424B5 (2025-03-25) https://aibio.space/news/opus-genetics-closes-public-offering-20-0-million-gross-proceeds-plus/https://aibio.space/news/opus-genetics-closes-public-offering-20-0-million-gross-proceeds-plus/Mon, 24 Mar 2025 12:00:00 GMTFinancingsThe Nasdaq-listed company sold shares, warrants and pre-funded warrants through Craig-Hallum for gross proceeds of approximately $20.0 million. Its CEO and board chairman bought in a separate private placement.Opus Genetics, Inc. Form 8-K filed March 24, 2025 (SEC EDGAR) https://aibio.space/news/senti-biosciences-files-300-000-000-shelf-sets-up-17-500-000-market/https://aibio.space/news/senti-biosciences-files-300-000-000-shelf-sets-up-17-500-000-market/Mon, 24 Mar 2025 12:00:00 GMTFinancingsLeerink Partners will act as sales agent for a 3.0% commission. The company's public float was approximately $57.81 million.Senti Biosciences Holdings, Inc. 8-K (2025-03-24) https://aibio.space/news/tnf-pharmaceuticals-now-q-c-technologies-gets-nasdaq-minimum-bid/https://aibio.space/news/tnf-pharmaceuticals-now-q-c-technologies-gets-nasdaq-minimum-bid/Fri, 21 Mar 2025 12:00:00 GMTListingsNasdaq told TNF Pharmaceuticals on March 17, 2025 that its closing bid price was below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance and remains listed on the Nasdaq Capital Market.Q/C TECHNOLOGIES, INC. Form 8-K filed March 21, 2025 (SEC EDGAR) https://aibio.space/news/tnf-pharmaceuticals-now-q-c-technologies-gets-nasdaq-minimum-bid/https://aibio.space/news/tnf-pharmaceuticals-now-q-c-technologies-gets-nasdaq-minimum-bid/Fri, 21 Mar 2025 12:00:00 GMTListingsTNF Pharmaceuticals, now Q/C Technologies, has until September 15, 2025 to bring its closing bid price back to $1.00 for ten business days.Q/C Technologies, Inc. 8-K (2025-03-21) https://aibio.space/news/vaxart-sets-up-50-000-000-market-stock-program/https://aibio.space/news/vaxart-sets-up-50-000-000-market-stock-program/Fri, 21 Mar 2025 12:00:00 GMTFinancingsVaxart agreed on March 21, 2025 to sell up to $50 million of common stock through Citizens JMP Securities and B. Riley Securities, which may each receive a commission of up to 3% of gross sales. The stock closed at $0.5754 on March 17, 2025.Vaxart, Inc. 424B5 (2025-03-21) https://aibio.space/news/cns-pharmaceuticals-increases-market-stock-program-43-5-million/https://aibio.space/news/cns-pharmaceuticals-increases-market-stock-program-43-5-million/Thu, 20 Mar 2025 12:00:00 GMTFinancingsThe company has sold 2,522,755 shares for about $23.75 million so far under the program. It had 2,944,381 shares outstanding as of March 20, 2025.CNS Pharmaceuticals, Inc. 8-K (2025-03-20) https://aibio.space/news/foghorn-therapeutics-cuts-market-program-100-million-200-million/https://aibio.space/news/foghorn-therapeutics-cuts-market-program-100-million-200-million/Thu, 20 Mar 2025 12:00:00 GMTFinancingsAn amendment with TD Cowen cuts the program to $100 million, and the 8-K gives no reason for the cut. The new supplement shows immediate dilution of $3.78 per share at the $4.44 reference price.Foghorn Therapeutics Inc. 424B5 (2025-03-20) https://aibio.space/news/bausch-health-launches-4-0-billion-senior-secured-notes-offering/https://aibio.space/news/bausch-health-launches-4-0-billion-senior-secured-notes-offering/Wed, 19 Mar 2025 12:00:00 GMTMergersBausch Health's subsidiary launched a $4.0 billion offering of senior secured notes due 2032, and the parent began syndicating new secured credit facilities. The proceeds would retire 2025 and 2027 debt, but the filing gives no interest rate on the new notes or the term loan.Bausch Health Companies Inc. Form 8-K filed March 19, 2025 (SEC EDGAR) https://aibio.space/news/akebia-launches-stock-offering-then-prices-25-000-000-shares-2-00-50-0/https://aibio.space/news/akebia-launches-stock-offering-then-prices-25-000-000-shares-2-00-50-0/Wed, 19 Mar 2025 12:00:00 GMTFinancingsAkebia priced 25,000,000 shares at $2.00 for gross proceeds of $50.0 million, below the $2.84 last sale price the final prospectus cites for March 19, 2025. The company estimates net proceeds of about $46.5 million and reports an accumulated deficit of $1,678,360 thousand.Akebia Therapeutics, Inc. 424B5 (2025-03-19) https://aibio.space/news/minerva-neurosciences-keeps-nasdaq-listing-after-meeting-500-000-net/https://aibio.space/news/minerva-neurosciences-keeps-nasdaq-listing-after-meeting-500-000-net/Wed, 19 Mar 2025 12:00:00 GMTListingsMinerva keeps its Nasdaq listing on a net income test, not an equity test, and now faces a one-year panel monitor. The company reported $21.5 million in cash at the end of 2024 and says it will need more capital.Minerva Neurosciences, Inc 8-K (2025-03-19) https://aibio.space/news/allovir-now-kalaris-therapeutics-completes-kalaris-merger-shares-trade/https://aibio.space/news/allovir-now-kalaris-therapeutics-completes-kalaris-merger-shares-trade/Tue, 18 Mar 2025 12:00:00 GMTMergersThe combined company expects about $100 million in cash at closing to fund operations into the fourth quarter of 2026, while its lead drug candidate, TH103, is still in an open-label Phase 1 trial. Former Kalaris holders own about 74.47% on a fully diluted basis.Kalaris Therapeutics, Inc. Form 8-K filed March 18, 2025 (SEC EDGAR) https://aibio.space/news/kalaris-therapeutics-closes-merger-allovir-stock-trades-klrs-march-19/https://aibio.space/news/kalaris-therapeutics-closes-merger-allovir-stock-trades-klrs-march-19/Tue, 18 Mar 2025 12:00:00 GMTMergersPre-merger Kalaris holders own about 74.47% of the combined company. Cash of about $100 million is expected to last into the fourth quarter of 2026.Kalaris Therapeutics, Inc. 8-K (2025-03-18) https://aibio.space/news/milestone-pharmaceuticals-lifts-jefferies-market-program-up-77-800-000/https://aibio.space/news/milestone-pharmaceuticals-lifts-jefferies-market-program-up-77-800-000/Tue, 18 Mar 2025 12:00:00 GMTFinancingsMilestone amended its Jefferies sales agreement to allow up to $75,000,000 of new common shares, within a $77,800,000 total that includes about $2.8 million already sold. Jefferies can earn up to 3.0% commission, and the shares closed at $2.41 on March 17, 2025.Milestone Pharmaceuticals Inc. 8-K (2025-03-18) https://aibio.space/news/harrow-files-nt-10-k-late-filing-notice-2024-annual-report-citing/https://aibio.space/news/harrow-files-nt-10-k-late-filing-notice-2024-annual-report-citing/Mon, 17 Mar 2025 12:00:00 GMTDistressHarrow says it needs more time for accounting analyses and its internal controls evaluation. It expects no changes to preliminary 2024 results, including revenues of between $198 million and $200 million.HARROW, INC. Form NT 10-K filed March 17, 2025 (SEC EDGAR) https://aibio.space/news/entera-bio-signs-opko-oral-glp-1-glucagon-deal-sells-opko-shares-8-0/https://aibio.space/news/entera-bio-signs-opko-oral-glp-1-glucagon-deal-sells-opko-shares-8-0/Mon, 17 Mar 2025 12:00:00 GMTFinancingsOPKO bought 3,685,226 Entera ordinary shares at about $2.17. Entera will hold the money in escrow to fund its 40% share of development costs. Entera can opt out after Phase 1.Entera Bio Ltd. Form 8-K filed March 17, 2025 (SEC EDGAR) https://aibio.space/news/fibrogen-now-kyntra-bio-appeals-nasdaq-delisting-notice-after-missing/https://aibio.space/news/fibrogen-now-kyntra-bio-appeals-nasdaq-delisting-notice-after-missing/Mon, 17 Mar 2025 12:00:00 GMTListingsFibroGen did not regain compliance by March 11, 2025 and appealed a Nasdaq delisting decision on March 14, 2025. The delisting is stayed pending a Hearings Panel ruling.KYNTRA BIO, INC. Form 8-K filed March 17, 2025 (SEC EDGAR) https://aibio.space/news/nasdaq-panel-delists-avenue-therapeutics-stock-moves-otc-march-19-2025/https://aibio.space/news/nasdaq-panel-delists-avenue-therapeutics-stock-moves-otc-march-19-2025/Mon, 17 Mar 2025 12:00:00 GMTListingsThe company failed to meet Nasdaq's $2,500,000 stockholders' equity rule by the panel's deadline. Trading moves to the OTC Markets under the ATXI symbol.Avenue Therapeutics, Inc. 8-K (2025-03-17) https://aibio.space/news/opko-health-buys-3-685-226-entera-bio-shares-2-17-obesity/https://aibio.space/news/opko-health-buys-3-685-226-entera-bio-shares-2-17-obesity/Mon, 17 Mar 2025 12:00:00 GMTFinancingsThe two companies will hold 60% and 40% ownership interests in an oral GLP-1/glucagon program. Entera says the proceeds will fund its 40% share through Phase 1.Entera Bio Ltd. 8-K (2025-03-17) https://aibio.space/news/metagenomi-files-250-000-000-shelf-75-000-000-market-program/https://aibio.space/news/metagenomi-files-250-000-000-shelf-75-000-000-market-program/Mon, 17 Mar 2025 12:00:00 GMTFinancingsMetagenomi filed a $250,000,000 shelf and signed a $75,000,000 at-the-market sales agreement with Jefferies LLC, which can earn up to 3.0% commission. The filing does not state the company's cash balance, and sales can start only after the registration statement is declared effective.Metagenomi Therapeutics, Inc. S-3 (2025-03-17) https://aibio.space/news/vaccinex-files-form-25-voluntarily-withdraw-stock-nasdaq/https://aibio.space/news/vaccinex-files-form-25-voluntarily-withdraw-stock-nasdaq/Mon, 17 Mar 2025 12:00:00 GMTListingsThe Rochester, New York company filed the notice on March 17, 2025. It covers its common stock, par value $0.0001 per share.Vaccinex, Inc. 25 (2025-03-17) https://aibio.space/news/gelteq-signs-deal-sell-up-12-000-000-shares-lincoln-park/https://aibio.space/news/gelteq-signs-deal-sell-up-12-000-000-shares-lincoln-park/Fri, 14 Mar 2025 12:00:00 GMTListingsGelteq cannot sell to Lincoln Park until a resale registration statement is declared effective. The agreement caps issuance at 1,881,328 shares unless shareholders approve more or the average price reaches $1.29.Gelteq Limited 6-K (2025-03-14) https://aibio.space/news/tiziana-life-sciences-regains-compliance-nasdaq-minimum-bid-price-rule/https://aibio.space/news/tiziana-life-sciences-regains-compliance-nasdaq-minimum-bid-price-rule/Fri, 14 Mar 2025 12:00:00 GMTListingsThe requirement was met on March 12, 2025 after a notice dated January 29, 2025. Nasdaq considers the matter closed.Tiziana Life Sciences Ltd 6-K (2025-03-14) https://aibio.space/news/pliant-therapeutics-inc-adopts-stockholder-rights-plan-12-64-exercise/https://aibio.space/news/pliant-therapeutics-inc-adopts-stockholder-rights-plan-12-64-exercise/Thu, 13 Mar 2025 12:00:00 GMTMergersPliant's board adopted a limited-duration rights plan on March 12, 2025, citing recent accumulations of its common stock. The rights trigger at 10% ownership, or 20% for certain passive investors, and expire on March 11, 2026.PLIANT THERAPEUTICS, INC. Form 8-K filed March 13, 2025 (SEC EDGAR) https://aibio.space/news/sutro-biopharma-cut-about-50-percent-workforce-restructuring-names-new/https://aibio.space/news/sutro-biopharma-cut-about-50-percent-workforce-restructuring-names-new/Thu, 13 Mar 2025 12:00:00 GMTDistressSutro will deprioritize luvelta, exit its manufacturing facility and cut about 50% of staff, with costs of $40 million to $45 million. Jane Chung succeeds William J. Newell as CEO. Cash was $316.9 million at year-end.SUTRO BIOPHARMA, INC. Form 8-K filed March 13, 2025 (SEC EDGAR) https://aibio.space/news/pliant-therapeutics-adopts-one-year-shareholder-rights-plan-after/https://aibio.space/news/pliant-therapeutics-adopts-one-year-shareholder-rights-plan-after/Thu, 13 Mar 2025 12:00:00 GMTMergersPliant's board adopted a one-year stockholder rights plan, and the company's trigger is a 10% stake bought without board approval. The release cites unspecified "recent accumulations" of stock and does not name who was buying, less than two weeks after its annual report disclosed the discontinuation of its lead Phase 2b trial.Pliant Therapeutics, Inc. 8-K (2025-03-13) https://aibio.space/news/rallybio-cuts-market-stock-program-9-550-000-100-000-000/https://aibio.space/news/rallybio-cuts-market-stock-program-9-550-000-100-000-000/Thu, 13 Mar 2025 12:00:00 GMTFinancingsRallybio cut its at-the-market stock program from $100,000,000 to $9,550,000 on March 13, 2025. The company says it has sold no shares under the agreement, and the cut follows an SEC rule that limits sales for companies with a public float below $75.0 million.Rallybio Corporation 424B5 (2025-03-13) https://aibio.space/news/shuttle-pharma-prices-5-75-million-underwritten-offering-0-30-share/https://aibio.space/news/shuttle-pharma-prices-5-75-million-underwritten-offering-0-30-share/Thu, 13 Mar 2025 12:00:00 GMTListingsShuttle Pharmaceuticals priced 19,166,667 shares, or pre-funded warrants, at $0.30 per share for gross proceeds expected to be about $5.75 million. WestPark Capital, Inc. is the sole book-runner on a firm commitment basis.Shuttle Pharmaceuticals Holdings, Inc. 8-K (2025-03-13) https://aibio.space/news/allovir-now-kalaris-therapeutics-stockholders-approve-kalaris-merger/https://aibio.space/news/allovir-now-kalaris-therapeutics-stockholders-approve-kalaris-merger/Wed, 12 Mar 2025 12:00:00 GMTMergersAt a March 12, 2025 special meeting, AlloVir holders approved the share issuance and change of control under Nasdaq rules, and a stock plan increase. The merger is expected to close as soon as practicable.Kalaris Therapeutics, Inc. Form 8-K filed March 12, 2025 (SEC EDGAR) https://aibio.space/news/eterna-therapeutics-now-ernexa-therapeutics-issues-1-500-000-note/https://aibio.space/news/eterna-therapeutics-now-ernexa-therapeutics-issues-1-500-000-note/Wed, 12 Mar 2025 12:00:00 GMTFinancingsEterna Therapeutics (now Ernexa Therapeutics, Nasdaq: ERNA) received $1,500,000 on March 11, 2025, under a promissory note with 5.0% interest that matures no later than June 15, 2025.Ernexa Therapeutics Inc. Form 8-K filed March 12, 2025 (SEC EDGAR) https://aibio.space/news/dogwood-therapeutics-exchanges-19-5-million-conjoint-loan-preferred/https://aibio.space/news/dogwood-therapeutics-exchanges-19-5-million-conjoint-loan-preferred/Wed, 12 Mar 2025 12:00:00 GMTFinancingsDogwood will cancel its loans from Conjoint Inc., a subsidiary of its largest shareholder, for 284.2638 shares of Series A-1 preferred stock convertible into 10,000 common shares each.Dogwood Therapeutics, Inc. Form 8-K filed March 12, 2025 (SEC EDGAR) https://aibio.space/news/armata-pharmaceuticals-signs-10-million-loan-largest-holder-innoviva/https://aibio.space/news/armata-pharmaceuticals-signs-10-million-loan-largest-holder-innoviva/Wed, 12 Mar 2025 12:00:00 GMTDebt FinancingThe secured term loan matures on March 12, 2026. Armata also pushed back the maturity of three earlier Innoviva credit agreements to the same date.Armata Pharmaceuticals, Inc. 8-K (2025-03-12) https://aibio.space/news/allovir-now-kalaris-therapeutics-stockholders-approve-merger-kalaris/https://aibio.space/news/allovir-now-kalaris-therapeutics-stockholders-approve-merger-kalaris/Wed, 12 Mar 2025 12:00:00 GMTMergersAlloVir holders backed all proposals at a special meeting on March 12, 2025. The combined company is expected to be renamed Kalaris Therapeutics and trade on Nasdaq as KLRS.Kalaris Therapeutics, Inc. 8-K (2025-03-12) https://aibio.space/news/anika-therapeutics-sells-parcus-medical-medacta-4-500-000-cash/https://aibio.space/news/anika-therapeutics-sells-parcus-medical-medacta-4-500-000-cash/Tue, 11 Mar 2025 12:00:00 GMTMergersAnika completed the sale of its former subsidiary Parcus Medical to Medacta Americas Manufacturing on March 7, 2025 for $4,500,000 in cash at closing, still subject to post-closing adjustments. The 2023 annual report shows a $62.2 million impairment on the Parcus and Arthrosurface intangibles.Anika Therapeutics, Inc. Form 8-K filed March 11, 2025 (SEC EDGAR) https://aibio.space/news/viking-therapeutics-agrees-150-million-prepayments-cordenpharma-vk2735/https://aibio.space/news/viking-therapeutics-agrees-150-million-prepayments-cordenpharma-vk2735/Tue, 11 Mar 2025 12:00:00 GMTFinancingsViking Therapeutics' Irish subsidiary agreed on March 10, 2025 to make prepayments to CordenPharma for supply of its obesity candidate VK2735. The 8-K puts the prepayments at $90.0 million through 2028, and the press release gives a $150 million total. This is money Viking pays out, not money it raises, and neither document gives a cash balance against which to test it.Viking Therapeutics, Inc. Form 8-K filed March 11, 2025 (SEC EDGAR) https://aibio.space/news/anika-therapeutics-completes-sale-parcus-medical-medacta-group/https://aibio.space/news/anika-therapeutics-completes-sale-parcus-medical-medacta-group/Tue, 11 Mar 2025 12:00:00 GMTMergersThe deal closed on March 7, 2025 for an undisclosed amount, paid in cash at closing. Anika will now focus on hyaluronic acid pain products and regenerative solutions.Anika Therapeutics, Inc. 8-K (2025-03-11) https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics-files/https://aibio.space/news/helix-acquisition-corp-ii-now-bridgebio-oncology-therapeutics-files/Tue, 11 Mar 2025 12:00:00 GMTDistressThe blank-check company's annual report says it must liquidate if it does not close its deal with BridgeBio Oncology by February 14, 2026, and that doubt over its ability to continue is substantial.BridgeBio Oncology Therapeutics, Inc. 10-K (2025-03-11) https://aibio.space/news/xilio-therapeutics-sets-up-50-000-000-market-stock-program-leerink/https://aibio.space/news/xilio-therapeutics-sets-up-50-000-000-market-stock-program-leerink/Tue, 11 Mar 2025 12:00:00 GMTFinancingsLeerink Partners will earn 3.0% of gross proceeds on any sales. The stock last sold at $0.8449 on March 10, 2025.Xilio Therapeutics, Inc. 424B5 (2025-03-11) https://aibio.space/news/alector-cut-workforce-approximately-13-percent-expects-2-4-million/https://aibio.space/news/alector-cut-workforce-approximately-13-percent-expects-2-4-million/Mon, 10 Mar 2025 12:00:00 GMTDistressThe company says the cut affects about 25 employees and will cost about $2.4 million. It still says cash lasts through 2026, while its lead frontotemporal dementia trial has yet to report and its term loan is secured on substantially all assets.Alector, Inc. Form 8-K filed March 10, 2025 (SEC EDGAR) https://aibio.space/news/acurx-pharmaceuticals-agrees-1-1-million-registered-direct-offering-0/https://aibio.space/news/acurx-pharmaceuticals-agrees-1-1-million-registered-direct-offering-0/Mon, 10 Mar 2025 12:00:00 GMTFinancingsAcurx Pharmaceuticals sold 2,150,000 shares and pre-funded warrants for 595,000 more at about $0.40 each, and added private warrants for up to 8,235,000 shares. The price is far below the $1.015 the company got in a January offering, and a Nasdaq bid-price notice arrived on February 24, 2025.Acurx Pharmaceuticals, Inc. 424B5 (2025-03-10) https://aibio.space/news/fortress-biotechs-checkpoint-unit-agrees-sun-pharma-deal-4-10-share/https://aibio.space/news/fortress-biotechs-checkpoint-unit-agrees-sun-pharma-deal-4-10-share/Mon, 10 Mar 2025 12:00:00 GMTMergersCheckpoint Therapeutics, the majority-controlled unit of Fortress Biotech, agreed to be bought by Sun Pharma for $4.10 in cash per share plus a contingent value right of up to $0.70. Fortress has agreed to vote in favor and will receive a 2.5% royalty.Fortress Biotech, Inc. 8-K (2025-03-10) https://aibio.space/news/creative-medical-technology-holdings-signs-warrant-inducement-about-3/https://aibio.space/news/creative-medical-technology-holdings-signs-warrant-inducement-about-3/Fri, 07 Mar 2025 12:00:00 GMTFinancingsHolders of warrants for 837,104 shares agreed to exercise at $4.42 per share and receive new warrants at $3.75. Roth Capital Partners acted as financial advisor.CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Form 8-K filed March 7, 2025 (SEC EDGAR) https://aibio.space/news/adial-pharmaceuticals-gets-nasdaq-minimum-bid-price-deficiency-notice/https://aibio.space/news/adial-pharmaceuticals-gets-nasdaq-minimum-bid-price-deficiency-notice/Fri, 07 Mar 2025 12:00:00 GMTListingsNasdaq told Adial Pharmaceuticals on March 5, 2025 that its stock had closed below $1.00 for 30 consecutive business days. The company has until September 1, 2025 to regain compliance, and its annual report carries a going-concern warning.ADIAL PHARMACEUTICALS, INC. Form 8-K filed March 7, 2025 (SEC EDGAR) https://aibio.space/news/arrowhead-registers-resale-11-926-301-shares-selling-stockholder/https://aibio.space/news/arrowhead-registers-resale-11-926-301-shares-selling-stockholder/Fri, 07 Mar 2025 12:00:00 GMTFinancingsThe company will not receive any proceeds from sales by the stockholder. The shares were acquired under a stock purchase agreement dated November 25, 2024.Arrowhead Pharmaceuticals, Inc. 424B7 (2025-03-07) https://aibio.space/news/replimune-adds-baker-bros-employee-board-grants-bba-funds-resale/https://aibio.space/news/replimune-adds-baker-bros-employee-board-grants-bba-funds-resale/Fri, 07 Mar 2025 12:00:00 GMTFinancingsReplimune's board grew from nine to ten members on March 5, 2025 to seat Michael Goller, an employee of Baker Bros. Advisors. The same day the company agreed to resale registration rights for the BBA Funds, which bought stock in two financings in 2024.Replimune Group, Inc. 8-K (2025-03-07) https://aibio.space/news/nuvation-bio-files-automatic-shelf-200-000-000-atm-sales-agreement/https://aibio.space/news/nuvation-bio-files-automatic-shelf-200-000-000-atm-sales-agreement/Thu, 06 Mar 2025 12:00:00 GMTFinancingsNuvation Bio's automatic shelf lets it sell up to $200,000,000 of common stock through Jefferies LLC as sales agent, at up to 3.0% of gross proceeds. The stock last sold at $1.82 on March 4, 2025, and the company's lead drug is still waiting on an FDA decision.Nuvation Bio Inc. S-3ASR (2025-03-06) https://aibio.space/news/tenax-therapeutics-agrees-25-million-private-placement-rtw-investments/https://aibio.space/news/tenax-therapeutics-agrees-25-million-private-placement-rtw-investments/Thu, 06 Mar 2025 12:00:00 GMTFinancingsRTW is to buy 378,346 shares at $6.04 and pre-funded warrants for 3,760,726 shares. Tenax plans to use the money for Phase 3 trials.Tenax Therapeutics, Inc. 8-K (2025-03-06) https://aibio.space/news/alx-oncology-approves-30-percent-workforce-reduction-will-eliminate/https://aibio.space/news/alx-oncology-approves-30-percent-workforce-reduction-will-eliminate/Wed, 05 Mar 2025 12:00:00 GMTDistressALX Oncology's board approved a cut of about 30% of staff on Feb 28, 2025, and eliminates its president and chief scientific officer role. The company estimates about $2.2 million in severance and benefits for a lead drug that has not completed a pivotal trial.ALX ONCOLOGY HOLDINGS INC Form 8-K filed March 5, 2025 (SEC EDGAR) https://aibio.space/news/calcimedica-signs-loan-agreement-up-32-5-million-funds-10-million/https://aibio.space/news/calcimedica-signs-loan-agreement-up-32-5-million-funds-10-million/Wed, 05 Mar 2025 12:00:00 GMTDebt FinancingThe Avenue Venture Opportunities Fund II loan matures September 1, 2028 and carries a warrant for 641,163 shares at $2.32. CalciMedica says the first tranche extends its cash runway to the middle of 2026.CalciMedica, Inc. Form 8-K filed March 5, 2025 (SEC EDGAR) https://aibio.space/news/jazz-pharmaceuticals-agrees-acquire-chimerix-8-55-share-cash/https://aibio.space/news/jazz-pharmaceuticals-agrees-acquire-chimerix-8-55-share-cash/Wed, 05 Mar 2025 12:00:00 GMTMergersJazz Pharmaceuticals agreed to buy Chimerix for $8.55 a share in cash, about $935 million in total, through a tender offer. The main asset, dordaviprone, is still awaiting an FDA decision, and Chimerix owes Jazz a $35 million fee in some cases if it accepts a rival offer.Jazz Pharmaceuticals plc Form 8-K filed March 5, 2025 (SEC EDGAR) https://aibio.space/news/aadi-bioscience-now-whitehawk-therapeutics-closes-100-million-private/https://aibio.space/news/aadi-bioscience-now-whitehawk-therapeutics-closes-100-million-private/Tue, 04 Mar 2025 12:00:00 GMTFinancingsAadi Bioscience closed a private placement of about $100 million on March 4, 2025, selling 21,592,000 shares at $2.40 and pre-funded warrants for 20,076,500 more shares. The company says the money, with the FYARRO sale, should fund operations into 2028.Whitehawk Therapeutics, Inc. 8-K (2025-03-04) https://aibio.space/news/adma-biologics-files-nt-10-k-says-2024-annual-report-will-late/https://aibio.space/news/adma-biologics-files-nt-10-k-says-2024-annual-report-will-late/Mon, 03 Mar 2025 12:00:00 GMTDistressADMA Biologics said on March 3, 2025 that KPMG LLP has not finished its audit of 2024 and expects to file the annual report by March 18, 2025. The notice attaches unaudited 2024 net income of 197,673 thousand dollars, against a 2023 net loss of 28,239 thousand dollars.ADMA BIOLOGICS, INC. Form NT 10-K filed March 3, 2025 (SEC EDGAR) https://aibio.space/news/envoy-medical-receives-nasdaq-deficiency-notice-35-000-000-market/https://aibio.space/news/envoy-medical-receives-nasdaq-deficiency-notice-35-000-000-market/Mon, 03 Mar 2025 12:00:00 GMTListingsNasdaq says the market value of Envoy Medical's listed securities did not meet the minimum for 31 consecutive business days. The company has until August 25, 2025 to regain compliance.Envoy Medical, Inc. Form 8-K filed March 3, 2025 (SEC EDGAR) https://aibio.space/news/ibio-files-form-25-withdraw-common-stock-nyse-american/https://aibio.space/news/ibio-files-form-25-withdraw-common-stock-nyse-american/Mon, 03 Mar 2025 12:00:00 GMTListingsThe company says it is withdrawing its listing voluntarily and has complied with the exchange's rules for doing so.iBio, Inc. 25 (2025-03-03) https://aibio.space/news/ironwood-pharmaceuticals-delays-10-k-expects-material-weakness-finding/https://aibio.space/news/ironwood-pharmaceuticals-delays-10-k-expects-material-weakness-finding/Mon, 03 Mar 2025 12:00:00 GMTDistressIronwood said it expects its internal control over financial reporting to be ineffective as of December 31, 2024. It plans to file within the 15-day grace period.Ironwood Pharmaceuticals, Inc. NT 10-K (2025-03-03) https://aibio.space/news/aerovate-therapeutics-now-jade-biosciences-files-merger-material-jade/https://aibio.space/news/aerovate-therapeutics-now-jade-biosciences-files-merger-material-jade/Mon, 03 Mar 2025 12:00:00 GMTMergersAerovate filed a Jade communication on March 3, 2025, under their October 30, 2024 merger agreement. The combined company is expected to trade on Nasdaq as JBIO.Jade Biosciences, Inc. 425 (2025-03-03) https://aibio.space/news/tenaya-therapeutics-prices-52-5-million-offering-75-000-000-units-0-70/https://aibio.space/news/tenaya-therapeutics-prices-52-5-million-offering-75-000-000-units-0-70/Mon, 03 Mar 2025 12:00:00 GMTFinancingsTenaya priced 75,000,000 units at $0.70 for about $52.5 million, with two warrant series attached to each unit. Its lead gene therapies are in early trials with only a few patients dosed, and the stock's last reported sale price on the pricing day was $0.9469.Tenaya Therapeutics, Inc. 424B5 (2025-03-03) https://aibio.space/news/court-denies-liquidias-challenge-fda-exclusivity-tyvaso-dpi/https://aibio.space/news/court-denies-liquidias-challenge-fda-exclusivity-tyvaso-dpi/Fri, 28 Feb 2025 12:00:00 GMTLegalA federal judge in Washington denied Liquidia's summary judgment motion on February 27, 2025, upholding the FDA's three-year exclusivity for United Therapeutics' Tyvaso DPI. The exclusivity still ends May 23, 2025, and a related cross claim remains pending.Liquidia Corp Form 8-K filed February 28, 2025 (SEC EDGAR) https://aibio.space/news/mustang-bio-sells-worcester-equipment-abbvie-1-0-million-exits/https://aibio.space/news/mustang-bio-sells-worcester-equipment-abbvie-1-0-million-exits/Thu, 27 Feb 2025 12:00:00 GMTMergersMustang Bio received the $1.0 million purchase price from escrow on February 25, 2025. It expects about $2.0 million in cash savings on the lease over the next 24 months and has moved its headquarters to Waltham.MUSTANG BIO, INC. Form 8-K filed February 27, 2025 (SEC EDGAR) https://aibio.space/news/curis-gets-nasdaq-deficiency-notice-market-value-listed-securities/https://aibio.space/news/curis-gets-nasdaq-deficiency-notice-market-value-listed-securities/Thu, 27 Feb 2025 12:00:00 GMTListingsNasdaq told Curis that its listed securities were worth less than $35,000,000 for 30 consecutive business days. The company has until August 20, 2025 to regain compliance.CURIS INC Form 8-K filed February 27, 2025 (SEC EDGAR) https://aibio.space/news/abcellera-biologics-files-automatic-shelf-registration-shares-debt/https://aibio.space/news/abcellera-biologics-files-automatic-shelf-registration-shares-debt/Thu, 27 Feb 2025 12:00:00 GMTFinancingsAbCellera's common shares last sold at $2.92 per share on February 26, 2025. The prospectus sets no dollar amount for the offerings and names no bank or agent.AbCellera Biologics Inc. S-3ASR (2025-02-27) https://aibio.space/news/altimmune-files-400-000-000-shelf-150-000-000-equity-distribution/https://aibio.space/news/altimmune-files-400-000-000-shelf-150-000-000-equity-distribution/Thu, 27 Feb 2025 12:00:00 GMTFinancingsAltimmune's $400 million shelf would also carry a $150 million share sales program, with Leerink Partners, Piper Sandler and Stifel as sales agents. The filing itself sells no shares.Altimmune, Inc. S-3 (2025-02-27) https://aibio.space/news/crescent-still-expects-glycomimetics-reverse-merger-close-second/https://aibio.space/news/crescent-still-expects-glycomimetics-reverse-merger-close-second/Thu, 27 Feb 2025 12:00:00 GMTMergersCrescent Biopharma said on February 24, 2025 that it still expects its reverse merger with GlycoMimetics to close in the second quarter of 2025. The merger filing says the deal depends on a financing transaction and on GlycoMimetics stockholder approval.Crescent Biopharma, Inc. 425 (2025-02-27) https://aibio.space/news/mustang-bio-sells-fixed-assets-abbvie-1-0-million-exits-worcester/https://aibio.space/news/mustang-bio-sells-fixed-assets-abbvie-1-0-million-exits-worcester/Thu, 27 Feb 2025 12:00:00 GMTMergersThe company expects about $2.0 million in lease savings over 24 months. It has moved its headquarters to Waltham, Massachusetts.Mustang Bio, Inc. 8-K (2025-02-27) https://aibio.space/news/shuttle-pharmaceuticals-pays-alto-75-000-waive-rights-10-million-notes/https://aibio.space/news/shuttle-pharmaceuticals-pays-alto-75-000-waive-rights-10-million-notes/Thu, 27 Feb 2025 12:00:00 GMTFinancingsShuttle paid Alto Opportunity Master Fund $75,000 under an amendment signed February 26, 2025. The holder gave up its right to buy up to $10 million of additional notes and warrants, and waived its right to join a contemplated registered offering.Shuttle Pharmaceuticals Holdings, Inc. 8-K (2025-02-27) https://aibio.space/news/zevra-therapeutics-agrees-sell-priority-review-voucher-150-million/https://aibio.space/news/zevra-therapeutics-agrees-sell-priority-review-voucher-150-million/Thu, 27 Feb 2025 12:00:00 GMTFinancingsThe company expects the sale to close within 30 to 45 days, subject to customary conditions including a Hart-Scott-Rodino waiting period.Zevra Therapeutics, Inc. 8-K (2025-02-27) https://aibio.space/news/sintx-technologies-closes-5-0-million-private-placement-warrants/https://aibio.space/news/sintx-technologies-closes-5-0-million-private-placement-warrants/Wed, 26 Feb 2025 12:00:00 GMTFinancingsSINTX (Nasdaq: SINT) sold shares, pre-funded warrants and warrants for gross proceeds of $5.0 million before fees. H.C. Wainwright & Co. was placement agent, and the company will use net proceeds for working capital.Sintx Technologies, Inc. Form 8-K filed February 26, 2025 (SEC EDGAR) https://aibio.space/news/cytomx-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice/https://aibio.space/news/cytomx-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice/Wed, 26 Feb 2025 12:00:00 GMTListingsNasdaq said CytomX stock did not hold a $1.00 minimum bid for 30 consecutive business days. The company has 180 calendar days to regain compliance, and the notice has no immediate effect on its listing.CytomX Therapeutics, Inc. Form 8-K filed February 26, 2025 (SEC EDGAR) https://aibio.space/news/agenus-extends-10-5-million-2015-notes-july-2026-reprices-warrants-3/https://aibio.space/news/agenus-extends-10-5-million-2015-notes-july-2026-reprices-warrants-3/Wed, 26 Feb 2025 12:00:00 GMTFinancingsThe interest rate on the notes rises from 8% to 9%, and Agenus will grant a subordinate mortgage on properties owned by Agenus West, LLC. New warrants cover 67,500 shares.AGENUS INC Form 8-K filed February 26, 2025 (SEC EDGAR) https://aibio.space/news/kiniksa-ends-abiprubart-phase-2b-trial-terminates-mavrilimumab-license/https://aibio.space/news/kiniksa-ends-abiprubart-phase-2b-trial-terminates-mavrilimumab-license/Tue, 25 Feb 2025 12:00:00 GMTDistressKiniksa has incurred about $19 million in expenses from ending the Sjögren's trial and expects $14 million to $17 million more. It reported $243.6 million in cash, cash equivalents and short-term investments and no debt, and its 2024 net loss was $43.2 million.Kiniksa Pharmaceuticals International, plc Form 8-K filed February 25, 2025 (SEC EDGAR) https://aibio.space/news/rallybio-gets-nasdaq-minimum-bid-price-notice-has-until-august-25-2025/https://aibio.space/news/rallybio-gets-nasdaq-minimum-bid-price-notice-has-until-august-25-2025/Tue, 25 Feb 2025 12:00:00 GMTListingsRallybio's closing bid price was below $1.00 for 30 consecutive business days. It may be eligible for another 180-day period if it applies to move its listing to the Nasdaq Capital Market.Rallybio Corp Form 8-K filed February 25, 2025 (SEC EDGAR) https://aibio.space/news/maia-biotechnology-prices-1-43-million-private-placement-shares/https://aibio.space/news/maia-biotechnology-prices-1-43-million-private-placement-shares/Tue, 25 Feb 2025 12:00:00 GMTFinancingsMAIA Biotechnology agreed on February 24, 2025 to sell 894,300 shares at $1.50 each, with warrants at $1.85, to accredited investors and certain directors. Combined gross proceeds are expected to be about $1.43 million, and the company's 2023 annual report carried a going-concern warning.MAIA Biotechnology, Inc. Form 8-K filed February 25, 2025 (SEC EDGAR) https://aibio.space/news/universe-pharmaceuticals-gets-nasdaq-delisting-notice-delayed-form-20/https://aibio.space/news/universe-pharmaceuticals-gets-nasdaq-delisting-notice-delayed-form-20/Tue, 25 Feb 2025 12:00:00 GMTListingsThe company is already before a Nasdaq Hearings Panel over a separate rule, 5550(a)(2). It says it will ask for a stay of the suspension and is working on the report.Universe Pharmaceuticals Inc 6-K (2025-02-25) https://aibio.space/news/atossa-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice/https://aibio.space/news/atossa-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice/Mon, 24 Feb 2025 12:00:00 GMTListingsNasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until August 20, 2025 to cure, and a second 180-day period is possible.ATOSSA THERAPEUTICS, INC. Form 8-K filed February 24, 2025 (SEC EDGAR) https://aibio.space/news/inhibikase-acquires-corhepta-merger-paying-15-0-million-4-979-101/https://aibio.space/news/inhibikase-acquires-corhepta-merger-paying-15-0-million-4-979-101/Mon, 24 Feb 2025 12:00:00 GMTFinancingsInhibikase paid $15.0 million for CorHepta in 4,979,101 newly issued shares, with part held in escrow or tied to a milestone. The 8-K names no bank, placement agent or financial adviser for the stock issuance.Inhibikase Therapeutics, Inc. Form 8-K filed February 24, 2025 (SEC EDGAR) https://aibio.space/news/fibrogen-now-kyntra-bio-sets-up-30-0-million-market-stock-program/https://aibio.space/news/fibrogen-now-kyntra-bio-sets-up-30-0-million-market-stock-program/Mon, 24 Feb 2025 12:00:00 GMTFinancingsBofA Securities will sell shares as agent for a commission of up to 3.0%. The stock last sold at $0.7724 before the filing.Kyntra Bio, Inc. 424B5 (2025-02-24) https://aibio.space/news/urogen-pharma-issues-374-843-shares-iconovir-icvb-1042-asset-purchase/https://aibio.space/news/urogen-pharma-issues-374-843-shares-iconovir-icvb-1042-asset-purchase/Thu, 20 Feb 2025 12:00:00 GMTFinancingsUroGen paid for IconOVir Bio's ICVB-1042 candidate with shares tied to a $4.0 million price, a possible $15.0 million sales milestone and a low single-digit royalty. Entities tied to UroGen's board chair hold IconOVir notes.UroGen Pharma Ltd. Form 8-K filed February 20, 2025 (SEC EDGAR) https://aibio.space/news/heron-therapeutics-extends-hercules-loan-maturity-late-september-1/https://aibio.space/news/heron-therapeutics-extends-hercules-loan-maturity-late-september-1/Thu, 20 Feb 2025 12:00:00 GMTDebt FinancingThe later date applies only if none of the company's 1.5% convertible notes due May 24, 2026 remain outstanding. Otherwise the loan comes due earlier.Heron Therapeutics, Inc. 8-K (2025-02-20) https://aibio.space/news/pharming-lifts-stake-abliva-92-70-percent-extends-cash-offer-march-6/https://aibio.space/news/pharming-lifts-stake-abliva-92-70-percent-extends-cash-offer-march-6/Thu, 20 Feb 2025 12:00:00 GMTListingsPharming's subsidiary now controls 92.70 percent of Abliva through its SEK 0.45 cash offer, and it has extended the acceptance period to March 6, 2025 for holders who have not yet tendered. Pharming plans a compulsory acquisition of the rest and a delisting from Nasdaq Stockholm.Pharming Group NV 6-K (2025-02-20) https://aibio.space/news/urogen-buys-iconovir-assets-374-843-shares-possible-15-0-million/https://aibio.space/news/urogen-buys-iconovir-assets-374-843-shares-possible-15-0-million/Thu, 20 Feb 2025 12:00:00 GMTFinancingsThe deal covers the product candidate ICVB-1042. A director's affiliates hold IconOVir notes that may entitle them to about 28.3% of the purchase price.UroGen Pharma Ltd. 8-K (2025-02-20) https://aibio.space/news/conduit-pharmaceuticals-now-cdt-equity-repays-nirland-note-nasdaq/https://aibio.space/news/conduit-pharmaceuticals-now-cdt-equity-repays-nirland-note-nasdaq/Wed, 19 Feb 2025 12:00:00 GMTListingsNasdaq's staff found on February 12, 2025 that Conduit Pharmaceuticals had not met two market value requirements within the 180-day grace period. The next day the company repaid the last $926,149 of a senior secured note to Nirland Limited, which it says was meant to help with the Nasdaq deficiencies.CDT Equity Inc. Form 8-K filed February 19, 2025 (SEC EDGAR) https://aibio.space/news/trisalus-life-sciences-receives-10-million-second-loan-tranche-issues/https://aibio.space/news/trisalus-life-sciences-receives-10-million-second-loan-tranche-issues/Wed, 19 Feb 2025 12:00:00 GMTFinancingsThe Second Tranche loan matures on April 30, 2029. Warrants issued to the initial lender and its affiliate carry an exercise price of $5.4787 and a term of 7 years.TriSalus Life Sciences, Inc. Form 8-K filed February 19, 2025 (SEC EDGAR) https://aibio.space/news/abbvie-prices-four-series-senior-notes-expects-about-3-98-billion-net/https://aibio.space/news/abbvie-prices-four-series-senior-notes-expects-about-3-98-billion-net/Wed, 19 Feb 2025 12:00:00 GMTFinancingsThe notes mature in 2028, 2030, 2035 and 2055. AbbVie plans to use the money and cash on hand to repay 2025 senior notes, and the sale is expected to close February 26, 2025.AbbVie Inc. Form 8-K filed February 19, 2025 (SEC EDGAR) https://aibio.space/news/petros-pharmaceuticals-prices-9-6-million-offering-stock-warrants-0-24/https://aibio.space/news/petros-pharmaceuticals-prices-9-6-million-offering-stock-warrants-0-24/Wed, 19 Feb 2025 12:00:00 GMTFinancingsPetros is selling about 40,000,000 shares, or pre-funded warrants in their place, at $0.24 for about $9.6 million gross. Dawson James Securities, Inc. is the placement agent, paid 8% of the gross proceeds, and the warrants cannot be exercised until stockholders approve them.Petros Pharmaceuticals, Inc. 424B4 (2025-02-19) https://aibio.space/news/painreform-now-prf-technologies-agrees-buy-deepsolar-business-shares/https://aibio.space/news/painreform-now-prf-technologies-agrees-buy-deepsolar-business-shares/Tue, 18 Feb 2025 12:00:00 GMTMergersThe drug-delivery company is acquiring an AI solar analytics platform from BladeRanger Ltd. BladeRanger would receive 178,769 ordinary shares plus four sets of warrants, and the release gives no price or valuation for the business.PRF Technologies Ltd. 6-K (2025-02-18) https://aibio.space/news/cumberland-pharmaceuticals-registers-up-10-000-000-share-sales/https://aibio.space/news/cumberland-pharmaceuticals-registers-up-10-000-000-share-sales/Fri, 14 Feb 2025 12:00:00 GMTFinancingsThe sales agreement with H.C. Wainwright still limits what it can sell now to $5,800,000, because of a cap tied to its public float.Cumberland Pharmaceuticals Inc. 424B5 (2025-02-14) https://aibio.space/news/citius-pharmaceuticals-reports-1-1-million-cash-expects-raise-capital/https://aibio.space/news/citius-pharmaceuticals-reports-1-1-million-cash-expects-raise-capital/Fri, 14 Feb 2025 12:00:00 GMTListingsCitius Pharmaceuticals ended its fiscal first quarter with $1,100,079 in cash, after operations used $4,725,852 and inventory absorbed $6,112,603. The release does not name a placement agent for the offerings it describes.Citius Pharmaceuticals, Inc. 8-K (2025-02-14) https://aibio.space/news/nasdaq-withdraws-evaxion-biotech-now-evaxion-s-delisting-determination/https://aibio.space/news/nasdaq-withdraws-evaxion-biotech-now-evaxion-s-delisting-determination/Fri, 14 Feb 2025 12:00:00 GMTListingsEvaxion says it restored stockholders' equity above the $2.5 million minimum and has cash runway into mid-2026. Nasdaq imposed a one-year monitor.Evaxion A/S 6-K (2025-02-14) https://aibio.space/news/xencor-says-2023-2024-interim-financials-cant-relied-will-restate/https://aibio.space/news/xencor-says-2023-2024-interim-financials-cant-relied-will-restate/Thu, 13 Feb 2025 12:00:00 GMTDistressXencor's audit committee concluded that a 2023 royalty deal with OMERS Life Sciences should be debt, not deferred income, and the company says its 2023 operating cash flow was overstated by $163.0 million. It also found tax misstatements. The company says cash and marketable debt securities are not affected.Xencor Inc Form 8-K filed February 13, 2025 (SEC EDGAR) https://aibio.space/news/ovid-therapeutics-gets-nasdaq-minimum-bid-price-notice-has-until/https://aibio.space/news/ovid-therapeutics-gets-nasdaq-minimum-bid-price-notice-has-until/Thu, 13 Feb 2025 12:00:00 GMTListingsNasdaq says Ovid's average closing bid price was below $1.00 for 31 consecutive trading days. The company has 180 calendar days to regain compliance and says its Nasdaq listing is unaffected for now.Ovid Therapeutics Inc. Form 8-K filed February 13, 2025 (SEC EDGAR) https://aibio.space/news/bio-rad-restructuring-cut-about-5-percent-workforce-45-million-50/https://aibio.space/news/bio-rad-restructuring-cut-about-5-percent-workforce-45-million-50/Thu, 13 Feb 2025 12:00:00 GMTDistressBio-Rad began the plan on February 7, 2025 and expects it to be substantially completed by the end of fiscal 2025. The company also made a binding offer to buy Stilla Technologies.BIO-RAD LABORATORIES, INC. Form 8-K filed February 13, 2025 (SEC EDGAR) https://aibio.space/news/briacell-therapeutics-regains-compliance-nasdaq-minimum-bid-price/https://aibio.space/news/briacell-therapeutics-regains-compliance-nasdaq-minimum-bid-price/Thu, 13 Feb 2025 12:00:00 GMTListingsNasdaq closed BriaCell's bid price matter on February 12, 2025, after an August 2024 letter cited 30 consecutive business days with closing bids below $1.00.BriaCell Therapeutics Corp 8-K (2025-02-13) https://aibio.space/news/edesa-biotech-closes-15-0-million-private-placement-led-velan-capital/https://aibio.space/news/edesa-biotech-closes-15-0-million-private-placement-led-velan-capital/Thu, 13 Feb 2025 12:00:00 GMTFinancingsEdesa sold 834 Series B-1 preferred shares at $10,000 each and 3,468,746 common shares at $1.92. A Velan Capital analyst joined its board.Edesa Biotech, Inc. 8-K (2025-02-13) https://aibio.space/news/genprex-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until/https://aibio.space/news/genprex-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until/Wed, 12 Feb 2025 12:00:00 GMTListingsNasdaq says Genprex does not meet the $1.00 minimum bid price, based on the last 30 consecutive business days. Separately, Nasdaq extended the company's deadline on the stockholders' equity requirement.Genprex, Inc. Form 8-K filed February 12, 2025 (SEC EDGAR) https://aibio.space/news/aligos-therapeutics-announces-105-million-private-placement/https://aibio.space/news/aligos-therapeutics-announces-105-million-private-placement/Wed, 12 Feb 2025 12:00:00 GMTFinancingsAligos is selling shares, pre-funded warrants and warrants at $26.0825 per share and warrant to fund a Phase 2 study of ALG-000184 and extend cash into the second half of 2026.Aligos Therapeutics, Inc. 8-K (2025-02-12) https://aibio.space/news/microbot-medical-agrees-13-0-million-registered-direct-offering-2-13/https://aibio.space/news/microbot-medical-agrees-13-0-million-registered-direct-offering-2-13/Tue, 11 Feb 2025 12:00:00 GMTFinancingsMicrobot Medical agreed to sell 6,103,289 shares at $2.13 in a registered direct offering, with unregistered warrants for up to 12,206,578 more shares. H.C. Wainwright & Co., LLC is the exclusive placement agent, and the company pays it a 7.0% cash fee.Microbot Medical Inc. Form 8-K filed February 11, 2025 (SEC EDGAR) https://aibio.space/news/q32-bio-announces-restructuring-workforce-reduction-focus-bempikibart/https://aibio.space/news/q32-bio-announces-restructuring-workforce-reduction-focus-bempikibart/Mon, 10 Feb 2025 12:00:00 GMTDistressQ32 Bio is ending its renal trial of ADX-097, cutting staff and betting on bempikibart in alopecia areata. It expects about $1.1 million in severance charges and says cash should last into the second half of 2026, but the release gives no cash balance.Q32 Bio Inc. Form 8-K filed February 10, 2025 (SEC EDGAR) https://aibio.space/news/grace-therapeutics-agrees-private-placement-expects-about-13-8-million/https://aibio.space/news/grace-therapeutics-agrees-private-placement-expects-about-13-8-million/Mon, 10 Feb 2025 12:00:00 GMTFinancingsGrace Therapeutics expects about $13.8 million in net proceeds from a private placement at $3.395 a share, with TD Securities (USA) LLC as placement agent. The same day, its Phase 3 safety trial of GTx-104 was reported, and the company's own release says the trial was not powered to show efficacy.Grace Therapeutics, Inc. Form 8-K filed February 10, 2025 (SEC EDGAR) https://aibio.space/news/akebia-therapeutics-draws-10-0-million-tranche-c-loan-kreos-receives-9/https://aibio.space/news/akebia-therapeutics-draws-10-0-million-tranche-c-loan-kreos-receives-9/Fri, 07 Feb 2025 12:00:00 GMTDebt FinancingAkebia drew the extended $10.0 million Tranche C loan on February 3, 2025, the last day of its extension. It received $9.3 million net and issued a warrant to a Kreos affiliate for 1,153,846 shares at $1.30 a share.Akebia Therapeutics, Inc. Form 8-K filed February 7, 2025 (SEC EDGAR) https://aibio.space/news/akebia-extends-kreos-loan-tranche-draws-10-0-million-issues-1-153-846/https://aibio.space/news/akebia-extends-kreos-loan-tranche-draws-10-0-million-issues-1-153-846/Fri, 07 Feb 2025 12:00:00 GMTDebt FinancingAkebia received net proceeds of $9.3 million on February 3, 2025. The warrant has an exercise price of $1.30 per share and runs eight years.Akebia Therapeutics, Inc. 8-K (2025-02-07) https://aibio.space/news/belite-bio-sells-258-309-adss-warrants-15-000-004/https://aibio.space/news/belite-bio-sells-258-309-adss-warrants-15-000-004/Fri, 07 Feb 2025 12:00:00 GMTFinancingsBelite Bio is selling 258,309 ADSs and warrants for the same number of ADSs at $58.07 each through Titan Partners Group LLC. The prospectus says the company has recorded net cash outflows from operations since inception.Belite Bio, Inc 424B5 (2025-02-07) https://aibio.space/news/mustang-bio-prices-8-million-offering-3-01-two-series-warrants/https://aibio.space/news/mustang-bio-prices-8-million-offering-3-01-two-series-warrants/Fri, 07 Feb 2025 12:00:00 GMTFinancingsThe warrants can be exercised only after stockholders approve. The offering follows a 1-for-50 reverse stock split on January 15, 2025.Mustang Bio, Inc. 424B4 (2025-02-07) https://aibio.space/news/sionna-therapeutics-prices-ipo-10-588-233-shares-18-00/https://aibio.space/news/sionna-therapeutics-prices-ipo-10-588-233-shares-18-00/Fri, 07 Feb 2025 12:00:00 GMTFinancingsThe offering totals $190,588,194, and the stock is approved to list on Nasdaq under SION. Proceeds to the company are $177,247,020 before expenses.Sionna Therapeutics, Inc. 424B4 (2025-02-07) https://aibio.space/news/60-degrees-pharmaceuticals-sells-1-503-500-shares-1-075-million/https://aibio.space/news/60-degrees-pharmaceuticals-sells-1-503-500-shares-1-075-million/Thu, 06 Feb 2025 12:00:00 GMTFinancings60 Degrees Pharmaceuticals sold 1,503,500 shares at $0.715 each in a registered direct offering that closed Feb 6, 2025. H.C. Wainwright was the placement agent, and the company reports about $908,627 of net proceeds, with matching warrants at $0.59.60 DEGREES PHARMACEUTICALS, INC. Form 8-K filed February 6, 2025 (SEC EDGAR) https://aibio.space/news/x4-pharmaceuticals-announces-restructuring-workforce-reduction-43/https://aibio.space/news/x4-pharmaceuticals-announces-restructuring-workforce-reduction-43/Thu, 06 Feb 2025 12:00:00 GMTDistressX4 will close its Vienna facility and pause preclinical programs to focus on mavorixafor in chronic neutropenia. It expects annual spending to fall by $30-35 million and believes its funds will last into the first half of 2026.X4 Pharmaceuticals, Inc Form 8-K filed February 6, 2025 (SEC EDGAR) https://aibio.space/news/alumis-agrees-all-stock-merger-acelyrin-pro-forma-cash-about-737/https://aibio.space/news/alumis-agrees-all-stock-merger-acelyrin-pro-forma-cash-about-737/Thu, 06 Feb 2025 12:00:00 GMTMergersACELYRIN holders would receive 0.4274 Alumis shares for each share and own about 45% of the combined company. The cash figures behind the deal are preliminary and unaudited, and ACELYRIN's lead program is being re-evaluated.ALUMIS INC. Form 8-K filed February 6, 2025 (SEC EDGAR) https://aibio.space/news/alumis-acelyrin-agree-all-stock-merger-737-million-pro-forma-cash/https://aibio.space/news/alumis-acelyrin-agree-all-stock-merger-737-million-pro-forma-cash/Thu, 06 Feb 2025 12:00:00 GMTMergersACELYRIN holders would receive 0.4274 Alumis shares for each share they own, and the $737 million pro forma cash figure rests on preliminary year-end balances.Alumis Inc. 8-K (2025-02-06) https://aibio.space/news/renovorx-prices-11-523-810-share-offering-1-05-12-100-001-gross/https://aibio.space/news/renovorx-prices-11-523-810-share-offering-1-05-12-100-001-gross/Thu, 06 Feb 2025 12:00:00 GMTFinancingsRenovoRx sold 11,523,810 shares at $1.05, below the $1.46 last sale on February 6, 2025, with Titan Partners Group as sole bookrunner. The company held about $9.6 million in cash and short-term securities at September 30, 2024, and its prospectus carries a going concern paragraph.RenovoRx, Inc. 424B5 (2025-02-06) https://aibio.space/news/briacell-closes-3-05-million-best-efforts-public-offering-762-500/https://aibio.space/news/briacell-closes-3-05-million-best-efforts-public-offering-762-500/Wed, 05 Feb 2025 12:00:00 GMTFinancingsBriaCell sold 762,500 common shares at $4.00 each through placement agent ThinkEquity. The $3.05 million in gross proceeds is before fees and expenses, and the agent also received warrants on 38,125 shares.BriaCell Therapeutics Corp. Form 8-K filed February 5, 2025 (SEC EDGAR) https://aibio.space/news/baxter-completes-kidney-care-business-sale-receives-about-3-71-billion/https://aibio.space/news/baxter-completes-kidney-care-business-sale-receives-about-3-71-billion/Mon, 03 Feb 2025 12:00:00 GMTMergersBaxter completed the sale of its Kidney Care business on January 31, 2025 and received about $3.71 billion in net, pre-tax cash at closing, against a $3.80 billion price set at signing. The price is still subject to post-closing adjustments, and executive Chris Toth stepped down on the closing date.BAXTER INTERNATIONAL INC Form 8-K filed February 3, 2025 (SEC EDGAR) https://aibio.space/news/alto-neuroscience-files-300-000-000-shelf-75-000-000-market-program/https://aibio.space/news/alto-neuroscience-files-300-000-000-shelf-75-000-000-market-program/Mon, 03 Feb 2025 12:00:00 GMTFinancingsAlto Neuroscience filed a $300,000,000 shelf on February 3, 2025 and signed a $75,000,000 at-the-market sales agreement with Leerink Partners LLC, but no sale can start until the SEC declares the shelf effective, and its year-end cash figure is still preliminary.Alto Neuroscience, Inc. S-3 (2025-02-03) https://aibio.space/news/annovis-bio-prices-21-000-000-public-offering-units-4-00/https://aibio.space/news/annovis-bio-prices-21-000-000-public-offering-units-4-00/Mon, 03 Feb 2025 12:00:00 GMTFinancingsAnnovis Bio priced 5,250,000 units at $4.00 for $21,000,000 on February 3, 2025, through ThinkEquity as underwriter, with a $1,260,000 discount and warrants exercisable at $5.00, which is 125% of the offering price.Annovis Bio, Inc. 424B5 (2025-02-03) https://aibio.space/news/arrivent-biopharma-files-automatic-shelf-250-000-000-atm-sales/https://aibio.space/news/arrivent-biopharma-files-automatic-shelf-250-000-000-atm-sales/Mon, 03 Feb 2025 12:00:00 GMTFinancingsJefferies is the sales agent. ArriVent's stock last sold at $29.09 per share on January 30, 2025.ArriVent BioPharma, Inc. S-3ASR (2025-02-03) https://aibio.space/news/enveric-biosciences-prices-5-million-public-offering-3-00-share/https://aibio.space/news/enveric-biosciences-prices-5-million-public-offering-3-00-share/Mon, 03 Feb 2025 12:00:00 GMTFinancingsH.C. Wainwright & Co. is the exclusive placement agent for a $3.00 offering of shares and warrants. The auditor's report on the 2023 financial statements already raised substantial doubt about the company's ability to continue as a going concern.Enveric Biosciences, Inc. 424B4 (2025-02-03) https://aibio.space/news/beta-bionics-closes-ipo-17-00-private-placement-229-1-million-gross/https://aibio.space/news/beta-bionics-closes-ipo-17-00-private-placement-229-1-million-gross/Fri, 31 Jan 2025 12:00:00 GMTFinancingsBeta Bionics told the SEC that its initial public offering and a concurrent private placement brought in gross proceeds of $229.1 million before underwriting discounts and expenses. The company's own release puts its share of the IPO at about $212.1 million, well below the $234.6 million headline figure.Beta Bionics, Inc. Form 8-K filed January 31, 2025 (SEC EDGAR) https://aibio.space/news/maze-therapeutics-prices-ipo-8-750-000-shares-16-00/https://aibio.space/news/maze-therapeutics-prices-ipo-8-750-000-shares-16-00/Fri, 31 Jan 2025 12:00:00 GMTFinancingsMaze priced at $16.00 and expects net proceeds of approximately $127.7 million. The company reported a net loss of $100.4 million for 2023 and has no product approved for sale.Maze Therapeutics, Inc. 424B4 (2025-01-31) https://aibio.space/news/tectonic-cites-159-million-cash-runway-then-agrees-185-0-million/https://aibio.space/news/tectonic-cites-159-million-cash-runway-then-agrees-185-0-million/Thu, 30 Jan 2025 12:00:00 GMTFinancingsTectonic's January 30, 2025 presentation put cash at $159 million as of September 30, 2024. On February 3 it agreed to a $185.0 million PIPE, with 3,689,465 shares sold at $50.00 each to funds and $54.14 each to officers and directors.Tectonic Therapeutic, Inc. 8-K (2025-01-30) https://aibio.space/news/zentalis-pharmaceuticals-announces-restructuring-workforce-reduction/https://aibio.space/news/zentalis-pharmaceuticals-announces-restructuring-workforce-reduction/Tue, 28 Jan 2025 12:00:00 GMTDistressThe board approved the plan on January 22, 2025. Zentalis expects one-time costs of $7.0 million to $8.0 million and believes its cash will fund operations into late 2027.Zentalis Pharmaceuticals, Inc. Form 8-K filed January 28, 2025 (SEC EDGAR) https://aibio.space/news/lineage-cell-therapeutics-closes-second-tranche-offering-proceeds/https://aibio.space/news/lineage-cell-therapeutics-closes-second-tranche-offering-proceeds/Mon, 27 Jan 2025 12:00:00 GMTFinancingsLineage received $6 million more after shareholders approved a sale to a director's affiliate. Milestone-linked warrants could add up to $36 million.Lineage Cell Therapeutics, Inc. 8-K (2025-01-27) https://aibio.space/news/china-sxt-pharmaceuticals-files-securities-purchase-agreement-priced-0/https://aibio.space/news/china-sxt-pharmaceuticals-files-securities-purchase-agreement-priced-0/Mon, 27 Jan 2025 12:00:00 GMTListingsThe January 21, 2025 agreement sells up to $2,840,000 of shares at $0.20 each, with warrants for 200 percent of each buyer's shares at $1.00. It also sets a penalty of 2.0 percent of the subscription amount for public information failures.China SXT Pharmaceuticals, Inc. 6-K (2025-01-27) https://aibio.space/news/universe-pharmaceuticals-says-20-f-will-late-expects-20-33-million-net/https://aibio.space/news/universe-pharmaceuticals-says-20-f-will-late-expects-20-33-million-net/Mon, 27 Jan 2025 12:00:00 GMTDistressThe company expects a net loss of about $20.33 million for the year ended September 30, 2024, up from $6.16 million a year earlier.Universe Pharmaceuticals Inc NT 20-F (2025-01-27) https://aibio.space/news/ascentage-pharma-prices-u-s-ipo-7-325-000-adss-us-17-25/https://aibio.space/news/ascentage-pharma-prices-u-s-ipo-7-325-000-adss-us-17-25/Fri, 24 Jan 2025 12:00:00 GMTFinancingsThe ADSs are approved to list on Nasdaq under AAPG, with J.P. Morgan and Citigroup as the underwriters named on the cover. The company's ordinary shares have traded in Hong Kong under code 6855 since October 28, 2019.Ascentage Pharma Group International 424B4 (2025-01-24) https://aibio.space/news/aardvark-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-aard/https://aibio.space/news/aardvark-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-aard/Thu, 23 Jan 2025 12:00:00 GMTFinancingsThe company applied to list on the Nasdaq Global Market. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are the underwriters named on the cover.Aardvark Therapeutics, Inc. S-1 (2025-01-23) https://aibio.space/news/arvinas-subsidiary-ends-new-haven-lab-lease-effective-december-31-2024/https://aibio.space/news/arvinas-subsidiary-ends-new-haven-lab-lease-effective-december-31-2024/Wed, 22 Jan 2025 12:00:00 GMTDistressUnder the January 15, 2025 agreement, Arvinas Operations owes no rent after the termination date if it clears the space by January 21, 2025.Arvinas, Inc. 8-K (2025-01-22) https://aibio.space/news/provectus-biopharmaceuticals-approves-plan-seek-up-10-000-000/https://aibio.space/news/provectus-biopharmaceuticals-approves-plan-seek-up-10-000-000/Wed, 22 Jan 2025 12:00:00 GMTDebt FinancingThe unsecured notes carry 8% interest and convert into Series D-1 preferred stock at $2.8620 per share. The board also approved the closing of a 2024 financing under which the company had received $1,000,000 in notes.Provectus Biopharmaceuticals, Inc. 8-K (2025-01-22) https://aibio.space/news/pluri-gets-nasdaq-extension-may-24-2025-regain-stockholders-equity/https://aibio.space/news/pluri-gets-nasdaq-extension-may-24-2025-regain-stockholders-equity/Tue, 21 Jan 2025 12:00:00 GMTListingsNasdaq accepted Pluri's compliance plan after a November 25, 2024 deficiency letter. The company must show $2,500,000 in stockholders' equity by the deadline or may face delisting, and its shares keep trading as PLUR.Pluri Inc. Form 8-K filed January 21, 2025 (SEC EDGAR) https://aibio.space/news/aadi-bioscience-now-whitehawk-therapeutics-seeks-vote-100-million/https://aibio.space/news/aadi-bioscience-now-whitehawk-therapeutics-seeks-vote-100-million/Tue, 21 Jan 2025 12:00:00 GMTMergersAadi Bioscience's preliminary proxy, filed January 21, 2025, asks holders to approve a $100 million cash sale of its FYARRO business to Kaken and a private placement of 21,592,000 shares at $2.40 each. The meeting date is still blank in that filing.Whitehawk Therapeutics, Inc. PREM14A (2025-01-21) https://aibio.space/news/phio-pharmaceuticals-closes-registered-direct-offering-warrants-nets/https://aibio.space/news/phio-pharmaceuticals-closes-registered-direct-offering-warrants-nets/Fri, 17 Jan 2025 12:00:00 GMTFinancingsPhio sold 610,000 shares at $3.00 per share and issued short-term warrants for up to 1,220,000 shares in a concurrent private placement. Net proceeds are approximately $1.6 million, after a placement agent fee of 7.5% plus a 1.0% management fee.Phio Pharmaceuticals Corp. Form 8-K filed January 17, 2025 (SEC EDGAR) https://aibio.space/news/kairos-pharma-closes-3-497-500-private-placement-pre-funded-units/https://aibio.space/news/kairos-pharma-closes-3-497-500-private-placement-pre-funded-units/Fri, 17 Jan 2025 12:00:00 GMTFinancingsKairos Pharma (NYSE American: KAPA) sold 2,500,000 pre-funded units, each with a common warrant at $1.40 per share. Boustead Securities and D. Boral Capital were co-placement agents.Kairos Pharma, LTD. Form 8-K filed January 17, 2025 (SEC EDGAR) https://aibio.space/news/polypid-says-14-5-million-private-placement-restored-nasdaq-equity/https://aibio.space/news/polypid-says-14-5-million-private-placement-restored-nasdaq-equity/Fri, 17 Jan 2025 12:00:00 GMTListingsThe company says stockholders' equity is now about $7.5 million, up from $2.2 million at September 30, 2024. Nasdaq staff will keep monitoring, and the company could face delisting if it cannot show compliance in its next periodic report.PolyPid Ltd. 6-K (2025-01-17) https://aibio.space/news/sionna-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-sion/https://aibio.space/news/sionna-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-sion/Fri, 17 Jan 2025 12:00:00 GMTFinancingsSionna Therapeutics filed a preliminary S-1 on January 17, 2025 for an IPO of common stock on the Nasdaq Global Market under SION. The filing leaves the share count, price range and net proceeds blank, and lists Goldman Sachs & Co. LLC, TD Cowen, Stifel and Guggenheim Securities as underwriters without marking a lead.Sionna Therapeutics, Inc. S-1 (2025-01-17) https://aibio.space/news/alto-neuroscience-amends-k2-healthventures-loan-20-0-million-funded/https://aibio.space/news/alto-neuroscience-amends-k2-healthventures-loan-20-0-million-funded/Thu, 16 Jan 2025 12:00:00 GMTDebt FinancingAlto Neuroscience's January 13, 2025 amendment lifts the maximum term loans from $35.0 million to $75.0 million and moves maturity to January 1, 2029. Only $20.0 million was funded at signing, and about $10 million of that went to refinance the old loan and pay fees.Alto Neuroscience, Inc. Form 8-K filed January 16, 2025 (SEC EDGAR) https://aibio.space/news/gain-therapeutics-regains-compliance-nasdaq-50-million-market-value/https://aibio.space/news/gain-therapeutics-regains-compliance-nasdaq-50-million-market-value/Wed, 15 Jan 2025 12:00:00 GMTListingsGain Therapeutics received a Nasdaq deficiency notice on January 8, 2025 over its Market Value of Listed Securities. Nasdaq staff confirmed in writing on January 15 that the company is back in compliance.Gain Therapeutics, Inc. Form 8-K filed January 15, 2025 (SEC EDGAR) https://aibio.space/news/coherus-biosciences-now-coherus-oncology-seeks-vote-483-4-million/https://aibio.space/news/coherus-biosciences-now-coherus-oncology-seeks-vote-483-4-million/Tue, 14 Jan 2025 12:00:00 GMTMergersCoherus could also earn two $37.5 million payments if UDENYCA sales hit set targets. The board unanimously recommends a vote for the sale.Coherus Oncology, Inc. PREM14A (2025-01-14) https://aibio.space/news/evaxion-biotech-now-evaxion-s-completes-ads-ratio-change-like-1-5/https://aibio.space/news/evaxion-biotech-now-evaxion-s-completes-ads-ratio-change-like-1-5/Tue, 14 Jan 2025 12:00:00 GMTListingsEach ADS now represents fifty ordinary shares instead of ten. The company says the change is meant to support liquidity in its ADSs on Nasdaq.Evaxion A/S 6-K (2025-01-14) https://aibio.space/news/inhibrx-biosciences-gets-100-0-million-close-oxford-finance-term-loan/https://aibio.space/news/inhibrx-biosciences-gets-100-0-million-close-oxford-finance-term-loan/Mon, 13 Jan 2025 12:00:00 GMTDebt FinancingThe loan agreement allows up to $150.0 million, with the remaining $50.0 million at the lenders' sole discretion. The loan matures January 1, 2030 and comes with warrants for 140,741 shares at $14.21. Oxford Finance LLC is collateral agent.Inhibrx Biosciences, Inc. Form 8-K filed January 13, 2025 (SEC EDGAR) https://aibio.space/news/verastem-sells-75-0-million-notes-oberland-capital-repays-oxford-loan/https://aibio.space/news/verastem-sells-75-0-million-notes-oberland-capital-repays-oxford-loan/Mon, 13 Jan 2025 12:00:00 GMTDebt FinancingThe note purchase agreement allows up to $150.0 million of notes with interest capped at 9.75%. Verastem also sold 1,416,939 shares to Oberland funds at $5.2931 per share and received about $32.3 million in net proceeds from the notes after the Oxford payoff. Its year-end cash figure is unaudited and preliminary.Verastem, Inc. Form 8-K filed January 13, 2025 (SEC EDGAR) https://aibio.space/news/ibio-sells-240-807-shares-officers-directors-655-000-private-placement/https://aibio.space/news/ibio-sells-240-807-shares-officers-directors-655-000-private-placement/Mon, 13 Jan 2025 12:00:00 GMTFinancingsiBio sold 240,807 common shares at $2.72 each to its directors and officers, for about $655,000 in gross proceeds, and the placement closed on January 10, 2025. The company says the price was at-the-market.iBio, Inc. Form 8-K filed January 13, 2025 (SEC EDGAR) https://aibio.space/news/inhibrx-biosciences-closes-oxford-finance-loan-up-150-million-funds/https://aibio.space/news/inhibrx-biosciences-closes-oxford-finance-loan-up-150-million-funds/Mon, 13 Jan 2025 12:00:00 GMTDebt FinancingThe five-year facility pays interest only until March 2028. Oxford also received warrants for 140,741 shares at $14.21 per share.Inhibrx Biosciences, Inc. 8-K (2025-01-13) https://aibio.space/news/opus-genetics-sets-up-40-000-000-market-program-leerink-partners/https://aibio.space/news/opus-genetics-sets-up-40-000-000-market-program-leerink-partners/Mon, 13 Jan 2025 12:00:00 GMTFinancingsOpus Genetics can sell up to $40,000,000 of stock through Leerink Partners, which takes 3.0% of gross proceeds. The company's last reported sale price was $1.42 on January 10, 2025, and the earlier JonesTrading program had sold about $26.4 million of stock.Opus Genetics, Inc. 424B5 (2025-01-13) https://aibio.space/news/protara-therapeutics-puts-cash-runway-2027-counting-102-7-million/https://aibio.space/news/protara-therapeutics-puts-cash-runway-2027-counting-102-7-million/Mon, 13 Jan 2025 12:00:00 GMTFinancingsProtara's January 2025 presentation says cash runway reaches into 2027 when it counts $102.7 million of gross proceeds from a recent offering. Its balance sheet figure is $81.5 million at September 30, 2024, and its bladder cancer efficacy data come from a small single-arm trial.Protara Therapeutics, Inc. 8-K (2025-01-13) https://aibio.space/news/neogen-files-nt-10-q-late-filing-notice-expects-461-4-million-goodwill/https://aibio.space/news/neogen-files-nt-10-q-late-filing-notice-expects-461-4-million-goodwill/Fri, 10 Jan 2025 12:00:00 GMTDistressNeogen filed a late-filing notice on January 10, 2025 for its quarterly report for the quarter ended November 30, 2024. The company expects a $461.4 million goodwill impairment on its Food Safety unit and a net loss of $456.3 million, against a loss of $3.5 million a year earlier.NEOGEN CORP Form NT 10-Q filed January 10, 2025 (SEC EDGAR) https://aibio.space/news/matinas-biopharma-gets-nyse-american-deficiency-notice-missing-2024/https://aibio.space/news/matinas-biopharma-gets-nyse-american-deficiency-notice-missing-2024/Fri, 10 Jan 2025 12:00:00 GMTListingsThe January 6, 2025 letter cites Section 704 of the NYSE American Company Guide. The shares stay listed with a ".BC" indicator, and Matinas says it will hold its annual meeting no later than December 31, 2025.Matinas BioPharma Holdings, Inc. Form 8-K filed January 10, 2025 (SEC EDGAR) https://aibio.space/news/incannex-gets-nasdaq-deficiency-notice-50-0-million-market-value/https://aibio.space/news/incannex-gets-nasdaq-deficiency-notice-50-0-million-market-value/Fri, 10 Jan 2025 12:00:00 GMTListingsIncannex Healthcare received a Nasdaq notice on January 3, 2025 that its market value of listed securities fell below the $50.0 million minimum for the Global Market. It has until July 2, 2025 to regain compliance, and its 2024 annual report carries a going-concern warning with $5.6 million of cash at June 30, 2024.Incannex Healthcare Inc. Form 8-K filed January 10, 2025 (SEC EDGAR) https://aibio.space/news/compass-pathways-prices-about-150-million-offering-adss-warrants/https://aibio.space/news/compass-pathways-prices-about-150-million-offering-adss-warrants/Fri, 10 Jan 2025 12:00:00 GMTFinancingsEach ADS sells for $4.275 with a warrant to buy another at $5.796. Full cash exercise of the warrants could lift gross proceeds to about $353 million.COMPASS Pathways Plc 424B5 (2025-01-10) https://aibio.space/news/entera-bio-adds-up-30-000-000-shares-market-program/https://aibio.space/news/entera-bio-adds-up-30-000-000-shares-market-program/Fri, 10 Jan 2025 12:00:00 GMTFinancingsEntera Bio Ltd. nearly used up the 5,000,000 shares first registered with Leerink Partners. The new supplement covers an additional block under the same sales agreement.Entera Bio Ltd. 424B5 (2025-01-10) https://aibio.space/news/intellia-plans-about-27-percent-net-workforce-cut-drops-ntla-3001-ends/https://aibio.space/news/intellia-plans-about-27-percent-net-workforce-cut-drops-ntla-3001-ends/Fri, 10 Jan 2025 12:00:00 GMTDistressIntellia says it is cutting its workforce by about 27% net in 2025 and dropping NTLA-3001 to focus on NTLA-2002 and nex-z. It ended 2024 with approximately $862 million and expects about $8 million in charges, but the release gives no headcount or savings figure.Intellia Therapeutics, Inc. 8-K (2025-01-10) https://aibio.space/news/citrine-global-now-skytech-orion-global-converts-partnership-loans/https://aibio.space/news/citrine-global-now-skytech-orion-global-converts-partnership-loans/Fri, 10 Jan 2025 12:00:00 GMTFinancingsThe company also agreed to sell units to Deer Light Ltd. for $137,000 and has received about $120,000 so far.SKYTECH ORION GLOBAL CORP. 8-K (2025-01-10) https://aibio.space/news/sensei-biotherapeutics-inc-now-faeth-therapeutics-inc-gets-180-more/https://aibio.space/news/sensei-biotherapeutics-inc-now-faeth-therapeutics-inc-gets-180-more/Tue, 07 Jan 2025 12:00:00 GMTListingsSensei Biotherapeutics told investors on January 7, 2025 that Nasdaq had moved its stock to the Capital Market and given it until July 7, 2025 to lift its share price above $1.00. Its 2023 annual report showed a $34,101 thousand net loss and cash that fell to $13,011 thousand at year end.Faeth Therapeutics, Inc. Form 8-K filed January 7, 2025 (SEC EDGAR) https://aibio.space/news/nasdaq-panel-keeps-revelation-biosciences-listed-condition-reverse/https://aibio.space/news/nasdaq-panel-keeps-revelation-biosciences-listed-condition-reverse/Tue, 07 Jan 2025 12:00:00 GMTListingsThe Nasdaq Hearings Panel kept the stock listed on two conditions: a reverse stock split by January 31, 2025 and a $1.00 close for ten straight trading days by February 14, 2025. The panel confirmed the equity deficiency is cured.REVELATION BIOSCIENCES, INC. Form 8-K filed January 7, 2025 (SEC EDGAR) https://aibio.space/news/cassava-sciences-now-filana-therapeutics-cuts-33-percent-workforce/https://aibio.space/news/cassava-sciences-now-filana-therapeutics-cuts-33-percent-workforce/Tue, 07 Jan 2025 12:00:00 GMTDistressAfter its Phase 3 ReThink-ALZ study of simufilam missed its co-primary endpoints, Cassava is cutting 10 employees, or 33% of its staff, at a one-time cost of about $0.4 million. It reported unaudited cash of about $128.6 million at December 31, 2024.FILANA THERAPEUTICS, INC. Form 8-K filed January 7, 2025 (SEC EDGAR) https://aibio.space/news/acurx-pharmaceuticals-prices-2-5-million-registered-direct-offering-1/https://aibio.space/news/acurx-pharmaceuticals-prices-2-5-million-registered-direct-offering-1/Tue, 07 Jan 2025 12:00:00 GMTFinancingsAcurx will sell 2,463,058 shares at $1.015 to institutional investors and six insiders, with Series E warrants for the same number of shares at $0.90. H.C. Wainwright & Co. is the exclusive placement agent, and it receives a 7.0% cash fee plus a 1.0% management fee.Acurx Pharmaceuticals, Inc. Form 8-K filed January 7, 2025 (SEC EDGAR) https://aibio.space/news/cassava-sciences-now-filana-therapeutics-cuts-workforce-about-33/https://aibio.space/news/cassava-sciences-now-filana-therapeutics-cuts-workforce-about-33/Tue, 07 Jan 2025 12:00:00 GMTDistressThe Alzheimer's drug developer expects about $0.4 million in one-time costs. The release gives no efficacy numbers for the two Phase 3 studies, and it still plans to report topline results from the one it is discontinuing.Filana Therapeutics, Inc. 8-K (2025-01-07) https://aibio.space/news/lifecore-biomedical-sells-unused-filling-equipment-17-million-7/https://aibio.space/news/lifecore-biomedical-sells-unused-filling-equipment-17-million-7/Tue, 07 Jan 2025 12:00:00 GMTFinancingsThe contract manufacturer received $7 million at closing and expects the rest in three tranches over 18 months. It says current capacity supports up to $300 million in annual revenue.Lifecore Biomedical, Inc. 8-K (2025-01-07) https://aibio.space/news/renovaro-now-lunai-bioworks-signs-binding-letter-buy-predictive/https://aibio.space/news/renovaro-now-lunai-bioworks-signs-binding-letter-buy-predictive/Tue, 07 Jan 2025 12:00:00 GMTMergersRenovaro plans to pay for Predictive Oncology with preferred stock in an all-stock deal. The letter of intent sets out the main terms, and the release gives no exchange ratio or value for the shares.Lunai Bioworks Inc. 8-K (2025-01-07) https://aibio.space/news/maze-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-maze/https://aibio.space/news/maze-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-maze/Tue, 07 Jan 2025 12:00:00 GMTFinancingsMaze's IPO filing names four underwriters and leaves the share count and price range blank. The nine months to September 30, 2024 include $167,500 thousand of license revenue.Maze Therapeutics, Inc. S-1 (2025-01-07) https://aibio.space/news/abvc-biopharma-cuts-warrant-price-0-40-lind-agrees-exercise-1-029-167/https://aibio.space/news/abvc-biopharma-cuts-warrant-price-0-40-lind-agrees-exercise-1-029-167/Mon, 06 Jan 2025 12:00:00 GMTFinancingsIt is the third such letter agreement with Lind Global Fund II, LP. The company agreed not to issue new shares for 15 days after closing.ABVC BioPharma, Inc. 8-K (2025-01-06) https://aibio.space/news/aeon-biopharma-prices-20-0-million-offering-units-0-50-each/https://aibio.space/news/aeon-biopharma-prices-20-0-million-offering-units-0-50-each/Mon, 06 Jan 2025 12:00:00 GMTFinancingsAEON Biopharma priced 40,000,000 units at $0.50 each for about $20.0 million gross, with Aegis Capital Corp. as sole book-running manager. Each unit carries two warrants that cannot be exercised until stockholders approve them, and their exercise price can reset lower.AEON Biopharma, Inc. 424B5 (2025-01-06) https://aibio.space/news/cyclacel-now-bio-green-med-solution-agrees-sell-3-1-million-preferred/https://aibio.space/news/cyclacel-now-bio-green-med-solution-agrees-sell-3-1-million-preferred/Mon, 06 Jan 2025 12:00:00 GMTMergersInvestor David Lazar agreed to subscribe for $3.1 million of convertible preferred stock and become interim chief executive. A separate warrant exchange would issue 24,844,725 common shares and pay $1,100,000 in cash. The Series D closing and the warrant exchange need stockholder approval, and the Nasdaq deadline is February 6, 2025.Bio Green Med Solution, Inc. 8-K (2025-01-06) https://aibio.space/news/cytomx-therapeutics-cut-about-40-percent-headcount-expects-5-million-6/https://aibio.space/news/cytomx-therapeutics-cut-about-40-percent-headcount-expects-5-million-6/Mon, 06 Jan 2025 12:00:00 GMTDistressThe restructuring focuses the company on CX-2051 and its research collaborations. CytomX expects the changes to extend its cash runway into the second quarter of 2026.CytomX Therapeutics, Inc. 8-K (2025-01-06) https://aibio.space/news/citius-oncology-hires-jefferies-explore-strategic-alternatives/https://aibio.space/news/citius-oncology-hires-jefferies-explore-strategic-alternatives/Mon, 06 Jan 2025 12:00:00 GMTDistressCitius Oncology has set no timeline for its strategic review, and the release says there is no assurance it will produce a deal. Its parent owns 92% of the company and has funded it since the subsidiary was formed.Citius Oncology, Inc. 8-K (2025-01-06) https://aibio.space/news/ocugen-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until-june/https://aibio.space/news/ocugen-gets-nasdaq-minimum-bid-price-deficiency-notice-has-until-june/Fri, 03 Jan 2025 12:00:00 GMTListingsOcugen received a Nasdaq deficiency notice because its stock closed below $1.00 for 30 consecutive business days. It has until June 30, 2025 to regain compliance and may qualify for a second 180-day period.Ocugen, Inc. Form 8-K filed January 3, 2025 (SEC EDGAR) https://aibio.space/news/eton-pharmaceuticals-completes-acquisition-galzin-teva-7-0-million/https://aibio.space/news/eton-pharmaceuticals-completes-acquisition-galzin-teva-7-0-million/Fri, 03 Jan 2025 12:00:00 GMTMergersEton bought the Wilson Disease treatment on December 31, 2024 for $7.0 million at closing plus $0.2 million for inventory. It will also pay Teva a 10% royalty on U.S. net sales through the tenth anniversary of its first U.S. sale.Eton Pharmaceuticals, Inc. Form 8-K filed January 3, 2025 (SEC EDGAR) https://aibio.space/news/veru-sells-fc2-female-condom-business-clear-future-18-0-million-cash/https://aibio.space/news/veru-sells-fc2-female-condom-business-clear-future-18-0-million-cash/Fri, 03 Jan 2025 12:00:00 GMTDistressThe sale closed December 30, 2024. Veru expects about $12.5 million in net proceeds after a $4.2 million change of control payment to SWK Funding LLC, which ended a residual royalty agreement.VERU INC. Form 8-K filed January 3, 2025 (SEC EDGAR) https://aibio.space/news/veru-closes-18-0-million-sale-fc2-female-condom-business/https://aibio.space/news/veru-closes-18-0-million-sale-fc2-female-condom-business/Fri, 03 Jan 2025 12:00:00 GMTDistressVeru closed the sale of its FC2 female condom business on December 30, 2024 for $18.0 million in cash. After a $4.2 million change of control payment to SWK Funding and other fees, it estimates about $12.5 million in proceeds.Veru Inc. 8-K (2025-01-03) https://aibio.space/news/ibio-licenses-anti-myostatin-antibody-astralbio-paying-750-000-upfront/https://aibio.space/news/ibio-licenses-anti-myostatin-antibody-astralbio-paying-750-000-upfront/Thu, 02 Jan 2025 12:00:00 GMTFinancingsiBio agreed to license an anti-myostatin antibody from AstralBio and paid the $750,000 upfront fee in common stock. AstralBio can earn up to $28 million in milestones, and the antibody's data so far are preclinical.iBio, Inc. Form 8-K filed January 2, 2025 (SEC EDGAR) https://aibio.space/news/psyence-biomedical-agrees-2-0-million-private-placement-warrants/https://aibio.space/news/psyence-biomedical-agrees-2-0-million-private-placement-warrants/Tue, 31 Dec 2024 12:00:00 GMTListingsThe deal covers 1,000,000 common shares at $2.00 each, plus two series of warrants. H.C. Wainwright & Co. is placement agent.Psyence Biomedical Ltd. 6-K (2024-12-31) https://aibio.space/news/kala-bio-agrees-10-750-000-private-placement-common-preferred-stock/https://aibio.space/news/kala-bio-agrees-10-750-000-private-placement-common-preferred-stock/Mon, 30 Dec 2024 12:00:00 GMTFinancingsThe company is selling 1,340,603 shares at $6.44 and 3,286 Series I preferred shares at $644.00. It expects the money to fund operations into the first quarter of 2026.KALA BIO, Inc. 8-K (2024-12-30) https://aibio.space/news/precigen-agrees-79-0-million-private-placement-convertible-preferred/https://aibio.space/news/precigen-agrees-79-0-million-private-placement-convertible-preferred/Mon, 30 Dec 2024 12:00:00 GMTFinancingsPrecigen agreed to sell 8.00% Series A convertible perpetual preferred stock for anticipated gross proceeds of $79.0 million, with warrants for 52,666,669 shares at $0.75 attached. The company says the money extends its cash runway into 2026, provided the PRGN-2012 launch comes after approval.Precigen, Inc. 8-K (2024-12-30) https://aibio.space/news/ascentage-pharma-files-u-s-ipo-adss-plans-nasdaq-listing-aapg/https://aibio.space/news/ascentage-pharma-files-u-s-ipo-adss-plans-nasdaq-listing-aapg/Fri, 27 Dec 2024 12:00:00 GMTFinancingsThe Cayman Islands company's shares have traded in Hong Kong under stock code 6855 since October 28, 2019. The ADS count and price are blank, and J.P. Morgan and Citigroup are named on the cover.Ascentage Pharma Group International F-1 (2024-12-27) https://aibio.space/news/powerup-acquisition-now-aspire-lakewood-gets-loan-up-500-000-before/https://aibio.space/news/powerup-acquisition-now-aspire-lakewood-gets-loan-up-500-000-before/Thu, 26 Dec 2024 12:00:00 GMTMergersThe lender is an entity controlled by Aspire Biopharma's director of investor relations. $184,543.80 had been loaned as of the filing.Aspire-Lakewood Holdings, Inc. 8-K (2024-12-26) https://aibio.space/news/regen-biopharma-files-form-15-common-series-preferred-stock/https://aibio.space/news/regen-biopharma-files-form-15-common-series-preferred-stock/Thu, 26 Dec 2024 12:00:00 GMTListingsThe notice lists 482 holders of record of common stock and 480 of Series A preferred stock. It relies on Rule 12h-3(b)(1)(ii).Regen Biopharma, Inc. 15-15D (2024-12-26) https://aibio.space/news/serina-therapeutics-sells-univerxome-juvenescence-which-takes-11-2/https://aibio.space/news/serina-therapeutics-sells-univerxome-juvenescence-which-takes-11-2/Thu, 26 Dec 2024 12:00:00 GMTMergersThe unit held the legacy AgeX assets. Juvenescence, Serina's largest holder, paid a nominal cash amount on top of assuming the secured debt.Serina Therapeutics, Inc. 8-K (2024-12-26) https://aibio.space/news/tscan-therapeutics-agrees-sell-30-0-million-pre-funded-warrants-lynx1/https://aibio.space/news/tscan-therapeutics-agrees-sell-30-0-million-pre-funded-warrants-lynx1/Thu, 26 Dec 2024 12:00:00 GMTFinancingsTScan sold pre-funded warrants for 7,500,000 voting shares at $4.00 each in a registered direct offering to Lynx1 entities, for about $30.0 million gross. It says cash will fund operations into the first quarter of 2027, on assumptions that may prove wrong.TScan Therapeutics, Inc. 424B5 (2024-12-26) https://aibio.space/news/cingulate-raises-5-million-net-through-5-480-000-unsecured-promissory/https://aibio.space/news/cingulate-raises-5-million-net-through-5-480-000-unsecured-promissory/Mon, 23 Dec 2024 12:00:00 GMTDebt FinancingThe note carries 9% annual interest and matures in 18 months. Cingulate says the money extends its cash runway into the fourth quarter of 2025.Cingulate Inc. 8-K (2024-12-23) https://aibio.space/news/context-therapeutics-sells-14-705-882-shares-about-15-million-mpm/https://aibio.space/news/context-therapeutics-sells-14-705-882-shares-about-15-million-mpm/Mon, 23 Dec 2024 12:00:00 GMTFinancingsThe shares were sold through the company's sales agreement with Leerink Partners on December 23, 2024.Context Therapeutics Inc. 8-K (2024-12-23) https://aibio.space/news/monopar-therapeutics-agrees-sell-798-655-shares-23-79-plus-pre-funded/https://aibio.space/news/monopar-therapeutics-agrees-sell-798-655-shares-23-79-plus-pre-funded/Mon, 23 Dec 2024 12:00:00 GMTFinancingsThe underwritten offering and a concurrent private placement are expected to bring net proceeds of about $37.6 million.Monopar Therapeutics Inc. 424B5 (2024-12-23) https://aibio.space/news/quoin-pharmaceuticals-prices-6-8-million-offering-adss-warrants-0-45/https://aibio.space/news/quoin-pharmaceuticals-prices-6-8-million-offering-adss-warrants-0-45/Mon, 23 Dec 2024 12:00:00 GMTFinancingsQuoin Pharmaceuticals priced a $6.8 million offering at $0.45 per ADS, below the $0.647 close on December 19. Older warrants were repriced to the same level, and the prospectus sets no minimum amount for the deal to close.Quoin Pharmaceuticals, Ltd. 424B4 (2024-12-23) https://aibio.space/news/bioatla-agrees-about-9-2-million-registered-direct-offering-0-9520/https://aibio.space/news/bioatla-agrees-about-9-2-million-registered-direct-offering-0-9520/Fri, 20 Dec 2024 12:00:00 GMTFinancingsBioAtla is selling 9,679,158 shares with warrants at a combined $0.9520 each, through sole placement agent Tungsten Advisors, for about $9.2 million gross and about $8.5 million net.BioAtla, Inc. 8-K (2024-12-20) https://aibio.space/news/altamira-therapeutics-moves-nasdaq-otcqb-after-panel-decision/https://aibio.space/news/altamira-therapeutics-moves-nasdaq-otcqb-after-panel-decision/Fri, 20 Dec 2024 12:00:00 GMTListingsThe Nasdaq Hearings Panel denied the company's request to stay listed over the $1.00 minimum bid price rule. Shares are to trade as CYTOF, and the company says it plans no reverse stock split.Altamira Therapeutics Ltd. 6-K (2024-12-20) https://aibio.space/news/fennec-pharmaceuticals-repays-13-million-convertible-debt-early/https://aibio.space/news/fennec-pharmaceuticals-repays-13-million-convertible-debt-early/Fri, 20 Dec 2024 12:00:00 GMTFinancingsThe payment to Petrichor comes from available cash. It cuts about $1.5 million in annual interest and removes about 1.6 million potential shares.Fennec Pharmaceuticals Inc. 8-K (2024-12-20) https://aibio.space/news/marker-therapeutics-signs-16-1-million-private-placement/https://aibio.space/news/marker-therapeutics-signs-16-1-million-private-placement/Thu, 19 Dec 2024 12:00:00 GMTFinancingsInvestors agreed to buy 1,783,805 shares plus warrants. The warrants need stockholder approval before they can be exercised.Marker Therapeutics, Inc. 8-K (2024-12-19) https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-agrees-all-stock-merger/https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-agrees-all-stock-merger/Wed, 18 Dec 2024 12:00:00 GMTMergersCara Therapeutics agreed on December 18, 2024 to combine with private Tvardi Therapeutics in an all-stock deal. Pre-merger Cara holders would own about 17.0% of the combined company, and the closing depends on Cara holding at least $18.0 million of net cash.Tvardi Therapeutics, Inc. 8-K (2024-12-18) https://aibio.space/news/bionomics-now-neuphoria-therapeutics-wins-court-approval-us-move/https://aibio.space/news/bionomics-now-neuphoria-therapeutics-wins-court-approval-us-move/Mon, 16 Dec 2024 12:00:00 GMTMergersThe Supreme Court of New South Wales approved the scheme of arrangement. Neuphoria shares are expected to start trading on Nasdaq as NEUP on December 24, 2024.Neuphoria Therapeutics Inc. 8-K (2024-12-16) https://aibio.space/news/salarius-pharmaceuticals-now-decoy-therapeutics-signs-equity-line-up/https://aibio.space/news/salarius-pharmaceuticals-now-decoy-therapeutics-signs-equity-line-up/Fri, 13 Dec 2024 12:00:00 GMTFinancingsSalarius Pharmaceuticals agreed on December 12, 2024 to let C/M Capital Master Fund, LP purchase up to $10 million of its common stock over 36 months, once a resale registration is effective. The 8-K names no placement agent or counsel, and it gives the company's Nasdaq symbol as SLRX.Decoy Therapeutics Inc. 8-K (2024-12-13) https://aibio.space/news/taysha-gene-therapies-files-300-000-000-shelf-100-000-000-atm/https://aibio.space/news/taysha-gene-therapies-files-300-000-000-shelf-100-000-000-atm/Fri, 13 Dec 2024 12:00:00 GMTFinancingsTaysha Gene Therapies filed a $300,000,000 shelf registration on December 13, 2024, with a $100,000,000 at-the-market sales agreement inside it. The company had sold $12,000,000 under its earlier agreement, and the stock's last reported price was $2.25.Taysha Gene Therapies, Inc. S-3 (2024-12-13) https://aibio.space/news/editas-medicine-ends-reni-cel-program-cuts-about-180-positions-65/https://aibio.space/news/editas-medicine-ends-reni-cel-program-cuts-about-180-positions-65/Thu, 12 Dec 2024 12:00:00 GMTDistressThe company expects costs of $55.0 million to $70.0 million for the discontinuation and $14.0 million to $18.0 million for the workforce reduction. It now sees cash lasting into the second quarter of 2027.Editas Medicine, Inc. 8-K (2024-12-12) https://aibio.space/news/eton-sells-583-334-shares-12-00-7-0-million-registered-direct-offering/https://aibio.space/news/eton-sells-583-334-shares-12-00-7-0-million-registered-direct-offering/Thu, 12 Dec 2024 12:00:00 GMTFinancingsThe shares went to one institutional investor, and the prospectus says no placement agent or underwriter was involved. The prospectus puts the immediate dilution to the buyer at $11.35 per share.Eton Pharmaceuticals, Inc. 424B5 (2024-12-12) https://aibio.space/news/inovio-pharmaceuticals-prices-30-million-offering-stock-warrants-3-00/https://aibio.space/news/inovio-pharmaceuticals-prices-30-million-offering-stock-warrants-3-00/Thu, 12 Dec 2024 12:00:00 GMTFinancingsInovio is selling 10,000,000 shares at $3.00 with warrants for 10,000,000 more shares at $3.76. The filing gives net proceeds of about $27.6 million and immediate dilution of $0.19 per share.Inovio Pharmaceuticals, Inc. 424B5 (2024-12-12) https://aibio.space/news/neutra-corp-files-form-15-end-sec-reporting-duties/https://aibio.space/news/neutra-corp-files-form-15-end-sec-reporting-duties/Thu, 12 Dec 2024 12:00:00 GMTListingsThe notice, dated December 11, 2024, lists 16 holders of record of its common stock.Neutra Corp. 15-12G (2024-12-12) https://aibio.space/news/cardiff-oncology-prices-40-million-share-offering-2-60-above-last-sale/https://aibio.space/news/cardiff-oncology-prices-40-million-share-offering-2-60-above-last-sale/Tue, 10 Dec 2024 12:00:00 GMTFinancingsThe company is selling 15,384,619 shares. The stock last traded at $2.44 on December 9, 2024. Cardiff plans to use proceeds for onvansertib trials in colorectal cancer.Cardiff Oncology, Inc. 8-K (2024-12-10) https://aibio.space/news/rocket-pharmaceuticals-launches-150-000-000-stock-offering-prices-12/https://aibio.space/news/rocket-pharmaceuticals-launches-150-000-000-stock-offering-prices-12/Tue, 10 Dec 2024 12:00:00 GMTFinancingsRocket Pharmaceuticals priced 13,200,000 shares at $12.50 on December 10, 2024, below the $13.84 last sale price on December 9. Net proceeds are about $154.8 million before the underwriters' option, and the company's own prospectus says the money will last into the second quarter of 2026.Rocket Pharmaceuticals, Inc. 424B5 (2024-12-10) https://aibio.space/news/celcuity-files-up-125-000-000-market-stock-sales/https://aibio.space/news/celcuity-files-up-125-000-000-market-stock-sales/Fri, 06 Dec 2024 12:00:00 GMTFinancingsThe supplement covers up to $125,000,000 of common stock sold through Jefferies LLC under a February 4, 2022 sales agreement. Shares with an aggregate offering price of up to $22,182,550 remained unsold under the 2022 supplement, and the filing gives a $12.71 last sale price on December 4, 2024.Celcuity Inc. 424B5 (2024-12-06) https://aibio.space/news/jupiter-neurosciences-prices-11-million-ipo-2-750-000-shares-4-00/https://aibio.space/news/jupiter-neurosciences-prices-11-million-ipo-2-750-000-shares-4-00/Mon, 02 Dec 2024 12:00:00 GMTFinancingsJupiter Neurosciences priced a firm commitment IPO of 2,750,000 shares at $4.00, or $11,000,000 gross. Its prospectus carries a going concern warning and an accumulated deficit of $23,903,481 at June 30, 2024.Jupiter Neurosciences, Inc. 424B4 (2024-12-02) https://aibio.space/news/korro-bio-files-400-000-000-shelf-100-000-000-stock-sales-program/https://aibio.space/news/korro-bio-files-400-000-000-shelf-100-000-000-stock-sales-program/Mon, 02 Dec 2024 12:00:00 GMTFinancingsKorro Bio's S-3 shelf registers up to $400,000,000 of securities. Its sales agreement with TD Securities (USA) LLC covers up to $100,000,000 of common stock, and the filing gives no cash balance.Korro Bio, Inc. S-3 (2024-12-02) https://aibio.space/news/nektar-completes-sale-huntsville-alabama-plant-ampersand-affiliate/https://aibio.space/news/nektar-completes-sale-huntsville-alabama-plant-ampersand-affiliate/Mon, 02 Dec 2024 12:00:00 GMTMergersNektar sold the Huntsville plant, certain other related manufacturing assets and certain related liabilities to the buyer under an agreement dated November 1, 2024.Nektar Therapeutics 8-K (2024-12-02) https://aibio.space/news/olema-oncology-announces-250-0-million-private-placement-novartis/https://aibio.space/news/olema-oncology-announces-250-0-million-private-placement-novartis/Mon, 02 Dec 2024 12:00:00 GMTFinancingsOlema is selling 19,928,875 shares at $9.08 and pre-funded warrants for 7,604,163 shares. Novartis will supply ribociclib for the planned Phase 3 OPERA-02 trial.Olema Pharmaceuticals, Inc. 8-K (2024-12-02) https://aibio.space/news/gyre-therapeutics-sets-up-50-000-000-market-stock-program-jefferies/https://aibio.space/news/gyre-therapeutics-sets-up-50-000-000-market-stock-program-jefferies/Wed, 27 Nov 2024 12:00:00 GMTFinancingsJefferies LLC is the sales agent for up to $50,000,000 of common stock. Its commission is up to 3.0% of gross proceeds, and a significant part of the business runs through a Chinese subsidiary.Gyre Therapeutics, Inc. 424B5 (2024-11-27) https://aibio.space/news/tuhura-biosciences-signs-letter-intent-acquire-kinetas-kva12123/https://aibio.space/news/tuhura-biosciences-signs-letter-intent-acquire-kinetas-kva12123/Mon, 25 Nov 2024 12:00:00 GMTMergersThe letter is non-binding and the release states no price. TuHURA targets a definitive agreement in Q4 2024 and completion of the acquisition in H1 2025.TuHURA Biosciences, Inc. 8-K (2024-11-25) https://aibio.space/news/scilex-noteholders-waive-defaults-tied-late-third-quarter-report/https://aibio.space/news/scilex-noteholders-waive-defaults-tied-late-third-quarter-report/Fri, 22 Nov 2024 12:00:00 GMTFinancingsOramed and the Tranche B holders waived the missed quarterly filing on November 21, 2024. Scilex must deliver its September 2024 financial statements by January 20, 2025, through a new independent auditor.Scilex Holding Company 8-K (2024-11-22) https://aibio.space/news/iovance-moves-san-carlos-headquarters-smaller-space-cutting-monthly/https://aibio.space/news/iovance-moves-san-carlos-headquarters-smaller-space-cutting-monthly/Thu, 21 Nov 2024 12:00:00 GMTDistressA 24-month sublease with Vaxcyte at $99,549.53 per month replaces a lease with original monthly rent of $279,540.80.Iovance Biotherapeutics, Inc. 8-K (2024-11-21) https://aibio.space/news/chromadex-now-niagen-bioscience-adds-roth-capital-market-program/https://aibio.space/news/chromadex-now-niagen-bioscience-adds-roth-capital-market-program/Thu, 21 Nov 2024 12:00:00 GMTFinancingsB. Riley Securities is removed from the program. Raymond James and Roth Capital Partners will continue as the sales agents.Niagen Bioscience, Inc. 8-K (2024-11-21) https://aibio.space/news/pmv-pharmaceuticals-files-200-000-000-shelf-113-792-846-40-atm/https://aibio.space/news/pmv-pharmaceuticals-files-200-000-000-shelf-113-792-846-40-atm/Wed, 20 Nov 2024 12:00:00 GMTFinancingsPMV can sell up to $113,792,846.40 of stock through Jefferies, which the filing says is paid 3.0% of gross proceeds. The stock last sold at $1.59 per share on November 19, 2024, far below the $6.97 weighted average on the earlier program.PMV Pharmaceuticals, Inc. S-3 (2024-11-20) https://aibio.space/news/verrica-pharmaceuticals-prices-42-007-776-stock-warrant-offering-0-89/https://aibio.space/news/verrica-pharmaceuticals-prices-42-007-776-stock-warrant-offering-0-89/Wed, 20 Nov 2024 12:00:00 GMTFinancingsVerrica priced 44,964,045 shares at $0.89 with Series A and B warrants, for a total public offering price of $42,007,776. Entities tied to director Paul B. Manning agreed to buy 22.9 million shares, and the filing carries a going-concern warning.Verrica Pharmaceuticals Inc. 424B5 (2024-11-21) https://aibio.space/news/atossa-therapeutics-sets-up-100-000-000-market-stock-program-jefferies/https://aibio.space/news/atossa-therapeutics-sets-up-100-000-000-market-stock-program-jefferies/Tue, 19 Nov 2024 12:00:00 GMTFinancingsJefferies will earn a commission of up to 3.0% on any shares sold. The stock last sold at $1.28 on November 15, 2024.Atossa Therapeutics, Inc. 424B5 (2024-11-19) https://aibio.space/news/aclaris-therapeutics-licenses-two-biosion-antibodies-ends-strategic/https://aibio.space/news/aclaris-therapeutics-licenses-two-biosion-antibodies-ends-strategic/Mon, 18 Nov 2024 12:00:00 GMTFinancingsAclaris also pointed to a private placement financing announced the same morning and said it maintains its cash runway into 2028. The release gives no license payment terms.Aclaris Therapeutics, Inc. 8-K (2024-11-18) https://aibio.space/news/aditxt-delays-quarterly-report-period-ended-september-30-2024/https://aibio.space/news/aditxt-delays-quarterly-report-period-ended-september-30-2024/Fri, 15 Nov 2024 12:00:00 GMTDistressThe company filed a late-filing notice on November 15, 2024. It plans to file the report no later than 5 days after the original due date.Aditxt, Inc. NT 10-Q (2024-11-15) https://aibio.space/news/neurogene-delays-quarterly-report-period-ended-september-30-2024/https://aibio.space/news/neurogene-delays-quarterly-report-period-ended-september-30-2024/Thu, 14 Nov 2024 12:00:00 GMTDistressThe company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days.Neurogene Inc. NT 10-Q (2024-11-14) https://aibio.space/news/scilex-holding-delays-third-quarter-10-q-notice-cites-ongoing-review/https://aibio.space/news/scilex-holding-delays-third-quarter-10-q-notice-cites-ongoing-review/Thu, 14 Nov 2024 12:00:00 GMTDistressThe company missed the November 14, 2024 due date for its report on the quarter ended September 30, 2024. The notice warns that an ongoing review may identify errors or control deficiencies in its accounting practices.Scilex Holding Company NT 10-Q (2024-11-14) https://aibio.space/news/cellectar-biosciences-delays-quarterly-report-after-restating-past/https://aibio.space/news/cellectar-biosciences-delays-quarterly-report-after-restating-past/Wed, 13 Nov 2024 12:00:00 GMTDistressThe company found that certain warrants and preferred stock issued before 2023 had not been accounted for properly. It estimated cash of $34.3 million at September 30, 2024.Cellectar Biosciences, Inc. NT 10-Q (2024-11-13) https://aibio.space/news/oruka-reports-410-875-thousand-cash-september-30-2024/https://aibio.space/news/oruka-reports-410-875-thousand-cash-september-30-2024/Wed, 13 Nov 2024 12:00:00 GMTDistressA separate exhibit carries an audited balance sheet dated February 6, 2024, the company's inception. The auditor's report on it raises going-concern doubt.Oruka Therapeutics, Inc. 10-Q (2024-11-13) https://aibio.space/news/rockwell-medical-files-sell-up-25-000-000-stock-market/https://aibio.space/news/rockwell-medical-files-sell-up-25-000-000-stock-market/Wed, 13 Nov 2024 12:00:00 GMTFinancingsRockwell Medical may sell up to $25,000,000 of stock through Cantor Fitzgerald, which takes a commission of up to 3.0%. At the assumed $4.43 price, the filing says new buyers would face an immediate dilution of $3.33 a share.Rockwell Medical, Inc. 424B5 (2024-11-13) https://aibio.space/news/mereo-biopharma-reports-80-5-million-cash-says-funds-operations-2027/https://aibio.space/news/mereo-biopharma-reports-80-5-million-cash-says-funds-operations-2027/Tue, 12 Nov 2024 12:00:00 GMTFinancingsThe balance includes net proceeds of a $50 million registered direct offering priced June 14, 2024. Third-quarter net loss was $15.0 million.Mereo BioPharma Group plc 8-K (2024-11-12) https://aibio.space/news/akari-therapeutics-shareholders-approve-share-issuance-peak-bio-merger/https://aibio.space/news/akari-therapeutics-shareholders-approve-share-issuance-peak-bio-merger/Fri, 08 Nov 2024 12:00:00 GMTMergersAbout 99% of shares present voted in support. Akari targets a close on November 13, 2024 and expects the deal to fix its Nasdaq equity deficiency.Akari Therapeutics Plc 8-K (2024-11-08) https://aibio.space/news/assembly-biosciences-sets-up-75-000-000-market-program-jefferies/https://aibio.space/news/assembly-biosciences-sets-up-75-000-000-market-program-jefferies/Thu, 07 Nov 2024 12:00:00 GMTFinancingsJefferies will earn up to 3.0% of gross proceeds. The stock last sold at $16.65 before the agreement.Assembly Biosciences, Inc. 8-K (2024-11-07) https://aibio.space/news/geron-completes-250-million-royalty-pharma-pharmakon-financings/https://aibio.space/news/geron-completes-250-million-royalty-pharma-pharmakon-financings/Thu, 07 Nov 2024 12:00:00 GMTMergersGeron drew $125 million under a Pharmakon term loan and took $125 million from Royalty Pharma, in a quarter with a $26.4 million net loss. The release gives no royalty rates or loan interest rate.Geron Corporation 8-K (2024-11-07) https://aibio.space/news/pieris-now-palvella-therapeutics-files-merger-partners-phase-3-dosing/https://aibio.space/news/pieris-now-palvella-therapeutics-files-merger-partners-phase-3-dosing/Thu, 07 Nov 2024 12:00:00 GMTMergersPalvella said the first patient was dosed in its SELVA Phase 3 trial. Later, Pieris added merger disclosures after nine stockholder demands and two lawsuits alleging disclosure gaps, which the defendants deny.Palvella Therapeutics, Inc. 425 (2024-11-07) https://aibio.space/news/scynexis-sets-up-market-program-up-50-000-000-stock-cantor/https://aibio.space/news/scynexis-sets-up-market-program-up-50-000-000-stock-cantor/Wed, 06 Nov 2024 12:00:00 GMTFinancingsSCYNEXIS can sell up to $50,000,000 of stock through Cantor Fitzgerald, which earns a 3.0% commission, with the stock at $1.33 on November 5, 2024. Its approved drug is off the market under a recall, and the supplement gives no cash balance.SCYNEXIS, Inc. 424B5 (2024-11-06) https://aibio.space/news/anaptysbio-files-500-000-000-shelf-100-000-000-stock-sales-program/https://aibio.space/news/anaptysbio-files-500-000-000-shelf-100-000-000-stock-sales-program/Tue, 05 Nov 2024 12:00:00 GMTFinancingsAnaptysBio's new shelf replaces one that expires January 11, 2025, and its $100,000,000 sales program with TD Securities (USA) LLC could sell up to 4,819,277 shares at $20.75 each, with immediate dilution of $15.59 per share for new buyers.AnaptysBio, Inc. S-3 (2024-11-05) https://aibio.space/news/relief-therapeutics-now-mindmaze-signs-non-binding-loi-renexxion/https://aibio.space/news/relief-therapeutics-now-mindmaze-signs-non-binding-loi-renexxion/Tue, 05 Nov 2024 12:00:00 GMTMergersRenexxion holders would own about 72.2% of the combined company under the initial ratio. The companies aim to sign a definitive agreement by December 31, 2024.MindMaze Therapeutics Holding SA 6-K (2024-11-05) https://aibio.space/news/neurogene-agrees-200-0-million-private-placement-50-00-share/https://aibio.space/news/neurogene-agrees-200-0-million-private-placement-50-00-share/Mon, 04 Nov 2024 12:00:00 GMTFinancingsNeurogene is selling 1,835,000 shares and pre-funded warrants for up to 2,165,042 shares to a group of healthcare investors.Neurogene Inc. 8-K (2024-11-04) https://aibio.space/news/lyell-immunopharma-completes-acquisition-immpact-bio/https://aibio.space/news/lyell-immunopharma-completes-acquisition-immpact-bio/Thu, 31 Oct 2024 12:00:00 GMTMergersLyell adds IMPT-314, a CAR T-cell candidate, through the ImmPACT Bio deal. The release gives no purchase price and no cash balance, and says cash will fund operations into 2027.Lyell Immunopharma, Inc. 8-K (2024-10-31) https://aibio.space/news/eterna-now-ernexa-closes-1-1-million-placement-0-75-after-stockholder/https://aibio.space/news/eterna-now-ernexa-closes-1-1-million-placement-0-75-after-stockholder/Tue, 29 Oct 2024 12:00:00 GMTFinancingsStockholders approved the share issuances at the annual meeting on October 29, 2024, the same day the placement closed. The company also agreed to register the new shares for resale, and its equity had been below Nasdaq's $2.5 million minimum.Ernexa Therapeutics Inc. 8-K (2024-10-29) https://aibio.space/news/immunome-buys-licensed-zentalis-ror1-assets-1-805-502-shares/https://aibio.space/news/immunome-buys-licensed-zentalis-ror1-assets-1-805-502-shares/Tue, 29 Oct 2024 12:00:00 GMTMergersImmunome owes Zentalis $5,000,000 in cash only if a developmental milestone is achieved. The purchase ends the January 2024 license agreement.Immunome, Inc. 8-K (2024-10-29) https://aibio.space/news/nyse-american-files-remove-calidi-biotherapeutics-warrants-listing/https://aibio.space/news/nyse-american-files-remove-calidi-biotherapeutics-warrants-listing/Mon, 28 Oct 2024 12:00:00 GMTListingsThe notice, dated October 28, 2024, covers the company's redeemable warrants with a $115.00 exercise price, not its common stock.Calidi Biotherapeutics, Inc. 25-NSE (2024-10-28) https://aibio.space/news/molecular-partners-prices-20-million-offering-3-642-988-adss-5-49/https://aibio.space/news/molecular-partners-prices-20-million-offering-3-642-988-adss-5-49/Mon, 28 Oct 2024 12:00:00 GMTFinancingsThe Swiss company plans to use the money for its radiopharmaceutical pipeline and working capital. Leerink Partners and TD Cowen are joint bookrunners.Molecular Partners AG 6-K (2024-10-28) https://aibio.space/news/bellevue-life-sciences-acquisition-now-osr-health-lends-300-000-osr/https://aibio.space/news/bellevue-life-sciences-acquisition-now-osr-health-lends-300-000-osr/Mon, 28 Oct 2024 12:00:00 GMTMergersBellevue's note to its merger partner bears interest at 3.96% a year and is due on October 25, 2025. Bellevue's chief executive is also chairman of OSR Holdings.OSR Health, Inc. 8-K (2024-10-28)